
<html lang="en"     class="pb-page"  data-request-id="67fd90c8-2f5b-441c-be83-6aea3e57f902"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.1c00629;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-13;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation" /></meta><meta name="dc.Creator" content="Jinyun  Dong" /></meta><meta name="dc.Creator" content="Xiang-Dong  Cheng" /></meta><meta name="dc.Creator" content="Wei-Dong  Zhang" /></meta><meta name="dc.Creator" content="Jiang-Jiang  Qin" /></meta><meta name="dc.Description" content="Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates various biological processes, including proliferation, metastasis, angiogenesis, immune response,..." /></meta><meta name="Description" content="Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates various biological processes, including proliferation, metastasis, angiogenesis, immune response,..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 25, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00629" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00629" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00629" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00629" /></link>
        
    
    

<title>Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00629" /></meta><meta property="og:title" content="Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0027.jpeg" /></meta><meta property="og:description" content="Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates various biological processes, including proliferation, metastasis, angiogenesis, immune response, and chemoresistance. In normal cells, STAT3 is tightly regulated to maintain a transiently active state, while persistent STAT3 activation occurs frequently in cancers, associating with a poor prognosis and tumor progression. Targeting the STAT3 protein is a potentially promising therapeutic strategy for tumors. Although none of the STAT3 inhibitors has been marketed yet, a few of them have succeeded in entering clinical trials. This Review aims to systematically summarize the progress of the last 5 years in the discovery of directive STAT3 small-molecule inhibitors and degraders, focusing primarily on their structural features, design strategies, and bioactivities. We hope this Review will shed light on future drug design and inhibitor optimization to accelerate the discovery process of STAT3 inhibitors or degraders." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00629"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00629">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/acsodf/largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/ancham/largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/cmatex/largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/jceda8/largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/jctcce/largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/langd5/largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/mamobx/largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00629&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00629&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00629&amp;href=/doi/10.1021/acs.jmedchem.1c00629" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 8884-8915</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02218" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00631" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jinyun Dong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinyun Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China</div><div class="loa-info-affiliations-info">Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310018, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinyun++Dong">Jinyun Dong</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Xiang-Dong Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiang-Dong Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China</div><div class="loa-info-affiliations-info">Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310018, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiang-Dong++Cheng">Xiang-Dong Cheng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Wei-Dong Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei-Dong Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Naval Medical University, Shanghai 200433, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei-Dong++Zhang">Wei-Dong Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Jiang-Jiang Qin</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiang-Jiang Qin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China</div><div class="loa-info-affiliations-info">Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310018, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#7812091116380d1b190b56191b561b16"><span class="__cf_email__" data-cfemail="5e342f37301e2b3d3f2d703f3d703d30">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiang-Jiang++Qin">Jiang-Jiang Qin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8559-616X" title="Orcid link">https://orcid.org/0000-0002-8559-616X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00629&amp;href=/doi/10.1021%2Facs.jmedchem.1c00629" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 8884â8915</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 25, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 April 2021</li><li><span class="item_label"><b>Published</b> online</span>25 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00629" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00629</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8884%26pageCount%3D32%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJinyun%2BDong%252C%2BXiang-Dong%2BCheng%252C%2BWei-Dong%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D13%26contentID%3Dacs.jmedchem.1c00629%26title%3DRecent%2BUpdate%2Bon%2BDevelopment%2Bof%2BSmall-Molecule%2BSTAT3%2BInhibitors%2Bfor%2BCancer%2BTherapy%253A%2BFrom%2BPhosphorylation%2BInhibition%2Bto%2BProtein%2BDegradation%26numPages%3D32%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8915%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00629"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1097</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00629" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jinyun&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Xiang-Dong&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Wei-Dong&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jiang-Jiang&quot;,&quot;last_name&quot;:&quot;Qin&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;8884-8915&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00629&quot;},&quot;abstract&quot;:&quot;Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates various biological processes, including proliferation, metastasis, angiogenesis, immune response, and chemoresistance. In normal cells, STAT3 is tightly regulated to maintain a transiently active state, while persistent STAT3 activation occurs frequently in cancers, associating with a poor prognosis and tumor progression. Targeting the STAT3 protein is a potentially promising therapeutic strategy for tumors. Although none of the STAT3 inhibitors has been marketed yet, a few of them have succeeded in entering clinical trials. This Review aims to systematically summarize the progress of the last 5 years in the discovery of directive STAT3 small-molecule inhibitors and degraders, focusing primarily on their structural features, design strategies, and bioactivities. We hope this Review will shed light on future drug design and inhibitor optimization to accelerate the discovery process of STAT3 inhibitors or degrade&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00629&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00629" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00629&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00629" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00629&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00629" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00629&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00629&amp;href=/doi/10.1021/acs.jmedchem.1c00629" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00629" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00629" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00629%26sid%3Dliteratum%253Aachs%26pmid%3D34170703%26genre%3Darticle%26aulast%3DDong%26date%3D2021%26atitle%3DRecent%2BUpdate%2Bon%2BDevelopment%2Bof%2BSmall-Molecule%2BSTAT3%2BInhibitors%2Bfor%2BCancer%2BTherapy%253A%2BFrom%2BPhosphorylation%2BInhibition%2Bto%2BProtein%2BDegradation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D13%26spage%3D8884%26epage%3D8915%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=290969" title="Cell and molecular biology">Cell and molecular biology</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates various biological processes, including proliferation, metastasis, angiogenesis, immune response, and chemoresistance. In normal cells, STAT3 is tightly regulated to maintain a transiently active state, while persistent STAT3 activation occurs frequently in cancers, associating with a poor prognosis and tumor progression. Targeting the STAT3 protein is a potentially promising therapeutic strategy for tumors. Although none of the STAT3 inhibitors has been marketed yet, a few of them have succeeded in entering clinical trials. This Review aims to systematically summarize the progress of the last 5 years in the discovery of directive STAT3 small-molecule inhibitors and degraders, focusing primarily on their structural features, design strategies, and bioactivities. We hope this Review will shed light on future drug design and inhibitor optimization to accelerate the discovery process of STAT3 inhibitors or degraders.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Signal transducer and activator of transcription (STAT) is a family of cytoplasmic transcription factors that are responsible for the transduction of extracellular cytokine and growth factor signaling as well as activation of gene transcription.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In mammalian cells, the STAT family consists of seven members, including STAT1, STAT2, STAT3, STAT4, STAT5Î±, STAT5Î², and STAT6, with homology between 20 and 50%.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Plenty of the genes that are regulated by STAT proteins include those involved in controlling cell cycle, cell survival, and immune response.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p last">In STAT family proteins, STAT2 is an essential transcription factor in the type I interferon (IFN-Î±/Î²) signal transduction pathway and is known for its role in mediating antiviral immunity and antiproliferative signaling.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Similar to the STAT2 protein, STAT6 and STAT4, activated specifically by IL-4 and IL-12, respectively, are central mediators in the regulation of immune response.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Apart from its role in regulating immune response, STAT1 has been shown to block tumor cell proliferation and promote apoptosis of tumor cells.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Contrary to the function of STAT1, both STAT3 and STAT5 proteins are oncogenic downstream mediators of the JAK-STAT pathway that promotes cancer cell proliferation and survival.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In particular, STAT3 controls cell cycle progression and antiapoptosis; hence, it is most often implicated in the progression and poor prognosis of diverse human cancers.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In addition to its involvement in cancer, STAT3 is also implicated in autoimmune and inflammatory diseases such as rheumatoid arthritis, Crohnâs disease, atherosclerosis, and inflammatory bowel disease.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> As a result, STAT3 has been widely considered as an attractive target for the development of inhibitors for STAT3-related disease therapy, such as cancers, autoimmune, and inflammatory diseases.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  STAT3 STRUCTURE AND SIGNALING PATHWAY</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Structurally, STAT3 contains about 770 amino acids with a relative molecular weight of 88 kDa, and there have been four isoforms identified for STAT3 in mammals, namely, STAT3Î±, STAT3Î², STAT3Î³, and STAT3Î´. As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, STAT3 shares common structural motifs with the other members of the family, including the N-terminal domain (NTD, residues 1â138), the coiled-coil domain (CCD, residues 139â320), the DNA-binding domain (DBD, residues 321â494), the linker domain (LD, residues 495â583), the Src homology 2 (SH2, residues 584â688) domain, and the transactivation domain (TAD, residues 689â770), each of which plays distinct roles in the process of signal transduction and activation of gene transcription.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12â14)</a> The N-terminal domain is a conserved sequence, performing multiple functions such as STAT3 dimers nuclear translocation and subsequently cooperative DNA binding.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The CCD, constituted by four Î±-helices connected by short loops, has a large hydrophilic surface predominantly involved in the recruitment of STAT3 to its receptor.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The DBD, characterized by an eight stranded Î²-barrel, is responsible for the recognition of and binding to a specific DNA sequence. The LD, a region composed of a series of Î±-helices, allows for connecting the DBD with the SH2 domain, and mutational studies have found that it is important for transcriptional activation.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> The SH2 domain is the most highly conserved region of the family, which is required for the formation of STAT3 dimers upon phosphorylation of specific tyrosine residues in the TAD.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Tyrosine 705 and serine 727, located in the TAD, are two important phosphorylation sites of STAT3. Upon activation, Tyr705 is phosphorylated and then promotes STAT3 dimerization by the binding of phosphorylated Tyr705 of one monomer to the SH2 domain in the opposing subunit.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Also, phosphorylation of Ser727 further enhances STAT3 target gene transcription.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structure of STAT3 homodimer bound to the DNA recognition site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BG1">1BG1</a>, this protein lacks the N-terminal domain, if needed, please see PDB entry code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZIA">4ZIA</a>). Structural domains are indicated by different colors, and the dashed line represents the missing residues. Spheres represent Cys542 or Cys259 that covalently binds some inhibitors. (B) SH2 domain characteristics of STAT3 in which blue represents hydrophilic areas, while orange-red represents hydrophobic areas.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inactive STAT3 is localized in the cytoplasm in the absence of stimuli. As presented in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, when stimulated by growth factors and cytokines, as well as oncogenic proteins such as epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), interleukin 6 (IL-6), IL-10, IL-11 and interferon-g (IFN-g) binding to their cognate receptors on the cell surface, the associated upstream kinases including Janus kinases (JAKs), receptor and nonreceptor tyrosine kinases (such as RTKs, Src, and ABL) are activated and subsequently phosphorylate the Tyr705 or Ser727 residue in the TAD of the STAT3 protein.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Among them, Src is one of the critical oncoproteins for constitutively activating STAT3. As a downstream effector of Src, Ras is a central regulator in the signaling pathways leading to MAPK activation. For the Ras-ERK pathway, sequential protein phosphorylations are mediated by Raf1 and MKK1/2, which in turn phosphorylate and activate ERK1/2. For the other branch, Ras/Rac1-mediated activities of p38 and JNK contribute to the STAT3 signaling. JNK is often activated by MKK4/MKK7, while MKK3/6 preferentially activate p38. Of particular note, the phosphorylation of STAT3 by ERKs is minimal in comparison with the levels achieved for JNK and p38.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Phosphorylation of Tyr705 or Ser727 triggers STAT3 dimerization, nuclear translocation, DNA binding, and target gene activation. The downstream genes are involved in numerous physiological processes including proliferation (e.g., c-Myc, CDC2, and cyclin D1), survival (e.g., Bcl-2, Bcl-xL, and survivin), differentiation (e.g., GM-CSF), metastasis (e.g., MMP-2 and MMP-9), angiogenesis (e.g., VEGF, HIF-1Î±, and MMP-9) and immune responses (e.g., COX-2, iNOS, PD-L1, and CXCR4).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. STAT3 signaling pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Although phosphorylation of Tyr705 or Ser727 is required for dimerization and nuclear translocation in most cases, some studies have shown that acetylation on Lys685 also enables stabilization of STAT3 dimers to initiate transactivation of target genes in the noncanonical STAT3 signaling pathway.<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26â28)</a> Notably, STAT3 acetylation further increases CpG island methylation of certain tumor-suppressor genes.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Apart from homodimerization, STAT3 can also form heterodimers with STAT1 and subsequently translocate into the nucleus, where they bind to promoter elements in target genes to regulate their transcription.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In addition to functioning as a direct transcription factor to regulate gene expression, epigenetic mechanisms such as DNA methylation and chromatin modification appear to represent an additional regulatory process for STAT3 to exert functions.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Besides the well-known cytoplasmic location, STAT3 can also be detected in mitochondrial fractions, contributing to diverse biological processes, including regulation of mitochondrial electron transport chain (ETC), cellular transformation, cardiac activity along with the neurological activity.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Overall, STAT3 signaling could be activated by multiple pathways and exerts diverse physiological/pathological functions in cells (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Meanwhile, negative regulatory factors such as Src homology region 2 domain-containing phosphatase-1 (SHP-1) and SHP-2, the suppressors of cytokine signaling (SOCS), glutathione S-transferase P1 (GSTP1), protein tyrosine phosphatase receptor T (PTPRT), and deacetylase Sirtuin 1 (SIRT1) play negative roles in regulating STAT3 signaling to maintain transient activation state under physiological conditions.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33â35)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  STAT3 ACTIVATION IN CANCER DEVELOPMENT</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34688" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34688" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">STAT3 signaling is tightly regulated to maintain a transiently active state under normal physiologic conditions. However, persistent STAT3 activation occurs frequently in a wide spectrum of (approximately 70%) human solid and hematological malignancies, including but not limited to colorectal, lung, melanoma, breast, prostate, renal, ovarian, liver, pancreas cancers, multiple myeloma, and leukemia.<a onclick="showRef(event, 'ref12 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref12 ref36 ref37">(12,36,37)</a> Furthermore, the constitutive STAT3 activation has also been found to be closely linked to the poor prognosis of cancers.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Mechanically, hyperactive STAT3 could drive uncontrolled cell proliferation and survival as well as confer chemoresistance to the cytotoxic and targeted drug therapies by generating and maintaining cancer stem cells (CSC) or by up-regulating antiapoptotic related proteins such as Bcl-xL, Mcl-1, Bcl-2, and surviving proteins.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Furthermore, aberrantly activated STAT3 also contributes to cancer invasion and metastasis by inducing the expression of matrix metalloproteinases (MMPs, especially MMP-1, MMP-2, and MMP-9) and other STAT3 target genes.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Also, constitutively active STAT3 promotes tumor immune evasion through downregulating proinflammatory cytokines/chemokines that are necessary for antitumor immune responses and upregulating tumor/immunosuppressive factors such as VEGF, IL-10, PD1/PD-L1, and COX2 that suppress immune reactions.<a onclick="showRef(event, 'ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44">(42â44)</a> These findings support that aberrant STAT3 signaling has been frequently linked to cancer progression through multiple mechanisms. Accordingly, targeting the STAT3 protein is a potentially promising therapeutic strategy for the treatment of tumors.</div><div class="NLM_p last">These observations have spurred considerable efforts over the last two decades to clinically exploit the beneficial effects of suppressing STAT3 in human malignancies, and thus, a variety of approaches have been proposed, including RNA interference, small-molecule inhibitors modulating upstream regulators (such as JAKs and Src), activating/inducing the expression of negative modulators, and targeting STAT3 protein directly.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> RNA interference is still far from wide application in clinics, and modulation of upstream regulators may not block STAT3 completely arising from the cross-talk between many molecular pathways as well as may suffer from low selectivity of action. Consequently, the development of small-molecule inhibitors directly targeting STAT3 may represent a feasible method to hamper STAT3 functions. Herein, this Review focuses on direct inhibitors and their development over the last 5 years.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">4.  RECENT DEVELOPMENT OF STAT3 INHIBITORS</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71124" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71124" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The early identified STAT3 inhibitors are molecular probes including peptides, peptidomimetics, and oligonucleotides, which had been reviewed in the previous publications.<a onclick="showRef(event, 'ref2 ref17'); return false;" href="javascript:void(0);" class="ref ref2 ref17">(2,17)</a> Although they present feasible strategies to block STAT3, many challenges exist with these approaches such as limited stability, low affinity, cell permeability, and bioavailability. These factors certainly hinder their clinical development. Alternatively, peptides and oligonucleotides are easy to initiate host immunogenic reactions. Peptidomimetics are the first group of inhibitors to target STAT3, but none of them have entered into phase I clinical trial. Compared with molecular probes, nonpeptidic small molecules offer the advantages of good cell permeability, high physicochemical stability, and target specificity.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Therefore, more research efforts have turned to develop small-molecule inhibitors targeting STAT3 in recent years, and a few of them such as TTI-101, OPB-31121, and OPB-111077 have been advanced into clinical trials to treat tumors (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> below). Direct STAT3 inhibitors can be divided into different categories with respect to their mechanisms of action, including blockade of STAT3 phosphorylation, acetylation (such as resveratrol), dimerization, nuclear translocation, and STAT3 DNA-binding activity. According to their origin, STAT3 inhibitors can be classified as natural, semisynthetic, and synthetic, while on the basis of their binding sites, STAT3 inhibitors are also functionally categorized into four major subgroups: (1) N-terminal domain; (2) Cys and p-Tyr; (3) SH2 domain; (4) DNA binding domain.</div><div class="NLM_p">SH2 domain represents an important binding site for many nonpeptide molecules such as S3I-201, Stattic, and STA-21 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). As shown in the crystal structure of the STAT3: STAT3-DNA ternary complex in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, the SH2 domain protein surface contains three solvent-accessible subpockets that can be targeted by small-molecule STAT3 inhibitors. These subpockets include: (1) the phosphorylated Tyr705 (p-Tyr705)-binding pocket (labeled as pY subpocket, residues 591, 609â620); (2) the Leu706 subsite (labeled as pY+1 subpocket, residues 626â639); and (3) a hydrophobic side pocket (labeled as pY-X subpocket, residues 592â605). The pY subpocket is broadly composed of polar residues Lys591, Ser611, Glu612, Ser613, and Arg609, which can form hydrogen bonds and salt bridges with p-Tyr705 in the process of STAT3 homodimerization or heterodimerization with other members of the STAT family. In contrast to the pY subpocket, subpockets pY+1 and pY-X are predominantly nonpolar and hydrophobic. The pY+1 pocket, surrounded by Thr620, Trp623, Lys626, Gln635, Val637, and Ile659, is the most dynamic and difficult to target. The pY-X subpocket, composed of residues such as Glu594, Arg595, Ile597, and Ile634, is unique to STAT3 and may help to design selective STAT3 inhibitors. It should be noted that most STAT3 inhibitors usually occupy more than one subpocket. However, these three subpockets do not contribute equally to the binding affinity, of which pY subpocket is the most prominent one. A wide range of STAT3 inhibitors were therefore designed to target this subpocket.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of representative STAT3 inhibitors targeting SH2 or DBD domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although SH2-domain-targeted small molecules have been in the mainstream of research, disrupting the SH2 domain and thereby inhibiting STAT3 phosphorylation and dimerization may not completely suppress aberrant STAT3 signaling. Studies have shown that STAT3 may be involved in oncogenesis and transcriptional regulation in the absence of tyrosine phosphorylation, and unphosphorylated dimeric STAT3 can bind to DNA to realize its biological functionality.<a onclick="showRef(event, 'ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48">(45â48)</a> Thus, targeting the DNA-binding domain (DBD) of STAT3 may represent another effective approach to eliminating STAT3 signaling. Despite, targeting DNA-binding domains of transcription factors is challenging because of potentially limited selectivity (active DNA-binding sites are too shallow or too similar to allow small molecules tight and specific binding to the corresponding DBD), accumulating research has demonstrated that inhibition of STAT3 function by targeting its DBD is a practicable approach, with successful examples including C48, MMPP, inS3â54, and inS3â54A18 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51 ref52 ref53">(49â53)</a> In light of the importance of STAT3 dimerization and DNA-binding in the whole signaling pathway, an array of direct STAT3 inhibitors have been developed with the rationale to target the SH2 domain and/or the DNA binding domain. Instead, LD- and CCD-targeting compounds have rarely been reported.</div><div class="NLM_p">It is generally accepted that STAT3 is one of the critical promoters of malignant transformation and tumorigenesis, thereby providing a valid target for drug-targeted therapy. Research over the past two decades has developed many potent STAT3 small-molecule inhibitors that have been extensively covered in previous reviews: Debnath and co-workers summarized the progress in the discovery of STAT3 inhibitors from 2006 to 2012;<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Lai et al. summarized STAT inhibitors presented in patent literature between 2011 and 2015;<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Gelain et al. systematically reviewed the direct STAT3 inhibitors and their development over the past decade until early 2018;<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and Huang also provided a comprehensive review of noncovalent and covalent STAT3 inhibitors discovered in the past 5 years until 2019.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In this paper, we attempt to update the design and discovery of direct STAT3 small-molecule inhibitors/degraders published in 2015 to early 2021 organized by chemo-type.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">4.1.  BTP-Based Derivatives as STAT3 Inhibitors</h3><div class="NLM_p">The benzo [<i>b</i>]thiophene 1, 1-dioxide (BTP) is an important pharmacophore that occurs in diverse STAT3 inhibitors such as Stattic (<b>1</b>), HJC0123 (<b>2</b>), and HJC0146 (<b>3</b>) (structures shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Inhibitors with this moiety generally showed potent antiproliferative activity and apoptosis-inductive effects on tumor cells by repressing Tyr705 phosphorylation of STAT3 and promoting reactive oxygen species (ROS) production. Boengler et al. found that the stimulation of ROS formation by Stattic was associated with complex I (NADH:ubiquinone oxidoreductase) of the electron transport chain accompanied by the reduced mitochondrial ATP production.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Chemically, the vinyl sulfone group is essential for STAT3 inhibition through a covalent irreversible interaction. By analyzing the docking mode of BTP in STAT3 protein, Kong et al. found that its planar scaffold only occupied the essential p-Tyr705 binding site and formed three hydrogen bonds with residues Arg609, Ser611, and Ser613.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> To increase the binding affinity, the authors introduced substituted aromatic benzene rings linked by a secondary amine at the C6 or C7 position of BTP to fit the neighboring hydrophobic side pocket.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Among them, the most potent compound <b>4</b> impaired the growth of four cancer lines (MDA-MB-231, A549, MCF-7, and HCT-116) with IC<sub>50</sub> values ranging from 0.33 to 0.75 Î¼M, which had 1.5- to 12-fold improvement in activity than the STAT3-SH2 domain inhibitor Stattic. Meanwhile, it showed significant antitumor activity with tumor growth inhibition (TGI) of 61% at a dose of 10 mg/kg in 4T1 breast cancer xenograft mouse model, albeit with slightly less efficacious than doxorubicin at 1 mg/kg (TGI = 67%). Compound <b>4</b> markedly suppressed the overexpression and IL-6-induced phosphorylation of STAT3 as well as DNA-binding activity at 5 Î¼M, without influencing STAT3 upstream activators such as p-JAK2, p-Src, and p-Erk1/2. Also, this compound could induce tumor apoptosis by downregulating the expression of STAT3 downstream gene, Bcl-2, and increasing the levels of ROS. In silico docking calculations suggested that <b>4</b> was well fitted into the SH2 domain of STAT3 with its 7-substituted aniline deeply buried into the side binding pocket by forming four hydrogen bonds (Arg609, Lys591, and Ser636 residues) and two cation-Ï interactions (Lys591 and Arg609).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of BTP-based derivatives <b>1</b>â<b>4</b>. (Hydrogen bonds were shown as dashed lines and cation-Ï interactions were shown as green lines.) Adapted with permission from ref <a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a>. Copyright 2016 Elsevier Masson SAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In light of the bioactivity of curcumin (<b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) in inhibiting multiple oncogenic processes, including blockade of JAK2/STAT3 pathway and induction of ROS production, the Kong group further investigated a set of curcumin-BTP conjugates as STAT3 inhibitors with ROS production activity.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In their structures, the piperazine group was introduced as a central linker to improve metabolic stability. Of note, the most potent hybrid <b>6</b> exhibited remarkable antineoplastic activity and selectivity for MCF-7 cells with an IC<sub>50</sub> of 0.52 Î¼M as well as suppressed the growth of MDA-MB-231 xenograft tumors <i>in vivo</i> at an intraperitoneal dose of 10 mg/kg without noticeable toxicity. It can effectively downregulate IL-6-induced STAT3 phosphorylation and STAT3 specific oncogenes expression, as well as block STAT3-mediated DNA binding activity. Additionally, the promoted intracellular ROS accumulation induced by <b>6</b> contributed to cancer cell apoptosis and cell cycle arrest. Furthermore, this compound could effectively inhibit the growth of drug-resistant MCF-7/DOX cells with an IC<sub>50</sub> of 0.4 Î¼M by downregulating P-glycoprotein (P-gp) expression, a pivotal protein in mediating drug resistance in cancer.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Molecular docking study indicated that <b>6</b> tightly bound to the SH2 domain of STAT3 via forming three hydrogen bonds with residues Arg609, Lys626, and Gln635. Its piperazine linker provided a suitable length and angle for interacting with the two binding pockets (Leu706 and pY705 sites) of STAT3. More recently, 4-bromo substituted derivative <b>7</b>, a compound similar to <b>6</b> identified by the Liu group, also displayed strong inhibitory effects on the growth of breast cancer cells both <i>in vitro</i> and <i>in vivo</i> through blocking the STAT3 activation.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of BTP-based derivatives <b>6</b>â<b>8</b> as STAT3 inhibitors. Adapted with permission from ref <a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a>. Copyright 2019 Elsevier Masson SAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Similar to curcumin, coumarin is also an important bioactive pharmacophore for inhibiting STAT3. For example, the bioactive coumarin derivative osthole showed high anticancer efficacy in both cultured cells and triple-negative breast cancer (TNBC) xenografts by, at least in part, targeting STAT3.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Using the same strategy, the Kong group continued to synthesize a library of coumarin-benzo [<i>b</i>]thiophene 1, 1-dioxide derivatives as STAT3 mitochondria-targeting inhibitors by structural hybridization of BTP and coumarin derivative.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> In these structures, the fluorescent <i>N</i>,<i>N</i>-diethyl-7-aminocoumarin functions as a mitochondria-targeted theranostic probe, whose structure with delocalized lipophilic cation can permeate the living cell membranes and accumulate preferentially in the mitochondria of cancer cells to increase intracellular ROS and further trigger apoptosis and necrosis. All compounds displayed potent antiproliferative activity against cancer cells (MDA-MB-231, HCT-116, HepG2, and MCF-7) with single-digit micromolar potency. As the representative, compound <b>8</b> with a 4-bromo substitute on the BTP ring was predominantly accumulated in mitochondria visualized by its fluorescence and preferentially inactivated STAT3 phosphorylation at Tyr705 and Ser727 instead of affecting the phosphorylation levels of STAT1, JAK2, Src, and Erk1/2. Also, it can down-regulate the expression of STAT3 target genes Bcl-2 and cyclin D1, increase ROS production, and remarkably reduce the mitochondrial membrane potential to trigger the mitochondrial apoptotic pathway. Following-up <i>in vivo</i> studies on the antitumor efficacy demonstrated that 52.29% and 61.20% of breast cancer 4T1 tumor volumes were shrunk upon treatment with compound <b>8</b> at intraperitoneal doses of 10 mg/kg and 20 mg/kg, respectively. The analysis of molecular docking simulations showed that <b>8</b> tightly bound to the SH2 domain of STAT3 and occupied the native hot spot pTyr705 site and side pocket via forming four hydrogen bonds with residues Arg609, Lys591, and Arg595.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">4.2.  Sulfonamide Derivatives as STAT3 Inhibitors</h3><div class="NLM_p">As described above, the SH2 domain contains three critical subpockets able to bind small-molecule ligands. However, most reported STAT3 inhibitors can only bind two of them. With the intention of improving STAT3-binding affinity and inhibitory efficacy, some tripedal SH2 domain inhibitors are developed by occupying these three pockets simultaneously. Of note, the pentafluorophenyl sulfonamide derivative BP-1-102 (<b>9</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), discovered by the Turkson research group as an orally bioavailable STAT3 SH2 domain inhibitor in an earlier stage, has been regarded as the most promising one to be translated into clinical practice.<a onclick="showRef(event, 'ref3 ref62 ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref3 ref62 ref63 ref64 ref65">(3,62â65)</a> BP-1-102 binds STAT3 with a strong binding affinity (<i>K</i><sub>d</sub>) of 504 nM in the surface plasmon resonance (SPR) assay and inhibits STAT3 DNA-binding activity with the IC<sub>50</sub> of 6.8 Î¼M in the electrophoretic mobility shift assay (EMSA). It can selectively inhibit growth, survival, migration, and invasion of STAT3-dependent tumor cells as well as impair the tumor growth of human breast (MDA-MB-231) and nonsmall-cell lung (A549) cancer xenograft models.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Taking BP-1-102 as a starting point, subsequent lead optimization efforts have generated several appealing STAT3 inhibitors, such as hydroxamic acid-based analogue SH5-07 (<b>10</b>) and benzoic-based derivative SH4-54 (<b>11</b>), both of which showed notable improvements from BP-1-102 (IC<sub>50</sub>s of 4.7 and 3.9 Î¼M in the EMSA assay, respectively).<a onclick="showRef(event, 'ref63 ref66 ref67 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref63 ref66 ref67 ref68 ref69">(63,66â69)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structural modification of BP-1-102. Adapted with permission from ref <a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a>. Copyright 2018 Elsevier Masson SAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More recently, taking an iterative medicinal chemistry approach, the Turkson group optimized the <i>N</i>-methylglycinamide linker of BP-1-102 to further improve potency and physicochemical properties.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Substitution at the glycine methylene group with a methyl afforded alanine-based derivatives with a chiral center, and the R-configuration <b>12</b> moderately improved the STAT3 DNA-binding inhibitory activity with an IC<sub>50</sub> of 3.0 Î¼M (IC<sub>50</sub> of 6.8 Î¼M for BP-1-102), while a somewhat lower potency was observed for its S-enantiomer (IC<sub>50</sub> of 5.0 Î¼M). The expansion of substitutions at the methylene position consistently confirmed that R-configuration analogues were more potent than the corresponding S-isomers. Further modification at the benzoic acid moiety of <b>12</b> led to the discovery of 3-fluorine substituted derivative <b>13</b>, whose inhibitory potency against STAT3 DNA-binding activity was enhanced nearly 2-times compared with compound <b>12</b>, achieving an IC<sub>50</sub> of 1.8 Î¼M. Given that these alanine-based derivatives are more prone to metabolic <i>N</i>-demethylation, the Pro-linker compounds were designed to improve metabolic stability. Expectedly, the representative derivative <b>14</b> showed a comparable effect to that of alanine-based analogue <b>13</b> in inhibiting STAT3 DNA-binding activity (IC<sub>50</sub> of 2.4 Î¼M) but with much improved microsomal metabolic stability. These three compounds have also been reported to be capable of suppressing constitutive STAT3 phosphorylation in human breast cancer and melanoma cell lines and inhibiting tumor cell viability, growth, colony formation, and migration <i>in vitro</i>. Very recently, they have identified a more exciting new series of (<i>R</i>)-azetidine-2-carboxamide as potent STAT3 inhibitors by extending the proline-based analogues into other cyclic amino acids.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Elaboration of the amine moiety with different functionalities led to the discovery of many promising candidates. For example, compound <b>15</b> showed strong STAT3-inhibitory activity with IC<sub>50</sub> of 0.52 Î¼M, and its derivatives <b>16</b> and <b>17</b> profoundly inhibited cell growth (EC<sub>50</sub> values of 0.9â1.9 Î¼M toward MDA-MB-231 and MDA-MB-468 cells).</div><div class="NLM_p">Considering that STAT3 inhibitors contain sulfanilamide portion generally possessed excellent anticancer activity and STAT3 selectivity, using a structure-based drug design approach, Guo et al. designed a panel of sulfanilamide-based tripedal STAT3 inhibitors with an explicit goal of improving selectivity and drug-like properties of BP-1-102.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> As the most potent one, compound <b>18</b> not only inhibited the proliferation of HCT-116 cells (IC<sub>50</sub> of 6.66 Î¼M vs 15.05 Î¼M for BP-1-102) but also attenuated their colony formation potential and induced their apoptosis. Additionally, this compound could markedly suppress STAT3 phosphorylation in a dose-dependent manner, with little impact on the STAT1, STAT5, and Src phosphorylation. Moreover, compound <b>18</b> was efficacious in HCT-116 xenograft tumors, with 58.12% (v/v) inhibition of tumor growth at an intraperitoneal dose of 20 mg/kg, without significant body loss and toxicity. Molecular modeling studies on <b>18</b> showed its phenylsulfonamide fragment bond to pY subpocket via a hydrogen bond interaction with Arg609 residue, while the nonpolar perfluorophenyl and isopropylphenyl moieties occupied the hydrophobic pY-X and pY+1 subpockets, respectively.</div><div class="NLM_p">TTI-101 (<b>19</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), also known as C188-9, is an oral STAT3 inhibitor that is currently undergoing clinical trials (phase I).<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> More recently, the Ball research group synthesized and evaluated a series of TTI-101 analogues as STAT3 inhibitors.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> SPR analysis demonstrates the substituents at 1,2,4 positions of the naphthalene ring markedly affected molecular recognition of the inhibitor to STAT3. Among the entities, S-linked compound <b>20</b> bearing a perfluorinated phenyl ring showed a notable binding affinity in SPR-based assay, being 6-fold more potent than TTI-101 (IC<sub>50</sub> values of 0.7 and 4 Î¼M, respectively). In addition, dose-dependent decreases in STAT3 phosphorylation were observed for compound <b>20</b> against tested AML cell lines (HL-60, MOLM-13, and Kasumi-1) with IC<sub>50</sub> values between 0.8 and 1.9 Î¼M. The xenograft model of AML further validated its roles in decreasing tumor progression. At the same time, they explored an unconventional approach to targeting STAT3 by using rhodium-small-molecule conjugates. The Rh-naphthylsulfonamide conjugate <b>21</b> was much more potent than TTI-101 in STAT3 binding, phosphorylation inhibition, and apoptosis induction. Of particular note, it is generally considered that TTI-101 selectively binds to the SH2 domain of STAT3, thus preventing its tyrosine phosphorylation and homodimerization,<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> while this group found the hybrid sulfonamide-rhodium(II) conjugates bind to a site distinct from the SH2 domain. They directly bind near Phe174 in the CCD of STAT3, thus inhibiting the association between STAT3 and pY-peptide.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of sulfonamide derivatives as STAT3 inhibitors</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In light of the known correlation of microtubule-targeting molecules with blockade of the STAT3 protein, the Liou group examined a set of <i>N</i>-sulfonyl-aminobiaryl derivatives as multifunctional bioactive molecules based on the candidate drug ABT-751 (<b>22</b>), an antitubulin agent that is currently being tested in phase I clinical trial.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Some compounds exhibited robust anticancer activity, especially the cyano substituted compound <b>23</b>, which strongly inhibited the growth of four cancer cell lines (pancreatic AsPC-1, lung A549, liver Hep3B, and prostate PC-3) with a mean GI<sub>50</sub> value of 57.5 nM. Mechanically, it inhibits not only tubulin polymerization but also the phosphorylation of STAT3 with an IC<sub>50</sub> value of 0.2 Î¼M. SAR study suggested that the benzenesulfonamide moiety is critical for the anticancer activity, while the cyano substitution is crucial for blocking STAT3 phosphorylation. Similarly, starting from ABT-751, the Qiao group synthesized a series of <i>N</i>-arylsulfonyl substituted indole derivatives, and coincidentally, the representative compound <b>24</b> with dual capabilities of inhibiting the STAT3 and tubulin also bears a cyano substituent.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p last">Niclosamide (<b>25</b>) is an FDA-approved antihelminthic drug, but it has been found to possess STAT3 inhibitory activity.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Considering that âSO<sub>2</sub>NH<sub>2</sub> is a key group to interact with STAT3 (containing both a hydrogen bond donor and a hydrogen bond acceptor, widely occurred in many STAT3 inhibitors), Wang et al. introduced a hydrophilic âSO<sub>2</sub>NH<sub>2</sub> group to niclosamide to improve its aqueous solubility and bioavailability.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Replacement of the âCl with âSO<sub>2</sub>NH<sub>2</sub> resulted in compound NGT 02 (<b>26</b>), showing improved hydrophilicity but decreased antitumor activity. Further structural modifications of NGT 02 led to compound <b>27</b>, which was characterized as the most active one in this series, with IC<sub>50</sub> values of 0.61â1.11 Î¼M against STAT3-overexpressing MDA-MB-231, HCT-116, and SW480 tumor cell lines (slightly more active than niclosamide). It can effectively induce apoptosis and inhibit the migration of cancer cells by inhibiting STAT3 phosphorylation and its downstream gene expression. Furthermore, this compound showed better antitumor activity than niclosamide in suppressing the MDA-MB-231 xenograft tumor growth in nude mice (30 mg/kg, i.g.) because of the improved hydrophilicity and bioavailability.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">4.3.  Quinone Analogues as STAT3 Inhibitors</h3><div class="NLM_p">Quinone derivatives as STAT3 inhibitors have also been widely documented, and some of the early discovered ones have been summarized in the previous reviews.<a onclick="showRef(event, 'ref14 ref54'); return false;" href="javascript:void(0);" class="ref ref14 ref54">(14,54)</a> Therefore, an updated summary of the latest progress is given in the following section. Quinone derivatives (containing 1,4- or 1,2- fragment) are highly active electrophiles and attractive molecules because of their immense applications in biology and pharmacology. 1,4-Benzoquinone is the most simple skeleton in quinone derivatives with various biological activities. In recent times, Koseki and co-workers have identified compound <b>28</b> (BPMP, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) as an irreversible STAT3 inhibitor that can inhibit STAT3-dependent transcriptional activity in the luciferase reporter assay (IC<sub>50</sub> = 3.57 Î¼M) and significantly attenuate the proliferation of human breast cancer cell lines (MDA-MB-231 and MDA-MB-468) harboring constitutive STAT3 at 3 Î¼M.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Of particular note, the mechanism by which compound <b>28</b> inhibits STAT3 is distinct from that of many other STAT3 inhibitors targeting the SH2 domain and/or the DNA binding domain. This compound does not affect the Tyr705 and Ser727 phosphorylation and nuclear translocation using Western blot analysis, while it was able to selectively alkylate Cys550 within the linker domain (LD) through a Michael addition as determined by matrix-assisted laser desorption/ionization-mass spectrometry analysis. Thus, <b>28</b> was reported to be the first STAT3 LD inhibitor.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of quinone analogues <b>28</b>â<b>31</b> as STAT3 inhibitors. Adapted with permissions from refs <a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> and <a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a>. Copyright 2017 American Chemical Society and Copyright 2019 The British Pharmacological Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Derivatives of 1,4-naphthoquinone are widely used in medicine. Repurposing old drugs for new uses provides a promising strategy for the development of anticancer drugs. Using a gene expression-based approach, Xiang and colleagues recently discovered naphthoquinone-based derivative atovaquone (<b>29</b>), an antimicrobial approved by the FDA, as a potent STAT3 inhibitor.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> It can substantially downregulate the expression of critical survival and proliferation-related target genes including survivin, Bcl-2 family members, and cyclin D1 by blocking STAT3 tyrosine phosphorylation and transcriptional activity. As a result, atovaquone suppressed the viability of STAT3-dependent cancer cells (NA-6, U266, and HEL cell lines with STAT3 activation mediated by IL-6 production or JAK2-V617F mutation) at concentrations routinely attained in patients. Consistently, the oral administration of atovaquone at a dose of 200 mg/kg effectively inhibited tumor growth and prolonged survival in the U266 human multiple myeloma xenograft model.</div><div class="NLM_p">Taking advantage of advanced multiple ligand simultaneous docking, the Kong group discovered an orally available, potent, and selective STAT3 inhibitor <b>30</b> with favorable druggability.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> This compound directly and specifically targeted the STAT3 SH2 domain with a low <i>K</i><sub>i</sub> value of 440 nM in the fluorescence polarization (FP) assay without binding to STAT1/5 proteins. <b>30</b> selectively inhibited the proliferation of a human breast cancer cell line (MDA-MB-231) with an IC<sub>50</sub> value of 0.7 Î¼M, which was considerably lower than that in MCF-10A normal breast epithelial cells (IC<sub>50</sub> value of 128.9 Î¼M). In addition to its good safety profile, compound <b>30</b> had desirable aqueous solubility and oral bioavailability (44.7%). Furthermore, <b>30</b> significantly reduced the tumor growth in MDA-MB-231 and S180 xenograft models with 60% and 73% reductions in tumor weight, respectively, at the oral dose of 5 mg/kg. A molecular modeling study revealed that the sulfonamide group of compound <b>30</b> bound to pY705 site via hydrogen bond interactions with Arg609, Ser611, Ser612, and Ser613 residues, and its 8-ketone group of naphthoquinone moiety is also a major pharmacophore to interact with residues Arg609 and Lys591. Interestingly, by cyclization of the sulfonamide group in <b>30</b>, the Lai group found the resulting compound <b>31</b> to be a potential therapeutic drug candidate for colorectal cancer via directly and selectively binding to STAT3 and disrupting the signal conduction process.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> It showed promising anticancer properties in an <i>in vitro</i> study, and the <i>in vivo</i> anticancer efficacy was stronger than that of Stattic. Regrettably, it lacks taking compound <b>30</b> as a control in this study. Similar to <b>30</b>, the cyclization derivative <b>31</b> also fits the hot spots of SH2 in STAT3 protein very well. It can directly bind to the STAT3 as determined by microscale thermophoresis (MST) and biolayer interferometry (BLI) assays with <i>K</i><sub>d</sub> values of 3.3 and 4.1 Î¼M, respectively. Moreover, EMSA and luciferase assays showed this compound was capable of inhibiting DNA binding and transcriptional activity of STAT3, respectively.</div><div class="NLM_p">Plumbagin (PL, <b>32</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), a naturally occurring naphthoquinone isolated from <i>Plumbago zeylanica</i>, showed potential anticancer activity against breast cancer by inhibition of STAT3 phosphorylation.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> It shares a very similar structure with efficient STAT3-SH2 inhibitors (1,4-naphthoquinone core, like STA-21 and LLL-3) and extends into the pTyr705 pocket via forming a hydrogen bond with Ser611 and cation-Ï interaction with Lys591, but it could not interact with the side pocket. In order to increase the STAT3 binding affinity of PL, the Sun group introduced an aromatic ring in PL to enable new derivatives to embed in site pTyr705 and side pocket simultaneously.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> SARs revealed that the hydroxyl group at C-5 was crucial for the STAT3 inhibitory activity. Additionally, the introduction of additional groups to the aromatic ring and suitable linkers are also beneficial for the activity. Compound <b>33</b> was validated as the most potent one in this series, which was 2-fold more potent than PL when tested against three cancer cell lines (MDA-MB-231, HepG2, and A549). Also, it could suppress the phosphorylation of STAT3 along with the downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) and p-STAT1 expression. Consistent with their initial hypothesis, molecular docking studies confirmed <b>33</b> could bind to the SH2 domain of STAT3 tighter than PL (one hydrogen bond and two cation-Ï interactions).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of naphthoquinone analogues <b>32</b>â<b>36</b> as STAT3 inhibitors. Adapted with permissions from refs <a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> and <a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a>. Copyright 2020 Elsevier Inc. and Copyright 2017 Elsevier Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Shikonin (<b>34</b>, SHK) is a natural naphthoquinone derivative that has been identified to possess STAT3 inhibitory potency.<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> Through exploring its binding mode to STAT3, the Yang group found that SHK mainly occupied the pY-X and pY subpockets by forming hydrogen bonds with Lys591, Glu594, and Ile634.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Taking SHK as a starting point and employing a scaffold growth strategy, this research group obtained a set of shikonin derivatives by structural modification of its hydroxyl group on the side chain. In this series, the most efficient compound <b>35</b> selectively blocked constitutive STAT3 activation, transcriptional activity, nuclear translocation along with downstream target genes expression in the MDA-MB-231 cell line, and dose-dependently induced cell apoptosis. In agreement with high antiproliferative activity for MDA-MB-231 cells (IC<sub>50</sub> value of 1.81 Î¼M), this compound also displayed a notable antitumor activity in the MDA-MB-231 xenograft tumor model <i>in vivo</i> without obvious side effects. A similar modification of SHK led to the discovery of <b>36</b>, which also showed high antiproliferative activity against MDA-MB-231 cells with an IC<sub>50</sub> of 1.98 Î¼M.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> This anticancer effect was due partly to its ability in inhibiting constitutive/inducible STAT3 activation and suppressing STAT3 nuclear localization along with STAT3 downstream target gene expression levels. Predicted docking modes for these two compounds in the SH2 binding cavity of STAT3 are similar to its scaffold SHK.</div><div class="NLM_p">Aromatic ring-fused naphthoquinones as STAT3 blockers have also been investigated, with furanonaphthoquinones being of particular interest. Napabucasin (<b>37</b>, also known as BBI608, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), isolated and characterized in 1982 as a stemness inhibitor by targeting the STAT3 pathway, has been approved by the FDA as an orphan drug for the treatment of gastric/pancreas cancer in late 2016.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> Han et al. expanded its application field and found that it has great potential in glioblastoma therapy.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> It should be noted that napabucasin has been claimed to inhibit STAT3 by binding to its SH2 domain in many studies, but there is a lack of crystallographic evidence. Additionally, although molecular modeling study provides an important insight into the binding model between inhibitor and protein, Yesylevskyy et al. found all the studied 13 selective STAT3 inhibitors nonspecifically bind to nearly the whole protein surfaces of STAT3 and STAT1 using extensive molecular dynamics and ensemble docking simulations, which is far from what is observed experimentally.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Structural modifications toward napabucasin may represent a promising approach for seeking anticancer drugs. In silico study revealed that napabucasin could form two hydrogen bonds (with Arg609 and Arg595 residues) and cation-Ï interactions (with Ser636 and Lys591 residues). Its acetyl moiety protrudes toward the protein surface, and thus, structural modification of this group would not decrease its STAT3 binding affinity. Li et al. introduced hydrophilic groups such as piperidyl, pyrazinyl, and substituted amino groups to the acetyl group to enhance the physicochemical property of napabucasin, leading to the discovery of the 2-(piperidin-1-yl)ethylamino-group substituted derivative <b>38</b>, with enhanced aqueous solubility and the highest anticancer efficacy.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> It can significantly decrease the expression of total STAT3 and p-STAT3 Y<sup>705</sup> at a concentration of 200 nM, and SPR evaluation demonstrated its high binding affinity to STAT3 with a K<sub>d</sub> of 110.2 nM. Compared with napabucasin, <b>38</b> was 10-fold more potent in inhibiting the growth of U251, HepG2, HT29, and CT26 cells with IC<sub>50</sub> values of 0.22, 0.49, 0.07, and 0.14 Î¼M, respectively. Consistent with <i>in vitro</i> findings, orally administration with <b>38</b> (50 mg/kg) led to 63% tumor growth inhibition in the CT26 mouse tumor model. Molecular docking simulations showed that <b>38</b> was well-matched with the configuration of the SH2 domain of STAT3 and provided two extra hydrogen bonds (with Lys591 and Arg595 residues) compared with napabucasin. Similarly, Zhou et al. replaced the side-chain carbonyl in napabucasin with the nitrogen atom, represented by the most active compounds <b>39</b>â<b>41</b>.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> These three compounds inhibited the viability of human hepatocellular carcinoma HepG2 cells harboring constitutively activated STAT3 with IC<sub>50</sub> values of 1.9, 3.5, and 2.9 Î¼M, respectively, which were more potent than napabucasin (IC<sub>50</sub> value of 10.2 Î¼M), but they did not show high selectivity for normal liver L-02 cells, especially compound <b>39</b>.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of napabucasin-based derivatives <b>37</b>â<b>42</b>. Adapted with permissions from refs <a onclick="showRef(event, 'ref95 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref95 ref96 ref97">(95â97)</a>. Copyright 2018 Elsevier Masson SAS and Copyright 2020 Elsevier Masson SAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In contrast to the most modifications focusing on the acetyl group at 2-position of the furan ring, Feng et al. structurally modified napabucasin by cleaving the benzene ring and introducing diverse functional groups to reach the pY-X site to improve the STAT3 binding affinity, based on the binding mode that the 2-acetylfuran group was located at the pY705 site, while the important pY-X site stayed vacant.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Among these, the most potent compound <b>42</b> exhibited a comparable antiproliferative activity to napabucasin against the tested cancer cells (IC<sub>50</sub> values of 0.67, 0.77, and 1.24 Î¼M toward MDA-MB-231, MDA-MB-468, and HepG2 cells, respectively) by inactivation of STAT3 (Y705) along with subsequently reducing the expression of STAT3 downstream genes cyclin D1 and c-Myc. Compound <b>42</b> directly targeted the STAT3 SH2 domain with the IC<sub>50</sub> value of 5.18 Î¼M, as validated by the FP assay. Furthermore, treatment with <b>42</b> resulted in an obvious reduction of the tumor volume at an intraperitoneal dose of 10 mg/kg (TGI = 54.62%) without significant body-weight loss. As expected, molecular modeling simulations showed the <i>p</i>-methoxyphenyl in compound <b>42</b> was extended to the pY-X site, accompanied by the formation of two hydrogen bonds with Arg595 and Ile634.</div><div class="NLM_p">The angular isonapabucasin derivatives as the isomers of the linear napabucasin have also been reported to possess STAT3 inhibitory activity. Based on the structures of napabucasin and Î²-lapachone (<b>43</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), LÃ¶cken et al. synthesized isonapabucasin <b>44</b> and found it was twice as potent against the phosphorylation of STAT3 as napabucasin in the homogeneous time-resolved fluorescence (HTRF) assays (EC<sub>50</sub> values of 0.87 and 2 Î¼M, respectively), which was in accordance with the antiproliferative activity of both agents against MDA-MB-231 cells (IC<sub>50</sub> values of 0.74 and 2.1 Î¼M, respectively).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Consistent with the experimental results, the predicted binding mode of isonapabucasin in the SH2 domain is more beneficial for activity than napabucasin. Given the moderate STAT3 inhibitory activity and limited selectivity of cryptotanshinone (<b>45</b>), a bioactive component extracted from the root of traditional Chinese medicine <i>Salvia miltiorrhiza</i> Bunge, the Yu group chemically modified this molecule by using a structure-based drug design strategy and obtained two isonapabucasin derivatives <b>46</b> and <b>47</b> with enhanced activity.<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99,100)</a> Especially, <b>46</b> showed a high affinity for directly binding to STAT3 protein with <i>K</i><sub>d</sub> of 6.6 Î¼M as determined by BLI assay.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> As expected, it can strongly and selectively inhibit the growth of STAT3 overexpression CRC cell lines HCT-116 and RKO with IC<sub>50</sub> values of approximately 4 Î¼M, which had a 6-fold improvement in antiproliferative activity over cryptotanshinone. The mechanism of action studies of <b>46</b> indicated that it inhibited the activation of STAT3 at Tyr705 site, prevented its nuclear translocation, and downregulated its transcription activity, independent of upstream kinases. Colorectal cancer cell cycle arrest and apoptosis induced by <b>46</b> were also attributed to targeting STAT3. Moreover, the <i>in vivo</i> antineoplastic efficacy study showed that the weight of the implanted human colorectal tumor was significantly reduced after an oral administration of compound <b>46</b> at a dose of 5 mg/kg or 10 mg/kg for 25 days.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of angular isonapabucasin derivatives <b>43</b>â<b>47</b>. Adapted with permission from ref <a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a>. Copyright 2018 American Chemical Society and American Society of Pharmacognosy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to the above-mentioned furan-fused naphthoquinones, a few benzene- or heterocycle-ring fused quinones have been reported to possess STAT3 inhibitory activity (shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). The benzene-fused naphthoquinone (anthraquinone) derivative <b>48</b> was discovered as an inhibitor of STAT3 through a structure-based screen.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Compound <b>48</b> directly bound to STAT3 protein with the binding affinity of 4.59 Î¼M as determined by SPR and markedly inhibited the phosphorylation and transcriptional activity of STAT3, which contributes to its high growth inhibition against MDA-MB-468 breast cancer cells harboring persistently active STAT3. Unfortunately, this compound also inhibited the phosphorylation of STAT1 and STAT5. In another study, Chen and colleagues synthesized a series of isothiazole-fused quinones as NQO1 (NAD(P)H: quinone oxidoreductase-1) substrates and STAT3 inhibitors. They observed that isothiazoloquinolinoquinones generally inhibited cancer cell growth effectively with IC<sub>50</sub> values in the nanomolar range.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Annexin V-FITC/PI staining assay was performed with isothiazoloquinolinoquinone <b>49</b> as a representative example. Consistent with its antiproliferative potency, compound <b>49</b> could effectively induce A549 cell apoptosis in a dose-dependent manner, being 2.5-fold stronger than that of napabucasin. The anticancer effect was found to be a result of the higher amount of ROS through NQO1-directed redox cycling and stronger inhibition of p-STAT3 in comparison to napabucasin. However, similar to napabucasin, it showed low selectivity between cancer and normal cells.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of benzene- or heterocycle-ring fused quinones analogues <b>48</b>â<b>50</b> as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Oximation of naphthoquinone provided an additional approach to structural modification. Catabolism of tryptophan to kynurenine by IDO, a heme-containing oxidoreductase, is widely considered as one of the most critical mechanisms evolved by tumors to escape immune surveillance, whereas inhibition of IDO could effectively stimulate antitumor immunity.<a onclick="showRef(event, 'ref103 ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref103 ref104 ref105">(103â105)</a> In light of the crucial roles of IDO and STA3 in cancer development, Huang and co-workers designed a diverse library of naphthoquinone derivatives as dual inhibitors of indoleamine-2,3-dioxygenase 1 (IDO1) and STAT3 based on the multiple pharmacological activities of naphthoquinone skeleton.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Among these, the oxime derivative <b>50</b> was found to be the most active one with equilibrium dissociation constants (<i>K</i><sub>d</sub>) of 0.08 and 0.53 Î¼M for IDO1 and STAT3, respectively, as evaluated by the SPR assay. Compound <b>50</b> showed potent cytotoxicity against HCT-116, SKOV3, A549, and HepG2 cancer cells with IC<sub>50</sub> values at double-digit nanomole concentrations. Remarkably, compound <b>50</b> decreased tumor growth to a significant extent in both immunocompetent and nude mice. Structurally, its quinone oxime fragment was critical for IDO1 inhibition, and the oxime oxygen functioned as the heme iron-binding group.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">4.4.  Flavonoids and Their Analogues as STAT3 Inhibitors</h3><div class="NLM_p">Flavonoids are a large class of therapeutically important phenolic derivatives including flavones, flavonols, flavanones, chalcones, isoflavones, and flavanols.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Research related to flavonoids has received great attention because of their multiple biological functions and low toxicity.<a onclick="showRef(event, 'ref58 ref107 ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref58 ref107 ref108 ref109">(58,107â109)</a> The underlying mechanism by which a wide range of naturally occurring flavonoids exert anticancer activity have not been fully elucidated yet, but recent studies have shown that the cytotoxic effects of some naturally occurring flavonoids at least arise from the disturbance of STAT3 pathway, as depicted in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. Combining experimental and computational approaches, Verdura and co-workers first established that the flavonolignan silibinin (<b>51</b>) is a direct STAT3 inhibitor by binding to both the SH2 domain and the DNA-binding domain, thereby impeding the activation, dimerization, nuclear translocation, DNA binding, and transcriptional activity of STAT3.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Similarly, apigenin (<b>52</b>) was found to dose-dependently inhibit the phosphorylation of STAT3 at the Tyr705 site, in parallel with the inhibition of STAT3 nuclear localization and transcriptional activity, contributing to its antimetastasis effect on melanoma cells.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Kim et al. confirmed the anticancer effect of morusin (<b>53</b>) on pancreatic tumor cells was partially ascribed to the specific inhibition of constitutive STAT3 activation both at Tyr705 and Ser727 sites.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> By inhibition of the phosphorylation and translocation of STAT3, Yue et al. also noted 2â²-hydroxyflavanone (2HF, <b>54</b>) could enhance pancreatic cancer cell chemosensitivity.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> It should be noted that the majority of natural flavonoids are not direct STAT3 inhibitors such as geranylnaringenin, icariin, and pectolinarigenin, but they inhibited STAT3 activation through attenuating upstream kinases (JAK-1/2, and c-Src), or restoring the expression of STAT3-negative mediator SHP-1/2.<a onclick="showRef(event, 'ref114 ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref114 ref115 ref116">(114â116)</a> Conversely, flavonoid analogues have widely reported as STAT3 inhibitors, especially chalcone derivatives.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures of naturally occurring flavonoids <b>51</b>â<b>54</b> as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The high degree of homology between STAT family members may provide an approach for developing STAT3 inhibitors. With this in mind, Lis and colleagues synthesized a series of chromone-based acylhydrazones as STAT3 inhibitors by incorporating various substitutions at the 6-position and by varying the terminal benzene ring of the most potent STAT5 inhibitor <b>55</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), whose structure bears a chromone scaffold that is presented in the flavones and isoflavones.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Notably, the introduction of a <i>tert</i>-butyl to the 6-position of chromone (compound <b>56</b>) led to an 8-fold increase in STAT3 inhibitory potency accompanied by a great loss in activity against STAT5 in the FP-based competitive binding assay compared to the original hit <b>55</b>, being the most active and selective STAT3 inhibitor in this class. This observation was explained by molecular modeling that the <i>tert</i>-butyl group occupied a hydrophobic pocket formed by Pro639, Glu612, and Ser613. In addition, compound <b>56</b> identically increased the apoptotic rate of parental HCC-827 cells and erlotinib-resistant HCC-827 cells by inhibiting STAT3 Tyr705 phosphorylation.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures of flavonoid derivatives <b>55</b>â<b>61</b> as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As we all know, the Î±,Î²-unsaturated carbonyl unit in the chalcone skeleton provides the basis for the reaction of a Michael acceptor with a nucleophile that may participate in a wide spectrum of biological activities. This was well supported by the study of Kim et al., in which the enone derivative <b>57</b> showed promising STAT3 inhibitory activity, while the variation of the Î±, Î²-unsaturated carbonyl moiety led to a complete loss of STAT3 inhibitory activity.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> As a result, <b>57</b> showed selective viability suppression in H-ras transformed MCF10A-ras and MDA-MB-231 human breast cell lines harboring constitutively active STAT3 by selective inhibition of STAT3 phosphorylation. Subsequently, the authors expanded the structural diversity of <b>57</b> and developed a more active compound <b>58</b>, being approximately 3-fold higher growth inhibitory activity than parent <b>57</b> in MBA-MB-231 cells.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Additional biochemical analyses also suggested a higher STAT3 inhibitory potency of <b>58</b> in comparison with <b>57</b>. Consistent with the <i>in vitro</i> results, an <i>in vivo</i> xenograft nude mouse model study further confirmed the finding that <b>46</b> had more potent antitumor activity than <b>57</b> (TGI of 60.2% and 56.9%, respectively, at 10 mg/kg), but it was slightly less potent than paclitaxel (5 mg/kg). Molecular docking studies showed <b>58</b> has the potential to covalently bind to STAT3, as the Michael acceptor of <b>58</b> was very close to the Michael donor of Cys259 in the CCD domain of STAT3 protein (3.4 Ã).</div><div class="NLM_p">Application of 3D shape- and electrostatic-based drug design approach in combination with a ligand-based virtual screening of the Specs chemical library, Huang et al. identified an Î±,Î²-unsaturated carbonyl linked derivative <b>61</b> as a new STAT3 inhibitor, based on the pharmacophore of DBD targeted STAT3 inhibitors inS3â54 (<b>59</b>) and inS3â54A18 (<b>60</b>).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Compound <b>61</b> decreased the viability of H1299 cells with an IC<sub>50</sub> of 8.1 Î¼M and inhibited STAT3 binding to the DNA domain with a <i>K</i><sub>i</sub> value of 3.92 Î¼M as determined by an MST-based assay. Also, compound <b>61</b> suppressed the growth of cisplatin-resistant ovarian cancer cells (SKOV3/DDP) with an IC<sub>50</sub> of 14.7 Î¼M by targeting STAT3.</div><div class="NLM_p">Curcumin (<b>5</b>), a naturally occurring bis-chalcone derivative, was isolated from the powdered root of <i>Curcuma longa</i> L. and exerts anticancer effects through regulation of various intracellular signaling pathways and proteinâprotein interactions including inhibition of JAK/STAT signaling.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> The Surh group has recently investigated the mechanism of the inactivation of STAT3 by curcumin and found that this compound can covalently bind to Cys259 of STAT3 as confirmed by multiple chemical biological approaches.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> However, owing to its poor bioavailability and low potency, structural modification of curcumin is needed, and some of the successful examples mainly focused on cyclization of the Î²-diketone linker such as compounds <b>62</b> and <b>63</b> (HO-3867, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124,125)</a> Compared with curcumin, these compounds showed an enhanced inhibitory activity against STAT3. Recently, Ji et al. synthesized a series of HO-3867 derivatives as anticancer agents based on the bioisosterism principle of rational drug design.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The presentative compound <b>64</b> potently suppressed the survival of MDA-MB-231, DU145, and A549 cancer cell lines with IC<sub>50</sub> values below 2 Î¼M, which were dozens of times lower than that of curcumin. The direct binding of <b>64</b> to STAT3 was confirmed by SPR assay with a <i>K</i><sub>d</sub> of 7.93 Î¼M, and a complete inhibition of Tyr705 phosphorylation was observed at 4 Î¼M using Western blot assays. In silico molecular modeling analysis showed that <b>64</b> inhibited STAT3 by simultaneously targeting the binding pocket composed of the p-Tyr705 site, Leu706 site, and a side pocket in the SH2 domain.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of flavonoid analogues <b>62</b>â<b>64</b> as STAT3 inhibitors. Adapted with permission from ref <a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a>. Copyright 2016 Elsevier Ltd.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">4.5.  Terpenes as STAT3 Inhibitors</h3><div class="NLM_p">Natural products have represented an important source for the identification of novel drug leads. Like the above-mentioned flavonoids, naturally occurring terpenes also possess a broad range of pharmacological properties such as antimicrobial, anti-inflammatory, and antitumor activities.<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127,128)</a> Wei et al. screened cytotoxic constituents from <i>Brucea javanica</i> and found bruceantinol (<b>65</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) having potent antiproliferative activity against human colorectal CRC cells at low nanomolar concentrations.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Mechanistic studies showed that the bruceantinol-mediated anticancer effect was accompanied by remarkable inhibition of STAT3-DNA binding activity, with the IC<sub>50</sub> value of 2.4 pM in an EMSA analysis. Consistent with the results <i>in vitro</i>, at the end of bruceantinol treatment, the tumor volume was decreased by 54% in the HCT-116 xenograft model, which was 3-fold more potent than in the STAT3-knockout group. The potential of <i>Tinospora crispa</i> extracts as STAT3 inhibitors has also been reported.<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130,131)</a> The Rahman group found Crispene E (<b>66</b>) inhibited STAT3 dimerization in a cell-free FP assay with an IC<sub>50</sub> of 10.27 Î¼M, thereby selectively decreasing the viability of STAT3-dependent MDA-MB 231 breast cancer cell line with an IC<sub>50</sub> of 5.35 Î¼M.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Furthermore, Crispene E downregulated the expression of STAT3 and STAT3 target genes cyclin D1, Fascin, and Bcl-2. Molecular docking calculations suggested that Crispene E has a greater affinity to the SH2 domain compared with that to the DNA binding domain of STAT3. Subsequently, this research group identified another two structurally related furanoid diterpenes crispene F (<b>67</b>) and crispene G (<b>68</b>) from <i>Tinospora crispa</i> as STAT3 inhibitors.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Although these two compounds were notably less active in both the FP assay (IC<sub>50</sub> values of 42 and 17 Î¼M, respectively) and the MTT cytotoxicity assay (IC<sub>50</sub> values of 10 and 7.8 Î¼M against MDA-MB-231 cells) as compared to crispene E, they provided a chemical scaffold for further modification because of their highly selective toxicity against tumor cells.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures of terpenes as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The fungal metabolite galiellalactone (<b>69</b>) has been reported to be an efficacious and specific inhibitor of STAT3 by covalently binding with the cysteine residues in STAT3, thereby preventing the binding to DNA.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> To gain insight into the systematic structureâactivity information on galiellalactone and to develop specific STAT3 inhibitors with cytotoxic activities against TNBC cells, Kim et al. focused on structural modification at the C4, C5, or C5a position of the tricyclic lactone skeleton in galiellalactone and the cyclohexene-truncated bicyclic system.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The results showed that the cyclohexene moiety of galiellalactone is unnecessary for its cytotoxicity as the inhibition of STAT3. Interestingly, the cyclohexene-truncated [3.3] bicyclic lactones were more potent than the parent galiellalactone, represented by exo-olefin derivatives <b>70</b> and <b>71</b>. They exerted cytotoxicity against three TNBC cell lines (MDA-MB-468, MDA-MB-231, and BT-549) with IC<sub>50</sub> values within 6.61 to 12.14 Î¼M by specifically inhibiting STAT3 phosphorylation at the Tyr705 residue (different from galiellalactone, which does not affect the phosphorylation of STAT3 but prevents DNA binding). These findings may be related to the reduced steric hindrance in the interaction with the cysteine in STAT3. Similarly, isoalantolactone (<b>72</b>) is also an exo-olefin terpene derivative that was identified to selectively inhibit the growth of cancer cells <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref134 ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref134 ref135 ref136">(134â136)</a> The molecular mechanism was associated with the induction of endoplasmic reticulum stress and blockade of STAT3.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> It can markedly suppress STAT3 phosphorylation at Tyr705 at 10 Î¼M, but whether this effect is conferred by covalent interaction is not clear yet.</div><div class="NLM_p">Although galiellalactone possesses good solubility and permeability as well as moderate plasma and hepatocyte stability, it has very low plasma exposure following oral administration. In an effort to protect galiellalactone from the initial conjugation with glutathione in the intestinal membrane, the Johansson group developed orally bioavailable prodrugs of cysteine reactive sesquiterpene lactones based on the observation that the addition of cysteine to galiellalactone is reversible.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> As expected, the plasma exposure of galiellalactone in mice was significantly increased up to 20-fold by oral administration of the <i>N</i>-acetyl cysteine methyl ester conjugate <b>73</b> compared to when galiellalactone was dosed orally. Consistently, galiellalactone significantly reduced tumor growth in the DU145 xenograft model.</div><div class="NLM_p last">Similar to the mechanism of galiellalactone, the thiazole-fused oridonin analogue <b>74</b> strongly inhibited the growth of multiple cancer cell lines via directly and covalently binding to Cys542 in the linker domain of STAT3, thereby allosterically disturbing the function of the SH2 domain and the activity of STAT3.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Herein, an additional nitrogen-containing side chain was introduced to result in an improved anticancer potency and aqueous solubility as compared with oridonin.<a onclick="showRef(event, 'ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref138 ref139">(138,139)</a> It should be noted that not all the Î±,Î²-unsaturated moieties in terpenes are the major contributor for STAT3 inhibition. For example, hirsutinolide derivatives <b>75</b> and <b>76</b> strongly inhibited STAT3:STAT3/DNA complexation via binding to its DBD and effectively inhibited glioma patientsâ tumor-derived cells harboring constitutively active STAT3, but these results could not be explained by a weak alkylation of STAT3 by Michael addition to Î±, Î²-unsaturated carbonyl groups in <b>75</b> and <b>76</b>.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">4.6.  Other Heterocyclic Compounds as STAT3 Inhibitors</h3><div class="NLM_p">Aromatic heterocyclic moieties like pyrimidine, quinazoline, quinoline, and azole heterocycles frequently occur in numerous chemicals and are associated with various bioactivities including anticancer properties. These heterocycles possess significant dipole moments that are capable of forming favorable hydrogen bonds to biomacromolecules.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Pyrimidine and pyrimidine-like derivatives are mostly known as kinase inhibitors, but they can also act as inhibitors of the STAT3-associated pathway (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Lamie et al. designed a series of 2-thiopyrimidine/chalcone hybrids and found compounds <b>77</b> and <b>78</b> showed remarkable inhibitory activity against STAT3 with IC<sub>50</sub>s of 160 and 113 Î¼M, respectively, especially <b>78</b> had an additional inhibitory effect on STAT5a, with IC<sub>50</sub> of 50.75 Î¼M.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> At the cellular level, these two compounds significantly attenuated the growth of K562 cells with IC<sub>50</sub>s of 0.77 and 1.05 Î¼M, respectively. Quinazolines (benzocondensed pyrimidines) are important skeletons in the field of medicinal chemistry and have also been developed as STAT3 inhibitors. Jamroskovic et al. synthesized a series of quinazoline analogues and found two compounds <b>79</b> and <b>80</b> interfered with STAT3 phosphorylation by directly binding to STAT3 protein with <i>K</i><sub>d</sub> values of 45 and 15.5 Î¼M, respectively, as determined by SPR analysis.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Apart from selective inhibition of STAT3, they can stabilize G-quadruplex (G4) DNA structures.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of pyrimidine derivatives <b>77</b>â<b>82</b> as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Purine derivative S3I-V4-01 (<b>81</b>) was previously reported by the Turkson group to have high affinity binding to STAT3 (<i>K</i><sub>d</sub> < 10 Î¼M), but it has poor antiproliferative activity (IC<sub>50</sub> of 82.4 Î¼M against MDA-MB-231 cells).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Based on this observation, Wang et al. designed a novel series of 2,6-disubstituted purine derivatives by removal of the <i>N</i><sup>9</sup>-carboxymethyl group of S3I-V4-01 for providing an extra hydrogen bond with Glu594 of STAT3.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Replacement of the morpholine and cyclohexane rings with various substituents led to the discovery of compound <b>82</b>, which showed prominent antiproliferative activity against HCT-116, SW480, and MDA-MB-231 cancer cell lines with IC<sub>50</sub> values of 1.77, 1.51, and 1.25 Î¼M, respectively, being approximately 20-fold more potent than S3I-V4-01. The subsequent biological assays unveiled that <b>82</b> effectively inhibited the phosphorylation of STAT3 without an obvious effect on upstream tyrosine kinases or STAT1 phosphorylation. Consistent with <i>in vitro</i> studies, intraperitoneal administration with <b>82</b> (30 mg/kg) resulted in a 47.8% reduction in tumor weight in the MDA-MB-231 xenograft model.</div><div class="NLM_p">The quinoline derivative STX-0119 (<b>83</b>, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) was found by the Asai group as a STAT3 dimerization inhibitor using a virtual screening method, whose pleiotropic anticancer effects have been demonstrated in diverse malignancies including Temozolomide-resistant glioblastoma cell line.<a onclick="showRef(event, 'ref144 ref145 ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref144 ref145 ref146 ref147">(144â147)</a> Recently, this research group has structurally optimized STX-0119 and identified a quinolinecarboxamide derivative YHO-1701 (structure not disclosed yet), which is more potent than STX-0119 in biochemical assays.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Consistently, YHO-1701 could insert into the hydrophobic cleft more deeply than that of STX-0119, as its docked position in the SH2 domain changed downward. Through inhibiting STAT3 dimerization, YHO-1701 exerted strong antiproliferative activity against a panel of human cancer cell lines addicted to STAT3 signaling, in particular for human oral cancer cell line SAS with an IC<sub>50</sub> of 0.7 Î¼M. Also, it showed statistically significant antitumor activity in the SAS xenograft model with long exposure to high levels of YHO-1701 (60 mg/kg), while combination with sorafenib led to significantly stronger antitumor activity. Very recently, they have further confirmed the synergistic effect of YHO-1701 with mechanistically different targeted agents.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures of quinoline derivatives <b>83</b>â<b>85</b> as STAT3 inhibitors. Adapted with permissions from refs <a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> and <a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a>. Copyright 2019 Elsevier Masson SAS and Copyright 2020 The Authors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on the structure of STX-0119, Kaoud et al. synthesized a series of substituted quinoline-1,2,4-triazole/oxime hybrids, hypothesizing that the oxime-based NO donor to augment its STAT3 inhibitory properties with the cytotoxic release of NO.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> In line with expectation, the oximes displayed an increase in the activity against most of the cancer cell lines tested, especially compounds <b>84</b> and <b>85</b>, whose IC<sub>50</sub>s were 7.7 and 1.9 Î¼M, respectively, compared with 16.2 Î¼M of STX-0119 toward the melanoma A375 cell line. More importantly, these two compounds showed significant cell growth inhibition and apoptosis induction in BRAF inhibitor-sensitive and resistant melanoma cell lines containing a BRAF V600E mutation. Their antitumorigenic effects were closely correlated with both STAT3 inhibition and NO releasing. They directly bond to the SH2 domain with IC<sub>50</sub> values of 0.32 and 0.25 Î¼M, respectively, as determined by displacement assay, and abrogated STAT3 tyrosine phosphorylation in several cancer cell lines, including the BRAF V600E mutant A375 cell line without affecting upstream kinases or other STAT isoforms. Structurally, the âOH group in the oxime moiety formed a hydrogen bond with the residue Arg595, and their 2-phenyl rings were extended into the hydrophobic cleft formed by Ile634, Val637, Pro639, and Thr632.</div><div class="NLM_p">As shown above, the oxadiazole ring in STX-0119 emerged as a key molecular feature for STAT3 inhibition.<a onclick="showRef(event, 'ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref150 ref151">(150,151)</a> Using structure-based computational database screening coupled to cell-based high-throughput screening, Kim et al. also discovered oxadiazole-based ODZ10117 (<b>86</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) as a specific STAT3 inhibitor.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> In comparison with the known STAT3 inhibitors S3I-201, STA-21, and nifuroxazide, ODZ10117 has a greater inhibition on STAT3 activation via directly blocking the SH2 domain of STAT3 and thereafter suppressing its homodimerization and transcriptional activity, which mediated its diverse anticancer effects against breast cancer cells including apoptosis induction as well as reduction of migration and invasion. Furthermore, ODZ10117 significantly reduced tumor growth and lung metastasis in BALB/c mice bearing MDA-MB-231 xenograft tumors at an intratumoral injection dose of 10 mg/kg. Subsequently, the authors further expanded the therapeutic efficacy of ODZ10117 in glioblastoma by targeting STAT3.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Similarly, Khanam et al. identified a 1,3,4-oxadiazole derivative <b>87</b> as a STAT3 inhibitor by screening their previously synthesized compounds.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> AlphaScree-based assays revealed <b>87</b> strongly interacted with the SH2 domain and exhibited significant activity against STAT3 (74.12% of inhibition at 60 Î¼g/mL concentration). Apart from diazole, triazolo and tetrazole have also been considered as critical moieties for STAT3 inhibitors.<a onclick="showRef(event, 'ref154 ref155'); return false;" href="javascript:void(0);" class="ref ref154 ref155">(154,155)</a> For instance, Pallandre and co-workers identified aminotetrazole derivative <b>88</b> as an efficient STAT3 inhibitor by combining a structure-based virtual screening approach with medicinal chemistry optimization.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> This compound specifically targeted STAT3 monomers to prevent its dimerization and transcriptional activity with an IC<sub>50</sub> of 25.7 Î¼M. SAR study revealed that the planar and hydrophilic aminotetrazole group is essential for modulating STAT1 and STAT3 inhibitory activities.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures of some other aromatic heterocyclic derivatives as STAT3 inhibitors</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Not only do these aromatic heterocycles play prominent roles in direct interacting with STAT3, but, in addition, they are known to form metal chelate complexes. In view of the roles of the oxadiazole ring in STAT3 inhibitory activity and platinum compounds in interfering with DNA replication, Porta et al. designed three 1,2,5-oxadiazole Pt(II) complex with an aim to enhance therapeutic benefits by simultaneously interacting with DNA and interrupting STAT3 signaling.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Among which, only compound <b>89</b> possessed such dual functions. It showed a stronger STAT3 inhibitory activity with an IC<sub>50</sub> of 1.4 Î¼M in the AphaScreen-based assay, but it was evidenced to have no obvious impact on the STAT3 tyrosine phosphorylation state. Meanwhile, <b>89</b> exhibited increased cytotoxicity on colorectal cancer HCT-116 cells with an IC<sub>50</sub> value of 18.4, being about 5 times more effective than the uncoordinated ligand. The <i>in vivo</i> tumor growth inhibition of 85.2% (i.p., 30 mg/kg) was observed for <b>89</b> in Lewis lung carcinoma (LLC) implanted C57BL mice, but it is slightly less potent than the reference cisplatin (TGI of 87.5 at i.p. doses of 1.5 mg/kg). In a similar study reported by Kang et al., they conjugated benzofuran motif with organometallic compounds, with the goal of generating a dual inhibitor of STAT3 and NF-ÎºB for prostate cancer treatment.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Among which, the iridium(III) complex <b>90</b> could engage STAT3 and NF-ÎºB directly and affect their downstream proteins. It exhibited the highest ability to inhibit IL-6-induced STAT3-driven luciferase activity, with 50% inhibition at 3 Î¼M, which is more potent than the known STAT3 inhibitor S3I-201. Compound <b>90</b> blocked the DNA-binding activity of STAT3 with an IC<sub>50</sub> value of 12.2 Î¼M in the enzyme-linked immunosorbent assay (ELISA) assay. Further, the tumor growth inhibition in a prostate cancer xenograft mouse model was up to 75% after intraperitoneal injection of complex <b>90</b> at 15 mg/kg daily for 10 days.</div><div class="NLM_p">On the basis of the structures and molecular docking of napabucasin and benzo[b]thiophene 1,1-dioxide derivative <b>91</b>, Wang et al. designed a series of 2-acetyl-7-phenylamino benzofuran analogues to occupy both the pY705 site and side pocket simultaneously by using scaffold fusion strategy.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Among them, compound <b>92</b> exhibited the most potent antiproliferative activities against MDA-MB-468 cells, which was better than napabucasin (IC<sub>50</sub> values of 0.16 and 1.14 Î¼M, respectively). Also, our research group found a natural dihydrobenzofuran derivative <b>93</b> that displayed cytotoxicities against gastric cancer cell lines (HGC27, MGC803, BGC823, and AGS), which may be due to its inhibitory effect on STAT3 phosphorylation.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Through molecular docking-based virtual screening and structural optimization, Gao et al. characterized benzothiazole derivative <b>94</b> as a potent STAT3 inhibitor, which can potently block the IL-6/STAT3 signaling pathway with an IC<sub>50</sub> value of 0.067 Î¼M.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Simultaneously, it has excellent antiproliferative activity against MDA-MB-468 and JAK2 mutant HEL cell lines with IC<sub>50</sub> values of 0.25 and 1.11 Î¼M, respectively.</div><div class="NLM_p last">Although no inhibitor that directly targets STAT3 has yet been approved by the FDA for clinical use, the underlying mechanisms of some anticancer drugs may be associated, at least in part, with their inhibitory effect on the STAT3. The marketed drug bendamustine (<b>95</b>) is an alkylating agent that suppresses the growth of cancer cells by binding to DNA and interfering with replication. Compared with conventional 2-chloroethylamine alkylating, the benzimidazole ring structure in bendamustine may contribute to its unique antitumor activity.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Asai et al. investigated the mechanism of action underlying its excellent clinical efficacy and found it bound tightly to cellular STAT3 in the biotinylated bendamustine-based pull-down assay.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> The AlphaScreen-based assays further demonstrated that bendamustine selectively and covalently antagonized STAT3-SH2, inhibiting the interaction of the SH2 domain with the phosphorpeptide. Pyrimethamine, an FDA-approved antimicrobial drug was identified as an inhibitor of STAT3 transcriptional function through a mechanistic-based screen.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Unlike STAT3 phosphorylation inhibitors and STAT3 SH2 domain inhibitors that disrupt STAT3 phosphorylation, nuclear translocation, or DNA binding, pyrimethamine exerts its STAT3-inhibitory effect via targeting dihydrofolate reductase.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Pyrimethamine is currently in phase I/II clinical trials as a standalone agent for the treatment of relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma (NCT01066663).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">4.7.  Summary of the Interactions between Inhibitors and STAT3</h3><div class="NLM_p">At the cellular level, most of the above-mentioned inhibitors exhibited strong inhibitory activity against human cancer cells that harbor constitutive STAT3 activation. Various types of human cancer cell lines with constitutively activated STAT3 include but not limited to MDA-MB-231, MDA-MB-468, HCT-116, SW480, RKO, HepG2, HDLM-2, L540, K562, KCL22, LAMA84, DU145, SKOV3, PANC-1, A549, NCI-H460, SW620, MKN-45, and A431. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, STAT3 inhibitors exerted their functions by inhibiting STAT3 phosphorylation, binding to the SH2 domain, directly disrupting STAT3-DNA binding, or inhibiting STAT3 transcriptional activity as determined by several <i>in vitro</i> assays including EMSA, MST, ELISA, SPR, FP, MST, BLI, luciferase assay, HTRF, and AlphaScreen at the molecular level. In light of opposite roles played by STAT3 and STAT1 in cancer progression, many of these compounds were proven to be selective STAT3 inhibitors with slight or no inhibitory effect on STAT1.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Compounds That Were Involved in <i>In Vitro</i> Assays of STAT3<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0021.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0022.gif" alt="" id="GRAPHIC-d7e1946-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0023.gif" alt="" id="GRAPHIC-d7e1947-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0024.gif" alt="" id="GRAPHIC-d7e1948-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Note: ND: Not detected; Low: Inhibitory effect on STAT1; Moderate: Little inhibitory effect on STAT1; High: No inhibitory effect on STAT1).</p></div></div><div></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">5.  PROTACs AS STAT3 DEGRADERS</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Strategies on oncotherapy using drugs include biological agents and small molecules to block the activity of oncogenic proteins. Currently, substantial efforts have been employed to develop new strategies for inducing protein degradation. One promising technology is proteolysis targeting chimeras (PROTACs) technology, which has emerged as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-related protein.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Typical PROTACs are heterobifunctional molecules that consist of three essential components: a ligand for binding the protein of interest (POI), a second ligand for binding to and recruiting an E3 ligase degradation complex, and a linker tethering the two ligands together. PROTACs simultaneously bind to a POI and an E3-ubiquitin ligase, thus causing ubiquitination and degradation of the POI by the proteasome in the cells.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Unlike the classical small-molecule inhibitors, binding affinity is no longer the most critical factor to be considered for the development of PROTACs, while their degradation activities were extremely different through changing the E3 ligand and linker.<a onclick="showRef(event, 'ref164 ref165'); return false;" href="javascript:void(0);" class="ref ref164 ref165">(164,165)</a></div><div class="NLM_p">Wangâs group recently reported for the first time the discovery of a highly potent and selective PROTAC degrader of STAT3 that could induce rapid degradation of the STAT3 at low nanomolar concentrations in cells.<a onclick="showRef(event, 'ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref166 ref167">(166,167)</a> In their studies, several rounds of optimization of the template molecule CJ-887 (<b>96</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>), a potent inhibitor of the STAT3 SH2 domain with poor cell permeability (<i>K</i><sub>i</sub> = 47 nM) gave SI-109 (<b>97</b>) as a suitable ligand to bind STA3 (<i>K</i><sub>i</sub> = 14 nM). The amino group of the eight-membered ring in SI-109 is exposed to the solvent as determined by the cocrystal structure of SI-109 in a complex with the STAT3 SH2 domain, suggesting that it is a suitable site to tether an E3 ligase ligand. Lenalidomide and pomalidomide with excellent physicochemical properties were selected to bind cereblon (CRBN) E3 ligase. An optimal linker is critical for protein degradation potencies. Variation of the length and the composition of the linker resulted in a series of potent STAT3 degraders, with SD-36 (<b>98</b>) being the best. SD-36 could reduce the levels of the total STAT3 and p-STAT3<sup>Y705</sup> proteins, with DC<sub>50</sub> values of 0.06 and 0.028 Î¼M in acute myeloid leukemia Molm-16 and anaplastic large cell lymphoma SU-DHL-1 cell lines, respectively. Not surprisingly, their effective STAT3 degradation results showed a good correlation with cell growth inhibition in both cell lines (IC<sub>50</sub> values of 0.013 and 0.61 Î¼M, respectively). Furthermore, SD-36 is highly efficacious in the Molm-16 xenograft model. An effective inhibition of tumor growth was observed at 50 mg/kg administered once weekly for 3 weeks, while a complete tumor regression was achieved at 100 mg/kg weekly dosing.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Design of PROTAC SI-109 as a STAT3 degrader, and its cocrystal structure with STAT3 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NUQ">6NUQ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">6.  STAT3 SMALL MOLECULE INHIBITORS IN CLINICAL TRIALS FOR CANCER TREATMENT</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36424" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36424" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although STAT3-targeted therapies have not yet been approved for the treatment of cancer, the results of many early-phase therapeutic trials have validated the clinical importance of targeting STAT3. <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> lists the major STAT3 small-molecule inhibitors (exclusive of antisense oligonucleotide drug AZD9150) that have moved into clinical trials to date (<a href="http://clinicaltrials.gov/" class="extLink">http://clinicaltrials.gov/</a>), and some of them show encouraging results. In these clinical trials, the STAT3 inhibitor has been administrated alone or in combination either with chemotherapeutic drugs or with targeted agents. It is anticipated that synergistic or additive therapeutic effects can be triggered by STAT3 inhibitors upon combining with other therapies because, on one hand, administration of some chemotherapeutics or radiation induces the feedback activation of STAT3, on the other hand, STAT3 inhibition results in feedback activation of other signaling cascades relating to cancer, inclusive of RAS/RAF/MEK/ERK pathway.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Therefore, the use of STAT3 inhibitors as monotherapy should be carefully considered.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Overview of STAT3 Small-Molecule Inhibitors in Clinical Trials</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0025.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0026.gif" alt="" id="GRAPHIC-d7e2043-autogenerated" /></img><div></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">7.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite extensive efforts, cancer is still much of a problem in disease treatment now, even with the advent of new therapies. Many studies have shown that a plethora of cancers are correlated with constitutively activated STAT3, while STAT3 blockage has been shown to inhibit tumor growth, induce apoptosis, reverse acquired resistance, and stimulate an immune response, with good tolerability in normal cells. Thus, the development of therapeutic molecules with STAT3-inhibitory modalities has been validated as a promising approach for cancer therapy. In the past two decades, a large diverse set of compounds have been discovered to directly inhibit STAT3 activity by various strategies, such as virtual and high-throughput screenings as well as structure- and ligand-based molecular modeling.</div><div class="NLM_p">SH2-targeting compounds presently constitute the largest proportion of direct STAT3 inhibitors because of the critical involvement of the SH2 domain in STAT3 activation. Given the pivotal role of STAT1 in blocking tumor cell proliferation, a successful STAT3 inhibitor should not affect an activity of closely related protein STAT1, which shares great similarity with STAT3 in the SH2 domain sequences. Because of a lack of full inhibition of STAT3 by targeting the SH2 domain, the other domains of STAT3 are being pursued, including DBD, LD, and CCD to overcome the limitations of SH2-targeting molecules. Apart from directive blockade of the activity of STAT3, degradation of STAT3 may represent another effective strategy for cancer therapy, as validated by the Wang group using the PROTAC technology. However, the development of PROTACs targeting STAT3 seems to be more challenge than the discovery of inhibitors. For example, Hanafi et al. very recently have designed and synthesized an array of napabucasin-based PROTACs.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Unexpectedly, these PROTACs induced a significant degradation of ZFP91 instead of STAT3. In addition to heterobifunctional PROTACs, the discovery of effective monomeric degraders may be an alternative strategy for targeting STAT3.</div><div class="NLM_p last">To date, although none of the STAT3 inhibitors has been marketed yet, a few of them have succeeded in entering clinical trials, which inspired us to explore more efficacious STAT3 inhibitors or degradation agents. Rational computational approaches coupled with reliable assays are crucial for achieving this goal. Also, an abundance of natural compounds with inhibitory properties against STAT3 could act as template compounds for the synthesis of more efficient molecules. In addition, the development of STAT3 inhibitors by targeting more than one domain of STAT3 or targeting additional STAT5 or in combination with other therapies may benefit therapeutic efficacy in the treatment of cancer and other STAT3-driven diseases.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00629" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiang-Jiang Qin</span> - <span class="hlFld-Affiliation affiliation">Cancer
Hospital of the University of Chinese Academy of Sciences (Zhejiang
Cancer Hospital), Hangzhou, Zhejiang 310022, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Institute
of Basic Medicine and Cancer (IBMC), Chinese
Academy of Sciences, Hangzhou, Zhejiang 310018, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8559-616X" title="Orcid link">https://orcid.org/0000-0002-8559-616X</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8fe5fee6e1cffaeceefca1eeeca1ece1"><span class="__cf_email__" data-cfemail="a9c3d8c0c7e9dccac8da87c8ca87cac7">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinyun Dong</span> - <span class="hlFld-Affiliation affiliation">Cancer
Hospital of the University of Chinese Academy of Sciences (Zhejiang
Cancer Hospital), Hangzhou, Zhejiang 310022, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Institute
of Basic Medicine and Cancer (IBMC), Chinese
Academy of Sciences, Hangzhou, Zhejiang 310018, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiang-Dong Cheng</span> - <span class="hlFld-Affiliation affiliation">Cancer
Hospital of the University of Chinese Academy of Sciences (Zhejiang
Cancer Hospital), Hangzhou, Zhejiang 310022, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Institute
of Basic Medicine and Cancer (IBMC), Chinese
Academy of Sciences, Hangzhou, Zhejiang 310018, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei-Dong Zhang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Naval Medical University, Shanghai 200433, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Jinyun Dong</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=BIO-d7e2059-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jinyun Dong</b> completed his doctoral degree in medicinal chemistry at Shanghai Jiao Tong University in 2019. Currently, he is an Assistant Professor at the Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences. The main focus of his research is the design, synthesis, and biological evaluation of small-molecule inhibitors with antitumor activity.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Xiang-Dong Cheng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=BIO-d7e2064-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiang-Dong Cheng</b> obtained his B.Sc. and Masterâs degree in Medicine from Zhejiang University in 1997 and 2001, respectively. He received his doctoral degree in Medicine at CharitÃ©-Berlin University of Medicine in 2006. He is currently a Professor at the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital). His research mainly focuses on elucidating the molecular mechanisms underlying gastric cancer development, progression, and immune resistance and identifying new venues for the development of therapeutic and diagnostic tools.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Wei-Dong Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=BIO-d7e2069-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wei-Dong Zhang</b> obtained his B.Sc. and Masterâs degree in Natural Medicinal Chemistry from the Second Military Medical University in 1988 and 1991, respectively. He received his Ph.D. in Natural Medicinal Chemistry from the Shanghai Institute of Pharmaceutical Industry (1998). He is currently a Professor at the Shanghai University of Traditional Chinese Medicine and Second Military Medical University. His research mainly focuses on isolation, structural identification and modification, total synthesis, and structureâactivity relationships of bioactive natural products.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Jiang-Jiang Qin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=BIO-d7e2074-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jiang-Jiang Qin</b> is currently a Professor of Cancer Pharmacology at the Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences and the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital). He received his B.S. degree in Pharmacy (2006) and Ph.D. in Biomedical Engineering with the highest honor (2011) from Shanghai Jiao Tong University. His research mainly focuses on the discovery and development of novel, effective, and safe anticancer agents as well as demonstrating the molecular targets and mechanisms of action. Dr. Qin has published more than 110 research papers and reviews. He is an Associate Editor of Frontiers in Pharmacology and Frontiers in Oncology and an Editorial Board Member of Recent Patents on Anti-Cancer Drug Discovery.</p></figure></div><div class="ack" id="ACK-d7e2085-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from Program of Zhejiang Provincial TCM Sci-tech Plan (2020ZZ005), Zhejiang Provincial Natural Science Foundation of China (LQ21B020003, LR21H280001), and National Natural Science Foundation of China (81903842)</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS USED</td></tr><tr><td class="NLM_term">BLI</td><td class="NLM_def"><p class="first last">biolayer interferometry</p></td></tr><tr><td class="NLM_term">CCD</td><td class="NLM_def"><p class="first last">coiled-coil domain</p></td></tr><tr><td class="NLM_term">CSC</td><td class="NLM_def"><p class="first last">cancer stem cells</p></td></tr><tr><td class="NLM_term">DBD</td><td class="NLM_def"><p class="first last">DNA-binding domain</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">EMSA</td><td class="NLM_def"><p class="first last">electrophoretic mobility shift assay</p></td></tr><tr><td class="NLM_term">FGF</td><td class="NLM_def"><p class="first last">fibroblast growth factor</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">fluorescence polarization</p></td></tr><tr><td class="NLM_term">GSTP1</td><td class="NLM_def"><p class="first last">glutathione S-transferase P1</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">IDO1</td><td class="NLM_def"><p class="first last">indoleamine-2,3-dioxygenase 1</p></td></tr><tr><td class="NLM_term">IGF</td><td class="NLM_def"><p class="first last">insulin-like growth factor</p></td></tr><tr><td class="NLM_term">IL-6</td><td class="NLM_def"><p class="first last">interleukin 6</p></td></tr><tr><td class="NLM_term">LD</td><td class="NLM_def"><p class="first last">linker domain</p></td></tr><tr><td class="NLM_term">NQO1</td><td class="NLM_def"><p class="first last">NAD(P)H: quinone oxidoreductase-1</p></td></tr><tr><td class="NLM_term">MST</td><td class="NLM_def"><p class="first last">microscale thermophoresis</p></td></tr><tr><td class="NLM_term">NTD</td><td class="NLM_def"><p class="first last">N-terminal domain</p></td></tr><tr><td class="NLM_term">PTPRT</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase receptor T</p></td></tr><tr><td class="NLM_term">PDGF</td><td class="NLM_def"><p class="first last">platelet-derived growth factor</p></td></tr><tr><td class="NLM_term">PROTACs</td><td class="NLM_def"><p class="first last">proteolysis targeting chimeras</p></td></tr><tr><td class="NLM_term">SH2</td><td class="NLM_def"><p class="first last">Src homology 2</p></td></tr><tr><td class="NLM_term">SHP-1</td><td class="NLM_def"><p class="first last">Src homology region 2 domain-containing phosphatase-1</p></td></tr><tr><td class="NLM_term">SIRT1</td><td class="NLM_def"><p class="first last">deacetylase Sirtuin 1</p></td></tr><tr><td class="NLM_term">SOCS</td><td class="NLM_def"><p class="first last">the suppressors of cytokine signaling</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">Signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">TAD</td><td class="NLM_def"><p class="first last">transactivation domain</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22134" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22134" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 169 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, J. E.</span></span> <span> </span><span class="NLM_article-title">STATs and gene regulation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">1630</span>â <span class="NLM_lpage">1635</span>, <span class="refDoi">Â DOI: 10.1126/science.277.5332.1630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1126%2Fscience.277.5332.1630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=9287210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADyaK2sXmtVSisLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=1630-1635&author=J.+E.+Darnell&title=STATs+and+gene+regulation&doi=10.1126%2Fscience.277.5332.1630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">STATs and gene regulation</span></div><div class="casAuthors">Darnell, James E., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5332</span>),
    <span class="NLM_cas:pages">1630-1635</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 100 refs.  STATs (signal transducers and activators of transcription) are a family of latent cytoplasmic proteins that are activated to participate in gene control when cells encounter various extracellular polypeptides.  Biochem. and mol. genetic explorations have defined a single tyrosine phosphorylation site and, in a dimeric partner mol., a Src homol. 2 (SH2) phosphotyrosine-binding domain, a DNA interaction domain, and a no. of protein-protein interaction domains (with receptors, other transcription factors, the transcription machinery, and perhaps a tyrosine phosphatase).  Mouse genetics expts. have defined crucial roles for each known mammalian STAT.  The discovery of a STAT in Drosophila, and most recently in Dictyostelium discoideum, implies an ancient evolutionary origin for this dual-function set of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2cN7IJWCm2rVg90H21EOLACvtfcHk0lgjzfxg9sf80g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtVSisLo%253D&md5=ce5d495245adb0ccaab93ba990a7e017</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5332.1630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5332.1630%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DSTATs%2520and%2520gene%2520regulation%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D1630%26epage%3D1635%26doi%3D10.1126%2Fscience.277.5332.1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span> <span> </span><span class="NLM_article-title">Signal transducer and activator of transcription protein 3 (STAT3): an update on its direct inhibitors as promising anticancer agents</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5165</span>â <span class="NLM_lpage">5206</span>, <span class="refDoi">Â DOI: 10.2174/0929867325666180719122729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.2174%2F0929867325666180719122729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30027840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVymt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=5165-5206&author=A.+Gelainauthor=M.+Moriauthor=F.+Meneghettiauthor=S.+Villa&title=Signal+transducer+and+activator+of+transcription+protein+3+%28STAT3%29%3A+an+update+on+its+direct+inhibitors+as+promising+anticancer+agents&doi=10.2174%2F0929867325666180719122729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents</span></div><div class="casAuthors">Gelain, Arianna; Mori, Matteo; Meneghetti, Fiorella; Villa, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">5165-5206</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Since Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor which plays an important role in multiple aspects of cancer, including progression and migration, and it is constitutively activated in various human tumors, STAT3 inhibition has emerged as a validated strategy for the treatment of several malignancies.  The aim of this review is to provide an update on the identification of new promising direct inhibitors targeting STAT3 domains, as potential anticancer agents.  Methods: A thorough literature search focused on recently reported STAT3 direct inhibitors was undertaken.  We considered the relevant developments regarding the STAT3 domains, which have been identified as potential drug targets.  Results: In detail, 135 peer-reviewed papers and 7 patents were cited; the inhibitors we took into account targeted the DNA binding domain (compds. were grouped into natural derivs., small mols., peptides, aptamers and oligonucleotides), the SH2 binding domain (natural, semi-synthetic and synthetic compds.) and specific residues, like cysteines (natural, semi-synthetic, synthetic compds. and dual inhibitors) and tyrosine 705.  Conclusion: The huge no. of direct STAT3 inhibitors recently identified demonstrates a strong interest in the investigation of this target, although it represents a challenging task considering that no drug targeting this enzyme is currently available for anticancer therapy.  Notably, many studies on the available inhibitors evidenced that some of them possess a dual mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQTc4wg6lMDbVg90H21EOLACvtfcHk0lgjzfxg9sf80g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVymt7bI&md5=1df39128edf16ad4b697263614ed36e5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F0929867325666180719122729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867325666180719122729%26sid%3Dliteratum%253Aachs%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26atitle%3DSignal%2520transducer%2520and%2520activator%2520of%2520transcription%2520protein%25203%2520%2528STAT3%2529%253A%2520an%2520update%2520on%2520its%2520direct%2520inhibitors%2520as%2520promising%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2019%26volume%3D26%26spage%3D5165%26epage%3D5206%26doi%3D10.2174%2F0929867325666180719122729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1398</span>â <span class="NLM_lpage">1409</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2010.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bcp.2010.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=20067773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVCnsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2010&pages=1398-1409&author=X.+Zhangauthor=P.+Yueauthor=S.+Fletcherauthor=W.+Zhaoauthor=P.+T.+Gunningauthor=J.+Turkson&title=A+novel+small-molecule+disrupts+Stat3+SH2+domain-phosphotyrosine+interactions+and+Stat3-dependent+tumor+processes&doi=10.1016%2Fj.bcp.2010.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes</span></div><div class="casAuthors">Zhang, Xiaolei; Yue, Peibin; Fletcher, Steven; Zhao, Wei; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1398-1409</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mol. modeling of the phosphotyrosine (pTyr)-SH2 domain interaction in the Stat3:Stat3 dimerization, combined with in silico structural anal. of the Stat3 dimerization disruptor, S3I-201, has furnished a diverse set of analogs.  We present evidence from in vitro biochem. and biophys. studies that the structural analog, S3I-201.1066 (I) directly interacts with Stat3 or the SH2 domain, with an affinity (KD) of 2.74 Î¼M, and disrupts the binding of Stat3 to the cognate pTyr-peptide, GpYLPQTV-NH2, with an IC50 of 23 Î¼M.  Moreover, I selectively blocks the assocn. of Stat3 with the epidermal growth factor receptor (EGFR), and inhibits Stat3 tyrosine phosphorylation and nuclear translocation in EGF-stimulated mouse fibroblasts.  In cancer cells that harbor aberrant Stat3 activity, I inhibits constitutive Stat3 DNA-binding and transcriptional activities.  By contrast, I has no effect on Src activation or the EGFR-mediated activation of the Erk1/2MAPK pathway.  I selectively suppresses the viability, survival, and malignant transformation of the human breast and pancreatic cancer lines and the v-Src-transformed mouse fibroblasts harboring persistently active Stat3.  Treatment with I of malignant cells harboring aberrantly active Stat3 down-regulated the expression of c-Myc, Bcl-xL, Survivin, the matrix metalloproteinase 9, and VEGF.  The in vivo administration of I-induced significant antitumor response in mouse models of human breast cancer, which correlates with the inhibition of constitutively active Stat3 and the suppression of known Stat3-regulated genes.  Our studies identify a novel small-mol. that binds with a high affinity to Stat3, blocks Stat3 activation and function, and thereby induces antitumor response in human breast tumor xenografts harboring persistently active Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxJzIoqCaQHbVg90H21EOLACvtfcHk0ljCGTWNfouJxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVCnsL8%253D&md5=4a196103d1d0f6d057715ff4cd2d7498</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DA%2520novel%2520small-molecule%2520disrupts%2520Stat3%2520SH2%2520domain-phosphotyrosine%2520interactions%2520and%2520Stat3-dependent%2520tumor%2520processes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D79%26spage%3D1398%26epage%3D1409%26doi%3D10.1016%2Fj.bcp.2010.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamero, A. M.</span></span> <span> </span><span class="NLM_article-title">STAT2 phosphorylation and signaling</span>. <i>Jak-stat</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e25790</span>, <span class="refDoi">Â DOI: 10.4161/jkst.25790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.4161%2Fjkst.25790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24416652" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e25790&author=H.+C.+Steenauthor=A.+M.+Gamero&title=STAT2+phosphorylation+and+signaling&doi=10.4161%2Fjkst.25790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4161%2Fjkst.25790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.25790%26sid%3Dliteratum%253Aachs%26aulast%3DSteen%26aufirst%3DH.%2BC.%26aulast%3DGamero%26aufirst%3DA.%2BM.%26atitle%3DSTAT2%2520phosphorylation%2520and%2520signaling%26jtitle%3DJak-stat%26date%3D2013%26volume%3D2%26spage%3De25790%26doi%3D10.4161%2Fjkst.25790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wurster, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grusby, M. J.</span></span> <span> </span><span class="NLM_article-title">The biology of Stat4 and Stat6</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2577</span>â <span class="NLM_lpage">2584</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1203485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fsj.onc.1203485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10851056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVGhtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2577-2584&author=A.+L.+Wursterauthor=T.+Tanakaauthor=M.+J.+Grusby&title=The+biology+of+Stat4+and+Stat6&doi=10.1038%2Fsj.onc.1203485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The biology of Stat4 and Stat6</span></div><div class="casAuthors">Wurster, Andrea L.; Tanaka, Takashi; Grusby, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2577-2584</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with approx. 75 refs.  IL-4 and IL-12 are cytokines that are important regulators of the proliferation, differentiation and functional capacity of lymphocytes.  STATs (signal transducers and activators of transcription) are transcription factors that provide a direct link between the cytokine receptors and cytokine induced gene transcription.  Stat6 and Stat4 are two STAT family members that specifically mediate signals that emanate from the IL-4 and IL-12 receptors, resp.  Recently a great deal of progress has been made in understanding the specific roles that Stat6 and Stat4 play in lymphocyte function through in vitro as well as in vivo studies using Stat6 and Stat4-deficient mice.  This report will summarize and describe the recent advances made in understanding the activation and regulation of Stat6 and Stat4 as well as their roles in the development of an immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8kzLh4Nl7sbVg90H21EOLACvtfcHk0ljCGTWNfouJxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVGhtr8%253D&md5=ae569d044101d2822164753b7d1b8286</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203485%26sid%3Dliteratum%253Aachs%26aulast%3DWurster%26aufirst%3DA.%2BL.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DGrusby%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520biology%2520of%2520Stat4%2520and%2520Stat6%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D2577%26epage%3D2584%26doi%3D10.1038%2Fsj.onc.1203485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">218</span>â <span class="NLM_lpage">232</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31254923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ynt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=218-232&author=X.+Wangauthor=Q.+Heauthor=K.+Wuauthor=T.+Guoauthor=X.+Duauthor=H.+Zhangauthor=L.+Fangauthor=N.+Zhengauthor=Q.+Zhangauthor=F.+Ye&title=Design%2C+synthesis+and+activity+of+novel+2%2C6-disubstituted+purine+derivatives%2C+potential+small+molecule+inhibitors+of+signal+transducer+and+activator+of+transcription+3&doi=10.1016%2Fj.ejmech.2019.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3</span></div><div class="casAuthors">Wang, Xuebao; He, Qin; Wu, Kaiqi; Guo, Taoning; Du, Xuze; Zhang, Huan; Fang, Longcheng; Zheng, Nan; Zhang, Qihong; Ye, Faqing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">218-232</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Three series of 2,6-disubstituted purines I [R1 = Et, MeCH:CH, cyclohexyl, Ph, 3-BrC6H4, etc.; R2R3N = morpholin-4-yl], I (R1 = Ph; R2 = H, 2-MeC6H4, 4-ClC6H4, etc.; R3 = H) and I (R1 = 2-MeOC6H4; R2 = H, 4-MeC6H4, 3-MeOC6H4, etc.; R3 = H) were designed and synthesized and their biol. activities as small mol. inhibitors of STAT3 were assessed.  Compd. I (R1 = Ph; R2 = 4-ClC6H4; R3 = H) (II) exhibited remarkable antiproliferative activity against three cancer cell lines (IC50 values for HCT-116, SW480 and MDA-MB-231 were 1.77 Â± 0.35, 1.51 Â± 0.19 and 1.25 Â± 0.38 Î¼M, resp.).  Moreover, detailed biol. assays revealed that compd. II could effectively inhibited STAT3 phosphorylation and had little inhibition to others.  The newly discovered compd. II displayed an expecting anticancer effect both in-vitro and in-vivo.  The mol. docking models revealed that this compd. could bind to the SH2 domain of STAT3.  Three addnl. compds. I [R1 = Ph; R2R3N = morpholin-4-yl], I (R1 = Ph; R2 = 3-MeC6H4; R3 = H) and I (R1 = 2-MeOC6H4; R2 = 3-MeOC6H4; R3 = H) were also able to inhibited this phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWPTTRn7G-GrVg90H21EOLACvtfcHk0lhXVgpkEjBnaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ynt7rN&md5=cef6348552fb2660f8e40fc0f274a464</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DYe%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%2520and%2520activity%2520of%2520novel%25202%252C6-disubstituted%2520purine%2520derivatives%252C%2520potential%2520small%2520molecule%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D218%26epage%3D232%26doi%3D10.1016%2Fj.ejmech.2019.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wingelhofer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriggl, R.</span></span> <span> </span><span class="NLM_article-title">Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1713</span>â <span class="NLM_lpage">1726</span>, <span class="refDoi">Â DOI: 10.1038/s41375-018-0117-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41375-018-0117-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29728695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1713-1726&author=B.+Wingelhoferauthor=H.+A.+Neubauerauthor=P.+Valentauthor=X.+Hanauthor=S.+N.+Constantinescuauthor=P.+T.+Gunningauthor=M.+M%C3%BCllerauthor=R.+Moriggl&title=Implications+of+STAT3+and+STAT5+signaling+on+gene+regulation+and+chromatin+remodeling+in+hematopoietic+cancer&doi=10.1038%2Fs41375-018-0117-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer</span></div><div class="casAuthors">Wingelhofer, Bettina; Neubauer, Heidi A.; Valent, Peter; Han, Xiaonan; Constantinescu, Stefan N.; Gunning, Patrick T.; Mueller, Mathias; Moriggl, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1713-1726</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">STAT3 and STAT5 proteins are oncogenic downstream mediators of the JAK-STAT pathway.  Deregulated STAT3 and STAT5 signaling promotes cancer cell proliferation and survival in conjunction with other core cancer pathways.  Nuclear phosphorylated STAT3 and STAT5 regulate cell-type-specific transcription profiles via binding to promoter elements and exert more complex functions involving interaction with various transcriptional coactivators or corepressors and chromatin remodeling proteins.  The JAK-STAT pathway can rapidly reshape the chromatin landscape upon cytokine, hormone, or growth factor stimulation and unphosphorylated STAT proteins also appear to be functional with respect to regulating chromatin accessibility.  Notably, cancer genome landscape studies have implicated mutations in various epigenetic modifiers as well as the JAK-STAT pathway as underlying causes of many cancers, particularly acute leukemia and lymphomas.  However, it is incompletely understood how mutations within these pathways can interact and synergize to promote cancer.  We summarize the current knowledge of oncogenic STAT3 and STAT5 functions downstream of cytokine signaling and provide details on prerequisites for DNA binding and gene transcription.  We also discuss key interactions of STAT3 and STAT5 with chromatin remodeling factors such as DNA methyltransferases, histone modifiers, cofactors, corepressors, and other transcription factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjly1PidwZ_LVg90H21EOLACvtfcHk0lhXVgpkEjBnaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrnP&md5=4f46319140344cef3212b871a8b2ff8c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0117-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0117-x%26sid%3Dliteratum%253Aachs%26aulast%3DWingelhofer%26aufirst%3DB.%26aulast%3DNeubauer%26aufirst%3DH.%2BA.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DMoriggl%26aufirst%3DR.%26atitle%3DImplications%2520of%2520STAT3%2520and%2520STAT5%2520signaling%2520on%2520gene%2520regulation%2520and%2520chromatin%2520remodeling%2520in%2520hematopoietic%2520cancer%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1713%26epage%3D1726%26doi%3D10.1038%2Fs41375-018-0117-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magdy
Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ³mez-Biagi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">A STAT inhibitor patent review: progress since 2011</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1397</span>â <span class="NLM_lpage">1421</span>, <span class="refDoi">Â DOI: 10.1517/13543776.2015.1086749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1517%2F13543776.2015.1086749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26394986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWhu7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1397-1421&author=P.+S.+Laiauthor=D.+A.+Rosaauthor=A.+Magdy%0AAliauthor=R.+F.+G%C3%B3mez-Biagiauthor=D.+P.+Ballauthor=A.+E.+Shouksmithauthor=P.+T.+Gunning&title=A+STAT+inhibitor+patent+review%3A+progress+since+2011&doi=10.1517%2F13543776.2015.1086749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A STAT inhibitor patent review: progress since 2011</span></div><div class="casAuthors">Lai, Ping-Shan; Rosa, David A.; Magdy Ali, Ahmed; Gomez-Biagi, Rodolfo F.; Ball, Daniel P.; Shouksmith, Andrew E.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1397-1421</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The clin. utility of effective direct STAT inhibitors, particularly STAT3 and STAT5, for treating cancer and other diseases is well studied and known.  This review will highlight the STAT inhibitor patent literature from 2011 to 2015 inclusive.  Emphasis will be placed on inhibitors of the STAT3, STAT5a/b, and STAT1 proteins for cancer treatment.  The review will, where suitably investigated, describe the mode and the site of inhibition, list indications that were evaluated, and rank the inhibitor's relative potency among compds. in the same class.  The reader will gain an understanding of the diverse set of approaches, used both in academia and industry, to target STAT proteins.  There is still much work to be done to directly target the STAT3 and STAT5 proteins.  As yet, there is still no direct STAT3 inhibitor in the clinic.  While the SH2 domain remains a popular target for therapeutic intervention, the DNA-binding domain and N-terminal region are now attracting attention as possible sites for inhibition.  Multiple putative STAT3 and STAT5 inhibitors have now been patented across a broad spectrum of chemotypes, each with their own advantages and limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0jiivJY_RxLVg90H21EOLACvtfcHk0lim4LjtYYa0XA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWhu7bM&md5=261a9efdcad66b3b8ef7df18b66ce593</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543776.2015.1086749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2015.1086749%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DP.%2BS.%26aulast%3DRosa%26aufirst%3DD.%2BA.%26aulast%3DMagdy%2BAli%26aufirst%3DA.%26aulast%3DG%25C3%25B3mez-Biagi%26aufirst%3DR.%2BF.%26aulast%3DBall%26aufirst%3DD.%2BP.%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DA%2520STAT%2520inhibitor%2520patent%2520review%253A%2520progress%2520since%25202011%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2015%26volume%3D25%26spage%3D1397%26epage%3D1421%26doi%3D10.1517%2F13543776.2015.1086749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mankan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greten, F. R.</span></span> <span> </span><span class="NLM_article-title">Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1263</span>â <span class="NLM_lpage">1275</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2011.601739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1517%2F13543784.2011.601739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21751940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWntbbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1263-1275&author=A.+K.+Mankanauthor=F.+R.+Greten&title=Inhibiting+signal+transducer+and+activator+of+transcription+3%3A+rationality+and+rationale+design+of+inhibitors&doi=10.1517%2F13543784.2011.601739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors</span></div><div class="casAuthors">Mankan, Arun K.; Greten, Florian R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1263-1275</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) controls a key signaling pathway in the development of many malignant diseases.  Several genetic studies have proven its central role in the regulation of apoptosis, proliferation, angiogenesis and immune responses making it an attractive target for cancer therapy.Areas covered: This article addresses the role of STAT3 in immune response modulation and highlights the contribution of STAT3 in inflammation-mediated tumorigenesis.  We also review the rationale to use novel STAT3 inhibitors and list some of these inhibitors such as STA-21, IS3 295, S3I- M2001 and small mol. JAK2 inhibitors AZD1480 and AZ960 that were found to be efficient against tumors.  We summarize the efforts that were made so far in identifying promising compds. and mention the barriers that need to be overcome for successful application of STAT3 inhibitors in clinics.Expert opinion: STAT3 is an important target in tumor biol. based on its frequent activation in various tumors and its pleiotropic effects on different cell types.  Screening large libraries of logically synthesized small mol. inhibitors is one way to rapidly generate many potential mols., which can then be tested in different biol. relevant models.  The stage is, therefore, set for the identification and development of novel STAT3 inhibitors that will, in the very near future, enter the clin. realm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwvaUgkhnpgbVg90H21EOLACvtfcHk0lim4LjtYYa0XA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWntbbP&md5=648ce046310a6fb7a3203e9be9367376</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.601739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.601739%26sid%3Dliteratum%253Aachs%26aulast%3DMankan%26aufirst%3DA.%2BK.%26aulast%3DGreten%26aufirst%3DF.%2BR.%26atitle%3DInhibiting%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%253A%2520rationality%2520and%2520rationale%2520design%2520of%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1263%26epage%3D1275%26doi%3D10.1517%2F13543784.2011.601739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STATs in cancer inflammation and immunity: a leading role for STAT3</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">798</span>â <span class="NLM_lpage">809</span>, <span class="refDoi">Â DOI: 10.1038/nrc2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fnrc2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=19851315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=798-809&author=H.+Yuauthor=D.+Pardollauthor=R.+Jove&title=STATs+in+cancer+inflammation+and+immunity%3A+a+leading+role+for+STAT3&doi=10.1038%2Fnrc2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">STATs in cancer inflammation and immunity: a leading role for STAT3</span></div><div class="casAuthors">Yu, Hua; Pardoll, Drew; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">798-809</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in detg. whether immune responses in the tumor microenvironment promote or inhibit cancer.  Persistently activated STAT3 and, to some extent, STAT5 increase tumor cell proliferation, survival and invasion while suppressing anti-tumor immunity.  The persistent activation of STAT3 also mediates tumor-promoting inflammation.  STAT3 has this dual role in tumor inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-ÎºB (NF-ÎºB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-ÎºB-mediated T helper 1 anti-tumor immune responses.  Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvEMN5YrxbbVg90H21EOLACvtfcHk0ljxrioB0jnjpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP&md5=e431d0bd9eabd8f1ef703211be3d5cc9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2734%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTATs%2520in%2520cancer%2520inflammation%2520and%2520immunity%253A%2520a%2520leading%2520role%2520for%2520STAT3%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D798%26epage%3D809%26doi%3D10.1038%2Fnrc2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mali, S. B.</span></span> <span> </span><span class="NLM_article-title">Review of STAT3 (signal transducers and activators of transcription) in head and neck cancer</span>. <i>Oral Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">565</span>â <span class="NLM_lpage">569</span>, <span class="refDoi">Â DOI: 10.1016/j.oraloncology.2015.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.oraloncology.2015.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25817923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFemsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=565-569&author=S.+B.+Mali&title=Review+of+STAT3+%28signal+transducers+and+activators+of+transcription%29+in+head+and+neck+cancer&doi=10.1016%2Fj.oraloncology.2015.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer</span></div><div class="casAuthors">Mali, Shrikant Balasaheb</div><div class="citationInfo"><span class="NLM_cas:title">Oral Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-569</span>CODEN:
                <span class="NLM_cas:coden">EJCCER</span>;
        ISSN:<span class="NLM_cas:issn">1368-8375</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">STATs can be activated independently of JAKs, most notably by c-Src kinases.  In cancer cells, STAT3 and STAT5 activation leads to the increased expression of downstream target genes, leading to increased cell proliferation, cell survival, angiogenesis, and immune system evasion.  STAT3 and STAT5 are expressed and activated in head and neck squamous cell carcinoma where they contribute to cell survival and proliferation.  STATs can be activated by a no. of signal transduction pathways, including the epidermal growth factor receptor (EGFR), nicotinic receptor, interleukin (IL) receptor, and erythropoietin receptor pathways.  Identifying agents that inhibit STAT-3, a cytosolic transcription factor involved in the activation of various genes implicated in tumor progression is a promising strategy for cancer chemoprevention.  Several approaches have been used to inhibit STAT3 in the hope of developing an antitumor agent.  Although several STAT3-specific agents are promising, none are in clin. development, mostly because of drug delivery and stability issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNhsiRGSIrurVg90H21EOLACvtfcHk0ljxrioB0jnjpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFemsLo%253D&md5=95c66236308869cb292b12e8a52e482c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.oraloncology.2015.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.oraloncology.2015.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DMali%26aufirst%3DS.%2BB.%26atitle%3DReview%2520of%2520STAT3%2520%2528signal%2520transducers%2520and%2520activators%2520of%2520transcription%2529%2520in%2520head%2520and%2520neck%2520cancer%26jtitle%3DOral%2520Oncol.%26date%3D2015%26volume%3D51%26spage%3D565%26epage%3D569%26doi%3D10.1016%2Fj.oraloncology.2015.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, S.</span></span> <span> </span><span class="NLM_article-title">Regulation of STAT signaling by acetylation</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1924</span>â <span class="NLM_lpage">1931</span>, <span class="refDoi">Â DOI: 10.1016/j.cellsig.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.cellsig.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23707527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOrs7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2013&pages=1924-1931&author=S.+Zhuang&title=Regulation+of+STAT+signaling+by+acetylation&doi=10.1016%2Fj.cellsig.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of STAT signaling by acetylation</span></div><div class="casAuthors">Zhuang, Shougang</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1924-1931</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Signal transducers and activators of transcription (STAT) belong to a family of latent cytoplasmic factors that can be activated by tyrosine phosphorylation by the members of the Jak tyrosine kinase family in response to a variety of cytokines and growth factors.  Activated STATs form dimers and translocate into nucleus to induce expression of crit. genes essential for normal cellular events.  In the past several years, significant progress has been made in the characterization of STAT acetylation, which is dependent on the balance between histone deacetylases (HDACs) and histone acetyltransferases (HATs) such as CBP/p300.  Acetylation of STAT1, STAT2, STAT3, STAT5b and STAT6 has been identified.  This review will highlight acetylation on the modulation of STAT activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWOAPz0pMzJrVg90H21EOLACvtfcHk0ljPfiG_jwmT9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOrs7bK&md5=04e6ecdf61d95e4f51762a2d81f83ef9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhuang%26aufirst%3DS.%26atitle%3DRegulation%2520of%2520STAT%2520signaling%2520by%2520acetylation%26jtitle%3DCell.%2520Signalling%26date%3D2013%26volume%3D25%26spage%3D1924%26epage%3D1931%26doi%3D10.1016%2Fj.cellsig.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sgrignani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merulla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catapano, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Structural biology of STAT3 and its implications for anticancer therapies development</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1591</span>, <span class="refDoi">Â DOI: 10.3390/ijms19061591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fijms19061591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSrt73O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1591&author=J.+Sgrignaniauthor=M.+Garofaloauthor=M.+Matkovicauthor=J.+Merullaauthor=C.+V.+Catapanoauthor=A.+Cavalli&title=Structural+biology+of+STAT3+and+its+implications+for+anticancer+therapies+development&doi=10.3390%2Fijms19061591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structural biology of STAT3 and its implications for anticancer therapies development</span></div><div class="casAuthors">Sgrignani, Jacopo; Garofalo, Maura; Matkovic, Milos; Merulla, Jessica; Catapano, Carlo V.; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1591/1-1591/14</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Transcription factors are proteins able to bind DNA and induce the transcription of specific genes.  Consequently, they play a pivotal role in multiple cellular pathways and are frequently over-expressed or dysregulated in cancer.  Here, we will focus on a specific "signal transducer and activator of transcription" (STAT3) factor that is involved in several pathologies, including cancer.  For long time, the mechanism by which STAT3 exerts its cellular functions has been summarized by a three steps process: (1) Protein phosphorylation by specific kinases, (2) dimerization promoted by phosphorylation, (3) activation of gene expression by the phosphorylated dimer.  Consequently, most of the inhibitors reported in literature aimed at blocking phosphorylation and dimerization.  However, recent observations reopened the debate and the entire functional mechanism has been revisited stimulating the scientific community to pursue new inhibition strategies.  In particular, the dimerization of the unphosphorylated species has been exptl. demonstrated and specific roles proposed also for these dimers.  Despite difficulties in the expression and purifn. of the full length STAT3, structural biol. investigations allowed the detn. of atomistic structures of STAT3 dimers and several protein domains.  Starting from this information, computational methods have been used both to improve the understanding of the STAT3 functional mechanism and to design new inhibitors to be used as anticancer drugs.  In this review, we will focus on the contribution of structural biol. to understand the roles of STAT3, to design new inhibitors and to suggest new strategies of pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwOe7is1W8ZLVg90H21EOLACvtfcHk0ljPfiG_jwmT9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSrt73O&md5=5144a31d327b9fd68e0956f8f2dffeeb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3390%2Fijms19061591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19061591%26sid%3Dliteratum%253Aachs%26aulast%3DSgrignani%26aufirst%3DJ.%26aulast%3DGarofalo%26aufirst%3DM.%26aulast%3DMatkovic%26aufirst%3DM.%26aulast%3DMerulla%26aufirst%3DJ.%26aulast%3DCatapano%26aufirst%3DC.%2BV.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DStructural%2520biology%2520of%2520STAT3%2520and%2520its%2520implications%2520for%2520anticancer%2520therapies%2520development%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D1591%26doi%3D10.3390%2Fijms19061591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go? <i>Eur</i></span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111922</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.111922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.111922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31810784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitleqsb3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111922&author=Q.+Huangauthor=Y.+Zhongauthor=H.+Dongauthor=Q.+Zhengauthor=S.+Shiauthor=K.+Zhuauthor=X.+Quauthor=W.+Huauthor=X.+Zhangauthor=Y.+Wang&title=Revisiting+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+as+an+anticancer+target+and+its+inhibitor+discovery%3A+where+are+we+and+where+should+we+go%3F+Eur&doi=10.1016%2Fj.ejmech.2019.111922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?</span></div><div class="casAuthors">Huang, Qiuyao; Zhong, Yan; Dong, Hui; Zheng, Qiyao; Shi, Shuo; Zhu, Kai; Qu, Xinming; Hu, Wenhao; Zhang, Xiaolei; Wang, Yuanxiang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111922</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  As a transcription factor, STAT3 protein transduces extracellular signals to the nucleus and then activates transcription of target genes.  STAT3 has been well validated as an attractive anticancer target due to its important roles in cancer initiation and progression.  Identification of specific and potent STAT3 inhibitors has attracted much attention, while there has been no STAT3 targeted drug approved for clin. application.  In this review, we will briefly introduce STAT3 protein and review its role in multiple aspects of cancer, and systematically summarize the recent advances in discovery of STAT3 inhibitors, esp. the ones discovered in the past five years.  In the last part of the review, we will discuss the possible new strategies to overcome the difficulties of developing potent and specific STAT3 inhibitors and hope to shed light on future drug design and inhibitor optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgUc7yryGAQ7Vg90H21EOLACvtfcHk0ljPfiG_jwmT9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitleqsb3E&md5=98f36d6eb8d622babb00c6135a486a7e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111922%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DRevisiting%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520as%2520an%2520anticancer%2520target%2520and%2520its%2520inhibitor%2520discovery%253A%2520where%2520are%2520we%2520and%2520where%2520should%2520we%2520go%253F%2520Eur%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111922%26doi%3D10.1016%2Fj.ejmech.2019.111922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">Impact of the N-terminal domain of STAT3 in STAT3-dependent transcriptional activity</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3284</span>â <span class="NLM_lpage">3300</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00060-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1128%2FMCB.00060-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26169829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtlKqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=3284-3300&author=T.+Huauthor=J.+E.+Yehauthor=L.+Pinelloauthor=J.+Jacobauthor=S.+Chakravarthyauthor=G.-C.+Yuanauthor=R.+Chopraauthor=D.+A.+Frank&title=Impact+of+the+N-terminal+domain+of+STAT3+in+STAT3-dependent+transcriptional+activity&doi=10.1128%2FMCB.00060-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of the N-terminal domain of STAT3 in STAT3-dependent transcriptional activity</span></div><div class="casAuthors">Hu, Tiancen; Yeh, Jennifer E.; Pinello, Luca; Jacob, Jaison; Chakravarthy, Srinivas; Yuan, Guo-Cheng; Chopra, Rajiv; Frank, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3284-3300</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is constitutively active in many cancers, where it mediates important biol. effects, including cell proliferation, differentiation, survival, and angiogenesis.  The N-terminal domain (NTD) of STAT3 performs multiple functions, such as cooperative DNA binding, nuclear translocation, and protein-protein interactions.  However, it is unclear which subsets of STAT3 target genes depend on the NTD for transcriptional regulation.  To identify such genes, we compared gene expression in STAT3-null mouse embryonic fibroblasts (MEFs) stably expressing wild-type STAT3 or STAT3 from which NTD was deleted.  NTD deletion reduced the cytokine-induced expression of specific STAT3 target genes by decreasing STAT3 binding to their regulatory regions.  To better understand the potential mechanisms of this effect, we detd. the crystal structure of the STAT3 NTD and identified a dimer interface responsible for cooperative DNA binding in vitro.  We also obsd. an Ni2+-mediated oligomer with an as yet unknown biol. function.  Mutations on both dimer and Ni2+-mediated interfaces affected the cytokine induction of STAT3 target genes.  These studies shed light on the role of the NTD in transcriptional regulation by STAT3 and provide a structural template with which to design STAT3 NTD inhibitors with potential therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT_6JMQ7jV3LVg90H21EOLACvtfcHk0lgUYOXKCCPfGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtlKqtQ%253D%253D&md5=9ff4b3664f457a00aa12be6777ae58f1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FMCB.00060-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00060-15%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DT.%26aulast%3DYeh%26aufirst%3DJ.%2BE.%26aulast%3DPinello%26aufirst%3DL.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DChakravarthy%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DG.-C.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DImpact%2520of%2520the%2520N-terminal%2520domain%2520of%2520STAT3%2520in%2520STAT3-dependent%2520transcriptional%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D3284%26epage%3D3300%26doi%3D10.1128%2FMCB.00060-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span> <span> </span><span class="NLM_article-title">A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">29252</span>â <span class="NLM_lpage">29260</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M304196200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M304196200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=12746441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsl2mt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=29252-29260&author=J.+Maauthor=T.+Zhangauthor=V.+Novotny-Diermayrauthor=A.+L.+C.+Tanauthor=X.+Cao&title=A+novel+sequence+in+the+coiled-coil+domain+of+Stat3+essential+for+its+nuclear+translocation&doi=10.1074%2Fjbc.M304196200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation</span></div><div class="casAuthors">Ma, Jing; Zhang, Tong; Novotny-Diermayr, Veronica; Tan, Agnes L. C.; Cao, Xinmin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">29252-29260</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Stat3 is activated by cytokines and growth factors via specific tyrosine phosphorylation, dimerization, and nuclear translocation.  However, the mechanism involved in its nuclear translocation is unclear.  In this study, by systematic deletion and site-directed mutagenesis we identified Arg-214/215 in the Î±-helix 2 region of the coiled-coil domain of Stat3 as a novel sequence element essential for its nuclear translocation, stimulated by epidermal growth factor as well as by interleukin-6.  Furthermore, we identified Arg-414/417 in the DNA binding domain as also required for the nuclear localization of Stat3.  This sequence element corresponds to Lys-410/413 of Stat1, a reported sequence for Stat1 nuclear translocation.  On the other hand, Leu-411 of Stat3, corresponding to Leu-407 of Stat1, a necessary residue for Stat1 nuclear transport, is not essential for Stat3 nuclear import.  The mutant of Arg-214/215 or Arg-414/417 was shown to be tyrosyl-phosphorylated normally but failed to enter the nucleus in response to epidermal growth factor or interleukin-6.  The defect, however, can be rescued by the wild-type Stat3 but cannot be compensated by these two mutants.  Mutations on Arg-414/417, but not Arg-214/215, destroy the DNA binding activity of Stat3.  Our data for the first time identified a sequence element located in the coiled-coil domain that is involved in the ligand-induced nuclear translocation of Stat3.  This novel sequence together with a conserved sequence element in the DNA binding domain coordinates to mediate the nuclear translocation of Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_piovgbYiabVg90H21EOLACvtfcHk0lgUYOXKCCPfGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsl2mt74%253D&md5=5aab663722249518f57b09e25652b244</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M304196200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M304196200%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DTan%26aufirst%3DA.%2BL.%2BC.%26aulast%3DCao%26aufirst%3DX.%26atitle%3DA%2520novel%2520sequence%2520in%2520the%2520coiled-coil%2520domain%2520of%2520Stat3%2520essential%2520for%2520its%2520nuclear%2520translocation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D29252%26epage%3D29260%26doi%3D10.1074%2Fjbc.M304196200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span> <span> </span><span class="NLM_article-title">Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">74</span>â <span class="NLM_lpage">91</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2018.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.pharmthera.2018.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29933035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2ltrfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2018&pages=74-91&author=J.+D.+Beebeauthor=J.+Y.+Liuauthor=J.+T.+Zhang&title=Two+decades+of+research+in+discovery+of+anticancer+drugs+targeting+STAT3%2C+how+close+are+we%3F&doi=10.1016%2Fj.pharmthera.2018.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we</span></div><div class="casAuthors">Beebe, Jenny D.; Liu, Jing-Yuan; Zhang, Jian-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-91</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) controls many biol. processes including differentiation, survival, proliferation, and angiogenesis.  In normal healthy cells, STAT3 is tightly regulated to maintain a momentary active state.  However, aberrant or constitutively activated STAT3 has been obsd. in many different cancers and constitutively activated STAT3 has been shown to assoc. with poor prognosis and tumor progression.  For this reason, STAT3 has been studied as a possible target in the treatment of many different types of cancers.  However, despite decades of research, a FDA-approved STAT3 inhibitor has yet to emerge.  In this , we will analyze past studies targeting STAT3 for drug discovery, understand possible causes of failure in these studies, and provide potential insights for future efforts to overcome these roadblocks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSWDPJOIaRKrVg90H21EOLACvtfcHk0lgghoOiQJAvhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2ltrfO&md5=048e7d95608bdab18335c55d084d62ab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DBeebe%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26atitle%3DTwo%2520decades%2520of%2520research%2520in%2520discovery%2520of%2520anticancer%2520drugs%2520targeting%2520STAT3%252C%2520how%2520close%2520are%2520we%253F%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D191%26spage%3D74%26epage%3D91%26doi%3D10.1016%2Fj.pharmthera.2018.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haripal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, J. E.</span></span> <span> </span><span class="NLM_article-title">Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">14811</span>â <span class="NLM_lpage">14816</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1515876112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.1515876112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26553978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyru7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=14811-14816&author=C.+Mertensauthor=B.+Haripalauthor=S.+Klingeauthor=J.+E.+Darnell&title=Mutations+in+the+linker+domain+affect+phospho-STAT3+function+and+suggest+targets+for+interrupting+STAT3+activity&doi=10.1073%2Fpnas.1515876112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity</span></div><div class="casAuthors">Mertens, Claudia; Haripal, Bhagwattie; Klinge, Sebastian; Darnell, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14811-14816</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Crystallog. of the cores of phosphotyrosine-activated dimers of STAT1 (132-713) and STAT3 (127-722) bound to a similar double-stranded deoxyoligonucleotide established the domain structure of the STATs and the structural basis for activation through tyrosine phosphorylation and dimerization.  The authors reported earlier that mutants in the linker domain of STAT1 that connect the DNA-binding domain and SH2 domain can prevent transcriptional activation.  Because of the pervasive importance of persistently activated STAT3 in many human cancers and the difficulty of finding useful drug candidates aimed at disrupting the pY interchange in active STAT3 dimers, the authors examd. the effects of an array of mutants in the STAT3 linker domain.  The authors found several STAT3 linker domain mutants to have profound effects of inhibiting STAT3 transcriptional activation.  From these results, the authors propose (1) there is definite functional interaction of the linker both with the DNA binding domain and with the SH2 domain, and (2) these putative contacts provide potential new targets for small mol.-induced pSTAT3 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov0W2HVoaitrVg90H21EOLACvtfcHk0lgghoOiQJAvhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyru7vP&md5=74698f2ed4b16e8f3e27a18c7bdfd889</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1515876112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1515876112%26sid%3Dliteratum%253Aachs%26aulast%3DMertens%26aufirst%3DC.%26aulast%3DHaripal%26aufirst%3DB.%26aulast%3DKlinge%26aufirst%3DS.%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DMutations%2520in%2520the%2520linker%2520domain%2520affect%2520phospho-STAT3%2520function%2520and%2520suggest%2520targets%2520for%2520interrupting%2520STAT3%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D14811%26epage%3D14816%26doi%3D10.1073%2Fpnas.1515876112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merulla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catapano, C. V.</span></span> <span> </span><span class="NLM_article-title">Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3)</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1194</span>â <span class="NLM_lpage">1206</span>, <span class="refDoi">Â DOI: 10.1016/j.molonc.2015.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.molonc.2015.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25777967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVKhtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=1194-1206&author=L.+Brambillaauthor=D.+Geniniauthor=E.+Lauriniauthor=J.+Merullaauthor=L.+Perezauthor=M.+Fermegliaauthor=G.+M.+Carboneauthor=S.+Priclauthor=C.+V.+Catapano&title=Hitting+the+right+spot%3A+mechanism+of+action+of+OPB-31121%2C+a+novel+and+potent+inhibitor+of+the+signal+transducer+and+activator+of+transcription+3+%28STAT3%29&doi=10.1016%2Fj.molonc.2015.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)</span></div><div class="casAuthors">Brambilla, Lara; Genini, Davide; Laurini, Erik; Merulla, Jessica; Perez, Laurent; Fermeglia, Maurizio; Carbone, Giuseppina M.; Pricl, Sabrina; Catapano, Carlo V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1194-1206</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">STAT3 is a key element in many oncogenic pathways and, like other transcription factors, is an attractive target for development of novel anticancer drugs.  However, interfering with STAT3 functions has been a difficult task and very few small mol. inhibitors have made their way to the clinic.  OPB-31121, an anticancer compd. currently in clin. trials, has been reported to affect STAT3 signaling, although its mechanism of action has not been unequivocally demonstrated.  In this study, we used a combined computational and exptl. approach to investigate the mol. target and the mode of interaction of OPB-31121 with STAT3.  In parallel, similar studies were performed with known STAT3 inhibitors (STAT3i) to validate our approach.  Computational docking and mol. dynamics simulation (MDS) showed that OPB-31121 interacted with high affinity with the SH2 domain of STAT3.  Interestingly, there was no overlap of the OPB-31121 binding site with those of the other STAT3i.  Computational predictions were confirmed by in vitro binding assays and competition expts. along with site-directed mutagenesis of crit. residues in the STAT3 SH2 domain.  Isothermal titrn. calorimetry expts. demonstrated the remarkably high affinity of OPB-31121 for STAT3 with Kd (10 nM) 2-3 orders lower than other STAT3i.  Notably, a similar ranking of the potency of the compds. was obsd. in terms of inhibition of STAT3 phosphorylation, cancer cell proliferation and clonogenicity.  These results suggest that the high affinity and efficacy of OPB-31121 might be related to the unique features and mode of interaction of OPB-31121 with STAT3.  These unique characteristics make OPB-31121 a promising candidate for further development and an interesting lead for designing new, more effective STAT3i.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUVETM9GX5ZbVg90H21EOLACvtfcHk0ljo_sx2VI3OLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVKhtbk%253D&md5=c6699a87e3fb26c658c3d6c33c802360</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2015.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2015.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DBrambilla%26aufirst%3DL.%26aulast%3DGenini%26aufirst%3DD.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DMerulla%26aufirst%3DJ.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DCarbone%26aufirst%3DG.%2BM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DCatapano%26aufirst%3DC.%2BV.%26atitle%3DHitting%2520the%2520right%2520spot%253A%2520mechanism%2520of%2520action%2520of%2520OPB-31121%252C%2520a%2520novel%2520and%2520potent%2520inhibitor%2520of%2520the%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26spage%3D1194%26epage%3D1206%26doi%3D10.1016%2Fj.molonc.2015.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. L.</span></span> <span> </span><span class="NLM_article-title">STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review)</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1181</span>â <span class="NLM_lpage">1191</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2012.1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3892%2Fijo.2012.1568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22842992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFyntLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=1181-1191&author=X.+Wangauthor=P.+J.+Croweauthor=D.+Goldsteinauthor=J.+L.+Yang&title=STAT3+inhibition%2C+a+novel+approach+to+enhancing+targeted+therapy+in+human+cancers+%28review%29&doi=10.3892%2Fijo.2012.1568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review)</span></div><div class="casAuthors">Wang, Xiaochun; Crowe, Philip J.; Goldstein, David; Yang, Jia-Lin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1181-1191</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) regulates many crit. functions in human normal and malignant tissues, such as differentiation, proliferation, survival, angiogenesis and immune function.  Constitutive activation of STAT3 is implicated in a wide range of human cancers.  As such, STAT3 has been studied as a tumor therapeutic target.  This review aimed principally to summarize the updated research on STAT3 inhibition studies and their therapeutic potential in solid tumors.  Recent literature assocd. with STAT3 inhibition was reviewed through PubMed and Medline database, followed by crit. comparison and anal.  Constitutive activation of STAT3 has been identified as abnormal and oncogenic.  The pathway of STAT3 activation and signal transduction identifies 3 approaches for inhibition: modulating upstream pos. or neg. regulators, regulating RNA (DN-STAT3, anti-sense RNA, siRNA and microRNA) or targeting STAT3 protein at different domains.  The last approach using small mol. STAT3 inhibitors has been the most examd. so far with both preclin. and clin. studies.  Targeting STAT3 using a specific inhibitor may be a useful cancer treatment approach, with the potential for a broad clin. impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnx1B_eI0cs7Vg90H21EOLACvtfcHk0ljru3btzfGUCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFyntLjF&md5=91d64864c492ebe00e5d6a1cc6072284</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3892%2Fijo.2012.1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2012.1568%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCrowe%26aufirst%3DP.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%2BL.%26atitle%3DSTAT3%2520inhibition%252C%2520a%2520novel%2520approach%2520to%2520enhancing%2520targeted%2520therapy%2520in%2520human%2520cancers%2520%2528review%2529%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2012%26volume%3D41%26spage%3D1181%26epage%3D1191%26doi%3D10.3892%2Fijo.2012.1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avalle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camporeale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camperi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, V.</span></span> <span> </span><span class="NLM_article-title">STAT3 in cancer: A double edged sword</span>. <i>Cytokine+</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">42</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1016/j.cyto.2017.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.cyto.2017.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28579221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVWrt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2017&pages=42-50&author=L.+Avalleauthor=A.+Camporealeauthor=A.+Camperiauthor=V.+Poli&title=STAT3+in+cancer%3A+A+double+edged+sword&doi=10.1016%2Fj.cyto.2017.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 in cancer: A double edged sword</span></div><div class="casAuthors">Avalle, Lidia; Camporeale, Annalisa; Camperi, Andrea; Poli, Valeria</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The transcription factor signal transducer and activator of transcription (STAT) 3 is activated downstream of cytokines, growth factors and oncogenes to mediate their functions under both physiol. and pathol. conditions.  In particular, aberrant/unrestrained STAT3 activity is detected in a wide variety of tumors, driving multiple pro-oncogenic functions.  For that, STAT3 is widely considered as an oncogene and is the object of intense translational studies.  One of the distinctive features of this factor is however, its ability to elicit different and sometimes contrasting effects under different conditions.  In particular, STAT3 activities have been shown to be either pro-oncogenic or tumor-suppressive according to the tumor etiol./mutational landscape, suggesting that the mol. bases underlining its functions are still incompletely understood.  Here we discuss some of the properties that may provide the bases to explain STAT3 heterogeneous functions, and in particular how post-translational modifications contribute shaping its sub-cellular localization and activities, the cross talk between these activities and cell metabolic conditions, and finally how its functions can control the behavior of both tumor and tumor microenvironment cell populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHMu-uQSt597Vg90H21EOLACvtfcHk0ljru3btzfGUCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVWrt7c%253D&md5=71a9398a10fe082cd2ccafb15672865a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2017.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2017.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DAvalle%26aufirst%3DL.%26aulast%3DCamporeale%26aufirst%3DA.%26aulast%3DCamperi%26aufirst%3DA.%26aulast%3DPoli%26aufirst%3DV.%26atitle%3DSTAT3%2520in%2520cancer%253A%2520A%2520double%2520edged%2520sword%26jtitle%3DCytokine%252B%26date%3D2017%26volume%3D98%26spage%3D42%26epage%3D50%26doi%3D10.1016%2Fj.cyto.2017.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Her, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H. Y.</span></span> <span> </span><span class="NLM_article-title">Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling</span>. <i>J. Nutr. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">228</span>â <span class="NLM_lpage">238</span>, <span class="refDoi">Â DOI: 10.1016/j.jnutbio.2010.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.jnutbio.2010.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21497499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVWmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=228-238&author=G.+T.+Kwonauthor=J.+I.+Jungauthor=H.+R.+Songauthor=E.+Y.+Wooauthor=J.-G.+Junauthor=J.-K.+Kimauthor=S.+Herauthor=J.+H.+Y.+Park&title=Piceatannol+inhibits+migration+and+invasion+of+prostate+cancer+cells%3A+possible+mediation+by+decreased+interleukin-6+signaling&doi=10.1016%2Fj.jnutbio.2010.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling</span></div><div class="casAuthors">Kwon, Gyoo Taik; Jung, Jae In; Song, Hye Rim; Woo, Eun Young; Jun, Jong-Gab; Kim, Jin-Kyung; Her, Song; Park, Jung Han Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutritional Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">228-238</span>CODEN:
                <span class="NLM_cas:coden">JNBIEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-2863</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Piceatannol (trans-3,4,3',5'-tetrahydroxystilbene) is a polyphenol detected in grapes, red wine and Rheum undulatum; it was also demonstrated to exert anticarcinogenic effects.  In this study, to det. whether piceatannol inhibits the lung metastasis of prostate cancer cells, MAT-Ly-Lu (MLL) rat prostate cancer cells expressing luciferase were injected into the tail veins of male nude mice.  The oral administration of piceatannol (20 mg/kg) significantly inhibited the accumulation of MLL cells in the lungs of these mice.  In the cell culture studies, piceatannol was demonstrated to inhibit the basal and epidermal growth factor (EGF)-induced migration and invasion of DU145 cells, in addn. to the migration of MLL, PC3, and TRAMP-C2 prostate cancer cells.  In DU145 cells, piceatannol attenuated the secretion and mRNA levels of matrix metalloproteinase-9, urokinase-type plasminogen activator (uPA), and vascular endothelial growth factor (VEGF).  Piceatannol increased the protein levels of tissue inhibitor of metalloproteinase-2 in a concn.-dependent fashion.  Addnl., piceatannol inhibited the phosphorylation of signal transducer and activator of transcription (STAT) 3.  Furthermore, piceatannol effected redns. in both basal and EGF-induced interleukin (IL)-6 secretion.  An IL-6 neutralizing antibody inhibited EGF-induced STAT3 phosphorylation and EGF-stimulated migration of DU145 cells.  Interleukin-6 treatment was also shown to enhance the secretion of uPA and VEGF, STAT3 phosphorylation, and the migration of DU145 cells; these increases were suppressed by piceatannol.  These results demonstrate that the inhibition of IL-6/STAT3 signaling may constitute a mechanism by which piceatannol regulates the expression of proteins involved in regulating the migration and invasion of DU145 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7iUsfwEWQKbVg90H21EOLACvtfcHk0ljscDRy0PPGeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVWmtLk%253D&md5=3e6835f5a66896262d5517185bd78b4d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jnutbio.2010.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jnutbio.2010.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DG.%2BT.%26aulast%3DJung%26aufirst%3DJ.%2BI.%26aulast%3DSong%26aufirst%3DH.%2BR.%26aulast%3DWoo%26aufirst%3DE.%2BY.%26aulast%3DJun%26aufirst%3DJ.-G.%26aulast%3DKim%26aufirst%3DJ.-K.%26aulast%3DHer%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%2BH.%2BY.%26atitle%3DPiceatannol%2520inhibits%2520migration%2520and%2520invasion%2520of%2520prostate%2520cancer%2520cells%253A%2520possible%2520mediation%2520by%2520decreased%2520interleukin-6%2520signaling%26jtitle%3DJ.%2520Nutr.%2520Biochem.%26date%3D2012%26volume%3D23%26spage%3D228%26epage%3D238%26doi%3D10.1016%2Fj.jnutbio.2010.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chau, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, P. P.</span></span> <span> </span><span class="NLM_article-title">Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">627</span>â <span class="NLM_lpage">631</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2008.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bbrc.2008.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=18930029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlykt7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2008&pages=627-631&author=M.+N.+Chauauthor=P.+P.+Banerjee&title=Development+of+a+STAT3+reporter+prostate+cancer+cell+line+for+high+throughput+screening+of+STAT3+activators+and+inhibitors&doi=10.1016%2Fj.bbrc.2008.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors</span></div><div class="casAuthors">Chau, My N.; Banerjee, Partha P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-631</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">STAT3 is constitutively activated in several cancers, including prostate cancer, and is therefore, a potential target for cancer therapy.  DU-145 prostate cancer cells were stably co-transfected with STAT3 reporter and puromycin resistant plasmids to create a stable STAT3 reporter cell line that can be used for high throughput screening of STAT3 modulators.  The applicability of this cell line was tested with two known activators and inhibitors of STAT3.  As expected, EGF and IL-6 increased STAT3 reporter activity and enhanced the nuclear localization of phosphorylated STAT3 (pSTAT3); whereas Cucurbitacin I and AG490 decreased STAT3 reporter activity dose and time-dependently and reduced the localization of pSTAT3 in the nuclei of prostate cancer cells.  Given the importance of STAT3 in cancer initiation and progression, the development of a stable STAT3 reporter cell line in prostate cancer cells provides a rapid, sensitive, and cost effective method for the screening of potential STAT3 modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjSY8FsvDnt7Vg90H21EOLACvtfcHk0ljscDRy0PPGeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlykt7nE&md5=dcdbd3c066f54ef2c3fd66a1de526229</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2008.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2008.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DChau%26aufirst%3DM.%2BN.%26aulast%3DBanerjee%26aufirst%3DP.%2BP.%26atitle%3DDevelopment%2520of%2520a%2520STAT3%2520reporter%2520prostate%2520cancer%2520cell%2520line%2520for%2520high%2520throughput%2520screening%2520of%2520STAT3%2520activators%2520and%2520inhibitors%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2008%26volume%3D377%26spage%3D627%26epage%3D631%26doi%3D10.1016%2Fj.bbrc.2008.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djeu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekharam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">7519</span>â <span class="NLM_lpage">7528</span>, <span class="refDoi">Â DOI: 10.1128/MCB.19.11.7519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1128%2FMCB.19.11.7519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10523640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADyaK1MXmvFekt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=7519-7528&author=J.+Turksonauthor=T.+Bowmanauthor=J.+Adnaneauthor=Y.+Zhangauthor=J.+Y.+Djeuauthor=M.+Sekharamauthor=D.+A.+Frankauthor=L.+B.+Holzmanauthor=J.+Wuauthor=S.+Sebtiauthor=R.+Jove&title=Requirement+for+Ras%2FRac1-mediated+p38+and+c-Jun+N-terminal+kinase+signaling+in+Stat3+transcriptional+activity+induced+by+the+Src+oncoprotein&doi=10.1128%2FMCB.19.11.7519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein</span></div><div class="casAuthors">Turkson, James; Bowman, Tammy; Adnane, Jalila; Zhang, Yi; Djeu, Julie Y.; Sekharam, Madhavi; Frank, David A.; Holzman, Lawrence B.; Wu, Jie; Sebti, Said; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7519-7528</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Signal transducers and activators of transcription (STATs) are transcription factors that mediate normal biol. responses to cytokines and growth factors.  However, abnormal activation of certain STAT family members, including Stat3, is increasingly assocd. with oncogenesis.  In fibroblasts expressing the Src oncoprotein, activation of Stat3 induces specific gene expression and is required for cell transformation.  Although the Src tyrosine kinase induces constitutive Stat3 phosphorylation on tyrosine, activation of Stat3-mediated gene regulation requires both tyrosine and serine phosphorylation of Stat3.  The authors investigated the signaling pathways underlying the constitutive Stat3 activation in Src oncogenesis.  Expression of Ras or Rac1 dominant neg. protein blocks Stat3-mediated gene regulation induced by Src in a manner consistent with dependence on p38 and c-Jun N-terminal kinase (JNK).  Both of these serine/threonine kinases and Stat3 serine phosphorylation are constitutively induced in Src-transformed fibroblasts.  Furthermore, inhibition of p38 and JNK activities suppresses constitutive Stat3 serine phosphorylation and Stat3-mediated gene regulation.  In vitro kinase assays with purified full-length Stat3 as the substrate show that both JNK and p38 can phosphorylate Stat3 on serine.  Moreover, inhibition of p38 activity and thus of Stat3 serine phosphorylation results in suppression of transformation by v-Src but not v-Ras, consistent with a requirement for Stat3 serine phosphorylation in Src transformation.  Thus, Ras- and Rac1-mediated p38 and JNK signals are required for Stat3 transcriptional activity induced by the Src oncoprotein.  These findings delineate a network of tyrosine and serine/threonine kinase signaling pathways that converge on Stat3 in the context of oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpirhwvHZUk8rVg90H21EOLACvtfcHk0lgqnyjPZWLVaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvFekt7o%253D&md5=5aa32d4a465f4a692b77f7cd11b43b2c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.11.7519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.11.7519%26sid%3Dliteratum%253Aachs%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DBowman%26aufirst%3DT.%26aulast%3DAdnane%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDjeu%26aufirst%3DJ.%2BY.%26aulast%3DSekharam%26aufirst%3DM.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DHolzman%26aufirst%3DL.%2BB.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSebti%26aufirst%3DS.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DRequirement%2520for%2520Ras%252FRac1-mediated%2520p38%2520and%2520c-Jun%2520N-terminal%2520kinase%2520signaling%2520in%2520Stat3%2520transcriptional%2520activity%2520induced%2520by%2520the%2520Src%2520oncoprotein%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D7519%26epage%3D7528%26doi%3D10.1128%2FMCB.19.11.7519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, D.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibitors of the STAT3 signaling pathway</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112122</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2020.112122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32066011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGquro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112122&author=J.+Qinauthor=X.+Shenauthor=J.+Zhangauthor=D.+Jia&title=Allosteric+inhibitors+of+the+STAT3+signaling+pathway&doi=10.1016%2Fj.ejmech.2020.112122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibitors of the STAT3 signaling pathway</span></div><div class="casAuthors">Qin, Junhong; Shen, Xiaofei; Zhang, Jian; Jia, Da</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112122</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Over-expression and/or hyperactivation of signal transducer and activator of transcription 3 (STAT3) signaling are found in various human diseases, including cancer, autoimmune disorders, and inflammatory diseases.  Therefore, STAT3 represents a highly promising therapeutic target for the treatment of these diseases.  However, the traditional orthosteric inhibitors of STAT3 exhibit limited clin. efficacy, with low selectivity, numerous side effects, and emerging acquired resistance.  Allosteric inhibitors targeting STAT3 or its upstream mols. have emerged as a promising approach to overcome these barriers.  In this review, we summarize the recent advances in the development of these inhibitors as well as their applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa406JYjL_hbVg90H21EOLACvtfcHk0lgqnyjPZWLVaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGquro%253D&md5=df6d54c3472afce40e63060605cabf73</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112122%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DD.%26atitle%3DAllosteric%2520inhibitors%2520of%2520the%2520STAT3%2520signaling%2520pathway%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112122%26doi%3D10.1016%2Fj.ejmech.2020.112122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, D.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.-m.</span></span> <span> </span><span class="NLM_article-title">Inhibition of STAT3 acetylation is associated with angiotesin renal fibrosis in the obstructed kidney</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1045</span>â <span class="NLM_lpage">1054</span>, <span class="refDoi">Â DOI: 10.1038/aps.2014.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Faps.2014.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24976155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Gqt7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=1045-1054&author=J.+Niauthor=Y.+Shenauthor=Z.+Wangauthor=D.-c.+Shaoauthor=J.+Liuauthor=L.-j.+Fuauthor=Y.-l.+Kongauthor=L.+Zhouauthor=H.+Xueauthor=Y.+Huangauthor=W.+Zhangauthor=C.+Yuauthor=L.-m.+Lu&title=Inhibition+of+STAT3+acetylation+is+associated+with+angiotesin+renal+fibrosis+in+the+obstructed+kidney&doi=10.1038%2Faps.2014.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of STAT3 acetylation is associated with angiotesin renal fibrosis in the obstructed kidney</span></div><div class="casAuthors">Ni, Jun; Shen, Yang; Wang, Zhen; Shao, De-cui; Liu, Jia; Fu, Lan-jun; Kong, Ya-li; Zhou, Li; Xue, Hong; Huang, Yu; Zhang, Wei; Yu, Chen; Lu, Li-min</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1045-1054</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: To explore the relationship between the signal transducer and activator of transcription 3 (STAT3) signaling and renal fibrosis.  Methods: Rat renal tubular epithelial NRK-52E cells were treated with angiotesin II (Ang II), nicotinamide (an inhibitor of NAD+-dependent class III protein deacetylases, SIRT1-7), or resveratrol (an activator of SIRT1).  Mice underwent unilateral ureteral obstruction (UUO) were used for in vivo studies.  Renal interstitial fibrosis was obsd. with HE and Masson's trichrome staining.  STAT3 acetylation and phosphorylation, fibronectin, collagen I, collagen IV, and Î±-smooth muscle actin (Î±-SMA) levels were examd. using Western blotting.  Results: Nicotinamide (0.625-10 mmol/L) dose-dependently increased STAT3 acetylation on Lys685 and phosphorylation on Tyr705 in NRK-52E cells, accompanied by accumulation of fibronectin and collagen IV.  Ang II increased STAT3 phosphorylation on Tyr705 and the expression of fibronectin, collagen IV and Î±-SMA in the cells.  Pretreatment with resveratrol (12.5 Î¼mol/L) blocked Ang II-induced effects in the cells.  UUO induced marked STAT3 phosphorylation, fibronectin, collagen IV and Î±-SMA accumulation, and renal interstitial fibrosis in the obstructed kidneys, which were significantly attenuated by daily administration of resveratrol (100 mg/kg).  Conclusion: STAT3 acetylation plays an important role in activation of STAT3 signaling pathway and consequent renal fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIN_kegmb64LVg90H21EOLACvtfcHk0lgqnyjPZWLVaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Gqt7rL&md5=41ea1a8d831258b61f18f9944bfd037b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Faps.2014.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2014.42%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DShao%26aufirst%3DD.-c.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.-j.%26aulast%3DKong%26aufirst%3DY.-l.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DL.-m.%26atitle%3DInhibition%2520of%2520STAT3%2520acetylation%2520is%2520associated%2520with%2520angiotesin%2520renal%2520fibrosis%2520in%2520the%2520obstructed%2520kidney%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D1045%26epage%3D1054%26doi%3D10.1038%2Faps.2014.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherukuri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span> <span> </span><span class="NLM_article-title">Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">11528</span>â <span class="NLM_lpage">11534</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M413930200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M413930200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=15649887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVyjtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=11528-11534&author=R.+Wangauthor=P.+Cherukuriauthor=J.+Luo&title=Activation+of+Stat3+sequence-specific+DNA+binding+and+transcription+by+p300%2FCREB-binding+protein-mediated+acetylation&doi=10.1074%2Fjbc.M413930200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Stat3 Sequence-specific DNA Binding and Transcription by p300/CREB-binding Protein-mediated Acetylation</span></div><div class="casAuthors">Wang, Rui; Cherukuri, Pratima; Luo, Jianyuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">11528-11534</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Signal transducers and activators of transcription (Stat) belong to a family of latent cytoplasmic factors that can be activated by tyrosine phosphorylation by members of the Jak tyrosine kinase family in response to a variety of cytokines and growth factors.  Activated Stats form dimers and translocate into nucleus to induce expression of crit. genes essential for normal cellular events.  Here we report for the first time that Stat3 can be modified by acetylation both in vivo and in vitro.  A major site of Stat3 that is acetylated by its coactivator, p300/CREB-binding protein (CBP), resides in the C-terminal transcriptional activation domain at lysine 685.  Furthermore, the acetylation of Stat3 can stimulate its sequence-specific DNA binding ability and transactivation activity.  Inhibition of histone deacetylase activity in cells results in increased Stat3 nuclear localization.  These observations clearly indicate a novel mechanism for Stat3 activation in mammalian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ra9np1B00LVg90H21EOLACvtfcHk0lgLYdygtMC86A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVyjtr0%253D&md5=902f7fd6c851e7c526abd0af7eb7fb44</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M413930200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M413930200%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DCherukuri%26aufirst%3DP.%26aulast%3DLuo%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520Stat3%2520sequence-specific%2520DNA%2520binding%2520and%2520transcription%2520by%2520p300%252FCREB-binding%2520protein-mediated%2520acetylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D11528%26epage%3D11534%26doi%3D10.1074%2Fjbc.M413930200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, Y. E.</span></span> <span> </span><span class="NLM_article-title">Stat3 dimerization regulated by reversible acetylation of a single lysine residue</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">273</span>, <span class="refDoi">Â DOI: 10.1126/science.1105166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1126%2Fscience.1105166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=15653507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVKktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=269-273&author=Z.-L.+Yuanauthor=Y.-J.+Guanauthor=D.+Chatterjeeauthor=Y.+E.+Chin&title=Stat3+dimerization+regulated+by+reversible+acetylation+of+a+single+lysine+residue&doi=10.1126%2Fscience.1105166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue</span></div><div class="casAuthors">Yuan, Zheng-long; Guan, Ying-jie; Chatterjee, Devasis; Chin, Y. Eugene</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5707</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Upon cytokine treatment, members of the signal transducers and activators of transcription (STAT) family of proteins are phosphorylated on tyrosine and serine sites within the carboxyl-terminal region in cells.  We show that in response to cytokine treatment, Stat3 is also acetylated on a single lysine residue, Lys685.  Histone acetyltransferase p300-mediated Stat3 acetylation on Lys685 was reversible by type I histone deacetylase (HDAC).  Use of a prostate cancer cell line (PC3) that lacks Stat3 and PC3 cells expressing wild-type Stat3 or a Stat3 mutant contg. a Lys685-to-Arg substitution revealed that Lys685 acetylation was crit. for Stat3 to form stable dimers required for cytokine-stimulated DNA binding and transcriptional regulation, to enhance transcription of cell growth-related genes, and to promote cell cycle progression in response to treatment with oncostatin M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw5wKGemOEgbVg90H21EOLACvtfcHk0lgLYdygtMC86A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVKktA%253D%253D&md5=0579f46bb06bf59d507295909c0c79be</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1126%2Fscience.1105166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1105166%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DZ.-L.%26aulast%3DGuan%26aufirst%3DY.-J.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DChin%26aufirst%3DY.%2BE.%26atitle%3DStat3%2520dimerization%2520regulated%2520by%2520reversible%2520acetylation%2520of%2520a%2520single%2520lysine%2520residue%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D269%26epage%3D273%26doi%3D10.1126%2Fscience.1105166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoon, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">7765</span>â <span class="NLM_lpage">7769</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1205132109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.1205132109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22547799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Kntrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=7765-7769&author=H.+Leeauthor=P.+Zhangauthor=A.+Herrmannauthor=C.+Yangauthor=H.+Xinauthor=Z.+Wangauthor=D.+S.+Hoonauthor=S.+J.+Formanauthor=R.+Joveauthor=A.+D.+Riggsauthor=H.+Yu&title=Acetylated+STAT3+is+crucial+for+methylation+of+tumor-suppressor+gene+promoters+and+inhibition+by+resveratrol+results+in+demethylation&doi=10.1073%2Fpnas.1205132109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation</span></div><div class="casAuthors">Lee, Heehyoung; Zhang, Peng; Herrmann, Andreas; Yang, Chunmei; Xin, Hong; Wang, Zhenghe; Hoon, Dave S. B.; Forman, Stephen J.; Jove, Richard; Riggs, Arthur D.; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7765-7769, S7765/1-S7765/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mechanisms underlying hypermethylation of tumor-suppressor gene promoters in cancer is not well understood.  Here, we report that lysine acetylation of the oncogenic transcription factor STAT3 is elevated in tumors.  We also show that genetically altering STAT3 at Lys685 reduces tumor growth, which is accompanied by demethylation and reactivation of several tumor-suppressor genes.  Moreover, mutating STAT3 at Lys685 disrupts DNA methyltransferase 1-STAT3 interactions in cultured tumor cells and in tumors.  These observations are confirmed by treatment with an acetylation inhibitor, resveratrol.  Furthermore, redn. of acetylated STAT3 in triple-neg. breast cancer cells leads to demethylation and activation of the estrogen receptor-Î± gene, sensitizing the tumor cells to antiestrogens.  Our results also demonstrate a correlation between STAT3 acetylation and methylation of estrogen receptor-a in melanoma, which predicts melanoma progression.  Taken together, these results suggest a role of STAT3 acetylation in regulating CpG island methylation, which may partially explain aberrant gene silencing in cancer.  These findings also provide a rationale for targeting acetylated STAT3 for chemoprevention and cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK2L3nwZs04LVg90H21EOLACvtfcHk0lh5rgp905oJJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Kntrw%253D&md5=5ebf41ab98d7784ffe266ed32e3d7ed8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1205132109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1205132109%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DXin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHoon%26aufirst%3DD.%2BS.%26aulast%3DForman%26aufirst%3DS.%2BJ.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DRiggs%26aufirst%3DA.%2BD.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DAcetylated%2520STAT3%2520is%2520crucial%2520for%2520methylation%2520of%2520tumor-suppressor%2520gene%2520promoters%2520and%2520inhibition%2520by%2520resveratrol%2520results%2520in%2520demethylation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D7765%26epage%3D7769%26doi%3D10.1073%2Fpnas.1205132109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, L. M.</span></span> <span> </span><span class="NLM_article-title">Unphosphorylated STAT3 regulates the antiproliferative, antiviral, and gene-inducing actions of type I interferons</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>490</i></span>,  <span class="NLM_fpage">739</span>â <span class="NLM_lpage">745</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2017.06.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bbrc.2017.06.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28642132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjtrvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2017&pages=739-745&author=S.+R.+Pfefferauthor=M.+Fanauthor=Z.+Duauthor=C.+H.+Yangauthor=L.+M.+Pfeffer&title=Unphosphorylated+STAT3+regulates+the+antiproliferative%2C+antiviral%2C+and+gene-inducing+actions+of+type+I+interferons&doi=10.1016%2Fj.bbrc.2017.06.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Unphosphorylated STAT3 regulates the antiproliferative, antiviral, and gene-inducing actions of type I interferons</span></div><div class="casAuthors">Pfeffer, Susan R.; Fan, Meiyun; Du, Ziyun; Yang, Chuan He; Pfeffer, Lawrence M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">490</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">739-745</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Type I interferon (IFNÎ±/Î²) induces antiviral and antiproliferative responses in cells through the induction of IFN-stimulated genes (ISGs).  Although the roles of IFN-activated STAT1 and STAT2 in the IFN response are well described, the function of STAT3 is poorly characterized.  We investigated the role of STAT3 in the biol. response to IFNÎ±/Î² in mouse embryonic fibroblasts (MEFs) with a germ line deletion of STAT3.  These STAT3 knockout (STAT3-KO) MEFs were reconstituted with STAT3 or the F705-STAT3 mutant (unphosphorylated STAT3) where the canonical Y705 tyrosine phosphorylation site was mutated.  We show that both STAT3 and unphosphorylated STAT3 expression enhance the sensitivity of MEFs to the antiviral, antiproliferative and gene-inducing actions of IFN.  By chromatin immunopptn. assays, unphosphorylated STAT3 appears to bind, albeit weakly, to select gene promoters to enhance their expression.  These results suggest that unphosphorylated STAT3 plays an important role in the IFN response pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-gQRT4n_fM7Vg90H21EOLACvtfcHk0lh5rgp905oJJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjtrvL&md5=07069fcc45ad9ef9901b401e07ac92da</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.06.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.06.111%26sid%3Dliteratum%253Aachs%26aulast%3DPfeffer%26aufirst%3DS.%2BR.%26aulast%3DFan%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DPfeffer%26aufirst%3DL.%2BM.%26atitle%3DUnphosphorylated%2520STAT3%2520regulates%2520the%2520antiproliferative%252C%2520antiviral%252C%2520and%2520gene-inducing%2520actions%2520of%2520type%2520I%2520interferons%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D490%26spage%3D739%26epage%3D745%26doi%3D10.1016%2Fj.bbrc.2017.06.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">736</span>â <span class="NLM_lpage">746</span>, <span class="refDoi">Â DOI: 10.1038/nrc3818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fnrc3818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25342631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=736-746&author=H.+Yuauthor=H.+Leeauthor=A.+Herrmannauthor=R.+Buettnerauthor=R.+Jove&title=Revisiting+STAT3+signalling+in+cancer%3A+new+and+unexpected+biological+functions&doi=10.1038%2Fnrc3818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span></div><div class="casAuthors">Yu, Hua; Lee, Heehyoung; Herrmann, Andreas; Buettner, Ralf; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">736-746</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins, particularly STAT3, are among the most promising new targets for cancer therapy.  In addn. to interleukin-6 (IL-6) and its family members, multiple pathways, including G-protein-coupled receptors (GPCRs), Toll-like receptors (TLRs) and microRNAs were recently identified to regulate JAK-STAT signalling in cancer.  Well known for its role in tumor cell proliferation, survival, invasion and immunosuppression, JAK-STAT3 signalling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche.  In addn. to its established role as a transcription factor in cancer, STAT3 regulates mitochondrion functions, as well as gene expression through epigenetic mechanisms.  Newly identified regulators and functions of JAK-STAT3 in tumors are important targets for potential therapeutic strategies in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3PGL62I5KvrVg90H21EOLACvtfcHk0lhnUawS8FKWdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF&md5=355a07303813d7ecadb4b085c33c5e0a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrc3818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3818%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DRevisiting%2520STAT3%2520signalling%2520in%2520cancer%253A%2520new%2520and%2520unexpected%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D736%26epage%3D746%26doi%3D10.1038%2Fnrc3818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rincon, M.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Stat3, the need for design thinking</span>. <i>Int. J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">532</span>â <span class="NLM_lpage">544</span>, <span class="refDoi">Â DOI: 10.7150/ijbs.15153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.7150%2Fijbs.15153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27019635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCitb7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=532-544&author=R.+Yangauthor=M.+Rincon&title=Mitochondrial+Stat3%2C+the+need+for+design+thinking&doi=10.7150%2Fijbs.15153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Stat3, the need for design thinking</span></div><div class="casAuthors">Yang, Rui; Rincon, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">532-544</span>CODEN:
                <span class="NLM_cas:coden">IJBSB9</span>;
        ISSN:<span class="NLM_cas:issn">1449-2288</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Stat3 has been studied extensively as a transcription factor, however the finding that Stat3 also localizes to mitochondria has opened a new area to discover non-classical functions.  Here we review the current knowledge of mitochondrial Stat3 as a regulator of the electron transport chain (ETC) and its impact on mitochondrial prodn. of ATP and ROS.  We also describe recent findings identifying Stat3 as a regulator of mitochondrial Ca2+ homeostasis through its effect on the ETC.  It is becoming evident that these non-classical functions of Stat3 can have a major impact on cancer progression, cardiovascular diseases, and inflammatory diseases.  Therefore, mitochondrial Stat3 functions challenge the current design of therapies that solely target Stat3 as a transcription factor and suggest the need for "design thinking," which leads to the development of novel strategies, to intervene the Stat3 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqREutDqjn__7Vg90H21EOLACvtfcHk0lhnUawS8FKWdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCitb7P&md5=f636d01092126fcc6ebc3b42fcb7cb29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.7150%2Fijbs.15153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijbs.15153%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DR.%26aulast%3DRincon%26aufirst%3DM.%26atitle%3DMitochondrial%2520Stat3%252C%2520the%2520need%2520for%2520design%2520thinking%26jtitle%3DInt.%2520J.%2520Biol.%2520Sci.%26date%3D2016%26volume%3D12%26spage%3D532%26epage%3D544%26doi%3D10.7150%2Fijbs.15153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reigan, P.</span></span> <span> </span><span class="NLM_article-title">Strategies and approaches of targeting STAT3 for cancer treatment</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">308</span>â <span class="NLM_lpage">318</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.5b00945</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00945" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOqsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=308-318&author=S.+L.+Furtekauthor=D.+S.+Backosauthor=C.+J.+Mathesonauthor=P.+Reigan&title=Strategies+and+approaches+of+targeting+STAT3+for+cancer+treatment&doi=10.1021%2Facschembio.5b00945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and Approaches of Targeting STAT3 for Cancer Treatment</span></div><div class="casAuthors">Furtek, Steffanie L.; Backos, Donald S.; Matheson, Christopher J.; Reigan, Philip</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-318</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates the expression of genes related to cell cycle, cell survival, and immune response assocd. with cancer progression and malignancy in a no. of cancer types.  Once activated, STAT3 forms a homodimer and translocates to the nucleus where it binds DNA promoting the translation of target genes assocd. with antiapoptosis, angiogenesis, and invasion/migration.  In normal cells, levels of activated STAT3 remain transient; however, STAT3 remains constitutively active in approx. 70% of human solid tumors.  The pivotal role of STAT3 in tumor progression has promoted a campaign in drug discovery to identify small mols. that disrupt the function of STAT3.  A range of approaches have been used to identify novel small mol. inhibitors of STAT3, including high-throughput screening of chem. libraries, computational-based virtual screening, and fragment-based design strategies.  The most common approaches in targeting STAT3 activity are either via the inhibition of tyrosine kinases capable of phosphorylating and thereby activating STAT3 or by preventing the formation of functional STAT3 dimers through disruption of the SH2 domains.  However, the targeting of the STAT3 DNA-binding domain and disruption of binding of STAT3 to its DNA promoter have not been thoroughly examd., mainly due to the lack of adequate assay systems.  This review summarizes the development of STAT3 inhibitors organized by the approach used to inhibit STAT3, the current inhibitors of each class, and the assay systems used to evaluate STAT3 inhibition and offers an insight into future approaches for small mol. STAT3 inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokCygAKrPD6rVg90H21EOLACvtfcHk0ljCyJPME2L_LQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOqsA%253D%253D&md5=379321e035a5dbce720e1c787da55aad</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00945%26sid%3Dliteratum%253Aachs%26aulast%3DFurtek%26aufirst%3DS.%2BL.%26aulast%3DBackos%26aufirst%3DD.%2BS.%26aulast%3DMatheson%26aufirst%3DC.%2BJ.%26aulast%3DReigan%26aufirst%3DP.%26atitle%3DStrategies%2520and%2520approaches%2520of%2520targeting%2520STAT3%2520for%2520cancer%2520treatment%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D308%26epage%3D318%26doi%3D10.1021%2Facschembio.5b00945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Montalvo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheibye-Knudsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armour, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohr, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinclair, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cabo, R.</span></span> <span> </span><span class="NLM_article-title">Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">19270</span>â <span class="NLM_lpage">19279</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M110.200311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M110.200311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21467030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms1Sjtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=19270-19279&author=M.+Bernierauthor=R.+K.+Paulauthor=A.+Martin-Montalvoauthor=M.+Scheibye-Knudsenauthor=S.+Songauthor=H.-J.+Heauthor=S.+M.+Armourauthor=B.+P.+Hubbardauthor=V.+A.+Bohrauthor=L.+Wangauthor=Y.+Zongauthor=D.+A.+Sinclairauthor=R.+de+Cabo&title=Negative+regulation+of+STAT3+protein-mediated+cellular+respiration+by+SIRT1+protein&doi=10.1074%2Fjbc.M110.200311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein</span></div><div class="casAuthors">Bernier, Michel; Paul, Rajib K.; Martin-Montalvo, Alejandro; Scheibye-Knudsen, Morten; Song, Shao-Ming; He, Hua-Jun; Armour, Sean M.; Hubbard, Basil P.; Bohr, Vilhelm A.; Wang, Li-Li; Zong, Ya-Ping; Sinclair, David A.; de Cabo, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">19270-19279</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In mammals, the transcriptional activity of signal transducer and activator of transcription 3 (STAT3) is regulated by the deacetylase SIRT1.  However, whether the newly described nongenomic actions of STAT3 toward mitochondrial oxidative phosphorylation are dependent on SIRT1 is unclear.  In this study, Sirt1 gene knock-out murine embryonic fibroblast (MEF) cells were used to delineate the role of SIRT1 in the regulation of STAT3 mitochondrial function.  Here, we show that STAT3 mRNA and protein levels and the accumulation of serine-phosphorylated STAT3 in mitochondria were increased significantly in Sirt1-KO cells as compared with wild-type MEFs.  Various mitochondrial bioenergetic parameters, such as the oxygen consumption rate in cell cultures, enzyme activities of the electron transport chain complexes in isolated mitochondria, and prodn. of ATP and lactate, indicated that Sirt1-KO cells exhibited higher mitochondrial respiration as compared with wild-type MEFs.  Two independent approaches, including ectopic expression of SIRT1 and siRNA-mediated knockdown of STAT3, led to redn. in intracellular ATP levels and increased lactate prodn. in Sirt1-KO cells that were approaching those of wild-type controls.  Comparison of profiles of phospho-antibody array data indicated that the deletion of SirT1 was accompanied by constitutive activation of the pro-inflammatory NF-ÎºB pathway, which is key for STAT3 induction and increased cellular respiration in Sirt1-KO cells.  Thus, SIRT1 appears to be a functional regulator of NF-ÎºB-dependent STAT3 expression that induces mitochondrial biogenesis.  These results have implications for understanding the interplay between STAT3 and SIRT1 in pro-inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9TaFKgtCL-LVg90H21EOLACvtfcHk0ljCyJPME2L_LQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms1Sjtro%253D&md5=e94cb12b2e1b79b18194acc406764972</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.200311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.200311%26sid%3Dliteratum%253Aachs%26aulast%3DBernier%26aufirst%3DM.%26aulast%3DPaul%26aufirst%3DR.%2BK.%26aulast%3DMartin-Montalvo%26aufirst%3DA.%26aulast%3DScheibye-Knudsen%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DH.-J.%26aulast%3DArmour%26aufirst%3DS.%2BM.%26aulast%3DHubbard%26aufirst%3DB.%2BP.%26aulast%3DBohr%26aufirst%3DV.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZong%26aufirst%3DY.%26aulast%3DSinclair%26aufirst%3DD.%2BA.%26aulast%3Dde%2BCabo%26aufirst%3DR.%26atitle%3DNegative%2520regulation%2520of%2520STAT3%2520protein-mediated%2520cellular%2520respiration%2520by%2520SIRT1%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D19270%26epage%3D19279%26doi%3D10.1074%2Fjbc.M110.200311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span> <span> </span><span class="NLM_article-title">GSTP1 negatively regulates Stat3 activation in epidermal growth factor signaling</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1053</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.3892/ol.2012.1098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3892%2Fol.2012.1098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23426146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Wmsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1053-1057&author=X.+Kouauthor=N.+Chenauthor=Z.+Fengauthor=L.+Luoauthor=Z.+Yin&title=GSTP1+negatively+regulates+Stat3+activation+in+epidermal+growth+factor+signaling&doi=10.3892%2Fol.2012.1098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">GSTP1 negatively regulates Stat3 activation in epidermal growth factor signaling</span></div><div class="casAuthors">Kou, Xianjuan; Chen, Ning; Feng, Zhiyong; Luo, Lan; Yin, Zhimin</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Glutathione S-transferases (GSTs) are the enzymes that defend cells against the damage mediated by oxidant and electrophilic carcinogens.  GSTÏ (GSTP1) is a member of the GST family and the hypermethylation GSTP1 CpG island DNA is detected in human hepatocellular carcinoma (HCC) tissues, which contributes to the neg. expression of GSTP1 mRNA and protein.  GSTP1 expression is considered to be an early event in HCC.  Stat3, a member of the signal transduction and activator of transcription (Stat) family, is important for promoting the proliferation, survival and other biol. processes of cells triggered by cytokines and growth factors.  Activated Stat3 may participate in oncogenesis.  Previous studies have demonstrated that overexpression of phosphorylated Stat3 is important in the proliferation of HCC cells, suggesting that disturbance of the Stat3 pathway may be an early event.  We hypothesize that the suppression of GSTP1 expression in HCC cells increases Stat3 activation.  In order to test this hypothesis, HepG2 cells were genetically modified to transiently express high levels of GSTP1.  The transient expression of GSTP1 specifically downregulated epidermal growth factor (EGF)-mediated tyrosine phosphorylation of Stat3, and subsequently suppressed the transcriptional activity of Stat3.  By contrast, GSTP1 RNAi was able to lead to an increase in the phosphorylation of Stat3.  In addn., overexpression of GSTP1 was capable of reducing the survival of HepG2 cells and inducing cell cycle arrest.  This inhibition was mediated by a direct interaction between GSTP1 and Stat3.  Overall, our results suggest that GSTP1 is important in the regulation of the transcriptional activity of Stat3, and that it is also a regulator of the cell cycle via EGF signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbB6S0_MGg8LVg90H21EOLACvtfcHk0lhcciLM0M1oLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Wmsrg%253D&md5=4c7fa3a65dd84ea32d96979517200aab</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3892%2Fol.2012.1098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2012.1098%26sid%3Dliteratum%253Aachs%26aulast%3DKou%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DZ.%26atitle%3DGSTP1%2520negatively%2520regulates%2520Stat3%2520activation%2520in%2520epidermal%2520growth%2520factor%2520signaling%26jtitle%3DOncol.%2520Lett.%26date%3D2013%26volume%3D5%26spage%3D1053%26epage%3D1057%26doi%3D10.3892%2Fol.2012.1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arfuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span> <span> </span><span class="NLM_article-title">The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">327</span>, <span class="refDoi">Â DOI: 10.3390/cancers10090327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fcancers10090327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyhsbrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=327&author=L.+Aroraauthor=A.+P.+Kumarauthor=F.+Arfusoauthor=W.+J.+Chngauthor=G.+Sethi&title=The+role+of+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+and+its+targeted+inhibition+in+hematological+malignancies&doi=10.3390%2Fcancers10090327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies</span></div><div class="casAuthors">Arora, Loukik; Kumar, Alan Prem; Arfuso, Frank; Chng, Wee Joo; Sethi, Gautam</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">327/1-327/17</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3), a member of the STAT protein family, can be phosphorylated by receptor-assocd. Janus kinases (JAKs) in response to stimulation by cytokines and growth factors.  It forms homo- or heterodimers that can translocate to the cell nucleus where they act as transcription activators.  Constitutive activation of STAT3 has been found to be assocd. with initiation and progression of various cancers.  It can exert proliferative as well as anti-apoptotic effects.  This review focuses on the role of STAT3 in pathogenesis i.e., proliferation, differentiation, migration, and apoptosis of hematol. malignancies viz. leukemia, lymphoma and myeloma, and briefly highlights the potential therapeutic approaches developed against STAT3 activation pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnoDRq06VAHbVg90H21EOLACvtfcHk0lhcciLM0M1oLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyhsbrK&md5=f6c9892a2c7980e5cde5984ca788b84a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.3390%2Fcancers10090327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers10090327%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DArfuso%26aufirst%3DF.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DSethi%26aufirst%3DG.%26atitle%3DThe%2520role%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520and%2520its%2520targeted%2520inhibition%2520in%2520hematological%2520malignancies%26jtitle%3DCancers%26date%3D2018%26volume%3D10%26spage%3D327%26doi%3D10.3390%2Fcancers10090327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. D.</span></span> <span> </span><span class="NLM_article-title">STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">195</span>, <span class="refDoi">Â DOI: 10.1186/s13046-019-1206-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2Fs13046-019-1206-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31088482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB3M7lslegsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=195&author=J.+J.+Qinauthor=L.+Yanauthor=J.+Zhangauthor=W.+D.+Zhang&title=STAT3+as+a+potential+therapeutic+target+in+triple+negative+breast+cancer%3A+a+systematic+review&doi=10.1186%2Fs13046-019-1206-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review</span></div><div class="casAuthors">Qin Jiang-Jiang; Yan Li; Zhang Wei-Dong; Zhang Jia; Zhang Wei-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple negative breast cancer (TNBC), which is typically lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), represents the most aggressive and mortal subtype of breast cancer.  Currently, only a few treatment options are available for TNBC due to the absence of molecular targets, which underscores the need for developing novel therapeutic and preventive approaches for this disease.  Recent evidence from clinical trials and preclinical studies has demonstrated a pivotal role of signal transducer and activator of transcription 3 (STAT3) in the initiation, progression, metastasis, and immune evasion of TNBC.  STAT3 is overexpressed and constitutively activated in TNBC cells and contributes to cell survival, proliferation, cell cycle progression, anti-apoptosis, migration, invasion, angiogenesis, chemoresistance, immunosuppression, and stem cells self-renewal and differentiation by regulating the expression of its downstream target genes.  STAT3 small molecule inhibitors have been developed and shown excellent anticancer activities in in vitro and in vivo models of TNBC.  This review discusses the recent advances in the understanding of STAT3, with a focus on STAT3's oncogenic role in TNBC.  The current targeting strategies and representative small molecule inhibitors of STAT3 are highlighted.  We also propose potential strategies that can be further examined for developing more specific and effective inhibitors for TNBC prevention and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmoOYd9tKrj0H3Rlp_k91zfW6udTcc2ebO73PsRpxrBbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7lslegsg%253D%253D&md5=b09ebc4b874740ae2ab1064e3ab493a8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1206-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1206-z%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%2BJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%2BD.%26atitle%3DSTAT3%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520triple%2520negative%2520breast%2520cancer%253A%2520a%2520systematic%2520review%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D195%26doi%3D10.1186%2Fs13046-019-1206-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagayasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, I.</span></span> <span> </span><span class="NLM_article-title">Activation of STAT3 is a marker of poor prognosis in human colorectal cancer</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1445</span>â <span class="NLM_lpage">1451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=16685378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVOisrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=1445-1451&author=T.+Kusabaauthor=T.+Nakayamaauthor=K.+Yamazumiauthor=Y.+Yakataauthor=A.+Yoshizakiauthor=K.+Inoueauthor=T.+Nagayasuauthor=I.+Sekine&title=Activation+of+STAT3+is+a+marker+of+poor+prognosis+in+human+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of STAT3 is a marker of poor prognosis in human colorectal cancer</span></div><div class="casAuthors">Kusaba, Takafumi; Nakayama, Toshiyuki; Yamazumi, Kazuyuki; Yakata, Yuichi; Yoshizaki, Ayumi; Inoue, Kenichiro; Nagayasu, Takeshi; Sekine, Ichiro</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1445-1451</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">It is known that the signal transducer and activator of transcription 3 (STAT3) is a key signaling mol. implicated in the regulation of growth and malignant transformation.  Constitutive activation of STAT3 has been obsd. in a no. of tumor-derived cell lines, as well as in a wide variety of human malignancies.  The present study was conducted to examine p-STAT3 (activated form of STAT3) expression and its assocn. with clinicopathol. factors and prognosis in human colorectal adenocarcinomas.  Expression of p-STAT3 was immunohistochem. examd. in 108 cases of colorectal adenocarcinoma tissue obtained at surgery and was found in 57.4% of tumors (62 of 108).  P-STAT3 immunoreactivity significantly correlated with the depth grading of tumor invasion (p<0.001), lymphatic invasion(p<0.05), Dukes' classification (p<0.05), stage (p<0.001) and prognosis after operation (p<0.001).  Expression of p-STAT3 was a marker of poor prognosis in overall survival (p<0.01).  Expression of p-STAT3 was detected by Western blot anal. in three colon carcinoma tissue samples obtained at surgery.  To our knowledge, this is the first study on the poor prognosis of p-STAT3 in human colorectal adenocarcinomas.  These findings suggest that expression of p-STAT3 is an important factor related to tumor invasion and poor prognosis of human colorectal adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnwaaijfYpMLVg90H21EOLACvtfcHk0liYeU_yJ_YVTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVOisrc%253D&md5=fce5c794143714b6c3f1cab70b3bc434</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKusaba%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DYamazumi%26aufirst%3DK.%26aulast%3DYakata%26aufirst%3DY.%26aulast%3DYoshizaki%26aufirst%3DA.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DNagayasu%26aufirst%3DT.%26aulast%3DSekine%26aufirst%3DI.%26atitle%3DActivation%2520of%2520STAT3%2520is%2520a%2520marker%2520of%2520poor%2520prognosis%2520in%2520human%2520colorectal%2520cancer%26jtitle%3DOncol.%2520Rep.%26date%3D2006%26volume%3D15%26spage%3D1445%26epage%3D1451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maennling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tur, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klockenbring, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeppernick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GattenlÃ¶hner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinhold-Heerlein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, A. F.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1826</span>, <span class="refDoi">Â DOI: 10.3390/cancers11121826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fcancers11121826" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVynsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1826&author=A.+E.+Maennlingauthor=M.+K.+Turauthor=M.+Niebertauthor=T.+Klockenbringauthor=F.+Zeppernickauthor=S.+Gattenl%C3%B6hnerauthor=I.+Meinhold-Heerleinauthor=A.+F.+Hussain&title=Molecular+targeting+therapy+against+EGFR+family+in+breast+cancer%3A+progress+and+future+potentials&doi=10.3390%2Fcancers11121826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials</span></div><div class="casAuthors">Maennling, Amaia Eleonora; Tur, Mehmet Kemal; Niebert, Marcus; Klockenbring, Torsten; Zeppernick, Felix; Gattenloehner, Stefan; Meinhold-Heerlein, Ivo; Hussain, Ahmad Fawzi</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1826</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands.  EGFRs are overexpressed in many solid tumors, including breast, pancreas, head-and-neck, prostate, ovarian, renal, colon, and non-small-cell lung cancer.  Such overexpression produces strong stimulation of downstream signaling pathways, which induce cell growth, cell differentiation, cell cycle progression, angiogenesis, cell motility and blocking of apoptosis.The high expression and/or functional activation of EGFRs correlates with the pathogenesis and progression of several cancers, which make them attractive targets for both diagnosis and therapy.  Several approaches have been developed to target these receptors and/or the EGFR modulated effects in cancer cells.  Most approaches include the development of anti-EGFRs antibodies and/or small-mol. EGFR inhibitors.  This review presents the state-of-the-art and future prospects of targeting EGFRs to treat breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRgawFJxhRYrVg90H21EOLACvtfcHk0liYeU_yJ_YVTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVynsbs%253D&md5=50f9789bad152dcbceb675d73af198b6</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3390%2Fcancers11121826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11121826%26sid%3Dliteratum%253Aachs%26aulast%3DMaennling%26aufirst%3DA.%2BE.%26aulast%3DTur%26aufirst%3DM.%2BK.%26aulast%3DNiebert%26aufirst%3DM.%26aulast%3DKlockenbring%26aufirst%3DT.%26aulast%3DZeppernick%26aufirst%3DF.%26aulast%3DGattenl%25C3%25B6hner%26aufirst%3DS.%26aulast%3DMeinhold-Heerlein%26aufirst%3DI.%26aulast%3DHussain%26aufirst%3DA.%2BF.%26atitle%3DMolecular%2520targeting%2520therapy%2520against%2520EGFR%2520family%2520in%2520breast%2520cancer%253A%2520progress%2520and%2520future%2520potentials%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1826%26doi%3D10.3390%2Fcancers11121826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahrmann, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshitz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somlo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandial, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT3-regulated fatty acid Î²-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">136</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2017.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.cmet.2017.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29249690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2js7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=136-150&author=T.+Wangauthor=J.+F.+Fahrmannauthor=H.+Leeauthor=Y.+J.+Liauthor=S.+C.+Tripathiauthor=C.+Yueauthor=C.+Zhangauthor=V.+Lifshitzauthor=J.+Songauthor=Y.+Yuanauthor=G.+Somloauthor=R.+Jandialauthor=D.+Annauthor=S.+Hanashauthor=R.+Joveauthor=H.+Yu&title=JAK%2FSTAT3-regulated+fatty+acid+%CE%B2-oxidation+is+critical+for+breast+cancer+stem+cell+self-renewal+and+chemoresistance&doi=10.1016%2Fj.cmet.2017.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT3-Regulated Fatty Acid Î²-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance</span></div><div class="casAuthors">Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung; Li, Yi-Jia; Tripathi, Satyendra C.; Yue, Chanyu; Zhang, Chunyan; Lifshitz, Veronica; Song, Jieun; Yuan, Yuan; Somlo, George; Jandial, Rahul; Ann, David; Hanash, Samir; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-150.e5</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are crit. for cancer progression and chemoresistance.  How lipid metab. regulates CSCs and chemoresistance remains elusive.  Here, we demonstrate that JAK/STAT3 regulates lipid metab., which promotes breast CSCs (BCSCs) and cancer chemoresistance.  Inhibiting JAK/STAT3 blocks BCSC self-renewal and expression of diverse lipid metabolic genes, including carnitine palmitoyltransferase 1B (CPT1B), which encodes the crit. enzyme for fatty acid Î²-oxidn. (FAO).  Moreover, mammary-adipocyte-derived leptin upregulates STAT3-induced CPT1B expression and FAO activity in BCSCs.  Human breast-cancer-derived data suggest that the STAT3-CPT1B-FAO pathway promotes cancer cell stemness and chemoresistance.  Blocking FAO and/or leptin re-sensitizes them to chemotherapy and inhibits BCSCs in mouse breast tumors in vivo.  We identify a crit. pathway for BCSC maintenance and breast cancer chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzVt0Snzhqc7Vg90H21EOLACvtfcHk0lhGDFcAog8KFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2js7%252FE&md5=a763990bd98b8b37a97e321aaf4fcd0f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2017.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2017.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DFahrmann%26aufirst%3DJ.%2BF.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DTripathi%26aufirst%3DS.%2BC.%26aulast%3DYue%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLifshitz%26aufirst%3DV.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DSomlo%26aufirst%3DG.%26aulast%3DJandial%26aufirst%3DR.%26aulast%3DAnn%26aufirst%3DD.%26aulast%3DHanash%26aufirst%3DS.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DJAK%252FSTAT3-regulated%2520fatty%2520acid%2520%25CE%25B2-oxidation%2520is%2520critical%2520for%2520breast%2520cancer%2520stem%2520cell%2520self-renewal%2520and%2520chemoresistance%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26spage%3D136%26epage%3D150%26doi%3D10.1016%2Fj.cmet.2017.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orgaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz-Moreno, V.</span></span> <span> </span><span class="NLM_article-title">Emerging molecular targets in melanoma invasion and metastasis</span>. <i>Pigm. Cell Melanoma Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">39</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.1111/pcmr.12041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1111%2Fpcmr.12041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23095214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislygs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=39-57&author=J.+L.+Orgazauthor=V.+Sanz-Moreno&title=Emerging+molecular+targets+in+melanoma+invasion+and+metastasis&doi=10.1111%2Fpcmr.12041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging molecular targets in melanoma invasion and metastasis</span></div><div class="casAuthors">Orgaz, Jose L.; Sanz-Moreno, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Pigment Cell & Melanoma Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-57</span>CODEN:
                <span class="NLM_cas:coden">PCMRCM</span>;
        ISSN:<span class="NLM_cas:issn">1755-1471</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Metastatic cutaneous melanoma accounts for the majority of skin cancer deaths due to its aggressiveness and high resistance to current therapies.  To efficiently metastasize, invasive melanoma cells need to change their cytoskeletal organization and alter contacts with the extracellular matrix and the surrounding stromal cells.  Melanoma cells can use different migratory strategies depending on varying environments to exit the primary tumor mass and invade surrounding and later distant tissues.  In this review, we have focused on tumor cell plasticity or the interconvertibility that melanoma cells have as one of the factors that contribute to melanoma metastasis.  This has been an area of very intense research in the last 5 yr yielding a vast no. of findings.  We have therefore reviewed all the possible clin. opportunities that this new knowledge offers to both stratify and treat cutaneous malignant melanoma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAAFwukf3SrVg90H21EOLACvtfcHk0lhGDFcAog8KFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislygs70%253D&md5=4a848e5e3d5e7a1b19f3f84eabd27288</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fpcmr.12041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcmr.12041%26sid%3Dliteratum%253Aachs%26aulast%3DOrgaz%26aufirst%3DJ.%2BL.%26aulast%3DSanz-Moreno%26aufirst%3DV.%26atitle%3DEmerging%2520molecular%2520targets%2520in%2520melanoma%2520invasion%2520and%2520metastasis%26jtitle%3DPigm.%2520Cell%2520Melanoma%2520Res.%26date%3D2013%26volume%3D26%26spage%3D39%26epage%3D57%26doi%3D10.1111%2Fpcmr.12041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span> <span> </span><span class="NLM_article-title">Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">567</span>â <span class="NLM_lpage">597</span>, <span class="refDoi">Â DOI: 10.4155/fmc.11.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.4155%2Ffmc.11.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21526897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlejtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=567-597&author=D.+Masciocchiauthor=A.+Gelainauthor=S.+Villaauthor=F.+Meneghettiauthor=D.+Barlocco&title=Signal+transducer+and+activator+of+transcription+3+%28STAT3%29%3A+a+promising+target+for+anticancer+therapy&doi=10.4155%2Ffmc.11.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy</span></div><div class="casAuthors">Masciocchi, Daniela; Gelain, Arianna; Villa, Stefania; Meneghetti, Fiorella; Barlocco, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">567-597</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) is an oncogenic protein whose inhibition is sought for the prevention and treatment of cancer.  In this review, the validated therapeutic strategy to block aberrant activity of STAT3 in many tumor cell lines is evaluated by presenting the most promising inhibitors to date.  The compds. are discussed in classes based on their different mechanisms of action, which are critically explained.  In addn., their future clin. development as anticancer agents is considered.  Furthermore, the efforts devoted to the comprehension of the structure--activity relationships and to the identification of the biol. effects are brought to attention.  The synthetic and technol. approaches recently developed to overcome the difficulties in the obtainment of clin. suitable drugs are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJPzLbSkoDLVg90H21EOLACvtfcHk0lha58H8MLcC_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlejtb0%253D&md5=a6e0f478fe6c9db89afea342f0aab536</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.22%26sid%3Dliteratum%253Aachs%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DSignal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%253A%2520a%2520promising%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D567%26epage%3D597%26doi%3D10.4155%2Ffmc.11.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goradia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghunath, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paessler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysocka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasik, M. A.</span></span> <span> </span><span class="NLM_article-title">Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">20852</span>â <span class="NLM_lpage">20857</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0810958105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.0810958105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=19088198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFSntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=20852-20857&author=M.+Marzecauthor=Q.+Zhangauthor=A.+Goradiaauthor=P.+N.+Raghunathauthor=X.+Liuauthor=M.+Paesslerauthor=H.+Y.+Wangauthor=M.+Wysockaauthor=M.+Chengauthor=B.+A.+Ruggeriauthor=M.+A.+Wasik&title=Oncogenic+kinase+NPM%2FALK+induces+through+STAT3+expression+of+immunosuppressive+protein+CD274+%28PD-L1%2C+B7-H1%29&doi=10.1073%2Fpnas.0810958105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)</span></div><div class="casAuthors">Marzec, Michal; Zhang, Qian; Goradia, Ami; Raghunath, Puthiyaveettil N.; Liu, Xiaobin; Paessler, Michele; Wang, Hong Yi; Wysocka, Maria; Cheng, Mangeng; Ruggeri, Bruce A.; Wasik, Mariusz A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">20852-20857</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mechanisms of malignant cell transformation caused by the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) remain only partially understood, with most of the previous studies focusing mainly on the impact of NPM/ALK on cell survival and proliferation.  Here we report that the NPM/ALK-carrying T cell lymphoma (ALK + TCL) cells strongly express the immunosuppressive cell-surface protein CD274 (PD-L1, B7-H1), as detd. on the mRNA and protein level.  The CD274 expression is strictly dependent on the expression and enzymic activity of NPM/ALK, as demonstrated by inhibition of the NPM/ALK function in ALK + TCL cells by the small mol. ALK inhibitor CEP-14083 and by documenting CD274 expression in IL-3-depleted BaF3 cells transfected with the wild-type NPM/ALK, but not the kinase-inactive NPM/ALK K210R mutant or empty vector alone.  NPM/ALK induces CD274 expression by activating its key signal transmitter, transcription factor STAT3.  STAT3 binds to the CD274 gene promoter in vitro and in vivo, as shown in the gel electromobility shift and chromatin immunopptn. assays, and is required for the PD-L1 gene expression, as demonstrated by siRNA-mediated STAT3 depletion.  These findings identify an addnl. cell-transforming property of NPM/ALK and describe a direct link between an oncoprotein and an immunosuppressive cell-surface protein.  These results also provide an addnl. rationale to therapeutically target NPM/ALK and STAT3 in ALK + TCL.  Finally, they suggest that future immunotherapeutic protocols for this type of lymphoma may need to include the inhibition of NPM/ALK and STAT3 to achieve optimal clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh87qHOgigfrVg90H21EOLACvtfcHk0lha58H8MLcC_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFSntw%253D%253D&md5=1e85c07581e48e5aa0b9c7d685b57eef</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0810958105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0810958105%26sid%3Dliteratum%253Aachs%26aulast%3DMarzec%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGoradia%26aufirst%3DA.%26aulast%3DRaghunath%26aufirst%3DP.%2BN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DPaessler%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWysocka%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DWasik%26aufirst%3DM.%2BA.%26atitle%3DOncogenic%2520kinase%2520NPM%252FALK%2520induces%2520through%2520STAT3%2520expression%2520of%2520immunosuppressive%2520protein%2520CD274%2520%2528PD-L1%252C%2520B7-H1%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D20852%26epage%3D20857%26doi%3D10.1073%2Fpnas.0810958105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">5952</span>â <span class="NLM_lpage">5966</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0379-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41388-018-0379-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29980788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12ltrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=5952-5966&author=A.+Liauthor=P.+Chenauthor=Y.+Lengauthor=J.+Kang&title=Histone+deacetylase+6+regulates+the+immunosuppressive+properties+of+cancer-associated+fibroblasts+in+breast+cancer+through+the+STAT3-COX2-dependent+pathway&doi=10.1038%2Fs41388-018-0379-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway</span></div><div class="casAuthors">Li, Ang; Chen, Ping; Leng, Ye; Kang, Jiuhong</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">5952-5966</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts (CAFs) are important components in breast tumors and essential for tumor progression and metastasis.  However, the role of epigenetic modification in driving the function of CAFs within breast tumors is only marginally known.  Herein, we reported that histone deacetylase 6 (HDAC6), one of class II histone deacetylases, was frequently upregulated in the CAFs of breast tumor and promotes an immunosuppressive microenvironment.  The genetic or pharmacol. disruption of HDAC6 in CAFs delays tumor growth, inhibits the tumor recruitment of myeloid-derived suppressor cells and regulatory T cells, alters the macrophage phenotype switch, and increases the CD8+ and CD4+ T-cell activation in vivo.  Mechanistically, we identified prostaglandin E2/cyclooxygenase-2 (COX2) as a major target of HDAC6 in CAFs by regulating STAT3 activation.  Overexpressing COX2 in HDAC6-knockdown CAFs can completely restore the immunosuppressive properties of the fibroblasts.  Clin., a pos. correlation among the stromal expression levels of HDAC6, p-STAT3, and COX2 in human breast cancer was obsd.  High-stromal expression of HDAC6 was markedly assocd. with poor survival outcome.  Overall, our findings indicated that fibroblastic HDAC6 was a vital epigenetic mediator involved in programming an immunosuppressive tumor microenvironment that dampens antitumor immunity.  Thus, HDAC6 may be a good potential target to improve breast cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMfVNR-7vuhbVg90H21EOLACvtfcHk0lha58H8MLcC_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12ltrjM&md5=c34f57fe88bcc9dbf43ee0ae09ca1bb6</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0379-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0379-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase%25206%2520regulates%2520the%2520immunosuppressive%2520properties%2520of%2520cancer-associated%2520fibroblasts%2520in%2520breast%2520cancer%2520through%2520the%2520STAT3-COX2-dependent%2520pathway%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D5952%26epage%3D5966%26doi%3D10.1038%2Fs41388-018-0379-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugimiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamano, K.</span></span> <span> </span><span class="NLM_article-title">JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>438</i></span>,  <span class="NLM_fpage">513</span>â <span class="NLM_lpage">518</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2013.07.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bbrc.2013.07.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23911788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12itrfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2013&pages=513-518&author=A.+Nishimotoauthor=N.+Kugimiyaauthor=T.+Hosoyamaauthor=T.+Enokiauthor=T.+S.+Liauthor=K.+Hamano&title=JAB1+regulates+unphosphorylated+STAT3+DNA-binding+activity+through+protein-protein+interaction+in+human+colon+cancer+cells&doi=10.1016%2Fj.bbrc.2013.07.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells</span></div><div class="casAuthors">Nishimoto, Arata; Kugimiya, Naruji; Hosoyama, Toru; Enoki, Tadahiko; Li, Tao-Sheng; Hamano, Kimikazu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">513-518</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent studies have revealed that unphosphorylated STAT3 forms a dimer, translocates to the nucleus, binds to the STAT3 binding site, and activates the transcription of STAT3 target genes, thereby playing an important role in oncogenesis in addn. to phosphorylated STAT3.  Among signaling steps of unphosphorylated STAT3, nuclear translocation and target DNA-binding are the crit. steps for its activation.  Therefore, elucidating the regulatory mechanism of these signaling steps of unphosphorylated STAT3 is a potential step in the discovery of a novel cancer drug.  However, the mechanism of unphosphorylated STAT3 binding to the promoter of target genes remains unclear.  In this study, we focused on Jun activation domain-binding protein 1 (JAB1) as a candidate protein that regulates unphosphorylated STAT3 DNA-binding activity.  Initially, we obsd. that both unphosphorylated STAT3 and JAB1 existed in the nucleus of human colon cancer cell line COLO205 at the basal state (no cytokine stimulation).  On the other hand, phosphorylated STAT3 did not exist in the nucleus of COLO205 cells at the basal state.  Immunopptn. using nuclear ext. of COLO205 cells revealed that JAB1 interacted with unphosphorylated STAT3.  To investigate the effect of JAB1 on unphosphorylated STAT3 activity, RNAi studies were performed.  Although JAB1 knockdown tended to increase nuclear STAT3 expression, it significantly decreased unphosphorylated STAT3 DNA-binding activity.  Subsequently, JAB1 knockdown significantly decreased the expression levels of MDR1, NANOG, and VEGF, which are STAT3 target genes.  Furthermore, the expression level of nuclear JAB1, but not nuclear STAT3, correlated with unphosphorylated STAT3 DNA-binding activity between COLO205 and LoVo cells.  Taken together, these results suggest that nuclear JAB1 pos. regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cell line COLO205.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY69k0T89OPrVg90H21EOLACvtfcHk0linF-KcZBkd7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12itrfE&md5=0f14d97602736856bdc60da775d94610</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.07.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.07.105%26sid%3Dliteratum%253Aachs%26aulast%3DNishimoto%26aufirst%3DA.%26aulast%3DKugimiya%26aufirst%3DN.%26aulast%3DHosoyama%26aufirst%3DT.%26aulast%3DEnoki%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DT.%2BS.%26aulast%3DHamano%26aufirst%3DK.%26atitle%3DJAB1%2520regulates%2520unphosphorylated%2520STAT3%2520DNA-binding%2520activity%2520through%2520protein-protein%2520interaction%2520in%2520human%2520colon%2520cancer%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D438%26spage%3D513%26epage%3D518%26doi%3D10.1016%2Fj.bbrc.2013.07.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auron, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, G. R.</span></span> <span> </span><span class="NLM_article-title">Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1396</span>â <span class="NLM_lpage">1408</span>, <span class="refDoi">Â DOI: 10.1101/gad.1553707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1101%2Fgad.1553707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=17510282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFSgsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1396-1408&author=J.+Yangauthor=X.+Liaoauthor=M.+K.+Agarwalauthor=L.+Barnesauthor=P.+E.+Auronauthor=G.+R.+Stark&title=Unphosphorylated+STAT3+accumulates+in+response+to+IL-6+and+activates+transcription+by+binding+to+NFkappaB&doi=10.1101%2Fgad.1553707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFÎºB</span></div><div class="casAuthors">Yang, Jinbo; Liao, Xudong; Agarwal, Mukesh K.; Barnes, Laura; Auron, Philip E.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1396-1408</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Gp130-linked cytokines such as interleukin-6 (IL-6) stimulate the formation of tyrosine-phosphorylated signal transducer and activator of transcription 3 (P-STAT3), which activates many genes, including the STAT3 gene itself.  The resulting increase in the concn. of unphosphorylated STAT3 (U-STAT3) drives a second wave of expression of genes such as RANTES, IL6, IL8, MET, and MRAS that do not respond directly to P-STAT3.  Thus, U-STAT3 sustains cytokine-dependent signaling at late times through a mechanism completely distinct from that used by P-STAT3.  Many U-STAT3-responsive genes have ÎºB elements that are activated by a novel transcription factor complex formed when U-STAT3 binds to unphosphorylated NFÎºB (U-NFÎºB), in competition with IÎºB.  The U-STAT3/U-NFÎºB complex accumulates in the nucleus with help from the nuclear localization signal of STAT3, activating a subset of ÎºB-dependent genes.  Addnl. genes respond to U-STAT3 through an NFÎºB-independent mechanism.  The role of signal-dependent increases in U-STAT3 expression in regulating gene expression is likely to be important in physiol. responses to gp130-linked cytokines and growth factors that activate STAT3, and in cancers that have constitutively active P-STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquGJGBFct9XrVg90H21EOLACvtfcHk0linF-KcZBkd7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFSgsbY%253D&md5=6ef4898e8f6a1657f01afea666327a7b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1101%2Fgad.1553707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1553707%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DX.%26aulast%3DAgarwal%26aufirst%3DM.%2BK.%26aulast%3DBarnes%26aufirst%3DL.%26aulast%3DAuron%26aufirst%3DP.%2BE.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DUnphosphorylated%2520STAT3%2520accumulates%2520in%2520response%2520to%2520IL-6%2520and%2520activates%2520transcription%2520by%2520binding%2520to%2520NFkappaB%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D1396%26epage%3D1408%26doi%3D10.1101%2Fgad.1553707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timofeeva, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chasovskikh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasova, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khavrutskii, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasov, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korostyshevskiy, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakshanamurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dritschilo, A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">14192</span>â <span class="NLM_lpage">14200</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M111.323899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M111.323899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22378781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGlu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=14192-14200&author=O.+A.+Timofeevaauthor=S.+Chasovskikhauthor=I.+Lonskayaauthor=N.+I.+Tarasovaauthor=L.+Khavrutskiiauthor=S.+G.+Tarasovauthor=X.+Zhangauthor=V.+R.+Korostyshevskiyauthor=A.+Cheemaauthor=L.+Zhangauthor=S.+Dakshanamurthyauthor=M.+L.+Brownauthor=A.+Dritschilo&title=Mechanisms+of+unphosphorylated+STAT3+transcription+factor+binding+to+DNA&doi=10.1074%2Fjbc.M111.323899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA</span></div><div class="casAuthors">Timofeeva, Olga A.; Chasovskikh, Sergey; Lonskaya, Irina; Tarasova, Nadya I.; Khavrutskii, Lyuba; Tarasov, Sergey G.; Zhang, Xueping; Korostyshevskiy, Valeriy R.; Cheema, Amrita; Zhang, Lihua; Dakshanamurthy, Sivanesan; Brown, Milton L.; Dritschilo, Anatoly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">14192-14200</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Phosphorylation of signal transducer and activator of transcription 3 (STAT3) on a single tyrosine residue in response to growth factors, cytokines, interferons, and oncogenes activates its dimerization, translocation to the nucleus, binding to the interferon Î³ (gamma)-activated sequence (GAS) DNA-binding site and activation of transcription of target genes.  STAT3 is constitutively phosphorylated in various cancers and drives gene expression from GAS-contg. promoters to promote tumorigenesis.  Recently, roles for unphosphorylated STAT3 (U-STAT3) have been described in response to cytokine stimulation, in cancers, and in maintenance of heterochromatin stability.  However, the mechanisms underlying U-STAT3 binding to DNA has not been fully investigated.  Here, the authors explore STAT3-DNA interactions by at. force microscopy (AFM) imaging.  They obsd. that U-STAT3 mols. bind to the GAS DNA-binding site as dimers and monomers.  In addn., U-STAT3 binds to AT-rich DNA sequence sites and recognizes specific DNA structures, such as 4-way junctions and DNA nodes, within neg. supercoiled plasmid DNA.  These structures are important for chromatin organization and the data suggest a role for U-STAT3 as a chromatin/genome organizer.  Unexpectedly, a C-terminal truncated 67.5-kDa STAT3 isoform recognizes single-stranded spacers within cruciform structures that also have a role in chromatin organization and gene expression.  This isoform appears to be abundant in the nuclei of cancer cells and, therefore, may have a role in regulation of gene expression.  Taken together, these data highlight novel mechanisms by which U-STAT3 binds to DNA and supports U-STAT3 function as a transcriptional activator and a chromatin/genomic organizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodgCG9j0qVLrVg90H21EOLACvtfcHk0linF-KcZBkd7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGlu78%253D&md5=3da0856a85b9d2a51b8797f09c00aedd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.323899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.323899%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeeva%26aufirst%3DO.%2BA.%26aulast%3DChasovskikh%26aufirst%3DS.%26aulast%3DLonskaya%26aufirst%3DI.%26aulast%3DTarasova%26aufirst%3DN.%2BI.%26aulast%3DKhavrutskii%26aufirst%3DL.%26aulast%3DTarasov%26aufirst%3DS.%2BG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKorostyshevskiy%26aufirst%3DV.%2BR.%26aulast%3DCheema%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDakshanamurthy%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DM.%2BL.%26aulast%3DDritschilo%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520unphosphorylated%2520STAT3%2520transcription%2520factor%2520binding%2520to%2520DNA%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D14192%26epage%3D14200%26doi%3D10.1074%2Fjbc.M111.323899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collie, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neidle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinzalla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilderspin, A. F.</span></span> <span> </span><span class="NLM_article-title">Observation of unphosphorylated STAT3 core protein binding to target dsDNA by PEMSA and X-ray crystallography</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>587</i></span>,  <span class="NLM_fpage">833</span>â <span class="NLM_lpage">839</span>, <span class="refDoi">Â DOI: 10.1016/j.febslet.2013.01.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.febslet.2013.01.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23434585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFCjsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=587&publication_year=2013&pages=833-839&author=E.+Nkansahauthor=R.+Shahauthor=G.+W.+Collieauthor=G.+N.+Parkinsonauthor=J.+Palmerauthor=K.+M.+Rahmanauthor=T.+T.+Buiauthor=A.+F.+Drakeauthor=J.+Husbyauthor=S.+Neidleauthor=G.+Zinzallaauthor=D.+E.+Thurstonauthor=A.+F.+Wilderspin&title=Observation+of+unphosphorylated+STAT3+core+protein+binding+to+target+dsDNA+by+PEMSA+and+X-ray+crystallography&doi=10.1016%2Fj.febslet.2013.01.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Observation of unphosphorylated STAT3 core protein binding to target dsDNA by PEMSA and X-ray crystallography</span></div><div class="casAuthors">Nkansah, Edwin; Shah, Rahi; Collie, Gavin W.; Parkinson, Gary N.; Palmer, Jonathan; Rahman, Khondaker M.; Bui, Tam T.; Drake, Alex F.; Husby, Jarmila; Neidle, Stephen; Zinzalla, Giovanna; Thurston, David E.; Wilderspin, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">587</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">833-839</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The STAT3 transcription factor plays a central role in a wide range of cancer types where it is over-expressed.  Previously, phosphorylation of this protein was thought to be a prerequisite for direct binding to DNA.  However, we have now shown complete binding of a purified unphosphorylated STAT3 (uSTAT3) core directly to M67 DNA, the high affinity STAT3 target DNA sequence, by a protein electrophoretic mobility shift assay (PEMSA).  Binding to M67 DNA was inhibited by addn. of increasing concns. of a phosphotyrosyl peptide.  X-ray crystallog. demonstrates one mode of binding that is similar to that known for the STAT3 core phosphorylated at Y705.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4GeAbWkvLMbVg90H21EOLACvtfcHk0lhsUw5YZDowyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFCjsbc%253D&md5=e88431e48b72f959b842d56652b24abf</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2013.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2013.01.065%26sid%3Dliteratum%253Aachs%26aulast%3DNkansah%26aufirst%3DE.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DCollie%26aufirst%3DG.%2BW.%26aulast%3DParkinson%26aufirst%3DG.%2BN.%26aulast%3DPalmer%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26aulast%3DBui%26aufirst%3DT.%2BT.%26aulast%3DDrake%26aufirst%3DA.%2BF.%26aulast%3DHusby%26aufirst%3DJ.%26aulast%3DNeidle%26aufirst%3DS.%26aulast%3DZinzalla%26aufirst%3DG.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DWilderspin%26aufirst%3DA.%2BF.%26atitle%3DObservation%2520of%2520unphosphorylated%2520STAT3%2520core%2520protein%2520binding%2520to%2520target%2520dsDNA%2520by%2520PEMSA%2520and%2520X-ray%2520crystallography%26jtitle%3DFEBS%2520Lett.%26date%3D2013%26volume%3D587%26spage%3D833%26epage%3D839%26doi%3D10.1016%2Fj.febslet.2013.01.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvvuri, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freilino, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapireddy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seethala, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooding, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, J. R.</span></span> <span> </span><span class="NLM_article-title">First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">694</span>â <span class="NLM_lpage">705</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-12-0191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1158%2F2159-8290.CD-12-0191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22719020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygs7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=694-705&author=M.+Senauthor=S.+M.+Thomasauthor=S.+Kimauthor=J.+I.+Yehauthor=R.+L.+Ferrisauthor=J.+T.+Johnsonauthor=U.+Duvvuriauthor=J.+Leeauthor=N.+Sahuauthor=S.+Joyceauthor=M.+L.+Freilinoauthor=H.+Shiauthor=C.+Liauthor=D.+Lyauthor=S.+Rapireddyauthor=J.+P.+Etterauthor=P.+K.+Liauthor=L.+Wangauthor=S.+Chioseaauthor=R.+R.+Seethalaauthor=W.+E.+Goodingauthor=X.+Chenauthor=N.+Kaminskiauthor=K.+Panditauthor=D.+E.+Johnsonauthor=J.+R.+Grandis&title=First-in-human+trial+of+a+STAT3+decoy+oligonucleotide+in+head+and+neck+tumors%3A+implications+for+cancer+therapy&doi=10.1158%2F2159-8290.CD-12-0191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy</span></div><div class="casAuthors">Sen, Malabika; Thomas, Sufi M.; Kim, Seungwon; Yeh, Joanne I.; Ferris, Robert L.; Johnson, Jonas T.; Duvvuri, Umamaheswar; Lee, Jessica; Sahu, Nivedita; Joyce, Sonali; Freilino, Maria L.; Shi, Haibin; Li, Changyou; Ly, Danith; Rapireddy, Srinivas; Etter, Jonathan P.; Li, Pui-Kai; Wang, Lin; Chiosea, Simion; Seethala, Raja R.; Gooding, William E.; Chen, Xiaomin; Kaminski, Naftali; Pandit, Kusum; Johnson, Daniel E.; Grandis, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">694-705</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Intratumoral injection of a STAT3 decoy oligonucleotide safely reduced target gene expression in a phase 0 clin. trial, and chem. modification may enable systemic delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-o4-IpQzSw7Vg90H21EOLACvtfcHk0lhsUw5YZDowyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygs7bI&md5=ba85a39a2036f3c5480c3cf5274b2f46</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0191%26sid%3Dliteratum%253Aachs%26aulast%3DSen%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DYeh%26aufirst%3DJ.%2BI.%26aulast%3DFerris%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DJ.%2BT.%26aulast%3DDuvvuri%26aufirst%3DU.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSahu%26aufirst%3DN.%26aulast%3DJoyce%26aufirst%3DS.%26aulast%3DFreilino%26aufirst%3DM.%2BL.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLy%26aufirst%3DD.%26aulast%3DRapireddy%26aufirst%3DS.%26aulast%3DEtter%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DP.%2BK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChiosea%26aufirst%3DS.%26aulast%3DSeethala%26aufirst%3DR.%2BR.%26aulast%3DGooding%26aufirst%3DW.%2BE.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKaminski%26aufirst%3DN.%26aulast%3DPandit%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DD.%2BE.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26atitle%3DFirst-in-human%2520trial%2520of%2520a%2520STAT3%2520decoy%2520oligonucleotide%2520in%2520head%2520and%2520neck%2520tumors%253A%2520implications%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D694%26epage%3D705%26doi%3D10.1158%2F2159-8290.CD-12-0191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span> <span> </span><span class="NLM_article-title">A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1188</span>â <span class="NLM_lpage">1196</span>, <span class="refDoi">Â DOI: 10.1021/cb500071v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500071v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVSjs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1188-1196&author=W.+Huangauthor=Z.+Dongauthor=F.+Wangauthor=H.+Pengauthor=J.+Y.+Liuauthor=J.+T.+Zhang&title=A+small+molecule+compound+targeting+STAT3+DNA-binding+domain+inhibits+cancer+cell+proliferation%2C+migration%2C+and+invasion&doi=10.1021%2Fcb500071v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion</span></div><div class="casAuthors">Huang, Wei; Dong, Zizheng; Wang, Fang; Peng, Hui; Liu, Jing-Yuan; Zhang, Jian-Ting</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1188-1196</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) plays important roles in multiple aspects of cancer aggressiveness including migration, invasion, survival, self-renewal, angiogenesis, and tumor cell immune evasion by regulating the expression of multiple downstream target genes.  STAT3 is constitutively activated in many malignant tumors and its activation is assocd. with high histol. grade and advanced cancer stages.  Thus, inhibiting STAT3 promises an attracting strategy for treatment of advanced and metastatic cancers.  Herein, the authors identified a STAT3 inhibitor, inS3-54, by targeting the DNA-binding domain of STAT3 using an improved virtual screening strategy.  InS3-54 preferentially suppresses proliferation of cancer over non-cancer cells and inhibits migration and invasion of malignant cells.  Biochem. analyses show that inS3-54 selectively inhibits STAT3 binding to DNA without affecting the activation and dimerization of STAT3.  Furthermore, inS3-54 inhibits expression of STAT3 downstream target genes and STAT3 binding to chromatin in situ.  Thus, inS3-54 represents a novel probe for development of specific inhibitors targeting the DNA-binding domain of STAT3 and a potential therapeutic for cancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc4i9uuvhaAbVg90H21EOLACvtfcHk0lhOCbx8WXV_sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVSjs74%253D&md5=df65197ba614fdf2251ad238a2e30ceb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb500071v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500071v%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26atitle%3DA%2520small%2520molecule%2520compound%2520targeting%2520STAT3%2520DNA-binding%2520domain%2520inhibits%2520cancer%2520cell%2520proliferation%252C%2520migration%252C%2520and%2520invasion%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1188%26epage%3D1196%26doi%3D10.1021%2Fcb500071v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangoc, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxmeyer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">783</span>â <span class="NLM_lpage">792</span>, <span class="refDoi">Â DOI: 10.1038/onc.2015.215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fonc.2015.215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26073084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xitl2gtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=783-792&author=W.+Huangauthor=Z.+Dongauthor=Y.+Chenauthor=F.+Wangauthor=C.+J.+Wangauthor=H.+Pengauthor=Y.+Heauthor=G.+Hangocauthor=K.+Pollokauthor=G.+Sanduskyauthor=X.+Y.+Fuauthor=H.+E.+Broxmeyerauthor=Z.+Y.+Zhangauthor=J.+Y.+Liuauthor=J.+T.+Zhang&title=Small-molecule+inhibitors+targeting+the+DNA-binding+domain+of+STAT3+suppress+tumor+growth%2C+metastasis+and+STAT3+target+gene+expression+in+vivo&doi=10.1038%2Fonc.2015.215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo</span></div><div class="casAuthors">Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C. J.; Peng, H.; He, Y.; Hangoc, G.; Pollok, K.; Sandusky, G.; Fu, X-Y.; Broxmeyer, H. E.; Zhang, Z-Y.; Liu, J-Y.; Zhang, J-T.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness.  Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors.  Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clin. trials.  Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its 'undruggable' nature and potentially limited selectivity.  In a previous study, the authors reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-mol. STAT3 inhibitor (inS3-54).  Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1.  In this study, the authors describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compd. (inS3-54A18) with increased specificity and pharmacol. properties.  InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes.  InS3-54A18 is completely sol. in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals.  Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be 'undruggable' as previously thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUfTEBNtpUqLVg90H21EOLACvtfcHk0lhOCbx8WXV_sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xitl2gtL8%253D&md5=9d05b09d30218f28894291192c258760</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.215%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DC.%2BJ.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DPollok%26aufirst%3DK.%26aulast%3DSandusky%26aufirst%3DG.%26aulast%3DFu%26aufirst%3DX.%2BY.%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26atitle%3DSmall-molecule%2520inhibitors%2520targeting%2520the%2520DNA-binding%2520domain%2520of%2520STAT3%2520suppress%2520tumor%2520growth%252C%2520metastasis%2520and%2520STAT3%2520target%2520gene%2520expression%2520in%2520vivo%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26spage%3D783%26epage%3D792%26doi%3D10.1038%2Fonc.2015.215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweon, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span> <span> </span><span class="NLM_article-title">MMPP attenuates non-small cell lung cancer growth by inhibiting the STAT3 DNA-binding activity via direct binding to the STAT3 DNA-binding domain</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">4632</span>â <span class="NLM_lpage">4642</span>, <span class="refDoi">Â DOI: 10.7150/thno.18630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.7150%2Fthno.18630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29158850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFaitL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=4632-4642&author=D.+J.+Sonauthor=J.+Zhengauthor=Y.+Y.+Jungauthor=C.+J.+Hwangauthor=H.+P.+Leeauthor=J.+R.+Wooauthor=S.+Y.+Baekauthor=Y.+W.+Hamauthor=M.+W.+Kangauthor=M.+Shongauthor=G.+R.+Kweonauthor=M.+J.+Songauthor=J.+K.+Jungauthor=S.+B.+Hanauthor=B.+Y.+Kimauthor=D.+Y.+Yoonauthor=B.+Y.+Choiauthor=J.+T.+Hong&title=MMPP+attenuates+non-small+cell+lung+cancer+growth+by+inhibiting+the+STAT3+DNA-binding+activity+via+direct+binding+to+the+STAT3+DNA-binding+domain&doi=10.7150%2Fthno.18630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">MMPP attenuates non-small cell lung cancer growth by inhibiting the STAT3 DNA-binding activity via direct binding to the STAT3 DNA-binding domain</span></div><div class="casAuthors">Son, Dong Ju; Zheng, Jie; Jung, Yu Yeon; Hwang, Chul Ju; Lee, Hee Pom; Woo, Ju Rang; Baek, Song Yi; Ham, Young Wan; Kang, Min Woong; Shong, Minho; Kweon, Gi Ryang; Song, Min Jong; Jung, Jae Kyung; Han, Sang-Bae; Kim, Bo Yeon; Yoon, Do Young; Choi, Bu Young; Hong, Jin Tae</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4632-4642</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription-3 (STAT3) plays a pivotal role in cancer biol.  Many small-mol. inhibitors that target STAT3 have been developed as potential anticancer drugs.  While designing small-mol. inhibitors that target the SH2 domain of STAT3 remains the leading focus for drug discovery, there has been a growing interest in targeting the DNA-binding domain (DBD) of the protein.  We demonstrated the potential antitumor activity of a novel, small-mol. (E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol (MMPP) that directly binds to the DBD of STAT3, in patient-derived non-small cell lung cancer (NSCLC) xenograft model as well as in NCI-H460 cell xenograft model in nude mice.  MMPP effectively inhibited the phosphorylation of STAT3 and its DNA binding activity in vitro and in vivo.  It induced G1-phase cell cycle arrest and apoptosis through the regulation of cell cycle- and apoptosis-regulating genes by directly binding to the hydroxyl residue of threonine 456 in the DBD of STAT3.  Furthermore, MMPP showed a similar or better antitumor activity than that of docetaxel or cisplatin.  MMPP is suggested to be a potential candidate for further development as an anticancer drug that targets the DBD of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre4VJDJApG0bVg90H21EOLACvtfcHk0limDy8mQI0EFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFaitL%252FF&md5=574afad3ff6b5e9789184a565330a605</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.7150%2Fthno.18630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.18630%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DD.%2BJ.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DY.%2BY.%26aulast%3DHwang%26aufirst%3DC.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BP.%26aulast%3DWoo%26aufirst%3DJ.%2BR.%26aulast%3DBaek%26aufirst%3DS.%2BY.%26aulast%3DHam%26aufirst%3DY.%2BW.%26aulast%3DKang%26aufirst%3DM.%2BW.%26aulast%3DShong%26aufirst%3DM.%26aulast%3DKweon%26aufirst%3DG.%2BR.%26aulast%3DSong%26aufirst%3DM.%2BJ.%26aulast%3DJung%26aufirst%3DJ.%2BK.%26aulast%3DHan%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DB.%2BY.%26aulast%3DYoon%26aufirst%3DD.%2BY.%26aulast%3DChoi%26aufirst%3DB.%2BY.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26atitle%3DMMPP%2520attenuates%2520non-small%2520cell%2520lung%2520cancer%2520growth%2520by%2520inhibiting%2520the%2520STAT3%2520DNA-binding%2520activity%2520via%2520direct%2520binding%2520to%2520the%2520STAT3%2520DNA-binding%2520domain%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26spage%3D4632%26epage%3D4642%26doi%3D10.7150%2Fthno.18630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corzano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedvat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakushijin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakushijin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidehi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gugiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. C.</span></span> <span> </span><span class="NLM_article-title">Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">432</span>â <span class="NLM_lpage">443</span>, <span class="refDoi">Â DOI: 10.1021/cb100253e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100253e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitVSisLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=432-443&author=R.+Buettnerauthor=R.+Corzanoauthor=R.+Rashidauthor=J.+Linauthor=M.+Senthilauthor=M.+Hedvatauthor=A.+Schroederauthor=A.+Maoauthor=A.+Herrmannauthor=J.+Yimauthor=H.+Liauthor=Y.+C.+Yuanauthor=K.+Yakushijinauthor=F.+Yakushijinauthor=N.+Vaidehiauthor=R.+Mooreauthor=G.+Gugiuauthor=T.+D.+Leeauthor=R.+Yipauthor=Y.+Chenauthor=R.+Joveauthor=D.+Horneauthor=J.+C.+Williams&title=Alkylation+of+cysteine+468+in+Stat3+defines+a+novel+site+for+therapeutic+development&doi=10.1021%2Fcb100253e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development</span></div><div class="casAuthors">Buettner, Ralf; Corzano, Renzo; Rashid, Rumana; Lin, Jian-Ping; Senthil, Maheswari; Hedvat, Michael; Schroeder, Anne; Mao, Allen; Herrmann, Andreas; Yim, John; Li, Hong-Zhi; Yuan, Yate-Ching; Yakushijin, Ken-Ichi; Yakushijin, Fumiko; Vaidehi, Nagarajan; Moore, Roger; Gugiu, Gabriel; Lee, Terry D.; Yip, Richard; Chen, Yuan; Jove, Richard; Horne, David; Williams, John C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">432-443</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stat3 is a latent transcription factor that promotes cell survival and proliferation and is often constitutively active in multiple cancers.  Inhibition of Stat3 signaling pathways suppresses cell survival signals and leads to apoptosis in cancer cells, suggesting direct inhibition of Stat3 function is a viable therapeutic approach.  Herein, we identify a small mol., C48, as a selective Stat3-family member inhibitor.  To det. its mechanism of action, we used site-directed mutagenesis and multiple biochem. techniques to show that C48 alkylates Cys468 in Stat3, a residue at the DNA-binding interface.  We further demonstrate that C48 blocks accumulation of activated Stat3 in the nucleus in tumor cell lines that overexpress active Stat3, leading to impressive inhibition of tumor growth in mouse models.  Collectively, these findings suggest Cys468 in Stat3 represents a novel site for therapeutic intervention and demonstrates the promise of alkylation as a potentially effective chem. approach for Stat3-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp63z_APNdkQLVg90H21EOLACvtfcHk0limDy8mQI0EFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitVSisLk%253D&md5=256b3b0921a625e19fe232488e1996db</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fcb100253e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100253e%26sid%3Dliteratum%253Aachs%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DCorzano%26aufirst%3DR.%26aulast%3DRashid%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSenthil%26aufirst%3DM.%26aulast%3DHedvat%26aufirst%3DM.%26aulast%3DSchroeder%26aufirst%3DA.%26aulast%3DMao%26aufirst%3DA.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DYim%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DY.%2BC.%26aulast%3DYakushijin%26aufirst%3DK.%26aulast%3DYakushijin%26aufirst%3DF.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DGugiu%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DYip%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DHorne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BC.%26atitle%3DAlkylation%2520of%2520cysteine%2520468%2520in%2520Stat3%2520defines%2520a%2520novel%2520site%2520for%2520therapeutic%2520development%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D432%26epage%3D443%26doi%3D10.1021%2Fcb100253e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6645</span>â <span class="NLM_lpage">6668</span>, <span class="refDoi">Â DOI: 10.1021/jm300207s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300207s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6645-6668&author=B.+Debnathauthor=S.+Xuauthor=N.+Neamati&title=Small+molecule+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28Stat3%29+protein&doi=10.1021%2Fjm300207s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span></div><div class="casAuthors">Debnath, Bikash; Xu, Shili; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6645-6668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (Stat3) is a transcription factor belonging to the STAT protein family, members of which regulate a wide variety of biol. processes, including cell growth, proliferation, survival, differentiation, development, movement and inflammation in response to extracellular signaling mols. such as cytokines and growth factors.  Receptor assocd. tyrosine kinases phosphorylate Stat3 protein at Tyr705 and enable it to dimerize and subsequently enter the nucleus where it activates the transcription of its target genes.  Accumulating evidence has established Stat3's role in oncogenesis, cardiovascular diseases, rheumatoid arthritis, fibrotic, and Alzheimer's diseases.  Thus, Stat3 inhibition is a promising therapeutic approach not only for cancer, but also for other diseases.  Although Stat3 has been considered as an important therapeutic target, progress in discovery and development of effective and specific Stat3 inhibitors remains slow.  In this article we summarize Stat3 inhibitors published between 2006 and 2011.  New strategies along with novel technologies are required to achieve breakthrough in the development of Stat3 inhibitors that can be translated into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWQl9gV1-ZLVg90H21EOLACvtfcHk0liGBwR1JCx4lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D&md5=f5f3ac9f8fc2326c75edd2a9c136275b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm300207s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300207s%26sid%3Dliteratum%253Aachs%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528Stat3%2529%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6645%26epage%3D6668%26doi%3D10.1021%2Fjm300207s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boengler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungefug, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heusch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, R.</span></span> <span> </span><span class="NLM_article-title">The STAT3 inhibitor stattic impairs cardiomyocyte mitochondrial function through increased reactive oxygen species formation</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6890</span>â <span class="NLM_lpage">6895</span>, <span class="refDoi">Â DOI: 10.2174/138161281939131127115940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.2174%2F138161281939131127115940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23590160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFelu7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6890-6895&author=K.+Boenglerauthor=E.+Ungefugauthor=G.+Heuschauthor=R.+Schulz&title=The+STAT3+inhibitor+stattic+impairs+cardiomyocyte+mitochondrial+function+through+increased+reactive+oxygen+species+formation&doi=10.2174%2F138161281939131127115940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The STAT3 Inhibitor Stattic Impairs Cardiomyocyte Mitochondrial Function Through Increased Reactive Oxygen Species Formation</span></div><div class="casAuthors">Boengler, Kerstin; Ungefug, Elvira; Heusch, Gerd; Schulz, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">6890-6895</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 (STAT3) transduces stress signals from the plasma membrane to the nucleus but has recently also been identified in mitochondria.  Inhibition of cardiomyocyte mitochondrial STAT3 with the STAT3-specific inhibitor Stattic decreases ADP-stimulated respiration and enhances calcium-induced mitochondrial permeability transition pore (MPTP) opening.  The aim of the present study was to analyze whether or not these effects of STAT3 inhibition by Stattic are mediated by the formation of reactive oxygen species (ROS).  The H2O2 formation from isolated rat left ventricular mitochondria was measured continuously in the presence of the complex 1 substrates glutamate and malate using the H2O2 indicator Amplex UltraRed.  Stattic dose-dependently increased mitochondrial ROS formation (slope of Amplex UltraRed fluorescence/time; DMSO: 0.39Â±0.01; 1 Î¼M Stattic: 0.40Â±0.03; 10 Î¼M Stattic: 0.71Â±0.04; 25 Î¼M Stattic: 1.43Â±0.05; 50 Î¼M Stattic: 3.53Â±0.23; 100 Î¼M Stattic: 9.23Â±0.69, n=5 mitochondrial prepns., p<0.05 for 10-100 Î¼M Stattic).  The increase in the ROS signal by 100 Î¼M Stattic was abolished in the presence of the ROS scavenger N-acetylcysteine (Nac, 0.46Â±0.02, n=7, p<0.05).  Mitochondria treated with 100 Î¼M Stattic produced less ATP than control mitochondria (86Â±3 arbitrary units (a.u.) vs. 128Â±7 a.u., n=9, p<0.05).  Again, in the presence of Nac ATP prodn. was similar between Stattic-treated and control mitochondria (142Â±4 a.u. vs. 147Â±12 a.u., n=5, p=ns).  MPTP opening was induced by lower amts. of calcium in Stattic-treated than in control mitochondria (in nmol CaCl2/mg protein, Stattic: 507Â±57, n=7; control: 857Â±70, n=7, p<0.05).  There was no difference in calcium-induced MPTP opening between Stattic-treated (833Â±57, n=6) and control mitochondria (921Â±75, n=7, p=ns) in the presence of Nac.  Taken together, our data show that inhibition of mitochondrial STAT3 by Stattic impacts on mitochondrial ATP prodn. and MPTP opening through enhanced ROS formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4JFfKxsWPMLVg90H21EOLACvtfcHk0liGBwR1JCx4lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFelu7jJ&md5=7136ef44cd562a11ae1c0e5b80a5ec79</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F138161281939131127115940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161281939131127115940%26sid%3Dliteratum%253Aachs%26aulast%3DBoengler%26aufirst%3DK.%26aulast%3DUngefug%26aufirst%3DE.%26aulast%3DHeusch%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DR.%26atitle%3DThe%2520STAT3%2520inhibitor%2520stattic%2520impairs%2520cardiomyocyte%2520mitochondrial%2520function%2520through%2520increased%2520reactive%2520oxygen%2520species%2520formation%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D6890%26epage%3D6895%26doi%3D10.2174%2F138161281939131127115940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">538</span>â <span class="NLM_lpage">550</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2016.09.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2016.09.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ejtL7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=538-550&author=W.+Zhangauthor=T.+Maauthor=S.+Liauthor=Y.+Yangauthor=J.+Guoauthor=W.+Yuauthor=L.+Kong&title=Antagonizing+STAT3+activation+with+benzo%5Bb%5Dthiophene+1%2C+1-dioxide+based+small+molecules&doi=10.1016%2Fj.ejmech.2016.09.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</span></div><div class="casAuthors">Zhang, Wenda; Ma, Ting; Li, Shanshan; Yang, Yanwei; Guo, Jianpeng; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">538-550</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 is an attractive therapeutic target for cancer therapy.  However, due to low potency or poor druggability, none of its inhibitors are clin. available.  Herein, a series of aminobenzo[b]thiophene 1,1-dioxides with good drug-likeness properties were designed, synthesized and evaluated as STAT3 inhibitors.  Most of them exhibited higher antitumor activity than the small-mol. STAT3 inhibitor, Stattic.  Compd. I was the most potent and had an IC50 range in 0.33-0.75 Î¼M in various cancer cell lines.  The overexpressed and IL-6 induced phosphorylation levels of STAT3 were both inhibited by I without influencing the phosphorylation levels of the upstream kinases Src and Jak2. 15 also suppressed the expressions of STAT3 downstream gene, Bcl-2.  I also suppressed the expressions of STAT3 downstream gene, Bcl-2.  I effectively increased the ROS levels of cancer cells, induced cancer cell apoptosis, and abolished the colony formation ability of cancer cells without affecting bypass kinase p-Erk.  Furthermore, I in vivo induced significant antitumor responses, and exhibited less toxicity than Doxorubicin.  Together, this study described a class of new STAT3 inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4EWN80TpUpbVg90H21EOLACvtfcHk0ljsVxTJxgOlDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ejtL7I&md5=395e6ea180776127e98bc2a92f3d603b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.068%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DAntagonizing%2520STAT3%2520activation%2520with%2520benzo%255Bb%255Dthiophene%25201%252C%25201-dioxide%2520based%2520small%2520molecules%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D538%26epage%3D550%26doi%3D10.1016%2Fj.ejmech.2016.09.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46352</span>, <span class="refDoi">Â DOI: 10.1038/srep46352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fsrep46352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28397855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVyitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46352&author=W.+Zhangauthor=J.+Guoauthor=S.+Liauthor=T.+Maauthor=D.+Xuauthor=C.+Hanauthor=F.+Liuauthor=W.+Yuauthor=L.+Kong&title=Discovery+of+monocarbonyl+curcumin-BTP+hybrids+as+STAT3+inhibitors+for+drug-sensitive+and+drug-resistant+breast+cancer+therapy&doi=10.1038%2Fsrep46352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy</span></div><div class="casAuthors">Zhang, Wenda; Guo, Jianpeng; Li, Shanshan; Ma, Ting; Xu, Dingqiao; Han, Chao; Liu, Feiyan; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46352</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a well-known antitumor target.  Exogenous ROS insult can lead to selective cytotoxicity against cancer cells.  A combination of STAT3 inhibition and "oxidn. therapy" may be a new strategy to address the multidrug-resistance issue due to their important roles in the survival and drug resistance of cancer cells.  Here, a series of novel curcumin-BTP hybrids were designed and evaluated as STAT3 inhibitors with ROS prodn. activity.  Compd. 6b exerted the best antitumor activity and selectivity for MCF-7 and MCF-7/DOX cells (IC50 = 0.52 Î¼M and 0.40 Î¼M, resp.), while its IC50 value for MCF-10A breast epithelial cells was 7.72 Î¼M.  Furthermore, compd. 6b suppressed STAT3 phosphorylation, nuclear translocation and DNA-binding activity and the expression of STAT3 specific oncogenes.  Increases in the level of IL-6-induced p-STAT3 were also inhibited by 6b without influencing IFN-Î³-induced p-STAT1 expression.  Addnl., 6b effectively promoted intracellular ROS accumulation, induced cancer cell apoptosis and cell cycle arrest, abolished the colony formation ability of breast cancer cells, and inhibited P-gp expression in MCF-7/DOX cells.  Finally, 6b suppressed the growth of implanted human breast cancer in vivo.  Our findings highlight that 6b may be a promising therapeutic agent for drug-sensitive and drug-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxX6NWyOZ_v7Vg90H21EOLACvtfcHk0ljsVxTJxgOlDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVyitbc%253D&md5=aa97b030e4e00945730f51a47f41837e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsrep46352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46352%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520monocarbonyl%2520curcumin-BTP%2520hybrids%2520as%2520STAT3%2520inhibitors%2520for%2520drug-sensitive%2520and%2520drug-resistant%2520breast%2520cancer%2520therapy%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46352%26doi%3D10.1038%2Fsrep46352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yehuda, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashby, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.-J.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">100681</span>, <span class="refDoi">Â DOI: 10.1016/j.drup.2020.100681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.drup.2020.100681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32014648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FnslOqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2020&pages=100681&author=J.+Dongauthor=Z.+Qinauthor=W.-D.+Zhangauthor=G.+Chengauthor=A.+G.+Yehudaauthor=C.+R.+Ashbyauthor=Z.-S.+Chenauthor=X.-D.+Chengauthor=J.-J.+Qin&title=Medicinal+chemistry+strategies+to+discover+P-glycoprotein+inhibitors%3A+an+update&doi=10.1016%2Fj.drup.2020.100681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update</span></div><div class="casAuthors">Dong Jinyun; Qin Zuodong; Zhang Wei-Dong; Cheng Gang; Yehuda Assaraf G; Ashby Charles R Jr; Chen Zhe-Sheng; Cheng Xiang-Dong; Qin Jiang-Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100681</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The presence of multidrug resistance (MDR) in malignant tumors is one of the primary causes of treatment failure in cancer chemotherapy.  The overexpression of the ATP binding cassette (ABC) transporter, P-glycoprotein (P-gp), which significantly increases the efflux of certain anticancer drugs from tumor cells, produces MDR.  Therefore, inhibition of P-gp may represent a viable therapeutic strategy to overcome cancer MDR.  Over the past 4 decades, many compounds with P-gp inhibitory efficacy (referred to as first- and second-generation P-gp inhibitors) have been identified or synthesized.  However, these compounds were not successful in clinical trials due to a lack of efficacy and/or untoward toxicity.  Subsequently, third- and fourth-generation P-gp inhibitors were developed but dedicated clinical trials did not indicate a significant therapeutic effect.  In recent years, an extraordinary array of highly potent, selective, and low-toxicity P-gp inhibitors have been reported.  Herein, we provide a comprehensive review of the synthetic and natural products that have specific inhibitory activity on P-gp drug efflux as well as promising chemosensitizing efficacy in MDR cancer cells.  The present review focuses primarily on the structural features, design strategies, and structure-activity relationships (SAR) of these compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1YMh2HAkQ1acY7HFp97qMfW6udTcc2ebSoHZr13p22rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FnslOqsQ%253D%253D&md5=2f6db0a7f8fc9499772a7c5e7dd6bd7c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2020.100681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2020.100681%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.-D.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DYehuda%26aufirst%3DA.%2BG.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DCheng%26aufirst%3DX.-D.%26aulast%3DQin%26aufirst%3DJ.-J.%26atitle%3DMedicinal%2520chemistry%2520strategies%2520to%2520discover%2520P-glycoprotein%2520inhibitors%253A%2520an%2520update%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2020%26volume%3D49%26spage%3D100681%26doi%3D10.1016%2Fj.drup.2020.100681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">109502</span>, <span class="refDoi">Â DOI: 10.1016/j.biopha.2019.109502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.biopha.2019.109502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31707351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemt73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2020&pages=109502&author=Z.+Liuauthor=X.+Geauthor=Y.+Guauthor=Y.+Huangauthor=H.+Liuauthor=M.+Yuauthor=Y.+Liu&title=Small+molecule+STAT3+inhibitor%2C+6Br-6a+suppresses+breast+cancer+growth+in+vitro+and+in+vivo&doi=10.1016%2Fj.biopha.2019.109502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo</span></div><div class="casAuthors">Liu, Zhe; Ge, Xianmin; Gu, Yuchen; Huang, Yingying; Liu, Hao; Yu, Meiling; Liu, Yamin</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109502</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) protein frequently overexpressed in many malignancies and plays an essential role in regulating proliferation, apoptosis, migration and invasion in cancer cells.  However, No STAT3 inhibitor was used clin.  In this study, we evaluated the toxic potential of a novel STAT3 inhibitor, 6Br-6a in breast cancer cell lines.  The anti-cancer effect and underlying mechanism of 6Br-6a on MDA-MB-231 and MCF-7 cells were detd. in vitro and in xenograft mouse model.  Our data demonstrated that 6Br-6a significantly induced cell cycle arrest and cell apoptosis in breast cancer via blocking the activation of STAT3.  Finally, we verified these inhibitory effects of 6Br-6a in the MDA-MB-231 xenograft mouse model.  In conclusion, 6Br-6a effectively inhibited activation of STAT3 and induced cell cycle arrest and apoptosis via regulating cyclin D1 and Bcl-2 expression.  All of these data indicate that 6Br-6a could be a potential candidate for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAgfx-oVyYZ7Vg90H21EOLACvtfcHk0lgJRyjyvrPnnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemt73P&md5=8c6a6bb70413a052a4a384614b49481d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2019.109502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2019.109502%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DSmall%2520molecule%2520STAT3%2520inhibitor%252C%25206Br-6a%2520suppresses%2520breast%2520cancer%2520growth%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2020%26volume%3D121%26spage%3D109502%26doi%3D10.1016%2Fj.biopha.2019.109502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Osthole inhibits triple negative breast cancer cells by suppressing STAT3</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">322</span>, <span class="refDoi">Â DOI: 10.1186/s13046-018-0992-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2Fs13046-018-0992-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30577812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFais7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=322&author=X.+Daiauthor=C.+Yinauthor=Y.+Zhangauthor=G.+Guoauthor=C.+Zhaoauthor=O.+Wangauthor=Y.+Xiangauthor=X.+Zhangauthor=G.+Liang&title=Osthole+inhibits+triple+negative+breast+cancer+cells+by+suppressing+STAT3&doi=10.1186%2Fs13046-018-0992-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Osthole inhibits triple negative breast cancer cells by suppressing STAT3</span></div><div class="casAuthors">Dai, Xuanxuan; Yin, Changtian; Zhang, Yi; Guo, Guilong; Zhao, Chengguang; Wang, Ouchen; Xiang, Youqun; Zhang, Xiaohua; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">322</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Triple-neg. breast cancer (TNBC) is an aggressive subgroup of human breast cancer.  Patients with TNBC have poor clin. outcome as they are non-responsive to current targeted therapies.  There is an urgent need to identify new therapeutic targets and develop more effective treatment options for TNBC patients.  Osthole, a natural product from C. monnieri, has been shown to inhibit certain cancer cells.  However, the mechanisms of action as well as its effect on TNBC cells are not currently known.  Methods: We investigated the effect of osthole in cultured TNBC cells as well as in a xenograft model of TNBC growth.  We also used a high-throughput proteomics platform to identify the direct binding protein of osthole.  Results: We found that osthole inhibited the growth of a panel of TNBC cells and induced apoptosis in both cultured cells and TNBC xenografts.  We used a high-throughput proteomics platform and identified signal transducer and activator of transcription 3 (STAT3) as a potential binding protein of osthole.  We further show that osthole suppressed STAT3 in TNBC cells to inhibit growth and induce apoptosis.  Overexpressing STAT3 in TNBC reduced the effectiveness of osthole treatment.  Conclusions: These results provide support for osthole as a potential new therapeutic agent for the management of TNBC.  Moreover, our results indicate that STAT3 may be targeted for the development of novel anti-TNBC drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6u28fEl000LVg90H21EOLACvtfcHk0lgJRyjyvrPnnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFais7jM&md5=cb82f4fc0ef326ac6215da0a25df58e5</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0992-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0992-z%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DO.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DOsthole%2520inhibits%2520triple%2520negative%2520breast%2520cancer%2520cells%2520by%2520suppressing%2520STAT3%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26spage%3D322%26doi%3D10.1186%2Fs13046-018-0992-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">251</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.04.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31048139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOju7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=236-251&author=G.+Caiauthor=W.+Yuauthor=D.+Songauthor=W.+Zhangauthor=J.+Guoauthor=J.+Zhuauthor=Y.+Renauthor=L.+Kong&title=Discovery+of+fluorescent+coumarin-benzo%5Bb%5Dthiophene+1%2C+1-dioxide+conjugates+as+mitochondria-targeting+antitumor+STAT3+inhibitors&doi=10.1016%2Fj.ejmech.2019.04.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors</span></div><div class="casAuthors">Cai, Guiping; Yu, Wenying; Song, Dongmei; Zhang, Wenda; Guo, Jianpeng; Zhu, Jiawen; Ren, Yuhao; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">236-251</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 has been extensively studied as a potential antitumor target.  Though studies on regulating STAT3 mainly focus on the inhibition of STAT3 phosphorylation at Tyr705 residue, the phosphorylation at Ser727 residue of STAT3 protein is also closely assocd. with the mitochondrial import of STAT3 protein.  N, N-diethyl-7-aminocoumarin is a fluorescent mitochondria-targeting probe.  In this study, a series of STAT3 inhibitors were developed by connecting N, N-diethyl-7-aminocoumarin fluorophore with benzo [b]thiophene 1, 1-dioxide moiety.  All designed compds. displayed potent anti-proliferative activity against cancer cells.  The representative compd. 7a(I) was mainly accumulated in mitochondria visualized by its fluorescence.  STAT3 phosphorylation was inhibited by I at both Tyr705 and Ser727 residues.  I inhibited STAT3 phosphorylation whereas had no influence on the phosphorylation levels of STAT1, JAK2, Src and Erk1/2, indicating good selectivity of I.  Moreover, I down-regulated the expression of STAT3 target genes Bcl-2 and Cyclin D1, increased ROS prodn. and remarkably reduced the mitochondrial membrane potential to induce mitochondrial apoptotic pathway.  Furthermore, I in vivo suppressed breast cancer 4T1 implanted tumor growth.  Taken together, these results highlighted that I might be a promising mitochondria-targeting STAT3 inhibitor for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliPyZjY43-rVg90H21EOLACvtfcHk0lihUqI4NTwrcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOju7o%253D&md5=5c1e2def16a6656c2d56cfe59168053c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520fluorescent%2520coumarin-benzo%255Bb%255Dthiophene%25201%252C%25201-dioxide%2520conjugates%2520as%2520mitochondria-targeting%2520antitumor%2520STAT3%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D236%26epage%3D251%26doi%3D10.1016%2Fj.ejmech.2019.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharmeen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1459</span>â <span class="NLM_lpage">1470</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201100194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1002%2Fcmdc.201100194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21618433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptFOjtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1459-1470&author=S.+Fletcherauthor=B.+D.+Pageauthor=X.+Zhangauthor=P.+Yueauthor=Z.+H.+Liauthor=S.+Sharmeenauthor=J.+Singhauthor=W.+Zhaoauthor=A.+D.+Schimmerauthor=S.+Trudelauthor=J.+Turksonauthor=P.+T.+Gunning&title=Antagonism+of+the+Stat3-Stat3+protein+dimer+with+salicylic+acid+based+small+molecules&doi=10.1002%2Fcmdc.201100194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules</span></div><div class="casAuthors">Fletcher, Steven; Page, Brent D. G.; Zhang, Xialoei; Yue, Peibin; Li, Zhi Hua; Sharmeen, Sumaiya; Singh, Jagdeep; Zhao, Wei; Schimmer, Aaron D.; Trudel, Suzanne; Turkson, James; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1459-1470</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">More than 50 new inhibitors of the oncogenic Stat3 protein were identified through a structure-activity relationship (SAR) study based on the previously identified inhibitor S3I-201 (IC50=86 Î¼M, Ki>300 Î¼M).  A key structural feature of these inhibitors is a salicylic acid moiety, which, by acting as a phosphotyrosine mimetic, is believed to facilitate binding to the Stat3 SH2 domain.  Several of the analogs exhibit higher potency than the lead compd. in inhibiting Stat3 DNA binding activity, with an in vitro IC50 range of 18.7-51.9 Î¼M, and disruption of Stat3-pTyr peptide interactions with Ki values in the 15.5-41 Î¼M range.  One agent in particular exhibited potent inhibition of Stat3 phosphorylation in both breast and multiple myeloma tumor cells, suppressed the expression of Stat3 target genes, and induced antitumor effects in tumor cells harboring activated Stat3 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0FBfupE80LVg90H21EOLACvtfcHk0lihUqI4NTwrcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptFOjtbg%253D&md5=ad6df40e36272bdf21215eb9cc3526ce</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100194%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DSharmeen%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DAntagonism%2520of%2520the%2520Stat3-Stat3%2520protein%2520dimer%2520with%2520salicylic%2520acid%2520based%2520small%2520molecules%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D1459%26epage%3D1470%26doi%3D10.1002%2Fcmdc.201100194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Zepeda, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spagnuolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colaguori, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7190</span>â <span class="NLM_lpage">7200</span>, <span class="refDoi">Â DOI: 10.1021/jm3017255</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3017255" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7190-7200&author=B.+D.+Pageauthor=D.+C.+Croucherauthor=Z.+H.+Liauthor=S.+Haftchenaryauthor=V.+H.+Jimenez-Zepedaauthor=J.+Atkinsonauthor=P.+A.+Spagnuoloauthor=Y.+L.+Wongauthor=R.+Colaguoriauthor=A.+M.+Lewisauthor=A.+D.+Schimmerauthor=S.+Trudelauthor=P.+T.+Gunning&title=Inhibiting+aberrant+signal+transducer+and+activator+of+transcription+protein+activation+with+tetrapodal%2C+small+molecule+Src+homology+2+domain+binders%3A+promising+agents+against+multiple+myeloma&doi=10.1021%2Fjm3017255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma</span></div><div class="casAuthors">Page, Brent D. G.; Croucher, Danielle C.; Li, Zhi Hua; Haftchenary, Sina; Jimenez-Zepeda, Victor H.; Atkinson, Jennifer; Spagnuolo, Paul A.; Wong, Yoong Lim; Colaguori, Robert; Lewis, Andrew M.; Schimmer, Aaron D.; Trudel, Suzanne; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7190-7200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">[(Arylsulfonyl)glycinyl](cyclohexylbenzyl)aminosalicylic acids such as I (R = 4-MeC6H4, F5C6; R1 = 2-F3CC6H4) were prepd. as inhibitors of the signal transducer and activator of transcription (STAT) protein Stat3 for potential use as treatments for multiple myeloma.  The hydrophobicities of I and their inhibition of Stat3 were detd.; mol. docking of selected compds. to the SH2 domain of Stat3 and inhibition of Stat3 phosphorylation under various conditions were detd. for selected compds., and the activity of I (R = 4-MeC6H4; R1 = 2-F3CC6H4) against human multiple myeloma cells and human hematopoietic cells and its induction of apoptosis in multiple myeloma cells was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9RTVwhgsvE7Vg90H21EOLACvtfcHk0lihUqI4NTwrcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbrL&md5=9cce9797681eccfcf43b0f8b1a813914</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm3017255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3017255%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DCroucher%26aufirst%3DD.%2BC.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DJimenez-Zepeda%26aufirst%3DV.%2BH.%26aulast%3DAtkinson%26aufirst%3DJ.%26aulast%3DSpagnuolo%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DY.%2BL.%26aulast%3DColaguori%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DA.%2BM.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DInhibiting%2520aberrant%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%2520protein%2520activation%2520with%2520tetrapodal%252C%2520small%2520molecule%2520Src%2520homology%25202%2520domain%2520binders%253A%2520promising%2520agents%2520against%2520multiple%2520myeloma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7190%26epage%3D7200%26doi%3D10.1021%2Fjm3017255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namanja, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">9623</span>â <span class="NLM_lpage">9628</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1121606109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.1121606109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22623533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWjtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=9623-9628&author=X.+Zhangauthor=P.+Yueauthor=B.+D.+Pageauthor=T.+Liauthor=W.+Zhaoauthor=A.+T.+Namanjaauthor=D.+Paladinoauthor=J.+Zhaoauthor=Y.+Chenauthor=P.+T.+Gunningauthor=J.+Turkson&title=Orally+bioavailable+small-molecule+inhibitor+of+transcription+factor+Stat3+regresses+human+breast+and+lung+cancer+xenografts&doi=10.1073%2Fpnas.1121606109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</span></div><div class="casAuthors">Zhang, Xiaolei; Yue, Peibin; Page, Brent D. G.; Li, Tianshu; Zhao, Wei; Namanja, Andrew T.; Paladino, David; Zhao, Jihe; Chen, Yuan; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9623-9628, S9623/1-S9623/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homol. 2 domain.  BP-1-102 binds Stat3 with an affinity (KD) of 504 nM, blocks Stat3-phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4-6.8 Î¼M, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells.  BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Kruppel-like factor 8, which is identified as a Stat3 target gene that promotes Stat3-mediated breast tumor cell migration and invasion.  Treatment of breast cancer cells with BP-1-102 further blocks Stat3-NF-ÎºB cross-talk, the release of granulocyte colony-stimulating factor, sol. intercellular adhesion mol. 1, macrophage migration-inhibitory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease inhibitor protein 1, and the phosphorylation of focal adhesion kinase and paxillin, while enhancing E-cadherin expression.  I.v. or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of human breast and lung tumor xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrljEafjbznr7Vg90H21EOLACvtfcHk0lh17rrx5m6XpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWjtLo%253D&md5=4da78174a7c00eacc1f1a1ce553c5aa7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1121606109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1121606109%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DNamanja%26aufirst%3DA.%2BT.%26aulast%3DPaladino%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DOrally%2520bioavailable%2520small-molecule%2520inhibitor%2520of%2520transcription%2520factor%2520Stat3%2520regresses%2520human%2520breast%2520and%2520lung%2520cancer%2520xenografts%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D9623%26epage%3D9628%26doi%3D10.1073%2Fpnas.1121606109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siddiquee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaskovich, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greedy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">7391</span>â <span class="NLM_lpage">7396</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0609757104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.0609757104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=17463090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlslWqsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=7391-7396&author=K.+Siddiqueeauthor=S.+Zhangauthor=W.+C.+Guidaauthor=M.+A.+Blaskovichauthor=B.+Greedyauthor=H.+R.+Lawrenceauthor=M.+L.+Yipauthor=R.+Joveauthor=M.+M.+McLaughlinauthor=N.+J.+Lawrenceauthor=S.+M.+Sebtiauthor=J.+Turkson&title=Selective+chemical+probe+inhibitor+of+Stat3%2C+identified+through+structure-based+virtual+screening%2C+induces+antitumor+activity&doi=10.1073%2Fpnas.0609757104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Elective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity</span></div><div class="casAuthors">Siddiquee, Khandaker; Zhang, Shumin; Guida, Wayne C.; Blaskovich, Michelle A.; Greddy, Benjamin; Lawrence, Harshani R.; Yip, M. L. Richard; Jove, Richard; McLaughlin, Mark M.; Lawrence, Nicholas J.; Sebti, Said M.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7391-7396</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">531-201 (NSC 74859) is a chem. probe inhibitor of Stat3 activity, which was identified from the National Cancer Institute chem. libraries by using structure-based virtual screening with a computer model of the Stat3 SH2 domain bound to its Stat3 phosphotyrosine peptide derived from the x-ray crystal structure of the Stat3Î² homodimer.  S3I-201 inhibits Stat3 Â· Stat3 complex formation and Stat3 DNA-binding and transcriptional activities.  Furthermore, S3I-201 inhibits growth and induces apoptosis preferentially in tumor cells that contain persistently activated Stat3.  Constitutively dimerized and active Stat3C and Stat3 SH2 domain rescue tumor cells from S3I-201-induced apoptosis.  Finally, S3I-201 inhibits the expression of the Stat3-regulated genes encoding cyclin D1, Bcl-xL, and surviving and inhibits the growth of human breast tumors in vivo.  These findings strongly suggest that the antitumor activity of S3I-201 is mediated in part through inhibition of aberrant Stat3 activation and provide the proof-of-concept for the potential clin. use of Stat3 inhibitors such as S3I-201 in tumors harboring aberrant Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAfmqUniFENbVg90H21EOLACvtfcHk0lh17rrx5m6XpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlslWqsbY%253D&md5=85decf56fc7852990f56c6f64165ad9d</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609757104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609757104%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiquee%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DBlaskovich%26aufirst%3DM.%2BA.%26aulast%3DGreedy%26aufirst%3DB.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DYip%26aufirst%3DM.%2BL.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DSelective%2520chemical%2520probe%2520inhibitor%2520of%2520Stat3%252C%2520identified%2520through%2520structure-based%2520virtual%2520screening%252C%2520induces%2520antitumor%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D7391%26epage%3D7396%26doi%3D10.1073%2Fpnas.0609757104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouk, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veloso, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinshtein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahani, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1102</span>â <span class="NLM_lpage">1107</span>, <span class="refDoi">Â DOI: 10.1021/ml4003138</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4003138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1102-1107&author=S.+Haftchenaryauthor=H.+A.+Luchmanauthor=A.+O.+Joukauthor=A.+J.+Velosoauthor=B.+D.+Pageauthor=X.+R.+Chengauthor=S.+S.+Dawsonauthor=N.+Grinshteinauthor=V.+M.+Shahaniauthor=K.+Kermanauthor=D.+R.+Kaplanauthor=C.+Griffinauthor=A.+M.+Amanauthor=R.+Al-Awarauthor=S.+Weissauthor=P.+T.+Gunning&title=Potent+targeting+of+the+STAT3+protein+in+brain+cancer+stem+cells%3A+a+promising+route+for+treating+glioblastoma&doi=10.1021%2Fml4003138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma</span></div><div class="casAuthors">Haftchenary, Sina; Luchman, H. Artee; Jouk, Andriana O.; Veloso, Anthony J.; Page, Brent D. G.; Cheng, Xin Ran; Dawson, Sean S.; Grinshtein, Natalie; Shahani, Vijay M.; Kerman, Kagan; Kaplan, David R.; Griffin, Carly; Aman, Ahmed M.; Al-awar, Rima; Weiss, Samuel; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1102-1107</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The STAT3 gene is abnormally active in glioblastoma (GBM) and is a critically important mediator of tumor growth and therapeutic resistance in GBM.  Thus, for poorly treated brain cancers such as gliomas, astrocytomas, and glioblastomas, which harbor constitutively activated STAT3, a STAT3-targeting therapeutic will be of significant importance.  Herein, we report a most potent, small mol., nonphosphorylated STAT3 inhibitor, I (SH-4-54) that strongly binds to STAT3 protein (KD = 300 nM).  Inhibitor I potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concns.  Moreover, in vivo, I exhibited blood-brain barrier permeability, potently controlled glioma tumor growth, and inhibited pSTAT3 in vivo.  This work, for the first time, demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8sxT0MMrOY7Vg90H21EOLACvtfcHk0lj5asHnG5MVUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7rK&md5=34a07baae61cd1b90eef1d9eae3d2ea9</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fml4003138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4003138%26sid%3Dliteratum%253Aachs%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DLuchman%26aufirst%3DH.%2BA.%26aulast%3DJouk%26aufirst%3DA.%2BO.%26aulast%3DVeloso%26aufirst%3DA.%2BJ.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DCheng%26aufirst%3DX.%2BR.%26aulast%3DDawson%26aufirst%3DS.%2BS.%26aulast%3DGrinshtein%26aufirst%3DN.%26aulast%3DShahani%26aufirst%3DV.%2BM.%26aulast%3DKerman%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGriffin%26aufirst%3DC.%26aulast%3DAman%26aufirst%3DA.%2BM.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DWeiss%26aufirst%3DS.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DPotent%2520targeting%2520of%2520the%2520STAT3%2520protein%2520in%2520brain%2520cancer%2520stem%2520cells%253A%2520a%2520promising%2520route%2520for%2520treating%2520glioblastoma%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1102%26epage%3D1107%26doi%3D10.1021%2Fml4003138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Tapia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namanja, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tius, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Hydroxamic acid and benzoic acid-based STAT3 inhibitors suppress human glioma and breast cancer phenotypes in vitro and in vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">652</span>â <span class="NLM_lpage">663</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-14-3558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1158%2F0008-5472.CAN-14-3558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26088127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSgtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=652-663&author=P.+Yueauthor=F.+Lopez-Tapiaauthor=D.+Paladinoauthor=Y.+Liauthor=C.+H.+Chenauthor=A.+T.+Namanjaauthor=T.+Hilliardauthor=Y.+Chenauthor=M.+A.+Tiusauthor=J.+Turkson&title=Hydroxamic+acid+and+benzoic+acid-based+STAT3+inhibitors+suppress+human+glioma+and+breast+cancer+phenotypes+in+vitro+and+in+vivo&doi=10.1158%2F0008-5472.CAN-14-3558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo</span></div><div class="casAuthors">Yue, Peibin; Lopez-Tapia, Francisco; Paladino, David; Li, Yifei; Chen, Chih-Hong; Namanja, Andrew T.; Hilliard, Tyvette; Chen, Yuan; Tius, Marcus A.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">652-663</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">STAT3 offers an attractive target for cancer therapy, but small-mol. inhibitors with appealing pharmacol. properties have been elusive.  Here, we report hydroxamic acid-based and benzoic acid-based inhibitors (SH5-07 and SH4-54, resp.) with robust bioactivity.  Both inhibitors blocked STAT3 DNA-binding activity in vitro and in human glioma, breast, and prostate cancer cells and in v-Src-transformed murine fibroblasts.  STAT3-dependent gene transcription was blocked along with Bcl-2, Bcl-xL, Mcl-1, cyclin D1, c-Myc, and survivin expression.  NMR anal. of STAT3-inhibitor complexes defined interactions with the SH2 and DNA-binding domains of STAT3.  Ectopic expression of the SH2 domain in cells was sufficient to counter the STAT3-inhibitory effects of SH4-54.  Neither compd. appreciably affected STAT1 or STAT5 DNA-binding activities, STAT3-independent gene transcription, or activation of a panel of oncogenic kinases in malignant cells.  Each compd. decreased the proliferation and viability of glioma, breast, and prostate cancer cells and v-Src-transformed murine fibroblasts harboring constitutively active STAT3.  Further, in mouse xenograft models of glioma and breast cancer, administration of SH5-07 or SH4-54 effectively inhibited tumor growth.  Our results offer preclin. proof of concept for SH5-07 and SH4-54 as candidates for further development as cancer therapeutics.  Cancer Res; 76(3); 652-63. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkHZXQZ-69bVg90H21EOLACvtfcHk0lgJDie5e_PGPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSgtrY%253D&md5=62397d5abc0b6e551289d44e808b6cd1</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3558%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DP.%26aulast%3DLopez-Tapia%26aufirst%3DF.%26aulast%3DPaladino%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DNamanja%26aufirst%3DA.%2BT.%26aulast%3DHilliard%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTius%26aufirst%3DM.%2BA.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DHydroxamic%2520acid%2520and%2520benzoic%2520acid-based%2520STAT3%2520inhibitors%2520suppress%2520human%2520glioma%2520and%2520breast%2520cancer%2520phenotypes%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D652%26epage%3D663%26doi%3D10.1158%2F0008-5472.CAN-14-3558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laister, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1047</span>â <span class="NLM_lpage">1055</span>, <span class="refDoi">Â DOI: 10.1021/jm200720n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200720n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SmtbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1047-1055&author=B.+D.+Pageauthor=H.+Khouryauthor=R.+C.+Laisterauthor=S.+Fletcherauthor=M.+Vellozoauthor=A.+Manzoliauthor=P.+Yueauthor=J.+Turksonauthor=M.+D.+Mindenauthor=P.+T.+Gunning&title=Small+molecule+STAT5-SH2+domain+inhibitors+exhibit+potent+antileukemia+activity&doi=10.1021%2Fjm200720n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity</span></div><div class="casAuthors">Page, Brent D. G.; Khoury, Haytham; Laister, Rob C.; Fletcher, Steven; Vellozo, Megan; Manzoli, Alessia; Yue, Piebin; Turkson, James; Minden, Mark D.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1047-1055</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A growing body of evidence shows that Signal Transducer and Activator of Transcription 5 (STAT5) protein, a key member of the STAT family of signaling proteins, plays a pivotal role in the progression of many human cancers, including acute myeloid leukemia and prostate cancer.  Unlike STAT3, where significant medicinal effort has been expended to identify potent direct inhibitors, Stat5 has been poorly investigated as a mol. therapeutic target.  Thus, in an effort to identify direct inhibitors of STAT5 protein, we conducted an in vitro screen of a focused library of SH2 domain binding salicylic acid-contg. inhibitors (â¼150) against STAT5, as well as against STAT3 and STAT1 proteins for SH2 domain selectivity.  We herein report the identification of several potent (Ki < 5 Î¼M) and STAT5 selective (>3-fold specificity for STAT5 cf. STAT1 and STAT3) inhibitors, BP-1-107, BP-1-108, SF-1-087, and SF-1-088.  Lead agents, evaluated in K562 and MV-4-11 human leukemia cells, showed potent induction of apoptosis (IC50's â¼ 20 Î¼M) which correlated with potent and selective suppression of STAT5 phosphorylation, as well as inhibition of STAT5 target genes cyclin D1, cyclin D2, C-MYC, and MCL-1.  Moreover, lead agent BP-1-108 showed negligible cytotoxic effects in normal bone marrow cells not expressing activated STAT5 protein.  Inhibitors identified in this study represent some of the most potent direct small mol., nonphosphorylated inhibitors of STAT5 to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKbueNkBRoE7Vg90H21EOLACvtfcHk0lgJDie5e_PGPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SmtbnE&md5=f4616995717eb02280cf17f10bc6bf6d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm200720n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200720n%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DKhoury%26aufirst%3DH.%26aulast%3DLaister%26aufirst%3DR.%2BC.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DVellozo%26aufirst%3DM.%26aulast%3DManzoli%26aufirst%3DA.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DSmall%2520molecule%2520STAT5-SH2%2520domain%2520inhibitors%2520exhibit%2520potent%2520antileukemia%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1047%26epage%3D1055%26doi%3D10.1021%2Fjm200720n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Tapia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotherton-Pleiss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa Araujo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis Dos Santos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichinotsubo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tius, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Linker variation and structure-activity relationship analyses of carboxylic acid-based small molecule STAT3 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">250</span>â <span class="NLM_lpage">255</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00544</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00544" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=250-255&author=F.+Lopez-Tapiaauthor=C.+Brotherton-Pleissauthor=P.+Yueauthor=H.+Murakamiauthor=A.+C.+Costa+Araujoauthor=B.+Reis+Dos+Santosauthor=E.+Ichinotsuboauthor=A.+Rabkinauthor=R.+Shahauthor=M.+Lantzauthor=S.+Chenauthor=M.+A.+Tiusauthor=J.+Turkson&title=Linker+variation+and+structure-activity+relationship+analyses+of+carboxylic+acid-based+small+molecule+STAT3+inhibitors&doi=10.1021%2Facsmedchemlett.7b00544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Linker variation and structure-activity relationship analysis of carboxylic acid-based small molecule STAT3 inhibitors</span></div><div class="casAuthors">Lopez-Tapia, Francisco; Brotherton-Pleiss, Christine; Yue, Peibin; Murakami, Heide; Costa Araujo, Ana Carolina; Reis dos Santos, Bruna; Ichinotsubo, Erin; Rabkin, Anna; Shah, Raj; Lantz, Megan; Chen, Suzie; Tius, Marcus A.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">250-255</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mol. determinants for the activities of the reported benzoic acid (SH4-54), salicylic acid (BP-1-102), and benzohydroxamic acid (SH5-07)-based STAT3 inhibitors were investigated to design optimized analogs.  All three leads are based on an N-methylglycinamide scaffold, with its two amine groups condensed with three different functionalities.  The three functionalities and the CH2 group of the glycinamide scaffold were sep. modified.  The replacement of the pentafluorobenzene or cyclohexylbenzene, or replacing the benzene ring of the arom. carboxylic or hydroxamic acid motif with heterocyclic components (contg. nitrogen and oxygen elements) all decreased potency.  Notably, the Ala-linker analogs, (I) (R1 = H and OH), and the Pro-based deriv. (II) (X = CH2), all with (R)-configuration at the chiral center, had improved inhibitory activity and selectivity against STAT3 DNA-binding activity in vitro, with IC50 of 3.0 Â± 0.9, 1.80 Â± 0.94, and 2.4 Â± 0.2 Î¼M, resp.  Compds. I and II and other analogs inhibited constitutive STAT3 phosphorylation and activation in human breast cancer and melanoma lines, and blocked tumor cell viability, growth, colony formation, and migration in vitro.  Pro-based analog, II (X = O)(sodium salt), with a relatively polar tetrahydropyranyl (THP) ring, instead of the cyclohexyl, showed improved permeability.  In general, the (R)-configuration Pro-based analogs showed the overall best profile, including physicochem. properties (e.g., microsomal metabolic stability, Caco-2 permeability), and in particular, II (X = CH2) showed improved tumor-cell specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6yrAyhBvV47Vg90H21EOLACvtfcHk0lgJDie5e_PGPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnsLs%253D&md5=c80cc2d96017675b30e13a0f0395103a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00544%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Tapia%26aufirst%3DF.%26aulast%3DBrotherton-Pleiss%26aufirst%3DC.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DCosta%2BAraujo%26aufirst%3DA.%2BC.%26aulast%3DReis%2BDos%2BSantos%26aufirst%3DB.%26aulast%3DIchinotsubo%26aufirst%3DE.%26aulast%3DRabkin%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DLantz%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DTius%26aufirst%3DM.%2BA.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DLinker%2520variation%2520and%2520structure-activity%2520relationship%2520analyses%2520of%2520carboxylic%2520acid-based%2520small%2520molecule%2520STAT3%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D250%26epage%3D255%26doi%3D10.1021%2Facsmedchemlett.7b00544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brotherton-Pleiss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Valenteen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhael, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Kauwe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tius, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Tapia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel azetidine amides as potent small-molecule STAT3 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">695</span>â <span class="NLM_lpage">710</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01705</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01705" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1Crs73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=695-710&author=C.+Brotherton-Pleissauthor=P.+Yueauthor=Y.+Zhuauthor=K.+Nakamuraauthor=W.+Chenauthor=W.+Fuauthor=C.+Kubotaauthor=J.+Chenauthor=F.+Alonso-Valenteenauthor=S.+Mikhaelauthor=L.+Medina-Kauweauthor=M.+A.+Tiusauthor=F.+Lopez-Tapiaauthor=J.+Turkson&title=Discovery+of+novel+azetidine+amides+as+potent+small-molecule+STAT3+inhibitors&doi=10.1021%2Facs.jmedchem.0c01705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors</span></div><div class="casAuthors">Brotherton-Pleiss, Christine; Yue, Peibin; Zhu, Yinsong; Nakamura, Kayo; Chen, Weiliang; Fu, Wenzhen; Kubota, Casie; Chen, Jasmine; Alonso-Valenteen, Felix; Mikhael, Simoun; Medina-Kauwe, Lali; Tius, Marcus A.; Lopez-Tapia, Francisco; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">695-710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We optimized our previously reported proline-based STAT3 inhibitors into an exciting new series of (R)-azetidine-2-carboxamide analogs that have sub-micromolar potencies. 5a, 5o, and 8i have STAT3-inhibitory potencies (IC50) of 0.55, 0.38, and 0.34 Î¼M, resp., compared to potencies greater than 18 Î¼M against STAT1 or STAT5 activity.  Further modifications derived analogs, including 7e, 7f, 7g, and 9k, that addressed cell membrane permeability and other physicochem. issues.  Isothermal titrn. calorimetry anal. confirmed high-affinity binding to STAT3, with KD of 880 nM (7g) and 960 nM (9k). 7g and 9k inhibited constitutive STAT3 phosphorylation and DNA-binding activity in human breast cancer, MDA-MB-231 or MDA-MB-468 cells.  Furthermore, treatment of breast cancer cells with 7e, 7f, 7g, or 9k inhibited viable cells, with an EC50 of 0.9-1.9 Î¼M, cell growth, and colony survival, and induced apoptosis while having relatively weaker effects on normal breast epithelial, MCF-10A or breast cancer, MCF-7 cells that do not harbor constitutively active STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEWK4CwywiqrVg90H21EOLACvtfcHk0lh4w38mgqkDzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1Crs73K&md5=2c05209d89dd376d9fba3a55819285f4</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01705%26sid%3Dliteratum%253Aachs%26aulast%3DBrotherton-Pleiss%26aufirst%3DC.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DKubota%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAlonso-Valenteen%26aufirst%3DF.%26aulast%3DMikhael%26aufirst%3DS.%26aulast%3DMedina-Kauwe%26aufirst%3DL.%26aulast%3DTius%26aufirst%3DM.%2BA.%26aulast%3DLopez-Tapia%26aufirst%3DF.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520azetidine%2520amides%2520as%2520potent%2520small-molecule%2520STAT3%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D695%26epage%3D710%26doi%3D10.1021%2Facs.jmedchem.0c01705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">752</span>â <span class="NLM_lpage">764</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.03.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.03.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29674294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslSru7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=752-764&author=J.+Guoauthor=W.+Yuauthor=G.+Caiauthor=W.+Zhangauthor=S.+Liauthor=J.+Zhuauthor=D.+Songauthor=L.+Kong&title=Discovery+of+new+benzensulfonamide+derivatives+as+tripedal+STAT3+inhibitors&doi=10.1016%2Fj.ejmech.2018.03.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</span></div><div class="casAuthors">Guo, Jianpeng; Yu, Wenying; Cai, Guiping; Zhang, Wenda; Li, Shanshan; Zhu, Jiawen; Song, Dongmei; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">752-764</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Persistent activated STAT3 has a striking correlation with cancer development and inhibition of STAT3 signaling pathway is a novel therapeutic way for human cancers.  Among STAT family, STAT1 and STAT3 play opposite roles in tumorigenesis.  However, the discovery of selective STAT3 inhibitors is still challenging to date.  In this study, a series of small-mol. (MW<500) benzensulfanilamide derivs. were designed to selectively suppress STAT3 activation for anti-cancer treatment.  The most potent compd. 11 inhibited both overexpressed and IL-6 induced STAT3 phosphorylation, whereas 11 displayed little effect on the phosphorylation of other STAT isoforms STAT1, STAT5, demonstrating 11 was a selective STAT3 inhibitor.  Meanwhile, 11 dismissed STAT3 DNA binding activity and colony formation.  In addn., 11 elevated the ROS level and induced apoptosis of cancer cells.  Furthermore, 11 effectively suppressed tumor growth in an in vivo mouse-xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjwneUbz5BgbVg90H21EOLACvtfcHk0lh4w38mgqkDzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslSru7w%253D&md5=9f46716463f5610a25bffcfb85b2031a</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.053%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520new%2520benzensulfonamide%2520derivatives%2520as%2520tripedal%2520STAT3%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D752%26epage%3D764%26doi%3D10.1016%2Fj.ejmech.2018.03.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redell, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonzo, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbing, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweardy, D. J.</span></span> <span> </span><span class="NLM_article-title">Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">5701</span>â <span class="NLM_lpage">5709</span>, <span class="refDoi">Â DOI: 10.1182/blood-2010-04-280123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1182%2Fblood-2010-04-280123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21447830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1Cms74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=5701-5709&author=M.+S.+Redellauthor=M.+J.+Ruizauthor=T.+A.+Alonzoauthor=R.+B.+Gerbingauthor=D.+J.+Tweardy&title=Stat3+signaling+in+acute+myeloid+leukemia%3A+ligand-dependent+and+-independent+activation+and+induction+of+apoptosis+by+a+novel+small-molecule+Stat3+inhibitor&doi=10.1182%2Fblood-2010-04-280123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor</span></div><div class="casAuthors">Redell, Michele S.; Ruiz, Marcos J.; Alonzo, Todd A.; Gerbing, Robert B.; Tweardy, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5701-5709</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is an aggressive malignancy with a relapse rate approaching 50%, despite aggressive chemotherapy.  New therapies for AML are targeted at signal transduction pathways known to support blast survival, such as the Stat3 pathway.  Aberrant activation of Stat3 was demonstrated in many different malignancies, including AML, and this finding is frequently assocd. with more aggressive disease.  The objectives of this study were: (1) to characterize Stat3 signaling patterns in AML cells lines and primary pediatric samples; and (2) to test the efficacy and potency of a novel Stat3 inhibitor in inducing apoptosis in AML cells.  We found that Stat3 was constitutively activated in 6 of 7 AML cell lines and 6 of 18 primary pediatric AML samples.  Moreover, constitutively phosphorylated Stat3 was frequent in samples with normal 3 but uncommon in samples with t(8;21).  Most cell lines and primary samples responded to G-CSF stimulation, although the sensitivity and magnitude of the response varied dramatically.  Our novel small-mol. Stat3 inhibitor, C188-9, inhibited G-CSF-induced Stat3 phosphorylation, induced apoptosis in AML cell lines and primary samples, and inhibited AML blast colony formation with potencies in the low micromolar range.  Therefore, Stat3 inhibition may be a valuable strategy for targeted therapies for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8xPOZdPixbLVg90H21EOLACvtfcHk0liah-gL8J9JYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1Cms74%253D&md5=9c577ac872bb03b0df3759c62a401a67</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-04-280123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-04-280123%26sid%3Dliteratum%253Aachs%26aulast%3DRedell%26aufirst%3DM.%2BS.%26aulast%3DRuiz%26aufirst%3DM.%2BJ.%26aulast%3DAlonzo%26aufirst%3DT.%2BA.%26aulast%3DGerbing%26aufirst%3DR.%2BB.%26aulast%3DTweardy%26aufirst%3DD.%2BJ.%26atitle%3DStat3%2520signaling%2520in%2520acute%2520myeloid%2520leukemia%253A%2520ligand-dependent%2520and%2520-independent%2520activation%2520and%2520induction%2520of%2520apoptosis%2520by%2520a%2520novel%2520small-molecule%2520Stat3%2520inhibitor%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D5701%26epage%3D5709%26doi%3D10.1182%2Fblood-2010-04-280123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minus, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangubat-Medina, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasembeli, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolosov, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweardy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redell, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, Z. T.</span></span> <span> </span><span class="NLM_article-title">Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3288</span>â <span class="NLM_lpage">3296</span>, <span class="refDoi">Â DOI: 10.1039/C9OB02682G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1039%2FC9OB02682G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32286579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVWhu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=3288-3296&author=M.+B.+Minusauthor=H.+Wangauthor=J.+O.+Munozauthor=A.+M.+Stevensauthor=A.+E.+Mangubat-Medinaauthor=M.+J.+Kruegerauthor=W.+Liuauthor=M.+M.+Kasembeliauthor=J.+C.+Cooperauthor=M.+I.+Kolosovauthor=D.+J.+Tweardyauthor=M.+S.+Redellauthor=Z.+T.+Ball&title=Targeting+STAT3+anti-apoptosis+pathways+with+organic+and+hybrid+organic-inorganic+inhibitors&doi=10.1039%2FC9OB02682G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors</span></div><div class="casAuthors">Minus, Matthew B.; Wang, Haopei; Munoz, Jaime O.; Stevens, Alexandra M.; Mangubat-Medina, Alicia E.; Krueger, Michael J.; Liu, Wei; Kasembeli, Moses M.; Cooper, Julian C.; Kolosov, Mikhail I.; Tweardy, David J.; Redell, Michele S.; Ball, Zachary T.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3288-3296</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Recurrence and drug resistance are major challenges in the treatment of acute myeloid leukemia (AML) that spur efforts to identify new clin. targets and active agents.  STAT3 has emerged as a potential target in resistant AML, but inhibiting STAT3 function has proven challenging.  This paper describes synthetic studies and biol. assays for a naphthalene sulfonamide inhibitor class of mols. that inhibit G-CSF-induced STAT3 phosphorylation in cellulo and induce apoptosis in AML cells.  We describe two different approaches to inhibitor design: first, variation of substituents on the naphthalene sulfonamide core allows improvements in anti-STAT activity and creates a more thorough understanding of anti-STAT SAR.  Second, a novel approach involving hybrid sulfonamide-rhodium(II) conjugates tests our ability to use cooperative org.-inorg. binding for drug development, and to use SAR studies to inform metal conjugate design.  Both approaches have produced compds. with improved binding potency.  In vivo and in cellulo expts. further demonstrate that these approaches can also lead to improved activity in living cells, and that compd. 3aa slows disease progression in a xenograft model of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXBPMaIct4FrVg90H21EOLACvtfcHk0liah-gL8J9JYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVWhu7s%253D&md5=90c9e27d70783f89799df5298c8e69b8</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1039%2FC9OB02682G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9OB02682G%26sid%3Dliteratum%253Aachs%26aulast%3DMinus%26aufirst%3DM.%2BB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMunoz%26aufirst%3DJ.%2BO.%26aulast%3DStevens%26aufirst%3DA.%2BM.%26aulast%3DMangubat-Medina%26aufirst%3DA.%2BE.%26aulast%3DKrueger%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKasembeli%26aufirst%3DM.%2BM.%26aulast%3DCooper%26aufirst%3DJ.%2BC.%26aulast%3DKolosov%26aufirst%3DM.%2BI.%26aulast%3DTweardy%26aufirst%3DD.%2BJ.%26aulast%3DRedell%26aufirst%3DM.%2BS.%26aulast%3DBall%26aufirst%3DZ.%2BT.%26atitle%3DTargeting%2520STAT3%2520anti-apoptosis%2520pathways%2520with%2520organic%2520and%2520hybrid%2520organic-inorganic%2520inhibitors%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2020%26volume%3D18%26spage%3D3288%26epage%3D3296%26doi%3D10.1039%2FC9OB02682G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitor C188â9 synergistically enhances the demethylated activity of low-dose 5-aza-2â²-deoxycytidine against pancreatic cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">612</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2020.00612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3389%2Ffonc.2020.00612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32457835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB38rhvFSnug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=612&author=R.+Kongauthor=G.+Sunauthor=X.+Liauthor=L.+Wuauthor=L.+Liauthor=Y.+Liauthor=F.+Wangauthor=P.+Xuanauthor=S.+Yangauthor=B.+Sunauthor=J.+Hu&title=Small+molecule+inhibitor+C188%E2%80%939+synergistically+enhances+the+demethylated+activity+of+low-dose+5-aza-2%E2%80%B2-deoxycytidine+against+pancreatic+cancer&doi=10.3389%2Ffonc.2020.00612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2'-Deoxycytidine Against Pancreatic Cancer</span></div><div class="casAuthors">Kong Rui; Sun Guangming; Li Xina; Wu Linfeng; Li Le; Li Yilong; Wang Fei; Yang Shifeng; Sun Bei; Hu Jisheng; Kong Rui; Sun Guangming; Wu Linfeng; Li Le; Li Yilong; Sun Bei; Hu Jisheng; Xuan Ping</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">612</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Aberrant DNA methylation, especially hypermethylation of tumor suppressor genes, has been associated with many cancers' progression. 5-Aza-2'-deoxycytidine (DAC) can reverse hypermethylation-induced gene silencing via regulating DNA methyltransferases (DNMTs) activity, In addition, low-dose of DAC was proved to exert durable antitumor effects against solid tumor cells.  Nevertheless, no clinical effect of DAC has been made when fighting against pancreatic cancer.  Hence, it is necessary to raise a novel therapeutic strategy that further enhance the efficacy of DAC but not increase side effect, which impede the utilization of DAC.  In the present study, we have discovered that C188-9, a novel signal transduction activator of transcription (STAT) inhibitor, could improve the antitumor effects of low-dose DAC in vivo and in vitro.  Further study demonstrated that such improvement was attributed to re-expression of Ras association domain family member 1A (RASSF1A), a well-known tumor suppressor gene.  Bisulfite sequencing PCR (BSP) assay showed that C188-9 combined with DAC treatment could significantly reverse the hypermethylation status of RASSF1A promoter, which indicated that C188-9 could enhance the demethylation efficacy of DAC.  Our data demonstrated that DNA methyltransferase 1 (DNMT1) was the underlying mechanism that C188-9 regulates the demethylation efficacy of DAC.  Overall, these findings provide a novel therapeutic strategy combining low-dose DAC and C188-9 to improve therapeutic efficacy by inhibiting DNMT1-inducing promoter methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT451E1cqig0d0Q2ypr7jHkfW6udTcc2eaYtBuaPnKwvbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38rhvFSnug%253D%253D&md5=1acf8c140d4dd4e4aa455138ddd94300</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00612%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXuan%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520inhibitor%2520C188%25E2%2580%25939%2520synergistically%2520enhances%2520the%2520demethylated%2520activity%2520of%2520low-dose%25205-aza-2%25E2%2580%25B2-deoxycytidine%2520against%2520pancreatic%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D612%26doi%3D10.3389%2Ffonc.2020.00612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Y.</span></span> <span> </span><span class="NLM_article-title">C188â9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">846</span>â <span class="NLM_lpage">853</span>, <span class="refDoi">Â DOI: 10.1097/CAD.0000000000000783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1097%2FCAD.0000000000000783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30870229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOqt77E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=846-853&author=J.+X.+Diauthor=H.+Y.+Zhang&title=C188%E2%80%939%2C+a+small-molecule+STAT3+inhibitor%2C+exerts+an+antitumor+effect+on+head+and+neck+squamous+cell+carcinoma&doi=10.1097%2FCAD.0000000000000783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma</span></div><div class="casAuthors">Di, Jian-Xin; Zhang, Hong-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">846-853</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">1473-5741</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Abnormal activation of signal transducer and activator of transcription 3 (STAT3) is complicated in the tumor progression of multiple cancers including human head and neck squamous cell carcinoma (HNSCC) and, therefore, serves as a potent therapeutic target.  In this study, we identify that C188-9, a small-mol. STAT3 inhibitor, exhibits an antitumor effect on HNSCC in vitro.  C188-9 significantly inhibits cell growth, arrests cell cycle at G0/G1 phase, and induces apoptosis in HNSCC.  Besides, the capacities of migration and invasion of HNSCC cells are impaired with the exposure to C188-9.  In addn., C188-9 treatment enhanced the chemosensitivity of HNSCC cellsin vitro.  Moreover, C188-9 inactivates STAT3 by reducing its phosphorylation at Tyr705.  Taken together, these results indicate that C188-9 could be a promising therapeutic strategy for patients suffered from HNSCC by suppressing the STAT3 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyKJNhva8ForVg90H21EOLACvtfcHk0lieqjFuMlnMBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOqt77E&md5=57cdf51a67cd746c0ce4dd80f98edcb8</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000783%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DJ.%2BX.%26aulast%3DZhang%26aufirst%3DH.%2BY.%26atitle%3DC188%25E2%2580%25939%252C%2520a%2520small-molecule%2520STAT3%2520inhibitor%252C%2520exerts%2520an%2520antitumor%2520effect%2520on%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2019%26volume%3D30%26spage%3D846%26epage%3D853%26doi%3D10.1097%2FCAD.0000000000000783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minus, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vohidov, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasembeli, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolosov, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweardy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sison, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redell, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, Z. T.</span></span> <span> </span><span class="NLM_article-title">Rhodium(II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">13085</span>â <span class="NLM_lpage">13089</span>, <span class="refDoi">Â DOI: 10.1002/anie.201506889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1002%2Fanie.201506889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOmsr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=13085-13089&author=M.+B.+Minusauthor=W.+Liuauthor=F.+Vohidovauthor=M.+M.+Kasembeliauthor=X.+Longauthor=M.+J.+Kruegerauthor=A.+Stevensauthor=M.+I.+Kolosovauthor=D.+J.+Tweardyauthor=E.+A.+Sisonauthor=M.+S.+Redellauthor=Z.+T.+Ball&title=Rhodium%28II%29+proximity-labeling+identifies+a+novel+target+site+on+STAT3+for+inhibitors+with+potent+anti-leukemia+activity&doi=10.1002%2Fanie.201506889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity</span></div><div class="casAuthors">Minus, Matthew B.; Liu, Wei; Vohidov, Farrukh; Kasembeli, Moses M.; Long, Xin; Krueger, Michael J.; Stevens, Alexandra; Kolosov, Mikhail I.; Tweardy, David J.; Sison, Edward Allan R.; Redell, Michele S.; Ball, Zachary T.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">13085-13089</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Nearly 40 % of children with acute myeloid leukemia (AML) suffer relapse arising from chemoresistance, often involving upregulation of the oncoprotein STAT3 (signal transducer and activator of transcription 3).  Herein, rhodium(II)-catalyzed, proximity-driven modification identifies the STAT3 coiled-coil domain (CCD) as a novel ligand-binding site, and we describe a new naphthalene sulfonamide inhibitor that targets the CCD, blocks STAT3 function, and halts its disease-promoting effects in vitro, in tumor growth models, and in a leukemia mouse model, validating this new therapeutic target for resistant AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaEI9lh5LaebVg90H21EOLACvtfcHk0lieqjFuMlnMBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOmsr3F&md5=8d1c509437ac74ff8382ff7a43898de9</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506889%26sid%3Dliteratum%253Aachs%26aulast%3DMinus%26aufirst%3DM.%2BB.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DVohidov%26aufirst%3DF.%26aulast%3DKasembeli%26aufirst%3DM.%2BM.%26aulast%3DLong%26aufirst%3DX.%26aulast%3DKrueger%26aufirst%3DM.%2BJ.%26aulast%3DStevens%26aufirst%3DA.%26aulast%3DKolosov%26aufirst%3DM.%2BI.%26aulast%3DTweardy%26aufirst%3DD.%2BJ.%26aulast%3DSison%26aufirst%3DE.%2BA.%26aulast%3DRedell%26aufirst%3DM.%2BS.%26aulast%3DBall%26aufirst%3DZ.%2BT.%26atitle%3DRhodium%2528II%2529%2520proximity-labeling%2520identifies%2520a%2520novel%2520target%2520site%2520on%2520STAT3%2520for%2520inhibitors%2520with%2520potent%2520anti-leukemia%2520activity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D13085%26epage%3D13089%26doi%3D10.1002%2Fanie.201506889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehndiratta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">N-sulfonyl-aminobiaryls as antitubulin agents and inhibitors of signal transducers and activators of transcription 3 (STAT3) signaling</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6549</span>â <span class="NLM_lpage">6558</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00659</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00659" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OqsLnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6549-6558&author=M.+J.+Laiauthor=H.+Y.+Leeauthor=H.+Y.+Chuangauthor=L.+H.+Changauthor=A.+C.+Tsaiauthor=M.+C.+Chenauthor=H.+L.+Huangauthor=Y.+W.+Wuauthor=C.+M.+Tengauthor=S.+L.+Panauthor=Y.+M.+Liuauthor=S.+Mehndirattaauthor=J.+P.+Liou&title=N-sulfonyl-aminobiaryls+as+antitubulin+agents+and+inhibitors+of+signal+transducers+and+activators+of+transcription+3+%28STAT3%29+signaling&doi=10.1021%2Facs.jmedchem.5b00659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling</span></div><div class="casAuthors">Lai, Mei-Jung; Lee, Hsueh-Yun; Chuang, Hsun-Yueh; Chang, Li-Hsun; Tsai, An-Chi; Chen, Mei-Chuan; Huang, Han-Lin; Wu, Yi-Wen; Teng, Che-Ming; Pan, Shiow-Lin; Liu, Yi-Min; Mehndiratta, Samir; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6549-6558</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-sulfonyl-aminobiaryl derivs. have been examd. as novel antitubulin agents.  Compd. I exhibits remarkable antiproliferative activity against four cancer cell lines (pancreatic AsPC-1, lung A549, liver Hep3B, and prostate PC-3) with a mean GI50 value of 57.5 nM.  Addnl. assays reveal that I inhibits not only tubulin polymn. but also the phosphorylation of STAT3 inhibition with an IC50 value of 0.2 Î¼M.  Four addnl. compds. are also able to inhibit this phosphorylation.  This study describes novel N-sulfonyl-aminobiaryl (biaryl-benzenesulfonamides) as potent anticancer agents targeting both STAT3 and tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN3n1lKtBuqbVg90H21EOLACvtfcHk0lieqjFuMlnMBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OqsLnI&md5=e0bb2c7f2fb75634ed66b0a910332b9a</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00659%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DChuang%26aufirst%3DH.%2BY.%26aulast%3DChang%26aufirst%3DL.%2BH.%26aulast%3DTsai%26aufirst%3DA.%2BC.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DMehndiratta%26aufirst%3DS.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DN-sulfonyl-aminobiaryls%2520as%2520antitubulin%2520agents%2520and%2520inhibitors%2520of%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%25203%2520%2528STAT3%2529%2520signaling%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6549%26epage%3D6558%26doi%3D10.1021%2Facs.jmedchem.5b00659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, C.</span></span> <span> </span><span class="NLM_article-title">N-arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">96</span>â <span class="NLM_lpage">106</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmc.2017.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29174507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKhsrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=96-106&author=Q.+Zhouauthor=J.+Zhuauthor=J.+Chenauthor=P.+Jiauthor=C.+Qiao&title=N-arylsulfonylsubstituted-1H+indole+derivatives+as+small+molecule+dual+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+and+tubulin&doi=10.1016%2Fj.bmc.2017.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">N-Arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin</span></div><div class="casAuthors">Zhou, Qiang; Zhu, Jinjin; Chen, Jinglei; Ji, Peng; Qiao, Chunhua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-106</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription (STAT3) is a proposed therapeutic target for the development of anti-cancer agents.  In this report, a series of N-arylsulfonylsubstituted-1H indole derivs. were designed and synthesized as STAT3 inhibitors, their anti-proliferative activities were evaluated against a no. of tumor cells, some potent compds. exhibited IC50 values less than 10Î¼M.  The most potent compd. 4a was further confirmed to inhibit STAT3 phosphorylation at Tyr705.  It was further revealed that 4a arrested the cell cycle at the G2/M phase and inhibited tubulin polymn.  This study describes a series of N-arylsulfonylsubstituted-1H indole derivs. as potent anti-cancer agents targeting both STAT3 and tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGramH1h65Up5bVg90H21EOLACvtfcHk0lgnt1MTPUrpOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKhsrjL&md5=42f4f6840d823edb8fe53918f7f4bafd</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DQiao%26aufirst%3DC.%26atitle%3DN-arylsulfonylsubstituted-1H%2520indole%2520derivatives%2520as%2520small%2520molecule%2520dual%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520and%2520tubulin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D96%26epage%3D106%26doi%3D10.1016%2Fj.bmc.2017.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of O-alkylamino-tethered niclosamide derivatives as potent and orally bioavailable anticancer agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">180</span>â <span class="NLM_lpage">185</span>, <span class="refDoi">Â DOI: 10.1021/ml3003082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3003082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1ejug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=180-185&author=H.+Chenauthor=Z.+Yangauthor=C.+Dingauthor=L.+Chuauthor=Y.+Zhangauthor=K.+Terryauthor=H.+Liuauthor=Q.+Shenauthor=J.+Zhou&title=Discovery+of+O-alkylamino-tethered+niclosamide+derivatives+as+potent+and+orally+bioavailable+anticancer+agents&doi=10.1021%2Fml3003082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents</span></div><div class="casAuthors">Chen, Haijun; Yang, Zhengduo; Ding, Chunyong; Chu, Lili; Zhang, Yusong; Terry, Kristin; Liu, Huiling; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-185</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Niclosamide has been identified to potently inhibit the activation, nuclear translocation, and transactivation of STAT3.  Nevertheless, the poor aq. soly. and bioavailability of niclosamide have hindered its further clin. development for cancer therapy.  To discover new mols. with enhanced druglike properties, a series of novel O-alkylamino-tethered derivs. of niclosamide have been designed, synthesized, and biol. evaluated.  Among them, compd. IÂ·HCl (HJC0152) has been demonstrated to significantly suppress MDA-MB-231 xenograft tumor growth in vivo (i.p. and po), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlkKSIbCSKsrVg90H21EOLACvtfcHk0lgnt1MTPUrpOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1ejug%253D%253D&md5=a481986f86800fc39f24a6af12c46a8e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fml3003082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3003082%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTerry%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520O-alkylamino-tethered%2520niclosamide%2520derivatives%2520as%2520potent%2520and%2520orally%2520bioavailable%2520anticancer%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D180%26epage%3D185%26doi%3D10.1021%2Fml3003082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on niclosamide</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>218</i></span>,  <span class="NLM_fpage">113362</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2021.113362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33774344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3MXns1ehs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2021&pages=113362&author=X.+Wangauthor=K.+Wuauthor=L.+Fangauthor=X.+Yangauthor=N.+Zhengauthor=Z.+Duauthor=Y.+Luauthor=Z.+Xieauthor=Z.+Liuauthor=Z.+Zuoauthor=F.+Ye&title=Discovery+of+N-substituted+sulfamoylbenzamide+derivatives+as+novel+inhibitors+of+STAT3+signaling+pathway+based+on+niclosamide&doi=10.1016%2Fj.ejmech.2021.113362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide</span></div><div class="casAuthors">Wang, Xuebao; Wu, Kaiqi; Fang, Longcheng; Yang, Xiaojiao; Zheng, Nan; Du, Zongxuan; Lu, Ying; Xie, Zixin; Liu, Zhiguo; Zuo, Zhigui; Ye, Faqing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113362</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) has been confirmed as an attractive therapeutic target for cancer therapy.  Herein, a series of N-substituted sulfamoylbenzamide STAT3 inhibitors I [R1 = H, OH; R2 = H, Cl; R3 = 2-MeOC6H4, 3,4,5-(OMe)3C6H2, 3-MeOC6H4CH2, etc.; R4 = H, C(O)Me, C(O)Ph, etc.] based on small-mol. STAT3 inhibitor Niclosamide was synthesized.  Compd. I [R1 = H, R2 = Cl, R3 = 4-CO2t-BuC6H4, R4 = H] the best active compd. of this series, was identified as an inhibitor of IL-6/STAT3 signaling with an IC50 of 0.61-1.11Î¼M in MDA-MB-231, HCT-116 and SW480 tumor cell lines with STAT3 overexpression, by inhibiting the phosphorylation of STAT3 of Tyr705 residue and the expression of STAT3 downstream genes, inducing apoptosis and inhibiting the migration of cancer cells.  Furthermore, in vivo study revealed that compd. I [R1 = H, R2 = Cl, R3 = 4-CO2t-BuC6H4, R4 = H] suppressed the MDA-MB-231 xenograft tumor growth in nude mice at the dose of 30 mg/kg (i.g.), which has better antitumor activity than the pos. control Niclosamide.  More importantly, compd. I [R1 = H, R2 = Cl, R3 = 4-CO2t-BuC6H4, R4 = H] was an orally bioavailable anticancer agent as a promising candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosKlZj-EOdd7Vg90H21EOLACvtfcHk0lgJCLkDfpDoFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXns1ehs7w%253D&md5=a634925c2b0cfde3408490a9904d0f64</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113362%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZuo%26aufirst%3DZ.%26aulast%3DYe%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520N-substituted%2520sulfamoylbenzamide%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520STAT3%2520signaling%2520pathway%2520based%2520on%2520niclosamide%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D218%26spage%3D113362%26doi%3D10.1016%2Fj.ejmech.2021.113362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koseki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suehiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a new STAT3 inhibitor acting on the linker domain</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">792</span>â <span class="NLM_lpage">800</span>, <span class="refDoi">Â DOI: 10.1248/bpb.b18-00992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1248%2Fbpb.b18-00992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31061322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVShsLnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=792-800&author=T.+Kosekiauthor=N.+Suehiroauthor=Y.+Masudaauthor=N.+Miyoshiauthor=D.+Muraokaauthor=N.+Ogoauthor=A.+Asai&title=Discovery+of+a+new+STAT3+inhibitor+acting+on+the+linker+domain&doi=10.1248%2Fbpb.b18-00992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a new STAT3 inhibitor acting on the linker domain</span></div><div class="casAuthors">Koseki, Tatsuya; Suehiro, Naoya; Masuda, Yoshiaki; Miyoshi, Nao; Muraoka, Daisuke; Ogo, Naohisa; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">792-800</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a latent transcription factor that contributes to tumor cell growth and survival and is often constitutively active in several types of cancers, which makes it an attractive target for cancer therapy.  We identified 5,5'-(pentane-1,5'-diyl)bis(2-methyl-1,4-benzoquinone) (BPMB) as a new STAT3 inhibitor.  BPMB inhibited the transcriptional activities of STAT3, despite its inability to reduce the phosphorylation and nuclear translocation of STAT3.  BPMB selectively inhibited the proliferation of human breast cancer cell lines with constitutively activated STAT3.  Furthermore, a gel retardation pattern was obtained by immunoblotting only when those STAT3-activated cell lines were treated with BPMB.  The shifted bands could be immunoblotted with anti-STAT3 antibody but not with anti-STAT1/STAT5 antibody, and were stable under reducing conditions.  The purified recombinant STAT3 protein treated with BPMB afforded a similar band shift pattern.  Matrix-assisted laser desorption/ionization-mass spectrometry anal. of the component comprising the main shifted band suggested that the complex is a STAT3 homodimer crosslinked by BPMB through a Michael addn. with Cys550 in the linker domain.  Alanine replacement at this position resulted in redn. of the STAT3 dimer formation in the gel retardation assay.  Thus, our results suggest that BPMB inhibits the proliferation of STAT3-activated cell lines, presumably through acylation of the linker domain and subsequent induction of the inactive STAT3 complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFOnrr8aXDNLVg90H21EOLACvtfcHk0lgJCLkDfpDoFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVShsLnL&md5=f7968e57b207518cf2231f769276eff6</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b18-00992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b18-00992%26sid%3Dliteratum%253Aachs%26aulast%3DKoseki%26aufirst%3DT.%26aulast%3DSuehiro%26aufirst%3DN.%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DMiyoshi%26aufirst%3DN.%26aulast%3DMuraoka%26aufirst%3DD.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520new%2520STAT3%2520inhibitor%2520acting%2520on%2520the%2520linker%2520domain%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2019%26volume%3D42%26spage%3D792%26epage%3D800%26doi%3D10.1248%2Fbpb.b18-00992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Natan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anahtar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppler, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blonquist, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiffer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1845</span>â <span class="NLM_lpage">1853</span>, <span class="refDoi">Â DOI: 10.1182/blood-2015-07-660506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1182%2Fblood-2015-07-660506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27531676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSiurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=1845-1853&author=M.+Xiangauthor=H.+Kimauthor=V.+T.+Hoauthor=S.+R.+Walkerauthor=M.+Bar-Natanauthor=M.+Anahtarauthor=S.+Liuauthor=P.+A.+Tonioloauthor=Y.+Krollauthor=N.+Jonesauthor=Z.+T.+Giacconeauthor=L.+N.+Hepplerauthor=D.+Q.+Yeauthor=J.+J.+Marineauauthor=D.+Shawauthor=J.+E.+Bradnerauthor=T.+Blonquistauthor=D.+Neubergauthor=C.+Hetzauthor=R.+M.+Stoneauthor=R.+J.+Soifferauthor=D.+A.+Frank&title=Gene+expression-based+discovery+of+atovaquone+as+a+STAT3+inhibitor+and+anticancer+agent&doi=10.1182%2Fblood-2015-07-660506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent</span></div><div class="casAuthors">Xiang, Michael; Kim, Haesook; Ho, Vincent T.; Walker, Sarah R.; Bar-Natan, Michal; Anahtar, Melodi; Liu, Suhu; Toniolo, Patricia A.; Kroll, Yasmin; Jones, Nichole; Giaccone, Zachary T.; Heppler, Lisa N.; Ye, Darwin Q.; Marineau, Jason J.; Shaw, Daniel; Bradner, James E.; Blonquist, Traci; Neuberg, Donna; Hetz, Claudio; Stone, Richard M.; Soiffer, Robert J.; Frank, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1845-1853</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is frequently activated inappropriately in a wide range of hematol. and solid cancers, but clin. available therapies targeting STAT3 are lacking.  Using a computational strategy to identify compds. opposing the gene expression signature of STAT3, we discovered atovaquone (Mepron), an antimicrobial approved by the US Food and Drug Administration, to be a potent STAT3 inhibitor.  We show that, at drug concns. routinely achieved clin. in human plasma, atovaquone inhibits STAT3 phosphorylation, the expression of STAT3 target genes, and the viability of STAT3-dependent hematol. cancer cells.  These effects were also obsd. with atovaquone treatment of primary blasts isolated from patients with acute myelogenous leukemia or acute lymphocytic leukemia.  Atovaquone is not a kinase inhibitor but instead rapidly and specifically downregulates cell-surface expression of glycoprotein 130, which is required for STAT3 activation in multiple contexts.  The administration of oral atovaquone to mice inhibited tumor growth and prolonged survival in a murine model of multiple myeloma.  Finally, in patients with acute myelogenous leukemia treated with hematopoietic stem cell transplantation, extended use of atovaquone for Pneumocystis prophylaxis was assocd. with improved relapse-free survival.  These findings establish atovaquone as a novel, clin. accessible STAT3 inhibitor with evidence of anticancer efficacy in both animal models and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kci57tYtb7Vg90H21EOLACvtfcHk0lgcN3r7dlrE9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSiurg%253D&md5=201e3d6ea0e204d1a631652caae8f987</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-07-660506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-07-660506%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DHo%26aufirst%3DV.%2BT.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DBar-Natan%26aufirst%3DM.%26aulast%3DAnahtar%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DToniolo%26aufirst%3DP.%2BA.%26aulast%3DKroll%26aufirst%3DY.%26aulast%3DJones%26aufirst%3DN.%26aulast%3DGiaccone%26aufirst%3DZ.%2BT.%26aulast%3DHeppler%26aufirst%3DL.%2BN.%26aulast%3DYe%26aufirst%3DD.%2BQ.%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBlonquist%26aufirst%3DT.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DHetz%26aufirst%3DC.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSoiffer%26aufirst%3DR.%2BJ.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DGene%2520expression-based%2520discovery%2520of%2520atovaquone%2520as%2520a%2520STAT3%2520inhibitor%2520and%2520anticancer%2520agent%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D1845%26epage%3D1853%26doi%3D10.1182%2Fblood-2015-07-660506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2718</span>â <span class="NLM_lpage">2731</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2718-2731&author=W.+Yuauthor=C.+Liauthor=W.+Zhangauthor=Y.+Xiaauthor=S.+Liauthor=J.+Y.+Linauthor=K.+Yuauthor=M.+Liuauthor=L.+Yangauthor=J.+Luoauthor=Y.+Chenauthor=H.+Sunauthor=L.+Kong&title=Discovery+of+an+orally+selective+inhibitor+of+signal+transducer+and+activator+of+transcription+3+using+advanced+multiple+ligand+simultaneous+docking&doi=10.1021%2Facs.jmedchem.6b01489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking</span></div><div class="casAuthors">Yu, Wenying; Li, Chenglong; Zhang, Wenda; Xia, Yuanzheng; Li, Shanshan; Lin, Jia-yuh; Yu, Keqin; Liu, Mu; Yang, Lei; Luo, Jianguang; Chen, Yijun; Sun, Hongbin; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2718-2731</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting signal transducer and activator of transcription 3 (STAT3) is a potential anticancer strategy.  However, STAT3 inhibitors with good selectivity and bioavailability are rare.  The aim of this study was to discover selective direct STAT3 inhibitors with good drug-likeness.  By advanced multiple ligand simultaneous docking (AMLSD) method, compd. 9 (5,8-dioxo-6-((2-(piperazin-1-yl)phenyl)amino)-5,8-dihydronaphthalene-1-sulfonamide) was designed as an orally-bioavailable STAT3 inhibitor, which presented superior druggability and selectivity to other representative STAT3 inhibitors.  Compd. 9 directly and selectively inhibited the pY705 site of STAT3 with an affinity (Ki) of 440nM.  The IC50 of 9 for breast cancer cell MDA-MB-231 was 184-fold lower than its IC50 for normal breast epithelial cell MCF-10A.  Compd. 9 in vivo induced significant antitumor responses better than Gefitinib and its therapeutic index should be over 100, indicating good safety of 9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiT8F_tCrky7Vg90H21EOLACvtfcHk0lgcN3r7dlrE9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D&md5=d9554e49fd17a559e8c7171f36c53607</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01489%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.%2BY.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520selective%2520inhibitor%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520using%2520advanced%2520multiple%2520ligand%2520simultaneous%2520docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2718%26epage%3D2731%26doi%3D10.1021%2Facs.jmedchem.6b01489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span> <span> </span><span class="NLM_article-title">LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">298</span>â <span class="NLM_lpage">313</span>, <span class="refDoi">Â DOI: 10.1111/bph.14863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1111%2Fbph.14863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31499589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGnt7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2020&pages=298-313&author=Z.+Liuauthor=H.+Wangauthor=L.+Guanauthor=C.+Laiauthor=W.+Yuauthor=M.+Lai&title=LL1%2C+a+novel+and+highly+selective+STAT3+inhibitor%2C+displays+anti-colorectal+cancer+activities+in+vitro+and+in+vivo&doi=10.1111%2Fbph.14863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo</span></div><div class="casAuthors">Liu, Zhe; Wang, Huan; Guan, Lingnan; Lai, Chong; Yu, Wenying; Lai, Maode</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We syntheised a novel, potent and small-mol. inhibitor of STAT3, LL1, and studied its antitumor effects and investigated its mechanism of action in two tumor models.  Exptl. Approach : Using structure-based drug design method, based on the crystal structure of STAT3 protein, we identified a potent STAT3 inhibitor (LL1) targeting STAT3 SH2 domain and characterized its therapeutic properties and potential toxicity in vitro and in vivo using the MTT assay, colony formation assay, histol., immunohistochem., flow cytometric anal., and tumor xenograft model.  Key Results : LL1 is highly selective among STATs family members and specifically inhibits phosphorylation of STAT3 Tyr-705 site, blocking the whole transmission process of STAT3 signalling.  LL1 inhibited proliferation, colony formation, migration, and invasion of colonic cell lines.  STAT3 is orally available to animals and suppresses tumor growth and metastasis in a dosage level compatible to clin. applications.  Importantly, it does not cause significant toxicity at several times the ED.  Conclusions and Implications : LL1 inhibits tumor growth and metastasis by blocking STAT3 signalling pathway.  LL1 could be a promising therapeutic drug candidate for colorectal cancer by inhibiting the STAT3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7y8svF0ourVg90H21EOLACvtfcHk0lgcN3r7dlrE9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGnt7bK&md5=847b83e3c992fee2d50b7f40bcf3978e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1111%2Fbph.14863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14863%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGuan%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DM.%26atitle%3DLL1%252C%2520a%2520novel%2520and%2520highly%2520selective%2520STAT3%2520inhibitor%252C%2520displays%2520anti-colorectal%2520cancer%2520activities%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2020%26volume%3D177%26spage%3D298%26epage%3D313%26doi%3D10.1111%2Fbph.14863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Z.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T.-t.</span></span> <span> </span><span class="NLM_article-title">Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions</span>. <i>Bone Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">362</span>â <span class="NLM_lpage">370</span>, <span class="refDoi">Â DOI: 10.4248/BR201304007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.4248%2FBR201304007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26273514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFyitbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=362-370&author=W.+Yanauthor=B.+Tuauthor=Y.-y.+Liuauthor=T.-y.+Wangauthor=H.+Qiaoauthor=Z.-j.+Zhaiauthor=H.-w.+Liauthor=T.-t.+Tang&title=Suppressive+effects+of+plumbagin+on+invasion+and+migration+of+breast+cancer+cells+via+the+inhibition+of+STAT3+signaling+and+down-regulation+of+inflammatory+cytokine+expressions&doi=10.4248%2FBR201304007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Suppressive Effects of Plumbagin on Invasion and Migration of Breast Cancer Cells via the Inhibition of STAT3 Signaling and Down-regulation of Inflammatory Cytokine Expressions</span></div><div class="casAuthors">Yan, Wei; Tu, Bing; Liu, Yun-yun; Wang, Ting-yu; Qiao, Han; Zhai, Zan-jing; Li, Hao-wei; Tang, Ting-ting</div><div class="citationInfo"><span class="NLM_cas:title">Bone Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">362-370</span>CODEN:
                <span class="NLM_cas:coden">BROEBB</span>;
        ISSN:<span class="NLM_cas:issn">2095-6231</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: The aim of this study was to investigate the effects of plumbagin (PL), a naphthoquinone derived from the medicinal plant plumbago zeylanica, on the invasion and migration of human breast cancer cells.  Methods: Human breast cancer MDA-MB-231SArfp cells were treated with different concns. of plumbagin for 24 h.  The effects of plumbagin on the migration and invasion were obsd. by a transwell method.  The expressions of IL-1Î±, IL-1Î², IL-6, IL-8, TGF-Î², TNFÎ±, MMP-2 and MMP-9 mRNA in MDA-MB-231SArfp cells were detected using Real-Time PCR.  MDA-MB-231SArfp cells were treated with plumbagin at different concns. for 45 min.  The activation of STAT3 was detected by western blot.  Following this anal., STAT3 in MDA-MB-231SArfp cells was knocked out using specific siRNA. mRNA levels of IL-1Î±, TGF-Î², MMP-2 and MMP-9 were then detected.  Consequently, MDA-MB-231SArfp cells were injected intracardially into BALB/c nude mice to construct a breast cancer bone metastatic model.  The mice were injected i.p. with plumbagin.  Non-invasive in vivo monitoring, X-ray imaging and histol. staining were performed to investigate the effects of plumbagin on the invasion and migration of breast cancer cells in vivo.  Results: The in vitro results showed that plumbagin could suppress the migration and invasion of breast cancer cells and down-regulate mRNA expressions of IL-1Î±, TGF-Î², MMP-2 and MMP-9.  Western blotting demonstrated that plumbagin inhibited the activation of STAT3 signaling in MDA-MB-231SArfp cells.  The inactivation of STAT3 was found to have an inhibitory effect on the expressions of IL-1Î±, TGF-Î², MMP-2 and MMP-9.  In vivo studies showed that plumbagin inhibited the metastasis of breast cancer cells and decreased osteolytic bone metastases, as well as the secretion of MMP-2 and MMP-9 by tumor cells at metastatic lesions.  Conclusions: Plumbagin can suppress the invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and by downregulation of IL-1Î±, TGF-Î², MMP-2 and MMP-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMAa_AcpJMQbVg90H21EOLACvtfcHk0lglKBR0ghE_cA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFyitbg%253D&md5=f66f25dac9688c407e29f7d10b5901e1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.4248%2FBR201304007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4248%252FBR201304007%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DTu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.-y.%26aulast%3DWang%26aufirst%3DT.-y.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DZhai%26aufirst%3DZ.-j.%26aulast%3DLi%26aufirst%3DH.-w.%26aulast%3DTang%26aufirst%3DT.-t.%26atitle%3DSuppressive%2520effects%2520of%2520plumbagin%2520on%2520invasion%2520and%2520migration%2520of%2520breast%2520cancer%2520cells%2520via%2520the%2520inhibition%2520of%2520STAT3%2520signaling%2520and%2520down-regulation%2520of%2520inflammatory%2520cytokine%2520expressions%26jtitle%3DBone%2520Res.%26date%3D2013%26volume%3D1%26spage%3D362%26epage%3D370%26doi%3D10.4248%2FBR201304007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">104208</span>, <span class="refDoi">Â DOI: 10.1016/j.bioorg.2020.104208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bioorg.2020.104208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32919131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVajt7bF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2020&pages=104208&author=N.+Liauthor=J.+Ouauthor=N.+Baoauthor=C.+Chenauthor=Z.+Shiauthor=L.+Chenauthor=J.+Sun&title=Design%2C+synthesis+and+biological+evaluation+of+novel+plumbagin+derivatives+as+potent+antitumor+agents+with+STAT3+inhibition&doi=10.1016%2Fj.bioorg.2020.104208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition</span></div><div class="casAuthors">Li, Na; Ou, Jinfeng; Bao, Na; Chen, Cheng; Shi, Zhixian; Chen, Li; Sun, Jianbo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104208</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on the structure of signal transducer and activator of transcription 3 (STAT3), a series of 1,4-naphthoquinones, e.g. I, derived from plumbagin (PL) with STAT3 inhibition potential were designed, synthesized, and biol. evaluated in vitro against several human cancer cell lines (MDA-MB-231, HepG2 and A549 cells) and three normal cells.  The structure-activity relationship (SAR) and mol. docking result showed that the presence of hydroxyl group at C-5 of PL might interact with STAT3 in the form of hydrogen bonds, which is conducive to the binding of this kind structures with STAT3.  Among the target compds., I displayed the most potent inhibition against cancer cells and weaker cytotoxicity on normal cells than PL.  The western bolting anal. showed that I could suppress the phosphorylation of STAT3 as well as the downstream genes instead of affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression.  Furthermore, mol. docking indicated that I bound to STAT3 more tightly than PL, and it could significantly induce the apoptosis of cancer cells in vitro.  All these results may provide ref. for the discovery of effective STAT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraBjcXkNqOu7Vg90H21EOLACvtfcHk0lglKBR0ghE_cA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVajt7bF&md5=9a47b9acc28a4a65235232dd881644cc</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.104208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.104208%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DJ.%26aulast%3DBao%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520plumbagin%2520derivatives%2520as%2520potent%2520antitumor%2520agents%2520with%2520STAT3%2520inhibition%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D104%26spage%3D104208%26doi%3D10.1016%2Fj.bioorg.2020.104208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span> <span> </span><span class="NLM_article-title">Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2/STAT3 pathway</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">327</span>â <span class="NLM_lpage">333</span>, <span class="refDoi">Â DOI: 10.1016/j.intimp.2014.01.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.intimp.2014.01.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24521871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFWqtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=327-333&author=Y.+Xuauthor=X.+Xuauthor=X.+Gaoauthor=H.+Chenauthor=L.+Geng&title=Shikonin+suppresses+IL-17-induced+VEGF+expression+via+blockage+of+JAK2%2FSTAT3+pathway&doi=10.1016%2Fj.intimp.2014.01.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2/STAT3 pathway</span></div><div class="casAuthors">Xu, Yuanyuan; Xu, Xuegang; Gao, Xinghua; Chen, Hongduo; Geng, Long</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-333</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">IL-17 signaling in keratinocytes plays an important role in psoriasis, which is a benign, chronic skin disease characterized by keratinocytes hyperproliferation and increased dermal vascularity.  Shikonin, isolated from the traditional medical herbs Lithospermum erythrorhizon, has long been found to possess different medicinal properties such as antibacterial, improving wound healing, anti-inflammatory and anti-tumor effects.  However, the effects and mechanisms of shikonin on VEGF expression in keratinocytes mediated by IL-17 signaling, are still not fully clarified.  In the present study, we investigated the effects and regulatory mechanisms of shikonin on VEGF expression in keratinocytes induced by IL-17 by in vitro and in vivo expts.  Our results showed that shikonin significantly inhibited IL-17-induced VEGF mRNA and protein expression in HaCaT cells and the secretion of VEGF by HaCaT cells, inhibited IL-17-induced IL-17R, pJAK2 and pSTAT3 expression, while up-regulated the expression of SOCS1 in HaCaT cells.  Addnl., shikonin effectively suppressed VEGF expression in the skin of IL-17 stimulated mice.  Furthermore, shikonin suppressed VEGF-induced tube formation of HUVECs and CD34 expression in the skin of IL-17 stimulated mice.  These results imply that shikonin suppresses IL-17-induced VEGF expression in vitro and in vivo and the mechanisms may be related to its effect in blockage of JAK2/STAT3 pathway.  These data deepen our understanding of shikonin in the inhibition of angiogenesis in inflammatory skin diseases such as psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow-1LUQSBDVLVg90H21EOLACvtfcHk0lglKBR0ghE_cA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFWqtbw%253D&md5=988b1acfc0c4b0132c0c8cb52b73e54a</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2014.01.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2014.01.027%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGeng%26aufirst%3DL.%26atitle%3DShikonin%2520suppresses%2520IL-17-induced%2520VEGF%2520expression%2520via%2520blockage%2520of%2520JAK2%252FSTAT3%2520pathway%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2014%26volume%3D19%26spage%3D327%26epage%3D333%26doi%3D10.1016%2Fj.intimp.2014.01.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span> <span> </span><span class="NLM_article-title">Shikonin inhibits IFN-Î³-induced K17 over-expression of HaCaT cells by interfering with STAT3 signaling</span>. <i>Int. J. Clin. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9202</span>â <span class="NLM_lpage">9207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26464667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC28zhtlyksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=9202-9207&author=L.+Liuauthor=Y.+Wuauthor=K.+Caoauthor=Y.+Y.+Xuauthor=X.+H.+Gaoauthor=H.+D.+Chenauthor=L.+Geng&title=Shikonin+inhibits+IFN-%CE%B3-induced+K17+over-expression+of+HaCaT+cells+by+interfering+with+STAT3+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Shikonin inhibits IFN-Î³-induced K17 over-expression of HaCaT cells by interfering with STAT3 signaling</span></div><div class="casAuthors">Liu Lili; Wu Yan; Xu Yuan-Yuan; Gao Xing-Hua; Chen Hong-Duo; Geng Long; Cao Kai</div><div class="citationInfo"><span class="NLM_cas:title">International journal of clinical and experimental pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">9202-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  We hypothesized that interferon-Î³ (IFN-Î³) induces K17 over-expression in HaCaT cells by activating STAT3 and that Sh might inhibit the over-expression through interference of STAT3 signaling.  METHODS:  In vitro culture of HaCaT cells treated with IFN-Î³ and measurement of K17 protein by enzyme linked immunosorbent assay.  RESULTS:  The level of K17 protein (one kind of keratin protein) in the supernatant induced by IFN-Î³ was significantly reduced by Shikonin at various concentrations.  Interference of STAT3 suppressed the effect of IFN-Î³ on K17 expression at both mRNA and protein levels.  The over-expression of K17 in IFN-Î³-induced HaCaT cells was significantly suppressed by 2 Î¼g/L Shikonin.  Interfering with STAT3 signaling with 2 Î¼g/L Shikonin resulted in an intermediate level of IFN-Î³-induced K17 protein in HaCaT cells.  CONCLUSIONS:  These data demonstrate that IFN-Î³ induces K17 protein over-expression of HaCaT cells by activating STAT3 and Shikonin may inhibit the over-expression partly through interference of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ29RZMba46OgHqQV89nF-2fW6udTcc2ebn8rKO-JMMgrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zhtlyksA%253D%253D&md5=e5feb4d2ffb575f2e6cb075bea19a7a4</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DY.%2BY.%26aulast%3DGao%26aufirst%3DX.%2BH.%26aulast%3DChen%26aufirst%3DH.%2BD.%26aulast%3DGeng%26aufirst%3DL.%26atitle%3DShikonin%2520inhibits%2520IFN-%25CE%25B3-induced%2520K17%2520over-expression%2520of%2520HaCaT%2520cells%2520by%2520interfering%2520with%2520STAT3%2520signaling%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Pathol.%26date%3D2015%26volume%3D8%26spage%3D9202%26epage%3D9207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. H.</span></span> <span> </span><span class="NLM_article-title">Identification of new shikonin derivatives as STAT3 inhibitors</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">74</span>â <span class="NLM_lpage">86</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2017.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bcp.2017.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29066190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslagtbjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2017&pages=74-86&author=H.+Y.+Qiuauthor=J.+Y.+Fuauthor=M.+K.+Yangauthor=H.+W.+Hanauthor=P.+F.+Wangauthor=Y.+H.+Zhangauthor=H.+Y.+Linauthor=C.+Y.+Tangauthor=J.+L.+Qiauthor=R.+W.+Yangauthor=X.+M.+Wangauthor=H.+L.+Zhuauthor=Y.+H.+Yang&title=Identification+of+new+shikonin+derivatives+as+STAT3+inhibitors&doi=10.1016%2Fj.bcp.2017.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new shikonin derivatives as STAT3 inhibitors</span></div><div class="casAuthors">Qiu, Han-Yue; Fu, Jiang-Yan; Yang, Min-Kai; Han, Hong-Wei; Wang, Peng-Fei; Zhang, Ya-Han; Lin, Hong-Yan; Tang, Cheng-Yi; Qi, Jin-Liang; Yang, Rong-Wu; Wang, Xiao-Ming; Zhu, Hai-Liang; Yang, Yong-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-86</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 is a constitutively activated oncogenic protein in various human tumors and represents a valid target for anticancer drug design.  In this study, the authors have achieved a new type of STAT3 inhibitors based on structural modifications on shikonin scaffold, guided by computational modeling.  By tests, PMMB-187 exhibited a more outstanding profile than shikonin on a small panel of human breast cancer cells, esp. for the MDA-MB-231 cells.  For the cellular mechanisms research, PMMB-187 was found to induce cell apoptosis in MDA-MB-231 cells, assocd. with the redn. of mitochondrial membrane potential, prodn. of ROS and alteration of the levels of apoptosis-related proteins.  Furthermore, PMMB-187 inhibited constitutive/inducible STAT3 activation, transcriptional activity, nuclear translocation and downstream target genes expression in STAT3-dependent breast cancer cells MDA-MB-231.  Besides, no obvious inhibitory effect on activation of STAT1 and STAT5 was obsd. with PMMB-187 treatment.  Most notably, the in vivo studies further revealed that PMMB-187 could dramatically suppress the MDA-MB-231 cells xenografted tumor growth.  The in vitro and in vivo results collectively suggest that PMMB-187 may serve as a promising lead compd. for the further development of potential therapeutic anti-neoplastic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBnm7HBRlgo7Vg90H21EOLACvtfcHk0lidIMJQohL2Jg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslagtbjM&md5=af3b70e4895b2902cdc20b0d9c4f4872</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DH.%2BY.%26aulast%3DFu%26aufirst%3DJ.%2BY.%26aulast%3DYang%26aufirst%3DM.%2BK.%26aulast%3DHan%26aufirst%3DH.%2BW.%26aulast%3DWang%26aufirst%3DP.%2BF.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DTang%26aufirst%3DC.%2BY.%26aulast%3DQi%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26aulast%3DYang%26aufirst%3DY.%2BH.%26atitle%3DIdentification%2520of%2520new%2520shikonin%2520derivatives%2520as%2520STAT3%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D146%26spage%3D74%26epage%3D86%26doi%3D10.1016%2Fj.bcp.2017.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. H.</span></span> <span> </span><span class="NLM_article-title">Identification of new shikonin derivatives as antitumor agents targeting STAT3 SH2 domain</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2863</span>, <span class="refDoi">Â DOI: 10.1038/s41598-017-02671-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41598-017-02671-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28588262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC1cnls12rtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=2863&author=H.+Y.+Qiuauthor=X.+Zhuauthor=Y.+L.+Luoauthor=H.+Y.+Linauthor=C.+Y.+Tangauthor=J.+L.+Qiauthor=Y.+J.+Pangauthor=R.+W.+Yangauthor=G.+H.+Luauthor=X.+M.+Wangauthor=Y.+H.+Yang&title=Identification+of+new+shikonin+derivatives+as+antitumor+agents+targeting+STAT3+SH2+domain&doi=10.1038%2Fs41598-017-02671-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain</span></div><div class="casAuthors">Qiu Han-Yue; Zhu Xiang; Luo Yue-Lin; Lin Hong-Yan; Tang Cheng-Yi; Qi Jin-Liang; Pang Yan-Jun; Yang Rong-Wu; Lu Gui-Hua; Wang Xiao-Ming; Yang Yong-Hua; Qiu Han-Yue; Zhu Xiang; Luo Yue-Lin; Lin Hong-Yan; Tang Cheng-Yi; Qi Jin-Liang; Lu Gui-Hua; Wang Xiao-Ming; Yang Yong-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2863</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is hyper-activated in diversiform human tumors and has been validated as an attractive therapeutic target.  Current research showed that a natural product, shikonin, along with its synthetic analogues, is able to inhibit the activity of STAT3 potently.  The potential space of shikonin in developing novel anti-cancer agents encouraged us to carry out the investigation of the probable binding mode with STAT3.  From this foundation, we have designed new types of STAT3 SH2 inhibitors.  Combined simulations were performed to filter for the lead compound, which was then substituted, synthesized and evaluated by a variety of bioassays.  Among the entities, PMM-172 exhibited the best anti-proliferative activity against MDA-MB-231 cells with IC50 value 1.98 Â± 0.49 Î¼M.  Besides, it was identified to decrease luciferase activity, induce cell apoptosis and reduce mitochondrial transmembrane potential in MDA-MB-231 cells.  Also, PMM-172 inhibited constitutive/inducible STAT3 activation without affecting STAT1 and STAT5 in MDA-MB-231 cells, and had no effect in non-tumorigenic MCF-10A cells.  Moreover, PMM-172 suppressed STAT3 nuclear localization and STAT3 downstream target genes expression.  Overall, these results indicate that the antitumor activity of PMM-172 is at least partially due to inhibition of STAT3 in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQogEd5p0-zuGxpATR2EQURfW6udTcc2ebn8rKO-JMMgrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnls12rtQ%253D%253D&md5=88f3ee8a230498d83ffe92d7971aa0b8</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-02671-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-02671-7%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DTang%26aufirst%3DC.%2BY.%26aulast%3DQi%26aufirst%3DJ.%2BL.%26aulast%3DPang%26aufirst%3DY.%2BJ.%26aulast%3DYang%26aufirst%3DR.%2BW.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DYang%26aufirst%3DY.%2BH.%26atitle%3DIdentification%2520of%2520new%2520shikonin%2520derivatives%2520as%2520antitumor%2520agents%2520targeting%2520STAT3%2520SH2%2520domain%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D2863%26doi%3D10.1038%2Fs41598-017-02671-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothey, A.</span></span> <span> </span><span class="NLM_article-title">Napabucasin: an update on the first-in-class cancer stemness inhibitor</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1091</span>â <span class="NLM_lpage">1103</span>, <span class="refDoi">Â DOI: 10.1007/s40265-017-0759-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1007%2Fs40265-017-0759-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28573435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Ogs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1091-1103&author=J.+M.+Hubbardauthor=A.+Grothey&title=Napabucasin%3A+an+update+on+the+first-in-class+cancer+stemness+inhibitor&doi=10.1007%2Fs40265-017-0759-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor</span></div><div class="casAuthors">Hubbard, Joleen M.; Grothey, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1091-1103</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Napabucasin (BBI608) is an orally administered small mol. that blocks stem cell activity in cancer cells by targeting the signal transducer and activator of transcription 3 pathway.  The signal transducer and activator of transcription 3 pathway is over-activated in many types of cancer and has been shown to be an important pathway in cancer stem cell-mediated propagation of cancer.  Cancer stem cells are a subpopulation of cancer cells considered to be the primary source of tumor growth, metastasis, and resistance to conventional therapies, and thus, responsible for cancer relapse.  This review describes the clin. development program of this first-in-class cancer stemness inhibitor, including preclin. discovery, early clin. trials, current phase III clin. trial evaluation, and future therapeutic combinations.  The therapeutic potential of napabucasin was first reported in a preclin. study that demonstrated the potent anti-tumor and anti-metastatic activity of napabucasin in several different cancer types, both in vitro and in vivo.  In mouse models, napabucasin was effective both as a monotherapy and in combination with other agents; in particular, synergy was obsd. with paclitaxel in vivo.  Napabucasin clin. trials have demonstrated encouraging anti-tumor activity as monotherapy and in combination with conventional therapeutics, with no significant pharmacokinetic interactions when used in combination therapies.  Adverse events attributed to napabucasin have been predominantly mild, although some patients have experienced grade 3 gastrointestinal adverse events.  More severe adverse events required reduced or discontinued dosing of napabucasin or medication to reverse or manage symptoms.  In conclusion, napabucasin may prove useful in targeting cancer stem cells, with the potential to suppress metastasis and prevent relapse in patients with varying cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOT80Q-y40g7Vg90H21EOLACvtfcHk0li_DKFKKiv6UQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Ogs7Y%253D&md5=bfe97dc2fe4fd82c07c1c34ca2f103a1</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0759-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0759-4%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DJ.%2BM.%26aulast%3DGrothey%26aufirst%3DA.%26atitle%3DNapabucasin%253A%2520an%2520update%2520on%2520the%2520first-in-class%2520cancer%2520stemness%2520inhibitor%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1091%26epage%3D1103%26doi%3D10.1007%2Fs40265-017-0759-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekaii-Saab, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Rayes, B.</span></span> <span> </span><span class="NLM_article-title">Identifying and targeting cancer stem cells in the treatment of gastric cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">1303</span>â <span class="NLM_lpage">1312</span>, <span class="refDoi">Â DOI: 10.1002/cncr.30538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1002%2Fcncr.30538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28117883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC1c7oslymtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2017&pages=1303-1312&author=T.+Bekaii-Saabauthor=B.+El-Rayes&title=Identifying+and+targeting+cancer+stem+cells+in+the+treatment+of+gastric+cancer&doi=10.1002%2Fcncr.30538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and targeting cancer stem cells in the treatment of gastric cancer</span></div><div class="casAuthors">Bekaii-Saab Tanios; Bekaii-Saab Tanios; El-Rayes Bassel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1303-1312</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current treatment regimens for gastric cancer are not adequate.  Cancer stem cells (CSCs) may be a key driving factor for growth and metastasis of this tumor type.  In contrast to the conventional clonal evolution hypothesis, CSCs can initiate tumor formation, self-renew, and differentiate into tumor-propagating cells.  Because gastric cancer can originate from CSCs, it is necessary to review current targets of signaling pathways for CSCs in gastric cancer that are being studied in clinical trials.  These pathways are known to regulate the self-renewal and differentiation process in gastric CSCs.  A better understanding of the clinical results of trials that target gastric CSCs will lead to better outcomes for patients with gastric cancer.  Cancer 2017;123:1303-1312. Â© 2017 The Authors.  Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.  This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTE1sDFdXBBh-vW160gIxP_fW6udTcc2eZ7RdKPlDvg17ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7oslymtQ%253D%253D&md5=e025904212b010f056759c5c009d094d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1002%2Fcncr.30538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.30538%26sid%3Dliteratum%253Aachs%26aulast%3DBekaii-Saab%26aufirst%3DT.%26aulast%3DEl-Rayes%26aufirst%3DB.%26atitle%3DIdentifying%2520and%2520targeting%2520cancer%2520stem%2520cells%2520in%2520the%2520treatment%2520of%2520gastric%2520cancer%26jtitle%3DCancer%26date%3D2017%26volume%3D123%26spage%3D1303%26epage%3D1312%26doi%3D10.1002%2Fcncr.30538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span> <span> </span><span class="NLM_article-title">Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">883</span>â <span class="NLM_lpage">895</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.12.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.12.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30580240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFyntr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=883-895&author=C.+Zhuangauthor=X.+Guanauthor=H.+Maauthor=H.+Congauthor=W.+Zhangauthor=Z.+Miao&title=Small+molecule-drug+conjugates%3A+a+novel+strategy+for+cancer-targeted+treatment&doi=10.1016%2Fj.ejmech.2018.12.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment</span></div><div class="casAuthors">Zhuang, Chunlin; Guan, Xianghong; Ma, Hao; Cong, Hui; Zhang, Wannian; Miao, Zhenyuan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">883-895</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Targeted therapy has become an effective strategy of precision medicine for improving cancer treatment.  Selectivity improvement is always popular in modern oncol. because of decreased side effects in conventional cancer chemotherapy.  The use of antibody-drug conjugates (ADC), a robust strategy for targeted therapy, applies antibodies to selectively deliver a potent cytotoxic compd. to tumor cells and thus improve the therapeutic efficacy of the chemotherapeutic agents.  Three ADC products (trastuzumab emtansine, brentuximab vedotin and inotuzumab ozogamicin) are already on the market, and several compds. are in clin. trials.  Compared with ADCs, small mol.-drug conjugates (SMDCs) provide a new, less established perspective for targeted delivery.  Nevertheless, SMDCs have several strengths: they have a non-immunogenic nature; much more manageable synthesis; and lower mol. wts., which confer a high potential for good cell penetration in solid tumors.  SMDCs might therefore be a promising alternative with similar efficacy to ADCs.  In this article, we highlight the medicinal chem. aspects of SMDC design.  SMDC targeting ligands, linkers and small-mol. payloads will be discussed.  Successful cases of SMDCs used as therapeutic agents and other applications of SMDC will also be included.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgh4NBoM7LQrVg90H21EOLACvtfcHk0li_DKFKKiv6UQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFyntr%252FK&md5=cf74e67689ca6887961b069273c151dd</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhuang%26aufirst%3DC.%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DCong%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMiao%26aufirst%3DZ.%26atitle%3DSmall%2520molecule-drug%2520conjugates%253A%2520a%2520novel%2520strategy%2520for%2520cancer-targeted%2520treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D883%26epage%3D895%26doi%3D10.1016%2Fj.ejmech.2018.12.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yesylevskyy, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramseyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pudlo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallandre, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, C.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of STAT3 with respect to STAT1: insights from molecular dynamics and ensemble docking simulations</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1588</span>â <span class="NLM_lpage">1596</span>, <span class="refDoi">Â DOI: 10.1021/acs.jcim.6b00198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Glur3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=1588-1596&author=S.+O.+Yesylevskyyauthor=C.+Ramseyerauthor=M.+Pudloauthor=J.-R.+Pallandreauthor=C.+Borg&title=Selective+inhibition+of+STAT3+with+respect+to+STAT1%3A+insights+from+molecular+dynamics+and+ensemble+docking+simulations&doi=10.1021%2Facs.jcim.6b00198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations</span></div><div class="casAuthors">Yesylevskyy, Semen O.; Ramseyer, Christophe; Pudlo, Marc; Pallandre, Jean-Rene; Borg, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1588-1596</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">STAT3 protein, which is known to be involved in cancer development, is a promising target for anticancer therapy.  Successful inhibitors of STAT3 should not affect an activity of closely related protein STAT1, which makes their development challenging.  The mechanisms of selectivity of several existing STAT3 inhibitors are not clear.  The authors studied mol. mechanisms of selectivity of 13 exptl. tested STAT3 inhibitors by extensive mol. dynamics and ensemble docking simulations.  It is shown that all studied inhibitors bind to the large part of the protein surface in an unspecific statistical manner.  The binding to the dimerization interface of the SH2 domain, which is usually considered as the main target region, is not energetically preferable.  Binding in this region is remarkably similar for STAT1 and STAT3 proteins and cannot explain exptl. obsd. selectivity toward STAT3.  The authors propose a new mechanism of selectivity called "selectivity by distraction" for existing STAT3 inhibitors.  This mechanism is based on equil. statistical partitioning of inhibitor mols. between protein domains.  The unspecific binding of inhibitors to the DNA-binding and the coil-coil domains is stronger in STAT1 in comparison to STAT3 while the energies of their binding to SH2 domains are comparable.  This "distracts" inhibitor mols. from the SH2 domain of STAT1 and leads to higher effective concn. of inhibitors in the vicinity of the SH2 domain of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_09BjY0JoUrVg90H21EOLACvtfcHk0ljMMhoLKIB2Bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Glur3J&md5=47f9fee7c0c117033fbaeba204c96ccd</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00198%26sid%3Dliteratum%253Aachs%26aulast%3DYesylevskyy%26aufirst%3DS.%2BO.%26aulast%3DRamseyer%26aufirst%3DC.%26aulast%3DPudlo%26aufirst%3DM.%26aulast%3DPallandre%26aufirst%3DJ.-R.%26aulast%3DBorg%26aufirst%3DC.%26atitle%3DSelective%2520inhibition%2520of%2520STAT3%2520with%2520respect%2520to%2520STAT1%253A%2520insights%2520from%2520molecular%2520dynamics%2520and%2520ensemble%2520docking%2520simulations%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D1588%26epage%3D1596%26doi%3D10.1021%2Facs.jcim.6b00198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span> <span> </span><span class="NLM_article-title">A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">554</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.10.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.10.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30472602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12ltLrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=543-554&author=C.+Liauthor=C.+Chenauthor=Q.+Anauthor=T.+Yangauthor=Z.+Sangauthor=Y.+Yangauthor=Y.+Juauthor=A.+Tongauthor=Y.+Luo&title=A+novel+series+of+napabucasin+derivatives+as+orally+active+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28STAT3%29&doi=10.1016%2Fj.ejmech.2018.10.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)</span></div><div class="casAuthors">Li, Chungen; Chen, Caili; An, Qi; Yang, Tao; Sang, Zitai; Yang, Yang; Ju, Yuan; Tong, Aiping; Luo, Youfu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">543-554</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is an attractive target for a variety of cancers therapy.  Napabucasin, applied in phase III clin. trials for the treatment of a variety of cancers, was regarded as one of the most promising anticancer drug by targeting STAT3.  Herein, a novel series of napabucasin derivs. were designed and synthesized, which presented a potent inhibitory activity on a variety of cancers cells.  Among the derivs. compd. 8q exhibited potent inhibitory activity on U251, HepG2, HT29 and CT26 cells with the IC50 values of 0.22, 0.49, 0.07 and 0.14 Î¼M, resp., which was over 10-fold more potent than napabucasin.  Treatment with compd. 8q decreased protein expression level of total STAT3 and p-STAT3Y705in vitro.  The binding of compd. 8q with STAT3 were further validated by electrophoretic mobility shift assay and surface plasmon resonance anal.  Compd. 8q has a KD of 110.2 nM for full-length STAT3 recombinant protein.  Moreover, the aq. soly. of 8q was over 4.5-fold than that of napabucasin.  In addn., compd. 8q in vivo significantly reduced tumor growth compared to untreated mice, and exhibited good safety profile, indicating its great potential as an efficacious drug candidate for oncotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdjaMcoHkmCbVg90H21EOLACvtfcHk0ljMMhoLKIB2Bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12ltLrE&md5=4b95a9d078c485681ef7cba49e51acec</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.067%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DSang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DJu%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DA%2520novel%2520series%2520of%2520napabucasin%2520derivatives%2520as%2520orally%2520active%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D162%26spage%3D543%26epage%3D554%26doi%3D10.1016%2Fj.ejmech.2018.10.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and activity of BBI608 derivatives targeting on stem cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">39</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.03.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.03.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29604543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslKgtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=39-50&author=Q.+Zhouauthor=C.+Pengauthor=F.+Duauthor=L.+Zhouauthor=Y.+Shiauthor=Y.+Duauthor=D.+Liuauthor=W.+Sunauthor=M.+Zhangauthor=G.+Chen&title=Design%2C+synthesis+and+activity+of+BBI608+derivatives+targeting+on+stem+cells&doi=10.1016%2Fj.ejmech.2018.03.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity of BBI608 derivatives targeting on stem cells</span></div><div class="casAuthors">Zhou, Qifan; Peng, Chen; Du, Fangyu; Zhou, Linbo; Shi, Yajie; Du, Yang; Liu, Dongdong; Sun, Wenjiao; Zhang, Meixia; Chen, Guoliang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39-50</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 plays a vital role in maintaining the self-renewal of tumor stem cells.  BBI608, a small mol. identified by its ability to inhibit gene transcription driven by STAT3 and cancer stemness properties, can inhibit stemness gene expression and kill stemness-high cancer cells isolated from a variety of cancer types.  In order to improve the pharmacokinetic properties of BBI608 and the antitumor activity, a series of BBI608 derivs. were designed and synthesized here.  Most of these compds. were more potent than BBI608 on HepG2 cells, compd. I had the most potent inhibitory activity among them and was 5.4-fold more potent than BBI608 (IC50=11.2Î¼M), but had considerable activity on normal liver cells L-02.  Compds. II (IC50=3.5Î¼M) and III (IC50=2.9Î¼M) were found to possess significant inhibitory activities and good selectivity.  The results showed that compd. LD-19 was worthy to investigate further as a lead compd. according to its potent inhibitory activity, ideal ClogP value and better water soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlEGtqRVLqrVg90H21EOLACvtfcHk0ljMMhoLKIB2Bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslKgtbc%253D&md5=3bd9949d032ee24e433b2e34b3ca9369</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.054%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520activity%2520of%2520BBI608%2520derivatives%2520targeting%2520on%2520stem%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D39%26epage%3D50%26doi%3D10.1016%2Fj.ejmech.2018.03.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">112428</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2020.112428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32603980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSiu7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2020&pages=112428&author=K.+R.+Fengauthor=F.+Wangauthor=X.+W.+Shiauthor=Y.+X.+Tanauthor=J.+Y.+Zhaoauthor=J.+W.+Zhangauthor=Q.+H.+Liauthor=G.+Q.+Linauthor=D.+Gaoauthor=P.+Tian&title=Design%2C+synthesis+and+biological+evaluation+of+novel+potent+STAT3+inhibitors+based+on+BBI608+for+cancer+therapy&doi=10.1016%2Fj.ejmech.2020.112428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy</span></div><div class="casAuthors">Feng, Kai-Rui; Wang, Feng; Shi, Xin-Wei; Tan, Yun-Xuan; Zhao, Jia-Ying; Zhang, Jian-Wei; Li, Qing-Hua; Lin, Guo-Qiang; Gao, Dingding; Tian, Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112428</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Persistently activated signal transducer and activator of transcription 3 (STAT3) plays an important role in the development of multiple cancers, and therefore is a potential therapeutic target for cancer prevention.  Herein, we report the rational design, synthesis, and biol. evaluation of novel potent STAT3 inhibitors based on BBI608.  Among them, compd. A11(I) exhibited the most potent in vitro tumor cell growth inhibitory activities toward MDA-MB-231, MDA-MB-468 and HepG2 cells with IC50 values as low as 0.67 Â± 0.02Î¼M, 0.77 Â± 0.01Î¼M and 1.24 Â± 0.16Î¼M, resp.  Fluorescence polarization (FP) assay validated the binding of compd. A11 in STAT3 SH2 domain with the IC50 value of 5.18Î¼M.  Further mechanistic studies indicated that A11 inhibited the activation of STAT3 (Y705), and thus reduced the expression of STAT3 downstream genes CyclinD1 and C-Myc.  Simultaneously, it induced cancer cell S phase arrest and apoptosis in a concn.-dependent manner.  An addnl. in vivo study revealed that A11 suppressed the MDA-MB-231 xenograft tumor growth in mice at the dose of 10 mg/kg (i.p.) without obvious body-wt. loss.  Finally, mol. docking study further elucidated the binding mode of A11 in STAT3 SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL-OvYqhC9K7Vg90H21EOLACvtfcHk0lhsKgjXAF7W1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSiu7rK&md5=5bcc68d18c51794f7ddd98805d318ee3</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112428%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DK.%2BR.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DX.%2BW.%26aulast%3DTan%26aufirst%3DY.%2BX.%26aulast%3DZhao%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DLi%26aufirst%3DQ.%2BH.%26aulast%3DLin%26aufirst%3DG.%2BQ.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520potent%2520STAT3%2520inhibitors%2520based%2520on%2520BBI608%2520for%2520cancer%2520therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D201%26spage%3D112428%26doi%3D10.1016%2Fj.ejmech.2020.112428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¶cken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clamor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, K.</span></span> <span> </span><span class="NLM_article-title">Napabucasin and related heterocycle-fused naphthoquinones as STAT3 inhibitors with antiproliferative activity against cancer cells</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1636</span>â <span class="NLM_lpage">1644</span>, <span class="refDoi">Â DOI: 10.1021/acs.jnatprod.8b00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.8b00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnslKisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=1636-1644&author=H.+L%C3%B6ckenauthor=C.+Clamorauthor=K.+M%C3%BCller&title=Napabucasin+and+related+heterocycle-fused+naphthoquinones+as+STAT3+inhibitors+with+antiproliferative+activity+against+cancer+cells&doi=10.1021%2Facs.jnatprod.8b00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells</span></div><div class="casAuthors">Locken Hauke; Clamor Cinzia; Muller Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of natural products</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1636-1644</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Napabucasin (6) and its angularly anellated isomer (7), for which the synthesis is described, together with related plant-derived naphthoquinones, were evaluated in vitro against human breast cancer (MDA-MB-231) and chronic myelogenous leukemia (K562) cells.  As observed for Î²-lapachone (3), the active naphthoquinones all induced apoptosis in a cell-cycle-independent fashion.  In contrast to the pyran-fused Î²-lapachone (3), however, the most potent furan-fused naphthoquinones were able to redox cycle and generate superoxide in cell-based assays, which was independent of NAD(P)H:quinone oxido-reductase 1.  In a homogeneous time-resolved fluorescence (HTRF) assays with MDA-MB-231 cells, both napabucasin (6) and isonapabucasin (7) were identified as targeting STAT3 phosphorylation.  In addition, drug affinity responsive target stability assays were performed to validate a direct interaction of the naphthoquinones with STAT3.  Isonapabucasin (7) turned out to be twice as potent against STAT3 as napabucasin (6) in the HTRF assay, with an EC50 in the submicromolar range, which was in excellent agreement with the potency of both agents to inhibit the growth of MDA-MB-231 cells.  Moreover, molecular docking experiments predicted different binding modes to the STAT3 SH2 domain for the linearly anellated napabucasin (6) and its angularly anellated isomer (7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSQACUhahgsEEgZCMqtRBifW6udTcc2easfbMXkbK5qbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnslKisw%253D%253D&md5=f7b8eca5ba22354ee3c13457409262f4</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.8b00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.8b00247%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6cken%26aufirst%3DH.%26aulast%3DClamor%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DNapabucasin%2520and%2520related%2520heterocycle-fused%2520naphthoquinones%2520as%2520STAT3%2520inhibitors%2520with%2520antiproliferative%2520activity%2520against%2520cancer%2520cells%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2018%26volume%3D81%26spage%3D1636%26epage%3D1644%26doi%3D10.1021%2Facs.jnatprod.8b00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span> <span> </span><span class="NLM_article-title">LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">104661</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2020.104661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.phrs.2020.104661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31982491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFarsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2020&pages=104661&author=H.+Wangauthor=Z.+Liuauthor=L.+Guanauthor=J.+Liauthor=S.+Chenauthor=W.+Yuauthor=M.+Lai&title=LYW-6%2C+a+novel+cryptotanshinone+derived+STAT3+targeting+inhibitor%2C+suppresses+colorectal+cancer+growth+and+metastasis&doi=10.1016%2Fj.phrs.2020.104661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis</span></div><div class="casAuthors">Wang, Huan; Liu, Zhe; Guan, Lingnan; Li, Jiankang; Chen, Siyi; Yu, Wenying; Lai, Maode</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104661</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The constitutive activation of signal transducer and activator of transcription 3(STAT3) is assocd. with aggressive development and metastasis in colorectal cancer (CRC), but STAT3-targeting drugs remain elusive in clinic.  Here, structure-based strategy was used to remodel the natural compd. cryptotanshinone into a more effective STAT3 inhibitor LYW-6.  Using the Biolayer Interferometry assay, we obsd. that LYW-6 exhibited specific interactions with STAT3(KD = 6.6 Â± 0.7 Î¼M).  Western blot anal. and electrophoretic mobility shift assays (EMSA) showed that LYW-6 inhibited the phosphorylation of STAT3 tyrosine 705 (Tyr-705) and had slight effects on STAT1 and STAT5 phosphorylation.  Western blot anal. on the upstream kinases of STAT3 confirmed that the inhibitory mechanism on p-STAT3 was independent of upstream kinases.  Further investigation demonstrated that LYW-6 downregulated the expression of downstream oncogenes to inhibit cell viability, cell cycle development, and potently increased cell apoptosis in human CRC cells.  The invasion and metastasis linked signaling was also blocked by LYW-6 treatment.  LYW-6 was found to reduce the metastasis foci in lung on tail-lung metastasis models.  In addn., it was obsd. that LYW-6 markedly diminished STAT3 phosphorylation in tumor tissue and significantly inhibited tumor growth on xenograft models.  Tumor development on chem.-induced colorectal cancer model also significantly inhibited by LYW-6 treatment.  These findings provided adequate evidence that STAT3 inhibitor LYW-6 might be a potential candidate agent for CRC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNZX6D4kSgBrVg90H21EOLACvtfcHk0lhsKgjXAF7W1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFarsrs%253D&md5=d013939ca63e3d03aff5be7610a2c0fd</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.104661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.104661%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGuan%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DM.%26atitle%3DLYW-6%252C%2520a%2520novel%2520cryptotanshinone%2520derived%2520STAT3%2520targeting%2520inhibitor%252C%2520suppresses%2520colorectal%2520cancer%2520growth%2520and%2520metastasis%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D153%26spage%3D104661%26doi%3D10.1016%2Fj.phrs.2020.104661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohassab, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, M.</span></span> <span> </span><span class="NLM_article-title">STAT3 transcription factor as target for anti-cancer therapy</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1101</span>â <span class="NLM_lpage">1124</span>, <span class="refDoi">Â DOI: 10.1007/s43440-020-00156-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1007%2Fs43440-020-00156-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32880101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslygsL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=1101-1124&author=A.+M.+Mohassabauthor=H.+A.+Hassanauthor=D.+Abdelhamidauthor=M.+Abdel-Aziz&title=STAT3+transcription+factor+as+target+for+anti-cancer+therapy&doi=10.1007%2Fs43440-020-00156-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 transcription factor as target for anti-cancer therapy</span></div><div class="casAuthors">Mohassab, Aliaa M.; Hassan, Heba A.; Abdelhamid, Dalia; Abdel-Aziz, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1101-1124</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  STATs constitute a large family of transcription activators and transducers of signals that have an important role in many cell functions as regulation of proliferation and differentiation of the cell also regulation of apoptosis and angiogenesis.  STAT3 as a member of that family, recently was discovered to have a vital role in progression of different types of cancers.  The activation of STAT3 was obsd. to regulate multiple gene functions during cancer-like cell proliferation, differentiation, apoptosis, metastasis, inflammation, immunity, cell survival, and angiogenesis.  The inhibition of STAT3 activation has been an important target for cancer therapy.  Inhibitors of STAT3 have been used for a long time for treatment of many types of cancers like leukemia, melanoma, colon, and renal cancer.  In this review article, we summarize and discuss different drugs inhibiting the action of STAT3 and used in treatment of different types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppi_HE4Tu9k7Vg90H21EOLACvtfcHk0lh74uDoJmkVEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslygsL%252FE&md5=ace0b41f53c3061797508eaff16ef170</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1007%2Fs43440-020-00156-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs43440-020-00156-5%26sid%3Dliteratum%253Aachs%26aulast%3DMohassab%26aufirst%3DA.%2BM.%26aulast%3DHassan%26aufirst%3DH.%2BA.%26aulast%3DAbdelhamid%26aufirst%3DD.%26aulast%3DAbdel-Aziz%26aufirst%3DM.%26atitle%3DSTAT3%2520transcription%2520factor%2520as%2520target%2520for%2520anti-cancer%2520therapy%26jtitle%3DPharmacol.%2520Rep.%26date%3D2020%26volume%3D72%26spage%3D1101%26epage%3D1124%26doi%3D10.1007%2Fs43440-020-00156-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span> <span> </span><span class="NLM_article-title">Screening and biological evaluation of a novel STAT3 signaling pathway inhibitor against cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5172</span>â <span class="NLM_lpage">5176</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.09.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmcl.2016.09.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27727126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CltLrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5172-5176&author=M.+Huangauthor=Z.+Chenauthor=L.+Zhangauthor=Z.+Huangauthor=Y.+Chenauthor=J.+Xuauthor=J.+Zhangauthor=X.+Shu&title=Screening+and+biological+evaluation+of+a+novel+STAT3+signaling+pathway+inhibitor+against+cancer&doi=10.1016%2Fj.bmcl.2016.09.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Screening and biological evaluation of a novel STAT3 signaling pathway inhibitor against cancer</span></div><div class="casAuthors">Huang, Min; Chen, Zhongjie; Zhang, Lu; Huang, Zhimin; Chen, Yiying; Xu, Jianrong; Zhang, Jian; Shu, Xiaohong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5172-5176</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It is now established that the specificity in signaling of signal transducer and activator of transcription 3 (STAT3) is mediated by the SH2 domain of STAT3, which mediates its interaction with the phosphopeptide docking sites displayed by receptors and JAKs, dimerization and subsequent DNA binding.  Thus, we aimed to identify and design a class of strong potential small mol. inhibitors of STAT3 for the discovery and development of novel anticancer agents.  Several classes of small mols. have been identified as STAT3 inhibitors after structure-based screening of the STAT3 SH2 domain.  Next, we detected the activity of these inhibitors using fluorescence polarization (FP) and identified the growth inhibition of DU145 and MDA-MB-468 cells using the CCK-8 assay.  Consequently, B9 inhibits the proliferation of tumor cells harboring abnormal activation of STAT3, such as, MDA-MB-468, MDA-MB-231 and DU145.  However, there is little inhibition of MCF-7 cells.  In addn., The Kd of B9 to STAT3 (I634S/Q635G) is 22.75 Î¼M compared to 4.59 Î¼M for WT as analyzed by SPR.  The phosphorylation of STAT3 in MDA-MB-468 cells was obviously decreased after treatment with B9 at the preconceived concn. of 30 Î¼M, as detected using immunoblotting.  Here, we evaluated the effect of B9 on the migration of MDA-MB-468 cells.  Taken together, our results indicate a novel small mol. that decreases STAT3 activation and function of the STAT3 signaling pathway, thereby inducing an antitumor response in human breast cancer cells harboring constitutively active STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzfnwZ1lpubLVg90H21EOLACvtfcHk0lh74uDoJmkVEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CltLrN&md5=976930827063d95ed50fa05589fef8dd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShu%26aufirst%3DX.%26atitle%3DScreening%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520STAT3%2520signaling%2520pathway%2520inhibitor%2520against%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5172%26epage%3D5176%26doi%3D10.1016%2Fj.bmcl.2016.09.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel isothiazoloquinoline quinone analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127286</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2020.127286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmcl.2020.127286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32631508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFylsbjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127286&author=L.+Chenauthor=Y.+Z.+Xieauthor=Z.+Y.+Luoauthor=L.+J.+Liuauthor=Z.+Z.+Zouauthor=H.+D.+Liuauthor=F.+R.+Kongauthor=Y.+Haoauthor=J.+L.+Gaoauthor=L.+L.+Wangauthor=D.+Y.+Maauthor=S.+Y.+Liu&title=Synthesis+and+biological+evaluation+of+novel+isothiazoloquinoline+quinone+analogues&doi=10.1016%2Fj.bmcl.2020.127286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel isothiazoloquinoline quinone analogues</span></div><div class="casAuthors">Chen, Ling; Xie, Yuan-Zhu; Luo, Zhi-Yong; Liu, Li-Jun; Zou, Zi-Zheng; Liu, Hong-Dou; Kong, Fan-Rong; Hao, Ying; Gao, Jin-Lei; Wang, Liu-Liu; Ma, Da-You; Liu, Su-You</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">127286</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Natural quinones and their analogs have attracted growing attention because of their novel anticancer activities.  A series of novel isothiazoloquinoline quinone analogs were synthesized and evaluated for antitumor activities against four different kind of cancer cells.  Among them, isothiazoloquinolinoquinones inhibited cancer cells proliferation effectively with IC50 values in the nanomolar range, and isothiazoloquinolinoquinone I induced the cell apoptosis.  Further exploration of possible mechanism of action indicates that I not only activates ROS prodn. through NQO1-directed redox cycling but also inhibits the phosphorylation of STAT3.  These findings indicate that I has potential use for the development of new skeleton drug candidate as an efficient substrate of NQO1 and STAT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqATbZejaLk_7Vg90H21EOLACvtfcHk0lh74uDoJmkVEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFylsbjJ&md5=7611bcb39e94513b998690e17b4cdd44</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127286%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DY.%2BZ.%26aulast%3DLuo%26aufirst%3DZ.%2BY.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DZou%26aufirst%3DZ.%2BZ.%26aulast%3DLiu%26aufirst%3DH.%2BD.%26aulast%3DKong%26aufirst%3DF.%2BR.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DMa%26aufirst%3DD.%2BY.%26aulast%3DLiu%26aufirst%3DS.%2BY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520isothiazoloquinoline%2520quinone%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127286%26doi%3D10.1016%2Fj.bmcl.2020.127286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">RÃ¶hrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9421</span>â <span class="NLM_lpage">9437</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9421-9437&author=U.+F.+R%C3%B6hrigauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=Challenges+in+the+discovery+of+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+inhibitors&doi=10.1021%2Facs.jmedchem.5b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9421-9437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies.  Many novel IDO1 inhibitor scaffolds have been described, and a few potent compds. have entered clin. trials.  However, a significant no. of the reported compds. contain problematic functional groups, suggesting that enzyme inhibition could be the result of undesirable side reactions instead of selective binding to IDO1.  Here, we describe issues in the employed exptl. protocols, review and classify reported IDO1 inhibitors, and suggest different approaches for confirming viable inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR3nr-l4vgNLVg90H21EOLACvtfcHk0lhm4NA9_drxHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D&md5=1b44178d33badc00215915c28d027b5d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00326%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6hrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DChallenges%2520in%2520the%2520discovery%2520of%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9421%26epage%3D9437%26doi%3D10.1021%2Facs.jmedchem.5b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-dioxygenase and tumor-induced tolerance</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1147</span>â <span class="NLM_lpage">1154</span>, <span class="refDoi">Â DOI: 10.1172/JCI31178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1172%2FJCI31178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=17476344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Omtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=1147-1154&author=D.+H.+Munnauthor=A.+L.+Mellor&title=Indoleamine+2%2C3-dioxygenase+and+tumor-induced+tolerance&doi=10.1172%2FJCI31178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase and tumor-induced tolerance</span></div><div class="casAuthors">Munn, David H.; Mellor, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1147-1154</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Tumors arise from normal cells of the body through genetic mutation.  Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; i.e., it is tolerant of these antigens.  This acquired state of tolerance must be overcome for cancer immunotherapy to succeed.  Indoleamine 2,3-dioxygenase (IDO) is one mol. mechanism that contributes to tumor-induced tolerance.  IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression.  It can also function as an antagonist to other activators of antitumor immunity.  Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmm42-SIElbVg90H21EOLACvtfcHk0lhm4NA9_drxHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Omtro%253D&md5=b8faf9b3398a23896cca34128636c787</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1172%2FJCI31178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31178%26sid%3Dliteratum%253Aachs%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26atitle%3DIndoleamine%25202%252C3-dioxygenase%2520and%2520tumor-induced%2520tolerance%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D1147%26epage%3D1154%26doi%3D10.1172%2FJCI31178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1845</span>â <span class="NLM_lpage">1853</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-09-3613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1158%2F0008-5472.CAN-09-3613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=20160032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1845-1853&author=A.+J.+Mullerauthor=J.+B.+DuHadawayauthor=D.+Jallerauthor=P.+Curtisauthor=R.+Metzauthor=G.+C.+Prendergast&title=Immunotherapeutic+suppression+of+indoleamine+2%2C3-dioxygenase+and+tumor+growth+with+ethyl+pyruvate&doi=10.1158%2F0008-5472.CAN-09-3613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate</span></div><div class="casAuthors">Muller, Alexander J.; DuHadaway, James B.; Jaller, Daniel; Curtis, Peter; Metz, Richard; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1845-1853</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Efforts to improve cancer care in the developing world will benefit from the identification of simple, inexpensive, and broadly applicable medical modalities based on emergent innovations in treatment, such as targeting mechanisms of tumoral immune tolerance.  In this report, we offer preclin. evidence that the low-cost, anti-inflammatory agent Et pyruvate elicits a potent immune-based antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic enzyme for many human tumors.  Consistent with its reported ability to interfere with NF-ÎºB function, Et pyruvate blocks IDO induction both in vitro and in vivo.  Antitumor activity was achieved in mice with a noncytotoxic dosing regimen of Et pyruvate shown previously to protect against lethality from sepsis.  Similar outcomes were obtained with the functional Et pyruvate analog 2-acetamidoacrylate.  Et pyruvate was ineffective at suppressing tumor outgrowth in both athymic and Ido1-deficient mice, providing in vivo corroboration of the importance of T-cell-dependent immunity and IDO targeting for Et pyruvate to achieve antitumor efficacy.  Although Et pyruvate has undergone early-phase clin. testing, this was done without consideration of its possible applicability to cancer.  Our findings that IDO is effectively blocked by Et pyruvate treatment deepen emerging links between IDO and inflammatory processes.  Further, these findings rationalize oncol. applications for this agent by providing a compelling basis to reposition Et pyruvate as a low-cost immunochemotherapy for clin. evaluation in cancer patients.  Cancer Res; 70(5); 1845-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkSC_ZW9ndLVg90H21EOLACvtfcHk0lhm4NA9_drxHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWju78%253D&md5=3d6e683754a5f97ef5215319ad454e2c</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3613%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DJaller%26aufirst%3DD.%26aulast%3DCurtis%26aufirst%3DP.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DImmunotherapeutic%2520suppression%2520of%2520indoleamine%25202%252C3-dioxygenase%2520and%2520tumor%2520growth%2520with%2520ethyl%2520pyruvate%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1845%26epage%3D1853%26doi%3D10.1158%2F0008-5472.CAN-09-3613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Bifunctional naphthoquinone aromatic amide-oxime derivatives exert combined immunotherapeutic and antitumor effects through simultaneous targeting of indoleamine-2,3-dioxygenase and signal transducer and activator of transcription 3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1544</span>â <span class="NLM_lpage">1563</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01386</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01386" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOhuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1544-1563&author=R.+Huangauthor=X.+Jingauthor=X.+Huangauthor=Y.+Panauthor=Y.+Fangauthor=G.+Liangauthor=Z.+Liaoauthor=H.+Wangauthor=Z.+Chenauthor=Y.+Zhang&title=Bifunctional+naphthoquinone+aromatic+amide-oxime+derivatives+exert+combined+immunotherapeutic+and+antitumor+effects+through+simultaneous+targeting+of+indoleamine-2%2C3-dioxygenase+and+signal+transducer+and+activator+of+transcription+3&doi=10.1021%2Facs.jmedchem.9b01386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3</span></div><div class="casAuthors">Huang, Rizhen; Jing, Xiaoteng; Huang, Xiaochao; Pan, Yingming; Fang, Yilin; Liang, Guibin; Liao, Zhixin; Wang, Hengshan; Chen, Zhenfeng; Zhang, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1544-1563</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase 1 (IDO1) and signal transducer and activator of transcription 3 (STAT3) are important targets in the tumor microenvironment for cancer therapy.  In the present study, a set of naphthoquinone arom. amide-oxime derivs. were designed, which stimulated the immune response via IDO1 inhibition and simultaneously displayed powerful antitumor activity against three selected cancer cell lines through suppressing STAT3 signaling.  The representative compd. 8u bound effectively to IDO1, with greater inhibitory activity relative to the com. IDO1 inhibitor 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L) in addn. to the efficient suppression of nuclear translocation of STAT3.  Consistently, in vivo assays demonstrated a higher antiproliferative activity of compd. 8u in both wild-type B16-F10 isograft tumors and an athymic HepG2 xenograft model relative to 1-methyl-L-tryptophan (1-MT) and doxorubicin (DOX).  This bifunctional compd. with dual immunotherapeutic and anticancer efficacy may represent a new generation of highly efficacious drug candidates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojfGgot8_60bVg90H21EOLACvtfcHk0liq0tuB5I6h1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOhuro%253D&md5=6f9aca12e3810617ebb48416b98d6d27</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01386%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DBifunctional%2520naphthoquinone%2520aromatic%2520amide-oxime%2520derivatives%2520exert%2520combined%2520immunotherapeutic%2520and%2520antitumor%2520effects%2520through%2520simultaneous%2520targeting%2520of%2520indoleamine-2%252C3-dioxygenase%2520and%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1544%26epage%3D1563%26doi%3D10.1021%2Facs.jmedchem.9b01386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies of Î±-naphthoflavone derivatives as CYP1B1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111938</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.111938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.111938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31830634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111938&author=J.+Dongauthor=Z.+Wangauthor=J.+Cuiauthor=Q.+Mengauthor=S.+Li&title=Synthesis+and+structure-activity+relationship+studies+of+%CE%B1-naphthoflavone+derivatives+as+CYP1B1+inhibitors&doi=10.1016%2Fj.ejmech.2019.111938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of Î±-naphthoflavone derivatives as CYP1B1 inhibitors</span></div><div class="casAuthors">Dong, Jinyun; Wang, Zengtao; Cui, Jiahua; Meng, Qingqing; Li, Shaoshun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111938</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In order to obtain potent and selective CYP1B1 inhibitors, a series of 41 Î±-naphthoflavone derivs. (ANF) I [X = S, SO2, Y = O; X = O, Y = O, S, NOH; R = Ph, 2-FC6H4, 3-ClC6H4, 3,4,5-(MeO)2C6H2, etc.] were synthesized, characterized and evaluated for CYP1B1, CYP1A1 and CYP1A2 inhibitory activities.  A closer look into the structure-activity relationship for the inhibitory effects on CYP1B1 indicated that modification of the C ring of ANF decreases the CYP1B1 inhibitory potency, while incorporation of substituent(s) into the different positions of the B ring yields analogs with varying CYP1B1 inhibitory capacity.  Among these derivs., compds. I (X = Y = O; R = 3-ClC6H4, 3-F3CC6H4) were identified as the most potent two selective CYP1B1 inhibitors with IC50 values of 0.49 and 0.52 nM, resp., which were 10-fold more potent than the lead compd. ANF.  In addn., mol. docking and a reasonable 3D-QSAR (three-dimensional quant. structure-activity relationship) study were performed to provide a better understanding of the key structural features influencing the CYP1B1 inhibitory activity.  The results achieved in this study would lay a foundation for future development of selective, potent, low-toxic and water-sol. CYP1B1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopO5mvQNRAVbVg90H21EOLACvtfcHk0liq0tuB5I6h1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7%252FI&md5=087b50f650ab4fe198edc72ea627cfb3</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111938%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520%25CE%25B1-naphthoflavone%2520derivatives%2520as%2520CYP1B1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111938%26doi%3D10.1016%2Fj.ejmech.2019.111938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of heterocycle-containing Î±-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112895</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2020.112895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33069055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFegs7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112895&author=J.+Dongauthor=G.+Huangauthor=Q.+Cuiauthor=Q.+Mengauthor=S.+Liauthor=J.+Cui&title=Discovery+of+heterocycle-containing+%CE%B1-naphthoflavone+derivatives+as+water-soluble%2C+highly+potent+and+selective+CYP1B1+inhibitors&doi=10.1016%2Fj.ejmech.2020.112895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of heterocycle-containing Î±-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors</span></div><div class="casAuthors">Dong, Jinyun; Huang, Guang; Cui, Qing; Meng, Qingqing; Li, Shaoshun; Cui, Jiahua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112895</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A set of forty-six 6,7,10-trimethoxy-Î±-naphthoflavone derivs. I [R = 2-furyl, 2-chloro-4-pyridyl, 5-bromo-2-pyridyl, etc.] was synthesized and screened against CYP1 enzymes, leading to the identification of fluorine-contg. compd. I [R = 5-bromo-2-pyridyl] as the most potent and selective CYP1B1 inhibitor (IC50 value of 0.07 nM), being 84-fold more potent than that of the template mol. ANF.  Alternatively, the amino-substituted deriv. I [R = 4-amino-3-pyridyl] not only possessed a potent inhibitory effect on CYP1B1 (IC50 value of 0.98 nM), but also had a substantially increased water soly. as compared with the lead ANF.  The current study expanded the structural diversity of CYP1B1 inhibitors and compd. I [R = 4-amino-3-pyridyl] could be considered as a promising starting point with great potential for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKW4P7AGPX97Vg90H21EOLACvtfcHk0liq0tuB5I6h1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFegs7fE&md5=11be82db8ac19fb7b678be9263f1a699</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112895%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DQ.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520heterocycle-containing%2520%25CE%25B1-naphthoflavone%2520derivatives%2520as%2520water-soluble%252C%2520highly%2520potent%2520and%2520selective%2520CYP1B1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112895%26doi%3D10.1016%2Fj.ejmech.2020.112895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1606</span>â <span class="NLM_lpage">1614</span>, <span class="refDoi">Â DOI: 10.1039/C9MD00258H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1039%2FC9MD00258H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31803401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ykurjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1606-1614&author=J.+Dongauthor=G.+Huangauthor=Q.+Zhangauthor=Z.+Wangauthor=J.+Cuiauthor=Y.+Wuauthor=Q.+Mengauthor=S.+Li&title=Development+of+benzochalcone+derivatives+as+selective+CYP1B1+inhibitors+and+anticancer+agents&doi=10.1039%2FC9MD00258H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents</span></div><div class="casAuthors">Dong, Jinyun; Huang, Guang; Zhang, Qijing; Wang, Zengtao; Cui, Jiahua; Wu, Yan; Meng, Qingqing; Li, Shaoshun</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1606-1614</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of benzochalcone derivs. have been synthesized and evaluated for CYP1 inhibitory activity and cytotoxic properties against wild type cell lines (MCF-7 and MDA-MB-231) and drug resistant cell lines (LCC6/P-gp and MCF-7/1B1).  All of these compds. were found to have selective inhibition towards CYP1B1 and the most potent two possessed single-digit nanomolar CYP1B1 potency.  In addn., some of them showed promising cytotoxic activities not only against wild type cells, but also against drug resistant cells at low micromolar concns.  More importantly, these multi-functional compds. may surmount drug-drug interactions that frequently occur during the combination of CYP1B1/P-gp inhibitors and anticancer drugs to overcome drug resistance.  This study may provide a good starting point for the further development of more potent multi-functional agents with CYP1B1 inhibitory activity and cytotoxic potency in cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzuiGxACVbzrVg90H21EOLACvtfcHk0lixDUGHxCbuZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ykurjE&md5=8cf0104c9a2be0ec4cfebe0489e85601</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1039%2FC9MD00258H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD00258H%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520benzochalcone%2520derivatives%2520as%2520selective%2520CYP1B1%2520inhibitors%2520and%2520anticancer%2520agents%26jtitle%3DMedChemComm%26date%3D2019%26volume%3D10%26spage%3D1606%26epage%3D1614%26doi%3D10.1039%2FC9MD00258H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CuyÃ s, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorach-ParÃ©s, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-SÃ¡nchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonell-Canals, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valiente, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez-MartÃ­nez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch-Barrera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, J. A.</span></span> <span> </span><span class="NLM_article-title">Silibinin is a direct inhibitor of STAT3</span>. <i>Food Chem. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">161</span>â <span class="NLM_lpage">172</span>, <span class="refDoi">Â DOI: 10.1016/j.fct.2018.04.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.fct.2018.04.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29660364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvVSrsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2018&pages=161-172&author=S.+Verduraauthor=E.+Cuy%C3%A0sauthor=L.+Llorach-Par%C3%A9sauthor=A.+P%C3%A9rez-S%C3%A1nchezauthor=V.+Micolauthor=A.+Nonell-Canalsauthor=J.+Jovenauthor=M.+Valienteauthor=M.+S%C3%A1nchez-Mart%C3%ADnezauthor=J.+Bosch-Barreraauthor=J.+A.+Menendez&title=Silibinin+is+a+direct+inhibitor+of+STAT3&doi=10.1016%2Fj.fct.2018.04.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Silibinin is a direct inhibitor of STAT3</span></div><div class="casAuthors">Verdura, Sara; Cuyas, Elisabet; Llorach-Pares, Laura; Perez-Sanchez, Almudena; Micol, Vicente; Nonell-Canals, Alfons; Joven, Jorge; Valiente, Manuel; Sanchez-Martinez, Melchor; Bosch-Barrera, Joaquim; Menendez, Javier A.</div><div class="citationInfo"><span class="NLM_cas:title">Food and Chemical Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">161-172</span>CODEN:
                <span class="NLM_cas:coden">FCTOD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-6915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We herein combined exptl. and computational efforts to delineate the mechanism of action through which the flavonolignan silibinin targets STAT3.  Silibinin reduced IL-6 inducible, constitutive, and acquired feedback activation of STAT3 at tyrosine 705 (Y705).  Silibinin attenuated the inducible phospho-activation of Y705 in GFP-STAT3 genetic fusions without drastically altering the kinase activity of the STAT3 upstream kinases JAK1 and JAK2.  A comparative computational study based on docking and mol. dynamics simulation over 14 different STAT3 inhibitors (STAT3i) predicted that silibinin could directly bind with high affinity to both the Src homol.-2 (SH2) domain and the DNA-binding domain (DBD) of STAT3.  Silibinin partially overlapped with the cavity occupied by other STAT3i in the SH2 domain to indirectly prevent Y705 phosphorylation, yet showing a unique binding mode.  Moreover, silibinin was the only STAT3i predicted to establish direct interactions with DNA in its targeting to the STAT3 DBD.  The prevention of STAT3 nuclear translocation, the blockade of the binding of activated STAT3 to its consensus DNA sequence, and the suppression of STAT3-directed transcriptional activity confirmed silibinin as a direct STAT3i.  The unique characteristics of silibinin as a bimodal SH2- and DBD-targeting STAT3i make silibinin a promising lead for designing new, more effective STAT3i.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrqDnBPi7e7Vg90H21EOLACvtfcHk0lixDUGHxCbuZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvVSrsbs%253D&md5=3e56f6313d0888cd4874ab96db59a2e4</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.fct.2018.04.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fct.2018.04.028%26sid%3Dliteratum%253Aachs%26aulast%3DVerdura%26aufirst%3DS.%26aulast%3DCuy%25C3%25A0s%26aufirst%3DE.%26aulast%3DLlorach-Par%25C3%25A9s%26aufirst%3DL.%26aulast%3DP%25C3%25A9rez-S%25C3%25A1nchez%26aufirst%3DA.%26aulast%3DMicol%26aufirst%3DV.%26aulast%3DNonell-Canals%26aufirst%3DA.%26aulast%3DJoven%26aufirst%3DJ.%26aulast%3DValiente%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DM.%26aulast%3DBosch-Barrera%26aufirst%3DJ.%26aulast%3DMenendez%26aufirst%3DJ.%2BA.%26atitle%3DSilibinin%2520is%2520a%2520direct%2520inhibitor%2520of%2520STAT3%26jtitle%3DFood%2520Chem.%2520Toxicol.%26date%3D2018%26volume%3D116%26spage%3D161%26epage%3D172%26doi%3D10.1016%2Fj.fct.2018.04.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21731</span>, <span class="refDoi">Â DOI: 10.1038/srep21731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fsrep21731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26911838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1erurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21731&author=H.+H.+Caoauthor=J.+H.+Chuauthor=H.+Y.+Kwanauthor=T.+Suauthor=H.+Yuauthor=C.+Y.+Chengauthor=X.+Q.+Fuauthor=H.+Guoauthor=T.+Liauthor=A.+K.+Tseauthor=G.+X.+Chouauthor=H.+B.+Moauthor=Z.+L.+Yu&title=Inhibition+of+the+STAT3+signaling+pathway+contributes+to+apigenin-mediated+anti-metastatic+effect+in+melanoma&doi=10.1038%2Fsrep21731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma</span></div><div class="casAuthors">Cao, Hui-Hui; Chu, Jian-Hong; Kwan, Hiu-Yee; Su, Tao; Yu, Hua; Cheng, Chi-Yan; Fu, Xiu-Qiong; Guo, Hui; Li, Ting; Tse, Anfernee Kai-Wing; Chou, Gui-Xin; Mo, Huan-Biao; Yu, Zhi-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21731</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) signaling is constantly activated in human melanoma, and promotes melanoma metastasis.  The dietary flavonoid apigenin is a bioactive compd. that possesses low toxicity and exerts anti-metastatic activity in melanoma.  However, the anti-metastasis mechanism of apigenin has not been fully elucidated.  In the present study, we showed that apigenin suppressed murine melanoma B16F10 cell lung metastasis in mice, and inhibited cell migration and invasion in human and murine melanoma cells.  Further study indicated that apigenin effectively suppressed STAT3 phosphorylation, decreased STAT3 nuclear localization and inhibited STAT3 transcriptional activity.  Apigenin also down-regulated STAT3 target genes MMP-2, MMP-9, VEGF and Twist1, which are involved in cell migration and invasion.  More importantly, overexpression of STAT3 or Twist1 partially reversed apigenin-impaired cell migration and invasion.  Our data not only reveal a novel anti-metastasis mechanism of apigenin but also support the notion that STAT3 is an attractive and promising target for melanoma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZra091yHGz7Vg90H21EOLACvtfcHk0liYhSA-DWdHjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1erurc%253D&md5=aab552a700cd2f4b0d10c4dd63d09383</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fsrep21731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21731%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DH.%2BH.%26aulast%3DChu%26aufirst%3DJ.%2BH.%26aulast%3DKwan%26aufirst%3DH.%2BY.%26aulast%3DSu%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DC.%2BY.%26aulast%3DFu%26aufirst%3DX.%2BQ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DTse%26aufirst%3DA.%2BK.%26aulast%3DChou%26aufirst%3DG.%2BX.%26aulast%3DMo%26aufirst%3DH.%2BB.%26aulast%3DYu%26aufirst%3DZ.%2BL.%26atitle%3DInhibition%2520of%2520the%2520STAT3%2520signaling%2520pathway%2520contributes%2520to%2520apigenin-mediated%2520anti-metastatic%2520effect%2520in%2520melanoma%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D21731%26doi%3D10.1038%2Fsrep21731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span> <span> </span><span class="NLM_article-title">Blockage of STAT3 signaling pathway by morusin induces apoptosis and inhibits invasion in human pancreatic tumor cells</span>. <i>Pancreas</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">409</span>â <span class="NLM_lpage">419</span>, <span class="refDoi">Â DOI: 10.1097/MPA.0000000000000496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1097%2FMPA.0000000000000496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26646273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVSguro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=409-419&author=C.+Kimauthor=J.+H.+Kimauthor=E.+Y.+Ohauthor=D.+Namauthor=S.+G.+Leeauthor=J.+Leeauthor=S.+H.+Kimauthor=B.+S.+Shimauthor=K.+S.+Ahn&title=Blockage+of+STAT3+signaling+pathway+by+morusin+induces+apoptosis+and+inhibits+invasion+in+human+pancreatic+tumor+cells&doi=10.1097%2FMPA.0000000000000496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Blockage of STAT3 Signaling Pathway by Morusin Induces Apoptosis and Inhibits Invasion in Human Pancreatic Tumor Cells</span></div><div class="casAuthors">Kim, Chulwon; Kim, Jin Ho; Oh, Eun Young; Nam, Dongwoo; Lee, Seok Geun; Lee, Junhee; Kim, Sung-Hoon; Shim, Bum Sang; Ahn, Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Pancreas (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-419</span>CODEN:
                <span class="NLM_cas:coden">PANCE4</span>;
        ISSN:<span class="NLM_cas:issn">0885-3177</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objectives: Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor implicated in carcinogenesis.  Here, we investigated the role of morusin, the major prenylflavonoid, isolated from Chinese herbal medicine in abrogating the constitutive STAT3 activation in human pancreatic tumor cells.  Methods: The effect of morusin on STAT3 activation, assocd. protein kinases, STAT3-regulated gene products, cellular proliferation, and apoptosis was examd.  Results: Morusin specifically inhibited constitutive STAT3 activation both at tyrosine residue 705 and serine residue 727 in 4 pancreatic tumor cells.  The inhibition of STAT3 was mediated through the suppression of activation of upstream JAK1, JAK2, and c-Src kinases.  Morusin led to the accumulation of the cells in different phases of the cell cycle and caused induction of apoptosis and loss of mitochondrial membrane potential.  Morusin downregulated the expression of various STAT3-regulated gene products; this correlated with induction of caspase-3 activation and anti-invasive effects.  Treatment with the protein tyrosine phosphatase inhibitor pervanadate reversed the morusin-induced downregulation of STAT3, thereby suggesting the involvement of a protein tyrosine phosphatase.  Conclusions: Morusin is a novel blocker of STAT3 activation and thus may have potential in neg. regulation of growth and metastasis of pancreatic tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI7lnyUmPSz7Vg90H21EOLACvtfcHk0liYhSA-DWdHjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVSguro%253D&md5=a0696f2c818afd9a2322f0372e748db2</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1097%2FMPA.0000000000000496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMPA.0000000000000496%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DOh%26aufirst%3DE.%2BY.%26aulast%3DNam%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DShim%26aufirst%3DB.%2BS.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26atitle%3DBlockage%2520of%2520STAT3%2520signaling%2520pathway%2520by%2520morusin%2520induces%2520apoptosis%2520and%2520inhibits%2520invasion%2520in%2520human%2520pancreatic%2520tumor%2520cells%26jtitle%3DPancreas%26date%3D2016%26volume%3D45%26spage%3D409%26epage%3D419%26doi%3D10.1097%2FMPA.0000000000000496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">2â²-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>471</i></span>,  <span class="NLM_fpage">135</span>â <span class="NLM_lpage">146</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2019.11.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.canlet.2019.11.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31811906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyhtr7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=471&publication_year=2020&pages=135-146&author=Y.+Yueauthor=W.+Qianauthor=J.+Liauthor=S.+Wuauthor=M.+Zhangauthor=Z.+Wuauthor=Q.+Maauthor=Z.+Wang&title=2%E2%80%B2-Hydroxyflavanone+inhibits+the+progression+of+pancreatic+cancer+cells+and+sensitizes+the+chemosensitivity+of+EGFR+inhibitors+via+repressing+STAT3+signaling&doi=10.1016%2Fj.canlet.2019.11.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling</span></div><div class="casAuthors">Yue, Yangyang; Qian, Weikun; Li, Jie; Wu, Shiqi; Zhang, Mengzhao; Wu, Zheng; Ma, Qingyong; Wang, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">471</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">135-146</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, and chemotherapy is still an important treatment.  It is urgent to develop new medicines because of the limitation and side effects of chemotherapy. 2'-Hydroxyflavanone (2HF) is a citrus-bioflavonoid that is considered to have anti-cancer efficacy.  Compared to human pancreatic ductal epithelial cells hTERT-HPNE, more significant growth-inhibitory effects were seen in PDAC cells BxPC-3 and MIA PaCa-2.  We showed that apoptosis was induced and that the cell cycle was arrested when cells were treated with 2HF.  The expression of the mol. proteins cleaved PARP, cleaved Caspase3, Bax, Bcl-2, CyclinD1, and p27 changed correspondingly.  Also, we obsd. anti-metastatic effects and changes in MMP9, E-cadherin, N-cadherin and Vimentin when cells were treated with a low dose of 2HF.  Suppression of STAT3 and EGFR phosphorylation was also identified as a result of treatment with a combination of 2HF and EGFR inhibitors.  The in vivo antitumor effects in KPC mice were consistent with those obsd. in vitro. 2HF has impactful anti-cancer efficacy and sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod7YVykVkNIbVg90H21EOLACvtfcHk0lgMKAFUC94r_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyhtr7I&md5=e09862ceac97e1e894aa18e50cbdecd1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.11.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.11.041%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3D2%25E2%2580%25B2-Hydroxyflavanone%2520inhibits%2520the%2520progression%2520of%2520pancreatic%2520cancer%2520cells%2520and%2520sensitizes%2520the%2520chemosensitivity%2520of%2520EGFR%2520inhibitors%2520via%2520repressing%2520STAT3%2520signaling%26jtitle%3DCancer%2520Lett.%26date%3D2020%26volume%3D471%26spage%3D135%26epage%3D146%26doi%3D10.1016%2Fj.canlet.2019.11.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namjoshi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Um, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span> <span> </span><span class="NLM_article-title">Anti-myeloma effects of icariin are mediated through the attenuation of JAK/STAT3-dependent signaling cascade</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">531</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2018.00531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3389%2Ffphar.2018.00531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29899697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyrur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=531&author=Y.+Y.+Jungauthor=J.+H.+Leeauthor=D.+Namauthor=A.+S.+Narulaauthor=O.+A.+Namjoshiauthor=B.+E.+Bloughauthor=J.+Y.+Umauthor=G.+Sethiauthor=K.+S.+Ahn&title=Anti-myeloma+effects+of+icariin+are+mediated+through+the+attenuation+of+JAK%2FSTAT3-dependent+signaling+cascade&doi=10.3389%2Ffphar.2018.00531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-myeloma effects of icariin are mediated through the attenuation of JAK/STAT3-dependent signaling cascade</span></div><div class="casAuthors">Jung, Young Yun; Lee, Jong Hyun; Nam, Dongwoo; Narula, Acharan S.; Namjoshi, Ojas A.; Blough, Bruce E.; Um, Jae-Young; Sethi, Gautam; Ahn, Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">531/1-531/15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Because of the essential role of signal transducer and activator of transcription 3 (STAT3) in proliferation, anti-apoptosis, and chemoresistance of multiple myeloma (MM), we investigated whether icariin, a prenylated flavonol glycoside, inhibits both constitutive and inducible STAT3 activation in human myeloma cell lines.  We noted that icariin could block constitutive STAT3 phosphorylation as well as its nuclear translocation and DNA binding ability in U266 cells.  Icariin also suppressed IL-6-induced STAT3 activation through the inhibition of upstream kinases (Janus activated kinase-1 and - 2, and c-Src).  We found that icariin downregulated the protein expression of STAT3 downstream target gene products such as Bcl-2, Bcl-xl, survivin, IAP-1/2, COX-2, VEGF, and matrix metallopeptidase 9 (MMP-9) in a concn.-dependent manner.  Moreover, this flavonoid also exhibited the capacity to significantly induce apoptosis and suppress proliferation of MM cells.  Interestingly, this agent also significantly potentiated the apoptotic effects of bortezomib through the suppression of STAT3 activation in MM cells.  Altogether, our data indicates that the potential application of icariin as a STAT3 blocker in myeloma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAFhYFeew-5bVg90H21EOLACvtfcHk0lgMKAFUC94r_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyrur4%253D&md5=274c4d87a7602f1c7218f848323aec7a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00531%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DY.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DNam%26aufirst%3DD.%26aulast%3DNarula%26aufirst%3DA.%2BS.%26aulast%3DNamjoshi%26aufirst%3DO.%2BA.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DUm%26aufirst%3DJ.%2BY.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26atitle%3DAnti-myeloma%2520effects%2520of%2520icariin%2520are%2520mediated%2520through%2520the%2520attenuation%2520of%2520JAK%252FSTAT3-dependent%2520signaling%2520cascade%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D531%26doi%3D10.3389%2Ffphar.2018.00531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span> <span> </span><span class="NLM_article-title">Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">140</span>â <span class="NLM_lpage">148</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2013.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.canlet.2013.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24333736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOht7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2014&pages=140-148&author=J.+H.+Leeauthor=S.+Y.+Chiangauthor=D.+Namauthor=W.+S.+Chungauthor=J.+Leeauthor=Y.+S.+Naauthor=G.+Sethiauthor=K.+S.+Ahn&title=Capillarisin+inhibits+constitutive+and+inducible+STAT3+activation+through+induction+of+SHP-1+and+SHP-2+tyrosine+phosphatases&doi=10.1016%2Fj.canlet.2013.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases</span></div><div class="casAuthors">Lee, Jong Hyun; Chiang, Shu Yuan; Nam, Dongwoo; Chung, Won-Seok; Lee, Junhee; Na, Young-Soon; Sethi, Gautam; Ahn, Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-148</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Signal transducers and activators of transcription (STAT)-3 is a latent cytosolic transcription factor that has been closely assocd. with survival, proliferation, chemoresistance, and metastasis of tumor cells.  Whether the anti-proliferative, pro-apoptotic, and anti-metastatic effects of capillarisin (CPS), derived from Artemisia capillaris (Compositae), are linked to its capability to inhibit STAT3 activation was investigated.  We found that CPS specifically inhibited both constitutive and inducible STAT3 activation at tyrosine residue 705 but not at serine residue 727 in human multiple myeloma cells.  Besides the inhibition of STAT3 phosphorylation, CPS also abrogated STAT3 constitutive activity and nuclear translocation.  The suppression of STAT3 was mediated through the inhibition of activation of upstream JAK1, JAK2, and c-Src kinases.  Treatment with the protein tyrosine phosphatase (PTP) inhibitor pervanadate treatment reversed the CPS-induced down-regulation of JAK1/2 and STAT3, thereby suggesting the involvement of a PTP.  Indeed, knockdown of the SHP-1 and SHP-2 genes by small interfering RNA suppressed the ability of CPS to inhibit JAK1 and STAT3 activation, suggesting the crit. role of both SHP-1 and SHP-2 in its possible mechanism of action.  CPS downregulated the expression of STAT3-regulated antiapoptotic and proliferative gene products; and this correlated with suppression of cell viability, the accumulation of cells in sub-G1 phase of cell cycle and induction of apoptosis.  Moreover, CPS potentiated bortezomib-induced apoptotic effects in MM cells, and this correlated with down-regulation of various gene products that mediate cell proliferation (Cyclin D1 and COX-2), cell survival (Bcl-2, Bcl-xl, IAP1, IAP2, and Survivin), invasion (MMP-9), and angiogenesis (VEGF).  Thus, overall, our results suggest that CPS is a novel blocker of STAT3 activation and thus may have a potential in neg. regulation of growth, metastasis, and chemoresistance of tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKazZFFIl8k7Vg90H21EOLACvtfcHk0lgMKAFUC94r_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOht7fK&md5=4d34bba3328ff4e2e2efcbd1765387f4</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DChiang%26aufirst%3DS.%2BY.%26aulast%3DNam%26aufirst%3DD.%26aulast%3DChung%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DNa%26aufirst%3DY.%2BS.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26atitle%3DCapillarisin%2520inhibits%2520constitutive%2520and%2520inducible%2520STAT3%2520activation%2520through%2520induction%2520of%2520SHP-1%2520and%2520SHP-2%2520tyrosine%2520phosphatases%26jtitle%3DCancer%2520Lett.%26date%3D2014%26volume%3D345%26spage%3D140%26epage%3D148%26doi%3D10.1016%2Fj.canlet.2013.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span></span> <span> </span><span class="NLM_article-title">Geranylnaringenin (CG902) inhibits constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2017.06.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bcp.2017.06.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28666623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=46-57&author=Y.+Jinauthor=Y.+J.+Yoonauthor=Y.+J.+Jeonauthor=J.+Choiauthor=Y.+J.+Leeauthor=J.+Leeauthor=S.+Choiauthor=O.+Nashauthor=D.+C.+Hanauthor=B.+M.+Kwon&title=Geranylnaringenin+%28CG902%29+inhibits+constitutive+and+inducible+STAT3+activation+through+the+activation+of+SHP-2+tyrosine+phosphatase&doi=10.1016%2Fj.bcp.2017.06.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Geranylnaringenin (CG902) inhibits constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase</span></div><div class="casAuthors">Jin, Yena; Yoon, Yae Jin; Jeon, Yoon Jung; Choi, Jiyeon; Lee, Yu-Jin; Lee, Joonku; Choi, Sangho; Nash, Oyekanmi; Han, Dong Cho; Kwon, Byoung-Mog</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-57</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The roles and significance of signal transducer and activator of transcription 3 (STAT3) in human cancers have been extensively studied and STAT3 is a promising therapeutic target for cancer drug discovery.  During the screening of natural products to identify STAT3 inhibitors, we identified geranylnaringenin (CG902), which decreased luciferase activity in a dose-dependent manner.  CG902 specifically inhibited STAT3 phosphorylation at Tyr-705 in DU145 prostate cancer cells and decreased the expression levels of STAT3 target genes, such as cyclin D1, cyclin A, and survivin.  Notably, the knockdown of the SHP-2 gene by small interfering RNA suppressed the ability of CG902 to inhibit STAT3 activation and CG902 activated the phosphatase activity of SHP-2 through direct interaction with SHP-2 and induced the phosphorylation of SHP-2.  The interactions between CG902 and SHP-2 were confirmed by pull-down assay using biotinylated CG902.  The interactions were also further validated by the drug affinity responsive target stability (DARTS) and cellular thermal shift assay (CETSA).  The inhibitory effect of CG902 on cell growth was confirmed using the DU145 mouse xenograft model.  We propose that CG902 inhibits STAT3 activity through a mechanism that involves the interactions between CG902 and SHP-2, and the phosphorylation of SHP-2, which leads to SHP-2 activation in DU145 cells.  CG902 is the first compd. to regulate STAT3 activity via the modulation of SHP-2 activity, and our results suggest that CG902 is a novel inhibitor of the STAT3 pathway and an activator of SHP-2, and may be a useful lead mol. for the development of a therapeutic STAT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoClPx4Nm8_SbVg90H21EOLACvtfcHk0lgemeE_LayiVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7jN&md5=279cd2f84ce66a2ac6013cb3748dbf1d</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.06.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.06.131%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DY.%26aulast%3DYoon%26aufirst%3DY.%2BJ.%26aulast%3DJeon%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DNash%26aufirst%3DO.%26aulast%3DHan%26aufirst%3DD.%2BC.%26aulast%3DKwon%26aufirst%3DB.%2BM.%26atitle%3DGeranylnaringenin%2520%2528CG902%2529%2520inhibits%2520constitutive%2520and%2520inducible%2520STAT3%2520activation%2520through%2520the%2520activation%2520of%2520SHP-2%2520tyrosine%2520phosphatase%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D142%26spage%3D46%26epage%3D57%26doi%3D10.1016%2Fj.bcp.2017.06.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamie, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philoppes, J. N.</span></span> <span> </span><span class="NLM_article-title">2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">864</span>â <span class="NLM_lpage">879</span>, <span class="refDoi">Â DOI: 10.1080/14756366.2020.1740922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1080%2F14756366.2020.1740922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32208772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFOqsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2020&pages=864-879&author=P.+F.+Lamieauthor=J.+N.+Philoppes&title=2-Thiopyrimidine%2Fchalcone+hybrids%3A+design%2C+synthesis%2C+ADMET+prediction%2C+and+anticancer+evaluation+as+STAT3%2FSTAT5a+inhibitors&doi=10.1080%2F14756366.2020.1740922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors</span></div><div class="casAuthors">Lamie, Phoebe F.; Philoppes, John N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">864-879</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A novel 2-thiopyrimidine/chalcone hybrid was designed, synthesized, and evaluated for their cytotoxic activities against three different cell lines, K-562, MCF-7, and HT-29.  The most active cytotoxic derivs. were , , , and (IC50=0.77-1.74Î¼M, against K-562 cell line), and (IC50=1.37-3.56Î¼M against MCF-7 cell line), and , , and (IC50=2.10 and 2.37Î¼M against HT-29 cell line).  Compds. , , , , and were further evaluated for their cytotoxicity against normal fibroblast cell line WI38.  Moreover, STAT3 and STAT5a inhibitory activities were detd. for the most active derivs. , , , , and .  Dual inhibitory activity was obsd. in compd. (IC50=113.31 and 50.75Î¼M, against STAT3 and STAT5a, resp.).  Prediction of physicochem. properties, drug likeness score, pharmacokinetic and toxic properties was detected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUHLoBtVvD-LVg90H21EOLACvtfcHk0lgemeE_LayiVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFOqsb0%253D&md5=49d920c8a1106f00200eb0a5c783bc92</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1080%2F14756366.2020.1740922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2020.1740922%26sid%3Dliteratum%253Aachs%26aulast%3DLamie%26aufirst%3DP.%2BF.%26aulast%3DPhiloppes%26aufirst%3DJ.%2BN.%26atitle%3D2-Thiopyrimidine%252Fchalcone%2520hybrids%253A%2520design%252C%2520synthesis%252C%2520ADMET%2520prediction%252C%2520and%2520anticancer%2520evaluation%2520as%2520STAT3%252FSTAT5a%2520inhibitors%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2020%26volume%3D35%26spage%3D864%26epage%3D879%26doi%3D10.1080%2F14756366.2020.1740922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roatsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krautscheid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">Development of erasin: a chromone-based STAT3 inhibitor which induces apoptosis in erlotinib-resistant lung cancer cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">17390</span>, <span class="refDoi">Â DOI: 10.1038/s41598-017-17600-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41598-017-17600-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29234062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC1MzgvValtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=17390&author=C.+Lisauthor=S.+Rubnerauthor=M.+Roatschauthor=A.+Bergauthor=T.+Gilcrestauthor=D.+Fuauthor=E.+Nguyenauthor=A.+M.+Schmidtauthor=H.+Krautscheidauthor=J.+Meilerauthor=T.+Berg&title=Development+of+erasin%3A+a+chromone-based+STAT3+inhibitor+which+induces+apoptosis+in+erlotinib-resistant+lung+cancer+cells&doi=10.1038%2Fs41598-017-17600-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells</span></div><div class="casAuthors">Lis Christian; Rubner Stefan; Roatsch Martin; Berg Angela; Schmidt Anne-Marie; Berg Thorsten; Gilcrest Tyler; Fu Darwin; Nguyen Elizabeth; Meiler Jens; Krautscheid Harald</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17390</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inhibition of protein-protein interactions by small molecules offers tremendous opportunities for basic research and drug development.  One of the fundamental challenges of this research field is the broad lack of available lead structures from nature.  Here, we demonstrate that modifications of a chromone-based inhibitor of the Src homology 2 (SH2) domain of the transcription factor STAT5 confer inhibitory activity against STAT3.  The binding mode of the most potent STAT3 inhibitor Erasin was analyzed by the investigation of structure-activity relationships, which was facilitated by chemical synthesis and biochemical activity analysis, in combination with molecular docking studies.  Erasin inhibits tyrosine phosphorylation of STAT3 with selectivity over STAT5 and STAT1 in cell-based assays, and increases the apoptotic rate of cultured NSCLC cells in a STAT3-dependent manner.  This ability of Erasin also extends to HCC-827 cells with acquired resistance against Erlotinib, a clinically used inhibitor of the EGF receptor.  Our work validates chromone-based acylhydrazones as privileged structures for antagonizing STAT SH2 domains, and demonstrates that apoptosis can be induced in NSCLC cells with acquired Erlotinib resistance by direct inhibition of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSothEGF92qRP6BottYdIAWfW6udTcc2eaKdPjFkJy4Jbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzgvValtQ%253D%253D&md5=e1be6e7fe119d34d49f6594e7813e4c7</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-17600-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-17600-x%26sid%3Dliteratum%253Aachs%26aulast%3DLis%26aufirst%3DC.%26aulast%3DRubner%26aufirst%3DS.%26aulast%3DRoatsch%26aufirst%3DM.%26aulast%3DBerg%26aufirst%3DA.%26aulast%3DGilcrest%26aufirst%3DT.%26aulast%3DFu%26aufirst%3DD.%26aulast%3DNguyen%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DA.%2BM.%26aulast%3DKrautscheid%26aufirst%3DH.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520erasin%253A%2520a%2520chromone-based%2520STAT3%2520inhibitor%2520which%2520induces%2520apoptosis%2520in%2520erlotinib-resistant%2520lung%2520cancer%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D17390%26doi%3D10.1038%2Fs41598-017-17600-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span> <span> </span><span class="NLM_article-title">Identification of small molecule inhibitors of the STAT3 signaling pathway: Insights into their structural features and mode of action</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5444</span>â <span class="NLM_lpage">5448</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.07.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmcl.2015.07.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26392052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1elsLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5444-5448&author=K.+Kimauthor=S.+J.+Kimauthor=Y.+T.+Hanauthor=S.+J.+Hongauthor=H.+Anauthor=D.+J.+Changauthor=T.+Kimauthor=B.+Limauthor=J.+Leeauthor=Y.+J.+Surhauthor=Y.+G.+Suh&title=Identification+of+small+molecule+inhibitors+of+the+STAT3+signaling+pathway%3A+Insights+into+their+structural+features+and+mode+of+action&doi=10.1016%2Fj.bmcl.2015.07.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small molecule inhibitors of the STAT3 signaling pathway: Insights into their structural features and mode of action</span></div><div class="casAuthors">Kim, Kyeojin; Kim, Su-Jung; Han, Young Taek; Hong, Sung-Jun; An, Hongchan; Chang, Dong-Jo; Kim, Taewoo; Lim, Bumhee; Lee, Jeeyeon; Surh, Young-Joon; Suh, Young-Ger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5444-5448</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel STAT3 inhibitors consisting of Michael acceptor has been identified through assays of the focused inhouse library.  In addn., their mode of action and structural feature responsible for the STAT3 inhibition were investigated.  In particular, analog I revealed promising STAT3 inhibitory activity in HeLa cell lines.  The analog also exhibited selective inhibition of STAT3 phosphorylation without affecting STAT1 phosphorylation and cytostatic effect in human breast epithelial cells (MCF10A-ras), which supports cancer cell-specific inhibitory properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHSfiwcPAuTLVg90H21EOLACvtfcHk0li46MkTVK7dbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1elsLjF&md5=1de619f752f6e3e223263915b7d15ba6</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.063%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DHan%26aufirst%3DY.%2BT.%26aulast%3DHong%26aufirst%3DS.%2BJ.%26aulast%3DAn%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DD.%2BJ.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSurh%26aufirst%3DY.%2BJ.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26atitle%3DIdentification%2520of%2520small%2520molecule%2520inhibitors%2520of%2520the%2520STAT3%2520signaling%2520pathway%253A%2520Insights%2520into%2520their%2520structural%2520features%2520and%2520mode%2520of%2520action%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5444%26epage%3D5448%26doi%3D10.1016%2Fj.bmcl.2015.07.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span> <span> </span><span class="NLM_article-title">A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">114053</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2020.114053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bcp.2020.114053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32450253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFSktr7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=114053&author=S.+K.+Parkauthor=W.+S.+Byunauthor=S.+Leeauthor=Y.+T.+Hanauthor=Y.+S.+Jeongauthor=K.+Jangauthor=S.+J.+Chungauthor=J.+Leeauthor=Y.+G.+Suhauthor=S.+K.+Lee&title=A+novel+small+molecule+STAT3+inhibitor+SLSI-1216+suppresses+proliferation+and+tumor+growth+of+triple-negative+breast+cancer+cells+through+apoptotic+induction&doi=10.1016%2Fj.bcp.2020.114053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction</span></div><div class="casAuthors">Park, Soo Kyung; Byun, Woong Sub; Lee, Seungbeom; Han, Young Taek; Jeong, Yoo-Seong; Jang, Kyungkuk; Chung, Suk-Jae; Lee, Jeeyeon; Suh, Young-Ger; Lee, Sang Kook</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114053</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most aggressive type of breast cancer, characterized by the lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  Owing to the absence of mol. targets, there are limited treatment options, and TNBC patients exhibit high mortality rates.  Signal transducer and activator of transcription 3 (STAT3) is overexpressed and aberrantly activated in TNBC cells.  Therefore, inhibition of STAT3-mediated signaling provides a potential strategy for the treatment of TNBC.  In this study, A series of synthetic derivs. of SLSI-1 (a STAT3 inhibitor) were designed and evaluated for antitumor activity in TNBC cells.  A novel deriv. (SLSI-1216) exhibited the most potent anti-proliferative activity.  SLSI-1216 effectively inhibited STAT3 activity and activation of STAT3, leading to the downregulation of AXL, a downstream target of STAT3 and epithelial-mesenchymal transition (EMT) progression.  The inhibition of EMT by SLSI-1216 was assocd. with modulation of E-cadherin and N-cadherin.  Furthermore, SLSI-1216 induced apoptosis by targeting STAT3 and effectively inhibited tumor growth in vivo.  These findings suggest that SLSI-1216, as a potential inhibitor of STAT3, may be a promising therapeutic agent for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Ghr0IzEk6rVg90H21EOLACvtfcHk0li46MkTVK7dbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFSktr7I&md5=f773209f279a27b9fad0d575ac2ecaea</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2020.114053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2020.114053%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DByun%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DY.%2BT.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DJang%26aufirst%3DK.%26aulast%3DChung%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BK.%26atitle%3DA%2520novel%2520small%2520molecule%2520STAT3%2520inhibitor%2520SLSI-1216%2520suppresses%2520proliferation%2520and%2520tumor%2520growth%2520of%2520triple-negative%2520breast%2520cancer%2520cells%2520through%2520apoptotic%2520induction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D178%26spage%3D114053%26doi%3D10.1016%2Fj.bcp.2020.114053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. R.</span></span> <span> </span><span class="NLM_article-title">Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">887</span>â <span class="NLM_lpage">897</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30145375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2gtr3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=887-897&author=W.+Huangauthor=Y.+Liuauthor=J.+Wangauthor=X.+Yuanauthor=H.+W.+Jinauthor=L.+R.+Zhangauthor=J.+T.+Zhangauthor=Z.+M.+Liuauthor=J.+R.+Cui&title=Small-molecule+compounds+targeting+the+STAT3+DNA-binding+domain+suppress+survival+of+cisplatin-resistant+human+ovarian+cancer+cells+by+inducing+apoptosis&doi=10.1016%2Fj.ejmech.2018.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis</span></div><div class="casAuthors">Huang, Wei; Liu, Yuan; Wang, Jun; Yuan, Xia; Jin, Hong-Wei; Zhang, Liang-Ren; Zhang, Jian-Ting; Liu, Zhen-Ming; Cui, Jing-Rong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">887-897</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription 3 (STAT3) plays important roles in oncogenic occurrence and transformation by regulating the expression of diverse downstream target genes important for tumor growth, metastasis, angiogenesis and immune evasion.  Feasibility of targeting the DNA-binding domain (DBD) of STAT3 has been proven previously.  With the aid of 3D shape- and electrostatic-based drug design, we identified a new STAT3 inhibitor, LC28, and its five analogs, based on the pharmacophore of a known STAT3 DBD inhibitor.  Microscale thermophoresis assay shows that these compds. inhibits STAT3 binding to DNA with a Ki value of 0.74-8.87 Î¼M.  Furthermore, LC28 and its analogs suppress survival of cisplatin-resistant ovarian cancer cells by inhibiting STAT3 signaling and inducing apoptosis.  Therefore, these compds. may serve as candidate compds. for further modification and development as anticancer therapeutics targeting the DBD of human STAT3 for treatment of cisplatin-resistant ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrsNxJakSRqrVg90H21EOLACvtfcHk0ljWaNEz-iFqHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2gtr3L&md5=43ff9b4ec08513e3b2b6196a438320ab</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DH.%2BW.%26aulast%3DZhang%26aufirst%3DL.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DZ.%2BM.%26aulast%3DCui%26aufirst%3DJ.%2BR.%26atitle%3DSmall-molecule%2520compounds%2520targeting%2520the%2520STAT3%2520DNA-binding%2520domain%2520suppress%2520survival%2520of%2520cisplatin-resistant%2520human%2520ovarian%2520cancer%2520cells%2520by%2520inducing%2520apoptosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D887%26epage%3D897%26doi%3D10.1016%2Fj.ejmech.2018.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, F.</span></span> <span> </span><span class="NLM_article-title">The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">303</span>, <span class="refDoi">Â DOI: 10.1186/s13046-018-0959-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2Fs13046-018-0959-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30518397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFais7vN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=303&author=Y.+Liuauthor=X.+Wangauthor=S.+Zengauthor=X.+Zhangauthor=J.+Zhaoauthor=X.+Zhangauthor=X.+Chenauthor=W.+Yangauthor=Y.+Yangauthor=Z.+Dongauthor=J.+Zhuauthor=X.+Xuauthor=F.+Tian&title=The+natural+polyphenol+curcumin+induces+apoptosis+by+suppressing+STAT3+signaling+in+esophageal+squamous+cell+carcinoma&doi=10.1186%2Fs13046-018-0959-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma</span></div><div class="casAuthors">Liu, Ying; Wang, Xinhua; Zeng, Shuang; Zhang, Xiane; Zhao, Jimin; Zhang, Xiaoyan; Chen, Xinhuan; Yang, Wanjing; Yang, Yili; Dong, Ziming; Zhu, Jingyu; Xu, Xin; Tian, Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">303</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: We and others have previously shown that the STAT3 signaling pathway is activated in some esophageal squamous cell carcinoma (ESCC) cells and is required for the survival and growth of these primary ESCC-derived xenografts.  It has also been shown that the natural polyphenol curcumin is an effective anti-tumor agent.  Methods: Luciferase assay and immunoblotting were performed to examine whether curcumin suppressed STAT3 signaling.  CCK-8 assay and xenografts were utilized for analyzing ESCC cell growth in culture and mice.  Soft agar assay was carried out to det. the colony formation ability of ESCC cells in the presence or absence of curcumin.  Cell death and cell cycle were assessed by In CELL Analyzer 2000.  Immunohistochem. and TUNEL assay were used for detecting apoptosis in ESCC tissues.  Mol. docking was performed to evaluate the interaction of curcumin with JAK2.  JAK2 activity was assessed using an in vitro cell-free system.  HE staining was used to evaluate the ESCC tissues.  Results: The natural polyphenol curcumin inhibited STAT3 phosphorylation rapidly and blocked STAT3-mediated signaling in ESCC cells.  It also induced growth arrest and apoptosis in cultured ESCC cells, which were attenuated by enforced expression of STAT3.  Furthermore, curcumin preferentially blocked the growth of primary ESCC-derived xenografts that harbored activated STAT3.  Conclusions: Curcumin is able to exert anti-tumor action through inhibiting the STAT3 signaling pathway.  Giving its wide use in traditional medicines with low toxicity and few adverse reactions, it is conceivable that curcumin might be further explored as a unique STAT3 inhibitor for anti-cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoohC88doUAarVg90H21EOLACvtfcHk0ljWaNEz-iFqHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFais7vN&md5=404ac18a0bac9a0853038f661dbc25b8</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0959-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0959-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DTian%26aufirst%3DF.%26atitle%3DThe%2520natural%2520polyphenol%2520curcumin%2520induces%2520apoptosis%2520by%2520suppressing%2520STAT3%2520signaling%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26spage%3D303%26doi%3D10.1186%2Fs13046-018-0959-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surh, Y. J.</span></span> <span> </span><span class="NLM_article-title">Curcumin interacts directly with the cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">6409</span>, <span class="refDoi">Â DOI: 10.1038/s41598-018-23840-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41598-018-23840-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29686295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjlslykug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=6409&author=Y.+I.+Hahnauthor=S.+J.+Kimauthor=B.+Y.+Choiauthor=K.+C.+Choauthor=R.+Banduauthor=K.+P.+Kimauthor=D.+H.+Kimauthor=W.+Kimauthor=J.+S.+Parkauthor=B.+W.+Hanauthor=J.+Leeauthor=H.+K.+Naauthor=Y.+N.+Chaauthor=Y.+J.+Surh&title=Curcumin+interacts+directly+with+the+cysteine+259+residue+of+STAT3+and+induces+apoptosis+in+H-Ras+transformed+human+mammary+epithelial+cells&doi=10.1038%2Fs41598-018-23840-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Curcumin interacts directly with the Cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells</span></div><div class="casAuthors">Hahn Young-Il; Kim Su-Jung; Kim Do-Hee; Kim Wonki; Park Joon Sung; Han Byung Woo; Lee Jeewoo; Surh Young-Joon; Choi Bu-Young; Cho Kyung-Cho; Bandu Raju; Kim Kwang Pyo; Na Hye-Kyung; Cha Young-Nam</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6409</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is latent but constitutively activated in many types of cancers.  It is well known that STAT3 plays a key role in inflammation-associated tumorigenesis.  Curcumin is an anti-inflammatory natural compound isolated from the turmeric (Curcuma longa L., Zingiberaceae) that has been extensively used in a traditional medicine over the centuries.  In the present study, we have found that curcumin inhibits STAT3 signaling that is persistently overactivated in H-Ras transformed breast epithelial cells (H-Ras MCF10A).  Specific cysteine residues present in STAT3 appear to be critical for the activity as well as conformation of this transcription factor.  We identified the cysteine residue 259 of STAT3 as a putative site for curcumin binding.  Site-directed mutation of this cysteine residue abolished curcumin-induced inactivation of STAT3 and apoptosis in H-Ras MCF10A cells.  The Î±,Î²-unsaturated carbonyl moiety of curcumin appears to be essential in its binding to STAT3 in H-Ras MCF10A cells.  Tetrahydrocurcumin that lacks such electrophilic moiety failed to interact with STAT3 and to induce apoptosis in the same cell line.  Taken together, our findings suggest that curcumin can abrogate aberrant activation of STAT3 through direct interaction, thereby inhibiting STAT3-mediated mammary carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0UUuEhL3mVSM8MEzWGjS9fW6udTcc2eYJwLabAiJFdLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjlslykug%253D%253D&md5=377518ff6836db0d821eb4abc2d43b32</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-23840-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-23840-2%26sid%3Dliteratum%253Aachs%26aulast%3DHahn%26aufirst%3DY.%2BI.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DChoi%26aufirst%3DB.%2BY.%26aulast%3DCho%26aufirst%3DK.%2BC.%26aulast%3DBandu%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BP.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DHan%26aufirst%3DB.%2BW.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DNa%26aufirst%3DH.%2BK.%26aulast%3DCha%26aufirst%3DY.%2BN.%26aulast%3DSurh%26aufirst%3DY.%2BJ.%26atitle%3DCurcumin%2520interacts%2520directly%2520with%2520the%2520cysteine%2520259%2520residue%2520of%2520STAT3%2520and%2520induces%2520apoptosis%2520in%2520H-Ras%2520transformed%2520human%2520mammary%2520epithelial%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D6409%26doi%3D10.1038%2Fs41598-018-23840-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deangelis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foust, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesinski, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">217</span>, <span class="refDoi">Â DOI: 10.1186/1476-4598-9-217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2F1476-4598-9-217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=20712901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC3cfhtFKksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=217&author=L.+Linauthor=S.+Deangelisauthor=E.+Foustauthor=J.+Fuchsauthor=C.+Liauthor=P.+K.+Liauthor=E.+B.+Schwartzauthor=G.+B.+Lesinskiauthor=D.+Bensonauthor=J.+L%C3%BCauthor=D.+Hoytauthor=J.+Lin&title=A+novel+small+molecule+inhibits+STAT3+phosphorylation+and+DNA+binding+activity+and+exhibits+potent+growth+suppressive+activity+in+human+cancer+cells&doi=10.1186%2F1476-4598-9-217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells</span></div><div class="casAuthors">Lin Li; Deangelis Stephanie; Foust Elizabeth; Fuchs James; Li Chenglong; Li Pui-Kai; Schwartz Eric B; Lesinski Gregory B; Benson Don; Lu Jiagao; Hoyt Dale; Lin Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">217</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Targeting Signal Transducer and Activator of Transcription 3 (STAT3) signaling is an attractive therapeutic approach for most types of human cancers with constitutively activated STAT3.  A novel small molecular STAT3 inhibitor, FLLL32 was specifically designed from dietary agent, curcumin to inhibit constitutive STAT3 signaling in multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells.  RESULTS:  FLLL32 was found to be a potent inhibitor of STAT3 phosphorylation, STAT3 DNA binding activity, and the expression of STAT3 downstream target genes in vitro, leading to the inhibition of cell proliferation as well as the induction of Caspase-3 and PARP cleavages in human multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cell lines.  However, FLLL32 exhibited little inhibition on some tyrosine kinases containing SH2 or both SH2 and SH3 domains, and other protein and lipid kinases using a kinase profile assay.  FLLL32 was also more potent than four previously reported JAK2 and STAT3 inhibitors as well as curcumin to inhibit cell viability in these cancer cells.  Furthermore, FLLL32 selectively inhibited the induction of STAT3 phosphorylation by Interleukin-6 but not STAT1 phosphorylation by IFN-Î³.  CONCLUSION:  Our findings indicate that FLLL32 exhibits potent inhibitory activity to STAT3 and has potential for targeting multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells expressing constitutive STAT3 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwSSxJacyutQ20zIbnCCI3fW6udTcc2eYJwLabAiJFdLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfhtFKksg%253D%253D&md5=60b9e2111ec36ec96625043347cc2f5e</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-9-217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-9-217%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%26aulast%3DDeangelis%26aufirst%3DS.%26aulast%3DFoust%26aufirst%3DE.%26aulast%3DFuchs%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DP.%2BK.%26aulast%3DSchwartz%26aufirst%3DE.%2BB.%26aulast%3DLesinski%26aufirst%3DG.%2BB.%26aulast%3DBenson%26aufirst%3DD.%26aulast%3DL%25C3%25BC%26aufirst%3DJ.%26aulast%3DHoyt%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DA%2520novel%2520small%2520molecule%2520inhibits%2520STAT3%2520phosphorylation%2520and%2520DNA%2520binding%2520activity%2520and%2520exhibits%2520potent%2520growth%2520suppressive%2520activity%2520in%2520human%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%26date%3D2010%26volume%3D9%26spage%3D217%26doi%3D10.1186%2F1476-4598-9-217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selvendiran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KÃ¡lai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, P.</span></span> <span> </span><span class="NLM_article-title">HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">837</span>â <span class="NLM_lpage">845</span>, <span class="refDoi">Â DOI: 10.4161/cbt.12.9.17713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.4161%2Fcbt.12.9.17713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21885917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1yis7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=837-845&author=K.+Selvendiranauthor=S.+Ahmedauthor=A.+Daytonauthor=M.+L.+Kuppusamyauthor=B.+K.+Riveraauthor=T.+K%C3%A1laiauthor=K.+Hidegauthor=P.+Kuppusamy&title=HO-3867%2C+a+curcumin+analog%2C+sensitizes+cisplatin-resistant+ovarian+carcinoma%2C+leading+to+therapeutic+synergy+through+STAT3+inhibition&doi=10.4161%2Fcbt.12.9.17713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition</span></div><div class="casAuthors">Selvendiran, Karuppaiyah; Ahmed, Shabnam; Dayton, Alex; Kuppusamy, M. Lakshmi; Rivera, Brian K.; Kalai, Tamas; Hideg, Kalman; Kuppusamy, Periannan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">837-845</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Cisplatin resistance is a major obstacle in the treatment of ovarian cancer.  Drug combinations with synergistic or complementary functions are a promising strategy to overcome this issue.  We studied the anticancer efficacy of a novel compd., HO-3867, used in combination with cisplatin against chemotherapy-resistant ovarian cancer.  A2780R cells, a cisplatin-resistant human ovarian cancer cell line, were exposed to 1, 5 or 10 Î¼M of HO-3867 alone or in combination with cisplatin (10 Î¼g/mL) for 24 h.  Cell viability (MTT), proliferation (BrdU), cell cycle anal. (FACS), and protein expression (protein gel blot) were used for in vitro studies.  STAT3 overexpression was performed using transfected STAT3 cDNA.  In vivo studies used cisplatin-resistant xenograft tumors grown in nude mice and treated with 100-ppm HO-3867 and weekly injections of 4-mg/kg cisplatin.  HO-3867/cisplatin combination treatment significantly inhibited cisplatin-resistant cell proliferation in a concn.-dependent manner.  The inhibition was assocd. with increased expression of p53 and p21, and decreased expression of cdk5 and cyclin D1.  Apoptosis was induced by activation of Bax, cytochrome c release, and stimulated cleavage of caspase-9, caspase-3 and PARP.  Overexpression of STAT3 decreased the HO-3867-induced apoptosis.  The combination treatment significantly inhibited the growth of cisplatin-resistant xenograft tumors with significant downregulation of pSTAT3, and without apparent toxicity to healthy tissues.  The combination treatment exhibited synergistic anticancer efficacy, which appears largely due to HO-3867-induced downregulation of pSTAT3.  The results, combined with the previously-reported safety features of HO-3867, suggest the potential use of this compd. as a safe and effective adjuvant for the treatment of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5WXOMmWUHX7Vg90H21EOLACvtfcHk0lhSchCDSBl0Rg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1yis7w%253D&md5=d20e2e40544163211fa3adadeccb8b26</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.4161%2Fcbt.12.9.17713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.12.9.17713%26sid%3Dliteratum%253Aachs%26aulast%3DSelvendiran%26aufirst%3DK.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DDayton%26aufirst%3DA.%26aulast%3DKuppusamy%26aufirst%3DM.%2BL.%26aulast%3DRivera%26aufirst%3DB.%2BK.%26aulast%3DK%25C3%25A1lai%26aufirst%3DT.%26aulast%3DHideg%26aufirst%3DK.%26aulast%3DKuppusamy%26aufirst%3DP.%26atitle%3DHO-3867%252C%2520a%2520curcumin%2520analog%252C%2520sensitizes%2520cisplatin-resistant%2520ovarian%2520carcinoma%252C%2520leading%2520to%2520therapeutic%2520synergy%2520through%2520STAT3%2520inhibition%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2011%26volume%3D12%26spage%3D837%26epage%3D845%26doi%3D10.4161%2Fcbt.12.9.17713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, C.</span></span> <span> </span><span class="NLM_article-title">4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6174</span>â <span class="NLM_lpage">6182</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.09.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmc.2016.09.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27816267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslyjtL7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6174-6182&author=P.+Jiauthor=C.+Yuanauthor=S.+Maauthor=J.+Fanauthor=W.+Fuauthor=C.+Qiao&title=4-Carbonyl-2%2C6-dibenzylidenecyclohexanone+derivatives+as+small+molecule+inhibitors+of+STAT3+signaling+pathway&doi=10.1016%2Fj.bmc.2016.09.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway</span></div><div class="casAuthors">Ji, Peng; Yuan, Congmin; Ma, Shuhua; Fan, Junchao; Fu, Wei; Qiao, Chunhua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6174-6182</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of STAT3 signaling pathway is proposed to be a promising strategy for cancer treatment.  In this study, a series of 4-carbonyl-2,6-dibenzylidenecyclohexanone derivs. were prepd. and evaluated as anticancer agents.  The most potent compd. 13r was discovered to exhibit antiproliferative activity against a broad rang of cancer cell lines and relatively low cytotoxicity against normal human cells.  Besides, 13r effectively suppressed STAT3 expression as well as phosphorylation, and surface plasmon resonance anal. confirmed the direct interaction of 13r with STAT3.  Docking simulation showed that 13r could inhibit STAT3 by targeting SH2 domain.  This study provided evidence for these compds. to be further developed as antitumor agents through inhibition of the STAT3 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZXB3I3C-fnrVg90H21EOLACvtfcHk0lg6JIZqv-zh-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslyjtL7M&md5=fe7960d11bd9d9067eea8dc9c5fc70b5</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.09.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.09.070%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DQiao%26aufirst%3DC.%26atitle%3D4-Carbonyl-2%252C6-dibenzylidenecyclohexanone%2520derivatives%2520as%2520small%2520molecule%2520inhibitors%2520of%2520STAT3%2520signaling%2520pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6174%26epage%3D6182%26doi%3D10.1016%2Fj.bmc.2016.09.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de CÃ¡ssia
da Silveira e SÃ¡, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Sousa, D. P.</span></span> <span> </span><span class="NLM_article-title">A review on anti-inflammatory activity of monoterpenes</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1227</span>â <span class="NLM_lpage">1254</span>, <span class="refDoi">Â DOI: 10.3390/molecules18011227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fmolecules18011227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23334570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeqsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1227-1254&author=R.+de+C%C3%A1ssia%0Ada+Silveira+e+S%C3%A1author=L.+N.+Andradeauthor=D.+P.+de+Sousa&title=A+review+on+anti-inflammatory+activity+of+monoterpenes&doi=10.3390%2Fmolecules18011227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A review on anti-inflammatory activity of monoterpenes</span></div><div class="casAuthors">de Cassia da Silveira e Sa, Rita; Andrade, Luciana Nalone; Pergentino de Sousa, Damiao</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1227-1254</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Faced with the need to find new anti-inflammatory agents, great effort has been expended on the development of drugs for the treatment of inflammation.  This disorder reduces the quality of life and overall av. productivity, causing huge financial losses.  In this review the anti-inflammatory activity of 32 bioactive monoterpenes found in essential oils is discussed.  The data demonstrate the pharmacol. potential of this group of natural chems. to act as anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIVVrVOYekALVg90H21EOLACvtfcHk0lg6JIZqv-zh-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeqsbg%253D&md5=f1dca4ad0ec041c4b0c9353245367b52</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.3390%2Fmolecules18011227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules18011227%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BC%25C3%25A1ssia%2Bda%2BSilveira%2Be%2BS%25C3%25A1%26aufirst%3DR.%26aulast%3DAndrade%26aufirst%3DL.%2BN.%26aulast%3Dde%2BSousa%26aufirst%3DD.%2BP.%26atitle%3DA%2520review%2520on%2520anti-inflammatory%2520activity%2520of%2520monoterpenes%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26spage%3D1227%26epage%3D1254%26doi%3D10.3390%2Fmolecules18011227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paduch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandefer-SzerszeÅ, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trytek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedurek, J.</span></span> <span> </span><span class="NLM_article-title">Terpenes: substances useful in human healthcare</span>. <i>Arch. Immunol. Ther. Exp.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">327</span>, <span class="refDoi">Â DOI: 10.1007/s00005-007-0039-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1007%2Fs00005-007-0039-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=18219762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGqsLzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2007&pages=315-327&author=R.+Paduchauthor=M.+Kandefer-Szersze%C5%84author=M.+Trytekauthor=J.+Fiedurek&title=Terpenes%3A+substances+useful+in+human+healthcare&doi=10.1007%2Fs00005-007-0039-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Terpenes: substances useful in human healthcare</span></div><div class="casAuthors">Paduch, Roman; Kandefer-Szerzen, Martyna; Trytek, Mariusz; Fiedurek, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Archivum Immunologiae et Therapiae Experimentalis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-327</span>CODEN:
                <span class="NLM_cas:coden">AITEAT</span>;
        ISSN:<span class="NLM_cas:issn">0004-069X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Terpenes are naturally occurring substances produced by a wide variety of plants and animals.  A broad range of the biol. properties of terpenoids is described, including cancer chemopreventive effects, antimicrobial, antifungal, antiviral, anti-hyperglycemic, anti-inflammatory, and antiparasitic activities.  Terpenes are also presented as skin penetration enhancers and agents involved in the prevention and therapy of several inflammatory diseases.  Moreover, a potential mechanism of their action against pathogens and their influence on skin permeability are discussed.  The major conclusion is that larger-scale use of terpenoids in modern medicine should be taken into consideration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPWXrsN016JbVg90H21EOLACvtfcHk0lhE0dUHhkTS7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGqsLzM&md5=15f8d9199ac8af186c17a627cd593e24</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1007%2Fs00005-007-0039-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00005-007-0039-1%26sid%3Dliteratum%253Aachs%26aulast%3DPaduch%26aufirst%3DR.%26aulast%3DKandefer-Szersze%25C5%2584%26aufirst%3DM.%26aulast%3DTrytek%26aufirst%3DM.%26aulast%3DFiedurek%26aufirst%3DJ.%26atitle%3DTerpenes%253A%2520substances%2520useful%2520in%2520human%2520healthcare%26jtitle%3DArch.%2520Immunol.%2520Ther.%2520Exp.%26date%3D2007%26volume%3D55%26spage%3D315%26epage%3D327%26doi%3D10.1007%2Fs00005-007-0039-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xirou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syrigos, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, J. C.</span></span> <span> </span><span class="NLM_article-title">Targeting colon cancer with the novel STAT3 inhibitor bruceantinol</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1676</span>â <span class="NLM_lpage">1687</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0547-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41388-018-0547-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30348989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFynsbrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=1676-1687&author=N.+Weiauthor=J.+Liauthor=C.+Fangauthor=J.+Changauthor=V.+Xirouauthor=N.+K.+Syrigosauthor=B.+J.+Marksauthor=E.+Chuauthor=J.+C.+Schmitz&title=Targeting+colon+cancer+with+the+novel+STAT3+inhibitor+bruceantinol&doi=10.1038%2Fs41388-018-0547-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting colon cancer with the novel STAT3 inhibitor bruceantinol</span></div><div class="casAuthors">Wei, Ning; Li, Jun; Fang, Cheng; Chang, Jin; Xirou, Vasiliki; Syrigos, Nick K.; Marks, Benjamin J.; Chu, Edward; Schmitz, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1676-1687</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">STAT3, a transcriptional mediator of oncogenic signaling, is constitutively active in â¼70% of human cancers.  The development of STAT3 inhibitors remains an active area of research as no inhibitors have yet to be approved for the treatment of human cancer.  Herein, we revealed that bruceantinol (BOL) is a novel STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models.  BOL strongly inhibited STAT3 DNA-binding ability (IC50 = 2.4 pM), blocked the constitutive and IL-6-induced STAT3 activation in a dose- and time-dependent manner, and suppressed transcription of STAT3 target genes encoding anti-apoptosis factors (MCL-1, PTTG1, and survivin) and cell-cycle regulators (c-Myc).  Structure-activity relationship studies demonstrated that the C15 side chain on BOL affected its ability to bind STAT3.  Administration of 4 mg/kg BOL significantly inhibited CRC tumor xenografts [p < 0.001], but no effect was obsd. in a STAT3-/- tumor model.  Addnl. studies showed that BOL effectively sensitized MEK inhibitors through repression of p-STAT3 and MCL-1 induction, known resistance mechanisms of MEK inhibition.  Taken together, our findings suggest BOL is a novel therapeutic STAT3 inhibitor that can be used either alone or in combination with MEK inhibitors for the treatment of human CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoszhsdy_chYLVg90H21EOLACvtfcHk0lhE0dUHhkTS7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFynsbrP&md5=401a8a656f44cde28fdb629f765ce53a</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0547-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0547-y%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DXirou%26aufirst%3DV.%26aulast%3DSyrigos%26aufirst%3DN.%2BK.%26aulast%3DMarks%26aufirst%3DB.%2BJ.%26aulast%3DChu%26aufirst%3DE.%26aulast%3DSchmitz%26aufirst%3DJ.%2BC.%26atitle%3DTargeting%2520colon%2520cancer%2520with%2520the%2520novel%2520STAT3%2520inhibitor%2520bruceantinol%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D1676%26epage%3D1687%26doi%3D10.1038%2Fs41388-018-0547-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mantaj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokshi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span> <span> </span><span class="NLM_article-title">Crispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3882</span>â <span class="NLM_lpage">3886</span>, <span class="refDoi">Â DOI: 10.1039/C5OB00052A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1039%2FC5OB00052A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25721973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislKitb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=3882-3886&author=J.+Mantajauthor=S.+M.+Rahmanauthor=B.+Bokshiauthor=C.+M.+Hasanauthor=P.+J.+Jacksonauthor=R.+B.+Parsonsauthor=K.+M.+Rahman&title=Crispene+E%2C+a+cis-clerodane+diterpene+inhibits+STAT3+dimerization+in+breast+cancer+cells&doi=10.1039%2FC5OB00052A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Crispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells</span></div><div class="casAuthors">Mantaj, Julia; Rahman, S. M. Abdur; Bokshi, Bishwajit; Hasan, Choudhury M.; Jackson, Paul J. M.; Parsons, Richard B.; Rahman, Khondaker M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3882-3886</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Crispene E, a new clerodane-type diterpene, inhibited STAT3 dimerization in a cell-free fluorescent polarisation assay and was found to have significant toxicity against STAT3-dependent MDA-MB 231 breast cancer cell line and selectively inhibited the expression of STAT3 and STAT3 target genes cyclin D1, Fascin and bcl-2.  Mol. docking studies suggest the mol. inhibits STAT3 by interacting with its SH2 domain.  The compd. has been isolated from Tinospora crispa and characterized using std. spectroscopic techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCsmkKjAMloLVg90H21EOLACvtfcHk0lhE0dUHhkTS7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislKitb0%253D&md5=258515b089974bb55fa2eb5238d684f6</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1039%2FC5OB00052A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB00052A%26sid%3Dliteratum%253Aachs%26aulast%3DMantaj%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DS.%2BM.%26aulast%3DBokshi%26aufirst%3DB.%26aulast%3DHasan%26aufirst%3DC.%2BM.%26aulast%3DJackson%26aufirst%3DP.%2BJ.%26aulast%3DParsons%26aufirst%3DR.%2BB.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26atitle%3DCrispene%2520E%252C%2520a%2520cis-clerodane%2520diterpene%2520inhibits%2520STAT3%2520dimerization%2520in%2520breast%2520cancer%2520cells%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2015%26volume%3D13%26spage%3D3882%26epage%3D3886%26doi%3D10.1039%2FC5OB00052A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noman, M. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahsan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span> <span> </span><span class="NLM_article-title">Crispenes F and G, cis-Clerodane furanoditerpenoids from tinospora crispa, inhibit STAT3 dimerization</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1021/acs.jnatprod.7b00377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.7b00377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyisr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=236-242&author=M.+A.+A.+Nomanauthor=T.+Hossainauthor=M.+Ahsanauthor=S.+Jamshidiauthor=C.+M.+Hasanauthor=K.+M.+Rahman&title=Crispenes+F+and+G%2C+cis-Clerodane+furanoditerpenoids+from+tinospora+crispa%2C+inhibit+STAT3+dimerization&doi=10.1021%2Facs.jnatprod.7b00377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Crispenes F and G, cis-clerodane furanoditerpenoids from Tinospora crispa, inhibit STAT3 dimerization</span></div><div class="casAuthors">Noman, Md. Abdullah Al; Hossain, Tasnova; Ahsan, Monira; Jamshidi, Shirin; Hasan, Choudhury Mahmood; Rahman, Khondaker Miraz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-242</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Two new cis-clerodane-type furanoditerpenes, crispenes F and G (1 and 2), together with 7 known compds., were isolated from the stems of T. crispa.  Compds. 1 and 2 inhibited STAT3 dimerization in a cell-free fluorescent polarization assay and were found to have significant cytotoxicity against a STAT3-dependent MDA-MB 231 breast cancer cell line, while being inactive in a STAT3-null A4 cell line.  These 2 compds. shared structural similarities with a previously reported STAT3 inhibitor, crispene E, isolated from the same plant.  Mol. docking studies suggested that the mols. inhibited STAT3 by interacting with its SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLHE05X1gE77Vg90H21EOLACvtfcHk0ljTg0FbI_vKlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyisr4%253D&md5=6c11119d48239d190f1db9629b4401b8</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.7b00377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.7b00377%26sid%3Dliteratum%253Aachs%26aulast%3DNoman%26aufirst%3DM.%2BA.%2BA.%26aulast%3DHossain%26aufirst%3DT.%26aulast%3DAhsan%26aufirst%3DM.%26aulast%3DJamshidi%26aufirst%3DS.%26aulast%3DHasan%26aufirst%3DC.%2BM.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26atitle%3DCrispenes%2520F%2520and%2520G%252C%2520cis-Clerodane%2520furanoditerpenoids%2520from%2520tinospora%2520crispa%252C%2520inhibit%2520STAT3%2520dimerization%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2018%26volume%3D81%26spage%3D236%26epage%3D242%26doi%3D10.1021%2Facs.jnatprod.7b00377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Don-Doncow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KjellstrÃ¶m, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjartell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellsten, R.</span></span> <span> </span><span class="NLM_article-title">Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">15969</span>â <span class="NLM_lpage">15978</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M114.564252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M114.564252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24755219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2qsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=15969-15978&author=N.+Don-Doncowauthor=Z.+Escobarauthor=M.+Johanssonauthor=S.+Kjellstr%C3%B6mauthor=V.+Garciaauthor=E.+Munozauthor=O.+Sternerauthor=A.+Bjartellauthor=R.+Hellsten&title=Galiellalactone+is+a+direct+inhibitor+of+the+transcription+factor+STAT3+in+prostate+cancer+cells&doi=10.1074%2Fjbc.M114.564252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Galiellalactone25 Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells</span></div><div class="casAuthors">Don-Doncow, Nicholas; Escobar, Zilma; Johansson, Martin; Kjellstroem, Sven; Garcia, Victor; Munoz, Eduardo; Sterner, Olov; Bjartell, Anders; Hellsten, Rebecka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">15969-15978</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is constitutively active in several malignancies including castration-resistant prostate cancer and has been identified as a promising therapeutic target.  The fungal metabolite galiellalactone, a STAT3 signaling inhibitor, inhibits the growth, both in vitro and in vivo, of prostate cancer cells expressing active STAT3 and induces apoptosis of prostate cancer stem cell-like cells expressing phosphorylated STAT3 (pSTAT3).  However, the mol. mechanism of this STAT3-inhibiting effect by galiellalactone has not been clarified.  A biotinylated analog of galiellalactone (GL-biot) was synthesized to be used for identification of galiellalactone target proteins.  By adding streptavidin-Sepharose beads to GL-biot-treated DU145 cell lyzates, STAT3 was isolated and identified as a target protein.  Confocal microscopy revealed GL-biot in both the cytoplasm and the nucleus of DU145 cells treated with GL-biot, appearing to co-localize with STAT3 in the nucleus.  Galiellalactone inhibited STAT3 binding to DNA in DU145 cell lyzates without affecting phosphorylation status of STAT3.  Mass spectrometry anal. of recombinant STAT3 protein pretreated with galiellalactone revealed three modified cysteines (Cys-367, Cys-468, and Cys-542).  Here we demonstrate with chem. and mol. pharmacol. methods that galiellalactone is a cysteine reactive inhibitor that covalently binds to one or more cysteines in STAT3 and that this leads to inhibition of STAT3 binding to DNA and thus blocks STAT3 signaling without affecting phosphorylation.  This further validates galiellalactone as a promising direct STAT3 inhibitor for treatment of castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3avlluHh2P7Vg90H21EOLACvtfcHk0ljTg0FbI_vKlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2qsL4%253D&md5=44961890281d144bd6f9283999c34aa1</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.564252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.564252%26sid%3Dliteratum%253Aachs%26aulast%3DDon-Doncow%26aufirst%3DN.%26aulast%3DEscobar%26aufirst%3DZ.%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DKjellstr%25C3%25B6m%26aufirst%3DS.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DMunoz%26aufirst%3DE.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DBjartell%26aufirst%3DA.%26aulast%3DHellsten%26aufirst%3DR.%26atitle%3DGaliellalactone%2520is%2520a%2520direct%2520inhibitor%2520of%2520the%2520transcription%2520factor%2520STAT3%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D15969%26epage%3D15978%26doi%3D10.1074%2Fjbc.M114.564252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span> <span> </span><span class="NLM_article-title">Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5032</span>â <span class="NLM_lpage">5040</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmc.2017.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28705432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtbbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5032-5040&author=H.+S.+Kimauthor=T.+Kimauthor=H.+Koauthor=J.+Leeauthor=Y.+S.+Kimauthor=Y.+G.+Suh&title=Identification+of+galiellalactone-based+novel+STAT3-selective+inhibitors+with+cytotoxic+activities+against+triple-negative+breast+cancer+cell+lines&doi=10.1016%2Fj.bmc.2017.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines</span></div><div class="casAuthors">Kim, Hyun Su; Kim, Taewoo; Ko, Hyejin; Lee, Jeeyeon; Kim, Yeong Shik; Suh, Young-Ger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5032-5040</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is phosphorylated in breast cancer cells, particularly triple-neg. breast cancers (TNBCs).  Therefore, the inhibition of constitutive phosphorylated STAT3 is a promising therapeutic for TNBC treatment.  Recently, a series of novel STAT3 inhibitors based on natural (-)-galiellalactone have been identified to inhibit STAT3 phosphorylation at the Tyr705 residue.  Interestingly, the truncation of the cyclohexene moiety of (-)-galiellalactone to [3.3] bicyclic lactone as a pharmacophoric core produced improved cytotoxic effects against TNBCs.  The potent analogs 16 and 17, identified from a STAT3-mediated luciferase reporter assay, selectively inhibited the STAT3 signaling pathway without affecting STAT1 or STAT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBskRR7L612rVg90H21EOLACvtfcHk0ljsApcOwhCggw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtbbE&md5=ddb78941b45c15c1a33bd7e6ded6269b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26atitle%3DIdentification%2520of%2520galiellalactone-based%2520novel%2520STAT3-selective%2520inhibitors%2520with%2520cytotoxic%2520activities%2520against%2520triple-negative%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D5032%26epage%3D5040%26doi%3D10.1016%2Fj.bmc.2017.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnihotri, V. K.</span></span> <span> </span><span class="NLM_article-title">UPLC/MS/MS method for quantification and cytotoxic activity of sesquiterpene lactones isolated from Saussurea lappa</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">1393</span>â <span class="NLM_lpage">1397</span>, <span class="refDoi">Â DOI: 10.1016/j.jep.2014.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.jep.2014.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25068579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCltLjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2014&pages=1393-1397&author=A.+Kumarauthor=S.+Kumarauthor=D.+Kumarauthor=V.+K.+Agnihotri&title=UPLC%2FMS%2FMS+method+for+quantification+and+cytotoxic+activity+of+sesquiterpene+lactones+isolated+from+Saussurea+lappa&doi=10.1016%2Fj.jep.2014.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">UPLC/MS/MS method for quantification and cytotoxic activity of sesquiterpene lactones isolated from Saussurea lappa</span></div><div class="casAuthors">Kumar, Ashish; Kumar, Shiv; Kumar, Dharmesh; Agnihotri, Vijai K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1393-1397</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Saussurea lappa (Asteraceae) roots have been reputed for the usage in traditional medicinal systems of India, China and Japan for the treatment of various kinds of disorders such as anti-ulcer, anti-convulsant, anti-cancer, hepatoprotective, anti-arthritic and anti-viral activities.Compds. were isolated using a column chromatog. technique.  The root ext., fractions and isolated compds. were tested for cytotoxicity against A549 (human lung carcinoma) and C-6 (rat glioma) cells using the Sulforhodamine B assay.  Chromatog. sepns. of active sesquiterpene lactones were accomplished on BEH-HSS-T3 column at 25 Â°C.Phytochem. investigation of Saussurea lappa root ext. resulted in the isolation of isoalantolactone (1), Î²-cyclocostunolide (2) Î±-cyclocostunolide (3), 4-hydroxy-3,5-dimethoxycinnamyl-9-O-Î²-D-glucopyranoside (4), sucrose (5), and alantolactone (6).  Their structures were detd. by spectroscopic means.  Ethanolic ext., chloroform fraction, compds. 1, 2, 3 and 6 possessed significant activity against both tested cells.  The quantification was performed using the transitions of m/z 233/105 for isoalantolactone and m/z 233/105 for alantolactone resp.  Costunolide and dehydrocostus lactone were also characterised by comparison of MS/MS fragmentation pattern.This is the first study on simultaneous quantification of isoalantolactone and alantolactone by the UPLC/MS/MS method in Saussurea lappa.  Our study against A549 and C-6 cells showed higher cytotoxicity.  It is suggested that roots of Saussurea lappa might be a potential source of anticancer compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqLcUpIkdzGrVg90H21EOLACvtfcHk0ljsApcOwhCggw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCltLjL&md5=4fb8b9e6afbc87fa21244996c9e0e78e</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2014.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2014.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DAgnihotri%26aufirst%3DV.%2BK.%26atitle%3DUPLC%252FMS%252FMS%2520method%2520for%2520quantification%2520and%2520cytotoxic%2520activity%2520of%2520sesquiterpene%2520lactones%2520isolated%2520from%2520Saussurea%2520lappa%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2014%26volume%3D155%26spage%3D1393%26epage%3D1397%26doi%3D10.1016%2Fj.jep.2014.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span> <span> </span><span class="NLM_article-title">Isoalantolactone induces apoptosis through reactive oxygen species-dependent upregulation of death receptor 5 in human esophageal cancer cells</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.1016/j.taap.2018.05.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.taap.2018.05.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29800641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVaisL3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2018&pages=46-58&author=Z.+Luauthor=G.+Zhangauthor=Y.+Zhangauthor=P.+Huaauthor=M.+Fangauthor=M.+Wuauthor=T.+Liu&title=Isoalantolactone+induces+apoptosis+through+reactive+oxygen+species-dependent+upregulation+of+death+receptor+5+in+human+esophageal+cancer+cells&doi=10.1016%2Fj.taap.2018.05.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Isoalantolactone induces apoptosis through reactive oxygen species-dependent upregulation of death receptor 5 in human esophageal cancer cells</span></div><div class="casAuthors">Lu, Zhengyang; Zhang, Guangxin; Zhang, Yifan; Hua, Peiyan; Fang, Meidan; Wu, Meiliang; Liu, Tongjun</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Esophageal cancer is the eighth most prevalent cancer and has high mortality in our society.  Isoalantolactone, extd. from Inula helenium L, has shown potent anticancer effects on a variety of cancers.  However, its effect on human esophageal cancer, and the underlying mol. mechanism, remain to be investigated.  In the present study, we demonstrated that isoalantolactone induced apoptosis in esophageal cancer cells.  Treatment with isoalantolactone activated caspases-3, -7, and -10, and upregulated death receptor (DR)5.  Furthermore, DR5 knockdown partially reversed the effect of isoalantolactone.  These results indicated the extrinsic apoptosis was induced by isoalantolactone.  In addn., intracellular reactive oxygen species (ROS) were significantly elevated after treatment with isoalantolactone.  N-Acetylcysteine, an ROS scavenger, blocked both the apoptosis and decreased cell viability caused by isoalantolactone.  In vivo, significant suppression of tumor growth by isoalantolactone was obsd. in an ECA109 cell xenograft mouse model.  Isoalantolactone showed no obvious adverse effects on mouse wt. and histol. of heart, liver, spleen, lung, and kidney.  In conclusion, our results revealed that isoalantolactone induced apoptosis through the extrinsic pathway via upregulation of DR5 and elevation of ROS in human esophageal cancer cells.  Isoalantolactone, therefore, could be a potential candidate in developing anticancer agents for esophageal cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXFinuSqIDUrVg90H21EOLACvtfcHk0ljsApcOwhCggw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVaisL3K&md5=c94d07defa456093b4686b4e899fe554</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2018.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2018.05.026%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHua%26aufirst%3DP.%26aulast%3DFang%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26atitle%3DIsoalantolactone%2520induces%2520apoptosis%2520through%2520reactive%2520oxygen%2520species-dependent%2520upregulation%2520of%2520death%2520receptor%25205%2520in%2520human%2520esophageal%2520cancer%2520cells%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2018%26volume%3D352%26spage%3D46%26epage%3D58%26doi%3D10.1016%2Fj.taap.2018.05.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Isoalantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">309</span>, <span class="refDoi">Â DOI: 10.1186/s13046-018-0987-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2Fs13046-018-0987-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30541589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaisL7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=309&author=W.+Chenauthor=P.+Liauthor=Y.+Liuauthor=Y.+Yangauthor=X.+Yeauthor=F.+Zhangauthor=H.+Huang&title=Isoalantolactone+induces+apoptosis+through+ROS-mediated+ER+stress+and+inhibition+of+STAT3+in+prostate+cancer+cells&doi=10.1186%2Fs13046-018-0987-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Isoalantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells</span></div><div class="casAuthors">Chen, Wei; Li, Ping; Liu, Yi; Yang, Yu; Ye, Xueting; Zhang, Fangyi; Huang, Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">309</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Prostate cancer is one of the most commonly diagnosed cancers in men worldwide.  Currently available therapies for metastatic prostate cancer are only marginally effective.  Therefore, new therapeutic agents are urgently needed to improve patient outcome.  Isoalantolactone (IATL), an active sesquiterpene naturally present in many vegetables and medicinal plants, is known to induce cell death and apoptosis in various cancer cell lines.  Nevertheless, antitumor mechanisms initiated by IATL in cancer cells have not been fully defined.  Cell apoptosis and cellular ROS levels were analyzed by flow cytometry.  Western blot and qRT-PCR were used to analyze the protein and mRNA levels of indicated mols., resp.  Nude mice xenograft model was used to test the effects of IATL on prostate cancer cell growth in vivo.  In this study, we found that IATL dose-dependently inhibited cancer cell growth and induced apoptosis in PC-3 and DU145 cells.  Mechanistically, our data found that IATL induced reactive oxygen species (ROS) prodn., resulting in the activation of endoplasmic reticulum stress pathway and eventually cell apoptosis in prostate cancer cells.  IATL also decreased the protein expression levels of p-STAT3 and STAT3, and the effects of IATL were reversed by pretreatment with N-acetyl-L-cysteine (NAC).  In vivo, we found that IATL inhibited the growth of prostate cancer xenografts without exhibiting toxicity.  Treatment of mice bearing human prostate cancer xenografts with IATL was also assocd. with induction of ER stress and inhibtion of STAT3.  In summary, our results unveil a previously unrecognized mechanism underlying the biol. activity of IATL, and provide a novel anti-cancer candidate for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8v5bRq7s8Y7Vg90H21EOLACvtfcHk0litD111BciTog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaisL7N&md5=44235d11eeac774f52ea531a3b3fbc86</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0987-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0987-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DIsoalantolactone%2520induces%2520apoptosis%2520through%2520ROS-mediated%2520ER%2520stress%2520and%2520inhibition%2520of%2520STAT3%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26spage%3D309%26doi%3D10.1186%2Fs13046-018-0987-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjartell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canesin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans-Axelsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellsten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, M. H.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of 3Î²-(N-Acetyl l-cysteine methyl ester)-2aÎ²,3-dihydrogaliellalactone (GPA512), a prodrug of a direct STAT3 inhibitor for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4551</span>â <span class="NLM_lpage">4562</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01814</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01814" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Gqu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4551-4562&author=Z.+Escobarauthor=A.+Bjartellauthor=G.+Canesinauthor=S.+Evans-Axelssonauthor=O.+Sternerauthor=R.+Hellstenauthor=M.+H.+Johansson&title=Preclinical+characterization+of+3%CE%B2-%28N-Acetyl+l-cysteine+methyl+ester%29-2a%CE%B2%2C3-dihydrogaliellalactone+%28GPA512%29%2C+a+prodrug+of+a+direct+STAT3+inhibitor+for+the+treatment+of+prostate+cancer&doi=10.1021%2Facs.jmedchem.5b01814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Characterization of 3Î²-(N-Acetyl L-cysteine methyl ester)-2aÎ²,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer</span></div><div class="casAuthors">Escobar, Zilma; Bjartell, Anders; Canesin, Giacomo; Evans-Axelsson, Susan; Sterner, Olov; Hellsten, Rebecka; Johansson, Martin H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4551-4562</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is a potential target for the treatment of castration-resistant prostate cancer.  Galiellalactone (1), a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes.  In this study we characterized 6, a prodrug of 1.  In vitro studies showed that 6 is rapidly converted to 1 in plasma and is stable in a buffer soln.  The pharmacokinetics of 6 following a single oral dose indicated that the prodrug was rapidly absorbed and converted to 1 with a tmax of 15 min.  Oral administration of 6 in mice increased the plasma exposure of the active parent compd. 20-fold compared to when 1 was dosed orally. 6 treated mice bearing DU145 xenograft tumors had significantly reduced tumor growth compared to untreated mice.  The favorable druglike properties and safety profile of 6 warrant further studies of 6 for the treatment of castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ-05xP9iOM7Vg90H21EOLACvtfcHk0litD111BciTog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Gqu7g%253D&md5=1ed1bfdda22e882cbcdad28162d9c719</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01814%26sid%3Dliteratum%253Aachs%26aulast%3DEscobar%26aufirst%3DZ.%26aulast%3DBjartell%26aufirst%3DA.%26aulast%3DCanesin%26aufirst%3DG.%26aulast%3DEvans-Axelsson%26aufirst%3DS.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DHellsten%26aufirst%3DR.%26aulast%3DJohansson%26aufirst%3DM.%2BH.%26atitle%3DPreclinical%2520characterization%2520of%25203%25CE%25B2-%2528N-Acetyl%2520l-cysteine%2520methyl%2520ester%2529-2a%25CE%25B2%252C3-dihydrogaliellalactone%2520%2528GPA512%2529%252C%2520a%2520prodrug%2520of%2520a%2520direct%2520STAT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4551%26epage%3D4562%26doi%3D10.1021%2Facs.jmedchem.5b01814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, D.</span></span> <span> </span><span class="NLM_article-title">A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">17471</span>â <span class="NLM_lpage">17486</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA119.009801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.RA119.009801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31594861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKlurnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=17471-17486&author=X.+Shenauthor=L.+Zhaoauthor=P.+Chenauthor=Y.+Gongauthor=D.+Liuauthor=X.+Zhangauthor=L.+Daiauthor=Q.+Sunauthor=J.+Louauthor=Z.+Jinauthor=B.+Zhangauthor=D.+Niuauthor=C.+Chenauthor=X.+Qiauthor=D.+Jia&title=A+thiazole-derived+oridonin+analogue+exhibits+antitumor+activity+by+directly+and+allosterically+inhibiting+STAT3&doi=10.1074%2Fjbc.RA119.009801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3</span></div><div class="casAuthors">Shen, Xiaofei; Zhao, Lin; Che, Peihao; Gong, Yanqiu; Liu, Dingdong; Zhang, Xia; Dai, Lunzhi; Sun, Qingxiang; Lo, Jizhong; Jin, Zhong; Zhang, Baohua; Niu, Dawen; Chen, Ceshi; Qi, Xiangbing; Jia, Da</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">17471-17487</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription 3 (STAT3) occurs in â¼70% of human cancers, and STAT3 is regarded as one of the most promising targets for cancer therapy.  However, specific direct STAT3 inhibitors remain to be developed.  Oridonin is an ent-kaurane plant-derived diterpenoid with anti-cancer and anti-inflammatory activities.  Here, using an array of cell-based and biochem. approaches, including cell proliferation and apoptosis assays, pulldown and reporter gene assays, site-directed mutagenesis, and mol. dynamics analyses, we report that a thiazole-derived oridonin analog, CYD0618, potently and directly inhibits STAT3.  We found that CYD0618 covalently binds to Cys-542 in STAT3 and suppresses its activity through an allosteric effect, effectively reducing STAT3 dimerization and nuclear translocation, as well as decreasing expression of STAT3-targeted oncogenes.  Remarkably, CYD0618 not only strongly inhibited growth of multiple cancer cell lines that harbor constitutive STAT3 activation, but it also suppressed in vivo tumor growth via STAT3 inhibition.  Taken together, our findings suggest Cys-542 as a druggable site for selectively inhibiting STAT3 and indicate that CYD0618 represents a promising lead compd. for developing therapeutic agents against STAT3-driven diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3b-VA4Ju-n7Vg90H21EOLACvtfcHk0lgMWjQOxQNnXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKlurnF&md5=0a0d85ef0cedb9ef3b4dc73449d0bb22</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.009801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.009801%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DLou%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DD.%26atitle%3DA%2520thiazole-derived%2520oridonin%2520analogue%2520exhibits%2520antitumor%2520activity%2520by%2520directly%2520and%2520allosterically%2520inhibiting%2520STAT3%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D17471%26epage%3D17486%26doi%3D10.1074%2Fjbc.RA119.009801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5048</span>â <span class="NLM_lpage">5058</span>, <span class="refDoi">Â DOI: 10.1021/jm400367n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400367n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVeqtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5048-5058&author=C.+Dingauthor=Y.+Zhangauthor=H.+Chenauthor=Z.+Yangauthor=C.+Wildauthor=L.+Chuauthor=H.+Liuauthor=Q.+Shenauthor=J.+Zhou&title=Novel+nitrogen-enriched+oridonin+analogues+with+thiazole-fused+A-ring%3A+protecting+group-free+synthesis%2C+enhanced+anticancer+profile%2C+and+improved+aqueous+solubility&doi=10.1021%2Fjm400367n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nitrogen-Enriched Oridonin Analogues with Thiazole-Fused A-Ring: Protecting Group-Free Synthesis, Enhanced Anticancer Profile, and Improved Aqueous Solubility</span></div><div class="casAuthors">Ding, Chunyong; Zhang, Yusong; Chen, Haijun; Yang, Zhengduo; Wild, Christopher; Chu, Lili; Liu, Huiling; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5048-5058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oridonin (I), a complex ent-kaurane diterpenoid isolated from the traditional Chinese herb Isodon rubescens, has demonstrated great potential in the treatment of various human cancers due to its unique and safe anticancer pharmacol. profile.  Nevertheless, the clin. development of oridonin for cancer therapy has been hampered by its relatively moderate potency, limited aq. soly., and poor bioavailability.  Herein, we report the concise synthesis of a series of novel nitrogen-enriched oridonin derivs. with thiazole-fused A-ring through an efficient protecting group-free synthetic strategy.  Most of them, including compds. II [R = Me; R = NR1R2, R1 = Me, CHMe2, n-Bu, cyclohexyl, 2-(piperidin-1-yl)ethyl, allyl], exhibited potent antiproliferative effects against breast, pancreatic, and prostate cancer cells with low micromolar to submicromolar IC50 values as well as markedly enhanced aq. soly.  These new analogs obtained by rationally modifying the natural product have been shown not only to significantly induce the apoptosis and suppress growth of triple-neg. MDA-MB-231 breast cancer both in vitro and in vivo but are also effective against drug-resistant ER-pos. MCF-7 clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnEskkayfSLVg90H21EOLACvtfcHk0lgMWjQOxQNnXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVeqtL0%253D&md5=b7ec95c47f40492b7aea80159cbbe9bb</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm400367n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400367n%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DNovel%2520nitrogen-enriched%2520oridonin%2520analogues%2520with%2520thiazole-fused%2520A-ring%253A%2520protecting%2520group-free%2520synthesis%252C%2520enhanced%2520anticancer%2520profile%252C%2520and%2520improved%2520aqueous%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5048%26epage%3D5058%26doi%3D10.1021%2Fjm400367n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miklossy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, U. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongwiwatthananukit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Hirsutinolide series inhibit Stat3 activity, alter GCN1, MAP1B, Hsp105, G6PD, vimentin, TrxR1, and importin Î±-2 expression, and induce antitumor effects against human glioma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7734</span>â <span class="NLM_lpage">7748</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCgu7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7734-7748&author=G.+Miklossyauthor=U.+J.+Younauthor=P.+Yueauthor=M.+Zhangauthor=C.+H.+Chenauthor=T.+S.+Hilliardauthor=D.+Paladinoauthor=Y.+Liauthor=J.+Choiauthor=J.+N.+Sarkariaauthor=J.+K.+Kawakamiauthor=S.+Wongwiwatthananukitauthor=Y.+Chenauthor=D.+Sunauthor=L.+C.+Changauthor=J.+Turkson&title=Hirsutinolide+series+inhibit+Stat3+activity%2C+alter+GCN1%2C+MAP1B%2C+Hsp105%2C+G6PD%2C+vimentin%2C+TrxR1%2C+and+importin+%CE%B1-2+expression%2C+and+induce+antitumor+effects+against+human+glioma&doi=10.1021%2Facs.jmedchem.5b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin Î±-2 Expression, and Induce Antitumor Effects against Human Glioma</span></div><div class="casAuthors">Miklossy, Gabriella; Youn, Ui Joung; Yue, Peibin; Zhang, Mingming; Chen, Chih-Hong; Hilliard, Tyvette S.; Paladino, David; Li, Yifei; Choi, Justin; Sarkaria, Jann N.; Kawakami, Joel K.; Wongwiwatthananukit, Supakit; Chen, Yuan; Sun, Dianqing; Chang, Leng Chee; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7734-7748</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report that hirsutinolide series and the semisynthetic analogs inhibit constitutively active signal transducer and activator of transcription (Stat)3 and malignant glioma phenotype.  A position 13 lipophilic ester group is required for activity.  Mol. modeling and NMR structural analyses reveal direct hirsutinolide:Stat3 binding.  One-hour treatment of cells with I and II also upregulated importin subunit Î±-2 levels and repressed translational activator GCN1, microtubule-assocd. protein (MAP)1B, thioredoxin reductase (TrxR)1 cytoplasmic isoform 3, glucose-6-phosphate 1-dehydrogenase isoform a, Hsp105, vimentin, and tumor necrosis factor Î±-induced protein (TNAP)2 expression.  Active hirsutinolides inhibited anchorage-dependent and three-dimensional spheroid growth, survival, and migration of human glioma lines and glioma patients' tumor-derived xenograft cells harboring constitutively active Stat3.  Oral gavage delivery of I or II inhibited human glioma tumor growth in s.c. mouse xenografts.  The inhibition of Stat3 signaling represents part of the hirsutinolide-mediated mechanisms to induce antitumor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-5VLBoRoafbVg90H21EOLACvtfcHk0lgMWjQOxQNnXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCgu7jN&md5=65cfae17ba81a38ca5dd00e0c07265b4</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00686%26sid%3Dliteratum%253Aachs%26aulast%3DMiklossy%26aufirst%3DG.%26aulast%3DYoun%26aufirst%3DU.%2BJ.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DHilliard%26aufirst%3DT.%2BS.%26aulast%3DPaladino%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DSarkaria%26aufirst%3DJ.%2BN.%26aulast%3DKawakami%26aufirst%3DJ.%2BK.%26aulast%3DWongwiwatthananukit%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DL.%2BC.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DHirsutinolide%2520series%2520inhibit%2520Stat3%2520activity%252C%2520alter%2520GCN1%252C%2520MAP1B%252C%2520Hsp105%252C%2520G6PD%252C%2520vimentin%252C%2520TrxR1%252C%2520and%2520importin%2520%25CE%25B1-2%2520expression%252C%2520and%2520induce%2520antitumor%2520effects%2520against%2520human%2520glioma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7734%26epage%3D7748%26doi%3D10.1021%2Facs.jmedchem.5b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaoud, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohassab, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Ravenstein, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, M.</span></span> <span> </span><span class="NLM_article-title">NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111885</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.111885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.111885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31784187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Cmu7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111885&author=T.+S.+Kaoudauthor=A.+M.+Mohassabauthor=H.+A.+Hassanauthor=C.+Yanauthor=S.+X.+Van+Ravensteinauthor=D.+Abdelhamidauthor=K.+N.+Dalbyauthor=M.+Abdel-Aziz&title=NO-releasing+STAT3+inhibitors+suppress+BRAF-mutant+melanoma+growth&doi=10.1016%2Fj.ejmech.2019.111885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth</span></div><div class="casAuthors">Kaoud, Tamer S.; Mohassab, Aliaa M.; Hassan, Heba A.; Yan, Chunli; Van Ravenstein, Sabrina X.; Abdelhamid, Dalia; Dalby, Kevin N.; Abdel-Aziz, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111885</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of substituted nitric oxide (NO)-releasing quinolone-1,2,4-triazole/oxime hybrids I [R = H, 4-chloro, 4-methoxy, 3,4-dimethoxy; R1 = H, methoxy; R2 = allyl, phenyl] hypothesizing that the introduction of a STAT3 binding scaffold would augment their cytotoxicity was studied.  All the hybrids tested showed a comparable level of in-vitro NO prodn. I [R = H, 4-chloro; R1 = H, R2 = allyl] exhibited direct binding to the STAT3-SH domain with IC50 of â¼ 0.5Î¼M.  Also, they abrogated STAT3 tyrosine phosphorylation in several cancer cell lines, including the A375 melanoma cell line that carries the BRAFV600E mutation.  At the same time, they did not affect the phosphorylation of upstream kinases or other STAT isoforms. I [R = 4-chloro; R1 = H, R2 = allyl] inhibited STAT3 nuclear translocation in mouse embryonic fibroblast while I [R = H, 4-chloro; R1 = H, R2 = allyl] inhibited STAT3 DNA-binding activity in the A375 cell line.  Their anti-proliferating activity was attributed to their ability to trigger the prodn. of reactive oxygen species and induce G1 cell cycle arrest in the A375 cell line.  Interestingly, compds. I [R = H, 4-chloro; R1 = H, R2 = allyl] showed robust cell growth suppression and apoptosis induction in two pairs of BRAF inhibitor-naive (-S) and resistant (-R) melanoma cell lines contg. a BRAF V600E mutation.  Surprisingly, MEL1617-R cells that are known to be more resistance to MEK inhibition by GSK1120212 than MEL1617-S cells exhibited a similar response to I [R = H, 4-chloro; R1 = H, R2 = allyl].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXmMSSocCxeLVg90H21EOLACvtfcHk0lja3Qxah8-GFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Cmu7jP&md5=13ac1d510a73228cd349ed100d8c622c</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111885%26sid%3Dliteratum%253Aachs%26aulast%3DKaoud%26aufirst%3DT.%2BS.%26aulast%3DMohassab%26aufirst%3DA.%2BM.%26aulast%3DHassan%26aufirst%3DH.%2BA.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DVan%2BRavenstein%26aufirst%3DS.%2BX.%26aulast%3DAbdelhamid%26aufirst%3DD.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26aulast%3DAbdel-Aziz%26aufirst%3DM.%26atitle%3DNO-releasing%2520STAT3%2520inhibitors%2520suppress%2520BRAF-mutant%2520melanoma%2520growth%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111885%26doi%3D10.1016%2Fj.ejmech.2019.111885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamroskovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doimo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BrÃ¤nnstrÃ¶m, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HedenstrÃ¶m, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nath Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhunzianov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasho, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulis Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourbozorgi, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ãhlund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanrooij, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabouri, N.</span></span> <span> </span><span class="NLM_article-title">Quinazoline ligands induce cancer cell death through selective STAT3 inhibition and G-quadruplex stabilization</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">2876</span>â <span class="NLM_lpage">2888</span>, <span class="refDoi">Â DOI: 10.1021/jacs.9b11232</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b11232" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1OmtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=2876-2888&author=J.+Jamroskovicauthor=M.+Doimoauthor=K.+Chandauthor=I.+Obiauthor=R.+Kumarauthor=K.+Br%C3%A4nnstr%C3%B6mauthor=M.+Hedenstr%C3%B6mauthor=R.+Nath+Dasauthor=A.+Akhunzianovauthor=M.+Deianaauthor=K.+Kashoauthor=S.+Sulis+Satoauthor=P.+L.+Pourbozorgiauthor=J.+E.+Masonauthor=P.+Mediniauthor=D.+%C3%96hlundauthor=S.+Wanrooijauthor=E.+Chorellauthor=N.+Sabouri&title=Quinazoline+ligands+induce+cancer+cell+death+through+selective+STAT3+inhibition+and+G-quadruplex+stabilization&doi=10.1021%2Fjacs.9b11232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization</span></div><div class="casAuthors">Jamroskovic, Jan; Doimo, Mara; Chand, Karam; Obi, Ikenna; Kumar, Rajendra; Braennstroem, Kristoffer; Hedenstroem, Mattias; Nath Das, Rabindra; Akhunzianov, Almaz; Deiana, Marco; Kasho, Kazutoshi; Sulis Sato, Sebastian; Pourbozorgi, Parham L.; Mason, James E.; Medini, Paolo; Oehlund, Daniel; Wanrooij, Sjoerd; Chorell, Erik; Sabouri, Nasim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2876-2888</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 (STAT3) protein is a master regulator of most key hallmarks and enablers of cancer, including cell proliferation and the response to DNA damage.  G-Quadruplex (G4) structures are four-stranded noncanonical DNA structures enriched at telomeres and oncogenes' promoters.  In cancer cells, stabilization of G4 DNAs leads to replication stress and DNA damage accumulation and is therefore considered a promising target for oncotherapy.  Here, we designed and synthesized novel quinazoline-based compds. that simultaneously and selectively affect these two well-recognized cancer targets, G4 DNA structures and the STAT3 protein.  Using a combination of in vitro assays, NMR, and mol. dynamics simulations, we show that these small, uncharged compds. not only bind to the STAT3 protein but also stabilize G4 structures.  In human cultured cells, the compds. inhibit phosphorylation-dependent activation of STAT3 without affecting the antiapoptotic factor STAT1 and cause increased formation of G4 structures, as revealed by the use of a G4 DNA-specific antibody.  As a result, treated cells show slower DNA replication, DNA damage checkpoint activation, and an increased apoptotic rate.  Importantly, cancer cells are more sensitive to these mols. compared to noncancerous cell lines.  This is the first report of a promising class of compds. that not only targets the DNA damage cancer response machinery but also simultaneously inhibits the STAT3-induced cancer cell proliferation, demonstrating a novel approach in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4mlLR-aBn8bVg90H21EOLACvtfcHk0liaqhWfaIBZXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1OmtL8%253D&md5=e6c1da298ac0bf9a0da3268b157d7330</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b11232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b11232%26sid%3Dliteratum%253Aachs%26aulast%3DJamroskovic%26aufirst%3DJ.%26aulast%3DDoimo%26aufirst%3DM.%26aulast%3DChand%26aufirst%3DK.%26aulast%3DObi%26aufirst%3DI.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DBr%25C3%25A4nnstr%25C3%25B6m%26aufirst%3DK.%26aulast%3DHedenstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DNath%2BDas%26aufirst%3DR.%26aulast%3DAkhunzianov%26aufirst%3DA.%26aulast%3DDeiana%26aufirst%3DM.%26aulast%3DKasho%26aufirst%3DK.%26aulast%3DSulis%2BSato%26aufirst%3DS.%26aulast%3DPourbozorgi%26aufirst%3DP.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BE.%26aulast%3DMedini%26aufirst%3DP.%26aulast%3D%25C3%2596hlund%26aufirst%3DD.%26aulast%3DWanrooij%26aufirst%3DS.%26aulast%3DChorell%26aufirst%3DE.%26aulast%3DSabouri%26aufirst%3DN.%26atitle%3DQuinazoline%2520ligands%2520induce%2520cancer%2520cell%2520death%2520through%2520selective%2520STAT3%2520inhibition%2520and%2520G-quadruplex%2520stabilization%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D2876%26epage%3D2888%26doi%3D10.1021%2Fjacs.9b11232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shahani, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukkarila, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Identification of purine-scaffold small-molecule inhibitors of Stat3 activation by QSAR studies</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">79</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1021/ml100224d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100224d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlalurbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=79-84&author=V.+M.+Shahaniauthor=P.+Yueauthor=S.+Haftchenaryauthor=W.+Zhaoauthor=J.+L.+Lukkarilaauthor=X.+Zhangauthor=D.+Ballauthor=C.+Nonaauthor=P.+T.+Gunningauthor=J.+Turkson&title=Identification+of+purine-scaffold+small-molecule+inhibitors+of+Stat3+activation+by+QSAR+studies&doi=10.1021%2Fml100224d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of purine-scaffold small-molecule inhibitors of Stat3 activation by QSAR studies</span></div><div class="casAuthors">Shahani, Vijay M.; Yue, Peibin; Haftchenary, Sina; Zhao, Wei; Lukkarila, Julie L.; Zhang, Xiaolei; Ball, Daniel; Nona, Christina; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-84</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To facilitate the discovery of clin. useful Stat3 inhibitors, computational anal. of the binding to Stat3 of the existing Stat3 dimerization disruptors and quant. structure-activity relationships (QSAR) were pursued, by which a pharmacophore model was derived for predicting optimized Stat3 dimerization inhibitors.  The 2,6,9-trisubstituted-purine scaffold was functionalized in order to access the three subpockets of the Stat3 SH2 domain surface and to derive potent Stat3-binding inhibitors.  Select purine scaffolds showed good affinities (KD, 0.8-12 Î¼M) for purified, nonphosphorylated Stat3 and inhibited Stat3 DNA-binding activity in vitro and intracellular phosphorylation at 20-60 Î¼M.  Furthermore, agents selectively suppressed viability of human prostate, breast and pancreatic cancer cells, and v-Src-transformed mouse fibroblasts that harbor aberrant Stat3 activity.  Studies herein identified novel small-mol. trisubstituted purines as effective inhibitors of constitutively active Stat3 and of the viability of Stat3-dependent tumor cells, and are the first to validate the use of purine bases as templates for building novel Stat3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQYIh7oNE9P7Vg90H21EOLACvtfcHk0liaqhWfaIBZXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlalurbF&md5=45c8fd816a6f3cbe66c871c9657d9c18</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fml100224d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100224d%26sid%3Dliteratum%253Aachs%26aulast%3DShahani%26aufirst%3DV.%2BM.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLukkarila%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNona%26aufirst%3DC.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520purine-scaffold%2520small-molecule%2520inhibitors%2520of%2520Stat3%2520activation%2520by%2520QSAR%2520studies%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D79%26epage%3D84%26doi%3D10.1021%2Fml100224d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muroya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokotagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshita, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Identification of a new series of STAT3 inhibitors by virtual screening</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">371</span>â <span class="NLM_lpage">375</span>, <span class="refDoi">Â DOI: 10.1021/ml1000273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1000273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1yju7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=371-375&author=K.+Matsunoauthor=Y.+Masudaauthor=Y.+Ueharaauthor=H.+Satoauthor=A.+Muroyaauthor=O.+Takahashiauthor=T.+Yokotagawaauthor=T.+Furuyaauthor=T.+Okawaraauthor=M.+Otsukaauthor=N.+Ogoauthor=T.+Ashizawaauthor=C.+Oshitaauthor=S.+Taiauthor=H.+Ishiiauthor=Y.+Akiyamaauthor=A.+Asai&title=Identification+of+a+new+series+of+STAT3+inhibitors+by+virtual+screening&doi=10.1021%2Fml1000273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a New Series of STAT3 Inhibitors by Virtual Screening</span></div><div class="casAuthors">Matsuno, Kenji; Masuda, Yoshiaki; Uehara, Yutaka; Sato, Hiroshi; Muroya, Ayumu; Takahashi, Osamu; Yokotagawa, Takane; Furuya, Toshio; Okawara, Tadashi; Otsuka, Masami; Ogo, Naohisa; Ashizawa, Tadashi; Oshita, Chie; Tai, Sachiko; Ishii, Hidee; Akiyama, Yasuto; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">371-375</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 (STAT3) is considered to be an attractive therapeutic target for oncol. drug development.  We identified a N-[2-(1,3,4-oxadiazolyl)]-4-quinolinecarboxamide deriv., STX-0119 (I), as a novel STAT3 dimerization inhibitor by a virtual screen using a customized version of the DOCK4 program with the crystal structure of STAT3.  In addn., we used in vitro cell-based assays such as the luciferase reporter gene assay and the fluorescence resonance energy transfer-based STAT3 dimerization assay.  STX-0119 selectively abrogated the DNA binding activity of STAT3 and suppressed the expression of STAT3-regulated oncoproteins such as c-myc and survivin in cancer cells.  In contrast, a truncated inactive analog, STX-0872, did not exhibit those activities.  Oral administration of STX-0119 effectively abrogated the growth of human lymphoma cells in a SCC-3 s.c. xenograft model without visible toxicity.  Structure-activity relationships of STX-0119 derivs. were investigated using the docking model of the STAT3-SH2 domain/STX-0119.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcvw7IsnKAqbVg90H21EOLACvtfcHk0liaqhWfaIBZXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1yju7w%253D&md5=c339cf4bd4b2add19deaf4ffc4f481fb</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fml1000273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1000273%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DUehara%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DMuroya%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DO.%26aulast%3DYokotagawa%26aufirst%3DT.%26aulast%3DFuruya%26aufirst%3DT.%26aulast%3DOkawara%26aufirst%3DT.%26aulast%3DOtsuka%26aufirst%3DM.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DOshita%26aufirst%3DC.%26aulast%3DTai%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520new%2520series%2520of%2520STAT3%2520inhibitors%2520by%2520virtual%2520screening%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D371%26epage%3D375%26doi%3D10.1021%2Fml1000273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakasu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span> <span> </span><span class="NLM_article-title">Effect of the STAT3 inhibitor STX-0119 on the proliferation of a Temozolomide-resistant glioblastoma cell line</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">411</span>â <span class="NLM_lpage">418</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2014.2439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3892%2Fijo.2014.2439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24820265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGrtLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=411-418&author=T.+Ashizawaauthor=Y.+Akiyamaauthor=H.+Miyataauthor=A.+Iizukaauthor=M.+Komiyamaauthor=A.+Kumeauthor=M.+Omiyaauthor=T.+Suginoauthor=A.+Asaiauthor=N.+Hayashiauthor=K.+Mitsuyaauthor=Y.+Nakasuauthor=K.+Yamaguchi&title=Effect+of+the+STAT3+inhibitor+STX-0119+on+the+proliferation+of+a+Temozolomide-resistant+glioblastoma+cell+line&doi=10.3892%2Fijo.2014.2439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line</span></div><div class="casAuthors">Ashizawa, Tadashi; Akiyama, Yasuto; Miyata, Haruo; Iizuka, Akira; Komiyama, Masaru; Kume, Akiko; Omiya, Maho; Sugino, Takashi; Asai, Akira; Hayashi, Nakamasa; Mitsuya, Koichi; Nakasu, Yoko; Yamaguchi, Ken</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">411-418</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is one of the most malignant and aggressive tumors and has a very poor prognosis, with a median survival time of less than 2 years.  Once recurrence develops, there are few therapeutic approaches to control the growth of glioblastoma.  In particular, temozolomide (TMZ)-resistant (TMZ-R) GBM is very difficult to treat, and a novel approach to overcome resistance is eagerly awaited.  Previously, we reported a novel small mol. inhibitor of STAT3 dimerization, STX-0119, as a cancer therapeutic.  In the current study, the efficacy of STX-0119 was evaluated against our established TMZ-resistant U87 cell line using quant. PCR-based gene expression anal., in vitro assay and animal expts.  The growth inhibitory effect of STX-0119 on U87 and TMZ-R U87 cells was moderate (IC50, 34 and 45 Î¼M, resp.).  In particular, STX-0119 did not show significant inhibition of U87 tumor growth; however, it suppressed the growth of the TMZ-R U87 tumor in nude mice by more than 50%, and prolonged the median survival time compared to the control group.  Quant. PCR revealed that YKL-40, MAGEC1, MGMT, several EMT genes, mesenchymal genes and STAT3 target genes were upregulated, but most of those genes were downregulated by STX-0119 treatment.  Furthermore, the invasive activity of TMZ-R U87 cells was significantly inhibited by STX-0119.  YKL-40 levels in TMZ-R U87 cells and their supernatants were significantly decreased by STX-0119 administration.  These results suggest that STX-0119 is an efficient therapeutic to overcome TMZ resistance in recurrent GBM tumors, and could be the next promising compd. leading to survival prolongation, and YKL-40 may be a possible surrogate marker for STAT3 targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokm0ePIqBVy7Vg90H21EOLACvtfcHk0linY1mCkynbvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGrtLzN&md5=62906d06dc755bb7298cddeaccad078f</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3892%2Fijo.2014.2439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2014.2439%26sid%3Dliteratum%253Aachs%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DMiyata%26aufirst%3DH.%26aulast%3DIizuka%26aufirst%3DA.%26aulast%3DKomiyama%26aufirst%3DM.%26aulast%3DKume%26aufirst%3DA.%26aulast%3DOmiya%26aufirst%3DM.%26aulast%3DSugino%26aufirst%3DT.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DN.%26aulast%3DMitsuya%26aufirst%3DK.%26aulast%3DNakasu%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DK.%26atitle%3DEffect%2520of%2520the%2520STAT3%2520inhibitor%2520STX-0119%2520on%2520the%2520proliferation%2520of%2520a%2520Temozolomide-resistant%2520glioblastoma%2520cell%2520line%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2014%26volume%3D45%26spage%3D411%26epage%3D418%26doi%3D10.3892%2Fijo.2014.2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakasu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span> <span> </span><span class="NLM_article-title">The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in Temozolomide-resistant glioblastoma cell line</span>. <i>Immunol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">20</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1016/j.imlet.2017.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.imlet.2017.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28716484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wht7bJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2017&pages=20-25&author=Y.+Akiyamaauthor=C.+Nonomuraauthor=T.+Ashizawaauthor=A.+Iizukaauthor=R.+Kondouauthor=H.+Miyataauthor=T.+Suginoauthor=K.+Mitsuyaauthor=N.+Hayashiauthor=Y.+Nakasuauthor=A.+Asaiauthor=M.+Itoauthor=Y.+Kiyoharaauthor=K.+Yamaguchi&title=The+anti-tumor+activity+of+the+STAT3+inhibitor+STX-0119+occurs+via+promotion+of+tumor-infiltrating+lymphocyte+accumulation+in+Temozolomide-resistant+glioblastoma+cell+line&doi=10.1016%2Fj.imlet.2017.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line</span></div><div class="casAuthors">Akiyama, Yasuto; Nonomura, Chizu; Ashizawa, Tadashi; Iizuka, Akira; Kondou, Ryota; Miyata, Haruo; Sugino, Takashi; Mitsuya, Koichi; Hayashi, Nakamasa; Nakasu, Yoko; Asai, Akira; Ito, Mamoru; Kiyohara, Yoshio; Yamaguchi, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-25</span>CODEN:
                <span class="NLM_cas:coden">IMLED6</span>;
        ISSN:<span class="NLM_cas:issn">0165-2478</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">STAT3 is considered to be a key mol. to mediating tumor-induced immunosuppression in various manners at tumor sites, by acting through immune-regulatory cytokines derived from the tumor cells.  Specific anti-STAT3 inhibitors have been developed using nude mouse models transplanted with human tumor cells.  However, mouse systems cannot accurately represent the human immune response induced by STAT3 inhibitors, and more humanized therapeutic model based on human immune cells and tumors are needed.  In the present study, an immune-deficient NOG mouse with the deletion of both MHC-class I and class II genes, an MHC-double knockout mouse (dKO-NOG), was developed and used to establish humanized immunotherapeutic model.  We investigated the immunol. effect of the STAT3 inhibitor STX-0119 against TMZ-resistant (TMZ-R) U87 glioma tumors by using humanized dKO-NOG mice.  We compared the anti-tumor effects of STX-0119 between the nude and humanized dKO-NOG mouse models.  An in vivo study using the nude mouse model showed that STX-0119 inhibited the growth of TMZR U87 tumors, but accumulation of tumor-infiltrating lymphocytes (TILs) were not promoted compared with the control levels.  In contrast, STX-0119 inhibited tumor growth more rapidly and strongly in humanized dKO-NOG mice than in nude mice, and a large amt. of TILs, mainly consisting of CD8+ T cells and macrophages, were found in the tumors.  These results suggest that STX-0119 has anti-tumor activity occurring through the promotion of TIL accumulation at the tumor site and that humanized dKO-NOG mouse system may be a powerful tool to evaluate the effects of STAT3 inhibitors on human systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFZxq830q_7LVg90H21EOLACvtfcHk0linY1mCkynbvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wht7bJ&md5=76893f69cb0b4fea2b2a9d37712e75f6</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.imlet.2017.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.imlet.2017.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DNonomura%26aufirst%3DC.%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DIizuka%26aufirst%3DA.%26aulast%3DKondou%26aufirst%3DR.%26aulast%3DMiyata%26aufirst%3DH.%26aulast%3DSugino%26aufirst%3DT.%26aulast%3DMitsuya%26aufirst%3DK.%26aulast%3DHayashi%26aufirst%3DN.%26aulast%3DNakasu%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DKiyohara%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DK.%26atitle%3DThe%2520anti-tumor%2520activity%2520of%2520the%2520STAT3%2520inhibitor%2520STX-0119%2520occurs%2520via%2520promotion%2520of%2520tumor-infiltrating%2520lymphocyte%2520accumulation%2520in%2520Temozolomide-resistant%2520glioblastoma%2520cell%2520line%26jtitle%3DImmunol.%2520Lett.%26date%3D2017%26volume%3D190%26spage%3D20%26epage%3D25%26doi%3D10.1016%2Fj.imlet.2017.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshita, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakasu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">219</span>â <span class="NLM_lpage">227</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2013.1916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3892%2Fijo.2013.1916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23612755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOltLnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=219-227&author=T.+Ashizawaauthor=H.+Miyataauthor=A.+Iizukaauthor=M.+Komiyamaauthor=C.+Oshitaauthor=A.+Kumeauthor=M.+Nogamiauthor=M.+Yagotoauthor=I.+Itoauthor=T.+Oishiauthor=R.+Watanabeauthor=K.+Mitsuyaauthor=K.+Matsunoauthor=T.+Furuyaauthor=T.+Okawaraauthor=M.+Otsukaauthor=N.+Ogoauthor=A.+Asaiauthor=Y.+Nakasuauthor=K.+Yamaguchiauthor=Y.+Akiyama&title=Effect+of+the+STAT3+inhibitor+STX-0119+on+the+proliferation+of+cancer+stem-like+cells+derived+from+recurrent+glioblastoma&doi=10.3892%2Fijo.2013.1916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma</span></div><div class="casAuthors">Ashizawa, Tadashi; Miyata, Haruo; Ilzuka, Akira; Komiyama, Masaru; Oshita, Chie; Kume, Akiko; Nogami, Masahiro; Yagoto, Mika; Ito, Ichiro; Oishi, Takuma; Watanabe, Reiko; Mitsuya, Koichi; Matsuno, Kenji; Furuya, Toshio; Okawara, Tadashi; Otsuka, Masami; Ogo, Naohisa; Asai, Akira; Nakasu, Yoko; Yamaguchi, Ken; Akiyama, Yasuto</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-227</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription (STAT) 3, a member of a family of DNA-binding mols., is a potential target in the treatment of cancer.  The highly phosphorylated STAT3 in cancer cells contributes to numerous physiol. and oncogenic signaling pathways.  Furthermore, a significant assocn. between STAT3 signaling and glioblastoma multiforme stem-like cell (GBM-SC) development and maintenance has been demonstrated in recent studies.  Previously, we reported a novel small mol. inhibitor of STAT3 dimerization, STX-0119, as a cancer therapeutic.  In the present study, we focused on cancer stem-like cells derived from recurrent GBM patients and investigated the efficacy of STX-0119.  Three GBM stem cell lines showed many stem cell markers such as CD133, EGFR, Nanog, Olig2, nestin and Yamanaka factors (c-myc, KLF4, Oct3/4 and SOX2) compared with parental cell lines.  These cell lines also formed tumors in vivo and had similar histol. to surgically resected tumors.  STAT3 phosphorylation was activated more in the GBM-SC lines than serum-derived GB cell lines.  The growth inhibitory effect of STX-0119 on GBM-SCs was moderate (IC50 15-44 Î¼M) and stronger compared to that of WP1066 in two cell lines.  On the other hand, the effect of temozolomide was weak in all the cell lines (IC50 53-226 Î¼M).  Notably, STX-0119 demonstrated strong inhibition of the expression of STAT3 target genes (c-myc, survivin, cyclin D1, HIF-1Î± and VEGF) and stem cell-assocd. genes (CD44, Nanog, nestin and CD133) as well as the induction of apoptosis in one stem-like cell line.  Interestingly, VEGFR2 mRNA was also remarkably inhibited by STX-0119.  In a model using transplantable stem-like cell lines in vivo GB-SCC010 and 026, STX-0119 inhibited the growth of GBM-SCs at 80 mg/kg.  STX-0119, an inhibitor of STAT3, may serve as a novel therapeutic compd. against GBM-SCs even in temozolomide-resistant GBM patients and has the potential for GBM-SC-specific therapeutics in combination with temozolomide plus radiation therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTi3UcmHgW7LVg90H21EOLACvtfcHk0lifvSMcmFuz-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOltLnN&md5=2cc077e2a1e30f1af9d1f2342e852663</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.3892%2Fijo.2013.1916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2013.1916%26sid%3Dliteratum%253Aachs%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DMiyata%26aufirst%3DH.%26aulast%3DIizuka%26aufirst%3DA.%26aulast%3DKomiyama%26aufirst%3DM.%26aulast%3DOshita%26aufirst%3DC.%26aulast%3DKume%26aufirst%3DA.%26aulast%3DNogami%26aufirst%3DM.%26aulast%3DYagoto%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DI.%26aulast%3DOishi%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DR.%26aulast%3DMitsuya%26aufirst%3DK.%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DFuruya%26aufirst%3DT.%26aulast%3DOkawara%26aufirst%3DT.%26aulast%3DOtsuka%26aufirst%3DM.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DNakasu%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DAkiyama%26aufirst%3DY.%26atitle%3DEffect%2520of%2520the%2520STAT3%2520inhibitor%2520STX-0119%2520on%2520the%2520proliferation%2520of%2520cancer%2520stem-like%2520cells%2520derived%2520from%2520recurrent%2520glioblastoma%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2013%26volume%3D43%26spage%3D219%26epage%3D227%26doi%3D10.3892%2Fijo.2013.1916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishisaka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsugane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asakawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1774</span>â <span class="NLM_lpage">1784</span>, <span class="refDoi">Â DOI: 10.1111/cas.14369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1111%2Fcas.14369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32112605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVeisL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2020&pages=1774-1784&author=F.+Nishisakaauthor=K.+Taniguchiauthor=M.+Tsuganeauthor=G.+Hirataauthor=A.+Takagiauthor=N.+Asakawaauthor=A.+Kuritaauthor=H.+Takahashiauthor=N.+Ogoauthor=Y.+Shishidoauthor=A.+Asai&title=Antitumor+activity+of+a+novel+oral+signal+transducer+and+activator+of+transcription+3+inhibitor+YHO-1701&doi=10.1111%2Fcas.14369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701</span></div><div class="casAuthors">Nishisaka, Fukiko; Taniguchi, Keisuke; Tsugane, Momomi; Hirata, Genya; Takagi, Akimitsu; Asakawa, Naoyuki; Kurita, Akinobu; Takahashi, Hiroyuki; Ogo, Naohisa; Shishido, Yoshiyuki; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1774-1784</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 (STAT3) signaling pathway is a key mediator of cancer cell proliferation, survival and invasion.  Aberrant STAT3 has been demonstrated in various malignant cancers.  YHO-1701 is a novel quinolinecarboxamide deriv. generated from STX-0119.  Here, we examd. the effect of YHO-1701 on STAT3 and evaluated antitumor activity of YHO-1701 as a single agent and in combination.  YHO-1701 inhibited STAT3-SH2 binding to phospho-Tyr peptide selectively and more potently than STX-0119 in biochem. assays.  Mol. docking studies with STAT3 suggested more stable interaction of YHO-1701 with the SH2 domain.  YHO-1701 exhibited approx. 10-fold stronger activity than STX-0119 in abrogating the STAT3 signaling pathway of human oral cancer cell line SAS.  Moreover, combination regimen with sorafenib led to significantly stronger antitumor activity.  In addn., the suppression level of survivin (a downstream target) was superior for the combination as compared with monotherapy groups within tumor tissues.  Thus, YHO-1701 had a favorable specificity for STAT3 and pharmacokinetics after oral treatment; it also contributed to the enhanced antitumor activity of sorafenib.  The evidence presented here provides justification using for this approach in future clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Z3CbJV1GOLVg90H21EOLACvtfcHk0lifvSMcmFuz-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVeisL0%253D&md5=fe4a7874ae44d959cff8879387633c8a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1111%2Fcas.14369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.14369%26sid%3Dliteratum%253Aachs%26aulast%3DNishisaka%26aufirst%3DF.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DTsugane%26aufirst%3DM.%26aulast%3DHirata%26aufirst%3DG.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DAsakawa%26aufirst%3DN.%26aulast%3DKurita%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DShishido%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520a%2520novel%2520oral%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520inhibitor%2520YHO-1701%26jtitle%3DCancer%2520Sci.%26date%3D2020%26volume%3D111%26spage%3D1774%26epage%3D1784%26doi%3D10.1111%2Fcas.14369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsugane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishisaka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6685</span>, <span class="refDoi">Â DOI: 10.1038/s41598-021-86021-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41598-021-86021-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33758275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnsVShu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2021&pages=6685&author=K.+Taniguchiauthor=H.+Konishiauthor=A.+Yoshinagaauthor=M.+Tsuganeauthor=H.+Takahashiauthor=F.+Nishisakaauthor=Y.+Shishidoauthor=A.+Asai&title=Efficacy+of+combination+treatment+using+YHO-1701%2C+an+orally+active+STAT3+inhibitor%2C+with+molecular-targeted+agents+on+cancer+cell+lines&doi=10.1038%2Fs41598-021-86021-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines</span></div><div class="casAuthors">Taniguchi, Keisuke; Konishi, Hiroaki; Yoshinaga, Akiko; Tsugane, Momomi; Takahashi, Hiroyuki; Nishisaka, Fukiko; Shishido, Yoshiyuki; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6685</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) plays a crit. role in regulating cell growth, survival, and metastasis.  STAT3 signaling is constitutively activated in various types of hematol. or solid malignancies.  YHO-1701 has been developed as an orally available STAT3 inhibitor.  Herein, YHO-1701 in combination with mol.-targeted agents was evaluated.  Additive or synergistic effects were obsd. in a broad spectrum of "combination treatment + cell line" pairs.  Of particular interest was the synergistic effect obsd. when YHO-1701 was combined with imatinib or dasatinib [breakpoint cluster region-abelson (BCR-ABL) inhibitors], osimertinib [epidermal growth factor receptor (EGFR) inhibitor], crizotinib, alectinib, or ceritinib [anaplastic lymphoma kinase (ALK) inhibitors].  The results further showed a close relationship between these synergistic effects and the cellular levels of the key mols. involved in the target pathways for YHO-1701 and each combination drug.  The combination of YHO-1701 with alectinib resulted in significantly greater antitumor activity without exhibiting body wt. loss in an NCI-H2228 [echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion] xenograft mouse model.  Our results strongly suggest that the logical strategy in combination with the novel STAT3 inhibitor YHO-1701 and other mechanistically different targeted agents, could be a promising approach in future clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW_V8XTO7uIbVg90H21EOLACvtfcHk0lifvSMcmFuz-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnsVShu7o%253D&md5=99060b6e66cf0a536e67701bccc2a4ef</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1038%2Fs41598-021-86021-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-021-86021-8%26sid%3Dliteratum%253Aachs%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DKonishi%26aufirst%3DH.%26aulast%3DYoshinaga%26aufirst%3DA.%26aulast%3DTsugane%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DNishisaka%26aufirst%3DF.%26aulast%3DShishido%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DEfficacy%2520of%2520combination%2520treatment%2520using%2520YHO-1701%252C%2520an%2520orally%2520active%2520STAT3%2520inhibitor%252C%2520with%2520molecular-targeted%2520agents%2520on%2520cancer%2520cell%2520lines%26jtitle%3DSci.%2520Rep.%26date%3D2021%26volume%3D11%26spage%3D6685%26doi%3D10.1038%2Fs41598-021-86021-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MarchianÃ², S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimoldi, I.</span></span> <span> </span><span class="NLM_article-title">An in vivo active 1,2,5-oxadiazole Pt(II) complex: a promising anticancer agent endowed with STAT3 inhibitory properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">196</span>â <span class="NLM_lpage">206</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2017.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28324784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVKrsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=196-206&author=F.+Portaauthor=G.+Facchettiauthor=N.+Ferriauthor=A.+Gelainauthor=F.+Meneghettiauthor=S.+Villaauthor=D.+Barloccoauthor=D.+Masciocchiauthor=A.+Asaiauthor=N.+Miyoshiauthor=S.+Marchian%C3%B2author=B.+M.+Kwonauthor=Y.+Jinauthor=V.+Gandinauthor=C.+Marzanoauthor=I.+Rimoldi&title=An+in+vivo+active+1%2C2%2C5-oxadiazole+Pt%28II%29+complex%3A+a+promising+anticancer+agent+endowed+with+STAT3+inhibitory+properties&doi=10.1016%2Fj.ejmech.2017.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties</span></div><div class="casAuthors">Porta, Federica; Facchetti, Giorgio; Ferri, Nicola; Gelain, Arianna; Meneghetti, Fiorella; Villa, Stefania; Barlocco, Daniela; Masciocchi, Daniela; Asai, Akira; Miyoshi, Nao; Marchiano, Silvia; Kwon, Byoung-Mog; Jin, Yena; Gandin, Valentina; Marzano, Cristina; Rimoldi, Isabella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196-206</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">New Pt(II) complexes (Pt-1-3) bearing 1,2,5-oxadiazole ligands (1-3) were synthesized, characterized and evaluated for their ability to disrupt STAT3 dimerization.  Ligand 3Â·HCl showed cytotoxic effects on HCT-116 cells (IC50 = 95.2 Î¼M) and a selective ability to interact with STAT3 (IC50 = 8.2 Î¼M) vs. STAT1 (IC50 > 30 Î¼M).  Its corresponding platinum complex Pt-3 exhibited an increased cytotoxicity (IC50 = 18.4 Î¼M) and a stronger interaction with STAT3 (IC50 = 1.4 Î¼M), leading to inhibition of its signaling pathway.  Pt-3 was also evaluated in cell-based assays for its action on p53 expression and on STAT3 phosphorylation.  In syngeneic murine Lewis lung carcinoma (LLC) implanted in C57BL/6 mice, Pt-3 showed a higher antitumor activity with fewer side effects than cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqivlmoUtNye7Vg90H21EOLACvtfcHk0lhQqM1xFnsDeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVKrsrg%253D&md5=3069d1f9605d1b0bb046e74b1e1cf1e8</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DFacchetti%26aufirst%3DG.%26aulast%3DFerri%26aufirst%3DN.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DMiyoshi%26aufirst%3DN.%26aulast%3DMarchian%25C3%25B2%26aufirst%3DS.%26aulast%3DKwon%26aufirst%3DB.%2BM.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DRimoldi%26aufirst%3DI.%26atitle%3DAn%2520in%2520vivo%2520active%25201%252C2%252C5-oxadiazole%2520Pt%2528II%2529%2520complex%253A%2520a%2520promising%2520anticancer%2520agent%2520endowed%2520with%2520STAT3%2520inhibitory%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D131%26spage%3D196%26epage%3D206%26doi%3D10.1016%2Fj.ejmech.2017.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hejazi, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahabuddin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athar, F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic evaluation, molecular docking and in vitro biological evaluation of 1, 3, 4-oxadiazole derivatives as potent antioxidants and STAT3 inhibitors</span>. <i>J. Pharm. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">133</span>â <span class="NLM_lpage">141</span>, <span class="refDoi">Â DOI: 10.1016/j.jpha.2018.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.jpha.2018.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31011470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FotVOisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=133-141&author=R.+Khanamauthor=I.+I.+Hejaziauthor=S.+Shahabuddinauthor=A.+R.+Bhatauthor=F.+Athar&title=Pharmacokinetic+evaluation%2C+molecular+docking+and+in+vitro+biological+evaluation+of+1%2C+3%2C+4-oxadiazole+derivatives+as+potent+antioxidants+and+STAT3+inhibitors&doi=10.1016%2Fj.jpha.2018.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic evaluation, molecular docking and in vitro biological evaluation of 1, 3, 4-oxadiazole derivatives as potent antioxidants and STAT3 inhibitors</span></div><div class="casAuthors">Khanam Rashmin; Hejazi Iram I; Athar Fareeda; Shahabuddin Syed; Bhat Abdul R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmaceutical analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-141</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">1, 3, 4-Oxadiazole derivatives (4a-5f) were previously synthesized to investigate their anticancer properties.  However, studies relating to their antioxidant potential and signal transducer and activator of transcription (STAT) inhibition have not been performed.  We investigated previously synthesized 1, 3, 4-oxadiazole derivatives (4a-5f) for various radical scavenging properties using several in vitro antioxidant assays and also for direct inhibition of STAT3 through molecular docking.  The data obtained from various antioxidant assays such as 2, 2,-diphenyl-1-picrylhydrazyl radical (DPPH), nitric oxide, hydrogen peroxide, and superoxide anion radical revealed that among all the derivatives, compound 5e displayed high antioxidant activities than the standard antioxidant L-ascorbic acid.  Additionally, the total reduction assay and antioxidant capacity assay further confirmed the antioxidant potential of compound 5e.  Furthermore, the molecular docking studies performed for all derivatives along with the standard inhibitor STX-0119 showed that binding energy released in direct binding with the SH2 domain of STAT3 was the highest for compound 5e (-9.91kcal/mol).  Through virtual screening, compound 5e was found to exhibit optimum competency in inhibiting STAT3 activity.  Compound 5e decreased the activation of STAT3 as observed with Western blot.  In brief, compound 5e was identified as a potent antioxidant agent and STAT3 inhibitor and effective agent for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwHAkIZy4YwrP3FVUi_gf8fW6udTcc2ebSYXCQgan11rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FotVOisA%253D%253D&md5=80d3d22095c5c7510482d9131ee5a95f</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.jpha.2018.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpha.2018.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DKhanam%26aufirst%3DR.%26aulast%3DHejazi%26aufirst%3DI.%2BI.%26aulast%3DShahabuddin%26aufirst%3DS.%26aulast%3DBhat%26aufirst%3DA.%2BR.%26aulast%3DAthar%26aufirst%3DF.%26atitle%3DPharmacokinetic%2520evaluation%252C%2520molecular%2520docking%2520and%2520in%2520vitro%2520biological%2520evaluation%2520of%25201%252C%25203%252C%25204-oxadiazole%2520derivatives%2520as%2520potent%2520antioxidants%2520and%2520STAT3%2520inhibitors%26jtitle%3DJ.%2520Pharm.%2520Anal.%26date%3D2019%26volume%3D9%26spage%3D133%26epage%3D141%26doi%3D10.1016%2Fj.jpha.2018.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadhe, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pae, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S. K.</span></span> <span> </span><span class="NLM_article-title">Development of oxadiazole-based ODZ10117 as a small-molecule inhibitor of STAT3 for targeted cancer therapy</span>. <i>J. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1847</span>, <span class="refDoi">Â DOI: 10.3390/jcm8111847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fjcm8111847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvVSmtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1847&author=B.+H.+Kimauthor=H.+Leeauthor=Y.+Songauthor=J.+S.+Parkauthor=C.+G.+Gadheauthor=J.+Choiauthor=C.+G.+Leeauthor=A.+N.+Paeauthor=S.+Kimauthor=S.+K.+Ye&title=Development+of+oxadiazole-based+ODZ10117+as+a+small-molecule+inhibitor+of+STAT3+for+targeted+cancer+therapy&doi=10.3390%2Fjcm8111847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Development of oxadiazole-based ODZ10117 as a small-molecule inhibitor of STAT3 for targeted cancer therapy</span></div><div class="casAuthors">Kim, Byung-Hak; Lee, Haeri; Song, Yeonghun; Park, Joon-Suk; Gadhe, Changdev G.; Choi, Jiwon; Lee, Chung-Gi; Pae, Ae Nim; Kim, Sanghee; Ye, Sang-Kyu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1847</span>CODEN:
                <span class="NLM_cas:coden">JCMOHK</span>;
        ISSN:<span class="NLM_cas:issn">2077-0383</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Persistently activated STAT3 is a promising target for a new class of anticancer drug development and cancer therapy, as it is assocd. with tumor initiation, progression, malignancy, drug resistance, cancer stem cell properties, and recurrence.  Here, we discovered 3-(2,4-dichloro-phenoxymethyl)-5-trichloromethyl-[1,2,4]oxadiazole (ODZ10117) as a small-mol. inhibitor of STAT3 to be used in STAT3-targeted cancer therapy.  ODZ10117 targeted the SH2 domain of STAT3 regardless of other STAT family proteins and upstream regulators of STAT3, leading to inhibition of the tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity of STAT3.  The inhibitory effect of ODZ10117 on STAT3 was stronger than the known STAT3 inhibitors such as S3I-201, STA-21, and nifuroxazide.  ODZ10117 suppressed the migration and invasion, induced apoptosis, reduced tumor growth and lung metastasis, and extended the survival rate in both in vitro and in vivo models of breast cancer.  Overall, we demonstrated that ODZ10117 is a novel STAT3 inhibitor and may be a promising agent for the development of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyBAg7cTwH7Vg90H21EOLACvtfcHk0lhQqM1xFnsDeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvVSmtbo%253D&md5=b2f33311762217f8b4a24acbfb3c4e85</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.3390%2Fjcm8111847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcm8111847%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DGadhe%26aufirst%3DC.%2BG.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DS.%2BK.%26atitle%3DDevelopment%2520of%2520oxadiazole-based%2520ODZ10117%2520as%2520a%2520small-molecule%2520inhibitor%2520of%2520STAT3%2520for%2520targeted%2520cancer%2520therapy%26jtitle%3DJ.%2520Clin.%2520Med.%26date%3D2019%26volume%3D8%26spage%3D1847%26doi%3D10.3390%2Fjcm8111847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paek, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S. K.</span></span> <span> </span><span class="NLM_article-title">STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">722</span>, <span class="refDoi">Â DOI: 10.3390/cells9030722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fcells9030722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVSqt7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=722&author=B.+H.+Kimauthor=H.+Leeauthor=C.+G.+Parkauthor=A.+J.+Jeongauthor=S.+H.+Leeauthor=K.+H.+Nohauthor=J.+B.+Parkauthor=C.+G.+Leeauthor=S.+H.+Paekauthor=H.+Kimauthor=S.+K.+Ye&title=STAT3+inhibitor+ODZ10117+suppresses+glioblastoma+malignancy+and+prolongs+survival+in+a+glioblastoma+xenograft+model&doi=10.3390%2Fcells9030722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model</span></div><div class="casAuthors">Kim, Byung-Hak; Lee, Haeri; Park, Cheol Gyu; Jeong, Ae Jin; Lee, Song-Hee; Noh, Kum Hee; Park, Jong Bae; Lee, Chung-Gi; Paek, Sun Ha; Kim, Hyunggee; Ye, Sang-Kyu</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">722</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Constitutively activated STAT3 plays an essential role in the initiation, progression, maintenance, malignancy, and drug resistance of cancer, including glioblastoma, suggesting that STAT3 is a potential therapeutic target for cancer therapy.  We recently identified ODZ10117 as a small mol. inhibitor of STAT3 and suggested that it may have an effective therapeutic utility for the STAT3-targeted cancer therapy.  Here, we demonstrated the therapeutic efficacy of ODZ10117 in glioblastoma by targeting STAT3.  ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells and patient-derived primary glioblastoma cells.  In addn., ODZ10117 suppressed stem cell properties in glioma stem cells (GSCs).  Finally, the administration of ODZ10117 showed significant therapeutic efficacy in mouse xenograft models of GSCs and glioblastoma cells.  Collectively, ODZ10117 is a promising therapeutic candidate for glioblastoma by targeting STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkptjqpse0s7Vg90H21EOLACvtfcHk0ljHhFrEJDESHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVSqt7zM&md5=4fb235c58a3be0eb7a695a6f8e04590a</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.3390%2Fcells9030722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9030722%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DC.%2BG.%26aulast%3DJeong%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DNoh%26aufirst%3DK.%2BH.%26aulast%3DPark%26aufirst%3DJ.%2BB.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DPaek%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DS.%2BK.%26atitle%3DSTAT3%2520inhibitor%2520ODZ10117%2520suppresses%2520glioblastoma%2520malignancy%2520and%2520prolongs%2520survival%2520in%2520a%2520glioblastoma%2520xenograft%2520model%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D722%26doi%3D10.3390%2Fcells9030722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pallandre, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boibessot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yesylevskyy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramseyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pudlo, M.</span></span> <span> </span><span class="NLM_article-title">Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.08.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2015.08.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26352675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOnu7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2015&pages=163-174&author=J.+R.+Pallandreauthor=C.+Borgauthor=D.+Rognanauthor=T.+Boibessotauthor=V.+Luzetauthor=S.+Yesylevskyyauthor=C.+Ramseyerauthor=M.+Pudlo&title=Novel+aminotetrazole+derivatives+as+selective+STAT3+non-peptide+inhibitors&doi=10.1016%2Fj.ejmech.2015.08.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors</span></div><div class="casAuthors">Pallandre, Jean-Rene; Borg, Christophe; Rognan, Didier; Boibessot, Thibault; Luzet, Vincent; Yesylevskyy, Semen; Ramseyer, Christophe; Pudlo, Marc</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-174</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The development of inhibitors blocking STAT3 transcriptional activity is a promising therapeutic approach against cancer and inflammatory diseases.  In this context, the selectivity of inhibitors against the STAT1 transcription factor is crucial as STAT3 and STAT1 play opposite roles in the apoptosis of tumor cells and polarization of the immune response.  A structure-based virtual screening followed by a luciferase-contg. promoter assay on STAT3 and STAT1 signaling were used to identify a selective STAT3 inhibitor.  An important role of the aminotetrazole group in modulating STAT3 and STAT1 inhibitory activities has been established.  Optimization of the hit compd. leads to 23.  This compd. inhibits growth and survival of cells with STAT3 signaling pathway while displaying a minimal effect on STAT1 signaling.  Moreover, it prevents lymphocyte T polarization into Th17 and Treg without affecting their differentiation into Th1 lymphocyte.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQOnVFWhVhLVg90H21EOLACvtfcHk0ljQh0OGNW9fqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOnu7vE&md5=a729d83ffc41a893681f2faddcfa8ece</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.08.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.08.054%26sid%3Dliteratum%253Aachs%26aulast%3DPallandre%26aufirst%3DJ.%2BR.%26aulast%3DBorg%26aufirst%3DC.%26aulast%3DRognan%26aufirst%3DD.%26aulast%3DBoibessot%26aufirst%3DT.%26aulast%3DLuzet%26aufirst%3DV.%26aulast%3DYesylevskyy%26aufirst%3DS.%26aulast%3DRamseyer%26aufirst%3DC.%26aulast%3DPudlo%26aufirst%3DM.%26atitle%3DNovel%2520aminotetrazole%2520derivatives%2520as%2520selective%2520STAT3%2520non-peptide%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D103%26spage%3D163%26epage%3D174%26doi%3D10.1016%2Fj.ejmech.2015.08.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaPorte, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peshkov, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurdak, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarco, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span> <span> </span><span class="NLM_article-title">Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3581</span>â <span class="NLM_lpage">3585</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmcl.2016.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27381083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Wnu7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3581-3585&author=M.+G.+LaPorteauthor=Z.+Wangauthor=R.+Colomboauthor=A.+Garzanauthor=V.+A.+Peshkovauthor=M.+Liangauthor=P.+A.+Johnstonauthor=M.+E.+Schurdakauthor=M.+Senauthor=D.+P.+Camarcoauthor=Y.+Huaauthor=N.+I.+Pollockauthor=J.+S.+Lazoauthor=J.+R.+Grandisauthor=P.+Wipfauthor=D.+M.+Huryn&title=Optimization+of+pyrazole-containing+1%2C2%2C4-triazolo-%5B3%2C4-b%5Dthiadiazines%2C+a+new+class+of+STAT3+pathway+inhibitors&doi=10.1016%2Fj.bmcl.2016.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors</span></div><div class="casAuthors">LaPorte, Matthew G.; Wang, Zhuzhu; Colombo, Raffaele; Garzan, Atefeh; Peshkov, Vsevolod A.; Liang, Mary; Johnston, Paul A.; Schurdak, Mark E.; Sen, Malabika; Camarco, Daniel P.; Hua, Yun; Pollock, Netanya I.; Lazo, John S.; Grandis, Jennifer R.; Wipf, Peter; Huryn, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3581-3585</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Structure-activity relationship studies of a 1,2,4-triazolo-[3,4-b]thiadiazine scaffold, identified in an HTS campaign for selective STAT3 pathway inhibitors, detd. that a pyrazole group and specific aryl substitution on the thiadiazine were necessary for activity.  Improvements in potency and metabolic stability were accomplished by the introduction of an Î±-Me group on the thiadiazine.  Optimized compds. exhibited anti-proliferative activity, redn. of phosphorylated STAT3 levels and effects on STAT3 target genes.  These compds. represent a starting point for further drug discovery efforts targeting the STAT3 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA9KD6JSgxObVg90H21EOLACvtfcHk0ljX3F1izlSgzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Wnu7nE&md5=844fb866fbb0524644d7eccd03656df3</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaPorte%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DGarzan%26aufirst%3DA.%26aulast%3DPeshkov%26aufirst%3DV.%2BA.%26aulast%3DLiang%26aufirst%3DM.%26aulast%3DJohnston%26aufirst%3DP.%2BA.%26aulast%3DSchurdak%26aufirst%3DM.%2BE.%26aulast%3DSen%26aufirst%3DM.%26aulast%3DCamarco%26aufirst%3DD.%2BP.%26aulast%3DHua%26aufirst%3DY.%26aulast%3DPollock%26aufirst%3DN.%2BI.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26atitle%3DOptimization%2520of%2520pyrazole-containing%25201%252C2%252C4-triazolo-%255B3%252C4-b%255Dthiadiazines%252C%2520a%2520new%2520class%2520of%2520STAT3%2520pathway%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3581%26epage%3D3585%26doi%3D10.1016%2Fj.bmcl.2016.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span> <span> </span><span class="NLM_article-title">An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-ÎºB</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>396</i></span>,  <span class="NLM_fpage">76</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2017.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.canlet.2017.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28323031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslOnsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=396&publication_year=2017&pages=76-84&author=T.+S.+Kangauthor=W.+Wangauthor=H.+J.+Zhongauthor=Z.+Z.+Dongauthor=Q.+Huangauthor=S.+W.+Mokauthor=C.+H.+Leungauthor=V.+K.+Wongauthor=D.+L.+Ma&title=An+anti-prostate+cancer+benzofuran-conjugated+iridium%28III%29+complex+as+a+dual+inhibitor+of+STAT3+and+NF-%CE%BAB&doi=10.1016%2Fj.canlet.2017.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-ÎºB</span></div><div class="casAuthors">Kang, Tian-Shu; Wang, Wanhe; Zhong, Hai-Jing; Dong, Zhen-Zhen; Huang, Qi; Mok, Simon Wing Fai; Leung, Chung-Hang; Wong, Vincent Kam Wai; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">396</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-84</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Four benzofuran-conjugated iridium(III) or rhodium (III)-based metal complexes are synthesized to screen as an inhibitor of STAT3 activity in prostate cancer cells.  All complexes show the high stability and soly. in the biol. system.  In this study, an iridium(III) complex engages STAT3 and NF-ÎºB to inhibit their translocation and transcriptional activities.  Moreover, complex 1 shows more potential antiproliferative activity against DU145 cells and suppresses tumor growth in a prostate cancer xenograft mouse without observable adverse effects.  Complex 1 may provide the basis for developing new therapeutic strategy in vivo and in vitro for the treatment of advanced prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGS7qZTHhEVrVg90H21EOLACvtfcHk0ljX3F1izlSgzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslOnsrk%253D&md5=d410face71ded9bdd70b16ad00eb8b11</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DT.%2BS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DH.%2BJ.%26aulast%3DDong%26aufirst%3DZ.%2BZ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMok%26aufirst%3DS.%2BW.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DWong%26aufirst%3DV.%2BK.%26aulast%3DMa%26aufirst%3DD.%2BL.%26atitle%3DAn%2520anti-prostate%2520cancer%2520benzofuran-conjugated%2520iridium%2528III%2529%2520complex%2520as%2520a%2520dual%2520inhibitor%2520of%2520STAT3%2520and%2520NF-%25CE%25BAB%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D396%26spage%3D76%26epage%3D84%26doi%3D10.1016%2Fj.canlet.2017.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, P.</span></span> <span> </span><span class="NLM_article-title">Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115822</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2020.115822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmc.2020.115822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33126089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit12hurbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115822&author=F.+Wangauthor=K.-R.+Fengauthor=J.-Y.+Zhaoauthor=J.-W.+Zhangauthor=X.-W.+Shiauthor=J.+Zhouauthor=D.+Gaoauthor=G.-Q.+Linauthor=P.+Tian&title=Identification+of+novel+STAT3+inhibitors+bearing+2-acetyl-7-phenylamino+benzofuran+scaffold+for+antitumour+study&doi=10.1016%2Fj.bmc.2020.115822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study</span></div><div class="casAuthors">Wang, Feng; Feng, Kai-Rui; Zhao, Jia-Ying; Zhang, Jian-Wei; Shi, Xin-Wei; Zhou, Jian; Gao, Dingding; Lin, Guo-Qiang; Tian, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">115822</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is identified as a promising target for multiple cancer therapy and attracts widespread concern.  Herein, we reported the discovery of a series of 2-acetyl-7-phenylamino benzofuran derivs. as STAT3 inhibitors using scaffold fusion strategy.  Further structure activity relationship study led to the discovery of compd. C6, which displayed the most potent anti-proliferation activities against MDA-MB-468 cells (IC50 = 0.16 Î¼M).  Western blot assay demonstrated that C6 inhibited the activation of STAT3 (Tyr705) without influencing the phosphorylation of STAT1 (Tyr701).  Further mechanistic studies indicated that C6 caused a notable G2/M cycle-arresting and early apoptosis in a concn.-dependent manner in MDA-MB-468 cells.  Finally, mol. modeling study elucidated the binding mode of C6 in STAT3 SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr95FVyr8O3k7Vg90H21EOLACvtfcHk0ljX3F1izlSgzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit12hurbM&md5=4d93e72ff3fc75c36b7bab363f1a6d88</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115822%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DK.-R.%26aulast%3DZhao%26aufirst%3DJ.-Y.%26aulast%3DZhang%26aufirst%3DJ.-W.%26aulast%3DShi%26aufirst%3DX.-W.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DG.-Q.%26aulast%3DTian%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520STAT3%2520inhibitors%2520bearing%25202-acetyl-7-phenylamino%2520benzofuran%2520scaffold%2520for%2520antitumour%2520study%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115822%26doi%3D10.1016%2Fj.bmc.2020.115822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span> <span> </span><span class="NLM_article-title">Aspeterreurone A, a cytotoxic dihydrobenzofuran-phenyl acrylate hybrid from the deep-sea-derived fungus aspergillus terreus CC-S06â18</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1998</span>â <span class="NLM_lpage">2003</span>, <span class="refDoi">Â DOI: 10.1021/acs.jnatprod.0c00189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.0c00189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVGltLvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2020&pages=1998-2003&author=W.+Wangauthor=J.+Yangauthor=Y.-Y.+Liaoauthor=G.+Chengauthor=J.+Chenauthor=S.+Moauthor=L.+Yuanauthor=X.-D.+Chengauthor=J.-J.+Qinauthor=Z.+Shao&title=Aspeterreurone+A%2C+a+cytotoxic+dihydrobenzofuran-phenyl+acrylate+hybrid+from+the+deep-sea-derived+fungus+aspergillus+terreus+CC-S06%E2%80%9318&doi=10.1021%2Facs.jnatprod.0c00189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Aspeterreurone A, a Cytotoxic Dihydrobenzofuran-Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus Aspergillus terreus CC-S06-18</span></div><div class="casAuthors">Wang, Weiyi; Yang, Jing; Liao, Yan-Yan; Cheng, Gang; Chen, Jing; Mo, Shaowei; Yuan, Li; Cheng, Xiang-Dong; Qin, Jiang-Jiang; Shao, Zongze</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1998-2003</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">A new dihydrobenzofuran-Ph acrylate hybrid, aspeterreurone A (I), was obtained from the culture of the deep-sea-derived fungus Aspergillus terreus CC-S06-18.  The relative configuration of I was elucidated by HSQMBC NMR, calcd. NMR chem. shifts coupled with a statistical procedure (DP4+), and the abs. configuration was established by ECD calcns. I exhibited cytotoxicities against the gastric cancer cell lines HGC27, MGC803, BGC823, and AGS, with minimal effects on normal gastric epithelial cell line GES-1.  Further studies showed that I inhibited cell cycle progression and induced apoptosis of gastric cancer MGC803 cells in a concn.-dependent manner.  Western blot anal. indicated that I inhibited the phosphorylation of STAT3, which might contribute to its cytotoxic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpukjrhnweI87Vg90H21EOLACvtfcHk0lgwMB-vRVJiqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVGltLvF&md5=24a23226db8687ec8afe7d9e451e724e</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.0c00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.0c00189%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DY.-Y.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DX.-D.%26aulast%3DQin%26aufirst%3DJ.-J.%26aulast%3DShao%26aufirst%3DZ.%26atitle%3DAspeterreurone%2520A%252C%2520a%2520cytotoxic%2520dihydrobenzofuran-phenyl%2520acrylate%2520hybrid%2520from%2520the%2520deep-sea-derived%2520fungus%2520aspergillus%2520terreus%2520CC-S06%25E2%2580%259318%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2020%26volume%3D83%26spage%3D1998%26epage%3D2003%26doi%3D10.1021%2Facs.jnatprod.0c00189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">113333</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2021.113333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33689932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmtFWlsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2021&pages=113333&author=D.+Gaoauthor=N.+Jinauthor=Y.+Fuauthor=Y.+Zhuauthor=Y.+Wangauthor=T.+Wangauthor=Y.+Chenauthor=M.+Zhangauthor=Q.+Xiaoauthor=M.+Huangauthor=Y.+Li&title=Rational+drug+design+of+benzothiazole-based+derivatives+as+potent+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+signaling+pathway+inhibitors&doi=10.1016%2Fj.ejmech.2021.113333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors</span></div><div class="casAuthors">Gao, Dingding; Jin, Nan; Fu, Yixian; Zhu, Yueyue; Wang, Yujie; Wang, Ting; Chen, Yuehong; Zhang, Mingming; Xiao, Qiang; Huang, Min; Li, Yingxia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113333</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The cumulative evidence supports STAT3, a transcriptional mediator of oncogenic signaling, as a therapeutic target in cancer.  The development of STAT3 inhibitors remain an active area of research as no inhibitors have yet to be approved for cancer treatment.  In a continuing effort to develop more potent STAT3 inhibitors based on our previously identified hit compd. 16w, a series of benzothiazole derivs. with unique binding mode in SH2 domain of STAT3 were designed, synthesized and biol. evaluated.  Of note, compd. B19 demonstrated excellent activity against IL-6/STAT3 signaling pathway with the IC50 value as low as 0.067 Î¼M as detd. by a luciferase reporter assay.  Moreover, multiple compds. displayed potent antiproliferative activity against MDA-MB-468 and JAK2 mutant HEL cell lines.  Further biochem. study using Western blot assay indicated that B19 blocked the phosphorylation of STAT3 at Tyr 705 and Ser 727 and thus suppressed STAT3-mediated gene expression of c-MYC and MCL-1.  Simultaneously, it induced cancer cell G2/M phase arrest and apoptosis both in MDA-MB-468 and HEL cell lines.  Finally, mol. docking study along with surface plasmon resonance (SPR) and fluorescence polarization (FP) assays disclosed the binding mode of B19 in STAT3 SH2 domain.  Taken together, our finding suggests that B19 is a promising therapeutic STAT3 inhibitor for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC2dHztNDzWrVg90H21EOLACvtfcHk0lgwMB-vRVJiqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmtFWlsrY%253D&md5=b92b8f1ef2d5596f4e0e78e07ed594b8</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113333%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DN.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DRational%2520drug%2520design%2520of%2520benzothiazole-based%2520derivatives%2520as%2520potent%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520signaling%2520pathway%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D216%26spage%3D113333%26doi%3D10.1016%2Fj.ejmech.2021.113333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of STAT3 by anticancer drug bendamustine</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0170709</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0170709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1371%2Fjournal.pone.0170709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28125678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFSlsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0170709&author=K.+Iwamotoauthor=Y.+Ueharaauthor=Y.+Inoueauthor=K.+Taguchiauthor=D.+Muraokaauthor=N.+Ogoauthor=K.+Matsunoauthor=A.+Asai&title=Inhibition+of+STAT3+by+anticancer+drug+bendamustine&doi=10.1371%2Fjournal.pone.0170709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of STAT3 by anticancer drug bendamustine</span></div><div class="casAuthors">Iwamoto, Kazunori; Uehara, Yutaka; Inoue, Yukie; Taguchi, Kyoko; Muraoka, Daisuke; Ogo, Naohisa; Matsuno, Kenji; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0170709/1-e0170709/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Bendamustine (BENDA), which bears the bis(2-chloroethyl)amino moiety, is an alkylating agent that stops the growth of cancer cells by binding to DNA and interfering with its replication.  However, the mechanism of action underlying its excellent clin. efficacy remains unclear.  In this work, we report that BENDA inhibits signal transducer and activator of transcription 3 (STAT3).  In an AlphaScreen-based biochem. assay using recombinant human STAT3, binding of STAT3Â±Src homol. 2 (SH2) to the phosphotyrosine (pTyr, pY) peptide was inhibited by BENDA but not by the inactive metabolite dihydroxy bendamustine (HP2).  When a single point mutation of C550A or C712A was introduced into recombinant human STAT3, its sensitivity to BENDA was substantially reduced, suggesting that these cysteine residues are important for BENDA to inhibit STAT3.  Furthermore, BENDA suppressed the function of cellular STAT3 as a transcriptional activator in a human breast cancer cell line, MDA-MB-468, with constitutively activated STAT3.  A competitive pull-down assay using biotinylated BENDA (Bio-BENDA) revealed that BENDA bound tightly to cellular STAT3, presumably through covalent bonds.  Therefore, our results suggest that the anticancer effects of BENDA may be assocd., at least in part, with its inhibitory effect on the SH2 domain of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTZ-C2K2sazrVg90H21EOLACvtfcHk0lgwMB-vRVJiqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFSlsbY%253D&md5=2d9ce3e5e42f57ef2415b06b2f0835ab</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0170709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0170709%26sid%3Dliteratum%253Aachs%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DUehara%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DTaguchi%26aufirst%3DK.%26aulast%3DMuraoka%26aufirst%3DD.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520STAT3%2520by%2520anticancer%2520drug%2520bendamustine%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0170709%26doi%3D10.1371%2Fjournal.pone.0170709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takakura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandi-Nejad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4143</span>â <span class="NLM_lpage">4154</span>, <span class="refDoi">Â DOI: 10.1093/hmg/ddr338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1093%2Fhmg%2Fddr338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21821671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yltrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=4143-4154&author=A.+Takakuraauthor=E.+A.+Nelsonauthor=N.+Haqueauthor=B.+D.+Humphreysauthor=K.+Zandi-Nejadauthor=D.+A.+Frankauthor=J.+Zhou&title=Pyrimethamine+inhibits+adult+polycystic+kidney+disease+by+modulating+STAT+signaling+pathways&doi=10.1093%2Fhmg%2Fddr338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways</span></div><div class="casAuthors">Takakura, Ayumi; Nelson, Erik A.; Haque, Nadeem; Humphreys, Benjamin D.; Zandi-Nejad, Kambiz; Frank, David A.; Zhou, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4143-4154</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Autosomal dominant polycystic kidney disease (ADPKD) is a commonly inherited disorder mostly caused by mutations in PKD1, encoding polycystin-1 (PC1).  The disease is characterized by development and growth of epithelium-lined cyst in both kidneys, often leading to renal failure.  There is no specific treatment for this disease.  Here, we report a sustained activation of the transcription factor signal transducer and activator of transcription 3 (STAT3) in ischemic injured and uninjured Pkd1 knockout polycystic kidneys and in human ADPKD kidneys.  Through a chem. library screen, we identified the anti-parasitic compd. pyrimethamine as an inhibitor of STAT3 function.  Treatment with pyrimethamine decreases cell proliferation in human ADPKD cells and blocks renal cyst formation in an adult and a neonatal PKD mouse model.  Moreover, we demonstrated that a specific STAT3 inhibitor, S3I-201, reduces cyst formation and growth in a neonatal PKD mouse model.  Our results suggest that PC1 acts as a neg. regulator of STAT3 and that blocking STAT3 signaling with pyrimethamine or similar drugs may be an attractive therapy for human ADPKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVEStaa2l9HbVg90H21EOLACvtfcHk0liRAXgJiNoj4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yltrjP&md5=e5bae0f5d88e2e44da18b96ca0c46236</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddr338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddr338%26sid%3Dliteratum%253Aachs%26aulast%3DTakakura%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DHaque%26aufirst%3DN.%26aulast%3DHumphreys%26aufirst%3DB.%2BD.%26aulast%3DZandi-Nejad%26aufirst%3DK.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DPyrimethamine%2520inhibits%2520adult%2520polycystic%2520kidney%2520disease%2520by%2520modulating%2520STAT%2520signaling%2520pathways%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2011%26volume%3D20%26spage%3D4143%26epage%3D4154%26doi%3D10.1093%2Fhmg%2Fddr338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heppler, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attarha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">Abstract 387: Pyrimethamine inhibits STAT3 transcriptional activity via dihydrofolate reductase</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">387</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30482775" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=387&author=L.+N.+Hepplerauthor=S.+R.+Walkerauthor=S.+Attarhaauthor=B.+D.+Pageauthor=D.+A.+Frank&title=Abstract+387%3A+Pyrimethamine+inhibits+STAT3+transcriptional+activity+via+dihydrofolate+reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeppler%26aufirst%3DL.%2BN.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DAttarha%26aufirst%3DS.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DAbstract%2520387%253A%2520Pyrimethamine%2520inhibits%2520STAT3%2520transcriptional%2520activity%2520via%2520dihydrofolate%2520reductase%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0liRAXgJiNoj4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Small molecule PROTACs in targeted therapy: an emerging strategy to induce protein degradation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">159</span>â <span class="NLM_lpage">180</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.04.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.04.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31035238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12isb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=159-180&author=M.+Xiauthor=Y.+Chenauthor=H.+Yangauthor=H.+Xuauthor=K.+Duauthor=C.+Wuauthor=Y.+Xuauthor=L.+Dengauthor=X.+Luoauthor=L.+Yuauthor=Y.+Wuauthor=X.+Gaoauthor=T.+Caiauthor=B.+Chenauthor=R.+Shenauthor=H.+Sun&title=Small+molecule+PROTACs+in+targeted+therapy%3A+an+emerging+strategy+to+induce+protein+degradation&doi=10.1016%2Fj.ejmech.2019.04.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation</span></div><div class="casAuthors">Xi, Meiyang; Chen, Yi; Yang, Hongyu; Xu, Huiting; Du, Kui; Wu, Chunlei; Xu, Yanfei; Deng, Liping; Luo, Xiang; Yu, Lemao; Wu, Yonghua; Gao, Xiaozhong; Cai, Tao; Chen, Bin; Shen, Runpu; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-180</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Inhibitors and nucleic acid based techniques were two main approaches to interfere with protein signaling and resp. cascade in the past.  Until recently, a new class of small mols. named proteolysis-targeting chimeras (PROTACs) have emerged.  Each contains a target warhead, a linker and an E3 ligand.  These bifunctional mols. recruit E3 ligases and target specific proteins for degrdn. via the ubiquitin (Ub) proteasome system (UPS).  The degrdn. provides several advantages over inhibition in potency, selectivity and drug resistance.  Thus, a variety of small mol. PROTACs have been discovered so far.  In this review, we summarize the biol. mechanism, advantages and recent progress of PROTACs, trying to offer an outlook in development of drugs targeting degrdn. in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY2xzp9ZKETLVg90H21EOLACvtfcHk0liRAXgJiNoj4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12isb8%253D&md5=3838c9de05e487121ec2a24a0d9a3ea3</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.036%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DSmall%2520molecule%2520PROTACs%2520in%2520targeted%2520therapy%253A%2520an%2520emerging%2520strategy%2520to%2520induce%2520protein%2520degradation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D159%26epage%3D180%26doi%3D10.1016%2Fj.ejmech.2019.04.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">114</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lgXtmh2vrWz-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">498</span>â <span class="NLM_lpage">511</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2019.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ccell.2019.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31715132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCjtrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=498-511&author=L.+Baiauthor=H.+Zhouauthor=R.+Xuauthor=Y.+Zhaoauthor=K.+Chinnaswamyauthor=D.+McEachernauthor=J.+Chenauthor=C.+Y.+Yangauthor=Z.+Liuauthor=M.+Wangauthor=L.+Liuauthor=H.+Jiangauthor=B.+Wenauthor=P.+Kumarauthor=J.+L.+Meagherauthor=D.+Sunauthor=J.+A.+Stuckeyauthor=S.+Wang&title=A+potent+and+selective+small-molecule+degrader+of+STAT3+achieves+complete+tumor+regression+in+vivo&doi=10.1016%2Fj.ccell.2019.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo</span></div><div class="casAuthors">Bai, Longchuan; Zhou, Haibin; Xu, Renqi; Zhao, Yujun; Chinnaswamy, Krishnapriya; McEachern, Donna; Chen, Jianyong; Yang, Chao-Yie; Liu, Zhaomin; Wang, Mi; Liu, Liu; Jiang, Hui; Wen, Bo; Kumar, Praveen; Meagher, Jennifer L.; Sun, Duxin; Stuckey, Jeanne A.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">498-511.e17</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is an attractive cancer therapeutic target.  Here we report the discovery of SD-36(I), a small-mol. degrader of STAT3.  SD-36 potently induces the degrdn. of STAT3 protein in vitro and in vivo and demonstrates high selectivity over other STAT members.  Induced degrdn. of STAT3 results in a strong suppression of its transcription network in leukemia and lymphoma cells.  SD-36 inhibits the growth of a subset of acute myeloid leukemia and anaplastic large-cell lymphoma cell lines by inducing cell-cycle arrest and/or apoptosis.  SD-36 achieves complete and long-lasting tumor regression in multiple xenograft mouse models at well-tolerated dose schedules.  Degrdn. of STAT3 protein, therefore, is a promising cancer therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUaP49Ap9DxLVg90H21EOLACvtfcHk0lgXtmh2vrWz-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCjtrjO&md5=71252c17d50a1a8be829352942175bd6</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DA%2520potent%2520and%2520selective%2520small-molecule%2520degrader%2520of%2520STAT3%2520achieves%2520complete%2520tumor%2520regression%2520in%2520vivo%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26spage%3D498%26epage%3D511%26doi%3D10.1016%2Fj.ccell.2019.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">11280</span>â <span class="NLM_lpage">11300</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01530</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01530" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SnsL3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11280-11300&author=H.+Zhouauthor=L.+Baiauthor=R.+Xuauthor=Y.+Zhaoauthor=J.+Chenauthor=D.+McEachernauthor=K.+Chinnaswamyauthor=B.+Wenauthor=L.+Daiauthor=P.+Kumarauthor=C.+Y.+Yangauthor=Z.+Liuauthor=M.+Wangauthor=L.+Liuauthor=J.+L.+Meagherauthor=H.+Yiauthor=D.+Sunauthor=J.+A.+Stuckeyauthor=S.+Wang&title=Structure-based+discovery+of+SD-36+as+a+potent%2C+selective%2C+and+efficacious+PROTAC+degrader+of+STAT3+protein&doi=10.1021%2Facs.jmedchem.9b01530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein</span></div><div class="casAuthors">Zhou, Haibin; Bai, Longchuan; Xu, Renqi; Zhao, Yujun; Chen, Jianyong; McEachern, Donna; Chinnaswamy, Krishnapriya; Wen, Bo; Dai, Lipeng; Kumar, Praveen; Yang, Chao-Yie; Liu, Zhaomin; Wang, Mi; Liu, Liu; Meagher, Jennifer L.; Yi, Han; Sun, Duxin; Stuckey, Jeanne A.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11280-11300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases.  Despite twenty-years of persistent research efforts, targeting STAT3 has been very challenging.  The authors report herein the structure-based discovery of potent small-mol. STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept.  The authors first designed SI-109 as a potent, small-mol. inhibitor of the STAT3 SH2 domain.  Employing ligands for cereblon/Cullin 4A E3 ligase and SI-109, the authors obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36.  SD-36 induces rapid STAT3 degrdn. at low nanomolar concns. in cells and fails to degrader other STAT proteins.  SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3.  A single dose of SD-36 results in complete STAT3 protein degrdn. in xenograft tumor tissue and normal mouse tissues.  SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules.  SD-36 is a potent, selective and efficacious STAT3 degrader.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIAWd1hiuqy7Vg90H21EOLACvtfcHk0lhSzdYuPrHK4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SnsL3J&md5=7d0c656a2d96196a3b71829c9efe715a</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01530%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DStructure-based%2520discovery%2520of%2520SD-36%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520PROTAC%2520degrader%2520of%2520STAT3%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D11280%26epage%3D11300%26doi%3D10.1021%2Facs.jmedchem.9b01530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shih, P. C.</span></span> <span> </span><span class="NLM_article-title">Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>242</i></span>,  <span class="NLM_fpage">117241</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2019.117241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.lfs.2019.117241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31891719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB3MblsFalsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=2020&pages=117241&author=P.+C.+Shih&title=Revisiting+the+development+of+small+molecular+inhibitors+that+directly+target+the+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+domains&doi=10.1016%2Fj.lfs.2019.117241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains</span></div><div class="casAuthors">Shih Po-Chang</div><div class="citationInfo"><span class="NLM_cas:title">Life sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">242</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117241</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) has been a protein target following its roles being found to play in the progression of cancer development, cancer stemness, chemoresistance and radioresistance.  Two decades of research efforts in STAT3 has, however, not yielded a marketed anti-STAT3 drug.  This review insightfully discusses structural views on the STAT3 domains (e.g. binding pockets and critical residues), approaches to discovering effective chemical structures (e.g. structure-based drug discovery, high-throughput screening, natural product derivatives, repurposing drugs and so on), how the domains were targeted (e.g. non-covalent or covalent inhibition), and rationale of domain targeting (e.g. prevention of homo-dimerization or DNA-binding).  In addition, the assays that have been used for the discovery of STAT3 inhibitors will be discussed.  Overall, with this review article, the progress of the development of STAT3 antagonists could be accelerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRV-OmEt84CrcScOqQTSkOffW6udTcc2ea826kxHrkMi7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MblsFalsw%253D%253D&md5=4ea0df34ea89ed4cc8f2e985bafaf8ff</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2019.117241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2019.117241%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DP.%2BC.%26atitle%3DRevisiting%2520the%2520development%2520of%2520small%2520molecular%2520inhibitors%2520that%2520directly%2520target%2520the%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520domains%26jtitle%3DLife%2520Sci.%26date%3D2020%26volume%3D242%26spage%3D117241%26doi%3D10.1016%2Fj.lfs.2019.117241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a napabucasin PROTAC as an effective degrader of the E3 ligase ZFP91</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1626</span>â <span class="NLM_lpage">1648</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01897</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01897" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3MXitV2rsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=1626-1648&author=M.+Hanafiauthor=X.+Chenauthor=N.+Neamati&title=Discovery+of+a+napabucasin+PROTAC+as+an+effective+degrader+of+the+E3+ligase+ZFP91&doi=10.1021%2Facs.jmedchem.0c01897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91</span></div><div class="casAuthors">Hanafi, Maha; Chen, Xinde; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1626-1648</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Napabucasin, undergoing multiple clin. trials, was reported to inhibit the signal transducer and transcription factor 3 (STAT3).  To better elucidate its mechanism of action, we designed a napabucasin-based proteolysis targeting chimera (PROTAC), XD2-149 that resulted in inhibition of STAT3 signaling in pancreatic cancer cell lines without inducing proteasome-dependent degrdn. of STAT3.  Proteomics anal. of XD2-149 revealed the downregulation of the E3 ubiquitin-protein ligase ZFP91.  XD2-149 degrades ZFP91 with DC50 values in the nanomolar range.  The cytotoxicity of XD2-149 was significantly, but not fully, reduced with ZFP91 knockdown providing evidence for its multi-targeted mechanism of action.  The NQO1 inhibitor, dicoumarol, rescued the cytotoxicity of XD2-149 but not ZFP91 degrdn., suggesting that the NQO1-induced cell death is independent of ZFP91.  ZFP91 plays a role in tumorigenesis and is involved in multiple oncogenic pathways including NF-ÎºB and HIF-1Î±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrnBARFW60pbVg90H21EOLACvtfcHk0lhSzdYuPrHK4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXitV2rsr0%253D&md5=4a15342a402ce15a85ebd5e9e622b53e</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01897%26sid%3Dliteratum%253Aachs%26aulast%3DHanafi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520a%2520napabucasin%2520PROTAC%2520as%2520an%2520effective%2520degrader%2520of%2520the%2520E3%2520ligase%2520ZFP91%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D1626%26epage%3D1648%26doi%3D10.1021%2Facs.jmedchem.0c01897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structure of STAT3 homodimer bound to the DNA recognition site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BG1">1BG1</a>, this protein lacks the N-terminal domain, if needed, please see PDB entry code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZIA">4ZIA</a>). Structural domains are indicated by different colors, and the dashed line represents the missing residues. Spheres represent Cys542 or Cys259 that covalently binds some inhibitors. (B) SH2 domain characteristics of STAT3 in which blue represents hydrophilic areas, while orange-red represents hydrophobic areas.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. STAT3 signaling pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of representative STAT3 inhibitors targeting SH2 or DBD domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of BTP-based derivatives <b>1</b>â<b>4</b>. (Hydrogen bonds were shown as dashed lines and cation-Ï interactions were shown as green lines.) Adapted with permission from ref <a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a>. Copyright 2016 Elsevier Masson SAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of BTP-based derivatives <b>6</b>â<b>8</b> as STAT3 inhibitors. Adapted with permission from ref <a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a>. Copyright 2019 Elsevier Masson SAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structural modification of BP-1-102. Adapted with permission from ref <a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a>. Copyright 2018 Elsevier Masson SAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of sulfonamide derivatives as STAT3 inhibitors</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of quinone analogues <b>28</b>â<b>31</b> as STAT3 inhibitors. Adapted with permissions from refs <a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> and <a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a>. Copyright 2017 American Chemical Society and Copyright 2019 The British Pharmacological Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of naphthoquinone analogues <b>32</b>â<b>36</b> as STAT3 inhibitors. Adapted with permissions from refs <a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> and <a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a>. Copyright 2020 Elsevier Inc. and Copyright 2017 Elsevier Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of napabucasin-based derivatives <b>37</b>â<b>42</b>. Adapted with permissions from refs <a onclick="showRef(event, 'ref95 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref95 ref96 ref97">(95â97)</a>. Copyright 2018 Elsevier Masson SAS and Copyright 2020 Elsevier Masson SAS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of angular isonapabucasin derivatives <b>43</b>â<b>47</b>. Adapted with permission from ref <a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a>. Copyright 2018 American Chemical Society and American Society of Pharmacognosy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of benzene- or heterocycle-ring fused quinones analogues <b>48</b>â<b>50</b> as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures of naturally occurring flavonoids <b>51</b>â<b>54</b> as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures of flavonoid derivatives <b>55</b>â<b>61</b> as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of flavonoid analogues <b>62</b>â<b>64</b> as STAT3 inhibitors. Adapted with permission from ref <a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a>. Copyright 2016 Elsevier Ltd.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures of terpenes as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of pyrimidine derivatives <b>77</b>â<b>82</b> as STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures of quinoline derivatives <b>83</b>â<b>85</b> as STAT3 inhibitors. Adapted with permissions from refs <a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> and <a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a>. Copyright 2019 Elsevier Masson SAS and Copyright 2020 The Authors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures of some other aromatic heterocyclic derivatives as STAT3 inhibitors</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/medium/jm1c00629_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Design of PROTAC SI-109 as a STAT3 degrader, and its cocrystal structure with STAT3 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NUQ">6NUQ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00629/20210629/images/large/jm1c00629_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00629&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54166" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54166" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 169 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, J. E.</span></span> <span> </span><span class="NLM_article-title">STATs and gene regulation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">1630</span>â <span class="NLM_lpage">1635</span>, <span class="refDoi">Â DOI: 10.1126/science.277.5332.1630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1126%2Fscience.277.5332.1630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=9287210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADyaK2sXmtVSisLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=1630-1635&author=J.+E.+Darnell&title=STATs+and+gene+regulation&doi=10.1126%2Fscience.277.5332.1630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">STATs and gene regulation</span></div><div class="casAuthors">Darnell, James E., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5332</span>),
    <span class="NLM_cas:pages">1630-1635</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 100 refs.  STATs (signal transducers and activators of transcription) are a family of latent cytoplasmic proteins that are activated to participate in gene control when cells encounter various extracellular polypeptides.  Biochem. and mol. genetic explorations have defined a single tyrosine phosphorylation site and, in a dimeric partner mol., a Src homol. 2 (SH2) phosphotyrosine-binding domain, a DNA interaction domain, and a no. of protein-protein interaction domains (with receptors, other transcription factors, the transcription machinery, and perhaps a tyrosine phosphatase).  Mouse genetics expts. have defined crucial roles for each known mammalian STAT.  The discovery of a STAT in Drosophila, and most recently in Dictyostelium discoideum, implies an ancient evolutionary origin for this dual-function set of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2cN7IJWCm2rVg90H21EOLACvtfcHk0liU0p7Q8iEUCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtVSisLo%253D&md5=ce5d495245adb0ccaab93ba990a7e017</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5332.1630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5332.1630%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DSTATs%2520and%2520gene%2520regulation%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D1630%26epage%3D1635%26doi%3D10.1126%2Fscience.277.5332.1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span> <span> </span><span class="NLM_article-title">Signal transducer and activator of transcription protein 3 (STAT3): an update on its direct inhibitors as promising anticancer agents</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5165</span>â <span class="NLM_lpage">5206</span>, <span class="refDoi">Â DOI: 10.2174/0929867325666180719122729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.2174%2F0929867325666180719122729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30027840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVymt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=5165-5206&author=A.+Gelainauthor=M.+Moriauthor=F.+Meneghettiauthor=S.+Villa&title=Signal+transducer+and+activator+of+transcription+protein+3+%28STAT3%29%3A+an+update+on+its+direct+inhibitors+as+promising+anticancer+agents&doi=10.2174%2F0929867325666180719122729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents</span></div><div class="casAuthors">Gelain, Arianna; Mori, Matteo; Meneghetti, Fiorella; Villa, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">5165-5206</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Since Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor which plays an important role in multiple aspects of cancer, including progression and migration, and it is constitutively activated in various human tumors, STAT3 inhibition has emerged as a validated strategy for the treatment of several malignancies.  The aim of this review is to provide an update on the identification of new promising direct inhibitors targeting STAT3 domains, as potential anticancer agents.  Methods: A thorough literature search focused on recently reported STAT3 direct inhibitors was undertaken.  We considered the relevant developments regarding the STAT3 domains, which have been identified as potential drug targets.  Results: In detail, 135 peer-reviewed papers and 7 patents were cited; the inhibitors we took into account targeted the DNA binding domain (compds. were grouped into natural derivs., small mols., peptides, aptamers and oligonucleotides), the SH2 binding domain (natural, semi-synthetic and synthetic compds.) and specific residues, like cysteines (natural, semi-synthetic, synthetic compds. and dual inhibitors) and tyrosine 705.  Conclusion: The huge no. of direct STAT3 inhibitors recently identified demonstrates a strong interest in the investigation of this target, although it represents a challenging task considering that no drug targeting this enzyme is currently available for anticancer therapy.  Notably, many studies on the available inhibitors evidenced that some of them possess a dual mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQTc4wg6lMDbVg90H21EOLACvtfcHk0liU0p7Q8iEUCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVymt7bI&md5=1df39128edf16ad4b697263614ed36e5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F0929867325666180719122729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867325666180719122729%26sid%3Dliteratum%253Aachs%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26atitle%3DSignal%2520transducer%2520and%2520activator%2520of%2520transcription%2520protein%25203%2520%2528STAT3%2529%253A%2520an%2520update%2520on%2520its%2520direct%2520inhibitors%2520as%2520promising%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2019%26volume%3D26%26spage%3D5165%26epage%3D5206%26doi%3D10.2174%2F0929867325666180719122729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1398</span>â <span class="NLM_lpage">1409</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2010.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bcp.2010.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=20067773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVCnsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2010&pages=1398-1409&author=X.+Zhangauthor=P.+Yueauthor=S.+Fletcherauthor=W.+Zhaoauthor=P.+T.+Gunningauthor=J.+Turkson&title=A+novel+small-molecule+disrupts+Stat3+SH2+domain-phosphotyrosine+interactions+and+Stat3-dependent+tumor+processes&doi=10.1016%2Fj.bcp.2010.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes</span></div><div class="casAuthors">Zhang, Xiaolei; Yue, Peibin; Fletcher, Steven; Zhao, Wei; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1398-1409</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mol. modeling of the phosphotyrosine (pTyr)-SH2 domain interaction in the Stat3:Stat3 dimerization, combined with in silico structural anal. of the Stat3 dimerization disruptor, S3I-201, has furnished a diverse set of analogs.  We present evidence from in vitro biochem. and biophys. studies that the structural analog, S3I-201.1066 (I) directly interacts with Stat3 or the SH2 domain, with an affinity (KD) of 2.74 Î¼M, and disrupts the binding of Stat3 to the cognate pTyr-peptide, GpYLPQTV-NH2, with an IC50 of 23 Î¼M.  Moreover, I selectively blocks the assocn. of Stat3 with the epidermal growth factor receptor (EGFR), and inhibits Stat3 tyrosine phosphorylation and nuclear translocation in EGF-stimulated mouse fibroblasts.  In cancer cells that harbor aberrant Stat3 activity, I inhibits constitutive Stat3 DNA-binding and transcriptional activities.  By contrast, I has no effect on Src activation or the EGFR-mediated activation of the Erk1/2MAPK pathway.  I selectively suppresses the viability, survival, and malignant transformation of the human breast and pancreatic cancer lines and the v-Src-transformed mouse fibroblasts harboring persistently active Stat3.  Treatment with I of malignant cells harboring aberrantly active Stat3 down-regulated the expression of c-Myc, Bcl-xL, Survivin, the matrix metalloproteinase 9, and VEGF.  The in vivo administration of I-induced significant antitumor response in mouse models of human breast cancer, which correlates with the inhibition of constitutively active Stat3 and the suppression of known Stat3-regulated genes.  Our studies identify a novel small-mol. that binds with a high affinity to Stat3, blocks Stat3 activation and function, and thereby induces antitumor response in human breast tumor xenografts harboring persistently active Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxJzIoqCaQHbVg90H21EOLACvtfcHk0lhwU4khEYGXCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVCnsL8%253D&md5=4a196103d1d0f6d057715ff4cd2d7498</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DA%2520novel%2520small-molecule%2520disrupts%2520Stat3%2520SH2%2520domain-phosphotyrosine%2520interactions%2520and%2520Stat3-dependent%2520tumor%2520processes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D79%26spage%3D1398%26epage%3D1409%26doi%3D10.1016%2Fj.bcp.2010.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamero, A. M.</span></span> <span> </span><span class="NLM_article-title">STAT2 phosphorylation and signaling</span>. <i>Jak-stat</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e25790</span>, <span class="refDoi">Â DOI: 10.4161/jkst.25790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.4161%2Fjkst.25790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24416652" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e25790&author=H.+C.+Steenauthor=A.+M.+Gamero&title=STAT2+phosphorylation+and+signaling&doi=10.4161%2Fjkst.25790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4161%2Fjkst.25790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.25790%26sid%3Dliteratum%253Aachs%26aulast%3DSteen%26aufirst%3DH.%2BC.%26aulast%3DGamero%26aufirst%3DA.%2BM.%26atitle%3DSTAT2%2520phosphorylation%2520and%2520signaling%26jtitle%3DJak-stat%26date%3D2013%26volume%3D2%26spage%3De25790%26doi%3D10.4161%2Fjkst.25790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wurster, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grusby, M. J.</span></span> <span> </span><span class="NLM_article-title">The biology of Stat4 and Stat6</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2577</span>â <span class="NLM_lpage">2584</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1203485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fsj.onc.1203485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10851056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVGhtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2577-2584&author=A.+L.+Wursterauthor=T.+Tanakaauthor=M.+J.+Grusby&title=The+biology+of+Stat4+and+Stat6&doi=10.1038%2Fsj.onc.1203485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The biology of Stat4 and Stat6</span></div><div class="casAuthors">Wurster, Andrea L.; Tanaka, Takashi; Grusby, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2577-2584</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with approx. 75 refs.  IL-4 and IL-12 are cytokines that are important regulators of the proliferation, differentiation and functional capacity of lymphocytes.  STATs (signal transducers and activators of transcription) are transcription factors that provide a direct link between the cytokine receptors and cytokine induced gene transcription.  Stat6 and Stat4 are two STAT family members that specifically mediate signals that emanate from the IL-4 and IL-12 receptors, resp.  Recently a great deal of progress has been made in understanding the specific roles that Stat6 and Stat4 play in lymphocyte function through in vitro as well as in vivo studies using Stat6 and Stat4-deficient mice.  This report will summarize and describe the recent advances made in understanding the activation and regulation of Stat6 and Stat4 as well as their roles in the development of an immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8kzLh4Nl7sbVg90H21EOLACvtfcHk0lhwU4khEYGXCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVGhtr8%253D&md5=ae569d044101d2822164753b7d1b8286</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203485%26sid%3Dliteratum%253Aachs%26aulast%3DWurster%26aufirst%3DA.%2BL.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DGrusby%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520biology%2520of%2520Stat4%2520and%2520Stat6%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D2577%26epage%3D2584%26doi%3D10.1038%2Fsj.onc.1203485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">218</span>â <span class="NLM_lpage">232</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31254923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ynt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=218-232&author=X.+Wangauthor=Q.+Heauthor=K.+Wuauthor=T.+Guoauthor=X.+Duauthor=H.+Zhangauthor=L.+Fangauthor=N.+Zhengauthor=Q.+Zhangauthor=F.+Ye&title=Design%2C+synthesis+and+activity+of+novel+2%2C6-disubstituted+purine+derivatives%2C+potential+small+molecule+inhibitors+of+signal+transducer+and+activator+of+transcription+3&doi=10.1016%2Fj.ejmech.2019.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3</span></div><div class="casAuthors">Wang, Xuebao; He, Qin; Wu, Kaiqi; Guo, Taoning; Du, Xuze; Zhang, Huan; Fang, Longcheng; Zheng, Nan; Zhang, Qihong; Ye, Faqing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">218-232</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Three series of 2,6-disubstituted purines I [R1 = Et, MeCH:CH, cyclohexyl, Ph, 3-BrC6H4, etc.; R2R3N = morpholin-4-yl], I (R1 = Ph; R2 = H, 2-MeC6H4, 4-ClC6H4, etc.; R3 = H) and I (R1 = 2-MeOC6H4; R2 = H, 4-MeC6H4, 3-MeOC6H4, etc.; R3 = H) were designed and synthesized and their biol. activities as small mol. inhibitors of STAT3 were assessed.  Compd. I (R1 = Ph; R2 = 4-ClC6H4; R3 = H) (II) exhibited remarkable antiproliferative activity against three cancer cell lines (IC50 values for HCT-116, SW480 and MDA-MB-231 were 1.77 Â± 0.35, 1.51 Â± 0.19 and 1.25 Â± 0.38 Î¼M, resp.).  Moreover, detailed biol. assays revealed that compd. II could effectively inhibited STAT3 phosphorylation and had little inhibition to others.  The newly discovered compd. II displayed an expecting anticancer effect both in-vitro and in-vivo.  The mol. docking models revealed that this compd. could bind to the SH2 domain of STAT3.  Three addnl. compds. I [R1 = Ph; R2R3N = morpholin-4-yl], I (R1 = Ph; R2 = 3-MeC6H4; R3 = H) and I (R1 = 2-MeOC6H4; R2 = 3-MeOC6H4; R3 = H) were also able to inhibited this phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWPTTRn7G-GrVg90H21EOLACvtfcHk0ljhlkbtwtnfQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ynt7rN&md5=cef6348552fb2660f8e40fc0f274a464</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DYe%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%2520and%2520activity%2520of%2520novel%25202%252C6-disubstituted%2520purine%2520derivatives%252C%2520potential%2520small%2520molecule%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D218%26epage%3D232%26doi%3D10.1016%2Fj.ejmech.2019.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wingelhofer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriggl, R.</span></span> <span> </span><span class="NLM_article-title">Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1713</span>â <span class="NLM_lpage">1726</span>, <span class="refDoi">Â DOI: 10.1038/s41375-018-0117-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41375-018-0117-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29728695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1713-1726&author=B.+Wingelhoferauthor=H.+A.+Neubauerauthor=P.+Valentauthor=X.+Hanauthor=S.+N.+Constantinescuauthor=P.+T.+Gunningauthor=M.+M%C3%BCllerauthor=R.+Moriggl&title=Implications+of+STAT3+and+STAT5+signaling+on+gene+regulation+and+chromatin+remodeling+in+hematopoietic+cancer&doi=10.1038%2Fs41375-018-0117-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer</span></div><div class="casAuthors">Wingelhofer, Bettina; Neubauer, Heidi A.; Valent, Peter; Han, Xiaonan; Constantinescu, Stefan N.; Gunning, Patrick T.; Mueller, Mathias; Moriggl, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1713-1726</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">STAT3 and STAT5 proteins are oncogenic downstream mediators of the JAK-STAT pathway.  Deregulated STAT3 and STAT5 signaling promotes cancer cell proliferation and survival in conjunction with other core cancer pathways.  Nuclear phosphorylated STAT3 and STAT5 regulate cell-type-specific transcription profiles via binding to promoter elements and exert more complex functions involving interaction with various transcriptional coactivators or corepressors and chromatin remodeling proteins.  The JAK-STAT pathway can rapidly reshape the chromatin landscape upon cytokine, hormone, or growth factor stimulation and unphosphorylated STAT proteins also appear to be functional with respect to regulating chromatin accessibility.  Notably, cancer genome landscape studies have implicated mutations in various epigenetic modifiers as well as the JAK-STAT pathway as underlying causes of many cancers, particularly acute leukemia and lymphomas.  However, it is incompletely understood how mutations within these pathways can interact and synergize to promote cancer.  We summarize the current knowledge of oncogenic STAT3 and STAT5 functions downstream of cytokine signaling and provide details on prerequisites for DNA binding and gene transcription.  We also discuss key interactions of STAT3 and STAT5 with chromatin remodeling factors such as DNA methyltransferases, histone modifiers, cofactors, corepressors, and other transcription factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjly1PidwZ_LVg90H21EOLACvtfcHk0ljhlkbtwtnfQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOmsrnP&md5=4f46319140344cef3212b871a8b2ff8c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0117-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0117-x%26sid%3Dliteratum%253Aachs%26aulast%3DWingelhofer%26aufirst%3DB.%26aulast%3DNeubauer%26aufirst%3DH.%2BA.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DMoriggl%26aufirst%3DR.%26atitle%3DImplications%2520of%2520STAT3%2520and%2520STAT5%2520signaling%2520on%2520gene%2520regulation%2520and%2520chromatin%2520remodeling%2520in%2520hematopoietic%2520cancer%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1713%26epage%3D1726%26doi%3D10.1038%2Fs41375-018-0117-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magdy
Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ³mez-Biagi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">A STAT inhibitor patent review: progress since 2011</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1397</span>â <span class="NLM_lpage">1421</span>, <span class="refDoi">Â DOI: 10.1517/13543776.2015.1086749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1517%2F13543776.2015.1086749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26394986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWhu7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1397-1421&author=P.+S.+Laiauthor=D.+A.+Rosaauthor=A.+Magdy%0AAliauthor=R.+F.+G%C3%B3mez-Biagiauthor=D.+P.+Ballauthor=A.+E.+Shouksmithauthor=P.+T.+Gunning&title=A+STAT+inhibitor+patent+review%3A+progress+since+2011&doi=10.1517%2F13543776.2015.1086749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A STAT inhibitor patent review: progress since 2011</span></div><div class="casAuthors">Lai, Ping-Shan; Rosa, David A.; Magdy Ali, Ahmed; Gomez-Biagi, Rodolfo F.; Ball, Daniel P.; Shouksmith, Andrew E.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1397-1421</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The clin. utility of effective direct STAT inhibitors, particularly STAT3 and STAT5, for treating cancer and other diseases is well studied and known.  This review will highlight the STAT inhibitor patent literature from 2011 to 2015 inclusive.  Emphasis will be placed on inhibitors of the STAT3, STAT5a/b, and STAT1 proteins for cancer treatment.  The review will, where suitably investigated, describe the mode and the site of inhibition, list indications that were evaluated, and rank the inhibitor's relative potency among compds. in the same class.  The reader will gain an understanding of the diverse set of approaches, used both in academia and industry, to target STAT proteins.  There is still much work to be done to directly target the STAT3 and STAT5 proteins.  As yet, there is still no direct STAT3 inhibitor in the clinic.  While the SH2 domain remains a popular target for therapeutic intervention, the DNA-binding domain and N-terminal region are now attracting attention as possible sites for inhibition.  Multiple putative STAT3 and STAT5 inhibitors have now been patented across a broad spectrum of chemotypes, each with their own advantages and limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0jiivJY_RxLVg90H21EOLACvtfcHk0lh8PKwklFOIwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWhu7bM&md5=261a9efdcad66b3b8ef7df18b66ce593</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543776.2015.1086749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2015.1086749%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DP.%2BS.%26aulast%3DRosa%26aufirst%3DD.%2BA.%26aulast%3DMagdy%2BAli%26aufirst%3DA.%26aulast%3DG%25C3%25B3mez-Biagi%26aufirst%3DR.%2BF.%26aulast%3DBall%26aufirst%3DD.%2BP.%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DA%2520STAT%2520inhibitor%2520patent%2520review%253A%2520progress%2520since%25202011%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2015%26volume%3D25%26spage%3D1397%26epage%3D1421%26doi%3D10.1517%2F13543776.2015.1086749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mankan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greten, F. R.</span></span> <span> </span><span class="NLM_article-title">Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1263</span>â <span class="NLM_lpage">1275</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2011.601739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1517%2F13543784.2011.601739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21751940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWntbbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1263-1275&author=A.+K.+Mankanauthor=F.+R.+Greten&title=Inhibiting+signal+transducer+and+activator+of+transcription+3%3A+rationality+and+rationale+design+of+inhibitors&doi=10.1517%2F13543784.2011.601739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors</span></div><div class="casAuthors">Mankan, Arun K.; Greten, Florian R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1263-1275</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) controls a key signaling pathway in the development of many malignant diseases.  Several genetic studies have proven its central role in the regulation of apoptosis, proliferation, angiogenesis and immune responses making it an attractive target for cancer therapy.Areas covered: This article addresses the role of STAT3 in immune response modulation and highlights the contribution of STAT3 in inflammation-mediated tumorigenesis.  We also review the rationale to use novel STAT3 inhibitors and list some of these inhibitors such as STA-21, IS3 295, S3I- M2001 and small mol. JAK2 inhibitors AZD1480 and AZ960 that were found to be efficient against tumors.  We summarize the efforts that were made so far in identifying promising compds. and mention the barriers that need to be overcome for successful application of STAT3 inhibitors in clinics.Expert opinion: STAT3 is an important target in tumor biol. based on its frequent activation in various tumors and its pleiotropic effects on different cell types.  Screening large libraries of logically synthesized small mol. inhibitors is one way to rapidly generate many potential mols., which can then be tested in different biol. relevant models.  The stage is, therefore, set for the identification and development of novel STAT3 inhibitors that will, in the very near future, enter the clin. realm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwvaUgkhnpgbVg90H21EOLACvtfcHk0lh8PKwklFOIwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWntbbP&md5=648ce046310a6fb7a3203e9be9367376</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.601739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.601739%26sid%3Dliteratum%253Aachs%26aulast%3DMankan%26aufirst%3DA.%2BK.%26aulast%3DGreten%26aufirst%3DF.%2BR.%26atitle%3DInhibiting%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%253A%2520rationality%2520and%2520rationale%2520design%2520of%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1263%26epage%3D1275%26doi%3D10.1517%2F13543784.2011.601739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STATs in cancer inflammation and immunity: a leading role for STAT3</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">798</span>â <span class="NLM_lpage">809</span>, <span class="refDoi">Â DOI: 10.1038/nrc2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fnrc2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=19851315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=798-809&author=H.+Yuauthor=D.+Pardollauthor=R.+Jove&title=STATs+in+cancer+inflammation+and+immunity%3A+a+leading+role+for+STAT3&doi=10.1038%2Fnrc2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">STATs in cancer inflammation and immunity: a leading role for STAT3</span></div><div class="casAuthors">Yu, Hua; Pardoll, Drew; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">798-809</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in detg. whether immune responses in the tumor microenvironment promote or inhibit cancer.  Persistently activated STAT3 and, to some extent, STAT5 increase tumor cell proliferation, survival and invasion while suppressing anti-tumor immunity.  The persistent activation of STAT3 also mediates tumor-promoting inflammation.  STAT3 has this dual role in tumor inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-ÎºB (NF-ÎºB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-ÎºB-mediated T helper 1 anti-tumor immune responses.  Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvEMN5YrxbbVg90H21EOLACvtfcHk0ljo-BhbkXLZaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP&md5=e431d0bd9eabd8f1ef703211be3d5cc9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2734%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTATs%2520in%2520cancer%2520inflammation%2520and%2520immunity%253A%2520a%2520leading%2520role%2520for%2520STAT3%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D798%26epage%3D809%26doi%3D10.1038%2Fnrc2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mali, S. B.</span></span> <span> </span><span class="NLM_article-title">Review of STAT3 (signal transducers and activators of transcription) in head and neck cancer</span>. <i>Oral Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">565</span>â <span class="NLM_lpage">569</span>, <span class="refDoi">Â DOI: 10.1016/j.oraloncology.2015.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.oraloncology.2015.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25817923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFemsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=565-569&author=S.+B.+Mali&title=Review+of+STAT3+%28signal+transducers+and+activators+of+transcription%29+in+head+and+neck+cancer&doi=10.1016%2Fj.oraloncology.2015.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer</span></div><div class="casAuthors">Mali, Shrikant Balasaheb</div><div class="citationInfo"><span class="NLM_cas:title">Oral Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-569</span>CODEN:
                <span class="NLM_cas:coden">EJCCER</span>;
        ISSN:<span class="NLM_cas:issn">1368-8375</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">STATs can be activated independently of JAKs, most notably by c-Src kinases.  In cancer cells, STAT3 and STAT5 activation leads to the increased expression of downstream target genes, leading to increased cell proliferation, cell survival, angiogenesis, and immune system evasion.  STAT3 and STAT5 are expressed and activated in head and neck squamous cell carcinoma where they contribute to cell survival and proliferation.  STATs can be activated by a no. of signal transduction pathways, including the epidermal growth factor receptor (EGFR), nicotinic receptor, interleukin (IL) receptor, and erythropoietin receptor pathways.  Identifying agents that inhibit STAT-3, a cytosolic transcription factor involved in the activation of various genes implicated in tumor progression is a promising strategy for cancer chemoprevention.  Several approaches have been used to inhibit STAT3 in the hope of developing an antitumor agent.  Although several STAT3-specific agents are promising, none are in clin. development, mostly because of drug delivery and stability issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNhsiRGSIrurVg90H21EOLACvtfcHk0ljo-BhbkXLZaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFemsLo%253D&md5=95c66236308869cb292b12e8a52e482c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.oraloncology.2015.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.oraloncology.2015.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DMali%26aufirst%3DS.%2BB.%26atitle%3DReview%2520of%2520STAT3%2520%2528signal%2520transducers%2520and%2520activators%2520of%2520transcription%2529%2520in%2520head%2520and%2520neck%2520cancer%26jtitle%3DOral%2520Oncol.%26date%3D2015%26volume%3D51%26spage%3D565%26epage%3D569%26doi%3D10.1016%2Fj.oraloncology.2015.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, S.</span></span> <span> </span><span class="NLM_article-title">Regulation of STAT signaling by acetylation</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1924</span>â <span class="NLM_lpage">1931</span>, <span class="refDoi">Â DOI: 10.1016/j.cellsig.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.cellsig.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23707527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOrs7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2013&pages=1924-1931&author=S.+Zhuang&title=Regulation+of+STAT+signaling+by+acetylation&doi=10.1016%2Fj.cellsig.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of STAT signaling by acetylation</span></div><div class="casAuthors">Zhuang, Shougang</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1924-1931</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Signal transducers and activators of transcription (STAT) belong to a family of latent cytoplasmic factors that can be activated by tyrosine phosphorylation by the members of the Jak tyrosine kinase family in response to a variety of cytokines and growth factors.  Activated STATs form dimers and translocate into nucleus to induce expression of crit. genes essential for normal cellular events.  In the past several years, significant progress has been made in the characterization of STAT acetylation, which is dependent on the balance between histone deacetylases (HDACs) and histone acetyltransferases (HATs) such as CBP/p300.  Acetylation of STAT1, STAT2, STAT3, STAT5b and STAT6 has been identified.  This review will highlight acetylation on the modulation of STAT activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWOAPz0pMzJrVg90H21EOLACvtfcHk0ljo-BhbkXLZaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOrs7bK&md5=04e6ecdf61d95e4f51762a2d81f83ef9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhuang%26aufirst%3DS.%26atitle%3DRegulation%2520of%2520STAT%2520signaling%2520by%2520acetylation%26jtitle%3DCell.%2520Signalling%26date%3D2013%26volume%3D25%26spage%3D1924%26epage%3D1931%26doi%3D10.1016%2Fj.cellsig.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sgrignani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merulla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catapano, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Structural biology of STAT3 and its implications for anticancer therapies development</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1591</span>, <span class="refDoi">Â DOI: 10.3390/ijms19061591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fijms19061591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSrt73O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1591&author=J.+Sgrignaniauthor=M.+Garofaloauthor=M.+Matkovicauthor=J.+Merullaauthor=C.+V.+Catapanoauthor=A.+Cavalli&title=Structural+biology+of+STAT3+and+its+implications+for+anticancer+therapies+development&doi=10.3390%2Fijms19061591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structural biology of STAT3 and its implications for anticancer therapies development</span></div><div class="casAuthors">Sgrignani, Jacopo; Garofalo, Maura; Matkovic, Milos; Merulla, Jessica; Catapano, Carlo V.; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1591/1-1591/14</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Transcription factors are proteins able to bind DNA and induce the transcription of specific genes.  Consequently, they play a pivotal role in multiple cellular pathways and are frequently over-expressed or dysregulated in cancer.  Here, we will focus on a specific "signal transducer and activator of transcription" (STAT3) factor that is involved in several pathologies, including cancer.  For long time, the mechanism by which STAT3 exerts its cellular functions has been summarized by a three steps process: (1) Protein phosphorylation by specific kinases, (2) dimerization promoted by phosphorylation, (3) activation of gene expression by the phosphorylated dimer.  Consequently, most of the inhibitors reported in literature aimed at blocking phosphorylation and dimerization.  However, recent observations reopened the debate and the entire functional mechanism has been revisited stimulating the scientific community to pursue new inhibition strategies.  In particular, the dimerization of the unphosphorylated species has been exptl. demonstrated and specific roles proposed also for these dimers.  Despite difficulties in the expression and purifn. of the full length STAT3, structural biol. investigations allowed the detn. of atomistic structures of STAT3 dimers and several protein domains.  Starting from this information, computational methods have been used both to improve the understanding of the STAT3 functional mechanism and to design new inhibitors to be used as anticancer drugs.  In this review, we will focus on the contribution of structural biol. to understand the roles of STAT3, to design new inhibitors and to suggest new strategies of pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwOe7is1W8ZLVg90H21EOLACvtfcHk0lgycKGL6j2ozA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSrt73O&md5=5144a31d327b9fd68e0956f8f2dffeeb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3390%2Fijms19061591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19061591%26sid%3Dliteratum%253Aachs%26aulast%3DSgrignani%26aufirst%3DJ.%26aulast%3DGarofalo%26aufirst%3DM.%26aulast%3DMatkovic%26aufirst%3DM.%26aulast%3DMerulla%26aufirst%3DJ.%26aulast%3DCatapano%26aufirst%3DC.%2BV.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DStructural%2520biology%2520of%2520STAT3%2520and%2520its%2520implications%2520for%2520anticancer%2520therapies%2520development%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D1591%26doi%3D10.3390%2Fijms19061591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go? <i>Eur</i></span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111922</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.111922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.111922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31810784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitleqsb3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111922&author=Q.+Huangauthor=Y.+Zhongauthor=H.+Dongauthor=Q.+Zhengauthor=S.+Shiauthor=K.+Zhuauthor=X.+Quauthor=W.+Huauthor=X.+Zhangauthor=Y.+Wang&title=Revisiting+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+as+an+anticancer+target+and+its+inhibitor+discovery%3A+where+are+we+and+where+should+we+go%3F+Eur&doi=10.1016%2Fj.ejmech.2019.111922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?</span></div><div class="casAuthors">Huang, Qiuyao; Zhong, Yan; Dong, Hui; Zheng, Qiyao; Shi, Shuo; Zhu, Kai; Qu, Xinming; Hu, Wenhao; Zhang, Xiaolei; Wang, Yuanxiang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111922</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  As a transcription factor, STAT3 protein transduces extracellular signals to the nucleus and then activates transcription of target genes.  STAT3 has been well validated as an attractive anticancer target due to its important roles in cancer initiation and progression.  Identification of specific and potent STAT3 inhibitors has attracted much attention, while there has been no STAT3 targeted drug approved for clin. application.  In this review, we will briefly introduce STAT3 protein and review its role in multiple aspects of cancer, and systematically summarize the recent advances in discovery of STAT3 inhibitors, esp. the ones discovered in the past five years.  In the last part of the review, we will discuss the possible new strategies to overcome the difficulties of developing potent and specific STAT3 inhibitors and hope to shed light on future drug design and inhibitor optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgUc7yryGAQ7Vg90H21EOLACvtfcHk0lgycKGL6j2ozA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitleqsb3E&md5=98f36d6eb8d622babb00c6135a486a7e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111922%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DRevisiting%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520as%2520an%2520anticancer%2520target%2520and%2520its%2520inhibitor%2520discovery%253A%2520where%2520are%2520we%2520and%2520where%2520should%2520we%2520go%253F%2520Eur%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111922%26doi%3D10.1016%2Fj.ejmech.2019.111922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">Impact of the N-terminal domain of STAT3 in STAT3-dependent transcriptional activity</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3284</span>â <span class="NLM_lpage">3300</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00060-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1128%2FMCB.00060-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26169829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtlKqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=3284-3300&author=T.+Huauthor=J.+E.+Yehauthor=L.+Pinelloauthor=J.+Jacobauthor=S.+Chakravarthyauthor=G.-C.+Yuanauthor=R.+Chopraauthor=D.+A.+Frank&title=Impact+of+the+N-terminal+domain+of+STAT3+in+STAT3-dependent+transcriptional+activity&doi=10.1128%2FMCB.00060-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of the N-terminal domain of STAT3 in STAT3-dependent transcriptional activity</span></div><div class="casAuthors">Hu, Tiancen; Yeh, Jennifer E.; Pinello, Luca; Jacob, Jaison; Chakravarthy, Srinivas; Yuan, Guo-Cheng; Chopra, Rajiv; Frank, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3284-3300</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is constitutively active in many cancers, where it mediates important biol. effects, including cell proliferation, differentiation, survival, and angiogenesis.  The N-terminal domain (NTD) of STAT3 performs multiple functions, such as cooperative DNA binding, nuclear translocation, and protein-protein interactions.  However, it is unclear which subsets of STAT3 target genes depend on the NTD for transcriptional regulation.  To identify such genes, we compared gene expression in STAT3-null mouse embryonic fibroblasts (MEFs) stably expressing wild-type STAT3 or STAT3 from which NTD was deleted.  NTD deletion reduced the cytokine-induced expression of specific STAT3 target genes by decreasing STAT3 binding to their regulatory regions.  To better understand the potential mechanisms of this effect, we detd. the crystal structure of the STAT3 NTD and identified a dimer interface responsible for cooperative DNA binding in vitro.  We also obsd. an Ni2+-mediated oligomer with an as yet unknown biol. function.  Mutations on both dimer and Ni2+-mediated interfaces affected the cytokine induction of STAT3 target genes.  These studies shed light on the role of the NTD in transcriptional regulation by STAT3 and provide a structural template with which to design STAT3 NTD inhibitors with potential therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT_6JMQ7jV3LVg90H21EOLACvtfcHk0lg7DcaFNrOQMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtlKqtQ%253D%253D&md5=9ff4b3664f457a00aa12be6777ae58f1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FMCB.00060-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00060-15%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DT.%26aulast%3DYeh%26aufirst%3DJ.%2BE.%26aulast%3DPinello%26aufirst%3DL.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DChakravarthy%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DG.-C.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DImpact%2520of%2520the%2520N-terminal%2520domain%2520of%2520STAT3%2520in%2520STAT3-dependent%2520transcriptional%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D3284%26epage%3D3300%26doi%3D10.1128%2FMCB.00060-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span> <span> </span><span class="NLM_article-title">A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">29252</span>â <span class="NLM_lpage">29260</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M304196200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M304196200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=12746441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsl2mt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=29252-29260&author=J.+Maauthor=T.+Zhangauthor=V.+Novotny-Diermayrauthor=A.+L.+C.+Tanauthor=X.+Cao&title=A+novel+sequence+in+the+coiled-coil+domain+of+Stat3+essential+for+its+nuclear+translocation&doi=10.1074%2Fjbc.M304196200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation</span></div><div class="casAuthors">Ma, Jing; Zhang, Tong; Novotny-Diermayr, Veronica; Tan, Agnes L. C.; Cao, Xinmin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">29252-29260</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Stat3 is activated by cytokines and growth factors via specific tyrosine phosphorylation, dimerization, and nuclear translocation.  However, the mechanism involved in its nuclear translocation is unclear.  In this study, by systematic deletion and site-directed mutagenesis we identified Arg-214/215 in the Î±-helix 2 region of the coiled-coil domain of Stat3 as a novel sequence element essential for its nuclear translocation, stimulated by epidermal growth factor as well as by interleukin-6.  Furthermore, we identified Arg-414/417 in the DNA binding domain as also required for the nuclear localization of Stat3.  This sequence element corresponds to Lys-410/413 of Stat1, a reported sequence for Stat1 nuclear translocation.  On the other hand, Leu-411 of Stat3, corresponding to Leu-407 of Stat1, a necessary residue for Stat1 nuclear transport, is not essential for Stat3 nuclear import.  The mutant of Arg-214/215 or Arg-414/417 was shown to be tyrosyl-phosphorylated normally but failed to enter the nucleus in response to epidermal growth factor or interleukin-6.  The defect, however, can be rescued by the wild-type Stat3 but cannot be compensated by these two mutants.  Mutations on Arg-414/417, but not Arg-214/215, destroy the DNA binding activity of Stat3.  Our data for the first time identified a sequence element located in the coiled-coil domain that is involved in the ligand-induced nuclear translocation of Stat3.  This novel sequence together with a conserved sequence element in the DNA binding domain coordinates to mediate the nuclear translocation of Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_piovgbYiabVg90H21EOLACvtfcHk0lg7DcaFNrOQMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsl2mt74%253D&md5=5aab663722249518f57b09e25652b244</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M304196200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M304196200%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DTan%26aufirst%3DA.%2BL.%2BC.%26aulast%3DCao%26aufirst%3DX.%26atitle%3DA%2520novel%2520sequence%2520in%2520the%2520coiled-coil%2520domain%2520of%2520Stat3%2520essential%2520for%2520its%2520nuclear%2520translocation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D29252%26epage%3D29260%26doi%3D10.1074%2Fjbc.M304196200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span> <span> </span><span class="NLM_article-title">Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">74</span>â <span class="NLM_lpage">91</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2018.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.pharmthera.2018.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29933035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2ltrfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2018&pages=74-91&author=J.+D.+Beebeauthor=J.+Y.+Liuauthor=J.+T.+Zhang&title=Two+decades+of+research+in+discovery+of+anticancer+drugs+targeting+STAT3%2C+how+close+are+we%3F&doi=10.1016%2Fj.pharmthera.2018.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we</span></div><div class="casAuthors">Beebe, Jenny D.; Liu, Jing-Yuan; Zhang, Jian-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-91</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) controls many biol. processes including differentiation, survival, proliferation, and angiogenesis.  In normal healthy cells, STAT3 is tightly regulated to maintain a momentary active state.  However, aberrant or constitutively activated STAT3 has been obsd. in many different cancers and constitutively activated STAT3 has been shown to assoc. with poor prognosis and tumor progression.  For this reason, STAT3 has been studied as a possible target in the treatment of many different types of cancers.  However, despite decades of research, a FDA-approved STAT3 inhibitor has yet to emerge.  In this , we will analyze past studies targeting STAT3 for drug discovery, understand possible causes of failure in these studies, and provide potential insights for future efforts to overcome these roadblocks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSWDPJOIaRKrVg90H21EOLACvtfcHk0lhFcaNDBRH1ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2ltrfO&md5=048e7d95608bdab18335c55d084d62ab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DBeebe%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26atitle%3DTwo%2520decades%2520of%2520research%2520in%2520discovery%2520of%2520anticancer%2520drugs%2520targeting%2520STAT3%252C%2520how%2520close%2520are%2520we%253F%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D191%26spage%3D74%26epage%3D91%26doi%3D10.1016%2Fj.pharmthera.2018.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haripal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, J. E.</span></span> <span> </span><span class="NLM_article-title">Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">14811</span>â <span class="NLM_lpage">14816</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1515876112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.1515876112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26553978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyru7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=14811-14816&author=C.+Mertensauthor=B.+Haripalauthor=S.+Klingeauthor=J.+E.+Darnell&title=Mutations+in+the+linker+domain+affect+phospho-STAT3+function+and+suggest+targets+for+interrupting+STAT3+activity&doi=10.1073%2Fpnas.1515876112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity</span></div><div class="casAuthors">Mertens, Claudia; Haripal, Bhagwattie; Klinge, Sebastian; Darnell, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14811-14816</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Crystallog. of the cores of phosphotyrosine-activated dimers of STAT1 (132-713) and STAT3 (127-722) bound to a similar double-stranded deoxyoligonucleotide established the domain structure of the STATs and the structural basis for activation through tyrosine phosphorylation and dimerization.  The authors reported earlier that mutants in the linker domain of STAT1 that connect the DNA-binding domain and SH2 domain can prevent transcriptional activation.  Because of the pervasive importance of persistently activated STAT3 in many human cancers and the difficulty of finding useful drug candidates aimed at disrupting the pY interchange in active STAT3 dimers, the authors examd. the effects of an array of mutants in the STAT3 linker domain.  The authors found several STAT3 linker domain mutants to have profound effects of inhibiting STAT3 transcriptional activation.  From these results, the authors propose (1) there is definite functional interaction of the linker both with the DNA binding domain and with the SH2 domain, and (2) these putative contacts provide potential new targets for small mol.-induced pSTAT3 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov0W2HVoaitrVg90H21EOLACvtfcHk0lhFcaNDBRH1ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyru7vP&md5=74698f2ed4b16e8f3e27a18c7bdfd889</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1515876112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1515876112%26sid%3Dliteratum%253Aachs%26aulast%3DMertens%26aufirst%3DC.%26aulast%3DHaripal%26aufirst%3DB.%26aulast%3DKlinge%26aufirst%3DS.%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DMutations%2520in%2520the%2520linker%2520domain%2520affect%2520phospho-STAT3%2520function%2520and%2520suggest%2520targets%2520for%2520interrupting%2520STAT3%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D14811%26epage%3D14816%26doi%3D10.1073%2Fpnas.1515876112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merulla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catapano, C. V.</span></span> <span> </span><span class="NLM_article-title">Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3)</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1194</span>â <span class="NLM_lpage">1206</span>, <span class="refDoi">Â DOI: 10.1016/j.molonc.2015.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.molonc.2015.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25777967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVKhtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=1194-1206&author=L.+Brambillaauthor=D.+Geniniauthor=E.+Lauriniauthor=J.+Merullaauthor=L.+Perezauthor=M.+Fermegliaauthor=G.+M.+Carboneauthor=S.+Priclauthor=C.+V.+Catapano&title=Hitting+the+right+spot%3A+mechanism+of+action+of+OPB-31121%2C+a+novel+and+potent+inhibitor+of+the+signal+transducer+and+activator+of+transcription+3+%28STAT3%29&doi=10.1016%2Fj.molonc.2015.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)</span></div><div class="casAuthors">Brambilla, Lara; Genini, Davide; Laurini, Erik; Merulla, Jessica; Perez, Laurent; Fermeglia, Maurizio; Carbone, Giuseppina M.; Pricl, Sabrina; Catapano, Carlo V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1194-1206</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">STAT3 is a key element in many oncogenic pathways and, like other transcription factors, is an attractive target for development of novel anticancer drugs.  However, interfering with STAT3 functions has been a difficult task and very few small mol. inhibitors have made their way to the clinic.  OPB-31121, an anticancer compd. currently in clin. trials, has been reported to affect STAT3 signaling, although its mechanism of action has not been unequivocally demonstrated.  In this study, we used a combined computational and exptl. approach to investigate the mol. target and the mode of interaction of OPB-31121 with STAT3.  In parallel, similar studies were performed with known STAT3 inhibitors (STAT3i) to validate our approach.  Computational docking and mol. dynamics simulation (MDS) showed that OPB-31121 interacted with high affinity with the SH2 domain of STAT3.  Interestingly, there was no overlap of the OPB-31121 binding site with those of the other STAT3i.  Computational predictions were confirmed by in vitro binding assays and competition expts. along with site-directed mutagenesis of crit. residues in the STAT3 SH2 domain.  Isothermal titrn. calorimetry expts. demonstrated the remarkably high affinity of OPB-31121 for STAT3 with Kd (10 nM) 2-3 orders lower than other STAT3i.  Notably, a similar ranking of the potency of the compds. was obsd. in terms of inhibition of STAT3 phosphorylation, cancer cell proliferation and clonogenicity.  These results suggest that the high affinity and efficacy of OPB-31121 might be related to the unique features and mode of interaction of OPB-31121 with STAT3.  These unique characteristics make OPB-31121 a promising candidate for further development and an interesting lead for designing new, more effective STAT3i.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUVETM9GX5ZbVg90H21EOLACvtfcHk0lhFcaNDBRH1ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVKhtbk%253D&md5=c6699a87e3fb26c658c3d6c33c802360</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2015.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2015.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DBrambilla%26aufirst%3DL.%26aulast%3DGenini%26aufirst%3DD.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DMerulla%26aufirst%3DJ.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DCarbone%26aufirst%3DG.%2BM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DCatapano%26aufirst%3DC.%2BV.%26atitle%3DHitting%2520the%2520right%2520spot%253A%2520mechanism%2520of%2520action%2520of%2520OPB-31121%252C%2520a%2520novel%2520and%2520potent%2520inhibitor%2520of%2520the%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26spage%3D1194%26epage%3D1206%26doi%3D10.1016%2Fj.molonc.2015.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. L.</span></span> <span> </span><span class="NLM_article-title">STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review)</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1181</span>â <span class="NLM_lpage">1191</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2012.1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3892%2Fijo.2012.1568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22842992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFyntLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=1181-1191&author=X.+Wangauthor=P.+J.+Croweauthor=D.+Goldsteinauthor=J.+L.+Yang&title=STAT3+inhibition%2C+a+novel+approach+to+enhancing+targeted+therapy+in+human+cancers+%28review%29&doi=10.3892%2Fijo.2012.1568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review)</span></div><div class="casAuthors">Wang, Xiaochun; Crowe, Philip J.; Goldstein, David; Yang, Jia-Lin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1181-1191</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) regulates many crit. functions in human normal and malignant tissues, such as differentiation, proliferation, survival, angiogenesis and immune function.  Constitutive activation of STAT3 is implicated in a wide range of human cancers.  As such, STAT3 has been studied as a tumor therapeutic target.  This review aimed principally to summarize the updated research on STAT3 inhibition studies and their therapeutic potential in solid tumors.  Recent literature assocd. with STAT3 inhibition was reviewed through PubMed and Medline database, followed by crit. comparison and anal.  Constitutive activation of STAT3 has been identified as abnormal and oncogenic.  The pathway of STAT3 activation and signal transduction identifies 3 approaches for inhibition: modulating upstream pos. or neg. regulators, regulating RNA (DN-STAT3, anti-sense RNA, siRNA and microRNA) or targeting STAT3 protein at different domains.  The last approach using small mol. STAT3 inhibitors has been the most examd. so far with both preclin. and clin. studies.  Targeting STAT3 using a specific inhibitor may be a useful cancer treatment approach, with the potential for a broad clin. impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnx1B_eI0cs7Vg90H21EOLACvtfcHk0li9oHzl9UZokw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFyntLjF&md5=91d64864c492ebe00e5d6a1cc6072284</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3892%2Fijo.2012.1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2012.1568%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCrowe%26aufirst%3DP.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%2BL.%26atitle%3DSTAT3%2520inhibition%252C%2520a%2520novel%2520approach%2520to%2520enhancing%2520targeted%2520therapy%2520in%2520human%2520cancers%2520%2528review%2529%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2012%26volume%3D41%26spage%3D1181%26epage%3D1191%26doi%3D10.3892%2Fijo.2012.1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avalle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camporeale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camperi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, V.</span></span> <span> </span><span class="NLM_article-title">STAT3 in cancer: A double edged sword</span>. <i>Cytokine+</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">42</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1016/j.cyto.2017.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.cyto.2017.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28579221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVWrt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2017&pages=42-50&author=L.+Avalleauthor=A.+Camporealeauthor=A.+Camperiauthor=V.+Poli&title=STAT3+in+cancer%3A+A+double+edged+sword&doi=10.1016%2Fj.cyto.2017.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 in cancer: A double edged sword</span></div><div class="casAuthors">Avalle, Lidia; Camporeale, Annalisa; Camperi, Andrea; Poli, Valeria</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The transcription factor signal transducer and activator of transcription (STAT) 3 is activated downstream of cytokines, growth factors and oncogenes to mediate their functions under both physiol. and pathol. conditions.  In particular, aberrant/unrestrained STAT3 activity is detected in a wide variety of tumors, driving multiple pro-oncogenic functions.  For that, STAT3 is widely considered as an oncogene and is the object of intense translational studies.  One of the distinctive features of this factor is however, its ability to elicit different and sometimes contrasting effects under different conditions.  In particular, STAT3 activities have been shown to be either pro-oncogenic or tumor-suppressive according to the tumor etiol./mutational landscape, suggesting that the mol. bases underlining its functions are still incompletely understood.  Here we discuss some of the properties that may provide the bases to explain STAT3 heterogeneous functions, and in particular how post-translational modifications contribute shaping its sub-cellular localization and activities, the cross talk between these activities and cell metabolic conditions, and finally how its functions can control the behavior of both tumor and tumor microenvironment cell populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHMu-uQSt597Vg90H21EOLACvtfcHk0li9oHzl9UZokw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVWrt7c%253D&md5=71a9398a10fe082cd2ccafb15672865a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2017.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2017.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DAvalle%26aufirst%3DL.%26aulast%3DCamporeale%26aufirst%3DA.%26aulast%3DCamperi%26aufirst%3DA.%26aulast%3DPoli%26aufirst%3DV.%26atitle%3DSTAT3%2520in%2520cancer%253A%2520A%2520double%2520edged%2520sword%26jtitle%3DCytokine%252B%26date%3D2017%26volume%3D98%26spage%3D42%26epage%3D50%26doi%3D10.1016%2Fj.cyto.2017.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Her, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H. Y.</span></span> <span> </span><span class="NLM_article-title">Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling</span>. <i>J. Nutr. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">228</span>â <span class="NLM_lpage">238</span>, <span class="refDoi">Â DOI: 10.1016/j.jnutbio.2010.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.jnutbio.2010.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21497499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVWmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=228-238&author=G.+T.+Kwonauthor=J.+I.+Jungauthor=H.+R.+Songauthor=E.+Y.+Wooauthor=J.-G.+Junauthor=J.-K.+Kimauthor=S.+Herauthor=J.+H.+Y.+Park&title=Piceatannol+inhibits+migration+and+invasion+of+prostate+cancer+cells%3A+possible+mediation+by+decreased+interleukin-6+signaling&doi=10.1016%2Fj.jnutbio.2010.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling</span></div><div class="casAuthors">Kwon, Gyoo Taik; Jung, Jae In; Song, Hye Rim; Woo, Eun Young; Jun, Jong-Gab; Kim, Jin-Kyung; Her, Song; Park, Jung Han Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutritional Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">228-238</span>CODEN:
                <span class="NLM_cas:coden">JNBIEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-2863</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Piceatannol (trans-3,4,3',5'-tetrahydroxystilbene) is a polyphenol detected in grapes, red wine and Rheum undulatum; it was also demonstrated to exert anticarcinogenic effects.  In this study, to det. whether piceatannol inhibits the lung metastasis of prostate cancer cells, MAT-Ly-Lu (MLL) rat prostate cancer cells expressing luciferase were injected into the tail veins of male nude mice.  The oral administration of piceatannol (20 mg/kg) significantly inhibited the accumulation of MLL cells in the lungs of these mice.  In the cell culture studies, piceatannol was demonstrated to inhibit the basal and epidermal growth factor (EGF)-induced migration and invasion of DU145 cells, in addn. to the migration of MLL, PC3, and TRAMP-C2 prostate cancer cells.  In DU145 cells, piceatannol attenuated the secretion and mRNA levels of matrix metalloproteinase-9, urokinase-type plasminogen activator (uPA), and vascular endothelial growth factor (VEGF).  Piceatannol increased the protein levels of tissue inhibitor of metalloproteinase-2 in a concn.-dependent fashion.  Addnl., piceatannol inhibited the phosphorylation of signal transducer and activator of transcription (STAT) 3.  Furthermore, piceatannol effected redns. in both basal and EGF-induced interleukin (IL)-6 secretion.  An IL-6 neutralizing antibody inhibited EGF-induced STAT3 phosphorylation and EGF-stimulated migration of DU145 cells.  Interleukin-6 treatment was also shown to enhance the secretion of uPA and VEGF, STAT3 phosphorylation, and the migration of DU145 cells; these increases were suppressed by piceatannol.  These results demonstrate that the inhibition of IL-6/STAT3 signaling may constitute a mechanism by which piceatannol regulates the expression of proteins involved in regulating the migration and invasion of DU145 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7iUsfwEWQKbVg90H21EOLACvtfcHk0li9oHzl9UZokw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVWmtLk%253D&md5=3e6835f5a66896262d5517185bd78b4d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jnutbio.2010.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jnutbio.2010.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DG.%2BT.%26aulast%3DJung%26aufirst%3DJ.%2BI.%26aulast%3DSong%26aufirst%3DH.%2BR.%26aulast%3DWoo%26aufirst%3DE.%2BY.%26aulast%3DJun%26aufirst%3DJ.-G.%26aulast%3DKim%26aufirst%3DJ.-K.%26aulast%3DHer%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%2BH.%2BY.%26atitle%3DPiceatannol%2520inhibits%2520migration%2520and%2520invasion%2520of%2520prostate%2520cancer%2520cells%253A%2520possible%2520mediation%2520by%2520decreased%2520interleukin-6%2520signaling%26jtitle%3DJ.%2520Nutr.%2520Biochem.%26date%3D2012%26volume%3D23%26spage%3D228%26epage%3D238%26doi%3D10.1016%2Fj.jnutbio.2010.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chau, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, P. P.</span></span> <span> </span><span class="NLM_article-title">Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">627</span>â <span class="NLM_lpage">631</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2008.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bbrc.2008.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=18930029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlykt7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2008&pages=627-631&author=M.+N.+Chauauthor=P.+P.+Banerjee&title=Development+of+a+STAT3+reporter+prostate+cancer+cell+line+for+high+throughput+screening+of+STAT3+activators+and+inhibitors&doi=10.1016%2Fj.bbrc.2008.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors</span></div><div class="casAuthors">Chau, My N.; Banerjee, Partha P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-631</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">STAT3 is constitutively activated in several cancers, including prostate cancer, and is therefore, a potential target for cancer therapy.  DU-145 prostate cancer cells were stably co-transfected with STAT3 reporter and puromycin resistant plasmids to create a stable STAT3 reporter cell line that can be used for high throughput screening of STAT3 modulators.  The applicability of this cell line was tested with two known activators and inhibitors of STAT3.  As expected, EGF and IL-6 increased STAT3 reporter activity and enhanced the nuclear localization of phosphorylated STAT3 (pSTAT3); whereas Cucurbitacin I and AG490 decreased STAT3 reporter activity dose and time-dependently and reduced the localization of pSTAT3 in the nuclei of prostate cancer cells.  Given the importance of STAT3 in cancer initiation and progression, the development of a stable STAT3 reporter cell line in prostate cancer cells provides a rapid, sensitive, and cost effective method for the screening of potential STAT3 modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjSY8FsvDnt7Vg90H21EOLACvtfcHk0liPz54gVXQa0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlykt7nE&md5=dcdbd3c066f54ef2c3fd66a1de526229</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2008.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2008.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DChau%26aufirst%3DM.%2BN.%26aulast%3DBanerjee%26aufirst%3DP.%2BP.%26atitle%3DDevelopment%2520of%2520a%2520STAT3%2520reporter%2520prostate%2520cancer%2520cell%2520line%2520for%2520high%2520throughput%2520screening%2520of%2520STAT3%2520activators%2520and%2520inhibitors%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2008%26volume%3D377%26spage%3D627%26epage%3D631%26doi%3D10.1016%2Fj.bbrc.2008.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djeu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekharam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">7519</span>â <span class="NLM_lpage">7528</span>, <span class="refDoi">Â DOI: 10.1128/MCB.19.11.7519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1128%2FMCB.19.11.7519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10523640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADyaK1MXmvFekt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=7519-7528&author=J.+Turksonauthor=T.+Bowmanauthor=J.+Adnaneauthor=Y.+Zhangauthor=J.+Y.+Djeuauthor=M.+Sekharamauthor=D.+A.+Frankauthor=L.+B.+Holzmanauthor=J.+Wuauthor=S.+Sebtiauthor=R.+Jove&title=Requirement+for+Ras%2FRac1-mediated+p38+and+c-Jun+N-terminal+kinase+signaling+in+Stat3+transcriptional+activity+induced+by+the+Src+oncoprotein&doi=10.1128%2FMCB.19.11.7519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein</span></div><div class="casAuthors">Turkson, James; Bowman, Tammy; Adnane, Jalila; Zhang, Yi; Djeu, Julie Y.; Sekharam, Madhavi; Frank, David A.; Holzman, Lawrence B.; Wu, Jie; Sebti, Said; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7519-7528</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Signal transducers and activators of transcription (STATs) are transcription factors that mediate normal biol. responses to cytokines and growth factors.  However, abnormal activation of certain STAT family members, including Stat3, is increasingly assocd. with oncogenesis.  In fibroblasts expressing the Src oncoprotein, activation of Stat3 induces specific gene expression and is required for cell transformation.  Although the Src tyrosine kinase induces constitutive Stat3 phosphorylation on tyrosine, activation of Stat3-mediated gene regulation requires both tyrosine and serine phosphorylation of Stat3.  The authors investigated the signaling pathways underlying the constitutive Stat3 activation in Src oncogenesis.  Expression of Ras or Rac1 dominant neg. protein blocks Stat3-mediated gene regulation induced by Src in a manner consistent with dependence on p38 and c-Jun N-terminal kinase (JNK).  Both of these serine/threonine kinases and Stat3 serine phosphorylation are constitutively induced in Src-transformed fibroblasts.  Furthermore, inhibition of p38 and JNK activities suppresses constitutive Stat3 serine phosphorylation and Stat3-mediated gene regulation.  In vitro kinase assays with purified full-length Stat3 as the substrate show that both JNK and p38 can phosphorylate Stat3 on serine.  Moreover, inhibition of p38 activity and thus of Stat3 serine phosphorylation results in suppression of transformation by v-Src but not v-Ras, consistent with a requirement for Stat3 serine phosphorylation in Src transformation.  Thus, Ras- and Rac1-mediated p38 and JNK signals are required for Stat3 transcriptional activity induced by the Src oncoprotein.  These findings delineate a network of tyrosine and serine/threonine kinase signaling pathways that converge on Stat3 in the context of oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpirhwvHZUk8rVg90H21EOLACvtfcHk0liPz54gVXQa0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvFekt7o%253D&md5=5aa32d4a465f4a692b77f7cd11b43b2c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.11.7519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.11.7519%26sid%3Dliteratum%253Aachs%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DBowman%26aufirst%3DT.%26aulast%3DAdnane%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDjeu%26aufirst%3DJ.%2BY.%26aulast%3DSekharam%26aufirst%3DM.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DHolzman%26aufirst%3DL.%2BB.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSebti%26aufirst%3DS.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DRequirement%2520for%2520Ras%252FRac1-mediated%2520p38%2520and%2520c-Jun%2520N-terminal%2520kinase%2520signaling%2520in%2520Stat3%2520transcriptional%2520activity%2520induced%2520by%2520the%2520Src%2520oncoprotein%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D7519%26epage%3D7528%26doi%3D10.1128%2FMCB.19.11.7519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, D.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibitors of the STAT3 signaling pathway</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112122</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2020.112122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32066011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGquro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112122&author=J.+Qinauthor=X.+Shenauthor=J.+Zhangauthor=D.+Jia&title=Allosteric+inhibitors+of+the+STAT3+signaling+pathway&doi=10.1016%2Fj.ejmech.2020.112122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibitors of the STAT3 signaling pathway</span></div><div class="casAuthors">Qin, Junhong; Shen, Xiaofei; Zhang, Jian; Jia, Da</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112122</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Over-expression and/or hyperactivation of signal transducer and activator of transcription 3 (STAT3) signaling are found in various human diseases, including cancer, autoimmune disorders, and inflammatory diseases.  Therefore, STAT3 represents a highly promising therapeutic target for the treatment of these diseases.  However, the traditional orthosteric inhibitors of STAT3 exhibit limited clin. efficacy, with low selectivity, numerous side effects, and emerging acquired resistance.  Allosteric inhibitors targeting STAT3 or its upstream mols. have emerged as a promising approach to overcome these barriers.  In this review, we summarize the recent advances in the development of these inhibitors as well as their applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa406JYjL_hbVg90H21EOLACvtfcHk0lh-dBORN1wxug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGquro%253D&md5=df6d54c3472afce40e63060605cabf73</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112122%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DD.%26atitle%3DAllosteric%2520inhibitors%2520of%2520the%2520STAT3%2520signaling%2520pathway%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112122%26doi%3D10.1016%2Fj.ejmech.2020.112122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, D.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.-m.</span></span> <span> </span><span class="NLM_article-title">Inhibition of STAT3 acetylation is associated with angiotesin renal fibrosis in the obstructed kidney</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1045</span>â <span class="NLM_lpage">1054</span>, <span class="refDoi">Â DOI: 10.1038/aps.2014.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Faps.2014.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24976155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Gqt7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=1045-1054&author=J.+Niauthor=Y.+Shenauthor=Z.+Wangauthor=D.-c.+Shaoauthor=J.+Liuauthor=L.-j.+Fuauthor=Y.-l.+Kongauthor=L.+Zhouauthor=H.+Xueauthor=Y.+Huangauthor=W.+Zhangauthor=C.+Yuauthor=L.-m.+Lu&title=Inhibition+of+STAT3+acetylation+is+associated+with+angiotesin+renal+fibrosis+in+the+obstructed+kidney&doi=10.1038%2Faps.2014.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of STAT3 acetylation is associated with angiotesin renal fibrosis in the obstructed kidney</span></div><div class="casAuthors">Ni, Jun; Shen, Yang; Wang, Zhen; Shao, De-cui; Liu, Jia; Fu, Lan-jun; Kong, Ya-li; Zhou, Li; Xue, Hong; Huang, Yu; Zhang, Wei; Yu, Chen; Lu, Li-min</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1045-1054</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: To explore the relationship between the signal transducer and activator of transcription 3 (STAT3) signaling and renal fibrosis.  Methods: Rat renal tubular epithelial NRK-52E cells were treated with angiotesin II (Ang II), nicotinamide (an inhibitor of NAD+-dependent class III protein deacetylases, SIRT1-7), or resveratrol (an activator of SIRT1).  Mice underwent unilateral ureteral obstruction (UUO) were used for in vivo studies.  Renal interstitial fibrosis was obsd. with HE and Masson's trichrome staining.  STAT3 acetylation and phosphorylation, fibronectin, collagen I, collagen IV, and Î±-smooth muscle actin (Î±-SMA) levels were examd. using Western blotting.  Results: Nicotinamide (0.625-10 mmol/L) dose-dependently increased STAT3 acetylation on Lys685 and phosphorylation on Tyr705 in NRK-52E cells, accompanied by accumulation of fibronectin and collagen IV.  Ang II increased STAT3 phosphorylation on Tyr705 and the expression of fibronectin, collagen IV and Î±-SMA in the cells.  Pretreatment with resveratrol (12.5 Î¼mol/L) blocked Ang II-induced effects in the cells.  UUO induced marked STAT3 phosphorylation, fibronectin, collagen IV and Î±-SMA accumulation, and renal interstitial fibrosis in the obstructed kidneys, which were significantly attenuated by daily administration of resveratrol (100 mg/kg).  Conclusion: STAT3 acetylation plays an important role in activation of STAT3 signaling pathway and consequent renal fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIN_kegmb64LVg90H21EOLACvtfcHk0lh-dBORN1wxug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Gqt7rL&md5=41ea1a8d831258b61f18f9944bfd037b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Faps.2014.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2014.42%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DShao%26aufirst%3DD.-c.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.-j.%26aulast%3DKong%26aufirst%3DY.-l.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DL.-m.%26atitle%3DInhibition%2520of%2520STAT3%2520acetylation%2520is%2520associated%2520with%2520angiotesin%2520renal%2520fibrosis%2520in%2520the%2520obstructed%2520kidney%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D1045%26epage%3D1054%26doi%3D10.1038%2Faps.2014.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherukuri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span> <span> </span><span class="NLM_article-title">Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">11528</span>â <span class="NLM_lpage">11534</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M413930200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M413930200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=15649887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVyjtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=11528-11534&author=R.+Wangauthor=P.+Cherukuriauthor=J.+Luo&title=Activation+of+Stat3+sequence-specific+DNA+binding+and+transcription+by+p300%2FCREB-binding+protein-mediated+acetylation&doi=10.1074%2Fjbc.M413930200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Stat3 Sequence-specific DNA Binding and Transcription by p300/CREB-binding Protein-mediated Acetylation</span></div><div class="casAuthors">Wang, Rui; Cherukuri, Pratima; Luo, Jianyuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">11528-11534</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Signal transducers and activators of transcription (Stat) belong to a family of latent cytoplasmic factors that can be activated by tyrosine phosphorylation by members of the Jak tyrosine kinase family in response to a variety of cytokines and growth factors.  Activated Stats form dimers and translocate into nucleus to induce expression of crit. genes essential for normal cellular events.  Here we report for the first time that Stat3 can be modified by acetylation both in vivo and in vitro.  A major site of Stat3 that is acetylated by its coactivator, p300/CREB-binding protein (CBP), resides in the C-terminal transcriptional activation domain at lysine 685.  Furthermore, the acetylation of Stat3 can stimulate its sequence-specific DNA binding ability and transactivation activity.  Inhibition of histone deacetylase activity in cells results in increased Stat3 nuclear localization.  These observations clearly indicate a novel mechanism for Stat3 activation in mammalian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ra9np1B00LVg90H21EOLACvtfcHk0lh-dBORN1wxug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVyjtr0%253D&md5=902f7fd6c851e7c526abd0af7eb7fb44</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M413930200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M413930200%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DCherukuri%26aufirst%3DP.%26aulast%3DLuo%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520Stat3%2520sequence-specific%2520DNA%2520binding%2520and%2520transcription%2520by%2520p300%252FCREB-binding%2520protein-mediated%2520acetylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D11528%26epage%3D11534%26doi%3D10.1074%2Fjbc.M413930200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, Y. E.</span></span> <span> </span><span class="NLM_article-title">Stat3 dimerization regulated by reversible acetylation of a single lysine residue</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">273</span>, <span class="refDoi">Â DOI: 10.1126/science.1105166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1126%2Fscience.1105166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=15653507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVKktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=269-273&author=Z.-L.+Yuanauthor=Y.-J.+Guanauthor=D.+Chatterjeeauthor=Y.+E.+Chin&title=Stat3+dimerization+regulated+by+reversible+acetylation+of+a+single+lysine+residue&doi=10.1126%2Fscience.1105166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue</span></div><div class="casAuthors">Yuan, Zheng-long; Guan, Ying-jie; Chatterjee, Devasis; Chin, Y. Eugene</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5707</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Upon cytokine treatment, members of the signal transducers and activators of transcription (STAT) family of proteins are phosphorylated on tyrosine and serine sites within the carboxyl-terminal region in cells.  We show that in response to cytokine treatment, Stat3 is also acetylated on a single lysine residue, Lys685.  Histone acetyltransferase p300-mediated Stat3 acetylation on Lys685 was reversible by type I histone deacetylase (HDAC).  Use of a prostate cancer cell line (PC3) that lacks Stat3 and PC3 cells expressing wild-type Stat3 or a Stat3 mutant contg. a Lys685-to-Arg substitution revealed that Lys685 acetylation was crit. for Stat3 to form stable dimers required for cytokine-stimulated DNA binding and transcriptional regulation, to enhance transcription of cell growth-related genes, and to promote cell cycle progression in response to treatment with oncostatin M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw5wKGemOEgbVg90H21EOLACvtfcHk0lhCOy9vtp9JeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVKktA%253D%253D&md5=0579f46bb06bf59d507295909c0c79be</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1126%2Fscience.1105166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1105166%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DZ.-L.%26aulast%3DGuan%26aufirst%3DY.-J.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DChin%26aufirst%3DY.%2BE.%26atitle%3DStat3%2520dimerization%2520regulated%2520by%2520reversible%2520acetylation%2520of%2520a%2520single%2520lysine%2520residue%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D269%26epage%3D273%26doi%3D10.1126%2Fscience.1105166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoon, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">7765</span>â <span class="NLM_lpage">7769</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1205132109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.1205132109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22547799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Kntrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=7765-7769&author=H.+Leeauthor=P.+Zhangauthor=A.+Herrmannauthor=C.+Yangauthor=H.+Xinauthor=Z.+Wangauthor=D.+S.+Hoonauthor=S.+J.+Formanauthor=R.+Joveauthor=A.+D.+Riggsauthor=H.+Yu&title=Acetylated+STAT3+is+crucial+for+methylation+of+tumor-suppressor+gene+promoters+and+inhibition+by+resveratrol+results+in+demethylation&doi=10.1073%2Fpnas.1205132109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation</span></div><div class="casAuthors">Lee, Heehyoung; Zhang, Peng; Herrmann, Andreas; Yang, Chunmei; Xin, Hong; Wang, Zhenghe; Hoon, Dave S. B.; Forman, Stephen J.; Jove, Richard; Riggs, Arthur D.; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7765-7769, S7765/1-S7765/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mechanisms underlying hypermethylation of tumor-suppressor gene promoters in cancer is not well understood.  Here, we report that lysine acetylation of the oncogenic transcription factor STAT3 is elevated in tumors.  We also show that genetically altering STAT3 at Lys685 reduces tumor growth, which is accompanied by demethylation and reactivation of several tumor-suppressor genes.  Moreover, mutating STAT3 at Lys685 disrupts DNA methyltransferase 1-STAT3 interactions in cultured tumor cells and in tumors.  These observations are confirmed by treatment with an acetylation inhibitor, resveratrol.  Furthermore, redn. of acetylated STAT3 in triple-neg. breast cancer cells leads to demethylation and activation of the estrogen receptor-Î± gene, sensitizing the tumor cells to antiestrogens.  Our results also demonstrate a correlation between STAT3 acetylation and methylation of estrogen receptor-a in melanoma, which predicts melanoma progression.  Taken together, these results suggest a role of STAT3 acetylation in regulating CpG island methylation, which may partially explain aberrant gene silencing in cancer.  These findings also provide a rationale for targeting acetylated STAT3 for chemoprevention and cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK2L3nwZs04LVg90H21EOLACvtfcHk0lhCOy9vtp9JeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Kntrw%253D&md5=5ebf41ab98d7784ffe266ed32e3d7ed8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1205132109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1205132109%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DXin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHoon%26aufirst%3DD.%2BS.%26aulast%3DForman%26aufirst%3DS.%2BJ.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DRiggs%26aufirst%3DA.%2BD.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DAcetylated%2520STAT3%2520is%2520crucial%2520for%2520methylation%2520of%2520tumor-suppressor%2520gene%2520promoters%2520and%2520inhibition%2520by%2520resveratrol%2520results%2520in%2520demethylation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D7765%26epage%3D7769%26doi%3D10.1073%2Fpnas.1205132109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, L. M.</span></span> <span> </span><span class="NLM_article-title">Unphosphorylated STAT3 regulates the antiproliferative, antiviral, and gene-inducing actions of type I interferons</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>490</i></span>,  <span class="NLM_fpage">739</span>â <span class="NLM_lpage">745</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2017.06.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bbrc.2017.06.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28642132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjtrvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2017&pages=739-745&author=S.+R.+Pfefferauthor=M.+Fanauthor=Z.+Duauthor=C.+H.+Yangauthor=L.+M.+Pfeffer&title=Unphosphorylated+STAT3+regulates+the+antiproliferative%2C+antiviral%2C+and+gene-inducing+actions+of+type+I+interferons&doi=10.1016%2Fj.bbrc.2017.06.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Unphosphorylated STAT3 regulates the antiproliferative, antiviral, and gene-inducing actions of type I interferons</span></div><div class="casAuthors">Pfeffer, Susan R.; Fan, Meiyun; Du, Ziyun; Yang, Chuan He; Pfeffer, Lawrence M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">490</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">739-745</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Type I interferon (IFNÎ±/Î²) induces antiviral and antiproliferative responses in cells through the induction of IFN-stimulated genes (ISGs).  Although the roles of IFN-activated STAT1 and STAT2 in the IFN response are well described, the function of STAT3 is poorly characterized.  We investigated the role of STAT3 in the biol. response to IFNÎ±/Î² in mouse embryonic fibroblasts (MEFs) with a germ line deletion of STAT3.  These STAT3 knockout (STAT3-KO) MEFs were reconstituted with STAT3 or the F705-STAT3 mutant (unphosphorylated STAT3) where the canonical Y705 tyrosine phosphorylation site was mutated.  We show that both STAT3 and unphosphorylated STAT3 expression enhance the sensitivity of MEFs to the antiviral, antiproliferative and gene-inducing actions of IFN.  By chromatin immunopptn. assays, unphosphorylated STAT3 appears to bind, albeit weakly, to select gene promoters to enhance their expression.  These results suggest that unphosphorylated STAT3 plays an important role in the IFN response pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-gQRT4n_fM7Vg90H21EOLACvtfcHk0lhCOy9vtp9JeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjtrvL&md5=07069fcc45ad9ef9901b401e07ac92da</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.06.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.06.111%26sid%3Dliteratum%253Aachs%26aulast%3DPfeffer%26aufirst%3DS.%2BR.%26aulast%3DFan%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DPfeffer%26aufirst%3DL.%2BM.%26atitle%3DUnphosphorylated%2520STAT3%2520regulates%2520the%2520antiproliferative%252C%2520antiviral%252C%2520and%2520gene-inducing%2520actions%2520of%2520type%2520I%2520interferons%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D490%26spage%3D739%26epage%3D745%26doi%3D10.1016%2Fj.bbrc.2017.06.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">736</span>â <span class="NLM_lpage">746</span>, <span class="refDoi">Â DOI: 10.1038/nrc3818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fnrc3818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25342631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=736-746&author=H.+Yuauthor=H.+Leeauthor=A.+Herrmannauthor=R.+Buettnerauthor=R.+Jove&title=Revisiting+STAT3+signalling+in+cancer%3A+new+and+unexpected+biological+functions&doi=10.1038%2Fnrc3818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span></div><div class="casAuthors">Yu, Hua; Lee, Heehyoung; Herrmann, Andreas; Buettner, Ralf; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">736-746</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins, particularly STAT3, are among the most promising new targets for cancer therapy.  In addn. to interleukin-6 (IL-6) and its family members, multiple pathways, including G-protein-coupled receptors (GPCRs), Toll-like receptors (TLRs) and microRNAs were recently identified to regulate JAK-STAT signalling in cancer.  Well known for its role in tumor cell proliferation, survival, invasion and immunosuppression, JAK-STAT3 signalling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche.  In addn. to its established role as a transcription factor in cancer, STAT3 regulates mitochondrion functions, as well as gene expression through epigenetic mechanisms.  Newly identified regulators and functions of JAK-STAT3 in tumors are important targets for potential therapeutic strategies in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3PGL62I5KvrVg90H21EOLACvtfcHk0lhogvTFApphMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF&md5=355a07303813d7ecadb4b085c33c5e0a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrc3818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3818%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DRevisiting%2520STAT3%2520signalling%2520in%2520cancer%253A%2520new%2520and%2520unexpected%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D736%26epage%3D746%26doi%3D10.1038%2Fnrc3818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rincon, M.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Stat3, the need for design thinking</span>. <i>Int. J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">532</span>â <span class="NLM_lpage">544</span>, <span class="refDoi">Â DOI: 10.7150/ijbs.15153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.7150%2Fijbs.15153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27019635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCitb7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=532-544&author=R.+Yangauthor=M.+Rincon&title=Mitochondrial+Stat3%2C+the+need+for+design+thinking&doi=10.7150%2Fijbs.15153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Stat3, the need for design thinking</span></div><div class="casAuthors">Yang, Rui; Rincon, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">532-544</span>CODEN:
                <span class="NLM_cas:coden">IJBSB9</span>;
        ISSN:<span class="NLM_cas:issn">1449-2288</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Stat3 has been studied extensively as a transcription factor, however the finding that Stat3 also localizes to mitochondria has opened a new area to discover non-classical functions.  Here we review the current knowledge of mitochondrial Stat3 as a regulator of the electron transport chain (ETC) and its impact on mitochondrial prodn. of ATP and ROS.  We also describe recent findings identifying Stat3 as a regulator of mitochondrial Ca2+ homeostasis through its effect on the ETC.  It is becoming evident that these non-classical functions of Stat3 can have a major impact on cancer progression, cardiovascular diseases, and inflammatory diseases.  Therefore, mitochondrial Stat3 functions challenge the current design of therapies that solely target Stat3 as a transcription factor and suggest the need for "design thinking," which leads to the development of novel strategies, to intervene the Stat3 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqREutDqjn__7Vg90H21EOLACvtfcHk0lhogvTFApphMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCitb7P&md5=f636d01092126fcc6ebc3b42fcb7cb29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.7150%2Fijbs.15153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijbs.15153%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DR.%26aulast%3DRincon%26aufirst%3DM.%26atitle%3DMitochondrial%2520Stat3%252C%2520the%2520need%2520for%2520design%2520thinking%26jtitle%3DInt.%2520J.%2520Biol.%2520Sci.%26date%3D2016%26volume%3D12%26spage%3D532%26epage%3D544%26doi%3D10.7150%2Fijbs.15153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reigan, P.</span></span> <span> </span><span class="NLM_article-title">Strategies and approaches of targeting STAT3 for cancer treatment</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">308</span>â <span class="NLM_lpage">318</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.5b00945</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00945" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOqsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=308-318&author=S.+L.+Furtekauthor=D.+S.+Backosauthor=C.+J.+Mathesonauthor=P.+Reigan&title=Strategies+and+approaches+of+targeting+STAT3+for+cancer+treatment&doi=10.1021%2Facschembio.5b00945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and Approaches of Targeting STAT3 for Cancer Treatment</span></div><div class="casAuthors">Furtek, Steffanie L.; Backos, Donald S.; Matheson, Christopher J.; Reigan, Philip</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-318</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates the expression of genes related to cell cycle, cell survival, and immune response assocd. with cancer progression and malignancy in a no. of cancer types.  Once activated, STAT3 forms a homodimer and translocates to the nucleus where it binds DNA promoting the translation of target genes assocd. with antiapoptosis, angiogenesis, and invasion/migration.  In normal cells, levels of activated STAT3 remain transient; however, STAT3 remains constitutively active in approx. 70% of human solid tumors.  The pivotal role of STAT3 in tumor progression has promoted a campaign in drug discovery to identify small mols. that disrupt the function of STAT3.  A range of approaches have been used to identify novel small mol. inhibitors of STAT3, including high-throughput screening of chem. libraries, computational-based virtual screening, and fragment-based design strategies.  The most common approaches in targeting STAT3 activity are either via the inhibition of tyrosine kinases capable of phosphorylating and thereby activating STAT3 or by preventing the formation of functional STAT3 dimers through disruption of the SH2 domains.  However, the targeting of the STAT3 DNA-binding domain and disruption of binding of STAT3 to its DNA promoter have not been thoroughly examd., mainly due to the lack of adequate assay systems.  This review summarizes the development of STAT3 inhibitors organized by the approach used to inhibit STAT3, the current inhibitors of each class, and the assay systems used to evaluate STAT3 inhibition and offers an insight into future approaches for small mol. STAT3 inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokCygAKrPD6rVg90H21EOLACvtfcHk0lhogvTFApphMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOqsA%253D%253D&md5=379321e035a5dbce720e1c787da55aad</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00945%26sid%3Dliteratum%253Aachs%26aulast%3DFurtek%26aufirst%3DS.%2BL.%26aulast%3DBackos%26aufirst%3DD.%2BS.%26aulast%3DMatheson%26aufirst%3DC.%2BJ.%26aulast%3DReigan%26aufirst%3DP.%26atitle%3DStrategies%2520and%2520approaches%2520of%2520targeting%2520STAT3%2520for%2520cancer%2520treatment%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D308%26epage%3D318%26doi%3D10.1021%2Facschembio.5b00945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Montalvo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheibye-Knudsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armour, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohr, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinclair, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cabo, R.</span></span> <span> </span><span class="NLM_article-title">Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">19270</span>â <span class="NLM_lpage">19279</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M110.200311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M110.200311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21467030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms1Sjtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=19270-19279&author=M.+Bernierauthor=R.+K.+Paulauthor=A.+Martin-Montalvoauthor=M.+Scheibye-Knudsenauthor=S.+Songauthor=H.-J.+Heauthor=S.+M.+Armourauthor=B.+P.+Hubbardauthor=V.+A.+Bohrauthor=L.+Wangauthor=Y.+Zongauthor=D.+A.+Sinclairauthor=R.+de+Cabo&title=Negative+regulation+of+STAT3+protein-mediated+cellular+respiration+by+SIRT1+protein&doi=10.1074%2Fjbc.M110.200311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein</span></div><div class="casAuthors">Bernier, Michel; Paul, Rajib K.; Martin-Montalvo, Alejandro; Scheibye-Knudsen, Morten; Song, Shao-Ming; He, Hua-Jun; Armour, Sean M.; Hubbard, Basil P.; Bohr, Vilhelm A.; Wang, Li-Li; Zong, Ya-Ping; Sinclair, David A.; de Cabo, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">19270-19279</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In mammals, the transcriptional activity of signal transducer and activator of transcription 3 (STAT3) is regulated by the deacetylase SIRT1.  However, whether the newly described nongenomic actions of STAT3 toward mitochondrial oxidative phosphorylation are dependent on SIRT1 is unclear.  In this study, Sirt1 gene knock-out murine embryonic fibroblast (MEF) cells were used to delineate the role of SIRT1 in the regulation of STAT3 mitochondrial function.  Here, we show that STAT3 mRNA and protein levels and the accumulation of serine-phosphorylated STAT3 in mitochondria were increased significantly in Sirt1-KO cells as compared with wild-type MEFs.  Various mitochondrial bioenergetic parameters, such as the oxygen consumption rate in cell cultures, enzyme activities of the electron transport chain complexes in isolated mitochondria, and prodn. of ATP and lactate, indicated that Sirt1-KO cells exhibited higher mitochondrial respiration as compared with wild-type MEFs.  Two independent approaches, including ectopic expression of SIRT1 and siRNA-mediated knockdown of STAT3, led to redn. in intracellular ATP levels and increased lactate prodn. in Sirt1-KO cells that were approaching those of wild-type controls.  Comparison of profiles of phospho-antibody array data indicated that the deletion of SirT1 was accompanied by constitutive activation of the pro-inflammatory NF-ÎºB pathway, which is key for STAT3 induction and increased cellular respiration in Sirt1-KO cells.  Thus, SIRT1 appears to be a functional regulator of NF-ÎºB-dependent STAT3 expression that induces mitochondrial biogenesis.  These results have implications for understanding the interplay between STAT3 and SIRT1 in pro-inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9TaFKgtCL-LVg90H21EOLACvtfcHk0lhKKkjSiUjt2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms1Sjtro%253D&md5=e94cb12b2e1b79b18194acc406764972</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.200311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.200311%26sid%3Dliteratum%253Aachs%26aulast%3DBernier%26aufirst%3DM.%26aulast%3DPaul%26aufirst%3DR.%2BK.%26aulast%3DMartin-Montalvo%26aufirst%3DA.%26aulast%3DScheibye-Knudsen%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DH.-J.%26aulast%3DArmour%26aufirst%3DS.%2BM.%26aulast%3DHubbard%26aufirst%3DB.%2BP.%26aulast%3DBohr%26aufirst%3DV.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZong%26aufirst%3DY.%26aulast%3DSinclair%26aufirst%3DD.%2BA.%26aulast%3Dde%2BCabo%26aufirst%3DR.%26atitle%3DNegative%2520regulation%2520of%2520STAT3%2520protein-mediated%2520cellular%2520respiration%2520by%2520SIRT1%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D19270%26epage%3D19279%26doi%3D10.1074%2Fjbc.M110.200311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span> <span> </span><span class="NLM_article-title">GSTP1 negatively regulates Stat3 activation in epidermal growth factor signaling</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1053</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.3892/ol.2012.1098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3892%2Fol.2012.1098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23426146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Wmsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1053-1057&author=X.+Kouauthor=N.+Chenauthor=Z.+Fengauthor=L.+Luoauthor=Z.+Yin&title=GSTP1+negatively+regulates+Stat3+activation+in+epidermal+growth+factor+signaling&doi=10.3892%2Fol.2012.1098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">GSTP1 negatively regulates Stat3 activation in epidermal growth factor signaling</span></div><div class="casAuthors">Kou, Xianjuan; Chen, Ning; Feng, Zhiyong; Luo, Lan; Yin, Zhimin</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Glutathione S-transferases (GSTs) are the enzymes that defend cells against the damage mediated by oxidant and electrophilic carcinogens.  GSTÏ (GSTP1) is a member of the GST family and the hypermethylation GSTP1 CpG island DNA is detected in human hepatocellular carcinoma (HCC) tissues, which contributes to the neg. expression of GSTP1 mRNA and protein.  GSTP1 expression is considered to be an early event in HCC.  Stat3, a member of the signal transduction and activator of transcription (Stat) family, is important for promoting the proliferation, survival and other biol. processes of cells triggered by cytokines and growth factors.  Activated Stat3 may participate in oncogenesis.  Previous studies have demonstrated that overexpression of phosphorylated Stat3 is important in the proliferation of HCC cells, suggesting that disturbance of the Stat3 pathway may be an early event.  We hypothesize that the suppression of GSTP1 expression in HCC cells increases Stat3 activation.  In order to test this hypothesis, HepG2 cells were genetically modified to transiently express high levels of GSTP1.  The transient expression of GSTP1 specifically downregulated epidermal growth factor (EGF)-mediated tyrosine phosphorylation of Stat3, and subsequently suppressed the transcriptional activity of Stat3.  By contrast, GSTP1 RNAi was able to lead to an increase in the phosphorylation of Stat3.  In addn., overexpression of GSTP1 was capable of reducing the survival of HepG2 cells and inducing cell cycle arrest.  This inhibition was mediated by a direct interaction between GSTP1 and Stat3.  Overall, our results suggest that GSTP1 is important in the regulation of the transcriptional activity of Stat3, and that it is also a regulator of the cell cycle via EGF signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbB6S0_MGg8LVg90H21EOLACvtfcHk0lhKKkjSiUjt2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Wmsrg%253D&md5=4c7fa3a65dd84ea32d96979517200aab</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3892%2Fol.2012.1098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2012.1098%26sid%3Dliteratum%253Aachs%26aulast%3DKou%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DZ.%26atitle%3DGSTP1%2520negatively%2520regulates%2520Stat3%2520activation%2520in%2520epidermal%2520growth%2520factor%2520signaling%26jtitle%3DOncol.%2520Lett.%26date%3D2013%26volume%3D5%26spage%3D1053%26epage%3D1057%26doi%3D10.3892%2Fol.2012.1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arfuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span> <span> </span><span class="NLM_article-title">The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">327</span>, <span class="refDoi">Â DOI: 10.3390/cancers10090327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fcancers10090327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyhsbrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=327&author=L.+Aroraauthor=A.+P.+Kumarauthor=F.+Arfusoauthor=W.+J.+Chngauthor=G.+Sethi&title=The+role+of+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+and+its+targeted+inhibition+in+hematological+malignancies&doi=10.3390%2Fcancers10090327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies</span></div><div class="casAuthors">Arora, Loukik; Kumar, Alan Prem; Arfuso, Frank; Chng, Wee Joo; Sethi, Gautam</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">327/1-327/17</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3), a member of the STAT protein family, can be phosphorylated by receptor-assocd. Janus kinases (JAKs) in response to stimulation by cytokines and growth factors.  It forms homo- or heterodimers that can translocate to the cell nucleus where they act as transcription activators.  Constitutive activation of STAT3 has been found to be assocd. with initiation and progression of various cancers.  It can exert proliferative as well as anti-apoptotic effects.  This review focuses on the role of STAT3 in pathogenesis i.e., proliferation, differentiation, migration, and apoptosis of hematol. malignancies viz. leukemia, lymphoma and myeloma, and briefly highlights the potential therapeutic approaches developed against STAT3 activation pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnoDRq06VAHbVg90H21EOLACvtfcHk0lhKKkjSiUjt2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyhsbrK&md5=f6c9892a2c7980e5cde5984ca788b84a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.3390%2Fcancers10090327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers10090327%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DArfuso%26aufirst%3DF.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DSethi%26aufirst%3DG.%26atitle%3DThe%2520role%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520and%2520its%2520targeted%2520inhibition%2520in%2520hematological%2520malignancies%26jtitle%3DCancers%26date%3D2018%26volume%3D10%26spage%3D327%26doi%3D10.3390%2Fcancers10090327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. D.</span></span> <span> </span><span class="NLM_article-title">STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">195</span>, <span class="refDoi">Â DOI: 10.1186/s13046-019-1206-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2Fs13046-019-1206-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31088482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB3M7lslegsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=195&author=J.+J.+Qinauthor=L.+Yanauthor=J.+Zhangauthor=W.+D.+Zhang&title=STAT3+as+a+potential+therapeutic+target+in+triple+negative+breast+cancer%3A+a+systematic+review&doi=10.1186%2Fs13046-019-1206-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review</span></div><div class="casAuthors">Qin Jiang-Jiang; Yan Li; Zhang Wei-Dong; Zhang Jia; Zhang Wei-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple negative breast cancer (TNBC), which is typically lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), represents the most aggressive and mortal subtype of breast cancer.  Currently, only a few treatment options are available for TNBC due to the absence of molecular targets, which underscores the need for developing novel therapeutic and preventive approaches for this disease.  Recent evidence from clinical trials and preclinical studies has demonstrated a pivotal role of signal transducer and activator of transcription 3 (STAT3) in the initiation, progression, metastasis, and immune evasion of TNBC.  STAT3 is overexpressed and constitutively activated in TNBC cells and contributes to cell survival, proliferation, cell cycle progression, anti-apoptosis, migration, invasion, angiogenesis, chemoresistance, immunosuppression, and stem cells self-renewal and differentiation by regulating the expression of its downstream target genes.  STAT3 small molecule inhibitors have been developed and shown excellent anticancer activities in in vitro and in vivo models of TNBC.  This review discusses the recent advances in the understanding of STAT3, with a focus on STAT3's oncogenic role in TNBC.  The current targeting strategies and representative small molecule inhibitors of STAT3 are highlighted.  We also propose potential strategies that can be further examined for developing more specific and effective inhibitors for TNBC prevention and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmoOYd9tKrj0H3Rlp_k91zfW6udTcc2eabCEV67XJA3rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7lslegsg%253D%253D&md5=b09ebc4b874740ae2ab1064e3ab493a8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1206-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1206-z%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%2BJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%2BD.%26atitle%3DSTAT3%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520triple%2520negative%2520breast%2520cancer%253A%2520a%2520systematic%2520review%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D195%26doi%3D10.1186%2Fs13046-019-1206-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagayasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, I.</span></span> <span> </span><span class="NLM_article-title">Activation of STAT3 is a marker of poor prognosis in human colorectal cancer</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1445</span>â <span class="NLM_lpage">1451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=16685378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVOisrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=1445-1451&author=T.+Kusabaauthor=T.+Nakayamaauthor=K.+Yamazumiauthor=Y.+Yakataauthor=A.+Yoshizakiauthor=K.+Inoueauthor=T.+Nagayasuauthor=I.+Sekine&title=Activation+of+STAT3+is+a+marker+of+poor+prognosis+in+human+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of STAT3 is a marker of poor prognosis in human colorectal cancer</span></div><div class="casAuthors">Kusaba, Takafumi; Nakayama, Toshiyuki; Yamazumi, Kazuyuki; Yakata, Yuichi; Yoshizaki, Ayumi; Inoue, Kenichiro; Nagayasu, Takeshi; Sekine, Ichiro</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1445-1451</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">It is known that the signal transducer and activator of transcription 3 (STAT3) is a key signaling mol. implicated in the regulation of growth and malignant transformation.  Constitutive activation of STAT3 has been obsd. in a no. of tumor-derived cell lines, as well as in a wide variety of human malignancies.  The present study was conducted to examine p-STAT3 (activated form of STAT3) expression and its assocn. with clinicopathol. factors and prognosis in human colorectal adenocarcinomas.  Expression of p-STAT3 was immunohistochem. examd. in 108 cases of colorectal adenocarcinoma tissue obtained at surgery and was found in 57.4% of tumors (62 of 108).  P-STAT3 immunoreactivity significantly correlated with the depth grading of tumor invasion (p<0.001), lymphatic invasion(p<0.05), Dukes' classification (p<0.05), stage (p<0.001) and prognosis after operation (p<0.001).  Expression of p-STAT3 was a marker of poor prognosis in overall survival (p<0.01).  Expression of p-STAT3 was detected by Western blot anal. in three colon carcinoma tissue samples obtained at surgery.  To our knowledge, this is the first study on the poor prognosis of p-STAT3 in human colorectal adenocarcinomas.  These findings suggest that expression of p-STAT3 is an important factor related to tumor invasion and poor prognosis of human colorectal adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnwaaijfYpMLVg90H21EOLACvtfcHk0liFJHWx1f3gTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVOisrc%253D&md5=fce5c794143714b6c3f1cab70b3bc434</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKusaba%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DYamazumi%26aufirst%3DK.%26aulast%3DYakata%26aufirst%3DY.%26aulast%3DYoshizaki%26aufirst%3DA.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DNagayasu%26aufirst%3DT.%26aulast%3DSekine%26aufirst%3DI.%26atitle%3DActivation%2520of%2520STAT3%2520is%2520a%2520marker%2520of%2520poor%2520prognosis%2520in%2520human%2520colorectal%2520cancer%26jtitle%3DOncol.%2520Rep.%26date%3D2006%26volume%3D15%26spage%3D1445%26epage%3D1451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maennling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tur, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klockenbring, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeppernick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GattenlÃ¶hner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinhold-Heerlein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, A. F.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1826</span>, <span class="refDoi">Â DOI: 10.3390/cancers11121826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fcancers11121826" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVynsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1826&author=A.+E.+Maennlingauthor=M.+K.+Turauthor=M.+Niebertauthor=T.+Klockenbringauthor=F.+Zeppernickauthor=S.+Gattenl%C3%B6hnerauthor=I.+Meinhold-Heerleinauthor=A.+F.+Hussain&title=Molecular+targeting+therapy+against+EGFR+family+in+breast+cancer%3A+progress+and+future+potentials&doi=10.3390%2Fcancers11121826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials</span></div><div class="casAuthors">Maennling, Amaia Eleonora; Tur, Mehmet Kemal; Niebert, Marcus; Klockenbring, Torsten; Zeppernick, Felix; Gattenloehner, Stefan; Meinhold-Heerlein, Ivo; Hussain, Ahmad Fawzi</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1826</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands.  EGFRs are overexpressed in many solid tumors, including breast, pancreas, head-and-neck, prostate, ovarian, renal, colon, and non-small-cell lung cancer.  Such overexpression produces strong stimulation of downstream signaling pathways, which induce cell growth, cell differentiation, cell cycle progression, angiogenesis, cell motility and blocking of apoptosis.The high expression and/or functional activation of EGFRs correlates with the pathogenesis and progression of several cancers, which make them attractive targets for both diagnosis and therapy.  Several approaches have been developed to target these receptors and/or the EGFR modulated effects in cancer cells.  Most approaches include the development of anti-EGFRs antibodies and/or small-mol. EGFR inhibitors.  This review presents the state-of-the-art and future prospects of targeting EGFRs to treat breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRgawFJxhRYrVg90H21EOLACvtfcHk0liFJHWx1f3gTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVynsbs%253D&md5=50f9789bad152dcbceb675d73af198b6</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3390%2Fcancers11121826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11121826%26sid%3Dliteratum%253Aachs%26aulast%3DMaennling%26aufirst%3DA.%2BE.%26aulast%3DTur%26aufirst%3DM.%2BK.%26aulast%3DNiebert%26aufirst%3DM.%26aulast%3DKlockenbring%26aufirst%3DT.%26aulast%3DZeppernick%26aufirst%3DF.%26aulast%3DGattenl%25C3%25B6hner%26aufirst%3DS.%26aulast%3DMeinhold-Heerlein%26aufirst%3DI.%26aulast%3DHussain%26aufirst%3DA.%2BF.%26atitle%3DMolecular%2520targeting%2520therapy%2520against%2520EGFR%2520family%2520in%2520breast%2520cancer%253A%2520progress%2520and%2520future%2520potentials%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1826%26doi%3D10.3390%2Fcancers11121826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahrmann, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshitz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somlo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandial, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT3-regulated fatty acid Î²-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">136</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2017.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.cmet.2017.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29249690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2js7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=136-150&author=T.+Wangauthor=J.+F.+Fahrmannauthor=H.+Leeauthor=Y.+J.+Liauthor=S.+C.+Tripathiauthor=C.+Yueauthor=C.+Zhangauthor=V.+Lifshitzauthor=J.+Songauthor=Y.+Yuanauthor=G.+Somloauthor=R.+Jandialauthor=D.+Annauthor=S.+Hanashauthor=R.+Joveauthor=H.+Yu&title=JAK%2FSTAT3-regulated+fatty+acid+%CE%B2-oxidation+is+critical+for+breast+cancer+stem+cell+self-renewal+and+chemoresistance&doi=10.1016%2Fj.cmet.2017.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT3-Regulated Fatty Acid Î²-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance</span></div><div class="casAuthors">Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung; Li, Yi-Jia; Tripathi, Satyendra C.; Yue, Chanyu; Zhang, Chunyan; Lifshitz, Veronica; Song, Jieun; Yuan, Yuan; Somlo, George; Jandial, Rahul; Ann, David; Hanash, Samir; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-150.e5</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are crit. for cancer progression and chemoresistance.  How lipid metab. regulates CSCs and chemoresistance remains elusive.  Here, we demonstrate that JAK/STAT3 regulates lipid metab., which promotes breast CSCs (BCSCs) and cancer chemoresistance.  Inhibiting JAK/STAT3 blocks BCSC self-renewal and expression of diverse lipid metabolic genes, including carnitine palmitoyltransferase 1B (CPT1B), which encodes the crit. enzyme for fatty acid Î²-oxidn. (FAO).  Moreover, mammary-adipocyte-derived leptin upregulates STAT3-induced CPT1B expression and FAO activity in BCSCs.  Human breast-cancer-derived data suggest that the STAT3-CPT1B-FAO pathway promotes cancer cell stemness and chemoresistance.  Blocking FAO and/or leptin re-sensitizes them to chemotherapy and inhibits BCSCs in mouse breast tumors in vivo.  We identify a crit. pathway for BCSC maintenance and breast cancer chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzVt0Snzhqc7Vg90H21EOLACvtfcHk0lgAMun-Lwr_WA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2js7%252FE&md5=a763990bd98b8b37a97e321aaf4fcd0f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2017.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2017.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DFahrmann%26aufirst%3DJ.%2BF.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DTripathi%26aufirst%3DS.%2BC.%26aulast%3DYue%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLifshitz%26aufirst%3DV.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DSomlo%26aufirst%3DG.%26aulast%3DJandial%26aufirst%3DR.%26aulast%3DAnn%26aufirst%3DD.%26aulast%3DHanash%26aufirst%3DS.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DJAK%252FSTAT3-regulated%2520fatty%2520acid%2520%25CE%25B2-oxidation%2520is%2520critical%2520for%2520breast%2520cancer%2520stem%2520cell%2520self-renewal%2520and%2520chemoresistance%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26spage%3D136%26epage%3D150%26doi%3D10.1016%2Fj.cmet.2017.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orgaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz-Moreno, V.</span></span> <span> </span><span class="NLM_article-title">Emerging molecular targets in melanoma invasion and metastasis</span>. <i>Pigm. Cell Melanoma Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">39</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.1111/pcmr.12041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1111%2Fpcmr.12041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23095214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislygs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=39-57&author=J.+L.+Orgazauthor=V.+Sanz-Moreno&title=Emerging+molecular+targets+in+melanoma+invasion+and+metastasis&doi=10.1111%2Fpcmr.12041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging molecular targets in melanoma invasion and metastasis</span></div><div class="casAuthors">Orgaz, Jose L.; Sanz-Moreno, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Pigment Cell & Melanoma Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-57</span>CODEN:
                <span class="NLM_cas:coden">PCMRCM</span>;
        ISSN:<span class="NLM_cas:issn">1755-1471</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Metastatic cutaneous melanoma accounts for the majority of skin cancer deaths due to its aggressiveness and high resistance to current therapies.  To efficiently metastasize, invasive melanoma cells need to change their cytoskeletal organization and alter contacts with the extracellular matrix and the surrounding stromal cells.  Melanoma cells can use different migratory strategies depending on varying environments to exit the primary tumor mass and invade surrounding and later distant tissues.  In this review, we have focused on tumor cell plasticity or the interconvertibility that melanoma cells have as one of the factors that contribute to melanoma metastasis.  This has been an area of very intense research in the last 5 yr yielding a vast no. of findings.  We have therefore reviewed all the possible clin. opportunities that this new knowledge offers to both stratify and treat cutaneous malignant melanoma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAAFwukf3SrVg90H21EOLACvtfcHk0lgAMun-Lwr_WA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislygs70%253D&md5=4a848e5e3d5e7a1b19f3f84eabd27288</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fpcmr.12041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcmr.12041%26sid%3Dliteratum%253Aachs%26aulast%3DOrgaz%26aufirst%3DJ.%2BL.%26aulast%3DSanz-Moreno%26aufirst%3DV.%26atitle%3DEmerging%2520molecular%2520targets%2520in%2520melanoma%2520invasion%2520and%2520metastasis%26jtitle%3DPigm.%2520Cell%2520Melanoma%2520Res.%26date%3D2013%26volume%3D26%26spage%3D39%26epage%3D57%26doi%3D10.1111%2Fpcmr.12041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span> <span> </span><span class="NLM_article-title">Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">567</span>â <span class="NLM_lpage">597</span>, <span class="refDoi">Â DOI: 10.4155/fmc.11.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.4155%2Ffmc.11.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21526897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlejtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=567-597&author=D.+Masciocchiauthor=A.+Gelainauthor=S.+Villaauthor=F.+Meneghettiauthor=D.+Barlocco&title=Signal+transducer+and+activator+of+transcription+3+%28STAT3%29%3A+a+promising+target+for+anticancer+therapy&doi=10.4155%2Ffmc.11.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy</span></div><div class="casAuthors">Masciocchi, Daniela; Gelain, Arianna; Villa, Stefania; Meneghetti, Fiorella; Barlocco, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">567-597</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) is an oncogenic protein whose inhibition is sought for the prevention and treatment of cancer.  In this review, the validated therapeutic strategy to block aberrant activity of STAT3 in many tumor cell lines is evaluated by presenting the most promising inhibitors to date.  The compds. are discussed in classes based on their different mechanisms of action, which are critically explained.  In addn., their future clin. development as anticancer agents is considered.  Furthermore, the efforts devoted to the comprehension of the structure--activity relationships and to the identification of the biol. effects are brought to attention.  The synthetic and technol. approaches recently developed to overcome the difficulties in the obtainment of clin. suitable drugs are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJPzLbSkoDLVg90H21EOLACvtfcHk0lgAMun-Lwr_WA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlejtb0%253D&md5=a6e0f478fe6c9db89afea342f0aab536</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.22%26sid%3Dliteratum%253Aachs%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DSignal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%253A%2520a%2520promising%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D567%26epage%3D597%26doi%3D10.4155%2Ffmc.11.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goradia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghunath, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paessler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysocka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasik, M. A.</span></span> <span> </span><span class="NLM_article-title">Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">20852</span>â <span class="NLM_lpage">20857</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0810958105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.0810958105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=19088198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFSntw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=20852-20857&author=M.+Marzecauthor=Q.+Zhangauthor=A.+Goradiaauthor=P.+N.+Raghunathauthor=X.+Liuauthor=M.+Paesslerauthor=H.+Y.+Wangauthor=M.+Wysockaauthor=M.+Chengauthor=B.+A.+Ruggeriauthor=M.+A.+Wasik&title=Oncogenic+kinase+NPM%2FALK+induces+through+STAT3+expression+of+immunosuppressive+protein+CD274+%28PD-L1%2C+B7-H1%29&doi=10.1073%2Fpnas.0810958105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)</span></div><div class="casAuthors">Marzec, Michal; Zhang, Qian; Goradia, Ami; Raghunath, Puthiyaveettil N.; Liu, Xiaobin; Paessler, Michele; Wang, Hong Yi; Wysocka, Maria; Cheng, Mangeng; Ruggeri, Bruce A.; Wasik, Mariusz A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">20852-20857</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mechanisms of malignant cell transformation caused by the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) remain only partially understood, with most of the previous studies focusing mainly on the impact of NPM/ALK on cell survival and proliferation.  Here we report that the NPM/ALK-carrying T cell lymphoma (ALK + TCL) cells strongly express the immunosuppressive cell-surface protein CD274 (PD-L1, B7-H1), as detd. on the mRNA and protein level.  The CD274 expression is strictly dependent on the expression and enzymic activity of NPM/ALK, as demonstrated by inhibition of the NPM/ALK function in ALK + TCL cells by the small mol. ALK inhibitor CEP-14083 and by documenting CD274 expression in IL-3-depleted BaF3 cells transfected with the wild-type NPM/ALK, but not the kinase-inactive NPM/ALK K210R mutant or empty vector alone.  NPM/ALK induces CD274 expression by activating its key signal transmitter, transcription factor STAT3.  STAT3 binds to the CD274 gene promoter in vitro and in vivo, as shown in the gel electromobility shift and chromatin immunopptn. assays, and is required for the PD-L1 gene expression, as demonstrated by siRNA-mediated STAT3 depletion.  These findings identify an addnl. cell-transforming property of NPM/ALK and describe a direct link between an oncoprotein and an immunosuppressive cell-surface protein.  These results also provide an addnl. rationale to therapeutically target NPM/ALK and STAT3 in ALK + TCL.  Finally, they suggest that future immunotherapeutic protocols for this type of lymphoma may need to include the inhibition of NPM/ALK and STAT3 to achieve optimal clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh87qHOgigfrVg90H21EOLACvtfcHk0lj9GfakHc1gew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFSntw%253D%253D&md5=1e85c07581e48e5aa0b9c7d685b57eef</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0810958105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0810958105%26sid%3Dliteratum%253Aachs%26aulast%3DMarzec%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGoradia%26aufirst%3DA.%26aulast%3DRaghunath%26aufirst%3DP.%2BN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DPaessler%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWysocka%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DWasik%26aufirst%3DM.%2BA.%26atitle%3DOncogenic%2520kinase%2520NPM%252FALK%2520induces%2520through%2520STAT3%2520expression%2520of%2520immunosuppressive%2520protein%2520CD274%2520%2528PD-L1%252C%2520B7-H1%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D20852%26epage%3D20857%26doi%3D10.1073%2Fpnas.0810958105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">5952</span>â <span class="NLM_lpage">5966</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0379-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41388-018-0379-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29980788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12ltrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=5952-5966&author=A.+Liauthor=P.+Chenauthor=Y.+Lengauthor=J.+Kang&title=Histone+deacetylase+6+regulates+the+immunosuppressive+properties+of+cancer-associated+fibroblasts+in+breast+cancer+through+the+STAT3-COX2-dependent+pathway&doi=10.1038%2Fs41388-018-0379-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway</span></div><div class="casAuthors">Li, Ang; Chen, Ping; Leng, Ye; Kang, Jiuhong</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">5952-5966</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts (CAFs) are important components in breast tumors and essential for tumor progression and metastasis.  However, the role of epigenetic modification in driving the function of CAFs within breast tumors is only marginally known.  Herein, we reported that histone deacetylase 6 (HDAC6), one of class II histone deacetylases, was frequently upregulated in the CAFs of breast tumor and promotes an immunosuppressive microenvironment.  The genetic or pharmacol. disruption of HDAC6 in CAFs delays tumor growth, inhibits the tumor recruitment of myeloid-derived suppressor cells and regulatory T cells, alters the macrophage phenotype switch, and increases the CD8+ and CD4+ T-cell activation in vivo.  Mechanistically, we identified prostaglandin E2/cyclooxygenase-2 (COX2) as a major target of HDAC6 in CAFs by regulating STAT3 activation.  Overexpressing COX2 in HDAC6-knockdown CAFs can completely restore the immunosuppressive properties of the fibroblasts.  Clin., a pos. correlation among the stromal expression levels of HDAC6, p-STAT3, and COX2 in human breast cancer was obsd.  High-stromal expression of HDAC6 was markedly assocd. with poor survival outcome.  Overall, our findings indicated that fibroblastic HDAC6 was a vital epigenetic mediator involved in programming an immunosuppressive tumor microenvironment that dampens antitumor immunity.  Thus, HDAC6 may be a good potential target to improve breast cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMfVNR-7vuhbVg90H21EOLACvtfcHk0lj9GfakHc1gew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12ltrjM&md5=c34f57fe88bcc9dbf43ee0ae09ca1bb6</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0379-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0379-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase%25206%2520regulates%2520the%2520immunosuppressive%2520properties%2520of%2520cancer-associated%2520fibroblasts%2520in%2520breast%2520cancer%2520through%2520the%2520STAT3-COX2-dependent%2520pathway%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D5952%26epage%3D5966%26doi%3D10.1038%2Fs41388-018-0379-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugimiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamano, K.</span></span> <span> </span><span class="NLM_article-title">JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>438</i></span>,  <span class="NLM_fpage">513</span>â <span class="NLM_lpage">518</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2013.07.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bbrc.2013.07.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23911788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12itrfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2013&pages=513-518&author=A.+Nishimotoauthor=N.+Kugimiyaauthor=T.+Hosoyamaauthor=T.+Enokiauthor=T.+S.+Liauthor=K.+Hamano&title=JAB1+regulates+unphosphorylated+STAT3+DNA-binding+activity+through+protein-protein+interaction+in+human+colon+cancer+cells&doi=10.1016%2Fj.bbrc.2013.07.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells</span></div><div class="casAuthors">Nishimoto, Arata; Kugimiya, Naruji; Hosoyama, Toru; Enoki, Tadahiko; Li, Tao-Sheng; Hamano, Kimikazu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">513-518</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent studies have revealed that unphosphorylated STAT3 forms a dimer, translocates to the nucleus, binds to the STAT3 binding site, and activates the transcription of STAT3 target genes, thereby playing an important role in oncogenesis in addn. to phosphorylated STAT3.  Among signaling steps of unphosphorylated STAT3, nuclear translocation and target DNA-binding are the crit. steps for its activation.  Therefore, elucidating the regulatory mechanism of these signaling steps of unphosphorylated STAT3 is a potential step in the discovery of a novel cancer drug.  However, the mechanism of unphosphorylated STAT3 binding to the promoter of target genes remains unclear.  In this study, we focused on Jun activation domain-binding protein 1 (JAB1) as a candidate protein that regulates unphosphorylated STAT3 DNA-binding activity.  Initially, we obsd. that both unphosphorylated STAT3 and JAB1 existed in the nucleus of human colon cancer cell line COLO205 at the basal state (no cytokine stimulation).  On the other hand, phosphorylated STAT3 did not exist in the nucleus of COLO205 cells at the basal state.  Immunopptn. using nuclear ext. of COLO205 cells revealed that JAB1 interacted with unphosphorylated STAT3.  To investigate the effect of JAB1 on unphosphorylated STAT3 activity, RNAi studies were performed.  Although JAB1 knockdown tended to increase nuclear STAT3 expression, it significantly decreased unphosphorylated STAT3 DNA-binding activity.  Subsequently, JAB1 knockdown significantly decreased the expression levels of MDR1, NANOG, and VEGF, which are STAT3 target genes.  Furthermore, the expression level of nuclear JAB1, but not nuclear STAT3, correlated with unphosphorylated STAT3 DNA-binding activity between COLO205 and LoVo cells.  Taken together, these results suggest that nuclear JAB1 pos. regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cell line COLO205.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY69k0T89OPrVg90H21EOLACvtfcHk0lgeH9QkGDey3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12itrfE&md5=0f14d97602736856bdc60da775d94610</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.07.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.07.105%26sid%3Dliteratum%253Aachs%26aulast%3DNishimoto%26aufirst%3DA.%26aulast%3DKugimiya%26aufirst%3DN.%26aulast%3DHosoyama%26aufirst%3DT.%26aulast%3DEnoki%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DT.%2BS.%26aulast%3DHamano%26aufirst%3DK.%26atitle%3DJAB1%2520regulates%2520unphosphorylated%2520STAT3%2520DNA-binding%2520activity%2520through%2520protein-protein%2520interaction%2520in%2520human%2520colon%2520cancer%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D438%26spage%3D513%26epage%3D518%26doi%3D10.1016%2Fj.bbrc.2013.07.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auron, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, G. R.</span></span> <span> </span><span class="NLM_article-title">Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1396</span>â <span class="NLM_lpage">1408</span>, <span class="refDoi">Â DOI: 10.1101/gad.1553707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1101%2Fgad.1553707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=17510282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFSgsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1396-1408&author=J.+Yangauthor=X.+Liaoauthor=M.+K.+Agarwalauthor=L.+Barnesauthor=P.+E.+Auronauthor=G.+R.+Stark&title=Unphosphorylated+STAT3+accumulates+in+response+to+IL-6+and+activates+transcription+by+binding+to+NFkappaB&doi=10.1101%2Fgad.1553707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFÎºB</span></div><div class="casAuthors">Yang, Jinbo; Liao, Xudong; Agarwal, Mukesh K.; Barnes, Laura; Auron, Philip E.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1396-1408</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Gp130-linked cytokines such as interleukin-6 (IL-6) stimulate the formation of tyrosine-phosphorylated signal transducer and activator of transcription 3 (P-STAT3), which activates many genes, including the STAT3 gene itself.  The resulting increase in the concn. of unphosphorylated STAT3 (U-STAT3) drives a second wave of expression of genes such as RANTES, IL6, IL8, MET, and MRAS that do not respond directly to P-STAT3.  Thus, U-STAT3 sustains cytokine-dependent signaling at late times through a mechanism completely distinct from that used by P-STAT3.  Many U-STAT3-responsive genes have ÎºB elements that are activated by a novel transcription factor complex formed when U-STAT3 binds to unphosphorylated NFÎºB (U-NFÎºB), in competition with IÎºB.  The U-STAT3/U-NFÎºB complex accumulates in the nucleus with help from the nuclear localization signal of STAT3, activating a subset of ÎºB-dependent genes.  Addnl. genes respond to U-STAT3 through an NFÎºB-independent mechanism.  The role of signal-dependent increases in U-STAT3 expression in regulating gene expression is likely to be important in physiol. responses to gp130-linked cytokines and growth factors that activate STAT3, and in cancers that have constitutively active P-STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquGJGBFct9XrVg90H21EOLACvtfcHk0lgeH9QkGDey3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFSgsbY%253D&md5=6ef4898e8f6a1657f01afea666327a7b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1101%2Fgad.1553707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1553707%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DX.%26aulast%3DAgarwal%26aufirst%3DM.%2BK.%26aulast%3DBarnes%26aufirst%3DL.%26aulast%3DAuron%26aufirst%3DP.%2BE.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DUnphosphorylated%2520STAT3%2520accumulates%2520in%2520response%2520to%2520IL-6%2520and%2520activates%2520transcription%2520by%2520binding%2520to%2520NFkappaB%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D1396%26epage%3D1408%26doi%3D10.1101%2Fgad.1553707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timofeeva, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chasovskikh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasova, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khavrutskii, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasov, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korostyshevskiy, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakshanamurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dritschilo, A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">14192</span>â <span class="NLM_lpage">14200</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M111.323899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M111.323899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22378781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGlu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=14192-14200&author=O.+A.+Timofeevaauthor=S.+Chasovskikhauthor=I.+Lonskayaauthor=N.+I.+Tarasovaauthor=L.+Khavrutskiiauthor=S.+G.+Tarasovauthor=X.+Zhangauthor=V.+R.+Korostyshevskiyauthor=A.+Cheemaauthor=L.+Zhangauthor=S.+Dakshanamurthyauthor=M.+L.+Brownauthor=A.+Dritschilo&title=Mechanisms+of+unphosphorylated+STAT3+transcription+factor+binding+to+DNA&doi=10.1074%2Fjbc.M111.323899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA</span></div><div class="casAuthors">Timofeeva, Olga A.; Chasovskikh, Sergey; Lonskaya, Irina; Tarasova, Nadya I.; Khavrutskii, Lyuba; Tarasov, Sergey G.; Zhang, Xueping; Korostyshevskiy, Valeriy R.; Cheema, Amrita; Zhang, Lihua; Dakshanamurthy, Sivanesan; Brown, Milton L.; Dritschilo, Anatoly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">14192-14200</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Phosphorylation of signal transducer and activator of transcription 3 (STAT3) on a single tyrosine residue in response to growth factors, cytokines, interferons, and oncogenes activates its dimerization, translocation to the nucleus, binding to the interferon Î³ (gamma)-activated sequence (GAS) DNA-binding site and activation of transcription of target genes.  STAT3 is constitutively phosphorylated in various cancers and drives gene expression from GAS-contg. promoters to promote tumorigenesis.  Recently, roles for unphosphorylated STAT3 (U-STAT3) have been described in response to cytokine stimulation, in cancers, and in maintenance of heterochromatin stability.  However, the mechanisms underlying U-STAT3 binding to DNA has not been fully investigated.  Here, the authors explore STAT3-DNA interactions by at. force microscopy (AFM) imaging.  They obsd. that U-STAT3 mols. bind to the GAS DNA-binding site as dimers and monomers.  In addn., U-STAT3 binds to AT-rich DNA sequence sites and recognizes specific DNA structures, such as 4-way junctions and DNA nodes, within neg. supercoiled plasmid DNA.  These structures are important for chromatin organization and the data suggest a role for U-STAT3 as a chromatin/genome organizer.  Unexpectedly, a C-terminal truncated 67.5-kDa STAT3 isoform recognizes single-stranded spacers within cruciform structures that also have a role in chromatin organization and gene expression.  This isoform appears to be abundant in the nuclei of cancer cells and, therefore, may have a role in regulation of gene expression.  Taken together, these data highlight novel mechanisms by which U-STAT3 binds to DNA and supports U-STAT3 function as a transcriptional activator and a chromatin/genomic organizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodgCG9j0qVLrVg90H21EOLACvtfcHk0lgeH9QkGDey3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGlu78%253D&md5=3da0856a85b9d2a51b8797f09c00aedd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.323899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.323899%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeeva%26aufirst%3DO.%2BA.%26aulast%3DChasovskikh%26aufirst%3DS.%26aulast%3DLonskaya%26aufirst%3DI.%26aulast%3DTarasova%26aufirst%3DN.%2BI.%26aulast%3DKhavrutskii%26aufirst%3DL.%26aulast%3DTarasov%26aufirst%3DS.%2BG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKorostyshevskiy%26aufirst%3DV.%2BR.%26aulast%3DCheema%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDakshanamurthy%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DM.%2BL.%26aulast%3DDritschilo%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520unphosphorylated%2520STAT3%2520transcription%2520factor%2520binding%2520to%2520DNA%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D14192%26epage%3D14200%26doi%3D10.1074%2Fjbc.M111.323899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collie, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neidle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinzalla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilderspin, A. F.</span></span> <span> </span><span class="NLM_article-title">Observation of unphosphorylated STAT3 core protein binding to target dsDNA by PEMSA and X-ray crystallography</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>587</i></span>,  <span class="NLM_fpage">833</span>â <span class="NLM_lpage">839</span>, <span class="refDoi">Â DOI: 10.1016/j.febslet.2013.01.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.febslet.2013.01.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23434585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFCjsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=587&publication_year=2013&pages=833-839&author=E.+Nkansahauthor=R.+Shahauthor=G.+W.+Collieauthor=G.+N.+Parkinsonauthor=J.+Palmerauthor=K.+M.+Rahmanauthor=T.+T.+Buiauthor=A.+F.+Drakeauthor=J.+Husbyauthor=S.+Neidleauthor=G.+Zinzallaauthor=D.+E.+Thurstonauthor=A.+F.+Wilderspin&title=Observation+of+unphosphorylated+STAT3+core+protein+binding+to+target+dsDNA+by+PEMSA+and+X-ray+crystallography&doi=10.1016%2Fj.febslet.2013.01.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Observation of unphosphorylated STAT3 core protein binding to target dsDNA by PEMSA and X-ray crystallography</span></div><div class="casAuthors">Nkansah, Edwin; Shah, Rahi; Collie, Gavin W.; Parkinson, Gary N.; Palmer, Jonathan; Rahman, Khondaker M.; Bui, Tam T.; Drake, Alex F.; Husby, Jarmila; Neidle, Stephen; Zinzalla, Giovanna; Thurston, David E.; Wilderspin, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">587</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">833-839</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The STAT3 transcription factor plays a central role in a wide range of cancer types where it is over-expressed.  Previously, phosphorylation of this protein was thought to be a prerequisite for direct binding to DNA.  However, we have now shown complete binding of a purified unphosphorylated STAT3 (uSTAT3) core directly to M67 DNA, the high affinity STAT3 target DNA sequence, by a protein electrophoretic mobility shift assay (PEMSA).  Binding to M67 DNA was inhibited by addn. of increasing concns. of a phosphotyrosyl peptide.  X-ray crystallog. demonstrates one mode of binding that is similar to that known for the STAT3 core phosphorylated at Y705.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4GeAbWkvLMbVg90H21EOLACvtfcHk0lg2W06XiamD6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFCjsbc%253D&md5=e88431e48b72f959b842d56652b24abf</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2013.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2013.01.065%26sid%3Dliteratum%253Aachs%26aulast%3DNkansah%26aufirst%3DE.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DCollie%26aufirst%3DG.%2BW.%26aulast%3DParkinson%26aufirst%3DG.%2BN.%26aulast%3DPalmer%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26aulast%3DBui%26aufirst%3DT.%2BT.%26aulast%3DDrake%26aufirst%3DA.%2BF.%26aulast%3DHusby%26aufirst%3DJ.%26aulast%3DNeidle%26aufirst%3DS.%26aulast%3DZinzalla%26aufirst%3DG.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DWilderspin%26aufirst%3DA.%2BF.%26atitle%3DObservation%2520of%2520unphosphorylated%2520STAT3%2520core%2520protein%2520binding%2520to%2520target%2520dsDNA%2520by%2520PEMSA%2520and%2520X-ray%2520crystallography%26jtitle%3DFEBS%2520Lett.%26date%3D2013%26volume%3D587%26spage%3D833%26epage%3D839%26doi%3D10.1016%2Fj.febslet.2013.01.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvvuri, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freilino, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapireddy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seethala, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooding, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, J. R.</span></span> <span> </span><span class="NLM_article-title">First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">694</span>â <span class="NLM_lpage">705</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-12-0191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1158%2F2159-8290.CD-12-0191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22719020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygs7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=694-705&author=M.+Senauthor=S.+M.+Thomasauthor=S.+Kimauthor=J.+I.+Yehauthor=R.+L.+Ferrisauthor=J.+T.+Johnsonauthor=U.+Duvvuriauthor=J.+Leeauthor=N.+Sahuauthor=S.+Joyceauthor=M.+L.+Freilinoauthor=H.+Shiauthor=C.+Liauthor=D.+Lyauthor=S.+Rapireddyauthor=J.+P.+Etterauthor=P.+K.+Liauthor=L.+Wangauthor=S.+Chioseaauthor=R.+R.+Seethalaauthor=W.+E.+Goodingauthor=X.+Chenauthor=N.+Kaminskiauthor=K.+Panditauthor=D.+E.+Johnsonauthor=J.+R.+Grandis&title=First-in-human+trial+of+a+STAT3+decoy+oligonucleotide+in+head+and+neck+tumors%3A+implications+for+cancer+therapy&doi=10.1158%2F2159-8290.CD-12-0191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy</span></div><div class="casAuthors">Sen, Malabika; Thomas, Sufi M.; Kim, Seungwon; Yeh, Joanne I.; Ferris, Robert L.; Johnson, Jonas T.; Duvvuri, Umamaheswar; Lee, Jessica; Sahu, Nivedita; Joyce, Sonali; Freilino, Maria L.; Shi, Haibin; Li, Changyou; Ly, Danith; Rapireddy, Srinivas; Etter, Jonathan P.; Li, Pui-Kai; Wang, Lin; Chiosea, Simion; Seethala, Raja R.; Gooding, William E.; Chen, Xiaomin; Kaminski, Naftali; Pandit, Kusum; Johnson, Daniel E.; Grandis, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">694-705</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Intratumoral injection of a STAT3 decoy oligonucleotide safely reduced target gene expression in a phase 0 clin. trial, and chem. modification may enable systemic delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-o4-IpQzSw7Vg90H21EOLACvtfcHk0lg2W06XiamD6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygs7bI&md5=ba85a39a2036f3c5480c3cf5274b2f46</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0191%26sid%3Dliteratum%253Aachs%26aulast%3DSen%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DYeh%26aufirst%3DJ.%2BI.%26aulast%3DFerris%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DJ.%2BT.%26aulast%3DDuvvuri%26aufirst%3DU.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSahu%26aufirst%3DN.%26aulast%3DJoyce%26aufirst%3DS.%26aulast%3DFreilino%26aufirst%3DM.%2BL.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLy%26aufirst%3DD.%26aulast%3DRapireddy%26aufirst%3DS.%26aulast%3DEtter%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DP.%2BK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChiosea%26aufirst%3DS.%26aulast%3DSeethala%26aufirst%3DR.%2BR.%26aulast%3DGooding%26aufirst%3DW.%2BE.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKaminski%26aufirst%3DN.%26aulast%3DPandit%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DD.%2BE.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26atitle%3DFirst-in-human%2520trial%2520of%2520a%2520STAT3%2520decoy%2520oligonucleotide%2520in%2520head%2520and%2520neck%2520tumors%253A%2520implications%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D694%26epage%3D705%26doi%3D10.1158%2F2159-8290.CD-12-0191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span> <span> </span><span class="NLM_article-title">A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1188</span>â <span class="NLM_lpage">1196</span>, <span class="refDoi">Â DOI: 10.1021/cb500071v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500071v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVSjs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1188-1196&author=W.+Huangauthor=Z.+Dongauthor=F.+Wangauthor=H.+Pengauthor=J.+Y.+Liuauthor=J.+T.+Zhang&title=A+small+molecule+compound+targeting+STAT3+DNA-binding+domain+inhibits+cancer+cell+proliferation%2C+migration%2C+and+invasion&doi=10.1021%2Fcb500071v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion</span></div><div class="casAuthors">Huang, Wei; Dong, Zizheng; Wang, Fang; Peng, Hui; Liu, Jing-Yuan; Zhang, Jian-Ting</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1188-1196</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) plays important roles in multiple aspects of cancer aggressiveness including migration, invasion, survival, self-renewal, angiogenesis, and tumor cell immune evasion by regulating the expression of multiple downstream target genes.  STAT3 is constitutively activated in many malignant tumors and its activation is assocd. with high histol. grade and advanced cancer stages.  Thus, inhibiting STAT3 promises an attracting strategy for treatment of advanced and metastatic cancers.  Herein, the authors identified a STAT3 inhibitor, inS3-54, by targeting the DNA-binding domain of STAT3 using an improved virtual screening strategy.  InS3-54 preferentially suppresses proliferation of cancer over non-cancer cells and inhibits migration and invasion of malignant cells.  Biochem. analyses show that inS3-54 selectively inhibits STAT3 binding to DNA without affecting the activation and dimerization of STAT3.  Furthermore, inS3-54 inhibits expression of STAT3 downstream target genes and STAT3 binding to chromatin in situ.  Thus, inS3-54 represents a novel probe for development of specific inhibitors targeting the DNA-binding domain of STAT3 and a potential therapeutic for cancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc4i9uuvhaAbVg90H21EOLACvtfcHk0lgNJ4l3IwMuaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVSjs74%253D&md5=df65197ba614fdf2251ad238a2e30ceb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb500071v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500071v%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26atitle%3DA%2520small%2520molecule%2520compound%2520targeting%2520STAT3%2520DNA-binding%2520domain%2520inhibits%2520cancer%2520cell%2520proliferation%252C%2520migration%252C%2520and%2520invasion%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1188%26epage%3D1196%26doi%3D10.1021%2Fcb500071v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangoc, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxmeyer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">783</span>â <span class="NLM_lpage">792</span>, <span class="refDoi">Â DOI: 10.1038/onc.2015.215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fonc.2015.215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26073084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xitl2gtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=783-792&author=W.+Huangauthor=Z.+Dongauthor=Y.+Chenauthor=F.+Wangauthor=C.+J.+Wangauthor=H.+Pengauthor=Y.+Heauthor=G.+Hangocauthor=K.+Pollokauthor=G.+Sanduskyauthor=X.+Y.+Fuauthor=H.+E.+Broxmeyerauthor=Z.+Y.+Zhangauthor=J.+Y.+Liuauthor=J.+T.+Zhang&title=Small-molecule+inhibitors+targeting+the+DNA-binding+domain+of+STAT3+suppress+tumor+growth%2C+metastasis+and+STAT3+target+gene+expression+in+vivo&doi=10.1038%2Fonc.2015.215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo</span></div><div class="casAuthors">Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C. J.; Peng, H.; He, Y.; Hangoc, G.; Pollok, K.; Sandusky, G.; Fu, X-Y.; Broxmeyer, H. E.; Zhang, Z-Y.; Liu, J-Y.; Zhang, J-T.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness.  Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors.  Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clin. trials.  Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its 'undruggable' nature and potentially limited selectivity.  In a previous study, the authors reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-mol. STAT3 inhibitor (inS3-54).  Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1.  In this study, the authors describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compd. (inS3-54A18) with increased specificity and pharmacol. properties.  InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes.  InS3-54A18 is completely sol. in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals.  Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be 'undruggable' as previously thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUfTEBNtpUqLVg90H21EOLACvtfcHk0lgNJ4l3IwMuaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xitl2gtL8%253D&md5=9d05b09d30218f28894291192c258760</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.215%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DC.%2BJ.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DPollok%26aufirst%3DK.%26aulast%3DSandusky%26aufirst%3DG.%26aulast%3DFu%26aufirst%3DX.%2BY.%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26atitle%3DSmall-molecule%2520inhibitors%2520targeting%2520the%2520DNA-binding%2520domain%2520of%2520STAT3%2520suppress%2520tumor%2520growth%252C%2520metastasis%2520and%2520STAT3%2520target%2520gene%2520expression%2520in%2520vivo%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26spage%3D783%26epage%3D792%26doi%3D10.1038%2Fonc.2015.215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweon, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. T.</span></span> <span> </span><span class="NLM_article-title">MMPP attenuates non-small cell lung cancer growth by inhibiting the STAT3 DNA-binding activity via direct binding to the STAT3 DNA-binding domain</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">4632</span>â <span class="NLM_lpage">4642</span>, <span class="refDoi">Â DOI: 10.7150/thno.18630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.7150%2Fthno.18630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29158850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFaitL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=4632-4642&author=D.+J.+Sonauthor=J.+Zhengauthor=Y.+Y.+Jungauthor=C.+J.+Hwangauthor=H.+P.+Leeauthor=J.+R.+Wooauthor=S.+Y.+Baekauthor=Y.+W.+Hamauthor=M.+W.+Kangauthor=M.+Shongauthor=G.+R.+Kweonauthor=M.+J.+Songauthor=J.+K.+Jungauthor=S.+B.+Hanauthor=B.+Y.+Kimauthor=D.+Y.+Yoonauthor=B.+Y.+Choiauthor=J.+T.+Hong&title=MMPP+attenuates+non-small+cell+lung+cancer+growth+by+inhibiting+the+STAT3+DNA-binding+activity+via+direct+binding+to+the+STAT3+DNA-binding+domain&doi=10.7150%2Fthno.18630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">MMPP attenuates non-small cell lung cancer growth by inhibiting the STAT3 DNA-binding activity via direct binding to the STAT3 DNA-binding domain</span></div><div class="casAuthors">Son, Dong Ju; Zheng, Jie; Jung, Yu Yeon; Hwang, Chul Ju; Lee, Hee Pom; Woo, Ju Rang; Baek, Song Yi; Ham, Young Wan; Kang, Min Woong; Shong, Minho; Kweon, Gi Ryang; Song, Min Jong; Jung, Jae Kyung; Han, Sang-Bae; Kim, Bo Yeon; Yoon, Do Young; Choi, Bu Young; Hong, Jin Tae</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4632-4642</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription-3 (STAT3) plays a pivotal role in cancer biol.  Many small-mol. inhibitors that target STAT3 have been developed as potential anticancer drugs.  While designing small-mol. inhibitors that target the SH2 domain of STAT3 remains the leading focus for drug discovery, there has been a growing interest in targeting the DNA-binding domain (DBD) of the protein.  We demonstrated the potential antitumor activity of a novel, small-mol. (E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol (MMPP) that directly binds to the DBD of STAT3, in patient-derived non-small cell lung cancer (NSCLC) xenograft model as well as in NCI-H460 cell xenograft model in nude mice.  MMPP effectively inhibited the phosphorylation of STAT3 and its DNA binding activity in vitro and in vivo.  It induced G1-phase cell cycle arrest and apoptosis through the regulation of cell cycle- and apoptosis-regulating genes by directly binding to the hydroxyl residue of threonine 456 in the DBD of STAT3.  Furthermore, MMPP showed a similar or better antitumor activity than that of docetaxel or cisplatin.  MMPP is suggested to be a potential candidate for further development as an anticancer drug that targets the DBD of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre4VJDJApG0bVg90H21EOLACvtfcHk0lgNJ4l3IwMuaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFaitL%252FF&md5=574afad3ff6b5e9789184a565330a605</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.7150%2Fthno.18630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.18630%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DD.%2BJ.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DY.%2BY.%26aulast%3DHwang%26aufirst%3DC.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BP.%26aulast%3DWoo%26aufirst%3DJ.%2BR.%26aulast%3DBaek%26aufirst%3DS.%2BY.%26aulast%3DHam%26aufirst%3DY.%2BW.%26aulast%3DKang%26aufirst%3DM.%2BW.%26aulast%3DShong%26aufirst%3DM.%26aulast%3DKweon%26aufirst%3DG.%2BR.%26aulast%3DSong%26aufirst%3DM.%2BJ.%26aulast%3DJung%26aufirst%3DJ.%2BK.%26aulast%3DHan%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DB.%2BY.%26aulast%3DYoon%26aufirst%3DD.%2BY.%26aulast%3DChoi%26aufirst%3DB.%2BY.%26aulast%3DHong%26aufirst%3DJ.%2BT.%26atitle%3DMMPP%2520attenuates%2520non-small%2520cell%2520lung%2520cancer%2520growth%2520by%2520inhibiting%2520the%2520STAT3%2520DNA-binding%2520activity%2520via%2520direct%2520binding%2520to%2520the%2520STAT3%2520DNA-binding%2520domain%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26spage%3D4632%26epage%3D4642%26doi%3D10.7150%2Fthno.18630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corzano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedvat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakushijin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakushijin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidehi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gugiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. C.</span></span> <span> </span><span class="NLM_article-title">Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">432</span>â <span class="NLM_lpage">443</span>, <span class="refDoi">Â DOI: 10.1021/cb100253e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100253e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitVSisLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=432-443&author=R.+Buettnerauthor=R.+Corzanoauthor=R.+Rashidauthor=J.+Linauthor=M.+Senthilauthor=M.+Hedvatauthor=A.+Schroederauthor=A.+Maoauthor=A.+Herrmannauthor=J.+Yimauthor=H.+Liauthor=Y.+C.+Yuanauthor=K.+Yakushijinauthor=F.+Yakushijinauthor=N.+Vaidehiauthor=R.+Mooreauthor=G.+Gugiuauthor=T.+D.+Leeauthor=R.+Yipauthor=Y.+Chenauthor=R.+Joveauthor=D.+Horneauthor=J.+C.+Williams&title=Alkylation+of+cysteine+468+in+Stat3+defines+a+novel+site+for+therapeutic+development&doi=10.1021%2Fcb100253e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development</span></div><div class="casAuthors">Buettner, Ralf; Corzano, Renzo; Rashid, Rumana; Lin, Jian-Ping; Senthil, Maheswari; Hedvat, Michael; Schroeder, Anne; Mao, Allen; Herrmann, Andreas; Yim, John; Li, Hong-Zhi; Yuan, Yate-Ching; Yakushijin, Ken-Ichi; Yakushijin, Fumiko; Vaidehi, Nagarajan; Moore, Roger; Gugiu, Gabriel; Lee, Terry D.; Yip, Richard; Chen, Yuan; Jove, Richard; Horne, David; Williams, John C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">432-443</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stat3 is a latent transcription factor that promotes cell survival and proliferation and is often constitutively active in multiple cancers.  Inhibition of Stat3 signaling pathways suppresses cell survival signals and leads to apoptosis in cancer cells, suggesting direct inhibition of Stat3 function is a viable therapeutic approach.  Herein, we identify a small mol., C48, as a selective Stat3-family member inhibitor.  To det. its mechanism of action, we used site-directed mutagenesis and multiple biochem. techniques to show that C48 alkylates Cys468 in Stat3, a residue at the DNA-binding interface.  We further demonstrate that C48 blocks accumulation of activated Stat3 in the nucleus in tumor cell lines that overexpress active Stat3, leading to impressive inhibition of tumor growth in mouse models.  Collectively, these findings suggest Cys468 in Stat3 represents a novel site for therapeutic intervention and demonstrates the promise of alkylation as a potentially effective chem. approach for Stat3-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp63z_APNdkQLVg90H21EOLACvtfcHk0lhPPsE5BX0MWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitVSisLk%253D&md5=256b3b0921a625e19fe232488e1996db</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fcb100253e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100253e%26sid%3Dliteratum%253Aachs%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DCorzano%26aufirst%3DR.%26aulast%3DRashid%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSenthil%26aufirst%3DM.%26aulast%3DHedvat%26aufirst%3DM.%26aulast%3DSchroeder%26aufirst%3DA.%26aulast%3DMao%26aufirst%3DA.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DYim%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DY.%2BC.%26aulast%3DYakushijin%26aufirst%3DK.%26aulast%3DYakushijin%26aufirst%3DF.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DGugiu%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DYip%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DHorne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BC.%26atitle%3DAlkylation%2520of%2520cysteine%2520468%2520in%2520Stat3%2520defines%2520a%2520novel%2520site%2520for%2520therapeutic%2520development%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D432%26epage%3D443%26doi%3D10.1021%2Fcb100253e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6645</span>â <span class="NLM_lpage">6668</span>, <span class="refDoi">Â DOI: 10.1021/jm300207s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300207s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6645-6668&author=B.+Debnathauthor=S.+Xuauthor=N.+Neamati&title=Small+molecule+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28Stat3%29+protein&doi=10.1021%2Fjm300207s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span></div><div class="casAuthors">Debnath, Bikash; Xu, Shili; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6645-6668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (Stat3) is a transcription factor belonging to the STAT protein family, members of which regulate a wide variety of biol. processes, including cell growth, proliferation, survival, differentiation, development, movement and inflammation in response to extracellular signaling mols. such as cytokines and growth factors.  Receptor assocd. tyrosine kinases phosphorylate Stat3 protein at Tyr705 and enable it to dimerize and subsequently enter the nucleus where it activates the transcription of its target genes.  Accumulating evidence has established Stat3's role in oncogenesis, cardiovascular diseases, rheumatoid arthritis, fibrotic, and Alzheimer's diseases.  Thus, Stat3 inhibition is a promising therapeutic approach not only for cancer, but also for other diseases.  Although Stat3 has been considered as an important therapeutic target, progress in discovery and development of effective and specific Stat3 inhibitors remains slow.  In this article we summarize Stat3 inhibitors published between 2006 and 2011.  New strategies along with novel technologies are required to achieve breakthrough in the development of Stat3 inhibitors that can be translated into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWQl9gV1-ZLVg90H21EOLACvtfcHk0lhPPsE5BX0MWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D&md5=f5f3ac9f8fc2326c75edd2a9c136275b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm300207s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300207s%26sid%3Dliteratum%253Aachs%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528Stat3%2529%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6645%26epage%3D6668%26doi%3D10.1021%2Fjm300207s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boengler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungefug, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heusch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, R.</span></span> <span> </span><span class="NLM_article-title">The STAT3 inhibitor stattic impairs cardiomyocyte mitochondrial function through increased reactive oxygen species formation</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6890</span>â <span class="NLM_lpage">6895</span>, <span class="refDoi">Â DOI: 10.2174/138161281939131127115940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.2174%2F138161281939131127115940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23590160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFelu7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6890-6895&author=K.+Boenglerauthor=E.+Ungefugauthor=G.+Heuschauthor=R.+Schulz&title=The+STAT3+inhibitor+stattic+impairs+cardiomyocyte+mitochondrial+function+through+increased+reactive+oxygen+species+formation&doi=10.2174%2F138161281939131127115940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The STAT3 Inhibitor Stattic Impairs Cardiomyocyte Mitochondrial Function Through Increased Reactive Oxygen Species Formation</span></div><div class="casAuthors">Boengler, Kerstin; Ungefug, Elvira; Heusch, Gerd; Schulz, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">6890-6895</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 (STAT3) transduces stress signals from the plasma membrane to the nucleus but has recently also been identified in mitochondria.  Inhibition of cardiomyocyte mitochondrial STAT3 with the STAT3-specific inhibitor Stattic decreases ADP-stimulated respiration and enhances calcium-induced mitochondrial permeability transition pore (MPTP) opening.  The aim of the present study was to analyze whether or not these effects of STAT3 inhibition by Stattic are mediated by the formation of reactive oxygen species (ROS).  The H2O2 formation from isolated rat left ventricular mitochondria was measured continuously in the presence of the complex 1 substrates glutamate and malate using the H2O2 indicator Amplex UltraRed.  Stattic dose-dependently increased mitochondrial ROS formation (slope of Amplex UltraRed fluorescence/time; DMSO: 0.39Â±0.01; 1 Î¼M Stattic: 0.40Â±0.03; 10 Î¼M Stattic: 0.71Â±0.04; 25 Î¼M Stattic: 1.43Â±0.05; 50 Î¼M Stattic: 3.53Â±0.23; 100 Î¼M Stattic: 9.23Â±0.69, n=5 mitochondrial prepns., p<0.05 for 10-100 Î¼M Stattic).  The increase in the ROS signal by 100 Î¼M Stattic was abolished in the presence of the ROS scavenger N-acetylcysteine (Nac, 0.46Â±0.02, n=7, p<0.05).  Mitochondria treated with 100 Î¼M Stattic produced less ATP than control mitochondria (86Â±3 arbitrary units (a.u.) vs. 128Â±7 a.u., n=9, p<0.05).  Again, in the presence of Nac ATP prodn. was similar between Stattic-treated and control mitochondria (142Â±4 a.u. vs. 147Â±12 a.u., n=5, p=ns).  MPTP opening was induced by lower amts. of calcium in Stattic-treated than in control mitochondria (in nmol CaCl2/mg protein, Stattic: 507Â±57, n=7; control: 857Â±70, n=7, p<0.05).  There was no difference in calcium-induced MPTP opening between Stattic-treated (833Â±57, n=6) and control mitochondria (921Â±75, n=7, p=ns) in the presence of Nac.  Taken together, our data show that inhibition of mitochondrial STAT3 by Stattic impacts on mitochondrial ATP prodn. and MPTP opening through enhanced ROS formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4JFfKxsWPMLVg90H21EOLACvtfcHk0ljxdvihL3vsaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFelu7jJ&md5=7136ef44cd562a11ae1c0e5b80a5ec79</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F138161281939131127115940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161281939131127115940%26sid%3Dliteratum%253Aachs%26aulast%3DBoengler%26aufirst%3DK.%26aulast%3DUngefug%26aufirst%3DE.%26aulast%3DHeusch%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DR.%26atitle%3DThe%2520STAT3%2520inhibitor%2520stattic%2520impairs%2520cardiomyocyte%2520mitochondrial%2520function%2520through%2520increased%2520reactive%2520oxygen%2520species%2520formation%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D6890%26epage%3D6895%26doi%3D10.2174%2F138161281939131127115940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">538</span>â <span class="NLM_lpage">550</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2016.09.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2016.09.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ejtL7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=538-550&author=W.+Zhangauthor=T.+Maauthor=S.+Liauthor=Y.+Yangauthor=J.+Guoauthor=W.+Yuauthor=L.+Kong&title=Antagonizing+STAT3+activation+with+benzo%5Bb%5Dthiophene+1%2C+1-dioxide+based+small+molecules&doi=10.1016%2Fj.ejmech.2016.09.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</span></div><div class="casAuthors">Zhang, Wenda; Ma, Ting; Li, Shanshan; Yang, Yanwei; Guo, Jianpeng; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">538-550</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 is an attractive therapeutic target for cancer therapy.  However, due to low potency or poor druggability, none of its inhibitors are clin. available.  Herein, a series of aminobenzo[b]thiophene 1,1-dioxides with good drug-likeness properties were designed, synthesized and evaluated as STAT3 inhibitors.  Most of them exhibited higher antitumor activity than the small-mol. STAT3 inhibitor, Stattic.  Compd. I was the most potent and had an IC50 range in 0.33-0.75 Î¼M in various cancer cell lines.  The overexpressed and IL-6 induced phosphorylation levels of STAT3 were both inhibited by I without influencing the phosphorylation levels of the upstream kinases Src and Jak2. 15 also suppressed the expressions of STAT3 downstream gene, Bcl-2.  I also suppressed the expressions of STAT3 downstream gene, Bcl-2.  I effectively increased the ROS levels of cancer cells, induced cancer cell apoptosis, and abolished the colony formation ability of cancer cells without affecting bypass kinase p-Erk.  Furthermore, I in vivo induced significant antitumor responses, and exhibited less toxicity than Doxorubicin.  Together, this study described a class of new STAT3 inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4EWN80TpUpbVg90H21EOLACvtfcHk0ljxdvihL3vsaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ejtL7I&md5=395e6ea180776127e98bc2a92f3d603b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.068%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DAntagonizing%2520STAT3%2520activation%2520with%2520benzo%255Bb%255Dthiophene%25201%252C%25201-dioxide%2520based%2520small%2520molecules%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D538%26epage%3D550%26doi%3D10.1016%2Fj.ejmech.2016.09.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46352</span>, <span class="refDoi">Â DOI: 10.1038/srep46352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fsrep46352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28397855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVyitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46352&author=W.+Zhangauthor=J.+Guoauthor=S.+Liauthor=T.+Maauthor=D.+Xuauthor=C.+Hanauthor=F.+Liuauthor=W.+Yuauthor=L.+Kong&title=Discovery+of+monocarbonyl+curcumin-BTP+hybrids+as+STAT3+inhibitors+for+drug-sensitive+and+drug-resistant+breast+cancer+therapy&doi=10.1038%2Fsrep46352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy</span></div><div class="casAuthors">Zhang, Wenda; Guo, Jianpeng; Li, Shanshan; Ma, Ting; Xu, Dingqiao; Han, Chao; Liu, Feiyan; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46352</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a well-known antitumor target.  Exogenous ROS insult can lead to selective cytotoxicity against cancer cells.  A combination of STAT3 inhibition and "oxidn. therapy" may be a new strategy to address the multidrug-resistance issue due to their important roles in the survival and drug resistance of cancer cells.  Here, a series of novel curcumin-BTP hybrids were designed and evaluated as STAT3 inhibitors with ROS prodn. activity.  Compd. 6b exerted the best antitumor activity and selectivity for MCF-7 and MCF-7/DOX cells (IC50 = 0.52 Î¼M and 0.40 Î¼M, resp.), while its IC50 value for MCF-10A breast epithelial cells was 7.72 Î¼M.  Furthermore, compd. 6b suppressed STAT3 phosphorylation, nuclear translocation and DNA-binding activity and the expression of STAT3 specific oncogenes.  Increases in the level of IL-6-induced p-STAT3 were also inhibited by 6b without influencing IFN-Î³-induced p-STAT1 expression.  Addnl., 6b effectively promoted intracellular ROS accumulation, induced cancer cell apoptosis and cell cycle arrest, abolished the colony formation ability of breast cancer cells, and inhibited P-gp expression in MCF-7/DOX cells.  Finally, 6b suppressed the growth of implanted human breast cancer in vivo.  Our findings highlight that 6b may be a promising therapeutic agent for drug-sensitive and drug-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxX6NWyOZ_v7Vg90H21EOLACvtfcHk0ljxdvihL3vsaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVyitbc%253D&md5=aa97b030e4e00945730f51a47f41837e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsrep46352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46352%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520monocarbonyl%2520curcumin-BTP%2520hybrids%2520as%2520STAT3%2520inhibitors%2520for%2520drug-sensitive%2520and%2520drug-resistant%2520breast%2520cancer%2520therapy%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46352%26doi%3D10.1038%2Fsrep46352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yehuda, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashby, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.-J.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">100681</span>, <span class="refDoi">Â DOI: 10.1016/j.drup.2020.100681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.drup.2020.100681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32014648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FnslOqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2020&pages=100681&author=J.+Dongauthor=Z.+Qinauthor=W.-D.+Zhangauthor=G.+Chengauthor=A.+G.+Yehudaauthor=C.+R.+Ashbyauthor=Z.-S.+Chenauthor=X.-D.+Chengauthor=J.-J.+Qin&title=Medicinal+chemistry+strategies+to+discover+P-glycoprotein+inhibitors%3A+an+update&doi=10.1016%2Fj.drup.2020.100681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update</span></div><div class="casAuthors">Dong Jinyun; Qin Zuodong; Zhang Wei-Dong; Cheng Gang; Yehuda Assaraf G; Ashby Charles R Jr; Chen Zhe-Sheng; Cheng Xiang-Dong; Qin Jiang-Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100681</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The presence of multidrug resistance (MDR) in malignant tumors is one of the primary causes of treatment failure in cancer chemotherapy.  The overexpression of the ATP binding cassette (ABC) transporter, P-glycoprotein (P-gp), which significantly increases the efflux of certain anticancer drugs from tumor cells, produces MDR.  Therefore, inhibition of P-gp may represent a viable therapeutic strategy to overcome cancer MDR.  Over the past 4 decades, many compounds with P-gp inhibitory efficacy (referred to as first- and second-generation P-gp inhibitors) have been identified or synthesized.  However, these compounds were not successful in clinical trials due to a lack of efficacy and/or untoward toxicity.  Subsequently, third- and fourth-generation P-gp inhibitors were developed but dedicated clinical trials did not indicate a significant therapeutic effect.  In recent years, an extraordinary array of highly potent, selective, and low-toxicity P-gp inhibitors have been reported.  Herein, we provide a comprehensive review of the synthetic and natural products that have specific inhibitory activity on P-gp drug efflux as well as promising chemosensitizing efficacy in MDR cancer cells.  The present review focuses primarily on the structural features, design strategies, and structure-activity relationships (SAR) of these compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1YMh2HAkQ1acY7HFp97qMfW6udTcc2ebUwdFtEnf5wrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FnslOqsQ%253D%253D&md5=2f6db0a7f8fc9499772a7c5e7dd6bd7c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2020.100681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2020.100681%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.-D.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DYehuda%26aufirst%3DA.%2BG.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DCheng%26aufirst%3DX.-D.%26aulast%3DQin%26aufirst%3DJ.-J.%26atitle%3DMedicinal%2520chemistry%2520strategies%2520to%2520discover%2520P-glycoprotein%2520inhibitors%253A%2520an%2520update%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2020%26volume%3D49%26spage%3D100681%26doi%3D10.1016%2Fj.drup.2020.100681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">109502</span>, <span class="refDoi">Â DOI: 10.1016/j.biopha.2019.109502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.biopha.2019.109502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31707351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemt73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2020&pages=109502&author=Z.+Liuauthor=X.+Geauthor=Y.+Guauthor=Y.+Huangauthor=H.+Liuauthor=M.+Yuauthor=Y.+Liu&title=Small+molecule+STAT3+inhibitor%2C+6Br-6a+suppresses+breast+cancer+growth+in+vitro+and+in+vivo&doi=10.1016%2Fj.biopha.2019.109502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo</span></div><div class="casAuthors">Liu, Zhe; Ge, Xianmin; Gu, Yuchen; Huang, Yingying; Liu, Hao; Yu, Meiling; Liu, Yamin</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109502</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) protein frequently overexpressed in many malignancies and plays an essential role in regulating proliferation, apoptosis, migration and invasion in cancer cells.  However, No STAT3 inhibitor was used clin.  In this study, we evaluated the toxic potential of a novel STAT3 inhibitor, 6Br-6a in breast cancer cell lines.  The anti-cancer effect and underlying mechanism of 6Br-6a on MDA-MB-231 and MCF-7 cells were detd. in vitro and in xenograft mouse model.  Our data demonstrated that 6Br-6a significantly induced cell cycle arrest and cell apoptosis in breast cancer via blocking the activation of STAT3.  Finally, we verified these inhibitory effects of 6Br-6a in the MDA-MB-231 xenograft mouse model.  In conclusion, 6Br-6a effectively inhibited activation of STAT3 and induced cell cycle arrest and apoptosis via regulating cyclin D1 and Bcl-2 expression.  All of these data indicate that 6Br-6a could be a potential candidate for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAgfx-oVyYZ7Vg90H21EOLACvtfcHk0li_BUNeCe1jaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemt73P&md5=8c6a6bb70413a052a4a384614b49481d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2019.109502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2019.109502%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DSmall%2520molecule%2520STAT3%2520inhibitor%252C%25206Br-6a%2520suppresses%2520breast%2520cancer%2520growth%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2020%26volume%3D121%26spage%3D109502%26doi%3D10.1016%2Fj.biopha.2019.109502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Osthole inhibits triple negative breast cancer cells by suppressing STAT3</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">322</span>, <span class="refDoi">Â DOI: 10.1186/s13046-018-0992-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2Fs13046-018-0992-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30577812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFais7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=322&author=X.+Daiauthor=C.+Yinauthor=Y.+Zhangauthor=G.+Guoauthor=C.+Zhaoauthor=O.+Wangauthor=Y.+Xiangauthor=X.+Zhangauthor=G.+Liang&title=Osthole+inhibits+triple+negative+breast+cancer+cells+by+suppressing+STAT3&doi=10.1186%2Fs13046-018-0992-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Osthole inhibits triple negative breast cancer cells by suppressing STAT3</span></div><div class="casAuthors">Dai, Xuanxuan; Yin, Changtian; Zhang, Yi; Guo, Guilong; Zhao, Chengguang; Wang, Ouchen; Xiang, Youqun; Zhang, Xiaohua; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">322</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Triple-neg. breast cancer (TNBC) is an aggressive subgroup of human breast cancer.  Patients with TNBC have poor clin. outcome as they are non-responsive to current targeted therapies.  There is an urgent need to identify new therapeutic targets and develop more effective treatment options for TNBC patients.  Osthole, a natural product from C. monnieri, has been shown to inhibit certain cancer cells.  However, the mechanisms of action as well as its effect on TNBC cells are not currently known.  Methods: We investigated the effect of osthole in cultured TNBC cells as well as in a xenograft model of TNBC growth.  We also used a high-throughput proteomics platform to identify the direct binding protein of osthole.  Results: We found that osthole inhibited the growth of a panel of TNBC cells and induced apoptosis in both cultured cells and TNBC xenografts.  We used a high-throughput proteomics platform and identified signal transducer and activator of transcription 3 (STAT3) as a potential binding protein of osthole.  We further show that osthole suppressed STAT3 in TNBC cells to inhibit growth and induce apoptosis.  Overexpressing STAT3 in TNBC reduced the effectiveness of osthole treatment.  Conclusions: These results provide support for osthole as a potential new therapeutic agent for the management of TNBC.  Moreover, our results indicate that STAT3 may be targeted for the development of novel anti-TNBC drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6u28fEl000LVg90H21EOLACvtfcHk0li_BUNeCe1jaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFais7jM&md5=cb82f4fc0ef326ac6215da0a25df58e5</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0992-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0992-z%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DO.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DOsthole%2520inhibits%2520triple%2520negative%2520breast%2520cancer%2520cells%2520by%2520suppressing%2520STAT3%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26spage%3D322%26doi%3D10.1186%2Fs13046-018-0992-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">251</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.04.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31048139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOju7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=236-251&author=G.+Caiauthor=W.+Yuauthor=D.+Songauthor=W.+Zhangauthor=J.+Guoauthor=J.+Zhuauthor=Y.+Renauthor=L.+Kong&title=Discovery+of+fluorescent+coumarin-benzo%5Bb%5Dthiophene+1%2C+1-dioxide+conjugates+as+mitochondria-targeting+antitumor+STAT3+inhibitors&doi=10.1016%2Fj.ejmech.2019.04.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors</span></div><div class="casAuthors">Cai, Guiping; Yu, Wenying; Song, Dongmei; Zhang, Wenda; Guo, Jianpeng; Zhu, Jiawen; Ren, Yuhao; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">236-251</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 has been extensively studied as a potential antitumor target.  Though studies on regulating STAT3 mainly focus on the inhibition of STAT3 phosphorylation at Tyr705 residue, the phosphorylation at Ser727 residue of STAT3 protein is also closely assocd. with the mitochondrial import of STAT3 protein.  N, N-diethyl-7-aminocoumarin is a fluorescent mitochondria-targeting probe.  In this study, a series of STAT3 inhibitors were developed by connecting N, N-diethyl-7-aminocoumarin fluorophore with benzo [b]thiophene 1, 1-dioxide moiety.  All designed compds. displayed potent anti-proliferative activity against cancer cells.  The representative compd. 7a(I) was mainly accumulated in mitochondria visualized by its fluorescence.  STAT3 phosphorylation was inhibited by I at both Tyr705 and Ser727 residues.  I inhibited STAT3 phosphorylation whereas had no influence on the phosphorylation levels of STAT1, JAK2, Src and Erk1/2, indicating good selectivity of I.  Moreover, I down-regulated the expression of STAT3 target genes Bcl-2 and Cyclin D1, increased ROS prodn. and remarkably reduced the mitochondrial membrane potential to induce mitochondrial apoptotic pathway.  Furthermore, I in vivo suppressed breast cancer 4T1 implanted tumor growth.  Taken together, these results highlighted that I might be a promising mitochondria-targeting STAT3 inhibitor for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliPyZjY43-rVg90H21EOLACvtfcHk0ljxHazmxfeaHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOju7o%253D&md5=5c1e2def16a6656c2d56cfe59168053c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520fluorescent%2520coumarin-benzo%255Bb%255Dthiophene%25201%252C%25201-dioxide%2520conjugates%2520as%2520mitochondria-targeting%2520antitumor%2520STAT3%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D236%26epage%3D251%26doi%3D10.1016%2Fj.ejmech.2019.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharmeen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1459</span>â <span class="NLM_lpage">1470</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201100194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1002%2Fcmdc.201100194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21618433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptFOjtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1459-1470&author=S.+Fletcherauthor=B.+D.+Pageauthor=X.+Zhangauthor=P.+Yueauthor=Z.+H.+Liauthor=S.+Sharmeenauthor=J.+Singhauthor=W.+Zhaoauthor=A.+D.+Schimmerauthor=S.+Trudelauthor=J.+Turksonauthor=P.+T.+Gunning&title=Antagonism+of+the+Stat3-Stat3+protein+dimer+with+salicylic+acid+based+small+molecules&doi=10.1002%2Fcmdc.201100194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules</span></div><div class="casAuthors">Fletcher, Steven; Page, Brent D. G.; Zhang, Xialoei; Yue, Peibin; Li, Zhi Hua; Sharmeen, Sumaiya; Singh, Jagdeep; Zhao, Wei; Schimmer, Aaron D.; Trudel, Suzanne; Turkson, James; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1459-1470</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">More than 50 new inhibitors of the oncogenic Stat3 protein were identified through a structure-activity relationship (SAR) study based on the previously identified inhibitor S3I-201 (IC50=86 Î¼M, Ki>300 Î¼M).  A key structural feature of these inhibitors is a salicylic acid moiety, which, by acting as a phosphotyrosine mimetic, is believed to facilitate binding to the Stat3 SH2 domain.  Several of the analogs exhibit higher potency than the lead compd. in inhibiting Stat3 DNA binding activity, with an in vitro IC50 range of 18.7-51.9 Î¼M, and disruption of Stat3-pTyr peptide interactions with Ki values in the 15.5-41 Î¼M range.  One agent in particular exhibited potent inhibition of Stat3 phosphorylation in both breast and multiple myeloma tumor cells, suppressed the expression of Stat3 target genes, and induced antitumor effects in tumor cells harboring activated Stat3 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0FBfupE80LVg90H21EOLACvtfcHk0ljxHazmxfeaHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptFOjtbg%253D&md5=ad6df40e36272bdf21215eb9cc3526ce</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100194%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DSharmeen%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DAntagonism%2520of%2520the%2520Stat3-Stat3%2520protein%2520dimer%2520with%2520salicylic%2520acid%2520based%2520small%2520molecules%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D1459%26epage%3D1470%26doi%3D10.1002%2Fcmdc.201100194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Zepeda, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spagnuolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colaguori, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7190</span>â <span class="NLM_lpage">7200</span>, <span class="refDoi">Â DOI: 10.1021/jm3017255</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3017255" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7190-7200&author=B.+D.+Pageauthor=D.+C.+Croucherauthor=Z.+H.+Liauthor=S.+Haftchenaryauthor=V.+H.+Jimenez-Zepedaauthor=J.+Atkinsonauthor=P.+A.+Spagnuoloauthor=Y.+L.+Wongauthor=R.+Colaguoriauthor=A.+M.+Lewisauthor=A.+D.+Schimmerauthor=S.+Trudelauthor=P.+T.+Gunning&title=Inhibiting+aberrant+signal+transducer+and+activator+of+transcription+protein+activation+with+tetrapodal%2C+small+molecule+Src+homology+2+domain+binders%3A+promising+agents+against+multiple+myeloma&doi=10.1021%2Fjm3017255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma</span></div><div class="casAuthors">Page, Brent D. G.; Croucher, Danielle C.; Li, Zhi Hua; Haftchenary, Sina; Jimenez-Zepeda, Victor H.; Atkinson, Jennifer; Spagnuolo, Paul A.; Wong, Yoong Lim; Colaguori, Robert; Lewis, Andrew M.; Schimmer, Aaron D.; Trudel, Suzanne; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7190-7200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">[(Arylsulfonyl)glycinyl](cyclohexylbenzyl)aminosalicylic acids such as I (R = 4-MeC6H4, F5C6; R1 = 2-F3CC6H4) were prepd. as inhibitors of the signal transducer and activator of transcription (STAT) protein Stat3 for potential use as treatments for multiple myeloma.  The hydrophobicities of I and their inhibition of Stat3 were detd.; mol. docking of selected compds. to the SH2 domain of Stat3 and inhibition of Stat3 phosphorylation under various conditions were detd. for selected compds., and the activity of I (R = 4-MeC6H4; R1 = 2-F3CC6H4) against human multiple myeloma cells and human hematopoietic cells and its induction of apoptosis in multiple myeloma cells was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9RTVwhgsvE7Vg90H21EOLACvtfcHk0liS-sh-PooyMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbrL&md5=9cce9797681eccfcf43b0f8b1a813914</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm3017255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3017255%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DCroucher%26aufirst%3DD.%2BC.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DJimenez-Zepeda%26aufirst%3DV.%2BH.%26aulast%3DAtkinson%26aufirst%3DJ.%26aulast%3DSpagnuolo%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DY.%2BL.%26aulast%3DColaguori%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DA.%2BM.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DInhibiting%2520aberrant%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%2520protein%2520activation%2520with%2520tetrapodal%252C%2520small%2520molecule%2520Src%2520homology%25202%2520domain%2520binders%253A%2520promising%2520agents%2520against%2520multiple%2520myeloma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7190%26epage%3D7200%26doi%3D10.1021%2Fjm3017255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namanja, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">9623</span>â <span class="NLM_lpage">9628</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1121606109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.1121606109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=22623533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWjtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=9623-9628&author=X.+Zhangauthor=P.+Yueauthor=B.+D.+Pageauthor=T.+Liauthor=W.+Zhaoauthor=A.+T.+Namanjaauthor=D.+Paladinoauthor=J.+Zhaoauthor=Y.+Chenauthor=P.+T.+Gunningauthor=J.+Turkson&title=Orally+bioavailable+small-molecule+inhibitor+of+transcription+factor+Stat3+regresses+human+breast+and+lung+cancer+xenografts&doi=10.1073%2Fpnas.1121606109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</span></div><div class="casAuthors">Zhang, Xiaolei; Yue, Peibin; Page, Brent D. G.; Li, Tianshu; Zhao, Wei; Namanja, Andrew T.; Paladino, David; Zhao, Jihe; Chen, Yuan; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9623-9628, S9623/1-S9623/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homol. 2 domain.  BP-1-102 binds Stat3 with an affinity (KD) of 504 nM, blocks Stat3-phospho-tyrosine (pTyr) peptide interactions and Stat3 activation at 4-6.8 Î¼M, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells.  BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Kruppel-like factor 8, which is identified as a Stat3 target gene that promotes Stat3-mediated breast tumor cell migration and invasion.  Treatment of breast cancer cells with BP-1-102 further blocks Stat3-NF-ÎºB cross-talk, the release of granulocyte colony-stimulating factor, sol. intercellular adhesion mol. 1, macrophage migration-inhibitory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease inhibitor protein 1, and the phosphorylation of focal adhesion kinase and paxillin, while enhancing E-cadherin expression.  I.v. or oral gavage delivery of BP-1-102 furnishes micromolar or microgram levels in tumor tissues and inhibits growth of human breast and lung tumor xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrljEafjbznr7Vg90H21EOLACvtfcHk0liS-sh-PooyMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWjtLo%253D&md5=4da78174a7c00eacc1f1a1ce553c5aa7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1121606109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1121606109%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DNamanja%26aufirst%3DA.%2BT.%26aulast%3DPaladino%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DOrally%2520bioavailable%2520small-molecule%2520inhibitor%2520of%2520transcription%2520factor%2520Stat3%2520regresses%2520human%2520breast%2520and%2520lung%2520cancer%2520xenografts%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D9623%26epage%3D9628%26doi%3D10.1073%2Fpnas.1121606109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siddiquee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaskovich, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greedy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">7391</span>â <span class="NLM_lpage">7396</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0609757104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1073%2Fpnas.0609757104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=17463090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlslWqsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=7391-7396&author=K.+Siddiqueeauthor=S.+Zhangauthor=W.+C.+Guidaauthor=M.+A.+Blaskovichauthor=B.+Greedyauthor=H.+R.+Lawrenceauthor=M.+L.+Yipauthor=R.+Joveauthor=M.+M.+McLaughlinauthor=N.+J.+Lawrenceauthor=S.+M.+Sebtiauthor=J.+Turkson&title=Selective+chemical+probe+inhibitor+of+Stat3%2C+identified+through+structure-based+virtual+screening%2C+induces+antitumor+activity&doi=10.1073%2Fpnas.0609757104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Elective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity</span></div><div class="casAuthors">Siddiquee, Khandaker; Zhang, Shumin; Guida, Wayne C.; Blaskovich, Michelle A.; Greddy, Benjamin; Lawrence, Harshani R.; Yip, M. L. Richard; Jove, Richard; McLaughlin, Mark M.; Lawrence, Nicholas J.; Sebti, Said M.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7391-7396</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">531-201 (NSC 74859) is a chem. probe inhibitor of Stat3 activity, which was identified from the National Cancer Institute chem. libraries by using structure-based virtual screening with a computer model of the Stat3 SH2 domain bound to its Stat3 phosphotyrosine peptide derived from the x-ray crystal structure of the Stat3Î² homodimer.  S3I-201 inhibits Stat3 Â· Stat3 complex formation and Stat3 DNA-binding and transcriptional activities.  Furthermore, S3I-201 inhibits growth and induces apoptosis preferentially in tumor cells that contain persistently activated Stat3.  Constitutively dimerized and active Stat3C and Stat3 SH2 domain rescue tumor cells from S3I-201-induced apoptosis.  Finally, S3I-201 inhibits the expression of the Stat3-regulated genes encoding cyclin D1, Bcl-xL, and surviving and inhibits the growth of human breast tumors in vivo.  These findings strongly suggest that the antitumor activity of S3I-201 is mediated in part through inhibition of aberrant Stat3 activation and provide the proof-of-concept for the potential clin. use of Stat3 inhibitors such as S3I-201 in tumors harboring aberrant Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAfmqUniFENbVg90H21EOLACvtfcHk0liS-sh-PooyMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlslWqsbY%253D&md5=85decf56fc7852990f56c6f64165ad9d</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609757104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609757104%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiquee%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DBlaskovich%26aufirst%3DM.%2BA.%26aulast%3DGreedy%26aufirst%3DB.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26aulast%3DYip%26aufirst%3DM.%2BL.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DSelective%2520chemical%2520probe%2520inhibitor%2520of%2520Stat3%252C%2520identified%2520through%2520structure-based%2520virtual%2520screening%252C%2520induces%2520antitumor%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D7391%26epage%3D7396%26doi%3D10.1073%2Fpnas.0609757104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouk, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veloso, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinshtein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahani, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1102</span>â <span class="NLM_lpage">1107</span>, <span class="refDoi">Â DOI: 10.1021/ml4003138</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4003138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1102-1107&author=S.+Haftchenaryauthor=H.+A.+Luchmanauthor=A.+O.+Joukauthor=A.+J.+Velosoauthor=B.+D.+Pageauthor=X.+R.+Chengauthor=S.+S.+Dawsonauthor=N.+Grinshteinauthor=V.+M.+Shahaniauthor=K.+Kermanauthor=D.+R.+Kaplanauthor=C.+Griffinauthor=A.+M.+Amanauthor=R.+Al-Awarauthor=S.+Weissauthor=P.+T.+Gunning&title=Potent+targeting+of+the+STAT3+protein+in+brain+cancer+stem+cells%3A+a+promising+route+for+treating+glioblastoma&doi=10.1021%2Fml4003138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma</span></div><div class="casAuthors">Haftchenary, Sina; Luchman, H. Artee; Jouk, Andriana O.; Veloso, Anthony J.; Page, Brent D. G.; Cheng, Xin Ran; Dawson, Sean S.; Grinshtein, Natalie; Shahani, Vijay M.; Kerman, Kagan; Kaplan, David R.; Griffin, Carly; Aman, Ahmed M.; Al-awar, Rima; Weiss, Samuel; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1102-1107</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The STAT3 gene is abnormally active in glioblastoma (GBM) and is a critically important mediator of tumor growth and therapeutic resistance in GBM.  Thus, for poorly treated brain cancers such as gliomas, astrocytomas, and glioblastomas, which harbor constitutively activated STAT3, a STAT3-targeting therapeutic will be of significant importance.  Herein, we report a most potent, small mol., nonphosphorylated STAT3 inhibitor, I (SH-4-54) that strongly binds to STAT3 protein (KD = 300 nM).  Inhibitor I potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concns.  Moreover, in vivo, I exhibited blood-brain barrier permeability, potently controlled glioma tumor growth, and inhibited pSTAT3 in vivo.  This work, for the first time, demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8sxT0MMrOY7Vg90H21EOLACvtfcHk0ljyDdjP19G-Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSls7rK&md5=34a07baae61cd1b90eef1d9eae3d2ea9</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fml4003138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4003138%26sid%3Dliteratum%253Aachs%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DLuchman%26aufirst%3DH.%2BA.%26aulast%3DJouk%26aufirst%3DA.%2BO.%26aulast%3DVeloso%26aufirst%3DA.%2BJ.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DCheng%26aufirst%3DX.%2BR.%26aulast%3DDawson%26aufirst%3DS.%2BS.%26aulast%3DGrinshtein%26aufirst%3DN.%26aulast%3DShahani%26aufirst%3DV.%2BM.%26aulast%3DKerman%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DGriffin%26aufirst%3DC.%26aulast%3DAman%26aufirst%3DA.%2BM.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DWeiss%26aufirst%3DS.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DPotent%2520targeting%2520of%2520the%2520STAT3%2520protein%2520in%2520brain%2520cancer%2520stem%2520cells%253A%2520a%2520promising%2520route%2520for%2520treating%2520glioblastoma%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D1102%26epage%3D1107%26doi%3D10.1021%2Fml4003138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Tapia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namanja, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tius, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Hydroxamic acid and benzoic acid-based STAT3 inhibitors suppress human glioma and breast cancer phenotypes in vitro and in vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">652</span>â <span class="NLM_lpage">663</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-14-3558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1158%2F0008-5472.CAN-14-3558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26088127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSgtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=652-663&author=P.+Yueauthor=F.+Lopez-Tapiaauthor=D.+Paladinoauthor=Y.+Liauthor=C.+H.+Chenauthor=A.+T.+Namanjaauthor=T.+Hilliardauthor=Y.+Chenauthor=M.+A.+Tiusauthor=J.+Turkson&title=Hydroxamic+acid+and+benzoic+acid-based+STAT3+inhibitors+suppress+human+glioma+and+breast+cancer+phenotypes+in+vitro+and+in+vivo&doi=10.1158%2F0008-5472.CAN-14-3558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo</span></div><div class="casAuthors">Yue, Peibin; Lopez-Tapia, Francisco; Paladino, David; Li, Yifei; Chen, Chih-Hong; Namanja, Andrew T.; Hilliard, Tyvette; Chen, Yuan; Tius, Marcus A.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">652-663</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">STAT3 offers an attractive target for cancer therapy, but small-mol. inhibitors with appealing pharmacol. properties have been elusive.  Here, we report hydroxamic acid-based and benzoic acid-based inhibitors (SH5-07 and SH4-54, resp.) with robust bioactivity.  Both inhibitors blocked STAT3 DNA-binding activity in vitro and in human glioma, breast, and prostate cancer cells and in v-Src-transformed murine fibroblasts.  STAT3-dependent gene transcription was blocked along with Bcl-2, Bcl-xL, Mcl-1, cyclin D1, c-Myc, and survivin expression.  NMR anal. of STAT3-inhibitor complexes defined interactions with the SH2 and DNA-binding domains of STAT3.  Ectopic expression of the SH2 domain in cells was sufficient to counter the STAT3-inhibitory effects of SH4-54.  Neither compd. appreciably affected STAT1 or STAT5 DNA-binding activities, STAT3-independent gene transcription, or activation of a panel of oncogenic kinases in malignant cells.  Each compd. decreased the proliferation and viability of glioma, breast, and prostate cancer cells and v-Src-transformed murine fibroblasts harboring constitutively active STAT3.  Further, in mouse xenograft models of glioma and breast cancer, administration of SH5-07 or SH4-54 effectively inhibited tumor growth.  Our results offer preclin. proof of concept for SH5-07 and SH4-54 as candidates for further development as cancer therapeutics.  Cancer Res; 76(3); 652-63. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkHZXQZ-69bVg90H21EOLACvtfcHk0ljyDdjP19G-Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSgtrY%253D&md5=62397d5abc0b6e551289d44e808b6cd1</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3558%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DP.%26aulast%3DLopez-Tapia%26aufirst%3DF.%26aulast%3DPaladino%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DNamanja%26aufirst%3DA.%2BT.%26aulast%3DHilliard%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTius%26aufirst%3DM.%2BA.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DHydroxamic%2520acid%2520and%2520benzoic%2520acid-based%2520STAT3%2520inhibitors%2520suppress%2520human%2520glioma%2520and%2520breast%2520cancer%2520phenotypes%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D652%26epage%3D663%26doi%3D10.1158%2F0008-5472.CAN-14-3558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laister, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1047</span>â <span class="NLM_lpage">1055</span>, <span class="refDoi">Â DOI: 10.1021/jm200720n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200720n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SmtbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1047-1055&author=B.+D.+Pageauthor=H.+Khouryauthor=R.+C.+Laisterauthor=S.+Fletcherauthor=M.+Vellozoauthor=A.+Manzoliauthor=P.+Yueauthor=J.+Turksonauthor=M.+D.+Mindenauthor=P.+T.+Gunning&title=Small+molecule+STAT5-SH2+domain+inhibitors+exhibit+potent+antileukemia+activity&doi=10.1021%2Fjm200720n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity</span></div><div class="casAuthors">Page, Brent D. G.; Khoury, Haytham; Laister, Rob C.; Fletcher, Steven; Vellozo, Megan; Manzoli, Alessia; Yue, Piebin; Turkson, James; Minden, Mark D.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1047-1055</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A growing body of evidence shows that Signal Transducer and Activator of Transcription 5 (STAT5) protein, a key member of the STAT family of signaling proteins, plays a pivotal role in the progression of many human cancers, including acute myeloid leukemia and prostate cancer.  Unlike STAT3, where significant medicinal effort has been expended to identify potent direct inhibitors, Stat5 has been poorly investigated as a mol. therapeutic target.  Thus, in an effort to identify direct inhibitors of STAT5 protein, we conducted an in vitro screen of a focused library of SH2 domain binding salicylic acid-contg. inhibitors (â¼150) against STAT5, as well as against STAT3 and STAT1 proteins for SH2 domain selectivity.  We herein report the identification of several potent (Ki < 5 Î¼M) and STAT5 selective (>3-fold specificity for STAT5 cf. STAT1 and STAT3) inhibitors, BP-1-107, BP-1-108, SF-1-087, and SF-1-088.  Lead agents, evaluated in K562 and MV-4-11 human leukemia cells, showed potent induction of apoptosis (IC50's â¼ 20 Î¼M) which correlated with potent and selective suppression of STAT5 phosphorylation, as well as inhibition of STAT5 target genes cyclin D1, cyclin D2, C-MYC, and MCL-1.  Moreover, lead agent BP-1-108 showed negligible cytotoxic effects in normal bone marrow cells not expressing activated STAT5 protein.  Inhibitors identified in this study represent some of the most potent direct small mol., nonphosphorylated inhibitors of STAT5 to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKbueNkBRoE7Vg90H21EOLACvtfcHk0li6_kL8OZFa8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SmtbnE&md5=f4616995717eb02280cf17f10bc6bf6d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm200720n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200720n%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DKhoury%26aufirst%3DH.%26aulast%3DLaister%26aufirst%3DR.%2BC.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DVellozo%26aufirst%3DM.%26aulast%3DManzoli%26aufirst%3DA.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DSmall%2520molecule%2520STAT5-SH2%2520domain%2520inhibitors%2520exhibit%2520potent%2520antileukemia%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1047%26epage%3D1055%26doi%3D10.1021%2Fjm200720n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Tapia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotherton-Pleiss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa Araujo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis Dos Santos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichinotsubo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tius, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Linker variation and structure-activity relationship analyses of carboxylic acid-based small molecule STAT3 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">250</span>â <span class="NLM_lpage">255</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00544</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00544" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=250-255&author=F.+Lopez-Tapiaauthor=C.+Brotherton-Pleissauthor=P.+Yueauthor=H.+Murakamiauthor=A.+C.+Costa+Araujoauthor=B.+Reis+Dos+Santosauthor=E.+Ichinotsuboauthor=A.+Rabkinauthor=R.+Shahauthor=M.+Lantzauthor=S.+Chenauthor=M.+A.+Tiusauthor=J.+Turkson&title=Linker+variation+and+structure-activity+relationship+analyses+of+carboxylic+acid-based+small+molecule+STAT3+inhibitors&doi=10.1021%2Facsmedchemlett.7b00544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Linker variation and structure-activity relationship analysis of carboxylic acid-based small molecule STAT3 inhibitors</span></div><div class="casAuthors">Lopez-Tapia, Francisco; Brotherton-Pleiss, Christine; Yue, Peibin; Murakami, Heide; Costa Araujo, Ana Carolina; Reis dos Santos, Bruna; Ichinotsubo, Erin; Rabkin, Anna; Shah, Raj; Lantz, Megan; Chen, Suzie; Tius, Marcus A.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">250-255</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mol. determinants for the activities of the reported benzoic acid (SH4-54), salicylic acid (BP-1-102), and benzohydroxamic acid (SH5-07)-based STAT3 inhibitors were investigated to design optimized analogs.  All three leads are based on an N-methylglycinamide scaffold, with its two amine groups condensed with three different functionalities.  The three functionalities and the CH2 group of the glycinamide scaffold were sep. modified.  The replacement of the pentafluorobenzene or cyclohexylbenzene, or replacing the benzene ring of the arom. carboxylic or hydroxamic acid motif with heterocyclic components (contg. nitrogen and oxygen elements) all decreased potency.  Notably, the Ala-linker analogs, (I) (R1 = H and OH), and the Pro-based deriv. (II) (X = CH2), all with (R)-configuration at the chiral center, had improved inhibitory activity and selectivity against STAT3 DNA-binding activity in vitro, with IC50 of 3.0 Â± 0.9, 1.80 Â± 0.94, and 2.4 Â± 0.2 Î¼M, resp.  Compds. I and II and other analogs inhibited constitutive STAT3 phosphorylation and activation in human breast cancer and melanoma lines, and blocked tumor cell viability, growth, colony formation, and migration in vitro.  Pro-based analog, II (X = O)(sodium salt), with a relatively polar tetrahydropyranyl (THP) ring, instead of the cyclohexyl, showed improved permeability.  In general, the (R)-configuration Pro-based analogs showed the overall best profile, including physicochem. properties (e.g., microsomal metabolic stability, Caco-2 permeability), and in particular, II (X = CH2) showed improved tumor-cell specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6yrAyhBvV47Vg90H21EOLACvtfcHk0li6_kL8OZFa8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnsLs%253D&md5=c80cc2d96017675b30e13a0f0395103a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00544%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Tapia%26aufirst%3DF.%26aulast%3DBrotherton-Pleiss%26aufirst%3DC.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DCosta%2BAraujo%26aufirst%3DA.%2BC.%26aulast%3DReis%2BDos%2BSantos%26aufirst%3DB.%26aulast%3DIchinotsubo%26aufirst%3DE.%26aulast%3DRabkin%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DLantz%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DTius%26aufirst%3DM.%2BA.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DLinker%2520variation%2520and%2520structure-activity%2520relationship%2520analyses%2520of%2520carboxylic%2520acid-based%2520small%2520molecule%2520STAT3%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D250%26epage%3D255%26doi%3D10.1021%2Facsmedchemlett.7b00544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brotherton-Pleiss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Valenteen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhael, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Kauwe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tius, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Tapia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel azetidine amides as potent small-molecule STAT3 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">695</span>â <span class="NLM_lpage">710</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01705</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01705" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1Crs73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=695-710&author=C.+Brotherton-Pleissauthor=P.+Yueauthor=Y.+Zhuauthor=K.+Nakamuraauthor=W.+Chenauthor=W.+Fuauthor=C.+Kubotaauthor=J.+Chenauthor=F.+Alonso-Valenteenauthor=S.+Mikhaelauthor=L.+Medina-Kauweauthor=M.+A.+Tiusauthor=F.+Lopez-Tapiaauthor=J.+Turkson&title=Discovery+of+novel+azetidine+amides+as+potent+small-molecule+STAT3+inhibitors&doi=10.1021%2Facs.jmedchem.0c01705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors</span></div><div class="casAuthors">Brotherton-Pleiss, Christine; Yue, Peibin; Zhu, Yinsong; Nakamura, Kayo; Chen, Weiliang; Fu, Wenzhen; Kubota, Casie; Chen, Jasmine; Alonso-Valenteen, Felix; Mikhael, Simoun; Medina-Kauwe, Lali; Tius, Marcus A.; Lopez-Tapia, Francisco; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">695-710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We optimized our previously reported proline-based STAT3 inhibitors into an exciting new series of (R)-azetidine-2-carboxamide analogs that have sub-micromolar potencies. 5a, 5o, and 8i have STAT3-inhibitory potencies (IC50) of 0.55, 0.38, and 0.34 Î¼M, resp., compared to potencies greater than 18 Î¼M against STAT1 or STAT5 activity.  Further modifications derived analogs, including 7e, 7f, 7g, and 9k, that addressed cell membrane permeability and other physicochem. issues.  Isothermal titrn. calorimetry anal. confirmed high-affinity binding to STAT3, with KD of 880 nM (7g) and 960 nM (9k). 7g and 9k inhibited constitutive STAT3 phosphorylation and DNA-binding activity in human breast cancer, MDA-MB-231 or MDA-MB-468 cells.  Furthermore, treatment of breast cancer cells with 7e, 7f, 7g, or 9k inhibited viable cells, with an EC50 of 0.9-1.9 Î¼M, cell growth, and colony survival, and induced apoptosis while having relatively weaker effects on normal breast epithelial, MCF-10A or breast cancer, MCF-7 cells that do not harbor constitutively active STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEWK4CwywiqrVg90H21EOLACvtfcHk0lgZexiHqrX_fQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1Crs73K&md5=2c05209d89dd376d9fba3a55819285f4</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01705%26sid%3Dliteratum%253Aachs%26aulast%3DBrotherton-Pleiss%26aufirst%3DC.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DKubota%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAlonso-Valenteen%26aufirst%3DF.%26aulast%3DMikhael%26aufirst%3DS.%26aulast%3DMedina-Kauwe%26aufirst%3DL.%26aulast%3DTius%26aufirst%3DM.%2BA.%26aulast%3DLopez-Tapia%26aufirst%3DF.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520azetidine%2520amides%2520as%2520potent%2520small-molecule%2520STAT3%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D695%26epage%3D710%26doi%3D10.1021%2Facs.jmedchem.0c01705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">752</span>â <span class="NLM_lpage">764</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.03.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.03.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29674294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslSru7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=752-764&author=J.+Guoauthor=W.+Yuauthor=G.+Caiauthor=W.+Zhangauthor=S.+Liauthor=J.+Zhuauthor=D.+Songauthor=L.+Kong&title=Discovery+of+new+benzensulfonamide+derivatives+as+tripedal+STAT3+inhibitors&doi=10.1016%2Fj.ejmech.2018.03.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</span></div><div class="casAuthors">Guo, Jianpeng; Yu, Wenying; Cai, Guiping; Zhang, Wenda; Li, Shanshan; Zhu, Jiawen; Song, Dongmei; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">752-764</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Persistent activated STAT3 has a striking correlation with cancer development and inhibition of STAT3 signaling pathway is a novel therapeutic way for human cancers.  Among STAT family, STAT1 and STAT3 play opposite roles in tumorigenesis.  However, the discovery of selective STAT3 inhibitors is still challenging to date.  In this study, a series of small-mol. (MW<500) benzensulfanilamide derivs. were designed to selectively suppress STAT3 activation for anti-cancer treatment.  The most potent compd. 11 inhibited both overexpressed and IL-6 induced STAT3 phosphorylation, whereas 11 displayed little effect on the phosphorylation of other STAT isoforms STAT1, STAT5, demonstrating 11 was a selective STAT3 inhibitor.  Meanwhile, 11 dismissed STAT3 DNA binding activity and colony formation.  In addn., 11 elevated the ROS level and induced apoptosis of cancer cells.  Furthermore, 11 effectively suppressed tumor growth in an in vivo mouse-xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjwneUbz5BgbVg90H21EOLACvtfcHk0lgZexiHqrX_fQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslSru7w%253D&md5=9f46716463f5610a25bffcfb85b2031a</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.053%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520new%2520benzensulfonamide%2520derivatives%2520as%2520tripedal%2520STAT3%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D752%26epage%3D764%26doi%3D10.1016%2Fj.ejmech.2018.03.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redell, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonzo, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbing, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweardy, D. J.</span></span> <span> </span><span class="NLM_article-title">Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">5701</span>â <span class="NLM_lpage">5709</span>, <span class="refDoi">Â DOI: 10.1182/blood-2010-04-280123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1182%2Fblood-2010-04-280123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21447830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1Cms74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=5701-5709&author=M.+S.+Redellauthor=M.+J.+Ruizauthor=T.+A.+Alonzoauthor=R.+B.+Gerbingauthor=D.+J.+Tweardy&title=Stat3+signaling+in+acute+myeloid+leukemia%3A+ligand-dependent+and+-independent+activation+and+induction+of+apoptosis+by+a+novel+small-molecule+Stat3+inhibitor&doi=10.1182%2Fblood-2010-04-280123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor</span></div><div class="casAuthors">Redell, Michele S.; Ruiz, Marcos J.; Alonzo, Todd A.; Gerbing, Robert B.; Tweardy, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5701-5709</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is an aggressive malignancy with a relapse rate approaching 50%, despite aggressive chemotherapy.  New therapies for AML are targeted at signal transduction pathways known to support blast survival, such as the Stat3 pathway.  Aberrant activation of Stat3 was demonstrated in many different malignancies, including AML, and this finding is frequently assocd. with more aggressive disease.  The objectives of this study were: (1) to characterize Stat3 signaling patterns in AML cells lines and primary pediatric samples; and (2) to test the efficacy and potency of a novel Stat3 inhibitor in inducing apoptosis in AML cells.  We found that Stat3 was constitutively activated in 6 of 7 AML cell lines and 6 of 18 primary pediatric AML samples.  Moreover, constitutively phosphorylated Stat3 was frequent in samples with normal 3 but uncommon in samples with t(8;21).  Most cell lines and primary samples responded to G-CSF stimulation, although the sensitivity and magnitude of the response varied dramatically.  Our novel small-mol. Stat3 inhibitor, C188-9, inhibited G-CSF-induced Stat3 phosphorylation, induced apoptosis in AML cell lines and primary samples, and inhibited AML blast colony formation with potencies in the low micromolar range.  Therefore, Stat3 inhibition may be a valuable strategy for targeted therapies for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8xPOZdPixbLVg90H21EOLACvtfcHk0lgZexiHqrX_fQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1Cms74%253D&md5=9c577ac872bb03b0df3759c62a401a67</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-04-280123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-04-280123%26sid%3Dliteratum%253Aachs%26aulast%3DRedell%26aufirst%3DM.%2BS.%26aulast%3DRuiz%26aufirst%3DM.%2BJ.%26aulast%3DAlonzo%26aufirst%3DT.%2BA.%26aulast%3DGerbing%26aufirst%3DR.%2BB.%26aulast%3DTweardy%26aufirst%3DD.%2BJ.%26atitle%3DStat3%2520signaling%2520in%2520acute%2520myeloid%2520leukemia%253A%2520ligand-dependent%2520and%2520-independent%2520activation%2520and%2520induction%2520of%2520apoptosis%2520by%2520a%2520novel%2520small-molecule%2520Stat3%2520inhibitor%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D5701%26epage%3D5709%26doi%3D10.1182%2Fblood-2010-04-280123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minus, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangubat-Medina, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasembeli, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolosov, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweardy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redell, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, Z. T.</span></span> <span> </span><span class="NLM_article-title">Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3288</span>â <span class="NLM_lpage">3296</span>, <span class="refDoi">Â DOI: 10.1039/C9OB02682G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1039%2FC9OB02682G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32286579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVWhu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=3288-3296&author=M.+B.+Minusauthor=H.+Wangauthor=J.+O.+Munozauthor=A.+M.+Stevensauthor=A.+E.+Mangubat-Medinaauthor=M.+J.+Kruegerauthor=W.+Liuauthor=M.+M.+Kasembeliauthor=J.+C.+Cooperauthor=M.+I.+Kolosovauthor=D.+J.+Tweardyauthor=M.+S.+Redellauthor=Z.+T.+Ball&title=Targeting+STAT3+anti-apoptosis+pathways+with+organic+and+hybrid+organic-inorganic+inhibitors&doi=10.1039%2FC9OB02682G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors</span></div><div class="casAuthors">Minus, Matthew B.; Wang, Haopei; Munoz, Jaime O.; Stevens, Alexandra M.; Mangubat-Medina, Alicia E.; Krueger, Michael J.; Liu, Wei; Kasembeli, Moses M.; Cooper, Julian C.; Kolosov, Mikhail I.; Tweardy, David J.; Redell, Michele S.; Ball, Zachary T.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3288-3296</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Recurrence and drug resistance are major challenges in the treatment of acute myeloid leukemia (AML) that spur efforts to identify new clin. targets and active agents.  STAT3 has emerged as a potential target in resistant AML, but inhibiting STAT3 function has proven challenging.  This paper describes synthetic studies and biol. assays for a naphthalene sulfonamide inhibitor class of mols. that inhibit G-CSF-induced STAT3 phosphorylation in cellulo and induce apoptosis in AML cells.  We describe two different approaches to inhibitor design: first, variation of substituents on the naphthalene sulfonamide core allows improvements in anti-STAT activity and creates a more thorough understanding of anti-STAT SAR.  Second, a novel approach involving hybrid sulfonamide-rhodium(II) conjugates tests our ability to use cooperative org.-inorg. binding for drug development, and to use SAR studies to inform metal conjugate design.  Both approaches have produced compds. with improved binding potency.  In vivo and in cellulo expts. further demonstrate that these approaches can also lead to improved activity in living cells, and that compd. 3aa slows disease progression in a xenograft model of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXBPMaIct4FrVg90H21EOLACvtfcHk0lisA1clrkszng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVWhu7s%253D&md5=90c9e27d70783f89799df5298c8e69b8</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1039%2FC9OB02682G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9OB02682G%26sid%3Dliteratum%253Aachs%26aulast%3DMinus%26aufirst%3DM.%2BB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMunoz%26aufirst%3DJ.%2BO.%26aulast%3DStevens%26aufirst%3DA.%2BM.%26aulast%3DMangubat-Medina%26aufirst%3DA.%2BE.%26aulast%3DKrueger%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKasembeli%26aufirst%3DM.%2BM.%26aulast%3DCooper%26aufirst%3DJ.%2BC.%26aulast%3DKolosov%26aufirst%3DM.%2BI.%26aulast%3DTweardy%26aufirst%3DD.%2BJ.%26aulast%3DRedell%26aufirst%3DM.%2BS.%26aulast%3DBall%26aufirst%3DZ.%2BT.%26atitle%3DTargeting%2520STAT3%2520anti-apoptosis%2520pathways%2520with%2520organic%2520and%2520hybrid%2520organic-inorganic%2520inhibitors%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2020%26volume%3D18%26spage%3D3288%26epage%3D3296%26doi%3D10.1039%2FC9OB02682G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitor C188â9 synergistically enhances the demethylated activity of low-dose 5-aza-2â²-deoxycytidine against pancreatic cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">612</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2020.00612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3389%2Ffonc.2020.00612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32457835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB38rhvFSnug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=612&author=R.+Kongauthor=G.+Sunauthor=X.+Liauthor=L.+Wuauthor=L.+Liauthor=Y.+Liauthor=F.+Wangauthor=P.+Xuanauthor=S.+Yangauthor=B.+Sunauthor=J.+Hu&title=Small+molecule+inhibitor+C188%E2%80%939+synergistically+enhances+the+demethylated+activity+of+low-dose+5-aza-2%E2%80%B2-deoxycytidine+against+pancreatic+cancer&doi=10.3389%2Ffonc.2020.00612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2'-Deoxycytidine Against Pancreatic Cancer</span></div><div class="casAuthors">Kong Rui; Sun Guangming; Li Xina; Wu Linfeng; Li Le; Li Yilong; Wang Fei; Yang Shifeng; Sun Bei; Hu Jisheng; Kong Rui; Sun Guangming; Wu Linfeng; Li Le; Li Yilong; Sun Bei; Hu Jisheng; Xuan Ping</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">612</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Aberrant DNA methylation, especially hypermethylation of tumor suppressor genes, has been associated with many cancers' progression. 5-Aza-2'-deoxycytidine (DAC) can reverse hypermethylation-induced gene silencing via regulating DNA methyltransferases (DNMTs) activity, In addition, low-dose of DAC was proved to exert durable antitumor effects against solid tumor cells.  Nevertheless, no clinical effect of DAC has been made when fighting against pancreatic cancer.  Hence, it is necessary to raise a novel therapeutic strategy that further enhance the efficacy of DAC but not increase side effect, which impede the utilization of DAC.  In the present study, we have discovered that C188-9, a novel signal transduction activator of transcription (STAT) inhibitor, could improve the antitumor effects of low-dose DAC in vivo and in vitro.  Further study demonstrated that such improvement was attributed to re-expression of Ras association domain family member 1A (RASSF1A), a well-known tumor suppressor gene.  Bisulfite sequencing PCR (BSP) assay showed that C188-9 combined with DAC treatment could significantly reverse the hypermethylation status of RASSF1A promoter, which indicated that C188-9 could enhance the demethylation efficacy of DAC.  Our data demonstrated that DNA methyltransferase 1 (DNMT1) was the underlying mechanism that C188-9 regulates the demethylation efficacy of DAC.  Overall, these findings provide a novel therapeutic strategy combining low-dose DAC and C188-9 to improve therapeutic efficacy by inhibiting DNMT1-inducing promoter methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT451E1cqig0d0Q2ypr7jHkfW6udTcc2ea_7j8BsRwBsbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38rhvFSnug%253D%253D&md5=1acf8c140d4dd4e4aa455138ddd94300</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00612%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXuan%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520inhibitor%2520C188%25E2%2580%25939%2520synergistically%2520enhances%2520the%2520demethylated%2520activity%2520of%2520low-dose%25205-aza-2%25E2%2580%25B2-deoxycytidine%2520against%2520pancreatic%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D612%26doi%3D10.3389%2Ffonc.2020.00612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Y.</span></span> <span> </span><span class="NLM_article-title">C188â9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">846</span>â <span class="NLM_lpage">853</span>, <span class="refDoi">Â DOI: 10.1097/CAD.0000000000000783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1097%2FCAD.0000000000000783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30870229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOqt77E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=846-853&author=J.+X.+Diauthor=H.+Y.+Zhang&title=C188%E2%80%939%2C+a+small-molecule+STAT3+inhibitor%2C+exerts+an+antitumor+effect+on+head+and+neck+squamous+cell+carcinoma&doi=10.1097%2FCAD.0000000000000783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma</span></div><div class="casAuthors">Di, Jian-Xin; Zhang, Hong-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">846-853</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">1473-5741</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Abnormal activation of signal transducer and activator of transcription 3 (STAT3) is complicated in the tumor progression of multiple cancers including human head and neck squamous cell carcinoma (HNSCC) and, therefore, serves as a potent therapeutic target.  In this study, we identify that C188-9, a small-mol. STAT3 inhibitor, exhibits an antitumor effect on HNSCC in vitro.  C188-9 significantly inhibits cell growth, arrests cell cycle at G0/G1 phase, and induces apoptosis in HNSCC.  Besides, the capacities of migration and invasion of HNSCC cells are impaired with the exposure to C188-9.  In addn., C188-9 treatment enhanced the chemosensitivity of HNSCC cellsin vitro.  Moreover, C188-9 inactivates STAT3 by reducing its phosphorylation at Tyr705.  Taken together, these results indicate that C188-9 could be a promising therapeutic strategy for patients suffered from HNSCC by suppressing the STAT3 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyKJNhva8ForVg90H21EOLACvtfcHk0li_s-_UBdNlPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOqt77E&md5=57cdf51a67cd746c0ce4dd80f98edcb8</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000783%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DJ.%2BX.%26aulast%3DZhang%26aufirst%3DH.%2BY.%26atitle%3DC188%25E2%2580%25939%252C%2520a%2520small-molecule%2520STAT3%2520inhibitor%252C%2520exerts%2520an%2520antitumor%2520effect%2520on%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2019%26volume%3D30%26spage%3D846%26epage%3D853%26doi%3D10.1097%2FCAD.0000000000000783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minus, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vohidov, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasembeli, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolosov, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweardy, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sison, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redell, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, Z. T.</span></span> <span> </span><span class="NLM_article-title">Rhodium(II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">13085</span>â <span class="NLM_lpage">13089</span>, <span class="refDoi">Â DOI: 10.1002/anie.201506889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1002%2Fanie.201506889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOmsr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=13085-13089&author=M.+B.+Minusauthor=W.+Liuauthor=F.+Vohidovauthor=M.+M.+Kasembeliauthor=X.+Longauthor=M.+J.+Kruegerauthor=A.+Stevensauthor=M.+I.+Kolosovauthor=D.+J.+Tweardyauthor=E.+A.+Sisonauthor=M.+S.+Redellauthor=Z.+T.+Ball&title=Rhodium%28II%29+proximity-labeling+identifies+a+novel+target+site+on+STAT3+for+inhibitors+with+potent+anti-leukemia+activity&doi=10.1002%2Fanie.201506889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity</span></div><div class="casAuthors">Minus, Matthew B.; Liu, Wei; Vohidov, Farrukh; Kasembeli, Moses M.; Long, Xin; Krueger, Michael J.; Stevens, Alexandra; Kolosov, Mikhail I.; Tweardy, David J.; Sison, Edward Allan R.; Redell, Michele S.; Ball, Zachary T.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">13085-13089</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Nearly 40 % of children with acute myeloid leukemia (AML) suffer relapse arising from chemoresistance, often involving upregulation of the oncoprotein STAT3 (signal transducer and activator of transcription 3).  Herein, rhodium(II)-catalyzed, proximity-driven modification identifies the STAT3 coiled-coil domain (CCD) as a novel ligand-binding site, and we describe a new naphthalene sulfonamide inhibitor that targets the CCD, blocks STAT3 function, and halts its disease-promoting effects in vitro, in tumor growth models, and in a leukemia mouse model, validating this new therapeutic target for resistant AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaEI9lh5LaebVg90H21EOLACvtfcHk0li_s-_UBdNlPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOmsr3F&md5=8d1c509437ac74ff8382ff7a43898de9</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506889%26sid%3Dliteratum%253Aachs%26aulast%3DMinus%26aufirst%3DM.%2BB.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DVohidov%26aufirst%3DF.%26aulast%3DKasembeli%26aufirst%3DM.%2BM.%26aulast%3DLong%26aufirst%3DX.%26aulast%3DKrueger%26aufirst%3DM.%2BJ.%26aulast%3DStevens%26aufirst%3DA.%26aulast%3DKolosov%26aufirst%3DM.%2BI.%26aulast%3DTweardy%26aufirst%3DD.%2BJ.%26aulast%3DSison%26aufirst%3DE.%2BA.%26aulast%3DRedell%26aufirst%3DM.%2BS.%26aulast%3DBall%26aufirst%3DZ.%2BT.%26atitle%3DRhodium%2528II%2529%2520proximity-labeling%2520identifies%2520a%2520novel%2520target%2520site%2520on%2520STAT3%2520for%2520inhibitors%2520with%2520potent%2520anti-leukemia%2520activity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D13085%26epage%3D13089%26doi%3D10.1002%2Fanie.201506889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehndiratta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">N-sulfonyl-aminobiaryls as antitubulin agents and inhibitors of signal transducers and activators of transcription 3 (STAT3) signaling</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6549</span>â <span class="NLM_lpage">6558</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00659</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00659" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OqsLnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6549-6558&author=M.+J.+Laiauthor=H.+Y.+Leeauthor=H.+Y.+Chuangauthor=L.+H.+Changauthor=A.+C.+Tsaiauthor=M.+C.+Chenauthor=H.+L.+Huangauthor=Y.+W.+Wuauthor=C.+M.+Tengauthor=S.+L.+Panauthor=Y.+M.+Liuauthor=S.+Mehndirattaauthor=J.+P.+Liou&title=N-sulfonyl-aminobiaryls+as+antitubulin+agents+and+inhibitors+of+signal+transducers+and+activators+of+transcription+3+%28STAT3%29+signaling&doi=10.1021%2Facs.jmedchem.5b00659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling</span></div><div class="casAuthors">Lai, Mei-Jung; Lee, Hsueh-Yun; Chuang, Hsun-Yueh; Chang, Li-Hsun; Tsai, An-Chi; Chen, Mei-Chuan; Huang, Han-Lin; Wu, Yi-Wen; Teng, Che-Ming; Pan, Shiow-Lin; Liu, Yi-Min; Mehndiratta, Samir; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6549-6558</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-sulfonyl-aminobiaryl derivs. have been examd. as novel antitubulin agents.  Compd. I exhibits remarkable antiproliferative activity against four cancer cell lines (pancreatic AsPC-1, lung A549, liver Hep3B, and prostate PC-3) with a mean GI50 value of 57.5 nM.  Addnl. assays reveal that I inhibits not only tubulin polymn. but also the phosphorylation of STAT3 inhibition with an IC50 value of 0.2 Î¼M.  Four addnl. compds. are also able to inhibit this phosphorylation.  This study describes novel N-sulfonyl-aminobiaryl (biaryl-benzenesulfonamides) as potent anticancer agents targeting both STAT3 and tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN3n1lKtBuqbVg90H21EOLACvtfcHk0li_s-_UBdNlPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OqsLnI&md5=e0bb2c7f2fb75634ed66b0a910332b9a</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00659%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DChuang%26aufirst%3DH.%2BY.%26aulast%3DChang%26aufirst%3DL.%2BH.%26aulast%3DTsai%26aufirst%3DA.%2BC.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DMehndiratta%26aufirst%3DS.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DN-sulfonyl-aminobiaryls%2520as%2520antitubulin%2520agents%2520and%2520inhibitors%2520of%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%25203%2520%2528STAT3%2529%2520signaling%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6549%26epage%3D6558%26doi%3D10.1021%2Facs.jmedchem.5b00659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, C.</span></span> <span> </span><span class="NLM_article-title">N-arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">96</span>â <span class="NLM_lpage">106</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmc.2017.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29174507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKhsrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=96-106&author=Q.+Zhouauthor=J.+Zhuauthor=J.+Chenauthor=P.+Jiauthor=C.+Qiao&title=N-arylsulfonylsubstituted-1H+indole+derivatives+as+small+molecule+dual+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+and+tubulin&doi=10.1016%2Fj.bmc.2017.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">N-Arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin</span></div><div class="casAuthors">Zhou, Qiang; Zhu, Jinjin; Chen, Jinglei; Ji, Peng; Qiao, Chunhua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-106</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription (STAT3) is a proposed therapeutic target for the development of anti-cancer agents.  In this report, a series of N-arylsulfonylsubstituted-1H indole derivs. were designed and synthesized as STAT3 inhibitors, their anti-proliferative activities were evaluated against a no. of tumor cells, some potent compds. exhibited IC50 values less than 10Î¼M.  The most potent compd. 4a was further confirmed to inhibit STAT3 phosphorylation at Tyr705.  It was further revealed that 4a arrested the cell cycle at the G2/M phase and inhibited tubulin polymn.  This study describes a series of N-arylsulfonylsubstituted-1H indole derivs. as potent anti-cancer agents targeting both STAT3 and tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGramH1h65Up5bVg90H21EOLACvtfcHk0liSGwiYMz-ApQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKhsrjL&md5=42f4f6840d823edb8fe53918f7f4bafd</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DQiao%26aufirst%3DC.%26atitle%3DN-arylsulfonylsubstituted-1H%2520indole%2520derivatives%2520as%2520small%2520molecule%2520dual%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520and%2520tubulin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D96%26epage%3D106%26doi%3D10.1016%2Fj.bmc.2017.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of O-alkylamino-tethered niclosamide derivatives as potent and orally bioavailable anticancer agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">180</span>â <span class="NLM_lpage">185</span>, <span class="refDoi">Â DOI: 10.1021/ml3003082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3003082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1ejug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=180-185&author=H.+Chenauthor=Z.+Yangauthor=C.+Dingauthor=L.+Chuauthor=Y.+Zhangauthor=K.+Terryauthor=H.+Liuauthor=Q.+Shenauthor=J.+Zhou&title=Discovery+of+O-alkylamino-tethered+niclosamide+derivatives+as+potent+and+orally+bioavailable+anticancer+agents&doi=10.1021%2Fml3003082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents</span></div><div class="casAuthors">Chen, Haijun; Yang, Zhengduo; Ding, Chunyong; Chu, Lili; Zhang, Yusong; Terry, Kristin; Liu, Huiling; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-185</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Niclosamide has been identified to potently inhibit the activation, nuclear translocation, and transactivation of STAT3.  Nevertheless, the poor aq. soly. and bioavailability of niclosamide have hindered its further clin. development for cancer therapy.  To discover new mols. with enhanced druglike properties, a series of novel O-alkylamino-tethered derivs. of niclosamide have been designed, synthesized, and biol. evaluated.  Among them, compd. IÂ·HCl (HJC0152) has been demonstrated to significantly suppress MDA-MB-231 xenograft tumor growth in vivo (i.p. and po), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlkKSIbCSKsrVg90H21EOLACvtfcHk0liSGwiYMz-ApQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1ejug%253D%253D&md5=a481986f86800fc39f24a6af12c46a8e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fml3003082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3003082%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTerry%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520O-alkylamino-tethered%2520niclosamide%2520derivatives%2520as%2520potent%2520and%2520orally%2520bioavailable%2520anticancer%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D180%26epage%3D185%26doi%3D10.1021%2Fml3003082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on niclosamide</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>218</i></span>,  <span class="NLM_fpage">113362</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2021.113362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33774344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3MXns1ehs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2021&pages=113362&author=X.+Wangauthor=K.+Wuauthor=L.+Fangauthor=X.+Yangauthor=N.+Zhengauthor=Z.+Duauthor=Y.+Luauthor=Z.+Xieauthor=Z.+Liuauthor=Z.+Zuoauthor=F.+Ye&title=Discovery+of+N-substituted+sulfamoylbenzamide+derivatives+as+novel+inhibitors+of+STAT3+signaling+pathway+based+on+niclosamide&doi=10.1016%2Fj.ejmech.2021.113362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide</span></div><div class="casAuthors">Wang, Xuebao; Wu, Kaiqi; Fang, Longcheng; Yang, Xiaojiao; Zheng, Nan; Du, Zongxuan; Lu, Ying; Xie, Zixin; Liu, Zhiguo; Zuo, Zhigui; Ye, Faqing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113362</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) has been confirmed as an attractive therapeutic target for cancer therapy.  Herein, a series of N-substituted sulfamoylbenzamide STAT3 inhibitors I [R1 = H, OH; R2 = H, Cl; R3 = 2-MeOC6H4, 3,4,5-(OMe)3C6H2, 3-MeOC6H4CH2, etc.; R4 = H, C(O)Me, C(O)Ph, etc.] based on small-mol. STAT3 inhibitor Niclosamide was synthesized.  Compd. I [R1 = H, R2 = Cl, R3 = 4-CO2t-BuC6H4, R4 = H] the best active compd. of this series, was identified as an inhibitor of IL-6/STAT3 signaling with an IC50 of 0.61-1.11Î¼M in MDA-MB-231, HCT-116 and SW480 tumor cell lines with STAT3 overexpression, by inhibiting the phosphorylation of STAT3 of Tyr705 residue and the expression of STAT3 downstream genes, inducing apoptosis and inhibiting the migration of cancer cells.  Furthermore, in vivo study revealed that compd. I [R1 = H, R2 = Cl, R3 = 4-CO2t-BuC6H4, R4 = H] suppressed the MDA-MB-231 xenograft tumor growth in nude mice at the dose of 30 mg/kg (i.g.), which has better antitumor activity than the pos. control Niclosamide.  More importantly, compd. I [R1 = H, R2 = Cl, R3 = 4-CO2t-BuC6H4, R4 = H] was an orally bioavailable anticancer agent as a promising candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosKlZj-EOdd7Vg90H21EOLACvtfcHk0liSGwiYMz-ApQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXns1ehs7w%253D&md5=a634925c2b0cfde3408490a9904d0f64</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113362%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZuo%26aufirst%3DZ.%26aulast%3DYe%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520N-substituted%2520sulfamoylbenzamide%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520STAT3%2520signaling%2520pathway%2520based%2520on%2520niclosamide%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D218%26spage%3D113362%26doi%3D10.1016%2Fj.ejmech.2021.113362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koseki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suehiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a new STAT3 inhibitor acting on the linker domain</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">792</span>â <span class="NLM_lpage">800</span>, <span class="refDoi">Â DOI: 10.1248/bpb.b18-00992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1248%2Fbpb.b18-00992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31061322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVShsLnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=792-800&author=T.+Kosekiauthor=N.+Suehiroauthor=Y.+Masudaauthor=N.+Miyoshiauthor=D.+Muraokaauthor=N.+Ogoauthor=A.+Asai&title=Discovery+of+a+new+STAT3+inhibitor+acting+on+the+linker+domain&doi=10.1248%2Fbpb.b18-00992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a new STAT3 inhibitor acting on the linker domain</span></div><div class="casAuthors">Koseki, Tatsuya; Suehiro, Naoya; Masuda, Yoshiaki; Miyoshi, Nao; Muraoka, Daisuke; Ogo, Naohisa; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">792-800</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a latent transcription factor that contributes to tumor cell growth and survival and is often constitutively active in several types of cancers, which makes it an attractive target for cancer therapy.  We identified 5,5'-(pentane-1,5'-diyl)bis(2-methyl-1,4-benzoquinone) (BPMB) as a new STAT3 inhibitor.  BPMB inhibited the transcriptional activities of STAT3, despite its inability to reduce the phosphorylation and nuclear translocation of STAT3.  BPMB selectively inhibited the proliferation of human breast cancer cell lines with constitutively activated STAT3.  Furthermore, a gel retardation pattern was obtained by immunoblotting only when those STAT3-activated cell lines were treated with BPMB.  The shifted bands could be immunoblotted with anti-STAT3 antibody but not with anti-STAT1/STAT5 antibody, and were stable under reducing conditions.  The purified recombinant STAT3 protein treated with BPMB afforded a similar band shift pattern.  Matrix-assisted laser desorption/ionization-mass spectrometry anal. of the component comprising the main shifted band suggested that the complex is a STAT3 homodimer crosslinked by BPMB through a Michael addn. with Cys550 in the linker domain.  Alanine replacement at this position resulted in redn. of the STAT3 dimer formation in the gel retardation assay.  Thus, our results suggest that BPMB inhibits the proliferation of STAT3-activated cell lines, presumably through acylation of the linker domain and subsequent induction of the inactive STAT3 complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFOnrr8aXDNLVg90H21EOLACvtfcHk0liEczRcFwZ8Qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVShsLnL&md5=f7968e57b207518cf2231f769276eff6</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b18-00992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b18-00992%26sid%3Dliteratum%253Aachs%26aulast%3DKoseki%26aufirst%3DT.%26aulast%3DSuehiro%26aufirst%3DN.%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DMiyoshi%26aufirst%3DN.%26aulast%3DMuraoka%26aufirst%3DD.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520new%2520STAT3%2520inhibitor%2520acting%2520on%2520the%2520linker%2520domain%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2019%26volume%3D42%26spage%3D792%26epage%3D800%26doi%3D10.1248%2Fbpb.b18-00992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Natan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anahtar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppler, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blonquist, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiffer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1845</span>â <span class="NLM_lpage">1853</span>, <span class="refDoi">Â DOI: 10.1182/blood-2015-07-660506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1182%2Fblood-2015-07-660506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27531676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSiurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=1845-1853&author=M.+Xiangauthor=H.+Kimauthor=V.+T.+Hoauthor=S.+R.+Walkerauthor=M.+Bar-Natanauthor=M.+Anahtarauthor=S.+Liuauthor=P.+A.+Tonioloauthor=Y.+Krollauthor=N.+Jonesauthor=Z.+T.+Giacconeauthor=L.+N.+Hepplerauthor=D.+Q.+Yeauthor=J.+J.+Marineauauthor=D.+Shawauthor=J.+E.+Bradnerauthor=T.+Blonquistauthor=D.+Neubergauthor=C.+Hetzauthor=R.+M.+Stoneauthor=R.+J.+Soifferauthor=D.+A.+Frank&title=Gene+expression-based+discovery+of+atovaquone+as+a+STAT3+inhibitor+and+anticancer+agent&doi=10.1182%2Fblood-2015-07-660506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent</span></div><div class="casAuthors">Xiang, Michael; Kim, Haesook; Ho, Vincent T.; Walker, Sarah R.; Bar-Natan, Michal; Anahtar, Melodi; Liu, Suhu; Toniolo, Patricia A.; Kroll, Yasmin; Jones, Nichole; Giaccone, Zachary T.; Heppler, Lisa N.; Ye, Darwin Q.; Marineau, Jason J.; Shaw, Daniel; Bradner, James E.; Blonquist, Traci; Neuberg, Donna; Hetz, Claudio; Stone, Richard M.; Soiffer, Robert J.; Frank, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1845-1853</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is frequently activated inappropriately in a wide range of hematol. and solid cancers, but clin. available therapies targeting STAT3 are lacking.  Using a computational strategy to identify compds. opposing the gene expression signature of STAT3, we discovered atovaquone (Mepron), an antimicrobial approved by the US Food and Drug Administration, to be a potent STAT3 inhibitor.  We show that, at drug concns. routinely achieved clin. in human plasma, atovaquone inhibits STAT3 phosphorylation, the expression of STAT3 target genes, and the viability of STAT3-dependent hematol. cancer cells.  These effects were also obsd. with atovaquone treatment of primary blasts isolated from patients with acute myelogenous leukemia or acute lymphocytic leukemia.  Atovaquone is not a kinase inhibitor but instead rapidly and specifically downregulates cell-surface expression of glycoprotein 130, which is required for STAT3 activation in multiple contexts.  The administration of oral atovaquone to mice inhibited tumor growth and prolonged survival in a murine model of multiple myeloma.  Finally, in patients with acute myelogenous leukemia treated with hematopoietic stem cell transplantation, extended use of atovaquone for Pneumocystis prophylaxis was assocd. with improved relapse-free survival.  These findings establish atovaquone as a novel, clin. accessible STAT3 inhibitor with evidence of anticancer efficacy in both animal models and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kci57tYtb7Vg90H21EOLACvtfcHk0liEczRcFwZ8Qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSiurg%253D&md5=201e3d6ea0e204d1a631652caae8f987</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-07-660506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-07-660506%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DHo%26aufirst%3DV.%2BT.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DBar-Natan%26aufirst%3DM.%26aulast%3DAnahtar%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DToniolo%26aufirst%3DP.%2BA.%26aulast%3DKroll%26aufirst%3DY.%26aulast%3DJones%26aufirst%3DN.%26aulast%3DGiaccone%26aufirst%3DZ.%2BT.%26aulast%3DHeppler%26aufirst%3DL.%2BN.%26aulast%3DYe%26aufirst%3DD.%2BQ.%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBlonquist%26aufirst%3DT.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DHetz%26aufirst%3DC.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSoiffer%26aufirst%3DR.%2BJ.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DGene%2520expression-based%2520discovery%2520of%2520atovaquone%2520as%2520a%2520STAT3%2520inhibitor%2520and%2520anticancer%2520agent%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D1845%26epage%3D1853%26doi%3D10.1182%2Fblood-2015-07-660506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2718</span>â <span class="NLM_lpage">2731</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2718-2731&author=W.+Yuauthor=C.+Liauthor=W.+Zhangauthor=Y.+Xiaauthor=S.+Liauthor=J.+Y.+Linauthor=K.+Yuauthor=M.+Liuauthor=L.+Yangauthor=J.+Luoauthor=Y.+Chenauthor=H.+Sunauthor=L.+Kong&title=Discovery+of+an+orally+selective+inhibitor+of+signal+transducer+and+activator+of+transcription+3+using+advanced+multiple+ligand+simultaneous+docking&doi=10.1021%2Facs.jmedchem.6b01489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking</span></div><div class="casAuthors">Yu, Wenying; Li, Chenglong; Zhang, Wenda; Xia, Yuanzheng; Li, Shanshan; Lin, Jia-yuh; Yu, Keqin; Liu, Mu; Yang, Lei; Luo, Jianguang; Chen, Yijun; Sun, Hongbin; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2718-2731</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting signal transducer and activator of transcription 3 (STAT3) is a potential anticancer strategy.  However, STAT3 inhibitors with good selectivity and bioavailability are rare.  The aim of this study was to discover selective direct STAT3 inhibitors with good drug-likeness.  By advanced multiple ligand simultaneous docking (AMLSD) method, compd. 9 (5,8-dioxo-6-((2-(piperazin-1-yl)phenyl)amino)-5,8-dihydronaphthalene-1-sulfonamide) was designed as an orally-bioavailable STAT3 inhibitor, which presented superior druggability and selectivity to other representative STAT3 inhibitors.  Compd. 9 directly and selectively inhibited the pY705 site of STAT3 with an affinity (Ki) of 440nM.  The IC50 of 9 for breast cancer cell MDA-MB-231 was 184-fold lower than its IC50 for normal breast epithelial cell MCF-10A.  Compd. 9 in vivo induced significant antitumor responses better than Gefitinib and its therapeutic index should be over 100, indicating good safety of 9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiT8F_tCrky7Vg90H21EOLACvtfcHk0lix1KT849SkcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D&md5=d9554e49fd17a559e8c7171f36c53607</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01489%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.%2BY.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520selective%2520inhibitor%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520using%2520advanced%2520multiple%2520ligand%2520simultaneous%2520docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2718%26epage%3D2731%26doi%3D10.1021%2Facs.jmedchem.6b01489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span> <span> </span><span class="NLM_article-title">LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">298</span>â <span class="NLM_lpage">313</span>, <span class="refDoi">Â DOI: 10.1111/bph.14863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1111%2Fbph.14863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31499589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGnt7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2020&pages=298-313&author=Z.+Liuauthor=H.+Wangauthor=L.+Guanauthor=C.+Laiauthor=W.+Yuauthor=M.+Lai&title=LL1%2C+a+novel+and+highly+selective+STAT3+inhibitor%2C+displays+anti-colorectal+cancer+activities+in+vitro+and+in+vivo&doi=10.1111%2Fbph.14863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo</span></div><div class="casAuthors">Liu, Zhe; Wang, Huan; Guan, Lingnan; Lai, Chong; Yu, Wenying; Lai, Maode</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We syntheised a novel, potent and small-mol. inhibitor of STAT3, LL1, and studied its antitumor effects and investigated its mechanism of action in two tumor models.  Exptl. Approach : Using structure-based drug design method, based on the crystal structure of STAT3 protein, we identified a potent STAT3 inhibitor (LL1) targeting STAT3 SH2 domain and characterized its therapeutic properties and potential toxicity in vitro and in vivo using the MTT assay, colony formation assay, histol., immunohistochem., flow cytometric anal., and tumor xenograft model.  Key Results : LL1 is highly selective among STATs family members and specifically inhibits phosphorylation of STAT3 Tyr-705 site, blocking the whole transmission process of STAT3 signalling.  LL1 inhibited proliferation, colony formation, migration, and invasion of colonic cell lines.  STAT3 is orally available to animals and suppresses tumor growth and metastasis in a dosage level compatible to clin. applications.  Importantly, it does not cause significant toxicity at several times the ED.  Conclusions and Implications : LL1 inhibits tumor growth and metastasis by blocking STAT3 signalling pathway.  LL1 could be a promising therapeutic drug candidate for colorectal cancer by inhibiting the STAT3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7y8svF0ourVg90H21EOLACvtfcHk0lix1KT849SkcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGnt7bK&md5=847b83e3c992fee2d50b7f40bcf3978e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1111%2Fbph.14863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14863%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGuan%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DM.%26atitle%3DLL1%252C%2520a%2520novel%2520and%2520highly%2520selective%2520STAT3%2520inhibitor%252C%2520displays%2520anti-colorectal%2520cancer%2520activities%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2020%26volume%3D177%26spage%3D298%26epage%3D313%26doi%3D10.1111%2Fbph.14863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Z.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T.-t.</span></span> <span> </span><span class="NLM_article-title">Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions</span>. <i>Bone Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">362</span>â <span class="NLM_lpage">370</span>, <span class="refDoi">Â DOI: 10.4248/BR201304007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.4248%2FBR201304007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26273514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFyitbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=362-370&author=W.+Yanauthor=B.+Tuauthor=Y.-y.+Liuauthor=T.-y.+Wangauthor=H.+Qiaoauthor=Z.-j.+Zhaiauthor=H.-w.+Liauthor=T.-t.+Tang&title=Suppressive+effects+of+plumbagin+on+invasion+and+migration+of+breast+cancer+cells+via+the+inhibition+of+STAT3+signaling+and+down-regulation+of+inflammatory+cytokine+expressions&doi=10.4248%2FBR201304007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Suppressive Effects of Plumbagin on Invasion and Migration of Breast Cancer Cells via the Inhibition of STAT3 Signaling and Down-regulation of Inflammatory Cytokine Expressions</span></div><div class="casAuthors">Yan, Wei; Tu, Bing; Liu, Yun-yun; Wang, Ting-yu; Qiao, Han; Zhai, Zan-jing; Li, Hao-wei; Tang, Ting-ting</div><div class="citationInfo"><span class="NLM_cas:title">Bone Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">362-370</span>CODEN:
                <span class="NLM_cas:coden">BROEBB</span>;
        ISSN:<span class="NLM_cas:issn">2095-6231</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: The aim of this study was to investigate the effects of plumbagin (PL), a naphthoquinone derived from the medicinal plant plumbago zeylanica, on the invasion and migration of human breast cancer cells.  Methods: Human breast cancer MDA-MB-231SArfp cells were treated with different concns. of plumbagin for 24 h.  The effects of plumbagin on the migration and invasion were obsd. by a transwell method.  The expressions of IL-1Î±, IL-1Î², IL-6, IL-8, TGF-Î², TNFÎ±, MMP-2 and MMP-9 mRNA in MDA-MB-231SArfp cells were detected using Real-Time PCR.  MDA-MB-231SArfp cells were treated with plumbagin at different concns. for 45 min.  The activation of STAT3 was detected by western blot.  Following this anal., STAT3 in MDA-MB-231SArfp cells was knocked out using specific siRNA. mRNA levels of IL-1Î±, TGF-Î², MMP-2 and MMP-9 were then detected.  Consequently, MDA-MB-231SArfp cells were injected intracardially into BALB/c nude mice to construct a breast cancer bone metastatic model.  The mice were injected i.p. with plumbagin.  Non-invasive in vivo monitoring, X-ray imaging and histol. staining were performed to investigate the effects of plumbagin on the invasion and migration of breast cancer cells in vivo.  Results: The in vitro results showed that plumbagin could suppress the migration and invasion of breast cancer cells and down-regulate mRNA expressions of IL-1Î±, TGF-Î², MMP-2 and MMP-9.  Western blotting demonstrated that plumbagin inhibited the activation of STAT3 signaling in MDA-MB-231SArfp cells.  The inactivation of STAT3 was found to have an inhibitory effect on the expressions of IL-1Î±, TGF-Î², MMP-2 and MMP-9.  In vivo studies showed that plumbagin inhibited the metastasis of breast cancer cells and decreased osteolytic bone metastases, as well as the secretion of MMP-2 and MMP-9 by tumor cells at metastatic lesions.  Conclusions: Plumbagin can suppress the invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and by downregulation of IL-1Î±, TGF-Î², MMP-2 and MMP-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMAa_AcpJMQbVg90H21EOLACvtfcHk0ljzeGJwbJAK-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFyitbg%253D&md5=f66f25dac9688c407e29f7d10b5901e1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.4248%2FBR201304007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4248%252FBR201304007%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DTu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.-y.%26aulast%3DWang%26aufirst%3DT.-y.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DZhai%26aufirst%3DZ.-j.%26aulast%3DLi%26aufirst%3DH.-w.%26aulast%3DTang%26aufirst%3DT.-t.%26atitle%3DSuppressive%2520effects%2520of%2520plumbagin%2520on%2520invasion%2520and%2520migration%2520of%2520breast%2520cancer%2520cells%2520via%2520the%2520inhibition%2520of%2520STAT3%2520signaling%2520and%2520down-regulation%2520of%2520inflammatory%2520cytokine%2520expressions%26jtitle%3DBone%2520Res.%26date%3D2013%26volume%3D1%26spage%3D362%26epage%3D370%26doi%3D10.4248%2FBR201304007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">104208</span>, <span class="refDoi">Â DOI: 10.1016/j.bioorg.2020.104208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bioorg.2020.104208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32919131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVajt7bF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2020&pages=104208&author=N.+Liauthor=J.+Ouauthor=N.+Baoauthor=C.+Chenauthor=Z.+Shiauthor=L.+Chenauthor=J.+Sun&title=Design%2C+synthesis+and+biological+evaluation+of+novel+plumbagin+derivatives+as+potent+antitumor+agents+with+STAT3+inhibition&doi=10.1016%2Fj.bioorg.2020.104208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition</span></div><div class="casAuthors">Li, Na; Ou, Jinfeng; Bao, Na; Chen, Cheng; Shi, Zhixian; Chen, Li; Sun, Jianbo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104208</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on the structure of signal transducer and activator of transcription 3 (STAT3), a series of 1,4-naphthoquinones, e.g. I, derived from plumbagin (PL) with STAT3 inhibition potential were designed, synthesized, and biol. evaluated in vitro against several human cancer cell lines (MDA-MB-231, HepG2 and A549 cells) and three normal cells.  The structure-activity relationship (SAR) and mol. docking result showed that the presence of hydroxyl group at C-5 of PL might interact with STAT3 in the form of hydrogen bonds, which is conducive to the binding of this kind structures with STAT3.  Among the target compds., I displayed the most potent inhibition against cancer cells and weaker cytotoxicity on normal cells than PL.  The western bolting anal. showed that I could suppress the phosphorylation of STAT3 as well as the downstream genes instead of affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression.  Furthermore, mol. docking indicated that I bound to STAT3 more tightly than PL, and it could significantly induce the apoptosis of cancer cells in vitro.  All these results may provide ref. for the discovery of effective STAT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraBjcXkNqOu7Vg90H21EOLACvtfcHk0ljzeGJwbJAK-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVajt7bF&md5=9a47b9acc28a4a65235232dd881644cc</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.104208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.104208%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DJ.%26aulast%3DBao%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520plumbagin%2520derivatives%2520as%2520potent%2520antitumor%2520agents%2520with%2520STAT3%2520inhibition%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D104%26spage%3D104208%26doi%3D10.1016%2Fj.bioorg.2020.104208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span> <span> </span><span class="NLM_article-title">Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2/STAT3 pathway</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">327</span>â <span class="NLM_lpage">333</span>, <span class="refDoi">Â DOI: 10.1016/j.intimp.2014.01.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.intimp.2014.01.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24521871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFWqtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=327-333&author=Y.+Xuauthor=X.+Xuauthor=X.+Gaoauthor=H.+Chenauthor=L.+Geng&title=Shikonin+suppresses+IL-17-induced+VEGF+expression+via+blockage+of+JAK2%2FSTAT3+pathway&doi=10.1016%2Fj.intimp.2014.01.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2/STAT3 pathway</span></div><div class="casAuthors">Xu, Yuanyuan; Xu, Xuegang; Gao, Xinghua; Chen, Hongduo; Geng, Long</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-333</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">IL-17 signaling in keratinocytes plays an important role in psoriasis, which is a benign, chronic skin disease characterized by keratinocytes hyperproliferation and increased dermal vascularity.  Shikonin, isolated from the traditional medical herbs Lithospermum erythrorhizon, has long been found to possess different medicinal properties such as antibacterial, improving wound healing, anti-inflammatory and anti-tumor effects.  However, the effects and mechanisms of shikonin on VEGF expression in keratinocytes mediated by IL-17 signaling, are still not fully clarified.  In the present study, we investigated the effects and regulatory mechanisms of shikonin on VEGF expression in keratinocytes induced by IL-17 by in vitro and in vivo expts.  Our results showed that shikonin significantly inhibited IL-17-induced VEGF mRNA and protein expression in HaCaT cells and the secretion of VEGF by HaCaT cells, inhibited IL-17-induced IL-17R, pJAK2 and pSTAT3 expression, while up-regulated the expression of SOCS1 in HaCaT cells.  Addnl., shikonin effectively suppressed VEGF expression in the skin of IL-17 stimulated mice.  Furthermore, shikonin suppressed VEGF-induced tube formation of HUVECs and CD34 expression in the skin of IL-17 stimulated mice.  These results imply that shikonin suppresses IL-17-induced VEGF expression in vitro and in vivo and the mechanisms may be related to its effect in blockage of JAK2/STAT3 pathway.  These data deepen our understanding of shikonin in the inhibition of angiogenesis in inflammatory skin diseases such as psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow-1LUQSBDVLVg90H21EOLACvtfcHk0ljzeGJwbJAK-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFWqtbw%253D&md5=988b1acfc0c4b0132c0c8cb52b73e54a</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2014.01.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2014.01.027%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGeng%26aufirst%3DL.%26atitle%3DShikonin%2520suppresses%2520IL-17-induced%2520VEGF%2520expression%2520via%2520blockage%2520of%2520JAK2%252FSTAT3%2520pathway%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2014%26volume%3D19%26spage%3D327%26epage%3D333%26doi%3D10.1016%2Fj.intimp.2014.01.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span> <span> </span><span class="NLM_article-title">Shikonin inhibits IFN-Î³-induced K17 over-expression of HaCaT cells by interfering with STAT3 signaling</span>. <i>Int. J. Clin. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9202</span>â <span class="NLM_lpage">9207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26464667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC28zhtlyksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=9202-9207&author=L.+Liuauthor=Y.+Wuauthor=K.+Caoauthor=Y.+Y.+Xuauthor=X.+H.+Gaoauthor=H.+D.+Chenauthor=L.+Geng&title=Shikonin+inhibits+IFN-%CE%B3-induced+K17+over-expression+of+HaCaT+cells+by+interfering+with+STAT3+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Shikonin inhibits IFN-Î³-induced K17 over-expression of HaCaT cells by interfering with STAT3 signaling</span></div><div class="casAuthors">Liu Lili; Wu Yan; Xu Yuan-Yuan; Gao Xing-Hua; Chen Hong-Duo; Geng Long; Cao Kai</div><div class="citationInfo"><span class="NLM_cas:title">International journal of clinical and experimental pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">9202-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  We hypothesized that interferon-Î³ (IFN-Î³) induces K17 over-expression in HaCaT cells by activating STAT3 and that Sh might inhibit the over-expression through interference of STAT3 signaling.  METHODS:  In vitro culture of HaCaT cells treated with IFN-Î³ and measurement of K17 protein by enzyme linked immunosorbent assay.  RESULTS:  The level of K17 protein (one kind of keratin protein) in the supernatant induced by IFN-Î³ was significantly reduced by Shikonin at various concentrations.  Interference of STAT3 suppressed the effect of IFN-Î³ on K17 expression at both mRNA and protein levels.  The over-expression of K17 in IFN-Î³-induced HaCaT cells was significantly suppressed by 2 Î¼g/L Shikonin.  Interfering with STAT3 signaling with 2 Î¼g/L Shikonin resulted in an intermediate level of IFN-Î³-induced K17 protein in HaCaT cells.  CONCLUSIONS:  These data demonstrate that IFN-Î³ induces K17 protein over-expression of HaCaT cells by activating STAT3 and Shikonin may inhibit the over-expression partly through interference of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ29RZMba46OgHqQV89nF-2fW6udTcc2eZckHeXyrmE5bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zhtlyksA%253D%253D&md5=e5feb4d2ffb575f2e6cb075bea19a7a4</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DY.%2BY.%26aulast%3DGao%26aufirst%3DX.%2BH.%26aulast%3DChen%26aufirst%3DH.%2BD.%26aulast%3DGeng%26aufirst%3DL.%26atitle%3DShikonin%2520inhibits%2520IFN-%25CE%25B3-induced%2520K17%2520over-expression%2520of%2520HaCaT%2520cells%2520by%2520interfering%2520with%2520STAT3%2520signaling%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Pathol.%26date%3D2015%26volume%3D8%26spage%3D9202%26epage%3D9207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. H.</span></span> <span> </span><span class="NLM_article-title">Identification of new shikonin derivatives as STAT3 inhibitors</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">74</span>â <span class="NLM_lpage">86</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2017.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bcp.2017.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29066190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslagtbjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2017&pages=74-86&author=H.+Y.+Qiuauthor=J.+Y.+Fuauthor=M.+K.+Yangauthor=H.+W.+Hanauthor=P.+F.+Wangauthor=Y.+H.+Zhangauthor=H.+Y.+Linauthor=C.+Y.+Tangauthor=J.+L.+Qiauthor=R.+W.+Yangauthor=X.+M.+Wangauthor=H.+L.+Zhuauthor=Y.+H.+Yang&title=Identification+of+new+shikonin+derivatives+as+STAT3+inhibitors&doi=10.1016%2Fj.bcp.2017.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new shikonin derivatives as STAT3 inhibitors</span></div><div class="casAuthors">Qiu, Han-Yue; Fu, Jiang-Yan; Yang, Min-Kai; Han, Hong-Wei; Wang, Peng-Fei; Zhang, Ya-Han; Lin, Hong-Yan; Tang, Cheng-Yi; Qi, Jin-Liang; Yang, Rong-Wu; Wang, Xiao-Ming; Zhu, Hai-Liang; Yang, Yong-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-86</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 is a constitutively activated oncogenic protein in various human tumors and represents a valid target for anticancer drug design.  In this study, the authors have achieved a new type of STAT3 inhibitors based on structural modifications on shikonin scaffold, guided by computational modeling.  By tests, PMMB-187 exhibited a more outstanding profile than shikonin on a small panel of human breast cancer cells, esp. for the MDA-MB-231 cells.  For the cellular mechanisms research, PMMB-187 was found to induce cell apoptosis in MDA-MB-231 cells, assocd. with the redn. of mitochondrial membrane potential, prodn. of ROS and alteration of the levels of apoptosis-related proteins.  Furthermore, PMMB-187 inhibited constitutive/inducible STAT3 activation, transcriptional activity, nuclear translocation and downstream target genes expression in STAT3-dependent breast cancer cells MDA-MB-231.  Besides, no obvious inhibitory effect on activation of STAT1 and STAT5 was obsd. with PMMB-187 treatment.  Most notably, the in vivo studies further revealed that PMMB-187 could dramatically suppress the MDA-MB-231 cells xenografted tumor growth.  The in vitro and in vivo results collectively suggest that PMMB-187 may serve as a promising lead compd. for the further development of potential therapeutic anti-neoplastic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBnm7HBRlgo7Vg90H21EOLACvtfcHk0lgmo2Tcxbr8-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslagtbjM&md5=af3b70e4895b2902cdc20b0d9c4f4872</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DH.%2BY.%26aulast%3DFu%26aufirst%3DJ.%2BY.%26aulast%3DYang%26aufirst%3DM.%2BK.%26aulast%3DHan%26aufirst%3DH.%2BW.%26aulast%3DWang%26aufirst%3DP.%2BF.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DTang%26aufirst%3DC.%2BY.%26aulast%3DQi%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26aulast%3DYang%26aufirst%3DY.%2BH.%26atitle%3DIdentification%2520of%2520new%2520shikonin%2520derivatives%2520as%2520STAT3%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D146%26spage%3D74%26epage%3D86%26doi%3D10.1016%2Fj.bcp.2017.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. H.</span></span> <span> </span><span class="NLM_article-title">Identification of new shikonin derivatives as antitumor agents targeting STAT3 SH2 domain</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2863</span>, <span class="refDoi">Â DOI: 10.1038/s41598-017-02671-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41598-017-02671-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28588262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC1cnls12rtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=2863&author=H.+Y.+Qiuauthor=X.+Zhuauthor=Y.+L.+Luoauthor=H.+Y.+Linauthor=C.+Y.+Tangauthor=J.+L.+Qiauthor=Y.+J.+Pangauthor=R.+W.+Yangauthor=G.+H.+Luauthor=X.+M.+Wangauthor=Y.+H.+Yang&title=Identification+of+new+shikonin+derivatives+as+antitumor+agents+targeting+STAT3+SH2+domain&doi=10.1038%2Fs41598-017-02671-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain</span></div><div class="casAuthors">Qiu Han-Yue; Zhu Xiang; Luo Yue-Lin; Lin Hong-Yan; Tang Cheng-Yi; Qi Jin-Liang; Pang Yan-Jun; Yang Rong-Wu; Lu Gui-Hua; Wang Xiao-Ming; Yang Yong-Hua; Qiu Han-Yue; Zhu Xiang; Luo Yue-Lin; Lin Hong-Yan; Tang Cheng-Yi; Qi Jin-Liang; Lu Gui-Hua; Wang Xiao-Ming; Yang Yong-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2863</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is hyper-activated in diversiform human tumors and has been validated as an attractive therapeutic target.  Current research showed that a natural product, shikonin, along with its synthetic analogues, is able to inhibit the activity of STAT3 potently.  The potential space of shikonin in developing novel anti-cancer agents encouraged us to carry out the investigation of the probable binding mode with STAT3.  From this foundation, we have designed new types of STAT3 SH2 inhibitors.  Combined simulations were performed to filter for the lead compound, which was then substituted, synthesized and evaluated by a variety of bioassays.  Among the entities, PMM-172 exhibited the best anti-proliferative activity against MDA-MB-231 cells with IC50 value 1.98 Â± 0.49 Î¼M.  Besides, it was identified to decrease luciferase activity, induce cell apoptosis and reduce mitochondrial transmembrane potential in MDA-MB-231 cells.  Also, PMM-172 inhibited constitutive/inducible STAT3 activation without affecting STAT1 and STAT5 in MDA-MB-231 cells, and had no effect in non-tumorigenic MCF-10A cells.  Moreover, PMM-172 suppressed STAT3 nuclear localization and STAT3 downstream target genes expression.  Overall, these results indicate that the antitumor activity of PMM-172 is at least partially due to inhibition of STAT3 in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQogEd5p0-zuGxpATR2EQURfW6udTcc2eZckHeXyrmE5bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnls12rtQ%253D%253D&md5=88f3ee8a230498d83ffe92d7971aa0b8</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-02671-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-02671-7%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DTang%26aufirst%3DC.%2BY.%26aulast%3DQi%26aufirst%3DJ.%2BL.%26aulast%3DPang%26aufirst%3DY.%2BJ.%26aulast%3DYang%26aufirst%3DR.%2BW.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DYang%26aufirst%3DY.%2BH.%26atitle%3DIdentification%2520of%2520new%2520shikonin%2520derivatives%2520as%2520antitumor%2520agents%2520targeting%2520STAT3%2520SH2%2520domain%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D2863%26doi%3D10.1038%2Fs41598-017-02671-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothey, A.</span></span> <span> </span><span class="NLM_article-title">Napabucasin: an update on the first-in-class cancer stemness inhibitor</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1091</span>â <span class="NLM_lpage">1103</span>, <span class="refDoi">Â DOI: 10.1007/s40265-017-0759-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1007%2Fs40265-017-0759-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28573435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Ogs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1091-1103&author=J.+M.+Hubbardauthor=A.+Grothey&title=Napabucasin%3A+an+update+on+the+first-in-class+cancer+stemness+inhibitor&doi=10.1007%2Fs40265-017-0759-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor</span></div><div class="casAuthors">Hubbard, Joleen M.; Grothey, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1091-1103</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Napabucasin (BBI608) is an orally administered small mol. that blocks stem cell activity in cancer cells by targeting the signal transducer and activator of transcription 3 pathway.  The signal transducer and activator of transcription 3 pathway is over-activated in many types of cancer and has been shown to be an important pathway in cancer stem cell-mediated propagation of cancer.  Cancer stem cells are a subpopulation of cancer cells considered to be the primary source of tumor growth, metastasis, and resistance to conventional therapies, and thus, responsible for cancer relapse.  This review describes the clin. development program of this first-in-class cancer stemness inhibitor, including preclin. discovery, early clin. trials, current phase III clin. trial evaluation, and future therapeutic combinations.  The therapeutic potential of napabucasin was first reported in a preclin. study that demonstrated the potent anti-tumor and anti-metastatic activity of napabucasin in several different cancer types, both in vitro and in vivo.  In mouse models, napabucasin was effective both as a monotherapy and in combination with other agents; in particular, synergy was obsd. with paclitaxel in vivo.  Napabucasin clin. trials have demonstrated encouraging anti-tumor activity as monotherapy and in combination with conventional therapeutics, with no significant pharmacokinetic interactions when used in combination therapies.  Adverse events attributed to napabucasin have been predominantly mild, although some patients have experienced grade 3 gastrointestinal adverse events.  More severe adverse events required reduced or discontinued dosing of napabucasin or medication to reverse or manage symptoms.  In conclusion, napabucasin may prove useful in targeting cancer stem cells, with the potential to suppress metastasis and prevent relapse in patients with varying cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOT80Q-y40g7Vg90H21EOLACvtfcHk0lhzVJz__IVqpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Ogs7Y%253D&md5=bfe97dc2fe4fd82c07c1c34ca2f103a1</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0759-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0759-4%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DJ.%2BM.%26aulast%3DGrothey%26aufirst%3DA.%26atitle%3DNapabucasin%253A%2520an%2520update%2520on%2520the%2520first-in-class%2520cancer%2520stemness%2520inhibitor%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1091%26epage%3D1103%26doi%3D10.1007%2Fs40265-017-0759-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekaii-Saab, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Rayes, B.</span></span> <span> </span><span class="NLM_article-title">Identifying and targeting cancer stem cells in the treatment of gastric cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">1303</span>â <span class="NLM_lpage">1312</span>, <span class="refDoi">Â DOI: 10.1002/cncr.30538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1002%2Fcncr.30538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28117883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC1c7oslymtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2017&pages=1303-1312&author=T.+Bekaii-Saabauthor=B.+El-Rayes&title=Identifying+and+targeting+cancer+stem+cells+in+the+treatment+of+gastric+cancer&doi=10.1002%2Fcncr.30538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and targeting cancer stem cells in the treatment of gastric cancer</span></div><div class="casAuthors">Bekaii-Saab Tanios; Bekaii-Saab Tanios; El-Rayes Bassel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1303-1312</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current treatment regimens for gastric cancer are not adequate.  Cancer stem cells (CSCs) may be a key driving factor for growth and metastasis of this tumor type.  In contrast to the conventional clonal evolution hypothesis, CSCs can initiate tumor formation, self-renew, and differentiate into tumor-propagating cells.  Because gastric cancer can originate from CSCs, it is necessary to review current targets of signaling pathways for CSCs in gastric cancer that are being studied in clinical trials.  These pathways are known to regulate the self-renewal and differentiation process in gastric CSCs.  A better understanding of the clinical results of trials that target gastric CSCs will lead to better outcomes for patients with gastric cancer.  Cancer 2017;123:1303-1312. Â© 2017 The Authors.  Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.  This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTE1sDFdXBBh-vW160gIxP_fW6udTcc2eZ0bnUSFCY_5rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7oslymtQ%253D%253D&md5=e025904212b010f056759c5c009d094d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1002%2Fcncr.30538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.30538%26sid%3Dliteratum%253Aachs%26aulast%3DBekaii-Saab%26aufirst%3DT.%26aulast%3DEl-Rayes%26aufirst%3DB.%26atitle%3DIdentifying%2520and%2520targeting%2520cancer%2520stem%2520cells%2520in%2520the%2520treatment%2520of%2520gastric%2520cancer%26jtitle%3DCancer%26date%3D2017%26volume%3D123%26spage%3D1303%26epage%3D1312%26doi%3D10.1002%2Fcncr.30538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span> <span> </span><span class="NLM_article-title">Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">883</span>â <span class="NLM_lpage">895</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.12.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.12.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30580240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFyntr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=883-895&author=C.+Zhuangauthor=X.+Guanauthor=H.+Maauthor=H.+Congauthor=W.+Zhangauthor=Z.+Miao&title=Small+molecule-drug+conjugates%3A+a+novel+strategy+for+cancer-targeted+treatment&doi=10.1016%2Fj.ejmech.2018.12.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment</span></div><div class="casAuthors">Zhuang, Chunlin; Guan, Xianghong; Ma, Hao; Cong, Hui; Zhang, Wannian; Miao, Zhenyuan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">883-895</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Targeted therapy has become an effective strategy of precision medicine for improving cancer treatment.  Selectivity improvement is always popular in modern oncol. because of decreased side effects in conventional cancer chemotherapy.  The use of antibody-drug conjugates (ADC), a robust strategy for targeted therapy, applies antibodies to selectively deliver a potent cytotoxic compd. to tumor cells and thus improve the therapeutic efficacy of the chemotherapeutic agents.  Three ADC products (trastuzumab emtansine, brentuximab vedotin and inotuzumab ozogamicin) are already on the market, and several compds. are in clin. trials.  Compared with ADCs, small mol.-drug conjugates (SMDCs) provide a new, less established perspective for targeted delivery.  Nevertheless, SMDCs have several strengths: they have a non-immunogenic nature; much more manageable synthesis; and lower mol. wts., which confer a high potential for good cell penetration in solid tumors.  SMDCs might therefore be a promising alternative with similar efficacy to ADCs.  In this article, we highlight the medicinal chem. aspects of SMDC design.  SMDC targeting ligands, linkers and small-mol. payloads will be discussed.  Successful cases of SMDCs used as therapeutic agents and other applications of SMDC will also be included.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgh4NBoM7LQrVg90H21EOLACvtfcHk0lhzVJz__IVqpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFyntr%252FK&md5=cf74e67689ca6887961b069273c151dd</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhuang%26aufirst%3DC.%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DCong%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMiao%26aufirst%3DZ.%26atitle%3DSmall%2520molecule-drug%2520conjugates%253A%2520a%2520novel%2520strategy%2520for%2520cancer-targeted%2520treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D883%26epage%3D895%26doi%3D10.1016%2Fj.ejmech.2018.12.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yesylevskyy, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramseyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pudlo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallandre, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, C.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of STAT3 with respect to STAT1: insights from molecular dynamics and ensemble docking simulations</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1588</span>â <span class="NLM_lpage">1596</span>, <span class="refDoi">Â DOI: 10.1021/acs.jcim.6b00198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Glur3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=1588-1596&author=S.+O.+Yesylevskyyauthor=C.+Ramseyerauthor=M.+Pudloauthor=J.-R.+Pallandreauthor=C.+Borg&title=Selective+inhibition+of+STAT3+with+respect+to+STAT1%3A+insights+from+molecular+dynamics+and+ensemble+docking+simulations&doi=10.1021%2Facs.jcim.6b00198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations</span></div><div class="casAuthors">Yesylevskyy, Semen O.; Ramseyer, Christophe; Pudlo, Marc; Pallandre, Jean-Rene; Borg, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1588-1596</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">STAT3 protein, which is known to be involved in cancer development, is a promising target for anticancer therapy.  Successful inhibitors of STAT3 should not affect an activity of closely related protein STAT1, which makes their development challenging.  The mechanisms of selectivity of several existing STAT3 inhibitors are not clear.  The authors studied mol. mechanisms of selectivity of 13 exptl. tested STAT3 inhibitors by extensive mol. dynamics and ensemble docking simulations.  It is shown that all studied inhibitors bind to the large part of the protein surface in an unspecific statistical manner.  The binding to the dimerization interface of the SH2 domain, which is usually considered as the main target region, is not energetically preferable.  Binding in this region is remarkably similar for STAT1 and STAT3 proteins and cannot explain exptl. obsd. selectivity toward STAT3.  The authors propose a new mechanism of selectivity called "selectivity by distraction" for existing STAT3 inhibitors.  This mechanism is based on equil. statistical partitioning of inhibitor mols. between protein domains.  The unspecific binding of inhibitors to the DNA-binding and the coil-coil domains is stronger in STAT1 in comparison to STAT3 while the energies of their binding to SH2 domains are comparable.  This "distracts" inhibitor mols. from the SH2 domain of STAT1 and leads to higher effective concn. of inhibitors in the vicinity of the SH2 domain of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_09BjY0JoUrVg90H21EOLACvtfcHk0lh_iWmyO9Aaqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Glur3J&md5=47f9fee7c0c117033fbaeba204c96ccd</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00198%26sid%3Dliteratum%253Aachs%26aulast%3DYesylevskyy%26aufirst%3DS.%2BO.%26aulast%3DRamseyer%26aufirst%3DC.%26aulast%3DPudlo%26aufirst%3DM.%26aulast%3DPallandre%26aufirst%3DJ.-R.%26aulast%3DBorg%26aufirst%3DC.%26atitle%3DSelective%2520inhibition%2520of%2520STAT3%2520with%2520respect%2520to%2520STAT1%253A%2520insights%2520from%2520molecular%2520dynamics%2520and%2520ensemble%2520docking%2520simulations%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D1588%26epage%3D1596%26doi%3D10.1021%2Facs.jcim.6b00198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span> <span> </span><span class="NLM_article-title">A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">554</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.10.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.10.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30472602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12ltLrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=543-554&author=C.+Liauthor=C.+Chenauthor=Q.+Anauthor=T.+Yangauthor=Z.+Sangauthor=Y.+Yangauthor=Y.+Juauthor=A.+Tongauthor=Y.+Luo&title=A+novel+series+of+napabucasin+derivatives+as+orally+active+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28STAT3%29&doi=10.1016%2Fj.ejmech.2018.10.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)</span></div><div class="casAuthors">Li, Chungen; Chen, Caili; An, Qi; Yang, Tao; Sang, Zitai; Yang, Yang; Ju, Yuan; Tong, Aiping; Luo, Youfu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">543-554</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is an attractive target for a variety of cancers therapy.  Napabucasin, applied in phase III clin. trials for the treatment of a variety of cancers, was regarded as one of the most promising anticancer drug by targeting STAT3.  Herein, a novel series of napabucasin derivs. were designed and synthesized, which presented a potent inhibitory activity on a variety of cancers cells.  Among the derivs. compd. 8q exhibited potent inhibitory activity on U251, HepG2, HT29 and CT26 cells with the IC50 values of 0.22, 0.49, 0.07 and 0.14 Î¼M, resp., which was over 10-fold more potent than napabucasin.  Treatment with compd. 8q decreased protein expression level of total STAT3 and p-STAT3Y705in vitro.  The binding of compd. 8q with STAT3 were further validated by electrophoretic mobility shift assay and surface plasmon resonance anal.  Compd. 8q has a KD of 110.2 nM for full-length STAT3 recombinant protein.  Moreover, the aq. soly. of 8q was over 4.5-fold than that of napabucasin.  In addn., compd. 8q in vivo significantly reduced tumor growth compared to untreated mice, and exhibited good safety profile, indicating its great potential as an efficacious drug candidate for oncotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdjaMcoHkmCbVg90H21EOLACvtfcHk0lh_iWmyO9Aaqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12ltLrE&md5=4b95a9d078c485681ef7cba49e51acec</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.067%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DSang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DJu%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DA%2520novel%2520series%2520of%2520napabucasin%2520derivatives%2520as%2520orally%2520active%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D162%26spage%3D543%26epage%3D554%26doi%3D10.1016%2Fj.ejmech.2018.10.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and activity of BBI608 derivatives targeting on stem cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">39</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.03.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.03.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29604543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslKgtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=39-50&author=Q.+Zhouauthor=C.+Pengauthor=F.+Duauthor=L.+Zhouauthor=Y.+Shiauthor=Y.+Duauthor=D.+Liuauthor=W.+Sunauthor=M.+Zhangauthor=G.+Chen&title=Design%2C+synthesis+and+activity+of+BBI608+derivatives+targeting+on+stem+cells&doi=10.1016%2Fj.ejmech.2018.03.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity of BBI608 derivatives targeting on stem cells</span></div><div class="casAuthors">Zhou, Qifan; Peng, Chen; Du, Fangyu; Zhou, Linbo; Shi, Yajie; Du, Yang; Liu, Dongdong; Sun, Wenjiao; Zhang, Meixia; Chen, Guoliang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39-50</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 plays a vital role in maintaining the self-renewal of tumor stem cells.  BBI608, a small mol. identified by its ability to inhibit gene transcription driven by STAT3 and cancer stemness properties, can inhibit stemness gene expression and kill stemness-high cancer cells isolated from a variety of cancer types.  In order to improve the pharmacokinetic properties of BBI608 and the antitumor activity, a series of BBI608 derivs. were designed and synthesized here.  Most of these compds. were more potent than BBI608 on HepG2 cells, compd. I had the most potent inhibitory activity among them and was 5.4-fold more potent than BBI608 (IC50=11.2Î¼M), but had considerable activity on normal liver cells L-02.  Compds. II (IC50=3.5Î¼M) and III (IC50=2.9Î¼M) were found to possess significant inhibitory activities and good selectivity.  The results showed that compd. LD-19 was worthy to investigate further as a lead compd. according to its potent inhibitory activity, ideal ClogP value and better water soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlEGtqRVLqrVg90H21EOLACvtfcHk0lh_iWmyO9Aaqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslKgtbc%253D&md5=3bd9949d032ee24e433b2e34b3ca9369</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.054%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520activity%2520of%2520BBI608%2520derivatives%2520targeting%2520on%2520stem%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D39%26epage%3D50%26doi%3D10.1016%2Fj.ejmech.2018.03.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">112428</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2020.112428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32603980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSiu7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2020&pages=112428&author=K.+R.+Fengauthor=F.+Wangauthor=X.+W.+Shiauthor=Y.+X.+Tanauthor=J.+Y.+Zhaoauthor=J.+W.+Zhangauthor=Q.+H.+Liauthor=G.+Q.+Linauthor=D.+Gaoauthor=P.+Tian&title=Design%2C+synthesis+and+biological+evaluation+of+novel+potent+STAT3+inhibitors+based+on+BBI608+for+cancer+therapy&doi=10.1016%2Fj.ejmech.2020.112428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy</span></div><div class="casAuthors">Feng, Kai-Rui; Wang, Feng; Shi, Xin-Wei; Tan, Yun-Xuan; Zhao, Jia-Ying; Zhang, Jian-Wei; Li, Qing-Hua; Lin, Guo-Qiang; Gao, Dingding; Tian, Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112428</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Persistently activated signal transducer and activator of transcription 3 (STAT3) plays an important role in the development of multiple cancers, and therefore is a potential therapeutic target for cancer prevention.  Herein, we report the rational design, synthesis, and biol. evaluation of novel potent STAT3 inhibitors based on BBI608.  Among them, compd. A11(I) exhibited the most potent in vitro tumor cell growth inhibitory activities toward MDA-MB-231, MDA-MB-468 and HepG2 cells with IC50 values as low as 0.67 Â± 0.02Î¼M, 0.77 Â± 0.01Î¼M and 1.24 Â± 0.16Î¼M, resp.  Fluorescence polarization (FP) assay validated the binding of compd. A11 in STAT3 SH2 domain with the IC50 value of 5.18Î¼M.  Further mechanistic studies indicated that A11 inhibited the activation of STAT3 (Y705), and thus reduced the expression of STAT3 downstream genes CyclinD1 and C-Myc.  Simultaneously, it induced cancer cell S phase arrest and apoptosis in a concn.-dependent manner.  An addnl. in vivo study revealed that A11 suppressed the MDA-MB-231 xenograft tumor growth in mice at the dose of 10 mg/kg (i.p.) without obvious body-wt. loss.  Finally, mol. docking study further elucidated the binding mode of A11 in STAT3 SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL-OvYqhC9K7Vg90H21EOLACvtfcHk0litHbTfy3lTcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSiu7rK&md5=5bcc68d18c51794f7ddd98805d318ee3</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112428%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DK.%2BR.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DX.%2BW.%26aulast%3DTan%26aufirst%3DY.%2BX.%26aulast%3DZhao%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DLi%26aufirst%3DQ.%2BH.%26aulast%3DLin%26aufirst%3DG.%2BQ.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520potent%2520STAT3%2520inhibitors%2520based%2520on%2520BBI608%2520for%2520cancer%2520therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D201%26spage%3D112428%26doi%3D10.1016%2Fj.ejmech.2020.112428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¶cken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clamor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, K.</span></span> <span> </span><span class="NLM_article-title">Napabucasin and related heterocycle-fused naphthoquinones as STAT3 inhibitors with antiproliferative activity against cancer cells</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1636</span>â <span class="NLM_lpage">1644</span>, <span class="refDoi">Â DOI: 10.1021/acs.jnatprod.8b00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.8b00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnslKisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=1636-1644&author=H.+L%C3%B6ckenauthor=C.+Clamorauthor=K.+M%C3%BCller&title=Napabucasin+and+related+heterocycle-fused+naphthoquinones+as+STAT3+inhibitors+with+antiproliferative+activity+against+cancer+cells&doi=10.1021%2Facs.jnatprod.8b00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells</span></div><div class="casAuthors">Locken Hauke; Clamor Cinzia; Muller Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of natural products</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1636-1644</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Napabucasin (6) and its angularly anellated isomer (7), for which the synthesis is described, together with related plant-derived naphthoquinones, were evaluated in vitro against human breast cancer (MDA-MB-231) and chronic myelogenous leukemia (K562) cells.  As observed for Î²-lapachone (3), the active naphthoquinones all induced apoptosis in a cell-cycle-independent fashion.  In contrast to the pyran-fused Î²-lapachone (3), however, the most potent furan-fused naphthoquinones were able to redox cycle and generate superoxide in cell-based assays, which was independent of NAD(P)H:quinone oxido-reductase 1.  In a homogeneous time-resolved fluorescence (HTRF) assays with MDA-MB-231 cells, both napabucasin (6) and isonapabucasin (7) were identified as targeting STAT3 phosphorylation.  In addition, drug affinity responsive target stability assays were performed to validate a direct interaction of the naphthoquinones with STAT3.  Isonapabucasin (7) turned out to be twice as potent against STAT3 as napabucasin (6) in the HTRF assay, with an EC50 in the submicromolar range, which was in excellent agreement with the potency of both agents to inhibit the growth of MDA-MB-231 cells.  Moreover, molecular docking experiments predicted different binding modes to the STAT3 SH2 domain for the linearly anellated napabucasin (6) and its angularly anellated isomer (7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSQACUhahgsEEgZCMqtRBifW6udTcc2eYev4VNFaNzX7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnslKisw%253D%253D&md5=f7b8eca5ba22354ee3c13457409262f4</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.8b00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.8b00247%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6cken%26aufirst%3DH.%26aulast%3DClamor%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DNapabucasin%2520and%2520related%2520heterocycle-fused%2520naphthoquinones%2520as%2520STAT3%2520inhibitors%2520with%2520antiproliferative%2520activity%2520against%2520cancer%2520cells%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2018%26volume%3D81%26spage%3D1636%26epage%3D1644%26doi%3D10.1021%2Facs.jnatprod.8b00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span> <span> </span><span class="NLM_article-title">LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">104661</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2020.104661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.phrs.2020.104661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31982491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFarsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2020&pages=104661&author=H.+Wangauthor=Z.+Liuauthor=L.+Guanauthor=J.+Liauthor=S.+Chenauthor=W.+Yuauthor=M.+Lai&title=LYW-6%2C+a+novel+cryptotanshinone+derived+STAT3+targeting+inhibitor%2C+suppresses+colorectal+cancer+growth+and+metastasis&doi=10.1016%2Fj.phrs.2020.104661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis</span></div><div class="casAuthors">Wang, Huan; Liu, Zhe; Guan, Lingnan; Li, Jiankang; Chen, Siyi; Yu, Wenying; Lai, Maode</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104661</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The constitutive activation of signal transducer and activator of transcription 3(STAT3) is assocd. with aggressive development and metastasis in colorectal cancer (CRC), but STAT3-targeting drugs remain elusive in clinic.  Here, structure-based strategy was used to remodel the natural compd. cryptotanshinone into a more effective STAT3 inhibitor LYW-6.  Using the Biolayer Interferometry assay, we obsd. that LYW-6 exhibited specific interactions with STAT3(KD = 6.6 Â± 0.7 Î¼M).  Western blot anal. and electrophoretic mobility shift assays (EMSA) showed that LYW-6 inhibited the phosphorylation of STAT3 tyrosine 705 (Tyr-705) and had slight effects on STAT1 and STAT5 phosphorylation.  Western blot anal. on the upstream kinases of STAT3 confirmed that the inhibitory mechanism on p-STAT3 was independent of upstream kinases.  Further investigation demonstrated that LYW-6 downregulated the expression of downstream oncogenes to inhibit cell viability, cell cycle development, and potently increased cell apoptosis in human CRC cells.  The invasion and metastasis linked signaling was also blocked by LYW-6 treatment.  LYW-6 was found to reduce the metastasis foci in lung on tail-lung metastasis models.  In addn., it was obsd. that LYW-6 markedly diminished STAT3 phosphorylation in tumor tissue and significantly inhibited tumor growth on xenograft models.  Tumor development on chem.-induced colorectal cancer model also significantly inhibited by LYW-6 treatment.  These findings provided adequate evidence that STAT3 inhibitor LYW-6 might be a potential candidate agent for CRC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNZX6D4kSgBrVg90H21EOLACvtfcHk0lhECyBaUpCKeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFarsrs%253D&md5=d013939ca63e3d03aff5be7610a2c0fd</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.104661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.104661%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGuan%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DM.%26atitle%3DLYW-6%252C%2520a%2520novel%2520cryptotanshinone%2520derived%2520STAT3%2520targeting%2520inhibitor%252C%2520suppresses%2520colorectal%2520cancer%2520growth%2520and%2520metastasis%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D153%26spage%3D104661%26doi%3D10.1016%2Fj.phrs.2020.104661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohassab, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, M.</span></span> <span> </span><span class="NLM_article-title">STAT3 transcription factor as target for anti-cancer therapy</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1101</span>â <span class="NLM_lpage">1124</span>, <span class="refDoi">Â DOI: 10.1007/s43440-020-00156-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1007%2Fs43440-020-00156-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32880101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslygsL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=1101-1124&author=A.+M.+Mohassabauthor=H.+A.+Hassanauthor=D.+Abdelhamidauthor=M.+Abdel-Aziz&title=STAT3+transcription+factor+as+target+for+anti-cancer+therapy&doi=10.1007%2Fs43440-020-00156-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 transcription factor as target for anti-cancer therapy</span></div><div class="casAuthors">Mohassab, Aliaa M.; Hassan, Heba A.; Abdelhamid, Dalia; Abdel-Aziz, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1101-1124</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  STATs constitute a large family of transcription activators and transducers of signals that have an important role in many cell functions as regulation of proliferation and differentiation of the cell also regulation of apoptosis and angiogenesis.  STAT3 as a member of that family, recently was discovered to have a vital role in progression of different types of cancers.  The activation of STAT3 was obsd. to regulate multiple gene functions during cancer-like cell proliferation, differentiation, apoptosis, metastasis, inflammation, immunity, cell survival, and angiogenesis.  The inhibition of STAT3 activation has been an important target for cancer therapy.  Inhibitors of STAT3 have been used for a long time for treatment of many types of cancers like leukemia, melanoma, colon, and renal cancer.  In this review article, we summarize and discuss different drugs inhibiting the action of STAT3 and used in treatment of different types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppi_HE4Tu9k7Vg90H21EOLACvtfcHk0lhECyBaUpCKeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslygsL%252FE&md5=ace0b41f53c3061797508eaff16ef170</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1007%2Fs43440-020-00156-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs43440-020-00156-5%26sid%3Dliteratum%253Aachs%26aulast%3DMohassab%26aufirst%3DA.%2BM.%26aulast%3DHassan%26aufirst%3DH.%2BA.%26aulast%3DAbdelhamid%26aufirst%3DD.%26aulast%3DAbdel-Aziz%26aufirst%3DM.%26atitle%3DSTAT3%2520transcription%2520factor%2520as%2520target%2520for%2520anti-cancer%2520therapy%26jtitle%3DPharmacol.%2520Rep.%26date%3D2020%26volume%3D72%26spage%3D1101%26epage%3D1124%26doi%3D10.1007%2Fs43440-020-00156-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span> <span> </span><span class="NLM_article-title">Screening and biological evaluation of a novel STAT3 signaling pathway inhibitor against cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5172</span>â <span class="NLM_lpage">5176</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.09.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmcl.2016.09.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27727126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CltLrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5172-5176&author=M.+Huangauthor=Z.+Chenauthor=L.+Zhangauthor=Z.+Huangauthor=Y.+Chenauthor=J.+Xuauthor=J.+Zhangauthor=X.+Shu&title=Screening+and+biological+evaluation+of+a+novel+STAT3+signaling+pathway+inhibitor+against+cancer&doi=10.1016%2Fj.bmcl.2016.09.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Screening and biological evaluation of a novel STAT3 signaling pathway inhibitor against cancer</span></div><div class="casAuthors">Huang, Min; Chen, Zhongjie; Zhang, Lu; Huang, Zhimin; Chen, Yiying; Xu, Jianrong; Zhang, Jian; Shu, Xiaohong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5172-5176</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It is now established that the specificity in signaling of signal transducer and activator of transcription 3 (STAT3) is mediated by the SH2 domain of STAT3, which mediates its interaction with the phosphopeptide docking sites displayed by receptors and JAKs, dimerization and subsequent DNA binding.  Thus, we aimed to identify and design a class of strong potential small mol. inhibitors of STAT3 for the discovery and development of novel anticancer agents.  Several classes of small mols. have been identified as STAT3 inhibitors after structure-based screening of the STAT3 SH2 domain.  Next, we detected the activity of these inhibitors using fluorescence polarization (FP) and identified the growth inhibition of DU145 and MDA-MB-468 cells using the CCK-8 assay.  Consequently, B9 inhibits the proliferation of tumor cells harboring abnormal activation of STAT3, such as, MDA-MB-468, MDA-MB-231 and DU145.  However, there is little inhibition of MCF-7 cells.  In addn., The Kd of B9 to STAT3 (I634S/Q635G) is 22.75 Î¼M compared to 4.59 Î¼M for WT as analyzed by SPR.  The phosphorylation of STAT3 in MDA-MB-468 cells was obviously decreased after treatment with B9 at the preconceived concn. of 30 Î¼M, as detected using immunoblotting.  Here, we evaluated the effect of B9 on the migration of MDA-MB-468 cells.  Taken together, our results indicate a novel small mol. that decreases STAT3 activation and function of the STAT3 signaling pathway, thereby inducing an antitumor response in human breast cancer cells harboring constitutively active STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzfnwZ1lpubLVg90H21EOLACvtfcHk0lhECyBaUpCKeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CltLrN&md5=976930827063d95ed50fa05589fef8dd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShu%26aufirst%3DX.%26atitle%3DScreening%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520STAT3%2520signaling%2520pathway%2520inhibitor%2520against%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5172%26epage%3D5176%26doi%3D10.1016%2Fj.bmcl.2016.09.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel isothiazoloquinoline quinone analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127286</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2020.127286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmcl.2020.127286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32631508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFylsbjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127286&author=L.+Chenauthor=Y.+Z.+Xieauthor=Z.+Y.+Luoauthor=L.+J.+Liuauthor=Z.+Z.+Zouauthor=H.+D.+Liuauthor=F.+R.+Kongauthor=Y.+Haoauthor=J.+L.+Gaoauthor=L.+L.+Wangauthor=D.+Y.+Maauthor=S.+Y.+Liu&title=Synthesis+and+biological+evaluation+of+novel+isothiazoloquinoline+quinone+analogues&doi=10.1016%2Fj.bmcl.2020.127286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel isothiazoloquinoline quinone analogues</span></div><div class="casAuthors">Chen, Ling; Xie, Yuan-Zhu; Luo, Zhi-Yong; Liu, Li-Jun; Zou, Zi-Zheng; Liu, Hong-Dou; Kong, Fan-Rong; Hao, Ying; Gao, Jin-Lei; Wang, Liu-Liu; Ma, Da-You; Liu, Su-You</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">127286</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Natural quinones and their analogs have attracted growing attention because of their novel anticancer activities.  A series of novel isothiazoloquinoline quinone analogs were synthesized and evaluated for antitumor activities against four different kind of cancer cells.  Among them, isothiazoloquinolinoquinones inhibited cancer cells proliferation effectively with IC50 values in the nanomolar range, and isothiazoloquinolinoquinone I induced the cell apoptosis.  Further exploration of possible mechanism of action indicates that I not only activates ROS prodn. through NQO1-directed redox cycling but also inhibits the phosphorylation of STAT3.  These findings indicate that I has potential use for the development of new skeleton drug candidate as an efficient substrate of NQO1 and STAT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqATbZejaLk_7Vg90H21EOLACvtfcHk0ljJLaLcqrGSmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFylsbjJ&md5=7611bcb39e94513b998690e17b4cdd44</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127286%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DY.%2BZ.%26aulast%3DLuo%26aufirst%3DZ.%2BY.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DZou%26aufirst%3DZ.%2BZ.%26aulast%3DLiu%26aufirst%3DH.%2BD.%26aulast%3DKong%26aufirst%3DF.%2BR.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DMa%26aufirst%3DD.%2BY.%26aulast%3DLiu%26aufirst%3DS.%2BY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520isothiazoloquinoline%2520quinone%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127286%26doi%3D10.1016%2Fj.bmcl.2020.127286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">RÃ¶hrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9421</span>â <span class="NLM_lpage">9437</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9421-9437&author=U.+F.+R%C3%B6hrigauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=Challenges+in+the+discovery+of+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+inhibitors&doi=10.1021%2Facs.jmedchem.5b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9421-9437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies.  Many novel IDO1 inhibitor scaffolds have been described, and a few potent compds. have entered clin. trials.  However, a significant no. of the reported compds. contain problematic functional groups, suggesting that enzyme inhibition could be the result of undesirable side reactions instead of selective binding to IDO1.  Here, we describe issues in the employed exptl. protocols, review and classify reported IDO1 inhibitors, and suggest different approaches for confirming viable inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR3nr-l4vgNLVg90H21EOLACvtfcHk0ljJLaLcqrGSmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D&md5=1b44178d33badc00215915c28d027b5d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00326%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6hrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DChallenges%2520in%2520the%2520discovery%2520of%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9421%26epage%3D9437%26doi%3D10.1021%2Facs.jmedchem.5b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-dioxygenase and tumor-induced tolerance</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1147</span>â <span class="NLM_lpage">1154</span>, <span class="refDoi">Â DOI: 10.1172/JCI31178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1172%2FJCI31178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=17476344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Omtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=1147-1154&author=D.+H.+Munnauthor=A.+L.+Mellor&title=Indoleamine+2%2C3-dioxygenase+and+tumor-induced+tolerance&doi=10.1172%2FJCI31178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase and tumor-induced tolerance</span></div><div class="casAuthors">Munn, David H.; Mellor, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1147-1154</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Tumors arise from normal cells of the body through genetic mutation.  Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; i.e., it is tolerant of these antigens.  This acquired state of tolerance must be overcome for cancer immunotherapy to succeed.  Indoleamine 2,3-dioxygenase (IDO) is one mol. mechanism that contributes to tumor-induced tolerance.  IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression.  It can also function as an antagonist to other activators of antitumor immunity.  Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmm42-SIElbVg90H21EOLACvtfcHk0ljJLaLcqrGSmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Omtro%253D&md5=b8faf9b3398a23896cca34128636c787</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1172%2FJCI31178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31178%26sid%3Dliteratum%253Aachs%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26atitle%3DIndoleamine%25202%252C3-dioxygenase%2520and%2520tumor-induced%2520tolerance%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D1147%26epage%3D1154%26doi%3D10.1172%2FJCI31178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1845</span>â <span class="NLM_lpage">1853</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-09-3613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1158%2F0008-5472.CAN-09-3613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=20160032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1845-1853&author=A.+J.+Mullerauthor=J.+B.+DuHadawayauthor=D.+Jallerauthor=P.+Curtisauthor=R.+Metzauthor=G.+C.+Prendergast&title=Immunotherapeutic+suppression+of+indoleamine+2%2C3-dioxygenase+and+tumor+growth+with+ethyl+pyruvate&doi=10.1158%2F0008-5472.CAN-09-3613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate</span></div><div class="casAuthors">Muller, Alexander J.; DuHadaway, James B.; Jaller, Daniel; Curtis, Peter; Metz, Richard; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1845-1853</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Efforts to improve cancer care in the developing world will benefit from the identification of simple, inexpensive, and broadly applicable medical modalities based on emergent innovations in treatment, such as targeting mechanisms of tumoral immune tolerance.  In this report, we offer preclin. evidence that the low-cost, anti-inflammatory agent Et pyruvate elicits a potent immune-based antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic enzyme for many human tumors.  Consistent with its reported ability to interfere with NF-ÎºB function, Et pyruvate blocks IDO induction both in vitro and in vivo.  Antitumor activity was achieved in mice with a noncytotoxic dosing regimen of Et pyruvate shown previously to protect against lethality from sepsis.  Similar outcomes were obtained with the functional Et pyruvate analog 2-acetamidoacrylate.  Et pyruvate was ineffective at suppressing tumor outgrowth in both athymic and Ido1-deficient mice, providing in vivo corroboration of the importance of T-cell-dependent immunity and IDO targeting for Et pyruvate to achieve antitumor efficacy.  Although Et pyruvate has undergone early-phase clin. testing, this was done without consideration of its possible applicability to cancer.  Our findings that IDO is effectively blocked by Et pyruvate treatment deepen emerging links between IDO and inflammatory processes.  Further, these findings rationalize oncol. applications for this agent by providing a compelling basis to reposition Et pyruvate as a low-cost immunochemotherapy for clin. evaluation in cancer patients.  Cancer Res; 70(5); 1845-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkSC_ZW9ndLVg90H21EOLACvtfcHk0ljqhgsPxlKSSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWju78%253D&md5=3d6e683754a5f97ef5215319ad454e2c</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3613%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DJaller%26aufirst%3DD.%26aulast%3DCurtis%26aufirst%3DP.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DImmunotherapeutic%2520suppression%2520of%2520indoleamine%25202%252C3-dioxygenase%2520and%2520tumor%2520growth%2520with%2520ethyl%2520pyruvate%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1845%26epage%3D1853%26doi%3D10.1158%2F0008-5472.CAN-09-3613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Bifunctional naphthoquinone aromatic amide-oxime derivatives exert combined immunotherapeutic and antitumor effects through simultaneous targeting of indoleamine-2,3-dioxygenase and signal transducer and activator of transcription 3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1544</span>â <span class="NLM_lpage">1563</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01386</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01386" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOhuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1544-1563&author=R.+Huangauthor=X.+Jingauthor=X.+Huangauthor=Y.+Panauthor=Y.+Fangauthor=G.+Liangauthor=Z.+Liaoauthor=H.+Wangauthor=Z.+Chenauthor=Y.+Zhang&title=Bifunctional+naphthoquinone+aromatic+amide-oxime+derivatives+exert+combined+immunotherapeutic+and+antitumor+effects+through+simultaneous+targeting+of+indoleamine-2%2C3-dioxygenase+and+signal+transducer+and+activator+of+transcription+3&doi=10.1021%2Facs.jmedchem.9b01386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3</span></div><div class="casAuthors">Huang, Rizhen; Jing, Xiaoteng; Huang, Xiaochao; Pan, Yingming; Fang, Yilin; Liang, Guibin; Liao, Zhixin; Wang, Hengshan; Chen, Zhenfeng; Zhang, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1544-1563</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase 1 (IDO1) and signal transducer and activator of transcription 3 (STAT3) are important targets in the tumor microenvironment for cancer therapy.  In the present study, a set of naphthoquinone arom. amide-oxime derivs. were designed, which stimulated the immune response via IDO1 inhibition and simultaneously displayed powerful antitumor activity against three selected cancer cell lines through suppressing STAT3 signaling.  The representative compd. 8u bound effectively to IDO1, with greater inhibitory activity relative to the com. IDO1 inhibitor 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L) in addn. to the efficient suppression of nuclear translocation of STAT3.  Consistently, in vivo assays demonstrated a higher antiproliferative activity of compd. 8u in both wild-type B16-F10 isograft tumors and an athymic HepG2 xenograft model relative to 1-methyl-L-tryptophan (1-MT) and doxorubicin (DOX).  This bifunctional compd. with dual immunotherapeutic and anticancer efficacy may represent a new generation of highly efficacious drug candidates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojfGgot8_60bVg90H21EOLACvtfcHk0ljqhgsPxlKSSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOhuro%253D&md5=6f9aca12e3810617ebb48416b98d6d27</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01386%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DBifunctional%2520naphthoquinone%2520aromatic%2520amide-oxime%2520derivatives%2520exert%2520combined%2520immunotherapeutic%2520and%2520antitumor%2520effects%2520through%2520simultaneous%2520targeting%2520of%2520indoleamine-2%252C3-dioxygenase%2520and%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1544%26epage%3D1563%26doi%3D10.1021%2Facs.jmedchem.9b01386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies of Î±-naphthoflavone derivatives as CYP1B1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111938</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.111938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.111938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31830634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111938&author=J.+Dongauthor=Z.+Wangauthor=J.+Cuiauthor=Q.+Mengauthor=S.+Li&title=Synthesis+and+structure-activity+relationship+studies+of+%CE%B1-naphthoflavone+derivatives+as+CYP1B1+inhibitors&doi=10.1016%2Fj.ejmech.2019.111938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of Î±-naphthoflavone derivatives as CYP1B1 inhibitors</span></div><div class="casAuthors">Dong, Jinyun; Wang, Zengtao; Cui, Jiahua; Meng, Qingqing; Li, Shaoshun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111938</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In order to obtain potent and selective CYP1B1 inhibitors, a series of 41 Î±-naphthoflavone derivs. (ANF) I [X = S, SO2, Y = O; X = O, Y = O, S, NOH; R = Ph, 2-FC6H4, 3-ClC6H4, 3,4,5-(MeO)2C6H2, etc.] were synthesized, characterized and evaluated for CYP1B1, CYP1A1 and CYP1A2 inhibitory activities.  A closer look into the structure-activity relationship for the inhibitory effects on CYP1B1 indicated that modification of the C ring of ANF decreases the CYP1B1 inhibitory potency, while incorporation of substituent(s) into the different positions of the B ring yields analogs with varying CYP1B1 inhibitory capacity.  Among these derivs., compds. I (X = Y = O; R = 3-ClC6H4, 3-F3CC6H4) were identified as the most potent two selective CYP1B1 inhibitors with IC50 values of 0.49 and 0.52 nM, resp., which were 10-fold more potent than the lead compd. ANF.  In addn., mol. docking and a reasonable 3D-QSAR (three-dimensional quant. structure-activity relationship) study were performed to provide a better understanding of the key structural features influencing the CYP1B1 inhibitory activity.  The results achieved in this study would lay a foundation for future development of selective, potent, low-toxic and water-sol. CYP1B1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopO5mvQNRAVbVg90H21EOLACvtfcHk0ljqhgsPxlKSSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7%252FI&md5=087b50f650ab4fe198edc72ea627cfb3</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111938%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520%25CE%25B1-naphthoflavone%2520derivatives%2520as%2520CYP1B1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111938%26doi%3D10.1016%2Fj.ejmech.2019.111938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of heterocycle-containing Î±-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112895</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2020.112895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33069055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFegs7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112895&author=J.+Dongauthor=G.+Huangauthor=Q.+Cuiauthor=Q.+Mengauthor=S.+Liauthor=J.+Cui&title=Discovery+of+heterocycle-containing+%CE%B1-naphthoflavone+derivatives+as+water-soluble%2C+highly+potent+and+selective+CYP1B1+inhibitors&doi=10.1016%2Fj.ejmech.2020.112895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of heterocycle-containing Î±-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors</span></div><div class="casAuthors">Dong, Jinyun; Huang, Guang; Cui, Qing; Meng, Qingqing; Li, Shaoshun; Cui, Jiahua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112895</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A set of forty-six 6,7,10-trimethoxy-Î±-naphthoflavone derivs. I [R = 2-furyl, 2-chloro-4-pyridyl, 5-bromo-2-pyridyl, etc.] was synthesized and screened against CYP1 enzymes, leading to the identification of fluorine-contg. compd. I [R = 5-bromo-2-pyridyl] as the most potent and selective CYP1B1 inhibitor (IC50 value of 0.07 nM), being 84-fold more potent than that of the template mol. ANF.  Alternatively, the amino-substituted deriv. I [R = 4-amino-3-pyridyl] not only possessed a potent inhibitory effect on CYP1B1 (IC50 value of 0.98 nM), but also had a substantially increased water soly. as compared with the lead ANF.  The current study expanded the structural diversity of CYP1B1 inhibitors and compd. I [R = 4-amino-3-pyridyl] could be considered as a promising starting point with great potential for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKW4P7AGPX97Vg90H21EOLACvtfcHk0ljr1SjziXWd-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFegs7fE&md5=11be82db8ac19fb7b678be9263f1a699</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112895%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DQ.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520heterocycle-containing%2520%25CE%25B1-naphthoflavone%2520derivatives%2520as%2520water-soluble%252C%2520highly%2520potent%2520and%2520selective%2520CYP1B1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112895%26doi%3D10.1016%2Fj.ejmech.2020.112895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1606</span>â <span class="NLM_lpage">1614</span>, <span class="refDoi">Â DOI: 10.1039/C9MD00258H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1039%2FC9MD00258H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31803401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ykurjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1606-1614&author=J.+Dongauthor=G.+Huangauthor=Q.+Zhangauthor=Z.+Wangauthor=J.+Cuiauthor=Y.+Wuauthor=Q.+Mengauthor=S.+Li&title=Development+of+benzochalcone+derivatives+as+selective+CYP1B1+inhibitors+and+anticancer+agents&doi=10.1039%2FC9MD00258H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents</span></div><div class="casAuthors">Dong, Jinyun; Huang, Guang; Zhang, Qijing; Wang, Zengtao; Cui, Jiahua; Wu, Yan; Meng, Qingqing; Li, Shaoshun</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1606-1614</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of benzochalcone derivs. have been synthesized and evaluated for CYP1 inhibitory activity and cytotoxic properties against wild type cell lines (MCF-7 and MDA-MB-231) and drug resistant cell lines (LCC6/P-gp and MCF-7/1B1).  All of these compds. were found to have selective inhibition towards CYP1B1 and the most potent two possessed single-digit nanomolar CYP1B1 potency.  In addn., some of them showed promising cytotoxic activities not only against wild type cells, but also against drug resistant cells at low micromolar concns.  More importantly, these multi-functional compds. may surmount drug-drug interactions that frequently occur during the combination of CYP1B1/P-gp inhibitors and anticancer drugs to overcome drug resistance.  This study may provide a good starting point for the further development of more potent multi-functional agents with CYP1B1 inhibitory activity and cytotoxic potency in cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzuiGxACVbzrVg90H21EOLACvtfcHk0ljr1SjziXWd-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ykurjE&md5=8cf0104c9a2be0ec4cfebe0489e85601</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1039%2FC9MD00258H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD00258H%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520benzochalcone%2520derivatives%2520as%2520selective%2520CYP1B1%2520inhibitors%2520and%2520anticancer%2520agents%26jtitle%3DMedChemComm%26date%3D2019%26volume%3D10%26spage%3D1606%26epage%3D1614%26doi%3D10.1039%2FC9MD00258H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CuyÃ s, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorach-ParÃ©s, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-SÃ¡nchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonell-Canals, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valiente, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez-MartÃ­nez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch-Barrera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, J. A.</span></span> <span> </span><span class="NLM_article-title">Silibinin is a direct inhibitor of STAT3</span>. <i>Food Chem. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">161</span>â <span class="NLM_lpage">172</span>, <span class="refDoi">Â DOI: 10.1016/j.fct.2018.04.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.fct.2018.04.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29660364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvVSrsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2018&pages=161-172&author=S.+Verduraauthor=E.+Cuy%C3%A0sauthor=L.+Llorach-Par%C3%A9sauthor=A.+P%C3%A9rez-S%C3%A1nchezauthor=V.+Micolauthor=A.+Nonell-Canalsauthor=J.+Jovenauthor=M.+Valienteauthor=M.+S%C3%A1nchez-Mart%C3%ADnezauthor=J.+Bosch-Barreraauthor=J.+A.+Menendez&title=Silibinin+is+a+direct+inhibitor+of+STAT3&doi=10.1016%2Fj.fct.2018.04.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Silibinin is a direct inhibitor of STAT3</span></div><div class="casAuthors">Verdura, Sara; Cuyas, Elisabet; Llorach-Pares, Laura; Perez-Sanchez, Almudena; Micol, Vicente; Nonell-Canals, Alfons; Joven, Jorge; Valiente, Manuel; Sanchez-Martinez, Melchor; Bosch-Barrera, Joaquim; Menendez, Javier A.</div><div class="citationInfo"><span class="NLM_cas:title">Food and Chemical Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">161-172</span>CODEN:
                <span class="NLM_cas:coden">FCTOD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-6915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We herein combined exptl. and computational efforts to delineate the mechanism of action through which the flavonolignan silibinin targets STAT3.  Silibinin reduced IL-6 inducible, constitutive, and acquired feedback activation of STAT3 at tyrosine 705 (Y705).  Silibinin attenuated the inducible phospho-activation of Y705 in GFP-STAT3 genetic fusions without drastically altering the kinase activity of the STAT3 upstream kinases JAK1 and JAK2.  A comparative computational study based on docking and mol. dynamics simulation over 14 different STAT3 inhibitors (STAT3i) predicted that silibinin could directly bind with high affinity to both the Src homol.-2 (SH2) domain and the DNA-binding domain (DBD) of STAT3.  Silibinin partially overlapped with the cavity occupied by other STAT3i in the SH2 domain to indirectly prevent Y705 phosphorylation, yet showing a unique binding mode.  Moreover, silibinin was the only STAT3i predicted to establish direct interactions with DNA in its targeting to the STAT3 DBD.  The prevention of STAT3 nuclear translocation, the blockade of the binding of activated STAT3 to its consensus DNA sequence, and the suppression of STAT3-directed transcriptional activity confirmed silibinin as a direct STAT3i.  The unique characteristics of silibinin as a bimodal SH2- and DBD-targeting STAT3i make silibinin a promising lead for designing new, more effective STAT3i.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrqDnBPi7e7Vg90H21EOLACvtfcHk0ljr1SjziXWd-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvVSrsbs%253D&md5=3e56f6313d0888cd4874ab96db59a2e4</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.fct.2018.04.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fct.2018.04.028%26sid%3Dliteratum%253Aachs%26aulast%3DVerdura%26aufirst%3DS.%26aulast%3DCuy%25C3%25A0s%26aufirst%3DE.%26aulast%3DLlorach-Par%25C3%25A9s%26aufirst%3DL.%26aulast%3DP%25C3%25A9rez-S%25C3%25A1nchez%26aufirst%3DA.%26aulast%3DMicol%26aufirst%3DV.%26aulast%3DNonell-Canals%26aufirst%3DA.%26aulast%3DJoven%26aufirst%3DJ.%26aulast%3DValiente%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DM.%26aulast%3DBosch-Barrera%26aufirst%3DJ.%26aulast%3DMenendez%26aufirst%3DJ.%2BA.%26atitle%3DSilibinin%2520is%2520a%2520direct%2520inhibitor%2520of%2520STAT3%26jtitle%3DFood%2520Chem.%2520Toxicol.%26date%3D2018%26volume%3D116%26spage%3D161%26epage%3D172%26doi%3D10.1016%2Fj.fct.2018.04.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21731</span>, <span class="refDoi">Â DOI: 10.1038/srep21731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fsrep21731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26911838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1erurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21731&author=H.+H.+Caoauthor=J.+H.+Chuauthor=H.+Y.+Kwanauthor=T.+Suauthor=H.+Yuauthor=C.+Y.+Chengauthor=X.+Q.+Fuauthor=H.+Guoauthor=T.+Liauthor=A.+K.+Tseauthor=G.+X.+Chouauthor=H.+B.+Moauthor=Z.+L.+Yu&title=Inhibition+of+the+STAT3+signaling+pathway+contributes+to+apigenin-mediated+anti-metastatic+effect+in+melanoma&doi=10.1038%2Fsrep21731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma</span></div><div class="casAuthors">Cao, Hui-Hui; Chu, Jian-Hong; Kwan, Hiu-Yee; Su, Tao; Yu, Hua; Cheng, Chi-Yan; Fu, Xiu-Qiong; Guo, Hui; Li, Ting; Tse, Anfernee Kai-Wing; Chou, Gui-Xin; Mo, Huan-Biao; Yu, Zhi-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21731</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) signaling is constantly activated in human melanoma, and promotes melanoma metastasis.  The dietary flavonoid apigenin is a bioactive compd. that possesses low toxicity and exerts anti-metastatic activity in melanoma.  However, the anti-metastasis mechanism of apigenin has not been fully elucidated.  In the present study, we showed that apigenin suppressed murine melanoma B16F10 cell lung metastasis in mice, and inhibited cell migration and invasion in human and murine melanoma cells.  Further study indicated that apigenin effectively suppressed STAT3 phosphorylation, decreased STAT3 nuclear localization and inhibited STAT3 transcriptional activity.  Apigenin also down-regulated STAT3 target genes MMP-2, MMP-9, VEGF and Twist1, which are involved in cell migration and invasion.  More importantly, overexpression of STAT3 or Twist1 partially reversed apigenin-impaired cell migration and invasion.  Our data not only reveal a novel anti-metastasis mechanism of apigenin but also support the notion that STAT3 is an attractive and promising target for melanoma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZra091yHGz7Vg90H21EOLACvtfcHk0lgR5vg7FEe0rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1erurc%253D&md5=aab552a700cd2f4b0d10c4dd63d09383</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fsrep21731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21731%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DH.%2BH.%26aulast%3DChu%26aufirst%3DJ.%2BH.%26aulast%3DKwan%26aufirst%3DH.%2BY.%26aulast%3DSu%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DC.%2BY.%26aulast%3DFu%26aufirst%3DX.%2BQ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DTse%26aufirst%3DA.%2BK.%26aulast%3DChou%26aufirst%3DG.%2BX.%26aulast%3DMo%26aufirst%3DH.%2BB.%26aulast%3DYu%26aufirst%3DZ.%2BL.%26atitle%3DInhibition%2520of%2520the%2520STAT3%2520signaling%2520pathway%2520contributes%2520to%2520apigenin-mediated%2520anti-metastatic%2520effect%2520in%2520melanoma%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D21731%26doi%3D10.1038%2Fsrep21731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span> <span> </span><span class="NLM_article-title">Blockage of STAT3 signaling pathway by morusin induces apoptosis and inhibits invasion in human pancreatic tumor cells</span>. <i>Pancreas</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">409</span>â <span class="NLM_lpage">419</span>, <span class="refDoi">Â DOI: 10.1097/MPA.0000000000000496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1097%2FMPA.0000000000000496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26646273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVSguro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=409-419&author=C.+Kimauthor=J.+H.+Kimauthor=E.+Y.+Ohauthor=D.+Namauthor=S.+G.+Leeauthor=J.+Leeauthor=S.+H.+Kimauthor=B.+S.+Shimauthor=K.+S.+Ahn&title=Blockage+of+STAT3+signaling+pathway+by+morusin+induces+apoptosis+and+inhibits+invasion+in+human+pancreatic+tumor+cells&doi=10.1097%2FMPA.0000000000000496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Blockage of STAT3 Signaling Pathway by Morusin Induces Apoptosis and Inhibits Invasion in Human Pancreatic Tumor Cells</span></div><div class="casAuthors">Kim, Chulwon; Kim, Jin Ho; Oh, Eun Young; Nam, Dongwoo; Lee, Seok Geun; Lee, Junhee; Kim, Sung-Hoon; Shim, Bum Sang; Ahn, Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Pancreas (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-419</span>CODEN:
                <span class="NLM_cas:coden">PANCE4</span>;
        ISSN:<span class="NLM_cas:issn">0885-3177</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objectives: Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor implicated in carcinogenesis.  Here, we investigated the role of morusin, the major prenylflavonoid, isolated from Chinese herbal medicine in abrogating the constitutive STAT3 activation in human pancreatic tumor cells.  Methods: The effect of morusin on STAT3 activation, assocd. protein kinases, STAT3-regulated gene products, cellular proliferation, and apoptosis was examd.  Results: Morusin specifically inhibited constitutive STAT3 activation both at tyrosine residue 705 and serine residue 727 in 4 pancreatic tumor cells.  The inhibition of STAT3 was mediated through the suppression of activation of upstream JAK1, JAK2, and c-Src kinases.  Morusin led to the accumulation of the cells in different phases of the cell cycle and caused induction of apoptosis and loss of mitochondrial membrane potential.  Morusin downregulated the expression of various STAT3-regulated gene products; this correlated with induction of caspase-3 activation and anti-invasive effects.  Treatment with the protein tyrosine phosphatase inhibitor pervanadate reversed the morusin-induced downregulation of STAT3, thereby suggesting the involvement of a protein tyrosine phosphatase.  Conclusions: Morusin is a novel blocker of STAT3 activation and thus may have potential in neg. regulation of growth and metastasis of pancreatic tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI7lnyUmPSz7Vg90H21EOLACvtfcHk0lgR5vg7FEe0rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVSguro%253D&md5=a0696f2c818afd9a2322f0372e748db2</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1097%2FMPA.0000000000000496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMPA.0000000000000496%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DOh%26aufirst%3DE.%2BY.%26aulast%3DNam%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DShim%26aufirst%3DB.%2BS.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26atitle%3DBlockage%2520of%2520STAT3%2520signaling%2520pathway%2520by%2520morusin%2520induces%2520apoptosis%2520and%2520inhibits%2520invasion%2520in%2520human%2520pancreatic%2520tumor%2520cells%26jtitle%3DPancreas%26date%3D2016%26volume%3D45%26spage%3D409%26epage%3D419%26doi%3D10.1097%2FMPA.0000000000000496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">2â²-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>471</i></span>,  <span class="NLM_fpage">135</span>â <span class="NLM_lpage">146</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2019.11.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.canlet.2019.11.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31811906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyhtr7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=471&publication_year=2020&pages=135-146&author=Y.+Yueauthor=W.+Qianauthor=J.+Liauthor=S.+Wuauthor=M.+Zhangauthor=Z.+Wuauthor=Q.+Maauthor=Z.+Wang&title=2%E2%80%B2-Hydroxyflavanone+inhibits+the+progression+of+pancreatic+cancer+cells+and+sensitizes+the+chemosensitivity+of+EGFR+inhibitors+via+repressing+STAT3+signaling&doi=10.1016%2Fj.canlet.2019.11.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling</span></div><div class="casAuthors">Yue, Yangyang; Qian, Weikun; Li, Jie; Wu, Shiqi; Zhang, Mengzhao; Wu, Zheng; Ma, Qingyong; Wang, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">471</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">135-146</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, and chemotherapy is still an important treatment.  It is urgent to develop new medicines because of the limitation and side effects of chemotherapy. 2'-Hydroxyflavanone (2HF) is a citrus-bioflavonoid that is considered to have anti-cancer efficacy.  Compared to human pancreatic ductal epithelial cells hTERT-HPNE, more significant growth-inhibitory effects were seen in PDAC cells BxPC-3 and MIA PaCa-2.  We showed that apoptosis was induced and that the cell cycle was arrested when cells were treated with 2HF.  The expression of the mol. proteins cleaved PARP, cleaved Caspase3, Bax, Bcl-2, CyclinD1, and p27 changed correspondingly.  Also, we obsd. anti-metastatic effects and changes in MMP9, E-cadherin, N-cadherin and Vimentin when cells were treated with a low dose of 2HF.  Suppression of STAT3 and EGFR phosphorylation was also identified as a result of treatment with a combination of 2HF and EGFR inhibitors.  The in vivo antitumor effects in KPC mice were consistent with those obsd. in vitro. 2HF has impactful anti-cancer efficacy and sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod7YVykVkNIbVg90H21EOLACvtfcHk0lgR5vg7FEe0rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyhtr7I&md5=e09862ceac97e1e894aa18e50cbdecd1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.11.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.11.041%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3D2%25E2%2580%25B2-Hydroxyflavanone%2520inhibits%2520the%2520progression%2520of%2520pancreatic%2520cancer%2520cells%2520and%2520sensitizes%2520the%2520chemosensitivity%2520of%2520EGFR%2520inhibitors%2520via%2520repressing%2520STAT3%2520signaling%26jtitle%3DCancer%2520Lett.%26date%3D2020%26volume%3D471%26spage%3D135%26epage%3D146%26doi%3D10.1016%2Fj.canlet.2019.11.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namjoshi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Um, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span> <span> </span><span class="NLM_article-title">Anti-myeloma effects of icariin are mediated through the attenuation of JAK/STAT3-dependent signaling cascade</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">531</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2018.00531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3389%2Ffphar.2018.00531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29899697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyrur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=531&author=Y.+Y.+Jungauthor=J.+H.+Leeauthor=D.+Namauthor=A.+S.+Narulaauthor=O.+A.+Namjoshiauthor=B.+E.+Bloughauthor=J.+Y.+Umauthor=G.+Sethiauthor=K.+S.+Ahn&title=Anti-myeloma+effects+of+icariin+are+mediated+through+the+attenuation+of+JAK%2FSTAT3-dependent+signaling+cascade&doi=10.3389%2Ffphar.2018.00531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-myeloma effects of icariin are mediated through the attenuation of JAK/STAT3-dependent signaling cascade</span></div><div class="casAuthors">Jung, Young Yun; Lee, Jong Hyun; Nam, Dongwoo; Narula, Acharan S.; Namjoshi, Ojas A.; Blough, Bruce E.; Um, Jae-Young; Sethi, Gautam; Ahn, Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">531/1-531/15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Because of the essential role of signal transducer and activator of transcription 3 (STAT3) in proliferation, anti-apoptosis, and chemoresistance of multiple myeloma (MM), we investigated whether icariin, a prenylated flavonol glycoside, inhibits both constitutive and inducible STAT3 activation in human myeloma cell lines.  We noted that icariin could block constitutive STAT3 phosphorylation as well as its nuclear translocation and DNA binding ability in U266 cells.  Icariin also suppressed IL-6-induced STAT3 activation through the inhibition of upstream kinases (Janus activated kinase-1 and - 2, and c-Src).  We found that icariin downregulated the protein expression of STAT3 downstream target gene products such as Bcl-2, Bcl-xl, survivin, IAP-1/2, COX-2, VEGF, and matrix metallopeptidase 9 (MMP-9) in a concn.-dependent manner.  Moreover, this flavonoid also exhibited the capacity to significantly induce apoptosis and suppress proliferation of MM cells.  Interestingly, this agent also significantly potentiated the apoptotic effects of bortezomib through the suppression of STAT3 activation in MM cells.  Altogether, our data indicates that the potential application of icariin as a STAT3 blocker in myeloma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAFhYFeew-5bVg90H21EOLACvtfcHk0lgaRDulOBFE0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyrur4%253D&md5=274c4d87a7602f1c7218f848323aec7a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00531%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DY.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DNam%26aufirst%3DD.%26aulast%3DNarula%26aufirst%3DA.%2BS.%26aulast%3DNamjoshi%26aufirst%3DO.%2BA.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DUm%26aufirst%3DJ.%2BY.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26atitle%3DAnti-myeloma%2520effects%2520of%2520icariin%2520are%2520mediated%2520through%2520the%2520attenuation%2520of%2520JAK%252FSTAT3-dependent%2520signaling%2520cascade%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D531%26doi%3D10.3389%2Ffphar.2018.00531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span> <span> </span><span class="NLM_article-title">Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">140</span>â <span class="NLM_lpage">148</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2013.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.canlet.2013.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24333736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOht7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2014&pages=140-148&author=J.+H.+Leeauthor=S.+Y.+Chiangauthor=D.+Namauthor=W.+S.+Chungauthor=J.+Leeauthor=Y.+S.+Naauthor=G.+Sethiauthor=K.+S.+Ahn&title=Capillarisin+inhibits+constitutive+and+inducible+STAT3+activation+through+induction+of+SHP-1+and+SHP-2+tyrosine+phosphatases&doi=10.1016%2Fj.canlet.2013.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases</span></div><div class="casAuthors">Lee, Jong Hyun; Chiang, Shu Yuan; Nam, Dongwoo; Chung, Won-Seok; Lee, Junhee; Na, Young-Soon; Sethi, Gautam; Ahn, Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-148</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Signal transducers and activators of transcription (STAT)-3 is a latent cytosolic transcription factor that has been closely assocd. with survival, proliferation, chemoresistance, and metastasis of tumor cells.  Whether the anti-proliferative, pro-apoptotic, and anti-metastatic effects of capillarisin (CPS), derived from Artemisia capillaris (Compositae), are linked to its capability to inhibit STAT3 activation was investigated.  We found that CPS specifically inhibited both constitutive and inducible STAT3 activation at tyrosine residue 705 but not at serine residue 727 in human multiple myeloma cells.  Besides the inhibition of STAT3 phosphorylation, CPS also abrogated STAT3 constitutive activity and nuclear translocation.  The suppression of STAT3 was mediated through the inhibition of activation of upstream JAK1, JAK2, and c-Src kinases.  Treatment with the protein tyrosine phosphatase (PTP) inhibitor pervanadate treatment reversed the CPS-induced down-regulation of JAK1/2 and STAT3, thereby suggesting the involvement of a PTP.  Indeed, knockdown of the SHP-1 and SHP-2 genes by small interfering RNA suppressed the ability of CPS to inhibit JAK1 and STAT3 activation, suggesting the crit. role of both SHP-1 and SHP-2 in its possible mechanism of action.  CPS downregulated the expression of STAT3-regulated antiapoptotic and proliferative gene products; and this correlated with suppression of cell viability, the accumulation of cells in sub-G1 phase of cell cycle and induction of apoptosis.  Moreover, CPS potentiated bortezomib-induced apoptotic effects in MM cells, and this correlated with down-regulation of various gene products that mediate cell proliferation (Cyclin D1 and COX-2), cell survival (Bcl-2, Bcl-xl, IAP1, IAP2, and Survivin), invasion (MMP-9), and angiogenesis (VEGF).  Thus, overall, our results suggest that CPS is a novel blocker of STAT3 activation and thus may have a potential in neg. regulation of growth, metastasis, and chemoresistance of tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKazZFFIl8k7Vg90H21EOLACvtfcHk0lgaRDulOBFE0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOht7fK&md5=4d34bba3328ff4e2e2efcbd1765387f4</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DChiang%26aufirst%3DS.%2BY.%26aulast%3DNam%26aufirst%3DD.%26aulast%3DChung%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DNa%26aufirst%3DY.%2BS.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26atitle%3DCapillarisin%2520inhibits%2520constitutive%2520and%2520inducible%2520STAT3%2520activation%2520through%2520induction%2520of%2520SHP-1%2520and%2520SHP-2%2520tyrosine%2520phosphatases%26jtitle%3DCancer%2520Lett.%26date%3D2014%26volume%3D345%26spage%3D140%26epage%3D148%26doi%3D10.1016%2Fj.canlet.2013.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span></span> <span> </span><span class="NLM_article-title">Geranylnaringenin (CG902) inhibits constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2017.06.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bcp.2017.06.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28666623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=46-57&author=Y.+Jinauthor=Y.+J.+Yoonauthor=Y.+J.+Jeonauthor=J.+Choiauthor=Y.+J.+Leeauthor=J.+Leeauthor=S.+Choiauthor=O.+Nashauthor=D.+C.+Hanauthor=B.+M.+Kwon&title=Geranylnaringenin+%28CG902%29+inhibits+constitutive+and+inducible+STAT3+activation+through+the+activation+of+SHP-2+tyrosine+phosphatase&doi=10.1016%2Fj.bcp.2017.06.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Geranylnaringenin (CG902) inhibits constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase</span></div><div class="casAuthors">Jin, Yena; Yoon, Yae Jin; Jeon, Yoon Jung; Choi, Jiyeon; Lee, Yu-Jin; Lee, Joonku; Choi, Sangho; Nash, Oyekanmi; Han, Dong Cho; Kwon, Byoung-Mog</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-57</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The roles and significance of signal transducer and activator of transcription 3 (STAT3) in human cancers have been extensively studied and STAT3 is a promising therapeutic target for cancer drug discovery.  During the screening of natural products to identify STAT3 inhibitors, we identified geranylnaringenin (CG902), which decreased luciferase activity in a dose-dependent manner.  CG902 specifically inhibited STAT3 phosphorylation at Tyr-705 in DU145 prostate cancer cells and decreased the expression levels of STAT3 target genes, such as cyclin D1, cyclin A, and survivin.  Notably, the knockdown of the SHP-2 gene by small interfering RNA suppressed the ability of CG902 to inhibit STAT3 activation and CG902 activated the phosphatase activity of SHP-2 through direct interaction with SHP-2 and induced the phosphorylation of SHP-2.  The interactions between CG902 and SHP-2 were confirmed by pull-down assay using biotinylated CG902.  The interactions were also further validated by the drug affinity responsive target stability (DARTS) and cellular thermal shift assay (CETSA).  The inhibitory effect of CG902 on cell growth was confirmed using the DU145 mouse xenograft model.  We propose that CG902 inhibits STAT3 activity through a mechanism that involves the interactions between CG902 and SHP-2, and the phosphorylation of SHP-2, which leads to SHP-2 activation in DU145 cells.  CG902 is the first compd. to regulate STAT3 activity via the modulation of SHP-2 activity, and our results suggest that CG902 is a novel inhibitor of the STAT3 pathway and an activator of SHP-2, and may be a useful lead mol. for the development of a therapeutic STAT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoClPx4Nm8_SbVg90H21EOLACvtfcHk0lgVn8q-Gqc8tA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7jN&md5=279cd2f84ce66a2ac6013cb3748dbf1d</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.06.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.06.131%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DY.%26aulast%3DYoon%26aufirst%3DY.%2BJ.%26aulast%3DJeon%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DNash%26aufirst%3DO.%26aulast%3DHan%26aufirst%3DD.%2BC.%26aulast%3DKwon%26aufirst%3DB.%2BM.%26atitle%3DGeranylnaringenin%2520%2528CG902%2529%2520inhibits%2520constitutive%2520and%2520inducible%2520STAT3%2520activation%2520through%2520the%2520activation%2520of%2520SHP-2%2520tyrosine%2520phosphatase%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D142%26spage%3D46%26epage%3D57%26doi%3D10.1016%2Fj.bcp.2017.06.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamie, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philoppes, J. N.</span></span> <span> </span><span class="NLM_article-title">2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">864</span>â <span class="NLM_lpage">879</span>, <span class="refDoi">Â DOI: 10.1080/14756366.2020.1740922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1080%2F14756366.2020.1740922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32208772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFOqsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2020&pages=864-879&author=P.+F.+Lamieauthor=J.+N.+Philoppes&title=2-Thiopyrimidine%2Fchalcone+hybrids%3A+design%2C+synthesis%2C+ADMET+prediction%2C+and+anticancer+evaluation+as+STAT3%2FSTAT5a+inhibitors&doi=10.1080%2F14756366.2020.1740922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors</span></div><div class="casAuthors">Lamie, Phoebe F.; Philoppes, John N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">864-879</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A novel 2-thiopyrimidine/chalcone hybrid was designed, synthesized, and evaluated for their cytotoxic activities against three different cell lines, K-562, MCF-7, and HT-29.  The most active cytotoxic derivs. were , , , and (IC50=0.77-1.74Î¼M, against K-562 cell line), and (IC50=1.37-3.56Î¼M against MCF-7 cell line), and , , and (IC50=2.10 and 2.37Î¼M against HT-29 cell line).  Compds. , , , , and were further evaluated for their cytotoxicity against normal fibroblast cell line WI38.  Moreover, STAT3 and STAT5a inhibitory activities were detd. for the most active derivs. , , , , and .  Dual inhibitory activity was obsd. in compd. (IC50=113.31 and 50.75Î¼M, against STAT3 and STAT5a, resp.).  Prediction of physicochem. properties, drug likeness score, pharmacokinetic and toxic properties was detected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUHLoBtVvD-LVg90H21EOLACvtfcHk0liEVqANBTlDaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFOqsb0%253D&md5=49d920c8a1106f00200eb0a5c783bc92</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1080%2F14756366.2020.1740922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2020.1740922%26sid%3Dliteratum%253Aachs%26aulast%3DLamie%26aufirst%3DP.%2BF.%26aulast%3DPhiloppes%26aufirst%3DJ.%2BN.%26atitle%3D2-Thiopyrimidine%252Fchalcone%2520hybrids%253A%2520design%252C%2520synthesis%252C%2520ADMET%2520prediction%252C%2520and%2520anticancer%2520evaluation%2520as%2520STAT3%252FSTAT5a%2520inhibitors%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2020%26volume%3D35%26spage%3D864%26epage%3D879%26doi%3D10.1080%2F14756366.2020.1740922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roatsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krautscheid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">Development of erasin: a chromone-based STAT3 inhibitor which induces apoptosis in erlotinib-resistant lung cancer cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">17390</span>, <span class="refDoi">Â DOI: 10.1038/s41598-017-17600-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41598-017-17600-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29234062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC1MzgvValtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=17390&author=C.+Lisauthor=S.+Rubnerauthor=M.+Roatschauthor=A.+Bergauthor=T.+Gilcrestauthor=D.+Fuauthor=E.+Nguyenauthor=A.+M.+Schmidtauthor=H.+Krautscheidauthor=J.+Meilerauthor=T.+Berg&title=Development+of+erasin%3A+a+chromone-based+STAT3+inhibitor+which+induces+apoptosis+in+erlotinib-resistant+lung+cancer+cells&doi=10.1038%2Fs41598-017-17600-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells</span></div><div class="casAuthors">Lis Christian; Rubner Stefan; Roatsch Martin; Berg Angela; Schmidt Anne-Marie; Berg Thorsten; Gilcrest Tyler; Fu Darwin; Nguyen Elizabeth; Meiler Jens; Krautscheid Harald</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17390</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inhibition of protein-protein interactions by small molecules offers tremendous opportunities for basic research and drug development.  One of the fundamental challenges of this research field is the broad lack of available lead structures from nature.  Here, we demonstrate that modifications of a chromone-based inhibitor of the Src homology 2 (SH2) domain of the transcription factor STAT5 confer inhibitory activity against STAT3.  The binding mode of the most potent STAT3 inhibitor Erasin was analyzed by the investigation of structure-activity relationships, which was facilitated by chemical synthesis and biochemical activity analysis, in combination with molecular docking studies.  Erasin inhibits tyrosine phosphorylation of STAT3 with selectivity over STAT5 and STAT1 in cell-based assays, and increases the apoptotic rate of cultured NSCLC cells in a STAT3-dependent manner.  This ability of Erasin also extends to HCC-827 cells with acquired resistance against Erlotinib, a clinically used inhibitor of the EGF receptor.  Our work validates chromone-based acylhydrazones as privileged structures for antagonizing STAT SH2 domains, and demonstrates that apoptosis can be induced in NSCLC cells with acquired Erlotinib resistance by direct inhibition of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSothEGF92qRP6BottYdIAWfW6udTcc2eY-dPsOFUFzirntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzgvValtQ%253D%253D&md5=e1be6e7fe119d34d49f6594e7813e4c7</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-17600-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-17600-x%26sid%3Dliteratum%253Aachs%26aulast%3DLis%26aufirst%3DC.%26aulast%3DRubner%26aufirst%3DS.%26aulast%3DRoatsch%26aufirst%3DM.%26aulast%3DBerg%26aufirst%3DA.%26aulast%3DGilcrest%26aufirst%3DT.%26aulast%3DFu%26aufirst%3DD.%26aulast%3DNguyen%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DA.%2BM.%26aulast%3DKrautscheid%26aufirst%3DH.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520erasin%253A%2520a%2520chromone-based%2520STAT3%2520inhibitor%2520which%2520induces%2520apoptosis%2520in%2520erlotinib-resistant%2520lung%2520cancer%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D17390%26doi%3D10.1038%2Fs41598-017-17600-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span> <span> </span><span class="NLM_article-title">Identification of small molecule inhibitors of the STAT3 signaling pathway: Insights into their structural features and mode of action</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5444</span>â <span class="NLM_lpage">5448</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.07.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmcl.2015.07.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26392052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1elsLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5444-5448&author=K.+Kimauthor=S.+J.+Kimauthor=Y.+T.+Hanauthor=S.+J.+Hongauthor=H.+Anauthor=D.+J.+Changauthor=T.+Kimauthor=B.+Limauthor=J.+Leeauthor=Y.+J.+Surhauthor=Y.+G.+Suh&title=Identification+of+small+molecule+inhibitors+of+the+STAT3+signaling+pathway%3A+Insights+into+their+structural+features+and+mode+of+action&doi=10.1016%2Fj.bmcl.2015.07.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small molecule inhibitors of the STAT3 signaling pathway: Insights into their structural features and mode of action</span></div><div class="casAuthors">Kim, Kyeojin; Kim, Su-Jung; Han, Young Taek; Hong, Sung-Jun; An, Hongchan; Chang, Dong-Jo; Kim, Taewoo; Lim, Bumhee; Lee, Jeeyeon; Surh, Young-Joon; Suh, Young-Ger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5444-5448</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel STAT3 inhibitors consisting of Michael acceptor has been identified through assays of the focused inhouse library.  In addn., their mode of action and structural feature responsible for the STAT3 inhibition were investigated.  In particular, analog I revealed promising STAT3 inhibitory activity in HeLa cell lines.  The analog also exhibited selective inhibition of STAT3 phosphorylation without affecting STAT1 phosphorylation and cytostatic effect in human breast epithelial cells (MCF10A-ras), which supports cancer cell-specific inhibitory properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHSfiwcPAuTLVg90H21EOLACvtfcHk0liEVqANBTlDaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1elsLjF&md5=1de619f752f6e3e223263915b7d15ba6</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.063%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DHan%26aufirst%3DY.%2BT.%26aulast%3DHong%26aufirst%3DS.%2BJ.%26aulast%3DAn%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DD.%2BJ.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSurh%26aufirst%3DY.%2BJ.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26atitle%3DIdentification%2520of%2520small%2520molecule%2520inhibitors%2520of%2520the%2520STAT3%2520signaling%2520pathway%253A%2520Insights%2520into%2520their%2520structural%2520features%2520and%2520mode%2520of%2520action%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5444%26epage%3D5448%26doi%3D10.1016%2Fj.bmcl.2015.07.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span> <span> </span><span class="NLM_article-title">A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">114053</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2020.114053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bcp.2020.114053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32450253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFSktr7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=114053&author=S.+K.+Parkauthor=W.+S.+Byunauthor=S.+Leeauthor=Y.+T.+Hanauthor=Y.+S.+Jeongauthor=K.+Jangauthor=S.+J.+Chungauthor=J.+Leeauthor=Y.+G.+Suhauthor=S.+K.+Lee&title=A+novel+small+molecule+STAT3+inhibitor+SLSI-1216+suppresses+proliferation+and+tumor+growth+of+triple-negative+breast+cancer+cells+through+apoptotic+induction&doi=10.1016%2Fj.bcp.2020.114053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction</span></div><div class="casAuthors">Park, Soo Kyung; Byun, Woong Sub; Lee, Seungbeom; Han, Young Taek; Jeong, Yoo-Seong; Jang, Kyungkuk; Chung, Suk-Jae; Lee, Jeeyeon; Suh, Young-Ger; Lee, Sang Kook</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114053</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most aggressive type of breast cancer, characterized by the lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  Owing to the absence of mol. targets, there are limited treatment options, and TNBC patients exhibit high mortality rates.  Signal transducer and activator of transcription 3 (STAT3) is overexpressed and aberrantly activated in TNBC cells.  Therefore, inhibition of STAT3-mediated signaling provides a potential strategy for the treatment of TNBC.  In this study, A series of synthetic derivs. of SLSI-1 (a STAT3 inhibitor) were designed and evaluated for antitumor activity in TNBC cells.  A novel deriv. (SLSI-1216) exhibited the most potent anti-proliferative activity.  SLSI-1216 effectively inhibited STAT3 activity and activation of STAT3, leading to the downregulation of AXL, a downstream target of STAT3 and epithelial-mesenchymal transition (EMT) progression.  The inhibition of EMT by SLSI-1216 was assocd. with modulation of E-cadherin and N-cadherin.  Furthermore, SLSI-1216 induced apoptosis by targeting STAT3 and effectively inhibited tumor growth in vivo.  These findings suggest that SLSI-1216, as a potential inhibitor of STAT3, may be a promising therapeutic agent for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Ghr0IzEk6rVg90H21EOLACvtfcHk0liEn238YfkVnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFSktr7I&md5=f773209f279a27b9fad0d575ac2ecaea</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2020.114053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2020.114053%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DByun%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DY.%2BT.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DJang%26aufirst%3DK.%26aulast%3DChung%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BK.%26atitle%3DA%2520novel%2520small%2520molecule%2520STAT3%2520inhibitor%2520SLSI-1216%2520suppresses%2520proliferation%2520and%2520tumor%2520growth%2520of%2520triple-negative%2520breast%2520cancer%2520cells%2520through%2520apoptotic%2520induction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D178%26spage%3D114053%26doi%3D10.1016%2Fj.bcp.2020.114053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. R.</span></span> <span> </span><span class="NLM_article-title">Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">887</span>â <span class="NLM_lpage">897</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2018.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30145375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2gtr3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=887-897&author=W.+Huangauthor=Y.+Liuauthor=J.+Wangauthor=X.+Yuanauthor=H.+W.+Jinauthor=L.+R.+Zhangauthor=J.+T.+Zhangauthor=Z.+M.+Liuauthor=J.+R.+Cui&title=Small-molecule+compounds+targeting+the+STAT3+DNA-binding+domain+suppress+survival+of+cisplatin-resistant+human+ovarian+cancer+cells+by+inducing+apoptosis&doi=10.1016%2Fj.ejmech.2018.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis</span></div><div class="casAuthors">Huang, Wei; Liu, Yuan; Wang, Jun; Yuan, Xia; Jin, Hong-Wei; Zhang, Liang-Ren; Zhang, Jian-Ting; Liu, Zhen-Ming; Cui, Jing-Rong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">887-897</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription 3 (STAT3) plays important roles in oncogenic occurrence and transformation by regulating the expression of diverse downstream target genes important for tumor growth, metastasis, angiogenesis and immune evasion.  Feasibility of targeting the DNA-binding domain (DBD) of STAT3 has been proven previously.  With the aid of 3D shape- and electrostatic-based drug design, we identified a new STAT3 inhibitor, LC28, and its five analogs, based on the pharmacophore of a known STAT3 DBD inhibitor.  Microscale thermophoresis assay shows that these compds. inhibits STAT3 binding to DNA with a Ki value of 0.74-8.87 Î¼M.  Furthermore, LC28 and its analogs suppress survival of cisplatin-resistant ovarian cancer cells by inhibiting STAT3 signaling and inducing apoptosis.  Therefore, these compds. may serve as candidate compds. for further modification and development as anticancer therapeutics targeting the DBD of human STAT3 for treatment of cisplatin-resistant ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrsNxJakSRqrVg90H21EOLACvtfcHk0liEn238YfkVnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2gtr3L&md5=43ff9b4ec08513e3b2b6196a438320ab</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DH.%2BW.%26aulast%3DZhang%26aufirst%3DL.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DZ.%2BM.%26aulast%3DCui%26aufirst%3DJ.%2BR.%26atitle%3DSmall-molecule%2520compounds%2520targeting%2520the%2520STAT3%2520DNA-binding%2520domain%2520suppress%2520survival%2520of%2520cisplatin-resistant%2520human%2520ovarian%2520cancer%2520cells%2520by%2520inducing%2520apoptosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D887%26epage%3D897%26doi%3D10.1016%2Fj.ejmech.2018.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, F.</span></span> <span> </span><span class="NLM_article-title">The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">303</span>, <span class="refDoi">Â DOI: 10.1186/s13046-018-0959-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2Fs13046-018-0959-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30518397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFais7vN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=303&author=Y.+Liuauthor=X.+Wangauthor=S.+Zengauthor=X.+Zhangauthor=J.+Zhaoauthor=X.+Zhangauthor=X.+Chenauthor=W.+Yangauthor=Y.+Yangauthor=Z.+Dongauthor=J.+Zhuauthor=X.+Xuauthor=F.+Tian&title=The+natural+polyphenol+curcumin+induces+apoptosis+by+suppressing+STAT3+signaling+in+esophageal+squamous+cell+carcinoma&doi=10.1186%2Fs13046-018-0959-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma</span></div><div class="casAuthors">Liu, Ying; Wang, Xinhua; Zeng, Shuang; Zhang, Xiane; Zhao, Jimin; Zhang, Xiaoyan; Chen, Xinhuan; Yang, Wanjing; Yang, Yili; Dong, Ziming; Zhu, Jingyu; Xu, Xin; Tian, Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">303</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: We and others have previously shown that the STAT3 signaling pathway is activated in some esophageal squamous cell carcinoma (ESCC) cells and is required for the survival and growth of these primary ESCC-derived xenografts.  It has also been shown that the natural polyphenol curcumin is an effective anti-tumor agent.  Methods: Luciferase assay and immunoblotting were performed to examine whether curcumin suppressed STAT3 signaling.  CCK-8 assay and xenografts were utilized for analyzing ESCC cell growth in culture and mice.  Soft agar assay was carried out to det. the colony formation ability of ESCC cells in the presence or absence of curcumin.  Cell death and cell cycle were assessed by In CELL Analyzer 2000.  Immunohistochem. and TUNEL assay were used for detecting apoptosis in ESCC tissues.  Mol. docking was performed to evaluate the interaction of curcumin with JAK2.  JAK2 activity was assessed using an in vitro cell-free system.  HE staining was used to evaluate the ESCC tissues.  Results: The natural polyphenol curcumin inhibited STAT3 phosphorylation rapidly and blocked STAT3-mediated signaling in ESCC cells.  It also induced growth arrest and apoptosis in cultured ESCC cells, which were attenuated by enforced expression of STAT3.  Furthermore, curcumin preferentially blocked the growth of primary ESCC-derived xenografts that harbored activated STAT3.  Conclusions: Curcumin is able to exert anti-tumor action through inhibiting the STAT3 signaling pathway.  Giving its wide use in traditional medicines with low toxicity and few adverse reactions, it is conceivable that curcumin might be further explored as a unique STAT3 inhibitor for anti-cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoohC88doUAarVg90H21EOLACvtfcHk0lgHMZRXPjik7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFais7vN&md5=404ac18a0bac9a0853038f661dbc25b8</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0959-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0959-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DTian%26aufirst%3DF.%26atitle%3DThe%2520natural%2520polyphenol%2520curcumin%2520induces%2520apoptosis%2520by%2520suppressing%2520STAT3%2520signaling%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26spage%3D303%26doi%3D10.1186%2Fs13046-018-0959-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surh, Y. J.</span></span> <span> </span><span class="NLM_article-title">Curcumin interacts directly with the cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">6409</span>, <span class="refDoi">Â DOI: 10.1038/s41598-018-23840-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41598-018-23840-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29686295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjlslykug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=6409&author=Y.+I.+Hahnauthor=S.+J.+Kimauthor=B.+Y.+Choiauthor=K.+C.+Choauthor=R.+Banduauthor=K.+P.+Kimauthor=D.+H.+Kimauthor=W.+Kimauthor=J.+S.+Parkauthor=B.+W.+Hanauthor=J.+Leeauthor=H.+K.+Naauthor=Y.+N.+Chaauthor=Y.+J.+Surh&title=Curcumin+interacts+directly+with+the+cysteine+259+residue+of+STAT3+and+induces+apoptosis+in+H-Ras+transformed+human+mammary+epithelial+cells&doi=10.1038%2Fs41598-018-23840-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Curcumin interacts directly with the Cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells</span></div><div class="casAuthors">Hahn Young-Il; Kim Su-Jung; Kim Do-Hee; Kim Wonki; Park Joon Sung; Han Byung Woo; Lee Jeewoo; Surh Young-Joon; Choi Bu-Young; Cho Kyung-Cho; Bandu Raju; Kim Kwang Pyo; Na Hye-Kyung; Cha Young-Nam</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6409</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is latent but constitutively activated in many types of cancers.  It is well known that STAT3 plays a key role in inflammation-associated tumorigenesis.  Curcumin is an anti-inflammatory natural compound isolated from the turmeric (Curcuma longa L., Zingiberaceae) that has been extensively used in a traditional medicine over the centuries.  In the present study, we have found that curcumin inhibits STAT3 signaling that is persistently overactivated in H-Ras transformed breast epithelial cells (H-Ras MCF10A).  Specific cysteine residues present in STAT3 appear to be critical for the activity as well as conformation of this transcription factor.  We identified the cysteine residue 259 of STAT3 as a putative site for curcumin binding.  Site-directed mutation of this cysteine residue abolished curcumin-induced inactivation of STAT3 and apoptosis in H-Ras MCF10A cells.  The Î±,Î²-unsaturated carbonyl moiety of curcumin appears to be essential in its binding to STAT3 in H-Ras MCF10A cells.  Tetrahydrocurcumin that lacks such electrophilic moiety failed to interact with STAT3 and to induce apoptosis in the same cell line.  Taken together, our findings suggest that curcumin can abrogate aberrant activation of STAT3 through direct interaction, thereby inhibiting STAT3-mediated mammary carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0UUuEhL3mVSM8MEzWGjS9fW6udTcc2eY5N-NQw3l0c7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjlslykug%253D%253D&md5=377518ff6836db0d821eb4abc2d43b32</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-23840-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-23840-2%26sid%3Dliteratum%253Aachs%26aulast%3DHahn%26aufirst%3DY.%2BI.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DChoi%26aufirst%3DB.%2BY.%26aulast%3DCho%26aufirst%3DK.%2BC.%26aulast%3DBandu%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BP.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DHan%26aufirst%3DB.%2BW.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DNa%26aufirst%3DH.%2BK.%26aulast%3DCha%26aufirst%3DY.%2BN.%26aulast%3DSurh%26aufirst%3DY.%2BJ.%26atitle%3DCurcumin%2520interacts%2520directly%2520with%2520the%2520cysteine%2520259%2520residue%2520of%2520STAT3%2520and%2520induces%2520apoptosis%2520in%2520H-Ras%2520transformed%2520human%2520mammary%2520epithelial%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D6409%26doi%3D10.1038%2Fs41598-018-23840-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deangelis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foust, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesinski, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">217</span>, <span class="refDoi">Â DOI: 10.1186/1476-4598-9-217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2F1476-4598-9-217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=20712901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BC3cfhtFKksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=217&author=L.+Linauthor=S.+Deangelisauthor=E.+Foustauthor=J.+Fuchsauthor=C.+Liauthor=P.+K.+Liauthor=E.+B.+Schwartzauthor=G.+B.+Lesinskiauthor=D.+Bensonauthor=J.+L%C3%BCauthor=D.+Hoytauthor=J.+Lin&title=A+novel+small+molecule+inhibits+STAT3+phosphorylation+and+DNA+binding+activity+and+exhibits+potent+growth+suppressive+activity+in+human+cancer+cells&doi=10.1186%2F1476-4598-9-217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells</span></div><div class="casAuthors">Lin Li; Deangelis Stephanie; Foust Elizabeth; Fuchs James; Li Chenglong; Li Pui-Kai; Schwartz Eric B; Lesinski Gregory B; Benson Don; Lu Jiagao; Hoyt Dale; Lin Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">217</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Targeting Signal Transducer and Activator of Transcription 3 (STAT3) signaling is an attractive therapeutic approach for most types of human cancers with constitutively activated STAT3.  A novel small molecular STAT3 inhibitor, FLLL32 was specifically designed from dietary agent, curcumin to inhibit constitutive STAT3 signaling in multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells.  RESULTS:  FLLL32 was found to be a potent inhibitor of STAT3 phosphorylation, STAT3 DNA binding activity, and the expression of STAT3 downstream target genes in vitro, leading to the inhibition of cell proliferation as well as the induction of Caspase-3 and PARP cleavages in human multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cell lines.  However, FLLL32 exhibited little inhibition on some tyrosine kinases containing SH2 or both SH2 and SH3 domains, and other protein and lipid kinases using a kinase profile assay.  FLLL32 was also more potent than four previously reported JAK2 and STAT3 inhibitors as well as curcumin to inhibit cell viability in these cancer cells.  Furthermore, FLLL32 selectively inhibited the induction of STAT3 phosphorylation by Interleukin-6 but not STAT1 phosphorylation by IFN-Î³.  CONCLUSION:  Our findings indicate that FLLL32 exhibits potent inhibitory activity to STAT3 and has potential for targeting multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells expressing constitutive STAT3 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwSSxJacyutQ20zIbnCCI3fW6udTcc2eY5N-NQw3l0c7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfhtFKksg%253D%253D&md5=60b9e2111ec36ec96625043347cc2f5e</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-9-217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-9-217%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%26aulast%3DDeangelis%26aufirst%3DS.%26aulast%3DFoust%26aufirst%3DE.%26aulast%3DFuchs%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DP.%2BK.%26aulast%3DSchwartz%26aufirst%3DE.%2BB.%26aulast%3DLesinski%26aufirst%3DG.%2BB.%26aulast%3DBenson%26aufirst%3DD.%26aulast%3DL%25C3%25BC%26aufirst%3DJ.%26aulast%3DHoyt%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DA%2520novel%2520small%2520molecule%2520inhibits%2520STAT3%2520phosphorylation%2520and%2520DNA%2520binding%2520activity%2520and%2520exhibits%2520potent%2520growth%2520suppressive%2520activity%2520in%2520human%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%26date%3D2010%26volume%3D9%26spage%3D217%26doi%3D10.1186%2F1476-4598-9-217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selvendiran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KÃ¡lai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, P.</span></span> <span> </span><span class="NLM_article-title">HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">837</span>â <span class="NLM_lpage">845</span>, <span class="refDoi">Â DOI: 10.4161/cbt.12.9.17713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.4161%2Fcbt.12.9.17713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21885917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1yis7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=837-845&author=K.+Selvendiranauthor=S.+Ahmedauthor=A.+Daytonauthor=M.+L.+Kuppusamyauthor=B.+K.+Riveraauthor=T.+K%C3%A1laiauthor=K.+Hidegauthor=P.+Kuppusamy&title=HO-3867%2C+a+curcumin+analog%2C+sensitizes+cisplatin-resistant+ovarian+carcinoma%2C+leading+to+therapeutic+synergy+through+STAT3+inhibition&doi=10.4161%2Fcbt.12.9.17713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition</span></div><div class="casAuthors">Selvendiran, Karuppaiyah; Ahmed, Shabnam; Dayton, Alex; Kuppusamy, M. Lakshmi; Rivera, Brian K.; Kalai, Tamas; Hideg, Kalman; Kuppusamy, Periannan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">837-845</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Cisplatin resistance is a major obstacle in the treatment of ovarian cancer.  Drug combinations with synergistic or complementary functions are a promising strategy to overcome this issue.  We studied the anticancer efficacy of a novel compd., HO-3867, used in combination with cisplatin against chemotherapy-resistant ovarian cancer.  A2780R cells, a cisplatin-resistant human ovarian cancer cell line, were exposed to 1, 5 or 10 Î¼M of HO-3867 alone or in combination with cisplatin (10 Î¼g/mL) for 24 h.  Cell viability (MTT), proliferation (BrdU), cell cycle anal. (FACS), and protein expression (protein gel blot) were used for in vitro studies.  STAT3 overexpression was performed using transfected STAT3 cDNA.  In vivo studies used cisplatin-resistant xenograft tumors grown in nude mice and treated with 100-ppm HO-3867 and weekly injections of 4-mg/kg cisplatin.  HO-3867/cisplatin combination treatment significantly inhibited cisplatin-resistant cell proliferation in a concn.-dependent manner.  The inhibition was assocd. with increased expression of p53 and p21, and decreased expression of cdk5 and cyclin D1.  Apoptosis was induced by activation of Bax, cytochrome c release, and stimulated cleavage of caspase-9, caspase-3 and PARP.  Overexpression of STAT3 decreased the HO-3867-induced apoptosis.  The combination treatment significantly inhibited the growth of cisplatin-resistant xenograft tumors with significant downregulation of pSTAT3, and without apparent toxicity to healthy tissues.  The combination treatment exhibited synergistic anticancer efficacy, which appears largely due to HO-3867-induced downregulation of pSTAT3.  The results, combined with the previously-reported safety features of HO-3867, suggest the potential use of this compd. as a safe and effective adjuvant for the treatment of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5WXOMmWUHX7Vg90H21EOLACvtfcHk0li6y6EpKggI7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1yis7w%253D&md5=d20e2e40544163211fa3adadeccb8b26</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.4161%2Fcbt.12.9.17713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.12.9.17713%26sid%3Dliteratum%253Aachs%26aulast%3DSelvendiran%26aufirst%3DK.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DDayton%26aufirst%3DA.%26aulast%3DKuppusamy%26aufirst%3DM.%2BL.%26aulast%3DRivera%26aufirst%3DB.%2BK.%26aulast%3DK%25C3%25A1lai%26aufirst%3DT.%26aulast%3DHideg%26aufirst%3DK.%26aulast%3DKuppusamy%26aufirst%3DP.%26atitle%3DHO-3867%252C%2520a%2520curcumin%2520analog%252C%2520sensitizes%2520cisplatin-resistant%2520ovarian%2520carcinoma%252C%2520leading%2520to%2520therapeutic%2520synergy%2520through%2520STAT3%2520inhibition%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2011%26volume%3D12%26spage%3D837%26epage%3D845%26doi%3D10.4161%2Fcbt.12.9.17713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, C.</span></span> <span> </span><span class="NLM_article-title">4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6174</span>â <span class="NLM_lpage">6182</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.09.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmc.2016.09.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27816267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslyjtL7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6174-6182&author=P.+Jiauthor=C.+Yuanauthor=S.+Maauthor=J.+Fanauthor=W.+Fuauthor=C.+Qiao&title=4-Carbonyl-2%2C6-dibenzylidenecyclohexanone+derivatives+as+small+molecule+inhibitors+of+STAT3+signaling+pathway&doi=10.1016%2Fj.bmc.2016.09.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway</span></div><div class="casAuthors">Ji, Peng; Yuan, Congmin; Ma, Shuhua; Fan, Junchao; Fu, Wei; Qiao, Chunhua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6174-6182</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of STAT3 signaling pathway is proposed to be a promising strategy for cancer treatment.  In this study, a series of 4-carbonyl-2,6-dibenzylidenecyclohexanone derivs. were prepd. and evaluated as anticancer agents.  The most potent compd. 13r was discovered to exhibit antiproliferative activity against a broad rang of cancer cell lines and relatively low cytotoxicity against normal human cells.  Besides, 13r effectively suppressed STAT3 expression as well as phosphorylation, and surface plasmon resonance anal. confirmed the direct interaction of 13r with STAT3.  Docking simulation showed that 13r could inhibit STAT3 by targeting SH2 domain.  This study provided evidence for these compds. to be further developed as antitumor agents through inhibition of the STAT3 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZXB3I3C-fnrVg90H21EOLACvtfcHk0li6y6EpKggI7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslyjtL7M&md5=fe7960d11bd9d9067eea8dc9c5fc70b5</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.09.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.09.070%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DQiao%26aufirst%3DC.%26atitle%3D4-Carbonyl-2%252C6-dibenzylidenecyclohexanone%2520derivatives%2520as%2520small%2520molecule%2520inhibitors%2520of%2520STAT3%2520signaling%2520pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6174%26epage%3D6182%26doi%3D10.1016%2Fj.bmc.2016.09.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de CÃ¡ssia
da Silveira e SÃ¡, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Sousa, D. P.</span></span> <span> </span><span class="NLM_article-title">A review on anti-inflammatory activity of monoterpenes</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1227</span>â <span class="NLM_lpage">1254</span>, <span class="refDoi">Â DOI: 10.3390/molecules18011227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fmolecules18011227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23334570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeqsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1227-1254&author=R.+de+C%C3%A1ssia%0Ada+Silveira+e+S%C3%A1author=L.+N.+Andradeauthor=D.+P.+de+Sousa&title=A+review+on+anti-inflammatory+activity+of+monoterpenes&doi=10.3390%2Fmolecules18011227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A review on anti-inflammatory activity of monoterpenes</span></div><div class="casAuthors">de Cassia da Silveira e Sa, Rita; Andrade, Luciana Nalone; Pergentino de Sousa, Damiao</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1227-1254</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Faced with the need to find new anti-inflammatory agents, great effort has been expended on the development of drugs for the treatment of inflammation.  This disorder reduces the quality of life and overall av. productivity, causing huge financial losses.  In this review the anti-inflammatory activity of 32 bioactive monoterpenes found in essential oils is discussed.  The data demonstrate the pharmacol. potential of this group of natural chems. to act as anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIVVrVOYekALVg90H21EOLACvtfcHk0li6y6EpKggI7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeqsbg%253D&md5=f1dca4ad0ec041c4b0c9353245367b52</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.3390%2Fmolecules18011227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules18011227%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BC%25C3%25A1ssia%2Bda%2BSilveira%2Be%2BS%25C3%25A1%26aufirst%3DR.%26aulast%3DAndrade%26aufirst%3DL.%2BN.%26aulast%3Dde%2BSousa%26aufirst%3DD.%2BP.%26atitle%3DA%2520review%2520on%2520anti-inflammatory%2520activity%2520of%2520monoterpenes%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26spage%3D1227%26epage%3D1254%26doi%3D10.3390%2Fmolecules18011227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paduch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandefer-SzerszeÅ, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trytek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedurek, J.</span></span> <span> </span><span class="NLM_article-title">Terpenes: substances useful in human healthcare</span>. <i>Arch. Immunol. Ther. Exp.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">327</span>, <span class="refDoi">Â DOI: 10.1007/s00005-007-0039-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1007%2Fs00005-007-0039-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=18219762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGqsLzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2007&pages=315-327&author=R.+Paduchauthor=M.+Kandefer-Szersze%C5%84author=M.+Trytekauthor=J.+Fiedurek&title=Terpenes%3A+substances+useful+in+human+healthcare&doi=10.1007%2Fs00005-007-0039-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Terpenes: substances useful in human healthcare</span></div><div class="casAuthors">Paduch, Roman; Kandefer-Szerzen, Martyna; Trytek, Mariusz; Fiedurek, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Archivum Immunologiae et Therapiae Experimentalis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-327</span>CODEN:
                <span class="NLM_cas:coden">AITEAT</span>;
        ISSN:<span class="NLM_cas:issn">0004-069X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Terpenes are naturally occurring substances produced by a wide variety of plants and animals.  A broad range of the biol. properties of terpenoids is described, including cancer chemopreventive effects, antimicrobial, antifungal, antiviral, anti-hyperglycemic, anti-inflammatory, and antiparasitic activities.  Terpenes are also presented as skin penetration enhancers and agents involved in the prevention and therapy of several inflammatory diseases.  Moreover, a potential mechanism of their action against pathogens and their influence on skin permeability are discussed.  The major conclusion is that larger-scale use of terpenoids in modern medicine should be taken into consideration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPWXrsN016JbVg90H21EOLACvtfcHk0lhSFHZqBIpP8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGqsLzM&md5=15f8d9199ac8af186c17a627cd593e24</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1007%2Fs00005-007-0039-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00005-007-0039-1%26sid%3Dliteratum%253Aachs%26aulast%3DPaduch%26aufirst%3DR.%26aulast%3DKandefer-Szersze%25C5%2584%26aufirst%3DM.%26aulast%3DTrytek%26aufirst%3DM.%26aulast%3DFiedurek%26aufirst%3DJ.%26atitle%3DTerpenes%253A%2520substances%2520useful%2520in%2520human%2520healthcare%26jtitle%3DArch.%2520Immunol.%2520Ther.%2520Exp.%26date%3D2007%26volume%3D55%26spage%3D315%26epage%3D327%26doi%3D10.1007%2Fs00005-007-0039-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xirou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syrigos, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, J. C.</span></span> <span> </span><span class="NLM_article-title">Targeting colon cancer with the novel STAT3 inhibitor bruceantinol</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1676</span>â <span class="NLM_lpage">1687</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0547-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41388-018-0547-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30348989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFynsbrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=1676-1687&author=N.+Weiauthor=J.+Liauthor=C.+Fangauthor=J.+Changauthor=V.+Xirouauthor=N.+K.+Syrigosauthor=B.+J.+Marksauthor=E.+Chuauthor=J.+C.+Schmitz&title=Targeting+colon+cancer+with+the+novel+STAT3+inhibitor+bruceantinol&doi=10.1038%2Fs41388-018-0547-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting colon cancer with the novel STAT3 inhibitor bruceantinol</span></div><div class="casAuthors">Wei, Ning; Li, Jun; Fang, Cheng; Chang, Jin; Xirou, Vasiliki; Syrigos, Nick K.; Marks, Benjamin J.; Chu, Edward; Schmitz, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1676-1687</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">STAT3, a transcriptional mediator of oncogenic signaling, is constitutively active in â¼70% of human cancers.  The development of STAT3 inhibitors remains an active area of research as no inhibitors have yet to be approved for the treatment of human cancer.  Herein, we revealed that bruceantinol (BOL) is a novel STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models.  BOL strongly inhibited STAT3 DNA-binding ability (IC50 = 2.4 pM), blocked the constitutive and IL-6-induced STAT3 activation in a dose- and time-dependent manner, and suppressed transcription of STAT3 target genes encoding anti-apoptosis factors (MCL-1, PTTG1, and survivin) and cell-cycle regulators (c-Myc).  Structure-activity relationship studies demonstrated that the C15 side chain on BOL affected its ability to bind STAT3.  Administration of 4 mg/kg BOL significantly inhibited CRC tumor xenografts [p < 0.001], but no effect was obsd. in a STAT3-/- tumor model.  Addnl. studies showed that BOL effectively sensitized MEK inhibitors through repression of p-STAT3 and MCL-1 induction, known resistance mechanisms of MEK inhibition.  Taken together, our findings suggest BOL is a novel therapeutic STAT3 inhibitor that can be used either alone or in combination with MEK inhibitors for the treatment of human CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoszhsdy_chYLVg90H21EOLACvtfcHk0lhSFHZqBIpP8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFynsbrP&md5=401a8a656f44cde28fdb629f765ce53a</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0547-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0547-y%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DXirou%26aufirst%3DV.%26aulast%3DSyrigos%26aufirst%3DN.%2BK.%26aulast%3DMarks%26aufirst%3DB.%2BJ.%26aulast%3DChu%26aufirst%3DE.%26aulast%3DSchmitz%26aufirst%3DJ.%2BC.%26atitle%3DTargeting%2520colon%2520cancer%2520with%2520the%2520novel%2520STAT3%2520inhibitor%2520bruceantinol%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D1676%26epage%3D1687%26doi%3D10.1038%2Fs41388-018-0547-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mantaj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokshi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span> <span> </span><span class="NLM_article-title">Crispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3882</span>â <span class="NLM_lpage">3886</span>, <span class="refDoi">Â DOI: 10.1039/C5OB00052A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1039%2FC5OB00052A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25721973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislKitb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=3882-3886&author=J.+Mantajauthor=S.+M.+Rahmanauthor=B.+Bokshiauthor=C.+M.+Hasanauthor=P.+J.+Jacksonauthor=R.+B.+Parsonsauthor=K.+M.+Rahman&title=Crispene+E%2C+a+cis-clerodane+diterpene+inhibits+STAT3+dimerization+in+breast+cancer+cells&doi=10.1039%2FC5OB00052A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Crispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells</span></div><div class="casAuthors">Mantaj, Julia; Rahman, S. M. Abdur; Bokshi, Bishwajit; Hasan, Choudhury M.; Jackson, Paul J. M.; Parsons, Richard B.; Rahman, Khondaker M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3882-3886</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Crispene E, a new clerodane-type diterpene, inhibited STAT3 dimerization in a cell-free fluorescent polarisation assay and was found to have significant toxicity against STAT3-dependent MDA-MB 231 breast cancer cell line and selectively inhibited the expression of STAT3 and STAT3 target genes cyclin D1, Fascin and bcl-2.  Mol. docking studies suggest the mol. inhibits STAT3 by interacting with its SH2 domain.  The compd. has been isolated from Tinospora crispa and characterized using std. spectroscopic techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCsmkKjAMloLVg90H21EOLACvtfcHk0lhSFHZqBIpP8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislKitb0%253D&md5=258515b089974bb55fa2eb5238d684f6</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1039%2FC5OB00052A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB00052A%26sid%3Dliteratum%253Aachs%26aulast%3DMantaj%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DS.%2BM.%26aulast%3DBokshi%26aufirst%3DB.%26aulast%3DHasan%26aufirst%3DC.%2BM.%26aulast%3DJackson%26aufirst%3DP.%2BJ.%26aulast%3DParsons%26aufirst%3DR.%2BB.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26atitle%3DCrispene%2520E%252C%2520a%2520cis-clerodane%2520diterpene%2520inhibits%2520STAT3%2520dimerization%2520in%2520breast%2520cancer%2520cells%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2015%26volume%3D13%26spage%3D3882%26epage%3D3886%26doi%3D10.1039%2FC5OB00052A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noman, M. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahsan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span> <span> </span><span class="NLM_article-title">Crispenes F and G, cis-Clerodane furanoditerpenoids from tinospora crispa, inhibit STAT3 dimerization</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1021/acs.jnatprod.7b00377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.7b00377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyisr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=236-242&author=M.+A.+A.+Nomanauthor=T.+Hossainauthor=M.+Ahsanauthor=S.+Jamshidiauthor=C.+M.+Hasanauthor=K.+M.+Rahman&title=Crispenes+F+and+G%2C+cis-Clerodane+furanoditerpenoids+from+tinospora+crispa%2C+inhibit+STAT3+dimerization&doi=10.1021%2Facs.jnatprod.7b00377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Crispenes F and G, cis-clerodane furanoditerpenoids from Tinospora crispa, inhibit STAT3 dimerization</span></div><div class="casAuthors">Noman, Md. Abdullah Al; Hossain, Tasnova; Ahsan, Monira; Jamshidi, Shirin; Hasan, Choudhury Mahmood; Rahman, Khondaker Miraz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-242</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Two new cis-clerodane-type furanoditerpenes, crispenes F and G (1 and 2), together with 7 known compds., were isolated from the stems of T. crispa.  Compds. 1 and 2 inhibited STAT3 dimerization in a cell-free fluorescent polarization assay and were found to have significant cytotoxicity against a STAT3-dependent MDA-MB 231 breast cancer cell line, while being inactive in a STAT3-null A4 cell line.  These 2 compds. shared structural similarities with a previously reported STAT3 inhibitor, crispene E, isolated from the same plant.  Mol. docking studies suggested that the mols. inhibited STAT3 by interacting with its SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLHE05X1gE77Vg90H21EOLACvtfcHk0lgPOelckVAqqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyisr4%253D&md5=6c11119d48239d190f1db9629b4401b8</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.7b00377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.7b00377%26sid%3Dliteratum%253Aachs%26aulast%3DNoman%26aufirst%3DM.%2BA.%2BA.%26aulast%3DHossain%26aufirst%3DT.%26aulast%3DAhsan%26aufirst%3DM.%26aulast%3DJamshidi%26aufirst%3DS.%26aulast%3DHasan%26aufirst%3DC.%2BM.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26atitle%3DCrispenes%2520F%2520and%2520G%252C%2520cis-Clerodane%2520furanoditerpenoids%2520from%2520tinospora%2520crispa%252C%2520inhibit%2520STAT3%2520dimerization%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2018%26volume%3D81%26spage%3D236%26epage%3D242%26doi%3D10.1021%2Facs.jnatprod.7b00377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Don-Doncow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KjellstrÃ¶m, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjartell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellsten, R.</span></span> <span> </span><span class="NLM_article-title">Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">15969</span>â <span class="NLM_lpage">15978</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M114.564252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.M114.564252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24755219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2qsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=15969-15978&author=N.+Don-Doncowauthor=Z.+Escobarauthor=M.+Johanssonauthor=S.+Kjellstr%C3%B6mauthor=V.+Garciaauthor=E.+Munozauthor=O.+Sternerauthor=A.+Bjartellauthor=R.+Hellsten&title=Galiellalactone+is+a+direct+inhibitor+of+the+transcription+factor+STAT3+in+prostate+cancer+cells&doi=10.1074%2Fjbc.M114.564252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Galiellalactone25 Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells</span></div><div class="casAuthors">Don-Doncow, Nicholas; Escobar, Zilma; Johansson, Martin; Kjellstroem, Sven; Garcia, Victor; Munoz, Eduardo; Sterner, Olov; Bjartell, Anders; Hellsten, Rebecka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">15969-15978</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is constitutively active in several malignancies including castration-resistant prostate cancer and has been identified as a promising therapeutic target.  The fungal metabolite galiellalactone, a STAT3 signaling inhibitor, inhibits the growth, both in vitro and in vivo, of prostate cancer cells expressing active STAT3 and induces apoptosis of prostate cancer stem cell-like cells expressing phosphorylated STAT3 (pSTAT3).  However, the mol. mechanism of this STAT3-inhibiting effect by galiellalactone has not been clarified.  A biotinylated analog of galiellalactone (GL-biot) was synthesized to be used for identification of galiellalactone target proteins.  By adding streptavidin-Sepharose beads to GL-biot-treated DU145 cell lyzates, STAT3 was isolated and identified as a target protein.  Confocal microscopy revealed GL-biot in both the cytoplasm and the nucleus of DU145 cells treated with GL-biot, appearing to co-localize with STAT3 in the nucleus.  Galiellalactone inhibited STAT3 binding to DNA in DU145 cell lyzates without affecting phosphorylation status of STAT3.  Mass spectrometry anal. of recombinant STAT3 protein pretreated with galiellalactone revealed three modified cysteines (Cys-367, Cys-468, and Cys-542).  Here we demonstrate with chem. and mol. pharmacol. methods that galiellalactone is a cysteine reactive inhibitor that covalently binds to one or more cysteines in STAT3 and that this leads to inhibition of STAT3 binding to DNA and thus blocks STAT3 signaling without affecting phosphorylation.  This further validates galiellalactone as a promising direct STAT3 inhibitor for treatment of castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3avlluHh2P7Vg90H21EOLACvtfcHk0lgPOelckVAqqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2qsL4%253D&md5=44961890281d144bd6f9283999c34aa1</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.564252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.564252%26sid%3Dliteratum%253Aachs%26aulast%3DDon-Doncow%26aufirst%3DN.%26aulast%3DEscobar%26aufirst%3DZ.%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DKjellstr%25C3%25B6m%26aufirst%3DS.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DMunoz%26aufirst%3DE.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DBjartell%26aufirst%3DA.%26aulast%3DHellsten%26aufirst%3DR.%26atitle%3DGaliellalactone%2520is%2520a%2520direct%2520inhibitor%2520of%2520the%2520transcription%2520factor%2520STAT3%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D15969%26epage%3D15978%26doi%3D10.1074%2Fjbc.M114.564252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span> <span> </span><span class="NLM_article-title">Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5032</span>â <span class="NLM_lpage">5040</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmc.2017.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28705432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtbbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5032-5040&author=H.+S.+Kimauthor=T.+Kimauthor=H.+Koauthor=J.+Leeauthor=Y.+S.+Kimauthor=Y.+G.+Suh&title=Identification+of+galiellalactone-based+novel+STAT3-selective+inhibitors+with+cytotoxic+activities+against+triple-negative+breast+cancer+cell+lines&doi=10.1016%2Fj.bmc.2017.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines</span></div><div class="casAuthors">Kim, Hyun Su; Kim, Taewoo; Ko, Hyejin; Lee, Jeeyeon; Kim, Yeong Shik; Suh, Young-Ger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5032-5040</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is phosphorylated in breast cancer cells, particularly triple-neg. breast cancers (TNBCs).  Therefore, the inhibition of constitutive phosphorylated STAT3 is a promising therapeutic for TNBC treatment.  Recently, a series of novel STAT3 inhibitors based on natural (-)-galiellalactone have been identified to inhibit STAT3 phosphorylation at the Tyr705 residue.  Interestingly, the truncation of the cyclohexene moiety of (-)-galiellalactone to [3.3] bicyclic lactone as a pharmacophoric core produced improved cytotoxic effects against TNBCs.  The potent analogs 16 and 17, identified from a STAT3-mediated luciferase reporter assay, selectively inhibited the STAT3 signaling pathway without affecting STAT1 or STAT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBskRR7L612rVg90H21EOLACvtfcHk0lgPOelckVAqqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtbbE&md5=ddb78941b45c15c1a33bd7e6ded6269b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26atitle%3DIdentification%2520of%2520galiellalactone-based%2520novel%2520STAT3-selective%2520inhibitors%2520with%2520cytotoxic%2520activities%2520against%2520triple-negative%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D5032%26epage%3D5040%26doi%3D10.1016%2Fj.bmc.2017.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnihotri, V. K.</span></span> <span> </span><span class="NLM_article-title">UPLC/MS/MS method for quantification and cytotoxic activity of sesquiterpene lactones isolated from Saussurea lappa</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">1393</span>â <span class="NLM_lpage">1397</span>, <span class="refDoi">Â DOI: 10.1016/j.jep.2014.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.jep.2014.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=25068579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCltLjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2014&pages=1393-1397&author=A.+Kumarauthor=S.+Kumarauthor=D.+Kumarauthor=V.+K.+Agnihotri&title=UPLC%2FMS%2FMS+method+for+quantification+and+cytotoxic+activity+of+sesquiterpene+lactones+isolated+from+Saussurea+lappa&doi=10.1016%2Fj.jep.2014.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">UPLC/MS/MS method for quantification and cytotoxic activity of sesquiterpene lactones isolated from Saussurea lappa</span></div><div class="casAuthors">Kumar, Ashish; Kumar, Shiv; Kumar, Dharmesh; Agnihotri, Vijai K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1393-1397</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Saussurea lappa (Asteraceae) roots have been reputed for the usage in traditional medicinal systems of India, China and Japan for the treatment of various kinds of disorders such as anti-ulcer, anti-convulsant, anti-cancer, hepatoprotective, anti-arthritic and anti-viral activities.Compds. were isolated using a column chromatog. technique.  The root ext., fractions and isolated compds. were tested for cytotoxicity against A549 (human lung carcinoma) and C-6 (rat glioma) cells using the Sulforhodamine B assay.  Chromatog. sepns. of active sesquiterpene lactones were accomplished on BEH-HSS-T3 column at 25 Â°C.Phytochem. investigation of Saussurea lappa root ext. resulted in the isolation of isoalantolactone (1), Î²-cyclocostunolide (2) Î±-cyclocostunolide (3), 4-hydroxy-3,5-dimethoxycinnamyl-9-O-Î²-D-glucopyranoside (4), sucrose (5), and alantolactone (6).  Their structures were detd. by spectroscopic means.  Ethanolic ext., chloroform fraction, compds. 1, 2, 3 and 6 possessed significant activity against both tested cells.  The quantification was performed using the transitions of m/z 233/105 for isoalantolactone and m/z 233/105 for alantolactone resp.  Costunolide and dehydrocostus lactone were also characterised by comparison of MS/MS fragmentation pattern.This is the first study on simultaneous quantification of isoalantolactone and alantolactone by the UPLC/MS/MS method in Saussurea lappa.  Our study against A549 and C-6 cells showed higher cytotoxicity.  It is suggested that roots of Saussurea lappa might be a potential source of anticancer compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqLcUpIkdzGrVg90H21EOLACvtfcHk0liqPllCoegtMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCltLjL&md5=4fb8b9e6afbc87fa21244996c9e0e78e</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2014.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2014.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DAgnihotri%26aufirst%3DV.%2BK.%26atitle%3DUPLC%252FMS%252FMS%2520method%2520for%2520quantification%2520and%2520cytotoxic%2520activity%2520of%2520sesquiterpene%2520lactones%2520isolated%2520from%2520Saussurea%2520lappa%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2014%26volume%3D155%26spage%3D1393%26epage%3D1397%26doi%3D10.1016%2Fj.jep.2014.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span> <span> </span><span class="NLM_article-title">Isoalantolactone induces apoptosis through reactive oxygen species-dependent upregulation of death receptor 5 in human esophageal cancer cells</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.1016/j.taap.2018.05.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.taap.2018.05.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=29800641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVaisL3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2018&pages=46-58&author=Z.+Luauthor=G.+Zhangauthor=Y.+Zhangauthor=P.+Huaauthor=M.+Fangauthor=M.+Wuauthor=T.+Liu&title=Isoalantolactone+induces+apoptosis+through+reactive+oxygen+species-dependent+upregulation+of+death+receptor+5+in+human+esophageal+cancer+cells&doi=10.1016%2Fj.taap.2018.05.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Isoalantolactone induces apoptosis through reactive oxygen species-dependent upregulation of death receptor 5 in human esophageal cancer cells</span></div><div class="casAuthors">Lu, Zhengyang; Zhang, Guangxin; Zhang, Yifan; Hua, Peiyan; Fang, Meidan; Wu, Meiliang; Liu, Tongjun</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Esophageal cancer is the eighth most prevalent cancer and has high mortality in our society.  Isoalantolactone, extd. from Inula helenium L, has shown potent anticancer effects on a variety of cancers.  However, its effect on human esophageal cancer, and the underlying mol. mechanism, remain to be investigated.  In the present study, we demonstrated that isoalantolactone induced apoptosis in esophageal cancer cells.  Treatment with isoalantolactone activated caspases-3, -7, and -10, and upregulated death receptor (DR)5.  Furthermore, DR5 knockdown partially reversed the effect of isoalantolactone.  These results indicated the extrinsic apoptosis was induced by isoalantolactone.  In addn., intracellular reactive oxygen species (ROS) were significantly elevated after treatment with isoalantolactone.  N-Acetylcysteine, an ROS scavenger, blocked both the apoptosis and decreased cell viability caused by isoalantolactone.  In vivo, significant suppression of tumor growth by isoalantolactone was obsd. in an ECA109 cell xenograft mouse model.  Isoalantolactone showed no obvious adverse effects on mouse wt. and histol. of heart, liver, spleen, lung, and kidney.  In conclusion, our results revealed that isoalantolactone induced apoptosis through the extrinsic pathway via upregulation of DR5 and elevation of ROS in human esophageal cancer cells.  Isoalantolactone, therefore, could be a potential candidate in developing anticancer agents for esophageal cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXFinuSqIDUrVg90H21EOLACvtfcHk0liqPllCoegtMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVaisL3K&md5=c94d07defa456093b4686b4e899fe554</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2018.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2018.05.026%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHua%26aufirst%3DP.%26aulast%3DFang%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26atitle%3DIsoalantolactone%2520induces%2520apoptosis%2520through%2520reactive%2520oxygen%2520species-dependent%2520upregulation%2520of%2520death%2520receptor%25205%2520in%2520human%2520esophageal%2520cancer%2520cells%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2018%26volume%3D352%26spage%3D46%26epage%3D58%26doi%3D10.1016%2Fj.taap.2018.05.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Isoalantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">309</span>, <span class="refDoi">Â DOI: 10.1186/s13046-018-0987-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1186%2Fs13046-018-0987-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30541589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaisL7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=309&author=W.+Chenauthor=P.+Liauthor=Y.+Liuauthor=Y.+Yangauthor=X.+Yeauthor=F.+Zhangauthor=H.+Huang&title=Isoalantolactone+induces+apoptosis+through+ROS-mediated+ER+stress+and+inhibition+of+STAT3+in+prostate+cancer+cells&doi=10.1186%2Fs13046-018-0987-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Isoalantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells</span></div><div class="casAuthors">Chen, Wei; Li, Ping; Liu, Yi; Yang, Yu; Ye, Xueting; Zhang, Fangyi; Huang, Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">309</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Prostate cancer is one of the most commonly diagnosed cancers in men worldwide.  Currently available therapies for metastatic prostate cancer are only marginally effective.  Therefore, new therapeutic agents are urgently needed to improve patient outcome.  Isoalantolactone (IATL), an active sesquiterpene naturally present in many vegetables and medicinal plants, is known to induce cell death and apoptosis in various cancer cell lines.  Nevertheless, antitumor mechanisms initiated by IATL in cancer cells have not been fully defined.  Cell apoptosis and cellular ROS levels were analyzed by flow cytometry.  Western blot and qRT-PCR were used to analyze the protein and mRNA levels of indicated mols., resp.  Nude mice xenograft model was used to test the effects of IATL on prostate cancer cell growth in vivo.  In this study, we found that IATL dose-dependently inhibited cancer cell growth and induced apoptosis in PC-3 and DU145 cells.  Mechanistically, our data found that IATL induced reactive oxygen species (ROS) prodn., resulting in the activation of endoplasmic reticulum stress pathway and eventually cell apoptosis in prostate cancer cells.  IATL also decreased the protein expression levels of p-STAT3 and STAT3, and the effects of IATL were reversed by pretreatment with N-acetyl-L-cysteine (NAC).  In vivo, we found that IATL inhibited the growth of prostate cancer xenografts without exhibiting toxicity.  Treatment of mice bearing human prostate cancer xenografts with IATL was also assocd. with induction of ER stress and inhibtion of STAT3.  In summary, our results unveil a previously unrecognized mechanism underlying the biol. activity of IATL, and provide a novel anti-cancer candidate for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8v5bRq7s8Y7Vg90H21EOLACvtfcHk0liqPllCoegtMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaisL7N&md5=44235d11eeac774f52ea531a3b3fbc86</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0987-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0987-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DIsoalantolactone%2520induces%2520apoptosis%2520through%2520ROS-mediated%2520ER%2520stress%2520and%2520inhibition%2520of%2520STAT3%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26spage%3D309%26doi%3D10.1186%2Fs13046-018-0987-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjartell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canesin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans-Axelsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellsten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, M. H.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of 3Î²-(N-Acetyl l-cysteine methyl ester)-2aÎ²,3-dihydrogaliellalactone (GPA512), a prodrug of a direct STAT3 inhibitor for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4551</span>â <span class="NLM_lpage">4562</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01814</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01814" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Gqu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4551-4562&author=Z.+Escobarauthor=A.+Bjartellauthor=G.+Canesinauthor=S.+Evans-Axelssonauthor=O.+Sternerauthor=R.+Hellstenauthor=M.+H.+Johansson&title=Preclinical+characterization+of+3%CE%B2-%28N-Acetyl+l-cysteine+methyl+ester%29-2a%CE%B2%2C3-dihydrogaliellalactone+%28GPA512%29%2C+a+prodrug+of+a+direct+STAT3+inhibitor+for+the+treatment+of+prostate+cancer&doi=10.1021%2Facs.jmedchem.5b01814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Characterization of 3Î²-(N-Acetyl L-cysteine methyl ester)-2aÎ²,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer</span></div><div class="casAuthors">Escobar, Zilma; Bjartell, Anders; Canesin, Giacomo; Evans-Axelsson, Susan; Sterner, Olov; Hellsten, Rebecka; Johansson, Martin H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4551-4562</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The transcription factor STAT3 is a potential target for the treatment of castration-resistant prostate cancer.  Galiellalactone (1), a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes.  In this study we characterized 6, a prodrug of 1.  In vitro studies showed that 6 is rapidly converted to 1 in plasma and is stable in a buffer soln.  The pharmacokinetics of 6 following a single oral dose indicated that the prodrug was rapidly absorbed and converted to 1 with a tmax of 15 min.  Oral administration of 6 in mice increased the plasma exposure of the active parent compd. 20-fold compared to when 1 was dosed orally. 6 treated mice bearing DU145 xenograft tumors had significantly reduced tumor growth compared to untreated mice.  The favorable druglike properties and safety profile of 6 warrant further studies of 6 for the treatment of castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ-05xP9iOM7Vg90H21EOLACvtfcHk0livlHElsxWcNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Gqu7g%253D&md5=1ed1bfdda22e882cbcdad28162d9c719</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01814%26sid%3Dliteratum%253Aachs%26aulast%3DEscobar%26aufirst%3DZ.%26aulast%3DBjartell%26aufirst%3DA.%26aulast%3DCanesin%26aufirst%3DG.%26aulast%3DEvans-Axelsson%26aufirst%3DS.%26aulast%3DSterner%26aufirst%3DO.%26aulast%3DHellsten%26aufirst%3DR.%26aulast%3DJohansson%26aufirst%3DM.%2BH.%26atitle%3DPreclinical%2520characterization%2520of%25203%25CE%25B2-%2528N-Acetyl%2520l-cysteine%2520methyl%2520ester%2529-2a%25CE%25B2%252C3-dihydrogaliellalactone%2520%2528GPA512%2529%252C%2520a%2520prodrug%2520of%2520a%2520direct%2520STAT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4551%26epage%3D4562%26doi%3D10.1021%2Facs.jmedchem.5b01814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, D.</span></span> <span> </span><span class="NLM_article-title">A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">17471</span>â <span class="NLM_lpage">17486</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA119.009801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1074%2Fjbc.RA119.009801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31594861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKlurnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=17471-17486&author=X.+Shenauthor=L.+Zhaoauthor=P.+Chenauthor=Y.+Gongauthor=D.+Liuauthor=X.+Zhangauthor=L.+Daiauthor=Q.+Sunauthor=J.+Louauthor=Z.+Jinauthor=B.+Zhangauthor=D.+Niuauthor=C.+Chenauthor=X.+Qiauthor=D.+Jia&title=A+thiazole-derived+oridonin+analogue+exhibits+antitumor+activity+by+directly+and+allosterically+inhibiting+STAT3&doi=10.1074%2Fjbc.RA119.009801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3</span></div><div class="casAuthors">Shen, Xiaofei; Zhao, Lin; Che, Peihao; Gong, Yanqiu; Liu, Dingdong; Zhang, Xia; Dai, Lunzhi; Sun, Qingxiang; Lo, Jizhong; Jin, Zhong; Zhang, Baohua; Niu, Dawen; Chen, Ceshi; Qi, Xiangbing; Jia, Da</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">17471-17487</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription 3 (STAT3) occurs in â¼70% of human cancers, and STAT3 is regarded as one of the most promising targets for cancer therapy.  However, specific direct STAT3 inhibitors remain to be developed.  Oridonin is an ent-kaurane plant-derived diterpenoid with anti-cancer and anti-inflammatory activities.  Here, using an array of cell-based and biochem. approaches, including cell proliferation and apoptosis assays, pulldown and reporter gene assays, site-directed mutagenesis, and mol. dynamics analyses, we report that a thiazole-derived oridonin analog, CYD0618, potently and directly inhibits STAT3.  We found that CYD0618 covalently binds to Cys-542 in STAT3 and suppresses its activity through an allosteric effect, effectively reducing STAT3 dimerization and nuclear translocation, as well as decreasing expression of STAT3-targeted oncogenes.  Remarkably, CYD0618 not only strongly inhibited growth of multiple cancer cell lines that harbor constitutive STAT3 activation, but it also suppressed in vivo tumor growth via STAT3 inhibition.  Taken together, our findings suggest Cys-542 as a druggable site for selectively inhibiting STAT3 and indicate that CYD0618 represents a promising lead compd. for developing therapeutic agents against STAT3-driven diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3b-VA4Ju-n7Vg90H21EOLACvtfcHk0livlHElsxWcNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKlurnF&md5=0a0d85ef0cedb9ef3b4dc73449d0bb22</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.009801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.009801%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DLou%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DD.%26atitle%3DA%2520thiazole-derived%2520oridonin%2520analogue%2520exhibits%2520antitumor%2520activity%2520by%2520directly%2520and%2520allosterically%2520inhibiting%2520STAT3%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D17471%26epage%3D17486%26doi%3D10.1074%2Fjbc.RA119.009801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5048</span>â <span class="NLM_lpage">5058</span>, <span class="refDoi">Â DOI: 10.1021/jm400367n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400367n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVeqtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5048-5058&author=C.+Dingauthor=Y.+Zhangauthor=H.+Chenauthor=Z.+Yangauthor=C.+Wildauthor=L.+Chuauthor=H.+Liuauthor=Q.+Shenauthor=J.+Zhou&title=Novel+nitrogen-enriched+oridonin+analogues+with+thiazole-fused+A-ring%3A+protecting+group-free+synthesis%2C+enhanced+anticancer+profile%2C+and+improved+aqueous+solubility&doi=10.1021%2Fjm400367n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nitrogen-Enriched Oridonin Analogues with Thiazole-Fused A-Ring: Protecting Group-Free Synthesis, Enhanced Anticancer Profile, and Improved Aqueous Solubility</span></div><div class="casAuthors">Ding, Chunyong; Zhang, Yusong; Chen, Haijun; Yang, Zhengduo; Wild, Christopher; Chu, Lili; Liu, Huiling; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5048-5058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oridonin (I), a complex ent-kaurane diterpenoid isolated from the traditional Chinese herb Isodon rubescens, has demonstrated great potential in the treatment of various human cancers due to its unique and safe anticancer pharmacol. profile.  Nevertheless, the clin. development of oridonin for cancer therapy has been hampered by its relatively moderate potency, limited aq. soly., and poor bioavailability.  Herein, we report the concise synthesis of a series of novel nitrogen-enriched oridonin derivs. with thiazole-fused A-ring through an efficient protecting group-free synthetic strategy.  Most of them, including compds. II [R = Me; R = NR1R2, R1 = Me, CHMe2, n-Bu, cyclohexyl, 2-(piperidin-1-yl)ethyl, allyl], exhibited potent antiproliferative effects against breast, pancreatic, and prostate cancer cells with low micromolar to submicromolar IC50 values as well as markedly enhanced aq. soly.  These new analogs obtained by rationally modifying the natural product have been shown not only to significantly induce the apoptosis and suppress growth of triple-neg. MDA-MB-231 breast cancer both in vitro and in vivo but are also effective against drug-resistant ER-pos. MCF-7 clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnEskkayfSLVg90H21EOLACvtfcHk0lhooIHGIqI5Ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVeqtL0%253D&md5=b7ec95c47f40492b7aea80159cbbe9bb</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm400367n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400367n%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DNovel%2520nitrogen-enriched%2520oridonin%2520analogues%2520with%2520thiazole-fused%2520A-ring%253A%2520protecting%2520group-free%2520synthesis%252C%2520enhanced%2520anticancer%2520profile%252C%2520and%2520improved%2520aqueous%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5048%26epage%3D5058%26doi%3D10.1021%2Fjm400367n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miklossy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, U. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongwiwatthananukit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Hirsutinolide series inhibit Stat3 activity, alter GCN1, MAP1B, Hsp105, G6PD, vimentin, TrxR1, and importin Î±-2 expression, and induce antitumor effects against human glioma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7734</span>â <span class="NLM_lpage">7748</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCgu7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7734-7748&author=G.+Miklossyauthor=U.+J.+Younauthor=P.+Yueauthor=M.+Zhangauthor=C.+H.+Chenauthor=T.+S.+Hilliardauthor=D.+Paladinoauthor=Y.+Liauthor=J.+Choiauthor=J.+N.+Sarkariaauthor=J.+K.+Kawakamiauthor=S.+Wongwiwatthananukitauthor=Y.+Chenauthor=D.+Sunauthor=L.+C.+Changauthor=J.+Turkson&title=Hirsutinolide+series+inhibit+Stat3+activity%2C+alter+GCN1%2C+MAP1B%2C+Hsp105%2C+G6PD%2C+vimentin%2C+TrxR1%2C+and+importin+%CE%B1-2+expression%2C+and+induce+antitumor+effects+against+human+glioma&doi=10.1021%2Facs.jmedchem.5b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin Î±-2 Expression, and Induce Antitumor Effects against Human Glioma</span></div><div class="casAuthors">Miklossy, Gabriella; Youn, Ui Joung; Yue, Peibin; Zhang, Mingming; Chen, Chih-Hong; Hilliard, Tyvette S.; Paladino, David; Li, Yifei; Choi, Justin; Sarkaria, Jann N.; Kawakami, Joel K.; Wongwiwatthananukit, Supakit; Chen, Yuan; Sun, Dianqing; Chang, Leng Chee; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7734-7748</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report that hirsutinolide series and the semisynthetic analogs inhibit constitutively active signal transducer and activator of transcription (Stat)3 and malignant glioma phenotype.  A position 13 lipophilic ester group is required for activity.  Mol. modeling and NMR structural analyses reveal direct hirsutinolide:Stat3 binding.  One-hour treatment of cells with I and II also upregulated importin subunit Î±-2 levels and repressed translational activator GCN1, microtubule-assocd. protein (MAP)1B, thioredoxin reductase (TrxR)1 cytoplasmic isoform 3, glucose-6-phosphate 1-dehydrogenase isoform a, Hsp105, vimentin, and tumor necrosis factor Î±-induced protein (TNAP)2 expression.  Active hirsutinolides inhibited anchorage-dependent and three-dimensional spheroid growth, survival, and migration of human glioma lines and glioma patients' tumor-derived xenograft cells harboring constitutively active Stat3.  Oral gavage delivery of I or II inhibited human glioma tumor growth in s.c. mouse xenografts.  The inhibition of Stat3 signaling represents part of the hirsutinolide-mediated mechanisms to induce antitumor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-5VLBoRoafbVg90H21EOLACvtfcHk0lhooIHGIqI5Ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCgu7jN&md5=65cfae17ba81a38ca5dd00e0c07265b4</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00686%26sid%3Dliteratum%253Aachs%26aulast%3DMiklossy%26aufirst%3DG.%26aulast%3DYoun%26aufirst%3DU.%2BJ.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DHilliard%26aufirst%3DT.%2BS.%26aulast%3DPaladino%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DSarkaria%26aufirst%3DJ.%2BN.%26aulast%3DKawakami%26aufirst%3DJ.%2BK.%26aulast%3DWongwiwatthananukit%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DL.%2BC.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DHirsutinolide%2520series%2520inhibit%2520Stat3%2520activity%252C%2520alter%2520GCN1%252C%2520MAP1B%252C%2520Hsp105%252C%2520G6PD%252C%2520vimentin%252C%2520TrxR1%252C%2520and%2520importin%2520%25CE%25B1-2%2520expression%252C%2520and%2520induce%2520antitumor%2520effects%2520against%2520human%2520glioma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7734%26epage%3D7748%26doi%3D10.1021%2Facs.jmedchem.5b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaoud, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohassab, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Ravenstein, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, M.</span></span> <span> </span><span class="NLM_article-title">NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111885</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.111885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.111885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31784187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Cmu7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111885&author=T.+S.+Kaoudauthor=A.+M.+Mohassabauthor=H.+A.+Hassanauthor=C.+Yanauthor=S.+X.+Van+Ravensteinauthor=D.+Abdelhamidauthor=K.+N.+Dalbyauthor=M.+Abdel-Aziz&title=NO-releasing+STAT3+inhibitors+suppress+BRAF-mutant+melanoma+growth&doi=10.1016%2Fj.ejmech.2019.111885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth</span></div><div class="casAuthors">Kaoud, Tamer S.; Mohassab, Aliaa M.; Hassan, Heba A.; Yan, Chunli; Van Ravenstein, Sabrina X.; Abdelhamid, Dalia; Dalby, Kevin N.; Abdel-Aziz, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111885</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of substituted nitric oxide (NO)-releasing quinolone-1,2,4-triazole/oxime hybrids I [R = H, 4-chloro, 4-methoxy, 3,4-dimethoxy; R1 = H, methoxy; R2 = allyl, phenyl] hypothesizing that the introduction of a STAT3 binding scaffold would augment their cytotoxicity was studied.  All the hybrids tested showed a comparable level of in-vitro NO prodn. I [R = H, 4-chloro; R1 = H, R2 = allyl] exhibited direct binding to the STAT3-SH domain with IC50 of â¼ 0.5Î¼M.  Also, they abrogated STAT3 tyrosine phosphorylation in several cancer cell lines, including the A375 melanoma cell line that carries the BRAFV600E mutation.  At the same time, they did not affect the phosphorylation of upstream kinases or other STAT isoforms. I [R = 4-chloro; R1 = H, R2 = allyl] inhibited STAT3 nuclear translocation in mouse embryonic fibroblast while I [R = H, 4-chloro; R1 = H, R2 = allyl] inhibited STAT3 DNA-binding activity in the A375 cell line.  Their anti-proliferating activity was attributed to their ability to trigger the prodn. of reactive oxygen species and induce G1 cell cycle arrest in the A375 cell line.  Interestingly, compds. I [R = H, 4-chloro; R1 = H, R2 = allyl] showed robust cell growth suppression and apoptosis induction in two pairs of BRAF inhibitor-naive (-S) and resistant (-R) melanoma cell lines contg. a BRAF V600E mutation.  Surprisingly, MEL1617-R cells that are known to be more resistance to MEK inhibition by GSK1120212 than MEL1617-S cells exhibited a similar response to I [R = H, 4-chloro; R1 = H, R2 = allyl].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXmMSSocCxeLVg90H21EOLACvtfcHk0lhooIHGIqI5Ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Cmu7jP&md5=13ac1d510a73228cd349ed100d8c622c</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111885%26sid%3Dliteratum%253Aachs%26aulast%3DKaoud%26aufirst%3DT.%2BS.%26aulast%3DMohassab%26aufirst%3DA.%2BM.%26aulast%3DHassan%26aufirst%3DH.%2BA.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DVan%2BRavenstein%26aufirst%3DS.%2BX.%26aulast%3DAbdelhamid%26aufirst%3DD.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26aulast%3DAbdel-Aziz%26aufirst%3DM.%26atitle%3DNO-releasing%2520STAT3%2520inhibitors%2520suppress%2520BRAF-mutant%2520melanoma%2520growth%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111885%26doi%3D10.1016%2Fj.ejmech.2019.111885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamroskovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doimo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BrÃ¤nnstrÃ¶m, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HedenstrÃ¶m, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nath Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhunzianov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasho, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulis Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourbozorgi, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ãhlund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanrooij, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabouri, N.</span></span> <span> </span><span class="NLM_article-title">Quinazoline ligands induce cancer cell death through selective STAT3 inhibition and G-quadruplex stabilization</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">2876</span>â <span class="NLM_lpage">2888</span>, <span class="refDoi">Â DOI: 10.1021/jacs.9b11232</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b11232" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1OmtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=2876-2888&author=J.+Jamroskovicauthor=M.+Doimoauthor=K.+Chandauthor=I.+Obiauthor=R.+Kumarauthor=K.+Br%C3%A4nnstr%C3%B6mauthor=M.+Hedenstr%C3%B6mauthor=R.+Nath+Dasauthor=A.+Akhunzianovauthor=M.+Deianaauthor=K.+Kashoauthor=S.+Sulis+Satoauthor=P.+L.+Pourbozorgiauthor=J.+E.+Masonauthor=P.+Mediniauthor=D.+%C3%96hlundauthor=S.+Wanrooijauthor=E.+Chorellauthor=N.+Sabouri&title=Quinazoline+ligands+induce+cancer+cell+death+through+selective+STAT3+inhibition+and+G-quadruplex+stabilization&doi=10.1021%2Fjacs.9b11232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization</span></div><div class="casAuthors">Jamroskovic, Jan; Doimo, Mara; Chand, Karam; Obi, Ikenna; Kumar, Rajendra; Braennstroem, Kristoffer; Hedenstroem, Mattias; Nath Das, Rabindra; Akhunzianov, Almaz; Deiana, Marco; Kasho, Kazutoshi; Sulis Sato, Sebastian; Pourbozorgi, Parham L.; Mason, James E.; Medini, Paolo; Oehlund, Daniel; Wanrooij, Sjoerd; Chorell, Erik; Sabouri, Nasim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2876-2888</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 (STAT3) protein is a master regulator of most key hallmarks and enablers of cancer, including cell proliferation and the response to DNA damage.  G-Quadruplex (G4) structures are four-stranded noncanonical DNA structures enriched at telomeres and oncogenes' promoters.  In cancer cells, stabilization of G4 DNAs leads to replication stress and DNA damage accumulation and is therefore considered a promising target for oncotherapy.  Here, we designed and synthesized novel quinazoline-based compds. that simultaneously and selectively affect these two well-recognized cancer targets, G4 DNA structures and the STAT3 protein.  Using a combination of in vitro assays, NMR, and mol. dynamics simulations, we show that these small, uncharged compds. not only bind to the STAT3 protein but also stabilize G4 structures.  In human cultured cells, the compds. inhibit phosphorylation-dependent activation of STAT3 without affecting the antiapoptotic factor STAT1 and cause increased formation of G4 structures, as revealed by the use of a G4 DNA-specific antibody.  As a result, treated cells show slower DNA replication, DNA damage checkpoint activation, and an increased apoptotic rate.  Importantly, cancer cells are more sensitive to these mols. compared to noncancerous cell lines.  This is the first report of a promising class of compds. that not only targets the DNA damage cancer response machinery but also simultaneously inhibits the STAT3-induced cancer cell proliferation, demonstrating a novel approach in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4mlLR-aBn8bVg90H21EOLACvtfcHk0ljEqAez8SZwmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1OmtL8%253D&md5=e6c1da298ac0bf9a0da3268b157d7330</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b11232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b11232%26sid%3Dliteratum%253Aachs%26aulast%3DJamroskovic%26aufirst%3DJ.%26aulast%3DDoimo%26aufirst%3DM.%26aulast%3DChand%26aufirst%3DK.%26aulast%3DObi%26aufirst%3DI.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DBr%25C3%25A4nnstr%25C3%25B6m%26aufirst%3DK.%26aulast%3DHedenstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DNath%2BDas%26aufirst%3DR.%26aulast%3DAkhunzianov%26aufirst%3DA.%26aulast%3DDeiana%26aufirst%3DM.%26aulast%3DKasho%26aufirst%3DK.%26aulast%3DSulis%2BSato%26aufirst%3DS.%26aulast%3DPourbozorgi%26aufirst%3DP.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BE.%26aulast%3DMedini%26aufirst%3DP.%26aulast%3D%25C3%2596hlund%26aufirst%3DD.%26aulast%3DWanrooij%26aufirst%3DS.%26aulast%3DChorell%26aufirst%3DE.%26aulast%3DSabouri%26aufirst%3DN.%26atitle%3DQuinazoline%2520ligands%2520induce%2520cancer%2520cell%2520death%2520through%2520selective%2520STAT3%2520inhibition%2520and%2520G-quadruplex%2520stabilization%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D2876%26epage%3D2888%26doi%3D10.1021%2Fjacs.9b11232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shahani, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haftchenary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukkarila, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">Identification of purine-scaffold small-molecule inhibitors of Stat3 activation by QSAR studies</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">79</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1021/ml100224d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100224d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlalurbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=79-84&author=V.+M.+Shahaniauthor=P.+Yueauthor=S.+Haftchenaryauthor=W.+Zhaoauthor=J.+L.+Lukkarilaauthor=X.+Zhangauthor=D.+Ballauthor=C.+Nonaauthor=P.+T.+Gunningauthor=J.+Turkson&title=Identification+of+purine-scaffold+small-molecule+inhibitors+of+Stat3+activation+by+QSAR+studies&doi=10.1021%2Fml100224d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of purine-scaffold small-molecule inhibitors of Stat3 activation by QSAR studies</span></div><div class="casAuthors">Shahani, Vijay M.; Yue, Peibin; Haftchenary, Sina; Zhao, Wei; Lukkarila, Julie L.; Zhang, Xiaolei; Ball, Daniel; Nona, Christina; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-84</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To facilitate the discovery of clin. useful Stat3 inhibitors, computational anal. of the binding to Stat3 of the existing Stat3 dimerization disruptors and quant. structure-activity relationships (QSAR) were pursued, by which a pharmacophore model was derived for predicting optimized Stat3 dimerization inhibitors.  The 2,6,9-trisubstituted-purine scaffold was functionalized in order to access the three subpockets of the Stat3 SH2 domain surface and to derive potent Stat3-binding inhibitors.  Select purine scaffolds showed good affinities (KD, 0.8-12 Î¼M) for purified, nonphosphorylated Stat3 and inhibited Stat3 DNA-binding activity in vitro and intracellular phosphorylation at 20-60 Î¼M.  Furthermore, agents selectively suppressed viability of human prostate, breast and pancreatic cancer cells, and v-Src-transformed mouse fibroblasts that harbor aberrant Stat3 activity.  Studies herein identified novel small-mol. trisubstituted purines as effective inhibitors of constitutively active Stat3 and of the viability of Stat3-dependent tumor cells, and are the first to validate the use of purine bases as templates for building novel Stat3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQYIh7oNE9P7Vg90H21EOLACvtfcHk0ljEqAez8SZwmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlalurbF&md5=45c8fd816a6f3cbe66c871c9657d9c18</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fml100224d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100224d%26sid%3Dliteratum%253Aachs%26aulast%3DShahani%26aufirst%3DV.%2BM.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DHaftchenary%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLukkarila%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNona%26aufirst%3DC.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520purine-scaffold%2520small-molecule%2520inhibitors%2520of%2520Stat3%2520activation%2520by%2520QSAR%2520studies%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D79%26epage%3D84%26doi%3D10.1021%2Fml100224d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muroya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokotagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshita, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Identification of a new series of STAT3 inhibitors by virtual screening</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">371</span>â <span class="NLM_lpage">375</span>, <span class="refDoi">Â DOI: 10.1021/ml1000273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1000273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1yju7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=371-375&author=K.+Matsunoauthor=Y.+Masudaauthor=Y.+Ueharaauthor=H.+Satoauthor=A.+Muroyaauthor=O.+Takahashiauthor=T.+Yokotagawaauthor=T.+Furuyaauthor=T.+Okawaraauthor=M.+Otsukaauthor=N.+Ogoauthor=T.+Ashizawaauthor=C.+Oshitaauthor=S.+Taiauthor=H.+Ishiiauthor=Y.+Akiyamaauthor=A.+Asai&title=Identification+of+a+new+series+of+STAT3+inhibitors+by+virtual+screening&doi=10.1021%2Fml1000273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a New Series of STAT3 Inhibitors by Virtual Screening</span></div><div class="casAuthors">Matsuno, Kenji; Masuda, Yoshiaki; Uehara, Yutaka; Sato, Hiroshi; Muroya, Ayumu; Takahashi, Osamu; Yokotagawa, Takane; Furuya, Toshio; Okawara, Tadashi; Otsuka, Masami; Ogo, Naohisa; Ashizawa, Tadashi; Oshita, Chie; Tai, Sachiko; Ishii, Hidee; Akiyama, Yasuto; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">371-375</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 (STAT3) is considered to be an attractive therapeutic target for oncol. drug development.  We identified a N-[2-(1,3,4-oxadiazolyl)]-4-quinolinecarboxamide deriv., STX-0119 (I), as a novel STAT3 dimerization inhibitor by a virtual screen using a customized version of the DOCK4 program with the crystal structure of STAT3.  In addn., we used in vitro cell-based assays such as the luciferase reporter gene assay and the fluorescence resonance energy transfer-based STAT3 dimerization assay.  STX-0119 selectively abrogated the DNA binding activity of STAT3 and suppressed the expression of STAT3-regulated oncoproteins such as c-myc and survivin in cancer cells.  In contrast, a truncated inactive analog, STX-0872, did not exhibit those activities.  Oral administration of STX-0119 effectively abrogated the growth of human lymphoma cells in a SCC-3 s.c. xenograft model without visible toxicity.  Structure-activity relationships of STX-0119 derivs. were investigated using the docking model of the STAT3-SH2 domain/STX-0119.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcvw7IsnKAqbVg90H21EOLACvtfcHk0lh5I59On3nZKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1yju7w%253D&md5=c339cf4bd4b2add19deaf4ffc4f481fb</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fml1000273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1000273%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DMasuda%26aufirst%3DY.%26aulast%3DUehara%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DMuroya%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DO.%26aulast%3DYokotagawa%26aufirst%3DT.%26aulast%3DFuruya%26aufirst%3DT.%26aulast%3DOkawara%26aufirst%3DT.%26aulast%3DOtsuka%26aufirst%3DM.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DOshita%26aufirst%3DC.%26aulast%3DTai%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520new%2520series%2520of%2520STAT3%2520inhibitors%2520by%2520virtual%2520screening%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D371%26epage%3D375%26doi%3D10.1021%2Fml1000273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakasu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span> <span> </span><span class="NLM_article-title">Effect of the STAT3 inhibitor STX-0119 on the proliferation of a Temozolomide-resistant glioblastoma cell line</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">411</span>â <span class="NLM_lpage">418</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2014.2439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3892%2Fijo.2014.2439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=24820265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGrtLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=411-418&author=T.+Ashizawaauthor=Y.+Akiyamaauthor=H.+Miyataauthor=A.+Iizukaauthor=M.+Komiyamaauthor=A.+Kumeauthor=M.+Omiyaauthor=T.+Suginoauthor=A.+Asaiauthor=N.+Hayashiauthor=K.+Mitsuyaauthor=Y.+Nakasuauthor=K.+Yamaguchi&title=Effect+of+the+STAT3+inhibitor+STX-0119+on+the+proliferation+of+a+Temozolomide-resistant+glioblastoma+cell+line&doi=10.3892%2Fijo.2014.2439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line</span></div><div class="casAuthors">Ashizawa, Tadashi; Akiyama, Yasuto; Miyata, Haruo; Iizuka, Akira; Komiyama, Masaru; Kume, Akiko; Omiya, Maho; Sugino, Takashi; Asai, Akira; Hayashi, Nakamasa; Mitsuya, Koichi; Nakasu, Yoko; Yamaguchi, Ken</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">411-418</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is one of the most malignant and aggressive tumors and has a very poor prognosis, with a median survival time of less than 2 years.  Once recurrence develops, there are few therapeutic approaches to control the growth of glioblastoma.  In particular, temozolomide (TMZ)-resistant (TMZ-R) GBM is very difficult to treat, and a novel approach to overcome resistance is eagerly awaited.  Previously, we reported a novel small mol. inhibitor of STAT3 dimerization, STX-0119, as a cancer therapeutic.  In the current study, the efficacy of STX-0119 was evaluated against our established TMZ-resistant U87 cell line using quant. PCR-based gene expression anal., in vitro assay and animal expts.  The growth inhibitory effect of STX-0119 on U87 and TMZ-R U87 cells was moderate (IC50, 34 and 45 Î¼M, resp.).  In particular, STX-0119 did not show significant inhibition of U87 tumor growth; however, it suppressed the growth of the TMZ-R U87 tumor in nude mice by more than 50%, and prolonged the median survival time compared to the control group.  Quant. PCR revealed that YKL-40, MAGEC1, MGMT, several EMT genes, mesenchymal genes and STAT3 target genes were upregulated, but most of those genes were downregulated by STX-0119 treatment.  Furthermore, the invasive activity of TMZ-R U87 cells was significantly inhibited by STX-0119.  YKL-40 levels in TMZ-R U87 cells and their supernatants were significantly decreased by STX-0119 administration.  These results suggest that STX-0119 is an efficient therapeutic to overcome TMZ resistance in recurrent GBM tumors, and could be the next promising compd. leading to survival prolongation, and YKL-40 may be a possible surrogate marker for STAT3 targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokm0ePIqBVy7Vg90H21EOLACvtfcHk0lh5I59On3nZKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGrtLzN&md5=62906d06dc755bb7298cddeaccad078f</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3892%2Fijo.2014.2439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2014.2439%26sid%3Dliteratum%253Aachs%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DMiyata%26aufirst%3DH.%26aulast%3DIizuka%26aufirst%3DA.%26aulast%3DKomiyama%26aufirst%3DM.%26aulast%3DKume%26aufirst%3DA.%26aulast%3DOmiya%26aufirst%3DM.%26aulast%3DSugino%26aufirst%3DT.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DN.%26aulast%3DMitsuya%26aufirst%3DK.%26aulast%3DNakasu%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DK.%26atitle%3DEffect%2520of%2520the%2520STAT3%2520inhibitor%2520STX-0119%2520on%2520the%2520proliferation%2520of%2520a%2520Temozolomide-resistant%2520glioblastoma%2520cell%2520line%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2014%26volume%3D45%26spage%3D411%26epage%3D418%26doi%3D10.3892%2Fijo.2014.2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakasu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span> <span> </span><span class="NLM_article-title">The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in Temozolomide-resistant glioblastoma cell line</span>. <i>Immunol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">20</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1016/j.imlet.2017.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.imlet.2017.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28716484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wht7bJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2017&pages=20-25&author=Y.+Akiyamaauthor=C.+Nonomuraauthor=T.+Ashizawaauthor=A.+Iizukaauthor=R.+Kondouauthor=H.+Miyataauthor=T.+Suginoauthor=K.+Mitsuyaauthor=N.+Hayashiauthor=Y.+Nakasuauthor=A.+Asaiauthor=M.+Itoauthor=Y.+Kiyoharaauthor=K.+Yamaguchi&title=The+anti-tumor+activity+of+the+STAT3+inhibitor+STX-0119+occurs+via+promotion+of+tumor-infiltrating+lymphocyte+accumulation+in+Temozolomide-resistant+glioblastoma+cell+line&doi=10.1016%2Fj.imlet.2017.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line</span></div><div class="casAuthors">Akiyama, Yasuto; Nonomura, Chizu; Ashizawa, Tadashi; Iizuka, Akira; Kondou, Ryota; Miyata, Haruo; Sugino, Takashi; Mitsuya, Koichi; Hayashi, Nakamasa; Nakasu, Yoko; Asai, Akira; Ito, Mamoru; Kiyohara, Yoshio; Yamaguchi, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-25</span>CODEN:
                <span class="NLM_cas:coden">IMLED6</span>;
        ISSN:<span class="NLM_cas:issn">0165-2478</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">STAT3 is considered to be a key mol. to mediating tumor-induced immunosuppression in various manners at tumor sites, by acting through immune-regulatory cytokines derived from the tumor cells.  Specific anti-STAT3 inhibitors have been developed using nude mouse models transplanted with human tumor cells.  However, mouse systems cannot accurately represent the human immune response induced by STAT3 inhibitors, and more humanized therapeutic model based on human immune cells and tumors are needed.  In the present study, an immune-deficient NOG mouse with the deletion of both MHC-class I and class II genes, an MHC-double knockout mouse (dKO-NOG), was developed and used to establish humanized immunotherapeutic model.  We investigated the immunol. effect of the STAT3 inhibitor STX-0119 against TMZ-resistant (TMZ-R) U87 glioma tumors by using humanized dKO-NOG mice.  We compared the anti-tumor effects of STX-0119 between the nude and humanized dKO-NOG mouse models.  An in vivo study using the nude mouse model showed that STX-0119 inhibited the growth of TMZR U87 tumors, but accumulation of tumor-infiltrating lymphocytes (TILs) were not promoted compared with the control levels.  In contrast, STX-0119 inhibited tumor growth more rapidly and strongly in humanized dKO-NOG mice than in nude mice, and a large amt. of TILs, mainly consisting of CD8+ T cells and macrophages, were found in the tumors.  These results suggest that STX-0119 has anti-tumor activity occurring through the promotion of TIL accumulation at the tumor site and that humanized dKO-NOG mouse system may be a powerful tool to evaluate the effects of STAT3 inhibitors on human systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFZxq830q_7LVg90H21EOLACvtfcHk0lh5I59On3nZKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wht7bJ&md5=76893f69cb0b4fea2b2a9d37712e75f6</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.imlet.2017.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.imlet.2017.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DNonomura%26aufirst%3DC.%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DIizuka%26aufirst%3DA.%26aulast%3DKondou%26aufirst%3DR.%26aulast%3DMiyata%26aufirst%3DH.%26aulast%3DSugino%26aufirst%3DT.%26aulast%3DMitsuya%26aufirst%3DK.%26aulast%3DHayashi%26aufirst%3DN.%26aulast%3DNakasu%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DKiyohara%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DK.%26atitle%3DThe%2520anti-tumor%2520activity%2520of%2520the%2520STAT3%2520inhibitor%2520STX-0119%2520occurs%2520via%2520promotion%2520of%2520tumor-infiltrating%2520lymphocyte%2520accumulation%2520in%2520Temozolomide-resistant%2520glioblastoma%2520cell%2520line%26jtitle%3DImmunol.%2520Lett.%26date%3D2017%26volume%3D190%26spage%3D20%26epage%3D25%26doi%3D10.1016%2Fj.imlet.2017.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshita, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakasu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">219</span>â <span class="NLM_lpage">227</span>, <span class="refDoi">Â DOI: 10.3892/ijo.2013.1916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3892%2Fijo.2013.1916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=23612755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOltLnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=219-227&author=T.+Ashizawaauthor=H.+Miyataauthor=A.+Iizukaauthor=M.+Komiyamaauthor=C.+Oshitaauthor=A.+Kumeauthor=M.+Nogamiauthor=M.+Yagotoauthor=I.+Itoauthor=T.+Oishiauthor=R.+Watanabeauthor=K.+Mitsuyaauthor=K.+Matsunoauthor=T.+Furuyaauthor=T.+Okawaraauthor=M.+Otsukaauthor=N.+Ogoauthor=A.+Asaiauthor=Y.+Nakasuauthor=K.+Yamaguchiauthor=Y.+Akiyama&title=Effect+of+the+STAT3+inhibitor+STX-0119+on+the+proliferation+of+cancer+stem-like+cells+derived+from+recurrent+glioblastoma&doi=10.3892%2Fijo.2013.1916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma</span></div><div class="casAuthors">Ashizawa, Tadashi; Miyata, Haruo; Ilzuka, Akira; Komiyama, Masaru; Oshita, Chie; Kume, Akiko; Nogami, Masahiro; Yagoto, Mika; Ito, Ichiro; Oishi, Takuma; Watanabe, Reiko; Mitsuya, Koichi; Matsuno, Kenji; Furuya, Toshio; Okawara, Tadashi; Otsuka, Masami; Ogo, Naohisa; Asai, Akira; Nakasu, Yoko; Yamaguchi, Ken; Akiyama, Yasuto</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-227</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription (STAT) 3, a member of a family of DNA-binding mols., is a potential target in the treatment of cancer.  The highly phosphorylated STAT3 in cancer cells contributes to numerous physiol. and oncogenic signaling pathways.  Furthermore, a significant assocn. between STAT3 signaling and glioblastoma multiforme stem-like cell (GBM-SC) development and maintenance has been demonstrated in recent studies.  Previously, we reported a novel small mol. inhibitor of STAT3 dimerization, STX-0119, as a cancer therapeutic.  In the present study, we focused on cancer stem-like cells derived from recurrent GBM patients and investigated the efficacy of STX-0119.  Three GBM stem cell lines showed many stem cell markers such as CD133, EGFR, Nanog, Olig2, nestin and Yamanaka factors (c-myc, KLF4, Oct3/4 and SOX2) compared with parental cell lines.  These cell lines also formed tumors in vivo and had similar histol. to surgically resected tumors.  STAT3 phosphorylation was activated more in the GBM-SC lines than serum-derived GB cell lines.  The growth inhibitory effect of STX-0119 on GBM-SCs was moderate (IC50 15-44 Î¼M) and stronger compared to that of WP1066 in two cell lines.  On the other hand, the effect of temozolomide was weak in all the cell lines (IC50 53-226 Î¼M).  Notably, STX-0119 demonstrated strong inhibition of the expression of STAT3 target genes (c-myc, survivin, cyclin D1, HIF-1Î± and VEGF) and stem cell-assocd. genes (CD44, Nanog, nestin and CD133) as well as the induction of apoptosis in one stem-like cell line.  Interestingly, VEGFR2 mRNA was also remarkably inhibited by STX-0119.  In a model using transplantable stem-like cell lines in vivo GB-SCC010 and 026, STX-0119 inhibited the growth of GBM-SCs at 80 mg/kg.  STX-0119, an inhibitor of STAT3, may serve as a novel therapeutic compd. against GBM-SCs even in temozolomide-resistant GBM patients and has the potential for GBM-SC-specific therapeutics in combination with temozolomide plus radiation therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTi3UcmHgW7LVg90H21EOLACvtfcHk0lgWhaIJlSWoYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOltLnN&md5=2cc077e2a1e30f1af9d1f2342e852663</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.3892%2Fijo.2013.1916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2013.1916%26sid%3Dliteratum%253Aachs%26aulast%3DAshizawa%26aufirst%3DT.%26aulast%3DMiyata%26aufirst%3DH.%26aulast%3DIizuka%26aufirst%3DA.%26aulast%3DKomiyama%26aufirst%3DM.%26aulast%3DOshita%26aufirst%3DC.%26aulast%3DKume%26aufirst%3DA.%26aulast%3DNogami%26aufirst%3DM.%26aulast%3DYagoto%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DI.%26aulast%3DOishi%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DR.%26aulast%3DMitsuya%26aufirst%3DK.%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DFuruya%26aufirst%3DT.%26aulast%3DOkawara%26aufirst%3DT.%26aulast%3DOtsuka%26aufirst%3DM.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DNakasu%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DAkiyama%26aufirst%3DY.%26atitle%3DEffect%2520of%2520the%2520STAT3%2520inhibitor%2520STX-0119%2520on%2520the%2520proliferation%2520of%2520cancer%2520stem-like%2520cells%2520derived%2520from%2520recurrent%2520glioblastoma%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2013%26volume%3D43%26spage%3D219%26epage%3D227%26doi%3D10.3892%2Fijo.2013.1916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishisaka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsugane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asakawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1774</span>â <span class="NLM_lpage">1784</span>, <span class="refDoi">Â DOI: 10.1111/cas.14369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1111%2Fcas.14369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=32112605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVeisL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2020&pages=1774-1784&author=F.+Nishisakaauthor=K.+Taniguchiauthor=M.+Tsuganeauthor=G.+Hirataauthor=A.+Takagiauthor=N.+Asakawaauthor=A.+Kuritaauthor=H.+Takahashiauthor=N.+Ogoauthor=Y.+Shishidoauthor=A.+Asai&title=Antitumor+activity+of+a+novel+oral+signal+transducer+and+activator+of+transcription+3+inhibitor+YHO-1701&doi=10.1111%2Fcas.14369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701</span></div><div class="casAuthors">Nishisaka, Fukiko; Taniguchi, Keisuke; Tsugane, Momomi; Hirata, Genya; Takagi, Akimitsu; Asakawa, Naoyuki; Kurita, Akinobu; Takahashi, Hiroyuki; Ogo, Naohisa; Shishido, Yoshiyuki; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1774-1784</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The signal transducer and activator of transcription 3 (STAT3) signaling pathway is a key mediator of cancer cell proliferation, survival and invasion.  Aberrant STAT3 has been demonstrated in various malignant cancers.  YHO-1701 is a novel quinolinecarboxamide deriv. generated from STX-0119.  Here, we examd. the effect of YHO-1701 on STAT3 and evaluated antitumor activity of YHO-1701 as a single agent and in combination.  YHO-1701 inhibited STAT3-SH2 binding to phospho-Tyr peptide selectively and more potently than STX-0119 in biochem. assays.  Mol. docking studies with STAT3 suggested more stable interaction of YHO-1701 with the SH2 domain.  YHO-1701 exhibited approx. 10-fold stronger activity than STX-0119 in abrogating the STAT3 signaling pathway of human oral cancer cell line SAS.  Moreover, combination regimen with sorafenib led to significantly stronger antitumor activity.  In addn., the suppression level of survivin (a downstream target) was superior for the combination as compared with monotherapy groups within tumor tissues.  Thus, YHO-1701 had a favorable specificity for STAT3 and pharmacokinetics after oral treatment; it also contributed to the enhanced antitumor activity of sorafenib.  The evidence presented here provides justification using for this approach in future clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Z3CbJV1GOLVg90H21EOLACvtfcHk0lgWhaIJlSWoYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVeisL0%253D&md5=fe4a7874ae44d959cff8879387633c8a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1111%2Fcas.14369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.14369%26sid%3Dliteratum%253Aachs%26aulast%3DNishisaka%26aufirst%3DF.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DTsugane%26aufirst%3DM.%26aulast%3DHirata%26aufirst%3DG.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DAsakawa%26aufirst%3DN.%26aulast%3DKurita%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DShishido%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520a%2520novel%2520oral%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520inhibitor%2520YHO-1701%26jtitle%3DCancer%2520Sci.%26date%3D2020%26volume%3D111%26spage%3D1774%26epage%3D1784%26doi%3D10.1111%2Fcas.14369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsugane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishisaka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6685</span>, <span class="refDoi">Â DOI: 10.1038/s41598-021-86021-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fs41598-021-86021-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33758275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnsVShu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2021&pages=6685&author=K.+Taniguchiauthor=H.+Konishiauthor=A.+Yoshinagaauthor=M.+Tsuganeauthor=H.+Takahashiauthor=F.+Nishisakaauthor=Y.+Shishidoauthor=A.+Asai&title=Efficacy+of+combination+treatment+using+YHO-1701%2C+an+orally+active+STAT3+inhibitor%2C+with+molecular-targeted+agents+on+cancer+cell+lines&doi=10.1038%2Fs41598-021-86021-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines</span></div><div class="casAuthors">Taniguchi, Keisuke; Konishi, Hiroaki; Yoshinaga, Akiko; Tsugane, Momomi; Takahashi, Hiroyuki; Nishisaka, Fukiko; Shishido, Yoshiyuki; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6685</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) plays a crit. role in regulating cell growth, survival, and metastasis.  STAT3 signaling is constitutively activated in various types of hematol. or solid malignancies.  YHO-1701 has been developed as an orally available STAT3 inhibitor.  Herein, YHO-1701 in combination with mol.-targeted agents was evaluated.  Additive or synergistic effects were obsd. in a broad spectrum of "combination treatment + cell line" pairs.  Of particular interest was the synergistic effect obsd. when YHO-1701 was combined with imatinib or dasatinib [breakpoint cluster region-abelson (BCR-ABL) inhibitors], osimertinib [epidermal growth factor receptor (EGFR) inhibitor], crizotinib, alectinib, or ceritinib [anaplastic lymphoma kinase (ALK) inhibitors].  The results further showed a close relationship between these synergistic effects and the cellular levels of the key mols. involved in the target pathways for YHO-1701 and each combination drug.  The combination of YHO-1701 with alectinib resulted in significantly greater antitumor activity without exhibiting body wt. loss in an NCI-H2228 [echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion] xenograft mouse model.  Our results strongly suggest that the logical strategy in combination with the novel STAT3 inhibitor YHO-1701 and other mechanistically different targeted agents, could be a promising approach in future clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW_V8XTO7uIbVg90H21EOLACvtfcHk0lgNCIPKjHVGUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnsVShu7o%253D&md5=99060b6e66cf0a536e67701bccc2a4ef</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1038%2Fs41598-021-86021-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-021-86021-8%26sid%3Dliteratum%253Aachs%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DKonishi%26aufirst%3DH.%26aulast%3DYoshinaga%26aufirst%3DA.%26aulast%3DTsugane%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DNishisaka%26aufirst%3DF.%26aulast%3DShishido%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DEfficacy%2520of%2520combination%2520treatment%2520using%2520YHO-1701%252C%2520an%2520orally%2520active%2520STAT3%2520inhibitor%252C%2520with%2520molecular-targeted%2520agents%2520on%2520cancer%2520cell%2520lines%26jtitle%3DSci.%2520Rep.%26date%3D2021%26volume%3D11%26spage%3D6685%26doi%3D10.1038%2Fs41598-021-86021-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneghetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masciocchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MarchianÃ², S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimoldi, I.</span></span> <span> </span><span class="NLM_article-title">An in vivo active 1,2,5-oxadiazole Pt(II) complex: a promising anticancer agent endowed with STAT3 inhibitory properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">196</span>â <span class="NLM_lpage">206</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2017.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28324784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVKrsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=196-206&author=F.+Portaauthor=G.+Facchettiauthor=N.+Ferriauthor=A.+Gelainauthor=F.+Meneghettiauthor=S.+Villaauthor=D.+Barloccoauthor=D.+Masciocchiauthor=A.+Asaiauthor=N.+Miyoshiauthor=S.+Marchian%C3%B2author=B.+M.+Kwonauthor=Y.+Jinauthor=V.+Gandinauthor=C.+Marzanoauthor=I.+Rimoldi&title=An+in+vivo+active+1%2C2%2C5-oxadiazole+Pt%28II%29+complex%3A+a+promising+anticancer+agent+endowed+with+STAT3+inhibitory+properties&doi=10.1016%2Fj.ejmech.2017.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties</span></div><div class="casAuthors">Porta, Federica; Facchetti, Giorgio; Ferri, Nicola; Gelain, Arianna; Meneghetti, Fiorella; Villa, Stefania; Barlocco, Daniela; Masciocchi, Daniela; Asai, Akira; Miyoshi, Nao; Marchiano, Silvia; Kwon, Byoung-Mog; Jin, Yena; Gandin, Valentina; Marzano, Cristina; Rimoldi, Isabella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196-206</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">New Pt(II) complexes (Pt-1-3) bearing 1,2,5-oxadiazole ligands (1-3) were synthesized, characterized and evaluated for their ability to disrupt STAT3 dimerization.  Ligand 3Â·HCl showed cytotoxic effects on HCT-116 cells (IC50 = 95.2 Î¼M) and a selective ability to interact with STAT3 (IC50 = 8.2 Î¼M) vs. STAT1 (IC50 > 30 Î¼M).  Its corresponding platinum complex Pt-3 exhibited an increased cytotoxicity (IC50 = 18.4 Î¼M) and a stronger interaction with STAT3 (IC50 = 1.4 Î¼M), leading to inhibition of its signaling pathway.  Pt-3 was also evaluated in cell-based assays for its action on p53 expression and on STAT3 phosphorylation.  In syngeneic murine Lewis lung carcinoma (LLC) implanted in C57BL/6 mice, Pt-3 showed a higher antitumor activity with fewer side effects than cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqivlmoUtNye7Vg90H21EOLACvtfcHk0lgNCIPKjHVGUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVKrsrg%253D&md5=3069d1f9605d1b0bb046e74b1e1cf1e8</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DFacchetti%26aufirst%3DG.%26aulast%3DFerri%26aufirst%3DN.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DMeneghetti%26aufirst%3DF.%26aulast%3DVilla%26aufirst%3DS.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DMasciocchi%26aufirst%3DD.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DMiyoshi%26aufirst%3DN.%26aulast%3DMarchian%25C3%25B2%26aufirst%3DS.%26aulast%3DKwon%26aufirst%3DB.%2BM.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DRimoldi%26aufirst%3DI.%26atitle%3DAn%2520in%2520vivo%2520active%25201%252C2%252C5-oxadiazole%2520Pt%2528II%2529%2520complex%253A%2520a%2520promising%2520anticancer%2520agent%2520endowed%2520with%2520STAT3%2520inhibitory%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D131%26spage%3D196%26epage%3D206%26doi%3D10.1016%2Fj.ejmech.2017.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hejazi, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahabuddin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athar, F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic evaluation, molecular docking and in vitro biological evaluation of 1, 3, 4-oxadiazole derivatives as potent antioxidants and STAT3 inhibitors</span>. <i>J. Pharm. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">133</span>â <span class="NLM_lpage">141</span>, <span class="refDoi">Â DOI: 10.1016/j.jpha.2018.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.jpha.2018.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31011470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FotVOisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=133-141&author=R.+Khanamauthor=I.+I.+Hejaziauthor=S.+Shahabuddinauthor=A.+R.+Bhatauthor=F.+Athar&title=Pharmacokinetic+evaluation%2C+molecular+docking+and+in+vitro+biological+evaluation+of+1%2C+3%2C+4-oxadiazole+derivatives+as+potent+antioxidants+and+STAT3+inhibitors&doi=10.1016%2Fj.jpha.2018.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic evaluation, molecular docking and in vitro biological evaluation of 1, 3, 4-oxadiazole derivatives as potent antioxidants and STAT3 inhibitors</span></div><div class="casAuthors">Khanam Rashmin; Hejazi Iram I; Athar Fareeda; Shahabuddin Syed; Bhat Abdul R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmaceutical analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-141</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">1, 3, 4-Oxadiazole derivatives (4a-5f) were previously synthesized to investigate their anticancer properties.  However, studies relating to their antioxidant potential and signal transducer and activator of transcription (STAT) inhibition have not been performed.  We investigated previously synthesized 1, 3, 4-oxadiazole derivatives (4a-5f) for various radical scavenging properties using several in vitro antioxidant assays and also for direct inhibition of STAT3 through molecular docking.  The data obtained from various antioxidant assays such as 2, 2,-diphenyl-1-picrylhydrazyl radical (DPPH), nitric oxide, hydrogen peroxide, and superoxide anion radical revealed that among all the derivatives, compound 5e displayed high antioxidant activities than the standard antioxidant L-ascorbic acid.  Additionally, the total reduction assay and antioxidant capacity assay further confirmed the antioxidant potential of compound 5e.  Furthermore, the molecular docking studies performed for all derivatives along with the standard inhibitor STX-0119 showed that binding energy released in direct binding with the SH2 domain of STAT3 was the highest for compound 5e (-9.91kcal/mol).  Through virtual screening, compound 5e was found to exhibit optimum competency in inhibiting STAT3 activity.  Compound 5e decreased the activation of STAT3 as observed with Western blot.  In brief, compound 5e was identified as a potent antioxidant agent and STAT3 inhibitor and effective agent for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwHAkIZy4YwrP3FVUi_gf8fW6udTcc2ebT6Bn1r5jgb7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FotVOisA%253D%253D&md5=80d3d22095c5c7510482d9131ee5a95f</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.jpha.2018.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpha.2018.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DKhanam%26aufirst%3DR.%26aulast%3DHejazi%26aufirst%3DI.%2BI.%26aulast%3DShahabuddin%26aufirst%3DS.%26aulast%3DBhat%26aufirst%3DA.%2BR.%26aulast%3DAthar%26aufirst%3DF.%26atitle%3DPharmacokinetic%2520evaluation%252C%2520molecular%2520docking%2520and%2520in%2520vitro%2520biological%2520evaluation%2520of%25201%252C%25203%252C%25204-oxadiazole%2520derivatives%2520as%2520potent%2520antioxidants%2520and%2520STAT3%2520inhibitors%26jtitle%3DJ.%2520Pharm.%2520Anal.%26date%3D2019%26volume%3D9%26spage%3D133%26epage%3D141%26doi%3D10.1016%2Fj.jpha.2018.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadhe, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pae, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S. K.</span></span> <span> </span><span class="NLM_article-title">Development of oxadiazole-based ODZ10117 as a small-molecule inhibitor of STAT3 for targeted cancer therapy</span>. <i>J. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1847</span>, <span class="refDoi">Â DOI: 10.3390/jcm8111847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fjcm8111847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvVSmtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1847&author=B.+H.+Kimauthor=H.+Leeauthor=Y.+Songauthor=J.+S.+Parkauthor=C.+G.+Gadheauthor=J.+Choiauthor=C.+G.+Leeauthor=A.+N.+Paeauthor=S.+Kimauthor=S.+K.+Ye&title=Development+of+oxadiazole-based+ODZ10117+as+a+small-molecule+inhibitor+of+STAT3+for+targeted+cancer+therapy&doi=10.3390%2Fjcm8111847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Development of oxadiazole-based ODZ10117 as a small-molecule inhibitor of STAT3 for targeted cancer therapy</span></div><div class="casAuthors">Kim, Byung-Hak; Lee, Haeri; Song, Yeonghun; Park, Joon-Suk; Gadhe, Changdev G.; Choi, Jiwon; Lee, Chung-Gi; Pae, Ae Nim; Kim, Sanghee; Ye, Sang-Kyu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1847</span>CODEN:
                <span class="NLM_cas:coden">JCMOHK</span>;
        ISSN:<span class="NLM_cas:issn">2077-0383</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Persistently activated STAT3 is a promising target for a new class of anticancer drug development and cancer therapy, as it is assocd. with tumor initiation, progression, malignancy, drug resistance, cancer stem cell properties, and recurrence.  Here, we discovered 3-(2,4-dichloro-phenoxymethyl)-5-trichloromethyl-[1,2,4]oxadiazole (ODZ10117) as a small-mol. inhibitor of STAT3 to be used in STAT3-targeted cancer therapy.  ODZ10117 targeted the SH2 domain of STAT3 regardless of other STAT family proteins and upstream regulators of STAT3, leading to inhibition of the tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity of STAT3.  The inhibitory effect of ODZ10117 on STAT3 was stronger than the known STAT3 inhibitors such as S3I-201, STA-21, and nifuroxazide.  ODZ10117 suppressed the migration and invasion, induced apoptosis, reduced tumor growth and lung metastasis, and extended the survival rate in both in vitro and in vivo models of breast cancer.  Overall, we demonstrated that ODZ10117 is a novel STAT3 inhibitor and may be a promising agent for the development of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyBAg7cTwH7Vg90H21EOLACvtfcHk0li-Uj-za7t34g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvVSmtbo%253D&md5=b2f33311762217f8b4a24acbfb3c4e85</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.3390%2Fjcm8111847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcm8111847%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DGadhe%26aufirst%3DC.%2BG.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DPae%26aufirst%3DA.%2BN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DS.%2BK.%26atitle%3DDevelopment%2520of%2520oxadiazole-based%2520ODZ10117%2520as%2520a%2520small-molecule%2520inhibitor%2520of%2520STAT3%2520for%2520targeted%2520cancer%2520therapy%26jtitle%3DJ.%2520Clin.%2520Med.%26date%3D2019%26volume%3D8%26spage%3D1847%26doi%3D10.3390%2Fjcm8111847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paek, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S. K.</span></span> <span> </span><span class="NLM_article-title">STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">722</span>, <span class="refDoi">Â DOI: 10.3390/cells9030722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.3390%2Fcells9030722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVSqt7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=722&author=B.+H.+Kimauthor=H.+Leeauthor=C.+G.+Parkauthor=A.+J.+Jeongauthor=S.+H.+Leeauthor=K.+H.+Nohauthor=J.+B.+Parkauthor=C.+G.+Leeauthor=S.+H.+Paekauthor=H.+Kimauthor=S.+K.+Ye&title=STAT3+inhibitor+ODZ10117+suppresses+glioblastoma+malignancy+and+prolongs+survival+in+a+glioblastoma+xenograft+model&doi=10.3390%2Fcells9030722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model</span></div><div class="casAuthors">Kim, Byung-Hak; Lee, Haeri; Park, Cheol Gyu; Jeong, Ae Jin; Lee, Song-Hee; Noh, Kum Hee; Park, Jong Bae; Lee, Chung-Gi; Paek, Sun Ha; Kim, Hyunggee; Ye, Sang-Kyu</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">722</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Constitutively activated STAT3 plays an essential role in the initiation, progression, maintenance, malignancy, and drug resistance of cancer, including glioblastoma, suggesting that STAT3 is a potential therapeutic target for cancer therapy.  We recently identified ODZ10117 as a small mol. inhibitor of STAT3 and suggested that it may have an effective therapeutic utility for the STAT3-targeted cancer therapy.  Here, we demonstrated the therapeutic efficacy of ODZ10117 in glioblastoma by targeting STAT3.  ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells and patient-derived primary glioblastoma cells.  In addn., ODZ10117 suppressed stem cell properties in glioma stem cells (GSCs).  Finally, the administration of ODZ10117 showed significant therapeutic efficacy in mouse xenograft models of GSCs and glioblastoma cells.  Collectively, ODZ10117 is a promising therapeutic candidate for glioblastoma by targeting STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkptjqpse0s7Vg90H21EOLACvtfcHk0li-Uj-za7t34g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVSqt7zM&md5=4fb235c58a3be0eb7a695a6f8e04590a</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.3390%2Fcells9030722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9030722%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DC.%2BG.%26aulast%3DJeong%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DNoh%26aufirst%3DK.%2BH.%26aulast%3DPark%26aufirst%3DJ.%2BB.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DPaek%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DS.%2BK.%26atitle%3DSTAT3%2520inhibitor%2520ODZ10117%2520suppresses%2520glioblastoma%2520malignancy%2520and%2520prolongs%2520survival%2520in%2520a%2520glioblastoma%2520xenograft%2520model%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D722%26doi%3D10.3390%2Fcells9030722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pallandre, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boibessot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yesylevskyy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramseyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pudlo, M.</span></span> <span> </span><span class="NLM_article-title">Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.08.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2015.08.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=26352675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOnu7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2015&pages=163-174&author=J.+R.+Pallandreauthor=C.+Borgauthor=D.+Rognanauthor=T.+Boibessotauthor=V.+Luzetauthor=S.+Yesylevskyyauthor=C.+Ramseyerauthor=M.+Pudlo&title=Novel+aminotetrazole+derivatives+as+selective+STAT3+non-peptide+inhibitors&doi=10.1016%2Fj.ejmech.2015.08.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors</span></div><div class="casAuthors">Pallandre, Jean-Rene; Borg, Christophe; Rognan, Didier; Boibessot, Thibault; Luzet, Vincent; Yesylevskyy, Semen; Ramseyer, Christophe; Pudlo, Marc</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-174</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The development of inhibitors blocking STAT3 transcriptional activity is a promising therapeutic approach against cancer and inflammatory diseases.  In this context, the selectivity of inhibitors against the STAT1 transcription factor is crucial as STAT3 and STAT1 play opposite roles in the apoptosis of tumor cells and polarization of the immune response.  A structure-based virtual screening followed by a luciferase-contg. promoter assay on STAT3 and STAT1 signaling were used to identify a selective STAT3 inhibitor.  An important role of the aminotetrazole group in modulating STAT3 and STAT1 inhibitory activities has been established.  Optimization of the hit compd. leads to 23.  This compd. inhibits growth and survival of cells with STAT3 signaling pathway while displaying a minimal effect on STAT1 signaling.  Moreover, it prevents lymphocyte T polarization into Th17 and Treg without affecting their differentiation into Th1 lymphocyte.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQOnVFWhVhLVg90H21EOLACvtfcHk0li-Uj-za7t34g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOnu7vE&md5=a729d83ffc41a893681f2faddcfa8ece</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.08.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.08.054%26sid%3Dliteratum%253Aachs%26aulast%3DPallandre%26aufirst%3DJ.%2BR.%26aulast%3DBorg%26aufirst%3DC.%26aulast%3DRognan%26aufirst%3DD.%26aulast%3DBoibessot%26aufirst%3DT.%26aulast%3DLuzet%26aufirst%3DV.%26aulast%3DYesylevskyy%26aufirst%3DS.%26aulast%3DRamseyer%26aufirst%3DC.%26aulast%3DPudlo%26aufirst%3DM.%26atitle%3DNovel%2520aminotetrazole%2520derivatives%2520as%2520selective%2520STAT3%2520non-peptide%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D103%26spage%3D163%26epage%3D174%26doi%3D10.1016%2Fj.ejmech.2015.08.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaPorte, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peshkov, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurdak, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarco, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span> <span> </span><span class="NLM_article-title">Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3581</span>â <span class="NLM_lpage">3585</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmcl.2016.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27381083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Wnu7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3581-3585&author=M.+G.+LaPorteauthor=Z.+Wangauthor=R.+Colomboauthor=A.+Garzanauthor=V.+A.+Peshkovauthor=M.+Liangauthor=P.+A.+Johnstonauthor=M.+E.+Schurdakauthor=M.+Senauthor=D.+P.+Camarcoauthor=Y.+Huaauthor=N.+I.+Pollockauthor=J.+S.+Lazoauthor=J.+R.+Grandisauthor=P.+Wipfauthor=D.+M.+Huryn&title=Optimization+of+pyrazole-containing+1%2C2%2C4-triazolo-%5B3%2C4-b%5Dthiadiazines%2C+a+new+class+of+STAT3+pathway+inhibitors&doi=10.1016%2Fj.bmcl.2016.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors</span></div><div class="casAuthors">LaPorte, Matthew G.; Wang, Zhuzhu; Colombo, Raffaele; Garzan, Atefeh; Peshkov, Vsevolod A.; Liang, Mary; Johnston, Paul A.; Schurdak, Mark E.; Sen, Malabika; Camarco, Daniel P.; Hua, Yun; Pollock, Netanya I.; Lazo, John S.; Grandis, Jennifer R.; Wipf, Peter; Huryn, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3581-3585</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Structure-activity relationship studies of a 1,2,4-triazolo-[3,4-b]thiadiazine scaffold, identified in an HTS campaign for selective STAT3 pathway inhibitors, detd. that a pyrazole group and specific aryl substitution on the thiadiazine were necessary for activity.  Improvements in potency and metabolic stability were accomplished by the introduction of an Î±-Me group on the thiadiazine.  Optimized compds. exhibited anti-proliferative activity, redn. of phosphorylated STAT3 levels and effects on STAT3 target genes.  These compds. represent a starting point for further drug discovery efforts targeting the STAT3 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA9KD6JSgxObVg90H21EOLACvtfcHk0lhD8x-4fLUytA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Wnu7nE&md5=844fb866fbb0524644d7eccd03656df3</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaPorte%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DGarzan%26aufirst%3DA.%26aulast%3DPeshkov%26aufirst%3DV.%2BA.%26aulast%3DLiang%26aufirst%3DM.%26aulast%3DJohnston%26aufirst%3DP.%2BA.%26aulast%3DSchurdak%26aufirst%3DM.%2BE.%26aulast%3DSen%26aufirst%3DM.%26aulast%3DCamarco%26aufirst%3DD.%2BP.%26aulast%3DHua%26aufirst%3DY.%26aulast%3DPollock%26aufirst%3DN.%2BI.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26atitle%3DOptimization%2520of%2520pyrazole-containing%25201%252C2%252C4-triazolo-%255B3%252C4-b%255Dthiadiazines%252C%2520a%2520new%2520class%2520of%2520STAT3%2520pathway%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3581%26epage%3D3585%26doi%3D10.1016%2Fj.bmcl.2016.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span> <span> </span><span class="NLM_article-title">An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-ÎºB</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>396</i></span>,  <span class="NLM_fpage">76</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2017.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.canlet.2017.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28323031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslOnsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=396&publication_year=2017&pages=76-84&author=T.+S.+Kangauthor=W.+Wangauthor=H.+J.+Zhongauthor=Z.+Z.+Dongauthor=Q.+Huangauthor=S.+W.+Mokauthor=C.+H.+Leungauthor=V.+K.+Wongauthor=D.+L.+Ma&title=An+anti-prostate+cancer+benzofuran-conjugated+iridium%28III%29+complex+as+a+dual+inhibitor+of+STAT3+and+NF-%CE%BAB&doi=10.1016%2Fj.canlet.2017.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-ÎºB</span></div><div class="casAuthors">Kang, Tian-Shu; Wang, Wanhe; Zhong, Hai-Jing; Dong, Zhen-Zhen; Huang, Qi; Mok, Simon Wing Fai; Leung, Chung-Hang; Wong, Vincent Kam Wai; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">396</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-84</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Four benzofuran-conjugated iridium(III) or rhodium (III)-based metal complexes are synthesized to screen as an inhibitor of STAT3 activity in prostate cancer cells.  All complexes show the high stability and soly. in the biol. system.  In this study, an iridium(III) complex engages STAT3 and NF-ÎºB to inhibit their translocation and transcriptional activities.  Moreover, complex 1 shows more potential antiproliferative activity against DU145 cells and suppresses tumor growth in a prostate cancer xenograft mouse without observable adverse effects.  Complex 1 may provide the basis for developing new therapeutic strategy in vivo and in vitro for the treatment of advanced prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGS7qZTHhEVrVg90H21EOLACvtfcHk0lhD8x-4fLUytA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslOnsrk%253D&md5=d410face71ded9bdd70b16ad00eb8b11</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DT.%2BS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DH.%2BJ.%26aulast%3DDong%26aufirst%3DZ.%2BZ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMok%26aufirst%3DS.%2BW.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DWong%26aufirst%3DV.%2BK.%26aulast%3DMa%26aufirst%3DD.%2BL.%26atitle%3DAn%2520anti-prostate%2520cancer%2520benzofuran-conjugated%2520iridium%2528III%2529%2520complex%2520as%2520a%2520dual%2520inhibitor%2520of%2520STAT3%2520and%2520NF-%25CE%25BAB%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D396%26spage%3D76%26epage%3D84%26doi%3D10.1016%2Fj.canlet.2017.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, P.</span></span> <span> </span><span class="NLM_article-title">Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115822</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2020.115822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.bmc.2020.115822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33126089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit12hurbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115822&author=F.+Wangauthor=K.-R.+Fengauthor=J.-Y.+Zhaoauthor=J.-W.+Zhangauthor=X.-W.+Shiauthor=J.+Zhouauthor=D.+Gaoauthor=G.-Q.+Linauthor=P.+Tian&title=Identification+of+novel+STAT3+inhibitors+bearing+2-acetyl-7-phenylamino+benzofuran+scaffold+for+antitumour+study&doi=10.1016%2Fj.bmc.2020.115822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study</span></div><div class="casAuthors">Wang, Feng; Feng, Kai-Rui; Zhao, Jia-Ying; Zhang, Jian-Wei; Shi, Xin-Wei; Zhou, Jian; Gao, Dingding; Lin, Guo-Qiang; Tian, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">115822</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is identified as a promising target for multiple cancer therapy and attracts widespread concern.  Herein, we reported the discovery of a series of 2-acetyl-7-phenylamino benzofuran derivs. as STAT3 inhibitors using scaffold fusion strategy.  Further structure activity relationship study led to the discovery of compd. C6, which displayed the most potent anti-proliferation activities against MDA-MB-468 cells (IC50 = 0.16 Î¼M).  Western blot assay demonstrated that C6 inhibited the activation of STAT3 (Tyr705) without influencing the phosphorylation of STAT1 (Tyr701).  Further mechanistic studies indicated that C6 caused a notable G2/M cycle-arresting and early apoptosis in a concn.-dependent manner in MDA-MB-468 cells.  Finally, mol. modeling study elucidated the binding mode of C6 in STAT3 SH2 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr95FVyr8O3k7Vg90H21EOLACvtfcHk0lhz4xLmkDIRaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit12hurbM&md5=4d93e72ff3fc75c36b7bab363f1a6d88</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115822%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DK.-R.%26aulast%3DZhao%26aufirst%3DJ.-Y.%26aulast%3DZhang%26aufirst%3DJ.-W.%26aulast%3DShi%26aufirst%3DX.-W.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DG.-Q.%26aulast%3DTian%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520STAT3%2520inhibitors%2520bearing%25202-acetyl-7-phenylamino%2520benzofuran%2520scaffold%2520for%2520antitumour%2520study%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115822%26doi%3D10.1016%2Fj.bmc.2020.115822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span> <span> </span><span class="NLM_article-title">Aspeterreurone A, a cytotoxic dihydrobenzofuran-phenyl acrylate hybrid from the deep-sea-derived fungus aspergillus terreus CC-S06â18</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1998</span>â <span class="NLM_lpage">2003</span>, <span class="refDoi">Â DOI: 10.1021/acs.jnatprod.0c00189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.0c00189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVGltLvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2020&pages=1998-2003&author=W.+Wangauthor=J.+Yangauthor=Y.-Y.+Liaoauthor=G.+Chengauthor=J.+Chenauthor=S.+Moauthor=L.+Yuanauthor=X.-D.+Chengauthor=J.-J.+Qinauthor=Z.+Shao&title=Aspeterreurone+A%2C+a+cytotoxic+dihydrobenzofuran-phenyl+acrylate+hybrid+from+the+deep-sea-derived+fungus+aspergillus+terreus+CC-S06%E2%80%9318&doi=10.1021%2Facs.jnatprod.0c00189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Aspeterreurone A, a Cytotoxic Dihydrobenzofuran-Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus Aspergillus terreus CC-S06-18</span></div><div class="casAuthors">Wang, Weiyi; Yang, Jing; Liao, Yan-Yan; Cheng, Gang; Chen, Jing; Mo, Shaowei; Yuan, Li; Cheng, Xiang-Dong; Qin, Jiang-Jiang; Shao, Zongze</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1998-2003</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">A new dihydrobenzofuran-Ph acrylate hybrid, aspeterreurone A (I), was obtained from the culture of the deep-sea-derived fungus Aspergillus terreus CC-S06-18.  The relative configuration of I was elucidated by HSQMBC NMR, calcd. NMR chem. shifts coupled with a statistical procedure (DP4+), and the abs. configuration was established by ECD calcns. I exhibited cytotoxicities against the gastric cancer cell lines HGC27, MGC803, BGC823, and AGS, with minimal effects on normal gastric epithelial cell line GES-1.  Further studies showed that I inhibited cell cycle progression and induced apoptosis of gastric cancer MGC803 cells in a concn.-dependent manner.  Western blot anal. indicated that I inhibited the phosphorylation of STAT3, which might contribute to its cytotoxic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpukjrhnweI87Vg90H21EOLACvtfcHk0lhz4xLmkDIRaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVGltLvF&md5=24a23226db8687ec8afe7d9e451e724e</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.0c00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.0c00189%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DY.-Y.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DX.-D.%26aulast%3DQin%26aufirst%3DJ.-J.%26aulast%3DShao%26aufirst%3DZ.%26atitle%3DAspeterreurone%2520A%252C%2520a%2520cytotoxic%2520dihydrobenzofuran-phenyl%2520acrylate%2520hybrid%2520from%2520the%2520deep-sea-derived%2520fungus%2520aspergillus%2520terreus%2520CC-S06%25E2%2580%259318%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2020%26volume%3D83%26spage%3D1998%26epage%3D2003%26doi%3D10.1021%2Facs.jnatprod.0c00189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">113333</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2021.113333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=33689932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmtFWlsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2021&pages=113333&author=D.+Gaoauthor=N.+Jinauthor=Y.+Fuauthor=Y.+Zhuauthor=Y.+Wangauthor=T.+Wangauthor=Y.+Chenauthor=M.+Zhangauthor=Q.+Xiaoauthor=M.+Huangauthor=Y.+Li&title=Rational+drug+design+of+benzothiazole-based+derivatives+as+potent+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+signaling+pathway+inhibitors&doi=10.1016%2Fj.ejmech.2021.113333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors</span></div><div class="casAuthors">Gao, Dingding; Jin, Nan; Fu, Yixian; Zhu, Yueyue; Wang, Yujie; Wang, Ting; Chen, Yuehong; Zhang, Mingming; Xiao, Qiang; Huang, Min; Li, Yingxia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113333</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The cumulative evidence supports STAT3, a transcriptional mediator of oncogenic signaling, as a therapeutic target in cancer.  The development of STAT3 inhibitors remain an active area of research as no inhibitors have yet to be approved for cancer treatment.  In a continuing effort to develop more potent STAT3 inhibitors based on our previously identified hit compd. 16w, a series of benzothiazole derivs. with unique binding mode in SH2 domain of STAT3 were designed, synthesized and biol. evaluated.  Of note, compd. B19 demonstrated excellent activity against IL-6/STAT3 signaling pathway with the IC50 value as low as 0.067 Î¼M as detd. by a luciferase reporter assay.  Moreover, multiple compds. displayed potent antiproliferative activity against MDA-MB-468 and JAK2 mutant HEL cell lines.  Further biochem. study using Western blot assay indicated that B19 blocked the phosphorylation of STAT3 at Tyr 705 and Ser 727 and thus suppressed STAT3-mediated gene expression of c-MYC and MCL-1.  Simultaneously, it induced cancer cell G2/M phase arrest and apoptosis both in MDA-MB-468 and HEL cell lines.  Finally, mol. docking study along with surface plasmon resonance (SPR) and fluorescence polarization (FP) assays disclosed the binding mode of B19 in STAT3 SH2 domain.  Taken together, our finding suggests that B19 is a promising therapeutic STAT3 inhibitor for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC2dHztNDzWrVg90H21EOLACvtfcHk0lhz4xLmkDIRaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmtFWlsrY%253D&md5=b92b8f1ef2d5596f4e0e78e07ed594b8</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113333%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DN.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DRational%2520drug%2520design%2520of%2520benzothiazole-based%2520derivatives%2520as%2520potent%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520signaling%2520pathway%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D216%26spage%3D113333%26doi%3D10.1016%2Fj.ejmech.2021.113333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of STAT3 by anticancer drug bendamustine</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0170709</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0170709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1371%2Fjournal.pone.0170709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28125678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFSlsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0170709&author=K.+Iwamotoauthor=Y.+Ueharaauthor=Y.+Inoueauthor=K.+Taguchiauthor=D.+Muraokaauthor=N.+Ogoauthor=K.+Matsunoauthor=A.+Asai&title=Inhibition+of+STAT3+by+anticancer+drug+bendamustine&doi=10.1371%2Fjournal.pone.0170709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of STAT3 by anticancer drug bendamustine</span></div><div class="casAuthors">Iwamoto, Kazunori; Uehara, Yutaka; Inoue, Yukie; Taguchi, Kyoko; Muraoka, Daisuke; Ogo, Naohisa; Matsuno, Kenji; Asai, Akira</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0170709/1-e0170709/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Bendamustine (BENDA), which bears the bis(2-chloroethyl)amino moiety, is an alkylating agent that stops the growth of cancer cells by binding to DNA and interfering with its replication.  However, the mechanism of action underlying its excellent clin. efficacy remains unclear.  In this work, we report that BENDA inhibits signal transducer and activator of transcription 3 (STAT3).  In an AlphaScreen-based biochem. assay using recombinant human STAT3, binding of STAT3Â±Src homol. 2 (SH2) to the phosphotyrosine (pTyr, pY) peptide was inhibited by BENDA but not by the inactive metabolite dihydroxy bendamustine (HP2).  When a single point mutation of C550A or C712A was introduced into recombinant human STAT3, its sensitivity to BENDA was substantially reduced, suggesting that these cysteine residues are important for BENDA to inhibit STAT3.  Furthermore, BENDA suppressed the function of cellular STAT3 as a transcriptional activator in a human breast cancer cell line, MDA-MB-468, with constitutively activated STAT3.  A competitive pull-down assay using biotinylated BENDA (Bio-BENDA) revealed that BENDA bound tightly to cellular STAT3, presumably through covalent bonds.  Therefore, our results suggest that the anticancer effects of BENDA may be assocd., at least in part, with its inhibitory effect on the SH2 domain of STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTZ-C2K2sazrVg90H21EOLACvtfcHk0lg_JvdfXMtjnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFSlsbY%253D&md5=2d9ce3e5e42f57ef2415b06b2f0835ab</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0170709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0170709%26sid%3Dliteratum%253Aachs%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DUehara%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DTaguchi%26aufirst%3DK.%26aulast%3DMuraoka%26aufirst%3DD.%26aulast%3DOgo%26aufirst%3DN.%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DAsai%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520STAT3%2520by%2520anticancer%2520drug%2520bendamustine%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0170709%26doi%3D10.1371%2Fjournal.pone.0170709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takakura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandi-Nejad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4143</span>â <span class="NLM_lpage">4154</span>, <span class="refDoi">Â DOI: 10.1093/hmg/ddr338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1093%2Fhmg%2Fddr338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=21821671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yltrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=4143-4154&author=A.+Takakuraauthor=E.+A.+Nelsonauthor=N.+Haqueauthor=B.+D.+Humphreysauthor=K.+Zandi-Nejadauthor=D.+A.+Frankauthor=J.+Zhou&title=Pyrimethamine+inhibits+adult+polycystic+kidney+disease+by+modulating+STAT+signaling+pathways&doi=10.1093%2Fhmg%2Fddr338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways</span></div><div class="casAuthors">Takakura, Ayumi; Nelson, Erik A.; Haque, Nadeem; Humphreys, Benjamin D.; Zandi-Nejad, Kambiz; Frank, David A.; Zhou, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4143-4154</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Autosomal dominant polycystic kidney disease (ADPKD) is a commonly inherited disorder mostly caused by mutations in PKD1, encoding polycystin-1 (PC1).  The disease is characterized by development and growth of epithelium-lined cyst in both kidneys, often leading to renal failure.  There is no specific treatment for this disease.  Here, we report a sustained activation of the transcription factor signal transducer and activator of transcription 3 (STAT3) in ischemic injured and uninjured Pkd1 knockout polycystic kidneys and in human ADPKD kidneys.  Through a chem. library screen, we identified the anti-parasitic compd. pyrimethamine as an inhibitor of STAT3 function.  Treatment with pyrimethamine decreases cell proliferation in human ADPKD cells and blocks renal cyst formation in an adult and a neonatal PKD mouse model.  Moreover, we demonstrated that a specific STAT3 inhibitor, S3I-201, reduces cyst formation and growth in a neonatal PKD mouse model.  Our results suggest that PC1 acts as a neg. regulator of STAT3 and that blocking STAT3 signaling with pyrimethamine or similar drugs may be an attractive therapy for human ADPKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVEStaa2l9HbVg90H21EOLACvtfcHk0lg_JvdfXMtjnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yltrjP&md5=e5bae0f5d88e2e44da18b96ca0c46236</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddr338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddr338%26sid%3Dliteratum%253Aachs%26aulast%3DTakakura%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DHaque%26aufirst%3DN.%26aulast%3DHumphreys%26aufirst%3DB.%2BD.%26aulast%3DZandi-Nejad%26aufirst%3DK.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DPyrimethamine%2520inhibits%2520adult%2520polycystic%2520kidney%2520disease%2520by%2520modulating%2520STAT%2520signaling%2520pathways%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2011%26volume%3D20%26spage%3D4143%26epage%3D4154%26doi%3D10.1093%2Fhmg%2Fddr338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heppler, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attarha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">Abstract 387: Pyrimethamine inhibits STAT3 transcriptional activity via dihydrofolate reductase</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">387</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=30482775" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=387&author=L.+N.+Hepplerauthor=S.+R.+Walkerauthor=S.+Attarhaauthor=B.+D.+Pageauthor=D.+A.+Frank&title=Abstract+387%3A+Pyrimethamine+inhibits+STAT3+transcriptional+activity+via+dihydrofolate+reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeppler%26aufirst%3DL.%2BN.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DAttarha%26aufirst%3DS.%26aulast%3DPage%26aufirst%3DB.%2BD.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DAbstract%2520387%253A%2520Pyrimethamine%2520inhibits%2520STAT3%2520transcriptional%2520activity%2520via%2520dihydrofolate%2520reductase%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lhBmFy3lrm4ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Small molecule PROTACs in targeted therapy: an emerging strategy to induce protein degradation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">159</span>â <span class="NLM_lpage">180</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.04.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ejmech.2019.04.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31035238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12isb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=159-180&author=M.+Xiauthor=Y.+Chenauthor=H.+Yangauthor=H.+Xuauthor=K.+Duauthor=C.+Wuauthor=Y.+Xuauthor=L.+Dengauthor=X.+Luoauthor=L.+Yuauthor=Y.+Wuauthor=X.+Gaoauthor=T.+Caiauthor=B.+Chenauthor=R.+Shenauthor=H.+Sun&title=Small+molecule+PROTACs+in+targeted+therapy%3A+an+emerging+strategy+to+induce+protein+degradation&doi=10.1016%2Fj.ejmech.2019.04.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation</span></div><div class="casAuthors">Xi, Meiyang; Chen, Yi; Yang, Hongyu; Xu, Huiting; Du, Kui; Wu, Chunlei; Xu, Yanfei; Deng, Liping; Luo, Xiang; Yu, Lemao; Wu, Yonghua; Gao, Xiaozhong; Cai, Tao; Chen, Bin; Shen, Runpu; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-180</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Inhibitors and nucleic acid based techniques were two main approaches to interfere with protein signaling and resp. cascade in the past.  Until recently, a new class of small mols. named proteolysis-targeting chimeras (PROTACs) have emerged.  Each contains a target warhead, a linker and an E3 ligand.  These bifunctional mols. recruit E3 ligases and target specific proteins for degrdn. via the ubiquitin (Ub) proteasome system (UPS).  The degrdn. provides several advantages over inhibition in potency, selectivity and drug resistance.  Thus, a variety of small mol. PROTACs have been discovered so far.  In this review, we summarize the biol. mechanism, advantages and recent progress of PROTACs, trying to offer an outlook in development of drugs targeting degrdn. in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY2xzp9ZKETLVg90H21EOLACvtfcHk0ljHutXkfvJ6PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12isb8%253D&md5=3838c9de05e487121ec2a24a0d9a3ea3</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.036%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DSmall%2520molecule%2520PROTACs%2520in%2520targeted%2520therapy%253A%2520an%2520emerging%2520strategy%2520to%2520induce%2520protein%2520degradation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D159%26epage%3D180%26doi%3D10.1016%2Fj.ejmech.2019.04.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">114</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0ljHutXkfvJ6PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">498</span>â <span class="NLM_lpage">511</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2019.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.ccell.2019.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31715132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCjtrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=498-511&author=L.+Baiauthor=H.+Zhouauthor=R.+Xuauthor=Y.+Zhaoauthor=K.+Chinnaswamyauthor=D.+McEachernauthor=J.+Chenauthor=C.+Y.+Yangauthor=Z.+Liuauthor=M.+Wangauthor=L.+Liuauthor=H.+Jiangauthor=B.+Wenauthor=P.+Kumarauthor=J.+L.+Meagherauthor=D.+Sunauthor=J.+A.+Stuckeyauthor=S.+Wang&title=A+potent+and+selective+small-molecule+degrader+of+STAT3+achieves+complete+tumor+regression+in+vivo&doi=10.1016%2Fj.ccell.2019.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo</span></div><div class="casAuthors">Bai, Longchuan; Zhou, Haibin; Xu, Renqi; Zhao, Yujun; Chinnaswamy, Krishnapriya; McEachern, Donna; Chen, Jianyong; Yang, Chao-Yie; Liu, Zhaomin; Wang, Mi; Liu, Liu; Jiang, Hui; Wen, Bo; Kumar, Praveen; Meagher, Jennifer L.; Sun, Duxin; Stuckey, Jeanne A.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">498-511.e17</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is an attractive cancer therapeutic target.  Here we report the discovery of SD-36(I), a small-mol. degrader of STAT3.  SD-36 potently induces the degrdn. of STAT3 protein in vitro and in vivo and demonstrates high selectivity over other STAT members.  Induced degrdn. of STAT3 results in a strong suppression of its transcription network in leukemia and lymphoma cells.  SD-36 inhibits the growth of a subset of acute myeloid leukemia and anaplastic large-cell lymphoma cell lines by inducing cell-cycle arrest and/or apoptosis.  SD-36 achieves complete and long-lasting tumor regression in multiple xenograft mouse models at well-tolerated dose schedules.  Degrdn. of STAT3 protein, therefore, is a promising cancer therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUaP49Ap9DxLVg90H21EOLACvtfcHk0lghziMT2tun7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCjtrjO&md5=71252c17d50a1a8be829352942175bd6</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DA%2520potent%2520and%2520selective%2520small-molecule%2520degrader%2520of%2520STAT3%2520achieves%2520complete%2520tumor%2520regression%2520in%2520vivo%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26spage%3D498%26epage%3D511%26doi%3D10.1016%2Fj.ccell.2019.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">11280</span>â <span class="NLM_lpage">11300</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01530</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01530" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SnsL3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11280-11300&author=H.+Zhouauthor=L.+Baiauthor=R.+Xuauthor=Y.+Zhaoauthor=J.+Chenauthor=D.+McEachernauthor=K.+Chinnaswamyauthor=B.+Wenauthor=L.+Daiauthor=P.+Kumarauthor=C.+Y.+Yangauthor=Z.+Liuauthor=M.+Wangauthor=L.+Liuauthor=J.+L.+Meagherauthor=H.+Yiauthor=D.+Sunauthor=J.+A.+Stuckeyauthor=S.+Wang&title=Structure-based+discovery+of+SD-36+as+a+potent%2C+selective%2C+and+efficacious+PROTAC+degrader+of+STAT3+protein&doi=10.1021%2Facs.jmedchem.9b01530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein</span></div><div class="casAuthors">Zhou, Haibin; Bai, Longchuan; Xu, Renqi; Zhao, Yujun; Chen, Jianyong; McEachern, Donna; Chinnaswamy, Krishnapriya; Wen, Bo; Dai, Lipeng; Kumar, Praveen; Yang, Chao-Yie; Liu, Zhaomin; Wang, Mi; Liu, Liu; Meagher, Jennifer L.; Yi, Han; Sun, Duxin; Stuckey, Jeanne A.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11280-11300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases.  Despite twenty-years of persistent research efforts, targeting STAT3 has been very challenging.  The authors report herein the structure-based discovery of potent small-mol. STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept.  The authors first designed SI-109 as a potent, small-mol. inhibitor of the STAT3 SH2 domain.  Employing ligands for cereblon/Cullin 4A E3 ligase and SI-109, the authors obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36.  SD-36 induces rapid STAT3 degrdn. at low nanomolar concns. in cells and fails to degrader other STAT proteins.  SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3.  A single dose of SD-36 results in complete STAT3 protein degrdn. in xenograft tumor tissue and normal mouse tissues.  SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules.  SD-36 is a potent, selective and efficacious STAT3 degrader.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIAWd1hiuqy7Vg90H21EOLACvtfcHk0lghziMT2tun7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SnsL3J&md5=7d0c656a2d96196a3b71829c9efe715a</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01530%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DStructure-based%2520discovery%2520of%2520SD-36%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520PROTAC%2520degrader%2520of%2520STAT3%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D11280%26epage%3D11300%26doi%3D10.1021%2Facs.jmedchem.9b01530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shih, P. C.</span></span> <span> </span><span class="NLM_article-title">Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>242</i></span>,  <span class="NLM_fpage">117241</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2019.117241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=10.1016%2Fj.lfs.2019.117241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=31891719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A280%3ADC%252BB3MblsFalsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=2020&pages=117241&author=P.+C.+Shih&title=Revisiting+the+development+of+small+molecular+inhibitors+that+directly+target+the+signal+transducer+and+activator+of+transcription+3+%28STAT3%29+domains&doi=10.1016%2Fj.lfs.2019.117241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains</span></div><div class="casAuthors">Shih Po-Chang</div><div class="citationInfo"><span class="NLM_cas:title">Life sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">242</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117241</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) has been a protein target following its roles being found to play in the progression of cancer development, cancer stemness, chemoresistance and radioresistance.  Two decades of research efforts in STAT3 has, however, not yielded a marketed anti-STAT3 drug.  This review insightfully discusses structural views on the STAT3 domains (e.g. binding pockets and critical residues), approaches to discovering effective chemical structures (e.g. structure-based drug discovery, high-throughput screening, natural product derivatives, repurposing drugs and so on), how the domains were targeted (e.g. non-covalent or covalent inhibition), and rationale of domain targeting (e.g. prevention of homo-dimerization or DNA-binding).  In addition, the assays that have been used for the discovery of STAT3 inhibitors will be discussed.  Overall, with this review article, the progress of the development of STAT3 antagonists could be accelerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRV-OmEt84CrcScOqQTSkOffW6udTcc2ebOCfg_X3dSzbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MblsFalsw%253D%253D&md5=4ea0df34ea89ed4cc8f2e985bafaf8ff</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2019.117241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2019.117241%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DP.%2BC.%26atitle%3DRevisiting%2520the%2520development%2520of%2520small%2520molecular%2520inhibitors%2520that%2520directly%2520target%2520the%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528STAT3%2529%2520domains%26jtitle%3DLife%2520Sci.%26date%3D2020%26volume%3D242%26spage%3D117241%26doi%3D10.1016%2Fj.lfs.2019.117241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a napabucasin PROTAC as an effective degrader of the E3 ligase ZFP91</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1626</span>â <span class="NLM_lpage">1648</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01897</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01897" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;key=1%3ACAS%3A528%3ADC%252BB3MXitV2rsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=1626-1648&author=M.+Hanafiauthor=X.+Chenauthor=N.+Neamati&title=Discovery+of+a+napabucasin+PROTAC+as+an+effective+degrader+of+the+E3+ligase+ZFP91&doi=10.1021%2Facs.jmedchem.0c01897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91</span></div><div class="casAuthors">Hanafi, Maha; Chen, Xinde; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1626-1648</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Napabucasin, undergoing multiple clin. trials, was reported to inhibit the signal transducer and transcription factor 3 (STAT3).  To better elucidate its mechanism of action, we designed a napabucasin-based proteolysis targeting chimera (PROTAC), XD2-149 that resulted in inhibition of STAT3 signaling in pancreatic cancer cell lines without inducing proteasome-dependent degrdn. of STAT3.  Proteomics anal. of XD2-149 revealed the downregulation of the E3 ubiquitin-protein ligase ZFP91.  XD2-149 degrades ZFP91 with DC50 values in the nanomolar range.  The cytotoxicity of XD2-149 was significantly, but not fully, reduced with ZFP91 knockdown providing evidence for its multi-targeted mechanism of action.  The NQO1 inhibitor, dicoumarol, rescued the cytotoxicity of XD2-149 but not ZFP91 degrdn., suggesting that the NQO1-induced cell death is independent of ZFP91.  ZFP91 plays a role in tumorigenesis and is involved in multiple oncogenic pathways including NF-ÎºB and HIF-1Î±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrnBARFW60pbVg90H21EOLACvtfcHk0lg9GaqrZS_4iw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXitV2rsr0%253D&md5=4a15342a402ce15a85ebd5e9e622b53e</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01897%26sid%3Dliteratum%253Aachs%26aulast%3DHanafi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520a%2520napabucasin%2520PROTAC%2520as%2520an%2520effective%2520degrader%2520of%2520the%2520E3%2520ligase%2520ZFP91%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D1626%26epage%3D1648%26doi%3D10.1021%2Facs.jmedchem.0c01897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BG1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BG1','PDB','1BG1'); return false;">PDB: 1BG1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZIA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZIA','PDB','4ZIA'); return false;">PDB: 4ZIA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NUQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NUQ','PDB','6NUQ'); return false;">PDB: 6NUQ</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00629&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00629%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-13%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00629" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0a697acbad187","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
